ABOUT ISHLT

2016-2017 BOARD OF DIRECTORS

ISHLT STAFF

2017 ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

2017 ABSTRACT REVIEWERS

ISHLT COMMITTEE ROSTERS

Corporate Development Committee
Education Committee
Governance Committee
Grants and Awards Committee
International and Inter-Society Coordination Committee (I2C2)
ISHLT Mechanically Assisted Circulatory Support (IMACS®) Registry Steering Committee
International DCD Registry Steering Committee
International Pediatric Heart Failure Registry (IPHFR) Steering Committee
International Thoracic Transplant Registry Steering Committee
Journal of Heart and Lung Transplantation (JHLT) Editorial Board
Registries and Databases Committee
Standards and Guidelines Committee
Links Newsletter Editorial Staff

ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS

Basic Science and Translational Research
Chronic Thromboembolic Pulmonary Hypertension
Heart Failure and Transplantation
Infectious Diseases
Junior Faculty and Trainee
Mechanical Circulatory Support
Nursing, Health Sciences and Allied Health
Pathology
Pediatric Thoracic Transplantation and Heart Failure
Pharmacy and Pharmacology
Pulmonary Hypertension
Pulmonary Transplantation

PAST PRESIDENTS

PAST PROGRAM CHAIRS

JOURNAL AND LINKS NEWSLETTER EDITORS

REGISTRY MEDICAL DIRECTORS

ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS:

ISHLT Pioneer Award
ISHLT Lifetime Achievement Award
ISHLT Lifetime Service Award
Emeritus Membership

GRANTS AND SCHOLARSHIPS:

ISHLT Norman E. Shumway Career Development Award
ISHLT Joel D. Cooper Career Development Award
ISHLT Nursing Research Grant Award
ISHLT Research Fellowship Award
ISHLT Transplant Registry Early Career Award
ISHLT/Bayer Pulmonary Hypertension Research Grant Award
ISHLT/O.H. Frazier Award in MCS Translational Research Sponsored by Medtronic
(Formerly ISHLT/O.H. Frazier Award in MCS Translational Research
Sponsored by Heartware and ISHLT/Heartware Award for Translational Research in MCS)
ISHLT Branislav Radovancevic Memorial Fellowship Grant (Supported by Thoratec)
ISHLT International Traveling Scholarship Award
ISHLT Leach-Abramson-Imhoff Links Travel Awards

ABSTRACT AWARDS:
Philip K. Caves Award
Nursing, Health Sciences & Allied Health Excellence in Research Award
JFTC Clinical Case Dilemmas in Thoracic Transplantation Best Presentation Award
ISHLT Branislav Radovancevic Memorial Best MCSD Paper Award (Supported by Thoratec)

ACCREDITATION INFORMATION CONTINUING MEDICAL EDUCATION INFORMATION

UNRESTRICTED EDUCATIONAL GRANTS

COMMERCIAL SUPPORT

HIGHLIGHTS OF THE MEETING
Basic Science and Translational Research
Heart Failure and Transplantation
Infectious Diseases
Lung Transplantation
Mechanical Circulatory Support
Nursing, Health Sciences and Allied Health
Pathology
Pediatric Thoracic Transplantation and Heart Failure
Pharmacy and Pharmacology
Pulmonary Hypertension

HOTEL FLOOR PLANS
Lobby Level
2nd Level - Harbor
2nd Level - Seaport
3rd Level - Harbor
3rd Level - Seaport
4th Level

POSTER MAPS
Coronado Poster Hall Wednesday
Harbor Poster Hall Wednesday
Regatta Poster Hall Wednesday
Seaport Poster Hall Wednesday
Coronado Poster Hall Thursday
Harbor Poster Hall Thursday
Regatta Poster Hall Thursday
Seaport Poster Hall Thursday
Coronado Poster Hall Friday
Harbor Poster Hall Friday
Regatta Poster Hall Friday
Seaport Poster Hall Friday

ACRONYMS

SCIENTIFIC COUNCIL MEETINGS & NETWORKING RECEPTIONS

DAILY SCHEDULE
Monday, April 3, 2017
Tuesday, April 4, 2017
Wednesday, April 5, 2017
WEDNESDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 05, 2017

SYMPOSIUM 01: Joint ISHLT/ICCAC Symposium: Besides the Surgery - How to Make VAD Patients Successful
SYMPOSIUM 02: When Should We Call It Quits? The Efficacy of Interventions to Ameliorate Psychosocial Risk Factors
SYMPOSIUM 03: Primary Graft Dysfunction (PGD) and Vasoplegia After Heart Transplantation: Sink or Swim
SYMPOSIUM 04: Thinking Outside the Box: Extra-Pulmonary Management in Lung Transplantation
SYMPOSIUM 05: Joint ISHLT/PHA Symposium: PH and Transplant: Where Do We Go From Here?
SYMPOSIUM 06: The Failing Fontan - Where Do We Go From Here?
SYMPOSIUM 07: Joint ISHLT/ESCMID Symposium: Ongoing Challenges in Transplant Infectious Diseases

OPENING PLENARY SESSION
ORAL SESSION 01: Too Thick or Too Thin? Bleeding and Thrombosis in MCS
ORAL SESSION 02: Engineering for Perfection in MCS
ORAL SESSION 03: Moving DCD Forward: Thinking Inside the Box
ORAL SESSION 04: Donor Lung Allocation Strategies
ORAL SESSION 05: Registries and Risk Scores in Pulmonary Hypertension: Updates, Lessons Learned, and Practice Changes
ORAL SESSION 06: Pediatric Heart Failure: Diagnosis, Management, and Confronting Risk
ORAL SESSION 07: Cutting Edge Updates in Infectious Diseases
ORAL SESSION 08: Bugs and Devices: A Bad Combination
ORAL SESSION 09: MCS Surgery: Does Nuance Make a Master?
ORAL SESSION 10: Movement on the Heart Transplant Wait List: VADS, Exceptions and Antibodies
ORAL SESSION 11: Improving Prognosis in Chronic Lung Allograft Dysfunction
ORAL SESSION 12: Innovation in Pediatric MCS
SYMPOSIUM 08: ECMO in Pre-Capillary PH: What is the Best Option for My Patient?
SYMPOSIUM 09: JHLT at ISHLT: The Year in a Capsule
MINI ORAL SESSION 1: Complicating Factors in MCS
MINI ORAL SESSION 2: Donor Evaluation and Management: DBD and DCD
MINI ORAL SESSION 3: Wretched Strangers: Mechanisms of Thoracic Organ Infection, Rejection and Tolerance
MINI ORAL SESSION 4: Allocation, Bridging and Lung Allograft Assessment Strategies
MINI ORAL SESSION 5: The Hardware of MCS
MINI ORAL SESSION 6: Therapeutics in Advanced Heart and Lung Disease

THURSDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 06, 2017

SUNRISE SYMPOSIUM 01: Walk With Me: Exercise Physiology in the LVAD Patient
SUNRISE SYMPOSIUM 02: Chagasic Cardiomyopathy: Lessons To Be Learned
SUNRISE SYMPOSIUM 03: Lifecycle Journey of Thrombosis in Mechanical Circulatory Support Patients
SUNRISE SYMPOSIUM 04: Completing the Picture: Patient Reported Outcomes (PROs) as an Essential Source of Information in Evaluating Transplantation Outcomes
SUNRISE SYMPOSIUM 05: Upcoming Opportunities and Challenges in Pediatric Lung Transplantation
SUNRISE SYMPOSIUM 06: "Those Dam CARVs": Community Acquired Respiratory Viruses in Lung Transplant
SYMPOSIUM 10: Antibodies in Mechanical Circulatory Support: The Phantom Menace
SYMPOSIUM 11: Not CAVing to CLADtastrophy: Emerging Mechanisms of Chronic Heart and Lung Allograft Disease
SYMPOSIUM 12: A Tale of Two Organs: Selecting and Managing Multi-Organ Transplant Recipients
SYMPOSIUM 13: Lung Allocation Scores (LAS): Making the Complex Simple, or Just the Simple Complex?
SYMPOSIUM 14: Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Current Controversies and New Directions
SYMPOSIUM 15: HLA, AMR and DSA - Approaching Antibodies in Kids
SYMPOSIUM 16: "Around the World in 80 Days": Infectious Challenges in Cardiothoracic Transplantation
PLENARY SESSION
ORAL SESSION 13: Contemporary LVAD Trials - Same Old Song or New Tune?
ORAL SESSION 14: Measure for Measure: In- and Ex-Vivo Cellular and Molecular Approaches for Thoracic Organ Tailoring
ORAL SESSION 15: Therapies and Monitoring After Heart Transplantation
ORAL SESSION 16: The Rise of the Machines: ECLS and EVLP in Lung Transplantation
ORAL SESSION 17: What's Up Next in Pulmonary Hypertension Research?
ORAL SESSION 18: Contemporary Challenges in Pediatric Heart Transplant
ORAL SESSION 19: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best
SYMPOSIUM 17: To Pulse or Not To Pulse? That is the Question
SYMPOSIUM 18: Weeding Out Fact from Fiction - the Highs and Lows of Marijuana Use in Transplant
SYMPOSIUM 19: Cardiogenic Shock: Types, Teams and Tactics
SYMPOSIUM 20: ECMO in Lung Transplantation: Sensational Success or Fantastic Failure?
SYMPOSIUM 21: Cardiopulmonary Hemodynamics, the Right Ventricle, and the Kidney: Connecting All the Dots
SYMPOSIUM 22: Let's Get Personal! Precision Diagnostics in Thoracic Transplantation
SYMPOSIUM 23: Taming of the Shrew: Mycobacterium Abscessus in Lung Transplantation
MINI ORAL SESSION 7: Factors that Drive Success in MCS
MINI ORAL SESSION 8: Infections, Induction and IVIG
MINI ORAL SESSION 9: Novel Strategies and Mechanisms in Lung Preservation, Heart Failure and Assist Devices
MINI ORAL SESSION 10: Challenges in Lung Transplantation
MINI ORAL SESSION 11: Outcomes in MCS
MINI ORAL SESSION 12: Hot Topics in Pediatric Heart Transplantation

FRIDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 07, 2017

SUNRISE SYMPOSIUM 07: Getting to the Heart of Muscular Dystrophies
SUNRISE SYMPOSIUM 08: Live Long and Prosper: Thriving After Pediatric Transplantation
SUNRISE SYMPOSIUM 09: Mixed Rejection (MR) of the Cardiac Allograft: The Next Frontier
SUNRISE SYMPOSIUM 10: Contrasts and Similarities in Children and Adults: IPAH, Portopulmonary Hypertension, and Perioperative Management
SUNRISE SYMPOSIUM 11: There is No Such Thing as Perfect: Selecting Recipients for Lung Transplantation
SUNRISE SYMPOSIUM 12: HIV and Transplantation: It Isn't Going Away...
ORAL SESSION 20: New and Improving? Evolving Outcomes with MCS
ORAL SESSION 21: New Fixes for an Old Problem: Preventing, Diagnosing, and Treating Pump Thrombosis
ORAL SESSION 22: Does Risk Reap Reward? Expanding the Heart Donor Pool
ORAL SESSION 23: Choosing Right: Lung Recipient Selection and Management
ORAL SESSION 24: An Amalgamation of Support in Heart Failure
ORAL SESSION 25: Improving Outcomes in Pediatric Lung Transplantation
ORAL SESSION 26: Philip K. Caves Award Candidate Presentations
ORAL SESSION 27: The Leaking Gut - New Strategies for GI Bleeding in MCS
ORAL SESSION 28: The Heart of the Matter: Cardiac Substrate in MCS Therapy
ORAL SESSION 29: Donor Utilization and Allocation in Heart Transplantation: Lessons to Learn
ORAL SESSION 30: Novel Mechanisms in Chronic Lung Allograft Dysfunction
ORAL SESSION 31: Saved by the Bell: Overcoming Adherence and Frailty
ORAL SESSION 32: The Tell Tale Heart: From Signals to Biomarkers
ORAL SESSION 33: PATH to Better Outcomes: Diagnostics in Heart and Lung Transplantation
SYMPOSIUM 24: Aiming Off Target: Non-Cardiac Consequences of LVAD Support
SYMPOSIUM 25: Dealing with Antibodies Before and After Heart Transplant: Do We Have New Arrows in our Quiver?
SYMPOSIUM 26: Making Every Heart Count
SYMPOSIUM 27: Bench to Bedside: How Advances in Immunology Shape the Care of Today’s Lung Transplant Recipients
SYMPOSIUM 28: Great Debates in Pulmonary Hypertension
SYMPOSIUM 29: How to Mend a Broken Heart: Approaches for Cardiac Regeneration
SYMPOSIUM 30: E-Health, Wearables, Social Media and Big Data in Transplantation: Fancy Toys or True Care Innovations?
ORAL SESSION 34: Short-Term MCS for Shock: New Paradigms
ORAL SESSION 35: Heart Failure in MCS
ORAL SESSION 36: CAV: New Insights to an Old Problem
ORAL SESSION 37: Impact of Donor Characteristics on Lung Transplant Outcomes
ORAL SESSION 38: The Nightmare of Primary Cardiac Allograft Dysfunction
ORAL SESSION 39: Early Career Scientist Award in Transplantation Finalist Presentations
ORAL SESSION 40: Drugs, Bleeding and Enzymes ... Oh My!
MINI ORAL SESSION 13: Controversies in Heart Transplantation
HTX, MCS
MINI ORAL SESSION 14: Recipient Risk Factors Affecting Outcome after Lung Transplantation
MINI ORAL SESSION 15: Pediatric Heart Failure, MCS, and Peri-Transplant Issues
MINI ORAL SESSION 16: Assessing and Managing the Failing Right Ventricle
MINI ORAL SESSION 17: Progress in MCS Outcomes
MINI ORAL SESSION 18: Patient Centered Outcomes in Advanced Heart and Lung Disease

SATURDAY ANNUAL MEETING SCIENTIFIC PROGRAM APRIL 08, 2017
SUNRISE SYMPOSIUM 13: Mechanical Circulatory Support - The Interface of Design and Outcome
SUNRISE SYMPOSIUM 14: The Tsunami of Adult Congenital Heart Disease (ACHD) Patients Who Need Advanced Therapies: Are We Prepared?
SUNRISE SYMPOSIUM 15: Extracorporeal Photopheresis: Shedding Light on Rejection?
SUNRISE SYMPOSIUM 16: Pregnant - Scared? So Are We.... Management of Pregnancy in Our Complex Patients
SUNRISE SYMPOSIUM 17: Living in a 'Bacterial' World: Microbiome in Thoracic Transplantation
ORAL SESSION 41: The Rhythm is Going to Get You: EP Issues in MCS
ORAL SESSION 42: The Weighting Game: Impact of Obesity, Age, and Other Comorbidities in MCS
ORAL SESSION 43: In the Mix of Heart Failure
ORAL SESSION 44: Optimizing Early Outcomes after Lung Transplantation
ORAL SESSION 45: Heart Transplant in Special Populations
ORAL SESSION 46: Rogue One: A Graft Wars Story of Rejection and Tolerance
PLENARY SESSION
ORAL SESSION 47: Not the Usual Suspects: Driving Outcomes in MCS
ORAL SESSION 48: Seeing the Patient Beyond the Device
ORAL SESSION 49: Antibodies and Other Determinants of Cardiac Rejection: Let's ROCK and Rho
ORAL SESSION 50: Influencing Long-term Outcomes in Lung Transplantation
ORAL SESSION 51: Optimizing Outcomes After Heart Transplantation: Predictors and Risk Scores
ORAL SESSION 52: Does Size Matter? Center Volume, Urgency Status and Managing Complications
ORAL SESSION 53: Getting to the Heart of the Matter: Psychosocial Factors Predict Outcomes in Transplant and MCS

WEDNESDAY POSTER SESSION 1 APRIL 05, 2017
Heart Failure
Heart Transplantation
Infectious Diseases
Mechanical Circulatory Support
Pediatrics
Junior Faculty Clinical Case Reports

THURSDAY POSTER SESSION 2 APRIL 06, 2017
Economics, Ethics, Public Policy
Heart Transplantation
Lung Transplantation
Mechanical Circulatory Support
Nursing, Health Sciences, Allied Health
Pulmonary Hypertension
Pharmacy & Pharmacology

FRIDAY POSTER SESSION 3 APRIL 07, 2017
Basic Science & Translational Research
Heart Transplantation
Lung Transplantation
Mechanical Circulatory Support
Pathology
Junior Faculty Clinical Case Reports

ISHLT ACADEMY: CORE COMPETENCIES IN INFECTIOUS DISEASES IN THORACIC TRANSPLANTATION AND MCS SCIENTIFIC PROGRAM
ISHLT ACADEMY: CORE COMPETENCIES IN MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC PROGRAM
ISHLT ACADEMY: CORE COMPETENCIES IN PEDIATRIC AND ADULT CONGENITAL MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC PROGRAM
ISHLT ACADEMY: MASTER CLASS IN MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC PROGRAM
ISHLT ACADEMY: MASTER CLASS IN PULMONARY HYPERTENSION

AFFILIATE EVENTS
CORPORATE EVENTS AND INDUSTRY THEATERS LISTINGS
EXHIBIT HALL FLOOR PLAN
2017 EXHIBITORS AND BOOTH NUMBERS
2017 EXHIBITOR PRODUCT DESCRIPTIONS
FUTURE ANNUAL MEETINGS
ABOUT ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators, and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

The purposes of the Society are:

1. To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease, and related sciences.
2. To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
3. To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
4. To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
5. To establish and maintain an international registry for heart and lung transplantation.
6. To award research grants and establish endowments for the study of these disciplines.
2016-2017 BOARD OF DIRECTORS

Maryl R. Johnson, MD, President, University of Wisconsin, Madison, WI
Andrew J. Fisher, FRCP PhD, President-Elect, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
R. Duane Davis, MD, MBA, Past President, Florida Hospital, Orlando, FL
Joseph Rogers, MD, Secretary-Treasurer, Duke University Medical Center, Durham, NC
Christian Benden, MD FCCP, Director, University Hospital Zurich, Zurich, Switzerland
Jason D. Christie, MD, Director, University of Pennsylvania, Philadelphia, PA
Lara Danziger-Isakov, MD, MPH, Director, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Tobias Deuse, MD, PhD, Director, University of California at San Francisco, San Francisco, CA
Howard J. Eisen, MD, Director, Drexel University College of Medicine, Philadelphia, PA
Stephan M. Ensminger, MD, DPhil, Director, Ruhr-University Bochum, Bad Oeynhausen, Germany
Daniel J. Goldstein, MD, Director, Montefiore Medical Center, Bronx, NY
Peter M. Hopkins, FRACP, Director, The Prince Charles Hospital, Brisbane, Australia
Michael G. Petty, PhD, RN, CNS, Director, University of Minnesota Medical Center, Minneapolis, MN
Jeffrey J. Teuteberg, MD, Director, University of Pittsburgh/Presbyterian, Pittsburgh, PA
Dirk Van Raemdonck, MD, PhD, Director, University Hospital Gasthuisberg, Leuven, Belgium

Ex Officio Board Members
Mandeep R. Mehra, MD, MBBS, FACC, FACP, Editor-in-Chief Journal of Heart and Lung Transplantation
Josef Stehlik, MD, MPH, International Thoracic Transplant Registry Medical Director
Christopher H. Wigfield, MD, FRCS (C/Th), Medical Director of Educational Affairs
Amanda W. Rowe, ISHLT Executive Director
ISHLT STAFF

Amanda W. Rowe
Executive Director

Phyllis Glenn
Director of Membership Services

Lisa Edwards
Director of Meetings

Lee Ann Mills
Director of Operations

Susie Newton
Communications Manager

Megan Barrett
Communications Assistant

Justin Hickman
Finance and Operations Assistant

14673 Midway Road, Suite 200
Addison, TX 75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ISHLT.org
2017 ANNUAL MEETING SCIENTIFIC PROGRAM COMMITTEE

◆ Symposium Planning Committee
★ Abstract Selection Committee

Jeffrey J. Teuteberg, MD, Pittsburgh, PA, USA, 2017 Program Chair◆◆
Maryl R. Johnson, MD, Madison, WI, USA ISHLT President◆◆
Andrew J. Fisher, FRCP, PhD, Newcastle Upon Tyne, UK, 2016 Program Chair◆◆
Christian Benden, MD, FCCP, Zurich, Switzerland, 2018 Program Chair◆◆
Saima Aslam, MD, MS, San Deigo, CA, USA◆◆
Fiorella Calabrese, MD, Padova, Italy◆◆
Chesney Castleberry, MD, St. Louis, MO, USA★
Sabina M. De Geest, RN, PhD, Basel, Switzerland◆◆
Shashank S. Desai, MD, Falls Church, VA, USA◆◆
Fabienne Dobbels, MSc, PhD, Leuven, Belgium★
Howard J. Eisen, MD, Philadelphia, PA, USA◆◆
Maryjane Farr, MD, New York, NY, USA◆◆
Savitri Fedson, MD, Houston, TX, USA★
Rochelle Gellatly, PharmD, Melbourne, Australia★
Patricia Ging, PharmD, Dublin, Ireland◆◆
Kristine Gulserian, MD, Dallas, TX, USA★
Christopher Hayward, MD, Sydney, Australia★
Are Martin Holm, MD, PhD, Oslo, Norway◆◆
Shahid Husain, MD, MS, Toronto, Canada★
Jonathan N. Johnson, MD, Rochester, MD◆◆
Kiran Khush, MD, Stanford, CA, USA★
Ivan Knezevic, Ljubljana, Slovenia★
Theodoros Kofidis, MD, PhD, FRCS, Singapore, Singapore◆◆
Brent Lampert, DO, Bexley, OH, USA★
Erika D. Lease, MD, Seattle, WA, USA◆◆
Claudius Mahr, DO, Seattle, WA, USA★
Tereza Martinu, MD, Toronto, Canada◆◆
Mandeep R. Mehra, MD, MBBS, FACC, FACP, Boston, MA, USA◆◆
Hirsch Mehta, MD, San Diego, CA, USA★
Joshua Mooney, MD, Stanford, CA, USA★
Sanem Nalbantgil, MD, Izmir, Turkey◆◆
Desley Neil, FRCPath, Birmingham, UK◆◆
Ivan Netuka, MD, PhD, Prague, Czech Republic◆◆
Francis Pagani, MD, PhD, Ann Arbor, MI, USA◆◆
Caroline Patterson, MD, Cambridge, UK★
Simon Pecha, MD, Hamburg, Germany◆◆
Axel Rahmel, MD, Frankfurt, Germany★
Joanna M. Schaeenman, MD, PhD, Los Angeles, CA, USA◆◆
Palak Shah, MD, MS, Falls Church, VA, USA★
Oksana A. Shlobin, MD, Falls Church, VA, USA◆◆
Michael Shullo, PharmD, Pittsburgh, PA, USA◆◆
Ryan J. Tedford, MD, Baltimore, MD, USA◆◆
Adriana Torres, MD, Bogota Colombia★
Marian Urban, MD, Newcastle Upon Tyne, UK◆◆
C. Dario Vizza, MD, Rome, Italy◆◆
Robin Vos, MD, PhD, Leuven, Belgium◆◆
Connie White-Williams, RN, PhD, Birmingham, AL, USA★
Christopher H. Wigfield, MD FRCS(C/Th), Chicago, IL, USA◆◆
Quincy Young, PhD, RPsych, Vancouver, BC, Canada◆◆
Roger Yusen, MD, MPH, St. Louis, MO, USA★
Daniel Zimpfer, MD, Vienna, Austria★
Deepak Acharya, MD, University of Alabama, Birmingham, AL, USA
Rasha Adam, RN, University of Minnesota Medical Center, Minneapolis, MN, USA
Sean Agbor-Enoh, MD, National Institutes of Health, Bethesda, MD, USA
Clemens Aigner, MD, University Clinic Essen, Essen, Germany
Hakim Ali, MD, Duke University, Durham, NC, USA
Larry Allen, MD, MHS, University of Colorado, Denver, CO, USA
Christopher Almond, MD, Stanford University, Stanford, CA, USA
Cristiano Amarelli, MD, Monaldi Hospital, Napoli, Italy
Amrut Ambarkarah, MD, University of Colorado, Denver, CO, USA
Allen Anderson, MD, FACC, Northwestern University, Chicago, IL, USA
Annalisa Angelini, MD, University of Padua, Padua, Italy
Samantha Anthony, PhD, MSW, The Hospital for Sick Children, Toronto, ON, Canada
Medhat Askar, MD, PhD, Baylor University Medical Center, Dallas, TX, USA
Estela Azeka, MD, University of Sao Paulo, Sao Paulo, Brazil
Carla Baan, PhD, Erasmus Medical Center, Rotterdam, Netherlands
Dipanjan Banerjee, MD, Stanford University, Stanford, CA, USA
Aditya Bansal, MD, Ochsner Clinic Foundation, New Orleans, LA, USA
David Baran, MD, Newark Beth Israel Medical Center, Newark, NJ, USA
Aliessa Barnes, MD, Children's Mercy Hospital, Kansas City, MO, USA
Markus Barten, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
George Belli, MD, Great Ormond Street Hospital, London, United Kingdom
Lavanya Bellumkonda, MD, Yale University School of Medicine, New Haven, CT, USA
Christian Bernudez, MD, University of Pennsylvania, Philadelphia, PA, USA
Alexander Bernhardt, MD, University Heart Center Hamburg, Hamburg, Germany
Gerald Berry, MD, Stanford University, Stanford, CA, USA
Arvind Bhimaraj, MD, Houston Methodist Hospital, Houston, TX, USA
Edo Birati, MD, University of Pennsylvania, Philadelphia, PA, USA
Joshua Blatter, MD, Washington University School of Medicine, St. Louis, MO, USA
Nancy Blumenthal, CRNP, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Udo Boeken, MD, PhD, University Hospital Duesseldorf, Duesseldorf, Germany
Massimo Bonacchi, MD, University of Florence, Florence, Italy
Pranod Bonde, MD, Yale University School of Medicine, New Haven, CT, USA
Andrew Boyle, MD, Thomas Jefferson University, Philadelphia, PA, USA
Mary Bradbury, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA
Meredith Brisco, MSCE, Temple University, Philadelphia, PA, USA
Patrick Bruneval, MD, Hospital European Georges Pompidou, Paris, France
Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH, USA
Fay Burrows, BPharm, St Vincent's Hospital, Sydney, Australia
Marco Caccamo, DO, Indiana University, Indianapolis, IN, USA
Barbara Cahill, MD, University of Utah, Salt Lake City, UT, USA
Charles Canver, MD, Duke Cardiovascular Surgery of Danville, Danville, VA, USA
Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia
Patricia Chang, MD, University of North Carolina, Chapel Hill, NC, USA
Anshuman Chaturvedi, MD, FRCP, Univ Hospital of South Manchester, Manchester, United Kingdom
Jonathan Chen, MD, Seattle Children's Hospital, Seattle, WA, USA
Leway Chen, MD, MPH, University of Rochester Medical Center, Rochester, NY, USA
Robert Chen, MD, MPH, Taipei Tzuchi Hospital, New Taipei City, Taiwan
Allen Cheng, MD, Jewish Hospital, University of Louisville, Louisville, KY, USA
Richard Cheng, MD, University of Washington, Seattle, WA, USA
Laveena Chhatwani, MD, Stanford University, Stanford, CA, USA
Young-Jae Cho, MD, MPH, Seoul National University Bundang Hospital, Seoul, Korea, Republic of
Dawn Christensen, MS, CRNP, MyLVAD, Pine Grove, PA, USA
Agnieszka Ciarka, MD, KU Leuven, Leuven, Belgium
Jose Cifrian, MD, Hospital Valdecilla, Santander, Spain
Tamara Claridge, PharmD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Stephen Clark, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Brian Clarke, MD, University of Calgary, Calgary, AB, Canada
Adam Cochrane, PharmD, Inova Fairfax Hospital, Falls Church, VA, USA
Erin Coglan, MD, Loyola University Medical Center, Maywood, IL, USA
Pamela Combs, PhD, RN, Jewish University Medical Center, Louisville, KY, USA
Mark Connellan, FRACS, St Vincent's Hospital, Sydney, Australia
Carol Conrad, MD, Stanford University, Stanford, CA, USA
Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada
Hannah Copeland, MD, VA McGuire Medical Center/Virginia Commonwealth Univ, Richmond, VA, USA
Vlad Cotaflan, MD, University of Iowa, Iowa City, IA, USA
Melissa Cousino, PhD, University of Michigan, Ann Arbor, MI, USA
Jennifer Cowger, MD, MS, St Vincent Hospital, Indianapolis, IN, USA
Rachel Crackett, MSc, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Todd Dardas, MD, University of Washington, Seattle, WA, USA
Hiroshi Date, MD, Kyoto University, Kyoto, Japan
Teresa De Marco, MD, FACC, UCSF, San Francisco, CA, USA
Marc de Perrot, MD, Toronto General Hospital/UHN, Toronto, ON, Canada
Fabio de Robertis, MD, Harefield Hospital, Harefield, United Kingdom
Juan F. Delgado, PhD, University Hospital 12 de Octubre, Madrid, Spain
Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Eugene DePasquale, MD, UCLA Medical Center, Los Angeles, CA, USA
Tobias Deuse, MD, PhD, UCSF, San Francisco, CA, USA
Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA
Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI, USA
Esmé Dijike, PhD, University of Alberta, Edmonton, AB, Canada
Daniel Dilling, MD, Loyola University School of Medicine, Maywood, IL, USA
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada
Karen Doucette, MD, MSc, University of Alberta, Edmonton, AB, Canada
Mark Drazner, MD, UT Southwestern Medical Center, Dallas, TX, USA
Ignacio Echenique, MD, Cleveland Clinic Florida, Weston, FL, USA
Peter Eckman, MD, Minneapolis Heart Institute, Minneapolis, MN, USA
Sittaramesh Emani, MD, The Ohio State University, Columbus, OH, USA
Christopher Ensor, PharmD, BCPS-CV, University of Pittsburgh, Pittsburgh, PA, USA
Eric Epailly, MD, Les Hopitaux University, Strasbourg, France
Jennifer Eshelman, PharmD, Children's Hospital Colorado, Denver, CO, USA
Melanie Everitt, MD, Children's Hospital Colorado, Denver, CO, USA
Elie Fadel, MD, Hôpital Marie Lannenlongue, Le Plessis Robinson, France
Marny Fedrigo, MD, University of Padova, Padova, Italy
Brian Feingold, MD, MS, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA
David Feldman, MD, PhD, The Ohio State University, Columbus, OH, USA
Matthew Fenton, MRCPCH, Great Ormond Street Hospital, London, United Kingdom
Nowell Fine, MD, University of Calgary, Calgary, AB, Canada
Katrina Ford, BPharm, Great Ormond Street Hospital, London, United Kingdom
Laura Frye, MD, University of Chicago, Chicago, IL, USA
Louise Fuller, PT, Alfred Hospital, Melbourne, Australia
Maria Gazzaneo, MD, Baylor College of Medicine, Houston, TX, USA
Mahazarin Ginwalla, MD, University Hospitals Case Medical Center, Cleveland, OH, USA
Reda Girgis, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA
Allan Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia
Laurent Godinas, MD, CHU UCL Namur, Yvoir, Belgium
Hilary Goldberg, MD, Brigham and Women's Hospital, Boston, MA, USA
Daniel Goldstein, MD, Montefiore Medical Center, New York, NY, USA
Ranny Goldwasser, MD, University Children's Hospital, Heidelberg, Germany
José González, MD, Hospital Universitari de Bellvitge, Barcelona, Spain
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany
Kathleen Grady, PhD, APN, FAAN, Northwestern University, Chicago, IL, USA
Emily Granger, MBBS, FRACP, St. Vincent's Hospital, Sydney, Australia
Steven Greenway, MD, University of Calgary, Calgary, AB, Canada
Mark Greer, MB Chb, Hannover Medical School, Hannover, Germany
Aric Gregson, MD, UCLA, Los Angeles, CA, USA
Bartley Griffith, MD, University of Maryland, Baltimore, MD, USA
Jan Gummert, MD, PhD, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany
Dipankar Gupta, MBBS, DCH, MD, University of Florida, Gainesville, FL, USA
Ramsey Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
David McGiffin, MBBS, FRACS, The Alfred Hospital, Melbourne, Australia
Tanya McWilliams, MD, PhD, Auckland City Hospital, Auckland, New Zealand
Ernestina Melicoff-Portillo, MD, Baylor College of Medicine, Houston, TX, USA
Anna Meyer, MD, Leipzig Heart Center, Leipzig, Germany
Sebastian Michel, MD, Cardiac Surgery, Ludwig Maximilian University, Munich, Germany
Rachel Miller, MD, Duke University Medical Center, Durham, NC, USA
Robert Miller, University of Calgary, Calgary, AB, Canada
Sonia Mirabet, MD, PhD, Hospital de Sant Pau, Barcelona, Spain
Nader Moazami, MD, Cleveland Clinic, Columbus, OH, USA
Ezequiel Molina, MD, MedStar Washington Hospital, Washington, DC, USA
Robert Morlend, MD, UT Southwestern Medical Center, Dallas, TX, USA
Matthew Morrell, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Catherine Murks, PhD, APN, University of Chicago, Chicago, IL, USA
Nandini Nair, MD, PhD, Texas Tech University Health Sciences Center, Lubbock, TX, USA
Johan Nilsson, MD, PhD, Skanes University Hospital, Lund, Sweden
Meinoshin Okumura, MD, Osaka University Graduate School of Medicine, Osaka, Japan
Minoru Ono, MD, PhD, The University of Tokyo Hospital, Tokyo, Japan
Mustafa Ozbaran, MD, Ege University School of Medicine, Izmir, Turkey
Robert Padera, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA
Jay Pal, MD, PhD, University of Washington, Seattle, WA, USA
Maryse Palardy, MD, University of Michigan, Ann Arbor, MI, USA
Alessandro Palleschi, MD, Fondazione IRCCS Ca' Granda, Milano, Italy
Chetan Patel, MD, Duke University, Durham, NC, USA
Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA
Michael Petty, PhD, RN, CNS, University of Minnesota, Minneapolis, MN, USA
Richard Pierson, MD, University of Maryland, Baltimore, MD, USA
Sean Pinney, MD, Mount Sinai Hospital, New York, NY, USA
Barbara Pisani, DO, Wake Forest Baptist Medical Center, Winston Salem, NC, USA
Evgenij Potapov, MD, PhD, German Heart Center, Berlin, Germany
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy
Ioana Preston, MD, Tufts Medical Center, Boston, MA, USA
Lynn Punnoose, MD, Temple University, Philadelphia, PA, USA
Amresh Raina, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Navin Rajagopalan, MD, University of Kentucky, Lexington, KY, USA
Alexandra Rice, FRCPath, Harefield Hospital, Harefield, United Kingdom
Desiree Robson, RN, BSc (Hons), St Vincent's Hospital, Sydney, Australia
Anja Roden, MD, Mayo Clinic, Rochester, MN, USA
Joseph Rogers, MD, Duke University, Durham, NC, USA
Eulalia Roig, MD, Hospital Sant Pau, Barcelona, Spain
Sebastian Rojas, MD, Hannover Medical School, Hannover, Germany
Joseph Rossano, MD, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
Victor Rossel, MD, Hospital Del Salvador, Santiago, Chile
Bart Rottier, MD, University Medical Center, Groningen, Netherlands
Stuart Russell, MD, Johns Hopkins Medical Center, Baltimore, MD, USA
Diyar Saeed, MD, PhD, Dusseldorf University Hospital, Dusseldorf, Germany
Christopher Salerno, MD, St Vincent Heart Center, Indianapolis, IN, USA
Nitasha Sarswat, MD, University of Chicago, Chicago, IL, USA
Janet Scheele, MD, Children's National Health System, Washington, DC, USA
Sarah Schettle, PA-C, Mayo Clinic, Rochester, MN, USA
Christof Schmid, MD, University Medical Center, Regensburg, Germany
Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Sebastian Schulte Eistrup, MD, PhD, Schuechtermann Klinik, Bad Rothenfelde, Germany
Kurt Schumacher, MD, University of Michigan, Ann Arbor, MI, USA
Martin Schweiger, MD, Children's Hospital Zurich, Zurich, Switzerland
Nicolaus Schwkek, MD, Hannover Medical School, Hannover, Germany
Javier Segovia, MD, PhD, Hospital Puerta de Hierro, Madrid, Spain
Marc Semigran, MD, Massachusetts General Hospital, Boston, MA, USA
Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA
Sara Shumway, MD, University of Minnesota, Minneapolis, MN, USA
Jorge Silva Enciso, MD, UCSD, San Diego, CA, USA
ISHLT COMMITTEE ROSTERS

CORPORATE DEVELOPMENT COMMITTEE
Joseph Rogers, MD, Chair
Maryl R. Johnson, MD, ISHLT President
Andrew J. Fisher, FRCP, PhD, President-Elect
Amanda Rowe, ISHLT Executive Director

EDUCATION COMMITTEE
Christopher H. Wigfield, MD, FRCS(C/TH), Director of Educational Affairs (2018)
Esme Dijke, PhD, Committee Vice Chair (2018)
Andrew J. Fisher, FRCP, PhD, Board of Directors Liaison (2019)
Amanda Rowe, ISHLT Executive Director

Additional Committee Members
David Baran, MD (2019)
Jennifer Cowger, MD, MS (2019)
Goran Dellgren, MD, PhD (2018)
Howard J. Eisen, MD (2017)
Mardi Gomberg-Maitland, MD, MSc (2017)
Donna M. Mancini, MD (2018)
Geert Verleden, MD, PhD (2019)

GOVERNANCE COMMITTEE
Duane Davis, MD, MBA, Chair (2017)
Maryl R. Johnson, MD, ISHLT President (2018)
Andrew J. Fisher, FRCP, PhD, President-Elect (2019)

At Large Members
David O. Taylor, MD, Past President (2019)
Richard Kirk, FRCP, FRCPCH, Past Director (2017)
Stuart C. Sweet, MD, PhD, Past Secretary/Treasurer (2019)

GRANTS AND AWARDS COMMITTEE
Stephan M. Ensminger, MD, DPhil, Co-Chair (2017)
Kathleen Grady, PhD, APN, FAAN, Co-Chair (2018)
Daniel Kreisel, MD, PhD, Co-Chair (2019)
Jason D. Christie, MD, Board of Directors Liaison

Lead Reviewers
Andrew E. Gelman, PhD
Mark S. Slaughter, MD
Laurie D. Snyder, MD
Dirk Van Raemdonck, MD, PhD
Louise M. Fuller, PT
Josef Stehlik, MD, MPH

INTERNATIONAL AND INTER-SOCIETY COORDINATION COMMITTEE (I2C2)
Andreas Zuckermann, MD, Co-Chair (International) (2017)
Howard J. Eisen, MD, FAHA, FACC, FACP, Co-Chair (Inter-Societal) (2019)
Duane Davis, MD, MBA, Board of Directors Liaison
David O. Taylor, MD, Standards & Guidelines Committee Chair
Christopher H. Wigfield, MD, FRCS(C/Th), Director of Educational Affairs
Joseph Rogers, MD, Finance Committee Chair
Josef Stehlik, MD, MPH, Thoracic Registry Medical Director
Council Workforce Leaders
Bryan A. Whitson, MD, PhD, Basic Science & Translational Research Council (2017)
Daniel H. Kim, MD, Heart Failure & Transplantation Council (2018)
Martha L. Mooney, MD, Infectious Disease Council (2017)
Hirsch S. Mehta, Junior Faculty & Trainee Council (2019)
Sean Pinney, MD, Mechanical Circulatory Support Council (2017)
Rasha Adams, RN, Nursing, Health Sciences & Allied Health Council (2019)
Annalisa Angelini, MD, Pathology Council (2018)
James D. St. Louis, MD, Pediatric Thoracic Transplantation & Heart Failure Council (2018)
Douglas L. Jennings, PharmD, Pharmacy & Pharmacology Council (2018)
Manreet Kanwar, MD, Pulmonary Hypertension Council (2019)
Denis Hadjiliadis, MD, Pulmonary Transplantation Council (2017)

Ad Hoc Members
Jacob Lavee, MD (2017)
Lori J. West, MD, DPhil (2017)

Global Ambassadors
Alejandro Bertolotti, MD (Argentina) (2017)
Paolo Fernandes, MD, PhD (Brazil) (2017)
Douglas Greig, MD (Chile) (2017)
Adriana Torres Navas, MD (Colombia) (2017)
Karine Nubret, MD (France) (2017)
Denis Hadjiliadis, MD (Greece) (2017)
Sandeep G. Attawar, MD (India, New Delhi) (2017)
Yury Pya, MD (Kazakhstan) (2017)
Ashari Yunus, MD (Malaysia) (2017)
Amal A. Alothaibi, MD (Saudi Arabia) (2017)
Cumara C. Sivathasan, MBBS, FRCS (Singapore) (2017)
Ivan Knezevic, MD (Slovenia, Ljubljana) (2017)
Martin Schweiger, MD (Switzerland) (2017)

ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT (IMACS®) REGISTRY STEERING COMMITTEE
James K. Kirklin, MD, Chair (2018)
Craig Collum, MPH, Administrator to Dr. Kirklin (2018)
Rongbing Xie, MPH, Statistician (2018)
Ryan Cantor, MSPH, Consulting Statistician (2018)
Jeffrey J. Teuteberg, MD, Board of Directors Liaison

Additional Members
Francisco Arabia, MD, USA (2017)
Theo DeBy, MBA, Germany (2018)
Anne I. Dipchand, MD, Canada (2017)
Daniel J. Goldstein, MD, USA (2018)
Margaret M. Hannan, MD, Ireland (2017)
Ulrich P. Jorde, MD, USA (2017)
Robert L. Kormos, MD, USA (2018)
Lars H. Lund, MD, PhD, Sweden (2017)
Mandeep Mehran, MD, MBBS, FACC, FACP, USA (2018)
Chris J. Merry, MD, Australia (2017)
Takeshi Nakatani, MD, PhD, Japan (2018)
Stephan Schueler, MD, PhD, FRCS, United Kingdom (2018)
Cumara C. Sivathasan, MBBS, FRCS, Singapore (2018)
Jose A. Tallaj, MD, USA (2020)
Maryl R. Johnson, MD, ISHLT President, Ex-Officio Member
Amanda Rowe, Executive Director, Ex-Officio Member
INTERNATIONAL DCD REGISTRY STEERING COMMITTEE
Dirk Van Raemdonck, MD, PhD, Chair (2018)

Active Participating Centers (LUNG)
Allan R. Glanville, MBBS, MD, FRACP
Michael T. Musk, MBBS
Peter M. Hopkinds, FRACP
Gregory I. Snell, MD
Marcelo Cypel, MD
Shaf Keshavjee, MD, FRCSC
Michiel E. Erasmus, MD, PhD
Marshall I. Hertz, MD
Roger D. Yusen, MD, MPH
Kenneth R. McCurry, MD, FACS
Frank D’Ovidio, MD, PhD

Starting Up Centers (Heart)
Stephen R. Large, FRCS
Steven SL Tsui, MD, FRCS
Kumud K. Dhital, MD, PhD
Peter MacDonald, MD, PhD

INTERNATIONAL PEDIATRIC HEART FAILURE REGISTRY (IPHFR) STEERING COMMITTEE
Anne I. Dipchand, MD, Chair (2018)
Jeffrey J. Teuteber, MD, Board of Directors Liaison
Christopher Almond, MD (2018)
Scott Auerbach, MD (2018)
Estela Azeka, MD (2018)
Wida S. Cherikh, PhD
Robert Gajarski, MD (2017)
Richard Kirk, FRCP, FRCPCH (2018)
Yuk Law, MD (2017)
Angela Lorts, MD (2018)
Elfriede Pahl, MD (2017)
Christina VanderPluym, MD (2018)
Warren Zuckerman, MD (2017)

INTERNATIONAL THORACIC TRANSPLANT REGISTRY STEERING COMMITTEE
Josef Stehlik, MD, MPH, Medical Director & Chair (2017)
Daniel J. Goldstein, MD, Board of Directors Liaison (2018)

Associate Medical Directors
Lars H. Lund, MD, PhD, Adult Heart (Sept 2017)
Kiran K. Khush, MD, Adult Heart (Sept 2021)
Roger D. Yusen, MD, MPH, Adult Lung/Heart-Lung (Sept 2017)
Daniel C. Chambers, MBBS, MRCP, FRACP, MD, Adult Lung/Heart-Lung (Sept 2021)
Joseph W. Rossano, MD, Pediatric Heart (Sept 2019)
Samuel B. Goldfarb, MD, Pediatric Lung/Heart-Lung (Sept 2018)

Additional Members
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Outcomes (Sept 2018)
Bruno M. Meiser, MD, OEO Relations (Sept 2018)
Wida S. Cherikh, PhD, Biostatistics
Jaime Williamson, SAS Analyst
Anna Kucheryavaya, MD, Assistant Biostatistician
Lewis Rubin, MD (USA)
Stephan Schueler, MD, PhD, FRCS (UK)
Martin Schweiger, MD (Switzerland)
Keyur B. Shah, MD (USA)
Jacqueline M. Smits, MD, PhD (The Netherlands)
Josef Stehlik, MD, MPH (USA)
Jeffrey J. Teuteberg, MD (USA)
Jean Luc Vachiery, MD (Belgium)
Hector O. Ventura, MD (USA)
Geert Verleden, MD, PhD (Belgium)
Robin Vos, MD, PhD (Belgium)
Aaron Waxman, MD, PhD (USA)
Lori J. West, MD, DPhil (Canada)
Roger D. Yusen, MD, MPH (USA)
Michael Zakliczynski, MD (Poland)

REGISTRIES AND DATABASES COMMITTEE
Josef Stehlik, MD, MPH, Chair (July 2017)
Jeffrey J. Teuteberg, MD, Board of Directors Liaison
Wida S. Cherikh, PhD, Biostatistician for the International Thoracic, International Pediatric Heart Failure, and Donation After Cardiac Death Registries
James K. Kirklin, MD, IMACS Registry Committee Chair (2018)
Rongbing Xie, MPH, IMACS Registry Biostatistician (2018)
Anne I. Dipchand, MD, International Pediatric Heart Failure Registry Committee Chair (2018)
Dirk Van Raemdonck, MD, PhD, International Donation after Cardiac Death (DCD) Registry Committee Chair
Roger D. Yusen, MD, MPH, Additional Member

STANDARDS AND GUIDELINES COMMITTEE
David O. Taylor, MD, Chair (2019)
Maryl R. Johnson, MD, Past Chair & Board of Directors Liaison (2017)

Council Workforce Leaders
Keshava Rajagopal, MD, PhD, Basic Science & Translational Research Council (2018)
Hannah Copeland, MD, Heart Failure & Transplantation Council (2019)
Valentina Stosor, MD, Infectious Disease Council (2018)
Jose Nativi, MD, Junior Faculty & Trainee Council (2017)
David A. D’Alessandro, MD, Mechanical Circulatory Support Council (2018)
Annemarie Kaan, MCN, RN, Nursing, Health Sciences & Allied Health Council (2017)
Anja C. Roden, MD, Pathology Council (2019)
Steven Kindl, MD, Pediatric Thoracic Transplantation & Heart Failure Council (2019)
Kevin Daly, MD, Pediatric Thoracic Transplantation & Heart Failure Council (Non-voting mentee through 2017)
Robert L. Page, II, Pharm D, MS, Pharmacy & Pharmacology Council (2019)
Teresa De Marco, MD, FACC, Pulmonary Hypertension Council (2017)
Peter Hopkins, FRACP, Pulmonary Transplantation Council (2017)

LINKS NEWSLETTER EDITORIAL STAFF
Vincent Valentine, MD, Editor
Megan Barrett, Managing Editor

Senior Associate Editors
Pamela Combs, PhD, RN
Paul Corris, MB, FRCP
John Dark, MB, FRCS
Roger Evans, PhD
Allan Glanville, MBBS, MD, FRACP
Maryl Johnson, MD
Associate Editors
Manreet Kanwar, MD, Cardiology
Claudius Mahr, DO, Cardiology
Joshua Mooney, MD, Junior Faculty & Trainee
Stephanie Pouch, MD, Infectious Disease
Emily Stimpson, MSN, FN, CCTC, Nursing, Health Sciences & Allied Health
Maryanne R. Chrisant, MD, Pediatrics
Daniel F. Dilling, MD, Pulmonary Transplantation

International Correspondents Board
Zargham Ahmadi, MD (Iran)
Javier Carbone, MD, PhD (Spain)
Marco Masetti, MD, PhD (Italy)
Andreas Zuckermann, MD (Austria)

Communications Liaisons
Howard J. Eisen, MD, Basic Science & Translational Research Council
David P. Nelson, MD, Heart Failure & Transplantation Council
Saima Aslam, MD, MS, Infectious Disease Council
Jorge Silva Enciso, MD, Junior Faculty & Trainee Council
Evgenij Potapov, MD, PhD, Mechanical Circulatory Support Council
Erin Wells, SBN, RN, CCTC, CPN, Nursing, Health Sciences & Allied Health Council
Brandon Larsen, MD, PhD, Pathology Council
Martin Schweiger, MD, Pediatric Thoracic Transplantation & Heart Failure Council
Ed Horn, PharmD, BCPS, Pharmacy & Pharmacology Council
Amresh Raina, MD, Pulmonary Hypertension Council
Jussi Tikkanen, MD, PhD, Pulmonary Transplantation Council
ISHLT SCIENTIFIC COUNCIL OPERATING BOARDS

BASIC SCIENCE AND TRANSLATIONAL RESEARCH
Sonja Schrepfer, MD, PhD, Chair
Edward Cantu, III, MD, Vice Chair
Joshua M. Diamond, MD, Vice Chair Elect
Kimberly L. Gandy, MD, PhD, Past Chair
Stephan M. Ensminger, MD, DPhil, Board of Directors Liaison
Mary Porteous, MD, Education Workforce Leader
Bryan A. Whitson, MD, PhD, I2C2 Workforce Leader
Keshava Rajagopal, MD, PhD, Standards & Guidelines Committee Workforce Leader
Doris A. Taylor, PhD, Senior Advisor
Jeffrey L. Platt, MD, Senior Advisor
Howard J. Eisen, MD, FAHA, FACC, FACP, ISHLT Links Newsletter Liaison
Pradeep P. A. Mammen, MD, FACC, FAHA, Heart Failure & Transplantation Council Liaison
Orla Morrissey, MD, Infectious Diseases Council Liaison
Simon Pecha, MD, Junior Faculty & Trainee Council Liaison
J. Michael DiMaio, MD, Mechanical Circulatory Support Council Liaison
Monica Horn, RN, CCRN, CCTC, Nursing, Health Sciences & Allied Health Council Liaison
Annalisa Angelini, MD, Pathology Council Liaison
Carol K. Conrad, MD, Pediatric Thoracic Transplantation & Heart Failure Council Liaison
Tam Khuu, PharmD, BCPS, Pharmacy & Pharmacology Council Liaison
Aaron B. Waxman, MD, PhD, Pulmonary Hypertension Council Liaison
Joshua M. Diamond, MD, Pulmonary Transplantation Council Liaison

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
William R. Auger, MD, Chair

HEART FAILURE AND TRANSPLANTATION
Michael Pham, MD, MPH, Chair
Jignesh K. Patel, MD, PhD, Vice Chair
Monica M. Colvin, MD, Past Chair
Howard J. Eisen, MD, FAHA, FACC, FACP, Board of Directors Liaison
Bojan Vrtovec, MD, PhD, Education Workforce Leader
Daniel H. Kim, MD, I2C2 Workforce Leader
Hannah Copeland, MD, Standards & Guidelines Committee Workforce Leader
David P. Nelson, MD, ISHLT Links Newsletter Liaison
Pradeep P.A. Mammen, MD, FACC, FAHA, Basic Science & Translational Research Council Liaison
Marco Masetti, MD, PhD, Junior Faculty & Trainee Council Liaison
Quincy Young, PhD, RPsych, Nursing, Health Sciences & Allied Health Council Liaison

INFECTIOUS DISEASES
Paolo A. Grossi, MD, PhD, Chair
Stanley I. Martin, MD, Vice Chair
Me-Linh Luong, MD, Vice Chair Elect
Fernanda Silveira, MD, Past Chair
Lara Danziger-Isakov, MD, MPH, Board of Directors Liaison
Me-Linh Luong, MD, Education Workforce Leader
Martha Mooney, MD, I2C2 Workforce Leader
Valentina Stosor, MD, Standards & Guidelines Committee Workforce Leader
Saima Aslam, MD, MS, ISHLT Links Newsletter Liaison
Catherine Orla Morrissey, MD, Basic Science & Translational Research Council Liaison
Ignacio A. Echenique, MD, Junior Faculty & Trainee Council Liaison
PEDIATRIC THORACIC TRANSPLANTATION AND HEART FAILURE
Tajinder P. Singh, MD, MSc, Chair
Brian Feingold, MD, MS, Vice Chair
Carol K. Conrad, MD, Vice Chair Elect
Janet N. Scheel, MD, Past Chair
Christian Benden, MD, Board of Directors Liaison
Debra A. Dodd, MD, Education Workforce Leader
James D. St. Louis, MD, I2C2 Workforce Leader
Steven Kindel, MD, Standards & Guidelines Committee Workforce Leader
Kevin Daly, MD, Standards & Guidelines Committee Workforce Leader
Ryan Butts, MD, Pediatric Heart Failure Workforce Leader
Martin Schweiger, MD, ISHLT Links Newsletter Liaison
Carol K. Conrad, MD, Basic Science & Translational Research Council Liaison
Claire Irving, MBChB, MRCPCH, Junior Faculty & Trainee Council Liaison
Angela Lorts, MD, Mechanical Circulatory Support Council Liaison
Erin Wells, RN, Nursing, Health Sciences & Allied Health Council Liaison

PHARMACY AND PHARMACOLOGY
Walter Uber, PharmD, Chair
Adam B. Cochrane, PharmD, Vice Chair
Haifa Lyster, MSc, Vice Chair Elect
Tamara E. Claridge, PharmD, Past Chair
Tobias Deuse, MD, PhD, Board of Directors Liaison
Kyle L. Dawson, PharmD, Education Workforce Leader
Douglas L. Jennings, PharmD, I2C2 Workforce Leader
Robert L. Page, II, PharmD, MS, Standards & Guidelines Committee Workforce Leader
Edward Horn, PharmD, BCPS, ISHLT Links Newsletter Liaison
Tam Khuu, PharmD, BCPS, Basic Science & Translational Research Council Liaison

PULMONARY HYPERTENSION
Dana P. McGlothlin, MD, Chair
Jean-Luc Vachiery, MD, Vice Chair
Mardi Gomberg-Maitland, MD, MSc, Past Chair
Andrew J. Fisher, FRCP, PhD, Board of Directors Liaison
Ioana R. Preston, MD, Education Workforce Leader
Oksana A. Shlobin, MD, I2C2 Workforce Leader
Teresa De Marco, MD, FACC, Standards & Guidelines Committee Workforce Leader
Amresh Raina, MD, ISHLT Links Newsletter Liaison
Aaron B. Waxman, MD, PhD, Basic Science & Translational Research Council Liaison
Marco A. Caccamo, MD, Junior Faculty & Trainee Council Liaison
Rachel M. Crackett, MSc, Nursing, Health Sciences & Allied Health Council Liaison

PULMONARY TRANSPLANTATION
Cynthia J. Gries, MD, MSc, Chair
Ramsey R. Hachem, MD, Vice Chair
Michael Mulligan, MD, Past Chair
Peter M. Hopkins, FRACP, Board of Directors Liaison and Standards & Guidelines Committee Workforce Leader
Lorriana E. Leard, MD, Education Workforce Leader
Denis Hadjiliadis, MD, I2C2 Workforce Leader
Jonathan P. Singer, MD, MS, Quality of Life Workforce Leader
Jussi Tikkanen, MD, PhD, ISHLT Links Newsletter Liaison
Joshua Diamond, MD, Basic Science & Translational Research Council Liaison
Joshua J. Mooney, MD, Junior Faculty & Trainee Council Liaison
Tara R. Fuller, Nursing, Health Sciences & Allied Health Council Liaison
<table>
<thead>
<tr>
<th>Year</th>
<th>President</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981-1982</td>
<td>Michael Hess, MD</td>
</tr>
<tr>
<td>1982-1984</td>
<td>Jack Copeland, MD</td>
</tr>
<tr>
<td>1984-1986</td>
<td>Terence English, KBE, FRCS</td>
</tr>
<tr>
<td>1986-1988</td>
<td>Stuart Jamieson, MD, FRCS</td>
</tr>
<tr>
<td>1988-1990</td>
<td>Bruno Reichart, MD</td>
</tr>
<tr>
<td>1990-1991</td>
<td>Margaret Billingham, MD</td>
</tr>
<tr>
<td>1991-1992</td>
<td>Christian Cabrol, MD</td>
</tr>
<tr>
<td>1992-1993</td>
<td>John O'Connell, MD</td>
</tr>
<tr>
<td>1993-1994</td>
<td>Eric Rose, MD</td>
</tr>
<tr>
<td>1994-1995</td>
<td>John Wallwork, FRCS</td>
</tr>
<tr>
<td>1995-1996</td>
<td>Sharon Hunt, MD</td>
</tr>
<tr>
<td>1996-1997</td>
<td>William Baumgartner, MD</td>
</tr>
<tr>
<td>1997-1998</td>
<td>Leslie Miller, MD</td>
</tr>
<tr>
<td>1998-1999</td>
<td>Alan Menkis, MD, FRCS(C)</td>
</tr>
<tr>
<td>1999-2000</td>
<td>Robert L. Kormos, MD, FRCS(C), FAHA</td>
</tr>
<tr>
<td>2000-2001</td>
<td>Anne Keogh, MBBS, MD</td>
</tr>
<tr>
<td>2001-2002</td>
<td>James B. Young, MD</td>
</tr>
<tr>
<td>2002-2003</td>
<td>Stephan Schueler, MD, PhD, FRCS</td>
</tr>
<tr>
<td>2003-2004</td>
<td>Jon Kobashigawa, MD</td>
</tr>
<tr>
<td>2004-2005</td>
<td>Alec Patterson, MD</td>
</tr>
<tr>
<td>2005-2006</td>
<td>Mark L. Barr, MD</td>
</tr>
<tr>
<td>2006-2007</td>
<td>Robert C. Robbins, MD</td>
</tr>
<tr>
<td>2007-2008</td>
<td>Paul A. Corris, MB FRCP</td>
</tr>
<tr>
<td>2008-2009</td>
<td>Mandeep R. Mehra, MD, MBBS, FACC, FACP</td>
</tr>
<tr>
<td>2009-2010</td>
<td>James K. Kirklin, MD</td>
</tr>
<tr>
<td>2010-2011</td>
<td>John Dark, MB, FRCS</td>
</tr>
<tr>
<td>2011-2012</td>
<td>Lori J. West, MD, DPhil</td>
</tr>
<tr>
<td>2012-2013</td>
<td>David O. Taylor, MD</td>
</tr>
<tr>
<td>2013-2014</td>
<td>Allan R. Glanville, MBBS, MD, FRACP</td>
</tr>
<tr>
<td>2014-2015</td>
<td>Hermann Reichenspurner, MD, PhD</td>
</tr>
<tr>
<td>2015-2016</td>
<td>Duane Davis, MD, MBA</td>
</tr>
</tbody>
</table>
PAST PROGRAM CHAIRS

1981  San Francisco, CA  Edward B. Stinson, MD and Michael L. Hess, MD
1982  Phoenix, AZ  Michael Kaye and Bernard Gersh
1983  New Orleans, LA  Stuart W. Jamieson, MD and Mark E. Thompson, MD
1984  New York, NY  Randall B. Grieppe, MD
1985  Anaheim, CA  Terence A. H. English and Hillel Laks
1986  New York, NY  Terence A. H. English
1987  New Orleans, LA  John C. Baldwin, MD
1988  Los Angeles, CA  John C. Baldwin, MD
1989  Munich, Germany  Bruno Reichart, MD
1990  San Diego, CA  D. Glenn Pennington, MD
1991  Paris, France  John B. O’Connell, MD
1992  San Diego, CA  Eric A. Rose, MD
1993  Boca Raton, FL  Maria Rosa Costanzo, MD
1994  Venice, Italy  John Wallwork, MBChB, FRCS
1995  San Francisco, CA  Leslie W. Miller, MD
1996  New York, NY  William A. Baumgartner, MD
1997  London, England  Stephan Schueler, MD
1998  Chicago, IL  James B. Young, MD
1999  San Francisco, CA  Mark L. Barr, MD
2000  Osaka, Japan  Jon Kobashigawa, MD
2001  Vancouver, Canada  David O. Taylor, MD
2002  Washington, DC  Robert C. Robbins, MD
2003  Vienna, Austria  Bruce R. Rosengard, MD
2004  San Francisco, CA  Mandeep R. Mehra, MD
2005  Philadelphia, PA  Shaf Keshavjee, MD
2006  Madrid, Spain  John Dark, MB, FRCS
2007  San Francisco, CA  Duane Davis, MD
2008  Boston, MA  Lori J. West, MD, DPhil
2009  Paris, France  Randall C. Starling, MD, MPH
2010  Chicago, IL  Hermann Reichenspurner, MD, PhD
2011  San Diego, CA  Richard N. Pierson, III, MD
2012  Prague, Czech Republic  Stuart C. Sweet, MD, PhD
2013  Montreal, Canada  Allan R. Glanville, MBBS, MD, FRACP
2014  San Diego, CA  Jason D. Christie, MD
2015  Nice, France  Andreas Zuckermann, MD
2016  Washington, DC  Andrew J. Fisher, FRCP, PhD
JOURNAL AND LINKS NEWSLETTER EDITORS

JOURNAL OF HEART AND LUNG TRANSPLANTATION
1981-1985  Jacques G. Losman, MD
1986-1994  Michael P. Kaye, MD
1995-1999  Maria Rosa Costanzo, MD
2000-2009  James K. Kirklin, MD
2010-Present  Mandeep R. Mehra, MD

LINKS NEWSLETTER
2008-2011  David S. Feldman, MD, PhD
2011-Present  Vincent G. Valentine, MD

REGISTRY MEDICAL DIRECTORS

INTERNATIONAL REGISTRY FOR HEART AND LUNG TRANSPLANTATION
1987-1993  Michael P. Kaye, MD
1993-2001  Jeffrey D. Hosenpud, MD
2001-2012  Marshall I. Hertz, MD
2012-Present  Josef Stehlik, MD, PhD
ISHLT AWARD RECIPIENTS

OUTSTANDING ACHIEVEMENT AWARDS:

ISHLT PIONEER AWARD
2000  Christiaan Barnard, MD
       Joel D. Cooper, MD
       Norman E. Shumway, MD
2002  Michael DeBakey, MD
       Bruce A. Reitz, MD
2006  Leonard L. Bailey, MD
2008  Richard E. Lower, MD
2009  Christian E. A. Cabrol, MD
2011  Elizabeth Hammond, MD
2013  Jack G. Copeland, MD
2015  Bruno Reichart, MD
2016  Sir Roy Calne, FRCP, FRCS, FRS

ISHLT LIFETIME ACHIEVEMENT AWARD
1996  Norman Shumway, MD
1999  Keith Reemtsma, MD
2004  Sir Magdi Yacoub, MD
2010  Margaret Billingham, MD
2012  Sharon Hunt, MD
2014  Sir Terence English, KBE, FRCS
2016  Adrian Kantrowitz, MD
       Jean Kantrowitz, MPH

ISHLT LIFETIME SERVICE AWARD
1996  Michael P. Kaye, MD
1997  Jacques G. Losman, MD

EMERITUS MEMBERSHIP
Margaret D. Allen, MD
Christian Cabrol, MD
Sir Terence English, KBE, FRCS
Albert J. Guerraty, MD
Sharon A. Hunt, MD
Carl V. Leier, MD
Bruno Reichart, MD
Marlene Rose, PhD
John Wallwork, FRCS
Elaine M. Winkel, MD
Prof. Magdi Yacoub, MD
GRANTS AND SCHOLARSHIPS:

ISHLT NORMAN E. SHUMWAY CAREER DEVELOPMENT AWARD
2000  Gordon D. Wu, MD (supported by Roche)
2002  Anthony Azakie, MD (supported by Roche)
2004  Allan M. Ramirez, MD (supported by Novartis Pharma)
2006  Dennis W. Wigle, MD, PhD (supported by Astellas Pharma)
2008  Glen Westall, MD, PhD (supported by Roche)
2010  Sonja Schrepfer, MD, PhD (supported by Astellas)
2012  Tereza Martinu, MD, PhD
2014  Keshava Rajagopal, MD, PhD
2015  Xingan Wang, MD, PhD
2016  Stephen Juvet, MD, PhD, FRCPC
2017  Nicole Valenzuela, PhD, D(ABHI) (supported by a gift from Enduring Hearts)

ISHLT JOEL D. COOPER CAREER DEVELOPMENT AWARD
2017  Keki Blasara, MD

ISHLT NURSING RESEARCH GRANT AWARD
1997  Eileen Collins, RN, PhD
1998  Katherine St. Clair, RN, MSN
1999  Jeanne Salyer, PhD
2000  Nancy M. Albert, MSN, RN
2001  Lynn Doering, RN, DNSc
2002  Annette J. De Vito Dabbs, RN, MN, PhD
2003  Diane H. Leloudis, RN, MSN
       Janet E. Madill, PhD
2004  Deidre E. Logan, PhD
2005  Annemarie F. Kaan, MCN
2006  Thierry Troosters, PhD
2007  Mi-Kyung Song, PhD
2008  Stacey M. Pollock-BarZiv, PhD
2009  Jane Maclver, RN, MSc
2010  Heike Spaderna, PhD
       Gerdi Weidner, PhD
2011  Christiane Kugler, PhD (supported by CSL Behring)
       Hilde Bollen, RN
2012  Lut Berben, PhD, RN (supported by CSL Behring)
       Connie White-Williams, PhD, RN, FAAN
2013  Jo Wray, PhD
       Jane Haines, DNP, RN, CMSRN
2014  Lea Ann Matura, PhD, RN
2015  JiYeon Choi, PhD, RN
2016  Mohammad Alrawashdeh, BSN, MSN
2016  Melissa Cousino, PhD (Jointly Funded by Enduring Hearts)
2017  Samantha Anthony, PhD, MSW

ISHLT RESEARCH FELLOWSHIP AWARD
1995  Frances L. Johnson, MD (supported by Ortho-Biotech)
1996  Tuija S. Ikonen, MD (supported by Roche)
       Andrew F. Pierre, MD (supported by Ortho-Biotech)
1997  Jonathan Chen, MD (supported by Roche)
       Alyssa M. Krasinskas, MD (supported by Astellas)
       Owen T. Lawrence, MD (supported by Ortho-Biotech)
       Anne K. Raisanen-Sokolowski, MD (supported by Roche)
1998  Kelly S.A. Blair, MD (supported by Roche)
<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007</td>
<td>Beth D. Kaufman, MD</td>
</tr>
</tbody>
</table>
| 2008 | Cynthia Gries, MD, MSc  
|      | Scott Halpern, MD, PhD |
|      | Josef Stehlik, MD, MPH |
| 2010 | Jennifer Conway, MD, FRCP  
|      | Kiran K. Khush, MD, MAS |
| 2011 | Jose Nativi, MD      |
| 2012 | Erin M. Lowery, MD  
|      | Omar E. Wever-Pinzon, MD |
| 2013 | Chesney Castleberry, MD  
|      | Eugene DePasquale, MD |
|      | Aaron Healy, MD |
| 2014 | Marian Urban, MD  
|      | Miranda Paraskeva, MBBS |
|      | Hrishikesh Kulkarni, MD |
|      | Agnieszka Ciarka, MD, PhD |
| 2015 | Livia Goldraich, MD, MSc  
|      | Deipanjan Nandi, MD, MSc |
|      | Evan Kransdorf, MD, PhD |
|      | Manreet Kanwar, MD  
|      | Natasha Loghmanpour, PhD |
|      | Alexander Bernhardt, MD |
|      | Jong-Chan Youn, MD, PhD |
| 2016 | Sai Bhagra, MBBS, MRCP  
|      | Forum Kamdar, MD |
|      | Marco Masetti, MD, PhD |
|      | Joshua Mooney, MD |
|      | Edit Nagy, MD, PhD |
| 2017 | Laith Alshawabkeh, MD, MSc  
|      | Yuka Furuya, MD |
|      | Christian Heim, MD  
|      | Monique Robinson, MBBS, MRCP, DPhil |
|      | Lorenzo Zaffiri, MD, PhD |

**ISHLT/BAYER PULMONARY HYPERTENSION RESEARCH GRANT AWARD**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>Benjamin Freed, MD</td>
</tr>
</tbody>
</table>

**ISHLT/O.H. FRAZIER AWARD IN MCS TRANSLATIONAL RESEARCH Sponsored by Medtronic (formerly ISHLT/O.H. FRAZIER AWARD IN MCS TRANSLATIONAL RESEARCH Sponsored by HeartWare and ISHLT/HeartWare Award for Translational Research in MCS)**

<table>
<thead>
<tr>
<th>Year</th>
<th>Name and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>Leigh Reardon, MD</td>
</tr>
<tr>
<td>2015</td>
<td>Alexander Bernhardt, MD</td>
</tr>
<tr>
<td>2016</td>
<td>Todd Dardas, MD, MS</td>
</tr>
<tr>
<td>2017</td>
<td>Yasuhiro Shudo, MD, PhD</td>
</tr>
</tbody>
</table>
**ISHLT Branislav Radovancevic Memorial Fellowship Grant (supported by Thoratec)**

2009  Sasa D. Borovic, MD  
2010  Iki Adachi, MD  
2012  Antigone Koliopoulou, MD  
2014  Masahiro Ono, MD, PhD  

**ISHLT INTERNATIONAL TRAVELING SCHOLARSHIP AWARD**

2011  Stephanie T. Yerkovich, PhD  
Sarah E. Gilpin, PhD  
Kimberly M. Derkatz, BNSc  
Jennifer Conway, MD, FRCPC  
2012  Ramin E. Beygui, MD  
Kevin C. Carney, MSN  
Alexandre Souza Cauduro, MD  
Esme Dijke, PhD  
Ana Belen Mendez, MD  
David Schibilsky, MD  
Aleen Siddique, MBBS  
Amparo Solé, MD, PhD  
Manon Huibers, MSc  
Daniel R. Goldstein, MD  
Laveena Munshi, MD, FRCPC  
Marco Masetti, MD  
Rochelle M. Gellatly, PScPharm, ACPR, PharmD  
2013  Alison Gareau, MSc  
Erin Schumer, MD, MS  
Bojan Vrtovec, MD, PhD  
Marsha Renikunta, PhD (student)  
Katie Morley, BA(Hons), RCN, MA  
Ali Yeginsu, MD  
Fabrizio Gandolfo, MD  
Marian Urban, MD  
Alexander Bernhardt, MD  
Victor Rossel, MD  
Mohammed Quader, MD  
2014  Marny Fedrigo, MD, PhD  
Zachary Kon, MD  
Evgenios Neofytou, MD  
Dong, Wang, MD  
Stephen Clark, DM, FRCS  
Caroline Patterson, BMBS, BMedSci, MRCP  
Tahaunty Pena, MD  
2015  Oisin O’Connell, MD, MRCPI  
Lucas Van Aelst, MD, PhD  
Arezu Aliabadi, MD  
Timothy Sladden, MBBS, BVSc  
Bao Tran, MD  
L G Saptharishi, MD, DM  
Allison Carroll, MD  
Akshay Pendyal, MD  
Stefania Paolillo, MD, PhD  
Soumitra Sinha Roy, MD  
2016  Lucas Van Aelst, MD, PhD  
Espeed Khoshin, MB ChB, MD, FRCS  

**ISHLT LEACH-ABRAMSON-IMHOFF LINKS TRAVEL AWARDS**

2012  Tereza Martinu, MD, Writer of the Year  
Stanley I. Martin, MD, First Runner-Up  
Luciano Potena, MD, PhD, First Runner-Up
Nancy P. Blumenthal, CRNP, Honorable Mention
Bronwyn J. Levvey, RN, Honorable Mention
Javier Carbone, MD, PhD, Honorable Mention
Stavros G. Drakos, MD, Honorable Mention
Daniel F. Dilling, MD, Honorable Mention
2013 Michele Estabrook, MD, Writer of the Year
Melanie Everitt, MD, First Runner-Up
Christina Migliore, MD, First Runner-Up
Veronica Franco, MD, Honorable Mention
Manreet Kanwar, MD, Honorable Mention
Luciano Potena, MD, PhD, Honorable Mention
Macé Schuurmans, MD, Honorable Mention
Jeffrey J. Teuteberg, MD, Honorable Mention
2014 Christopher R. Ensor, PharmD, BCPS-CV, Writer of the Year
Amanda Ingemi, PharmD, First Runner-Up
Simon Urschel, MD, Honorable Mention
2015 Pamela S. Combs, PhD, RN, Writer of the Year
Manreet Kanwar, MD, First Runner-Up
Oveimar De la Cruz, MD, Honorable Mention
Heather T. Henderson, MD, Honorable Mention
Simon Urschel, MD, Honorable Mention
Erin Wells, RN, BSN, CPN, Honorable Mention
2016 Kyle Dawson, PharmD, MBA, BCPS, Writer of the Year
Adam Cochrane, PharmD, BCPS, First Runner-Up
Christa Kirk, PharmD, First Runner-Up
Angela Velleca, RN, BSN, CCTC, Honorable Mention
Erin Wells, RN, BSN, CPN, Honorable Mention
2017 Quincy Young, PhD, RPsych, Writer of the Year
Monica Horn, RN, First Psychopharmacology
Melissa Cousino, PhD, Honorable Mention
Erin Wells, RN, BSN, CPN, Honorable Mention

ABSTRACT AWARDS:

PHILIP K. CAVES AWARD
1983 Robbin G. Cohen, MD
1984 Hermann Reichenspurner, MD
1985 Michael A. Breda, MD
1986 Stuart J. Knechtle, MD
1987 Wim Van Der Bij, MD
1988 Charles D. Fraser, Jr., MD
1989 A.M. Wood, MD
1990 Andres J. Duncan, MD
1991 A. Jiminez, MD
1992 David P. Kapelanski, MD
1993 David Marshman, MD
1994 Jobst Winter, MD
Alain Chapelier, MD
1995 Elizabeth A. Davis, MD
1996 Moninder S. Bhabra, MD
1997 Simon D. Eiref, MD
1998 Carla C. Baan, MD
1999 Joerg Koglin, MD
2000 Michael P. Fischbein, MD
2001 Alexander S. Krupnick, MD
2002 Peter Blaha, MD
2003 Sigrid Sandner, MD
2004 M.D. Peterson, MD
2005 Sigrid Sandner, MD
Frank D'Ovidio, MD  
2006  Gregor Warnecke, MD  
2007  Heather E. Merry, MD  
2008  Satish N. Nadig, MD  
2009  Howard Huang, MD  
2010  Tobias Deuse, MD, PhD  
2011  Ankit Bharat, MD  
2012  Simo Syriälä, MD  
2013  Alexey Dashkevich, MD  
2014  Jessica Spahn  
2015  Simon Pecha, MD  
2016  Corey E. Tabit, MD

NURSING, HEALTH SCIENCES & ALLIED HEALTH EXCELLENCE IN RESEARCH AWARD
2005  Mary Amanda Dew, PhD  
2006  Kathleen L. Grady, PhD, RN  
2007  Christiane Kugler, PhD  
2008  Annette DeVito Dabbs, RN, PhD  
2009  Connie White-Williams, MSN  
2010  Bronwyn Levvey, RN  
2011  Samantha J. Anthony, PhD, MSW  
2012  Kate Hayes, MPhysio (Cardio)  
2013  Jane Haines, DNP, RN, CMSRN  
2014  Louise Fuller, PT  
2015  Catherine Murks, PhD, APN  
2016  Fabienne Dobbels, MSc, PhD

JFTC CLINICAL CASE DILEMMAS IN THORACIC TRANSPLANTATION BEST PRESENTATION AWARD
2011  Michelle M. Kittleson, MD, PhD  
2012  Erin Albers, MD  
2013  Mustafa Ahmed, MD  
2014  Lauren Sacha  
2015  Ankit Bharat, MD  
2016  Yasufumi Goda, MD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCSD PAPER AWARD (supported by Thoratec)
2009  Nishant Shah, MD  
2010  Jose N. Nativi, MD  
2012  Arun Raghav Mahankali Sridhar, MD, MPH  
2013  Claire Watkins, MD  
2014  Jason O. Robertson, MD
ACCREDIDATION INFORMATION
CONTINUING MEDICAL EDUCATION INFORMATION

ACCME Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and allied health professionals.

CME Credit Designation Statement
ISHLT designates this live activity for a maximum of 32 AMA PRA Category 1 Credits™. Participants should claim only the credit commensurate with the extent of their participation in the activity.

ABTC Accreditation
The ABTC Board of Governors has granted a total of 32.0 Category 1 Continuing Education Points for Transplant Certification (CEPTCs) to the International Society for Heart & Lung Transplantation’s ISHLT 37th Annual Meeting and Scientific Sessions.

ACPE Accreditation
Pharmacists
Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 18.5 contact hours. Full attendance is required. No partial contact hours will be awarded for partial attendance. Unique Activity Numbers: 0453-9999-17-002-P through 0453-9999-17-039-L04-P.

ANCC Accreditation
Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by Amedco and the International Society for Heart and Lung Transplantation (ISHLT). Maximum of 32.00 contact hours.

Disclosure
Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Educational Objectives
The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

Educational Goals
The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience
The audience for this program includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives
1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical
techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from end stage heart and lung disease

2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies, outcome implications, and psychosocial management strategies for patients with end stage heart and lung failure.

3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end stage heart and lung disease management and prevention.
UNRESTRICTED EDUCATIONAL GRANTS

The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their unrestricted educational grants in support of the 37th Annual Meeting and Scientific Sessions:

Actelion Pharmaceuticals  
Bayer  
Gilead Sciences  
United Therapeutics
COMMERCIAL SUPPORT

The International Society for Heart and Lung Transplantation is grateful for the support of the following companies for the Society and its endeavors in 2017:

**Tier 1**
Medtronic

**Tier 2**
Abbott
Actelion Pharmaceuticals
Bayer
United Therapeutics

**Tier 3**
Gilead Sciences
Transmedics

**Tier 4**
Abiomed
Genentech
One Lambda/Thermo Fisher
XVIVO
Basic Science and Translational Research
The basic science and translational research symposia will feature diverse and dynamic speakers who are internationally recognized leaders in the field. We hope that each session will bring together in one room basic scientists as well as clinical researchers and clinicians who wish to further discuss and explore topics in heart and lung failure and transplantation. In Not CAVing to CLADtastrophy: Emerging Mechanisms in Chronic Heart and Lung Allograft Disease, experts will review endothelial biology, innate immunity, and antibody-based immunology in both heart and lung allograft dysfunction. The speakers will also explore the potential clinical implications of the available data. How to Mend a Broken Heart: Approaches for Cardiac Regeneration will be an exciting state-of-the-art set of lectures by thought-provoking speakers and experts in tissue engineering and cell therapy for heart failure who will discuss hurdles and perspectives of stem cell therapy on the way to clinical application. We will explore the evolving field of the microbiome in Living in a 'Bacterial' World: Microbiome in Thoracic Transplantation. The intricacies of the microbiome’s effects on health disease, on post-transplant immunity, and specifically on heart and lung transplantation will be addressed. In addition to these three primary symposia, other talks focused on basic and translational research have been incorporated into other symposia in order to create a well-rounded, high-quality program for the attendees.

Heart Failure and Transplantation
Our goal is to advance attendee’s knowledge of specific heart failure entities and controversies in heart transplantation. We begin with Cardiogenic Shock: Types, Teams and Tactics – defining shock types, care delivery and bridging strategies. Three additional symposia - 1) Getting to the Heart of Muscular Dystrophies, 2) Chagasic Cardiomyopathy: Lessons to Be Learned, and 3) The Tsunami of Adult Congenital Heart Disease Patients Who Need Advanced Therapies: Are We Prepared? – will explore less well known but growing etiologies of heart failure and their management, including the use of circulatory support and implications for post-transplant management. As an international community, we share a donor organ shortage, and the symposium Making Every Heart Count will discuss optimizing the use of donor organs. Controversy remains about when to proceed with combined heart-lung, heart-kidney, or heart-liver transplantation, topics that will be tackled in A Tale of Two Organs: Selecting and Managing Multi-Organ Transplant Recipients. To round things out, two symposia will be devoted to topics where consensus conferences have been held, but we still have a lot to learn: PGD and Vasoplegia After Heart Transplantation: Sink or Swim and Dealing with Antibodies Before and After Heart Transplant: Do We Have New Arrows in our Quiver? Join us in San Diego for the opportunity of a lifetime to learn from each other!

Infectious Diseases
ID content at ISHLT 2017 will kick off with the ISHLT Academy: Core Competencies in Infectious Diseases all day on Tuesday (separate registration required). The remainder of the meeting will feature an exciting line-up of ID content throughout the program, concentrated on the first two days of the meeting to make access to the presentations as convenient as possible for those ID specialists who cannot commit a week away from work. We start with a joint symposium featuring ISHLT and ESCMID speakers discussing Ongoing Challenges in Transplant Infectious Diseases, including fungi, multidrug resistant bacteria, and viruses including HCV, HIV, and EB. Following that we present Those Darn CARVs and learn about respiratory viruses in lung transplantation, the clinical and basic science correlations with CLAD, as well as treatment options and novel therapeutics in the pipeline. We then go Around the World in 80 Days to learn from experts about transplantation in areas endemic for Zika virus, tuberculosis, and HBV along with providing valuable advice for our patients when they travel. Mycobacterium abscessus has come of age with its very own symposium where we learn about Taming of the Shrew, with talks on epidemiology, clinical manifestations, and therapeutics. We end with a fiery debate to settle the issue of whether patients infected with M. abscessus can be safely transplanted. Other content that will be of interest to ID attendees includes a symposium dedicated to Chagasic cardiomyopathy, a sunrise symposium on HIV and cardiothoracic transplantation, and presentations on the respiratory microbiome and virome analysis for monitoring of post-transplant immune status.

Lung Transplantation
In times of a changing landscape in lung transplant management, this year’s lung transplant symposia will focus on important universal themes, including careful recipient selection, sensible donor allocation, safe peri-transplant ECMO use, pragmatic post-transplant treatment strategies and meticulous post-transplant follow-up. Excellent speakers will highlight the do’s and don’ts in There Is No Such Thing as Perfect: Selecting Recipients for Lung Transplantation, with emphasis on non-standard, controversial, rare or difficult transplant referrals. Recent results of implementing the 2015 US Lung Allocation Score model will be discussed in Lung Allocation Scores: Making the Complex Simple, or Just the Simple Complex? but will also address how to further improve equity in organ allocation world-wide. Practicalities and controversies of ECMO bridging to transplant, as well as its post-transplant use, will be debated in ECMO in Lung Transplantation: Sensational Success or Fantastic Failure? Light will be shed on novel post-transplant treatment strategies in Extracorporeal Photophoresis: Shedding Light on Rejection? and in Bench to
Bedside: How Advances in Immunobiology Shape the Care of Today’s Lung Transplant Recipients. Finally, the need for a holistic approach to patient care will be addressed in Thinking Outside the Box: Extra-Pulmonary Management in Lung Transplantation, focusing on the most common extra-pulmonary problems encountered in lung transplant recipients during follow-up. We are convinced that the meaningful reflections on these themes presented during this meeting will positively shape the daily care of all our lung transplant recipients.

Mechanical Circulatory Support
New ideas in MCS will be presented at ISHLT 2017 in San Diego. The symposium Mechanical Circulatory Support - The Interface of Design and Outcome will discuss the physical possibilities and ideas involved in designing mechanical pumps to perform better, reduce adverse events and become better connected to patients. In To Pulse or Not to Pulse? That is the Question, we will focus on the impact of pulsatility on brain and blood vessel function, as well as the design and rationale for pulsatile and counterpulsation technology. Dr. Mandep Mehra will talk about pulsatility from a scientific and existential perspective. Walk with Me: Exercise Physiology in the VAD Patient will look at the physiology of exercise in LVAD patients, delving into the increasingly complex world of antibodies in MCS patients. More LVAD complications will be explored in the Aiming off Target symposium, focusing on the non-cardiac consequences of LVADs. Finally, a joint ISHLT/ICCAC symposium will involve members from both societies looking at optimizing outpatient strategies in managing LVAD patients. With these and other symposia, we believe the ISHLT 2017 MCS symposia will have something for everyone.

Nursing, Health Sciences and Allied Health
Optimizing outcomes is a multidisciplinary endeavor that needs investments along the transplant continuum. Pre-transplant, there are many psychosocial risk factors that can be targeted for intervention. When Should We Call It Quits? The Efficacy of Interventions to Ameliorate Psychosocial Risk Factors will review the efficacy of treatments available to ameliorate psychosocial risk factors. The state-of-the-art of e-health technology in delivering care will be discussed in E-health, Wearables, Social Media and Big Data in Transplantation: Fancy Toys or True Care Innovations? Interactive communication options via social media and the value of the big data for transplantation will also be explored. Patient Reported Outcomes (PRO) are increasingly used to capture outcomes in transplantation. Completing the Picture: Patient Reported Outcomes as an Essential Source of Information in Evaluating Transplantation Outcomes will provide insights in the concept, measurement and application of PROs. Outcomes of pediatric transplant patients may be jeopardized due to specific challenges related to neurocognitive development, problems in communication with health care workers, and transition. Live Long and Prosper: Thriving after Pediatric Transplantation will focus on the psychosocial, behavioral challenges, as well as communication and developmental issues in pediatric transplant patients. Specific attention will be given to adolescence and models for transition.

Pathology
This year’s pathology symposium, Let’s Get Personal! Precision Diagnostics in Thoracic Transplantation, combines pathology and basic science and covers the topical issue of precision medicine/diagnosis for delivering personalized treatment, molecular diagnosis including cell free DNA (liquid biopsies), microRNA, next generation sequencing, and transcriptome analysis of biopsy material. A highlight will be the future possibilities with genome editing using CRISPR-Cas9 technology. A Sunrise Symposium, Mixed Rejection (MR) of the Cardiac Allograft: The Next Frontier, will discuss the relevance of mixed cellular and antibody mediated rejection in relation to diagnosis, management, and clinical outcomes.

Pediatric Thoracic Transplantation and Heart Failure
Difficult clinical situations sometimes require complex solutions. This year, the pediatric symposia will delve into difficult clinical situations that we all face in our practices. The Failing Fontan: Where Do We Go from Here? will discuss optimization of Fontan patients prior to transplant, timing of transplant listing, and multi-organ transplant options, as well as examine programmatic issues with taking on Fontan patients. HLA, AMR and DSA – Approaching Antibodies in Kids will examine antibodies before and after transplant, including how to measure antibodies, how to manage the allosensitized patient before transplant, and how to handle donor-specific antibodies and antibody-mediated rejection. Upcoming Opportunities and Challenges in Pediatric Lung Transplantation will address bridging to lung transplant via ECMO, changing indications in pediatric lung and heart-lung transplant, the limits of ABO-incompatible lung transplantation, and the Potts shunt in children with pulmonary hypertension. Lastly, Live Long and Prosper: Thriving after Pediatric Transplantation will include discussions of neurodevelopmental outcomes, the role of exercise and sports, recommendations for communicating with teenagers and young adults, and approaches for transition of children to adult transplant care.

Pharmacy and Pharmacology
Pharmacy and pharmacology will be the buzz of the meeting with four symposia appealing to all areas of the ISHLT membership. In our Thursday afternoon symposium, Weeding Out Fact from Fiction: Exploring the Highs and Lows of Marijuana Use in the Transplant Population, we will explore whether or not marijuana in all its forms is actually
detrimental for our patients and how programs can navigate this legal and clinical minefield. Back by popular
demand, join us at the Thursday Sunrise symposium for Lifecycle Journey of Thrombosis in Mechanical Circulatory
Support Patients. We discuss the latest insights into the science of thrombus formation and how surgical techniques
and medications can combine to give the best outcomes for our patients. The HOPE act assures that HIV and
Transplantation Isn’t Going Away and our Friday Sunrise symposium focuses the clinician on this vital topic. Experts
will provide clarity on the burning questions including: How should end-stage HIV associated lung and heart disease be
optimally managed? What unique infectious risks do HIV positive donors and recipients present, and how can the
transplant and HIV medications be managed in tandem to optimize care? During our Saturday Sunrise session, Pregnant
- Scared? So Are We, an expert panel will present the facts of life for our female transplant and CHD populations, many
of whom can now consider pregnancy. We will present the best and safest multidisciplinary management of pregnancy
after transplantation.

Pulmonary Hypertension
Pulmonary hypertension is once again at the forefront of the ISHLT Scientific Sessions with six outstanding and
provocative symposia! Symposia will explore current controversies in chronic thromboembolic disease, intricacies of
ECMO in pre-capillary pulmonary hypertension, as well as novel cardiopulmonary hemodynamics and their impact
on right ventricular and kidney function. A sunrise symposium will highlight similarities and differences in treatment of
children and adults with pulmonary hypertension focusing on the strategies to adopt from each other’s practices. This
year, we present a unique joint symposium of the ISHLT in partnership with the Pulmonary Hypertension
Association (PHA) which, along with the always exciting “Great Debates in Pulmonary Hypertension,” are two
symposia that are NOT TO BE MISSED! We look forward to seeing you in sunny San Diego!
HOTEL FLOOR PLANS

Lobby Level

GRAND HALL

LOBBY LEVEL
4th Level
POSTER MAPS

Coronado Poster Hall Wednesday

WEDNESDAY
APRIL 5, 2017

CORONADO
BALLROOM &
CORONADO
FOYER
WEDNESDAY
APRIL 5, 2017

REGATTA
FOYER
Seaport Poster Hall Wednesday

WEDNESDAY
APRIL 6, 2017

SEAPORT
FOYER
THURSDAY
APRIL 6, 2017

REGATTA
FOYER
FRIDAY
APRIL 7, 2017

CORONADO
FOYER
FRIDAY
APRIL 7, 2017

REGATTA
FOYER
FRIDAY
APRIL 8, 2017

SEAPORT
FOYER
ACRONYMS

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for. These codes are explained as follows:

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSTR</td>
<td>Basic Science and Translational Research</td>
</tr>
<tr>
<td>EEP</td>
<td>Economics, Ethics, Public Policy</td>
</tr>
<tr>
<td>HF</td>
<td>Heart Failure (Adult)</td>
</tr>
<tr>
<td>HTX</td>
<td>Heart Transplantation (Adult)</td>
</tr>
<tr>
<td>ID</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>LBCS</td>
<td>Late Breaking Clinical Science</td>
</tr>
<tr>
<td>LTX</td>
<td>Lung Transplantation (Adult)</td>
</tr>
<tr>
<td>MCS</td>
<td>Mechanical Circulatory Support (Adult)</td>
</tr>
<tr>
<td>NHSAH</td>
<td>Nursing, Heath Science, and Allied Health</td>
</tr>
<tr>
<td>PATH</td>
<td>Pathology</td>
</tr>
<tr>
<td>PEDS</td>
<td>Pediatrics</td>
</tr>
<tr>
<td>PHARM</td>
<td>Pharmacy and Pharmacology</td>
</tr>
<tr>
<td>PH</td>
<td>Pulmonary Hypertension</td>
</tr>
</tbody>
</table>
## SCIENTIFIC COUNCIL MEETINGS & NETWORKING RECEPTIONS

<table>
<thead>
<tr>
<th>Council</th>
<th>Meeting Date and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science and Translational Research</td>
<td>Fri April 7, 11:30 AM - 1:30 PM (Seaport F-H)</td>
</tr>
<tr>
<td>Chronic Thromboembolic Pulmonary Hypertension</td>
<td>Wed Apr 5, 6:15 – 7:15 PM (La Jolla AB)</td>
</tr>
<tr>
<td>Heart Failure &amp; Transplantation</td>
<td>Fri Apr 7, 11:30 AM - 1:30 PM (Grand Hall B)</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Wed Apr 5, 12:30 - 2:30 PM (Coronado A-C)</td>
</tr>
<tr>
<td>Junior Faculty and Trainees</td>
<td>Thurs Apr 6, 7:00 – 8:00 AM (Gaslamp A-C)</td>
</tr>
<tr>
<td>Mechanical Circulatory Support</td>
<td>Thurs Apr 6, 12:30 – 2:00 PM (Grand Hall A)</td>
</tr>
<tr>
<td>Nursing, Health Science, and Allied Health</td>
<td>Wed Apr 5, 12:30 - 2:30 PM (Grand Hall A)</td>
</tr>
<tr>
<td>Pathology</td>
<td>Fri Apr 7, 11:30 AM - 1:30 PM (Coronado A-C)</td>
</tr>
<tr>
<td>Pediatric Thoracic Transplantation &amp; Heart Failure</td>
<td>Wed Apr 5, 12:30 - 2:30 PM (Seaport F-H)</td>
</tr>
<tr>
<td>Pharmacy and Pharmacology</td>
<td>Thurs Apr 6, 12:30 – 2:00 PM (Seaport F-H)</td>
</tr>
<tr>
<td>Pulmonary Hypertension</td>
<td>Wed Apr 5, 12:30 - 2:30 PM (Grand Hall D)</td>
</tr>
<tr>
<td>Pulmonary Transplantation</td>
<td>Thurs Apr 6, 12:30 – 2:00 PM (Grand Hall C)</td>
</tr>
</tbody>
</table>

## COUNCIL NETWORKING RECEPTIONS

In response to feedback from Council members requesting more opportunities for networking at the ISHLT Annual Meetings, we are excited to announce the following Council receptions planned in association with respective evening poster sessions:

<table>
<thead>
<tr>
<th>Council</th>
<th>Reception Date and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science and Translational Research</td>
<td>Fri Apr 7, 5:45 - 6:45 PM (Harbor Terrace)</td>
</tr>
<tr>
<td>Heart Failure &amp; Transplantation</td>
<td>Wed Apr 5, 6:15 - 7:15 PM (Seaport Terrace)</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Wed Apr 5, 6:15 - 7:15 PM (Seaport Terrace)</td>
</tr>
<tr>
<td>Junior Faculty and Trainees</td>
<td>Wed Apr 5, 6:15 - 7:15 PM (Coronado Terrace)</td>
</tr>
<tr>
<td>Mechanical Circulatory Support</td>
<td>Thurs Apr 6, 6:15 - 7:15 PM (Seaport Terrace)</td>
</tr>
<tr>
<td>Nursing, Health Science, and Allied Health</td>
<td>Thurs Apr 6, 6:15 - 7:15 PM (Coronado Terrace)</td>
</tr>
<tr>
<td>Pathology</td>
<td>Fri Apr 7, 5:45 - 6:45 PM (Harbor Terrace)</td>
</tr>
<tr>
<td>Pediatric Thoracic Transplantation &amp; Heart Failure</td>
<td>Wed Apr 5, 6:15 - 7:15 PM (Harbor Terrace)</td>
</tr>
<tr>
<td>Pharmacy and Pharmacology</td>
<td>Thurs Apr 6, 6:15 - 7:15 PM (Coronado Terrace)</td>
</tr>
<tr>
<td>Pulmonary Hypertension</td>
<td>Thurs Apr 6, 6:15 - 7:15 PM (Harbor Terrace)</td>
</tr>
<tr>
<td>Pulmonary Transplantation</td>
<td>Thurs Apr 6, 6:15 - 7:15 PM (Harbor Terrace)</td>
</tr>
</tbody>
</table>
**DAILY SCHEDULE**

All meetings and activities will take place at the Manchester Grand Hyatt Hotel in San Diego, CA, USA, unless otherwise specified. All papers will be presented in English. Please check the ISHLT web site (www.ISHLT.org) for updates. This Final Program reflects the latest session schedule and room assignments.

**MONDAY, APRIL 3, 2017**

4:00 PM - 8:00 PM  
Academy Registration Open (Palm Foyer)  
Speaker Ready Room Open (*Academy Faculty only*) (Balboa ABC)

**TUESDAY, APRIL 4, 2017**

6:00 AM - 3:00 PM  
Academy Registration Open (Palm Foyer)

6:00 AM - 8:00 PM  
Speaker Ready Room Open (Balboa ABC)

7:45 AM – 12:50 PM  
ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Seaport F-G)

7:45 AM – 5:15 PM  
ISHLT ACADEMY: Core Competency Course in Pediatric and Adult Congenital MCS (Grand Hall A)  
ISHLT ACADEMY: Core Competency Course in Infectious Diseases in Thoracic Transplantation and MCS (Grand Hall C)

8:00 AM - 2:00 PM  
ISHLT Board of Directors Meeting (America’s Cup A-D)

8:00 AM – 5:30 PM  
ISHLT ACADEMY: Core Competency Course in Mechanical Circulatory Support (Grand Hall B)

1:45 PM – 6:50 PM  
ISHLT ACADEMY: Master Class in Mechanical Circulatory Support (Gaslamp A-D)

2:00 PM - 6:00 PM  
ISHLT Board/Committee/Council Leadership Orientation (Hillcrest A-D)

2:00 PM – 7:00 PM  
ISHLT ACADEMY: Master Class in Pulmonary Hypertension (Seaport F-G)

4:00 PM - 8:00 PM  
Annual Meeting Registration Open (Palm Foyer)

5:00 PM - 7:00 PM  
International Thoracic Transplant Registry Committee Meeting (Old Town B)

6:00 PM – 8:00 PM  
ISHLT Standards and Guidelines Committee Meeting (La Jolla AB)
WEDNESDAY, APRIL 5, 2017

7:00 AM - 10:00 AM
Exhibitor Set-Up (Harbor A-H)
Poster Session 1 Mount (Seaport/Harbor/Regatta/Coronado Foyers, and Coronado D)

7:00 AM - 6:15 PM
Registration Open (Palm Foyer)

7:00 AM – 7:30 PM
Speaker Ready Room Open (Balboa ABC)

8:00 AM - 10:00 AM
SYMPOSIUM 1: Joint ISHLT/ICCAC Symposium: Besides the Surgery - How to Make VAD Patients Successful
(Seaport A-E)
(MCS, HF, HTX, NHSAH)

SYMPOSIUM 2: When Should We Call It Quits? The Efficacy of Interventions to Ameliorate Psychosocial Risk
Factors (Grand Hall A)
(HTX, HF, MCS, NHSAH)

SYMPOSIUM 3: Primary Graft Dysfunction (PGD) and Vasoplegia After Heart Transplantation: Sink or Swim
(Grand Hall B)
(HTX, HF, MCS)

SYMPOSIUM 4: Thinking Outside the Box: Extra-Pulmonary Management in Lung Transplantation (Grand Hall C)
(LTX, BSTR, ID, NHSAH, PATH, PEDS, PHARM, PH)

SYMPOSIUM 5: Joint ISHLT/PHA Symposium: PH and Transplant: Where Do We Go from Here? (Grand Hall D)
(PH, HF, HTX, LTX, MCS, NHSAH, PEDS)

SYMPOSIUM 6: The Failing Fontan - Where Do We Go from Here? (Seaport F-H)
(PEDS, EEP, HF, HTX)

SYMPOSIUM 7: Joint ISHLT/ESCMID Symposium: Ongoing Challenges in Transplant Infectious Diseases
(Coronado A-C)
(ID, HTX, LTX, MCS, PHARM)

9:00 AM - 7:00 PM
Press Office Open (Old Town A)

10:00 AM - 10:30 AM
Coffee Break (Harbor A-H)

10:00 AM - 7:15 PM
Exhibit Hall Open (Harbor A-H)
Industry Theater Open (Harbor I)
Poster Halls Open (Seaport/Harbor/Regatta/Coronado Foyers, and Coronado D)

10:30 AM - 12:30 PM
OPENING PLENARY SESSION (Seaport A-E)
(ALL)

12:30 PM - 2:30 PM
Lunch Break
Education Committee Meeting (Gaslamp B)
Grants & Awards Committee Meeting (Gaslamp A)
International and Inter-Society Coordination Committee (I2C2) Meeting (Gaslamp C)
Infectious Diseases Scientific Council Meeting (Coronado A-C)
ISHLT Mechanically Assisted Circulatory Support (IMACS) Registry Committee Meeting (Old Town B)
Junior Faculty Mentor Lunch Meeting (Mission Beach A-C)
Nursing, Health Sciences & Allied Health Scientific Council Meeting (Grand Hall A)
Pediatric Thoracic Transplantation and Heart Failure Scientific Council Meeting (Seaport F-H)
Pulmonary Hypertension Scientific Council Meeting (Grand Hall D)
Pulmonary Transplant Council Quality of Life (QOL) Workforce Meeting (La Jolla AB)
Registries and Databases Committee Meeting (Gaslamp D)

2:30 PM - 4:00 PM
ORAL SESSION 1: Too Thick or Too Thin? Bleeding and Thrombosis in MCS (Seaport A-E)
(MCS, HF, NHSAH, PHARM)

ORAL SESSION 2: Engineering for Perfection in MCS (Grand Hall A)
(MCS, HF, NHSAH)

ORAL SESSION 3: Moving DCD Forward: Thinking Inside the Box (Grand Hall B)
(HTX, BSTR, MCS)

ORAL SESSION 4: Donor Lung Allocation Strategies (Grand Hall C)
(LTX, EEP, NHSAH)

ORAL SESSION 5: Registries and Risk Scores in Pulmonary Hypertension: Updates, Lessons Learned, and Practice Changes (Grand Hall D)
(PH, HF, HTX, LTX, NHSAH, PEDS, PHARM)

ORAL SESSION 6: Pediatric Heart Failure: Diagnosis, Management, and Confronting Risk (Seaport F-H)
(PEDS, HF, HTX)

ORAL SESSION 7: Cutting Edge Updates in Infectious Diseases (Coronado A-C)
(ID, ALL)

4:00 PM - 4:30 PM
Coffee Break (Harbor A-H)

4:30 PM - 6:00 PM
ORAL SESSION 8: Bugs and Devices: A Bad Combination (Seaport A-E)
(MCS, ID, NHSAH, PHARM)

ORAL SESSION 9: MCS Surgery: Does Nuance Make a Master? (Grand Hall A)
(MCS, HF, NHSAH)

ORAL SESSION 10: Movement on the Heart Transplant Wait List: VADS, Exceptions and Antibodies (Grand Hall B)
(HTX, EEP, MCS, NHSAH)

ORAL SESSION 11: Improving Prognosis in Chronic Lung Allograft Dysfunction (Grand Hall C)
(LTX, BSTR, EEP, ID, NHSAH, PATH, PHARM)

ORAL SESSION 12: Innovation in Pediatric MCS (Seaport F-H)
(PEDS, MCS)

SYMPOSIUM 8: ECMO in Pre-Capillary PH: What is the Best Option for My Patient? (Grand Hall D)
(PH, HF, LTX, PEDS, PH)

SYMPOSIUM 9: JHLT at ISHLT: The Year in a Capsule (Coronado A-C)
(ALL)

6:00 PM - 6:15 PM
Break (Harbor A-H)

6:15 PM - 7:15 PM
Inaugural Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Scientific Council Meeting (La Jolla A)
Exhibit Hall Opening Reception (Harbor A-H)
Council Networking Receptions:
Heart Failure and Transplantation (Seaport Terrace)
Infectious Diseases (Seaport Terrace)
Junior Faculty and Trainees (Coronado Terrace)
Pediatric Heart Failure and Transplantation (Harbor Terrace)

MODERATED POSTER SESSION 1:
Heart Failure (Seaport Foyer)
Heart Transplantation (Seaport Foyer)
Infectious Diseases (Seaport Foyer)
Junior Faculty Clinical Case Reports (Coronado D and Foyer)
Mechanical Circulatory Support (Regatta Foyer)
Pediatrics (Harbor Foyer)

MINI ORAL SESSION 1: Complicating Factors in MCS (Grand Hall A)
(MCS, HF, HTX, NHSAH, PHARM)

MINI ORAL SESSION 2: Donor Evaluation and Management: DBD and DCD (Grand Hall B)
(HTX, EEP, MCS)

MINI ORAL SESSION 3: Wretched Strangers: Mechanisms of Thoracic Organ Infection, Rejection and Tolerance
(Grand Hall C)
(BSTR, EEP, HF, HTX, ID, LTX, PATH, PEDS, PHARM, PH)

MINI ORAL SESSION 4: Allocation, Bridging and Lung Allograft Assessment Strategies (Grand Hall D)
(LTX, BSTR, EEP, ID, MCS, NHSAH, PATH, PHARM)

MINI ORAL SESSION 5: The Hardware of MCS (Seaport F-H)
(MCS, HF, NHSAH)

MINI ORAL SESSION 6: Therapeutics in Advanced Heart and Lung Disease (Coronado A-C)
(PHARM, HTX, ID, LTX, MCS, NHSAH)

7:15 PM - 8:15 PM
Poster Session 1 Removal (Seaport/Harbor/Regatta/Coronado Foyers, and Coronado D)

7:30 PM - 10:00 PM
ICCAC Annual Meeting (Grand Hall D)
THURSDAY, APRIL 6, 2017

6:00 AM - 7:30 PM
Speaker Ready Room Open (Balboa ABC)

7:00 AM - 10:00 AM
Poster Session 2 Mount (Seaport/ Harbor/Regatta/Coronado Foyers)

7:00 AM – 6:15 PM
Registration Open (Palm Foyer)

7:00 AM - 8:00 AM
Junior Faculty and Trainees Scientific Council Meeting (Gaslamp A-C)

SUNRISE SYMPOSIUM 1: Walk With Me: Exercise Physiology in the LVAD Patient (Grand Hall A)
(MCS, ALL)

SUNRISE SYMPOSIUM 2: Chagasic Cardiomyopathy: Lessons To Be Learned (Grand Hall B)
(HF, HTX, ID, MCS)

SUNRISE SYMPOSIUM 3: Lifecycle Journey of Thrombosis in Mechanical Circulatory Support Patients (Grand Hall C)
(PHARM, HF, HTX, MCS, NHSAH)

SUNRISE SYMPOSIUM 4: Completing the Picture: Patient Reported Outcomes (PROs) as an Essential Source of Information in Evaluating Transplantation Outcomes (Grand Hall D)
(NHSAH, ALL)

SUNRISE SYMPOSIUM 5: Upcoming Opportunities and Challenges in Pediatric Lung Transplantation (Seaport F-H)
(PEDS, HF, LTX, MCS, PEDS, PHARM)

SUNRISE SYMPOSIUM 6: "Those Darn CARVs": Community Acquired Respiratory Viruses in Lung Transplant (Coronado A-C)
(ID, LTX, PATH, PHARM)

8:00 AM - 10:00 AM
SYMPOSIUM 10: Antibodies in MCS: The Phantom Menace (Seaport A-E)
(MCS, BSTR, HF, HTX, PEDS, PHARM)

SYMPOSIUM 11: Not CAVing to CLADtastrophy: Emerging Mechanisms of Chronic Heart and Lung Allograft Disease (Grand Hall A)
(BSTR, HTX, LTX, PATH, PHARM)

SYMPOSIUM 12: A Tale of Two Organs: Selecting and Managing Multi-Organ Transplant Recipients (Grand Hall B)
(HTX, ALL)

SYMPOSIUM 13: Lung Allocation Scores (LAS): Making the Complex Simple, or Just the Simple Complex? (Grand Hall C)
(LTX, ALL)

SYMPOSIUM 14: Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Current Controversies and New Directions (Grand Hall D)
(PH)

SYMPOSIUM 15: HLA, AMR and DSA - Approaching Antibodies in Kids (Seaport F-H)
(ALL)
SYMPOSIUM 16: “Around the World in 80 Days”: Infectious Challenges in Cardiothoracic Transplantation (Coronado A-C) (ID, HF, HTX, LTX)

9:00 AM - 7:00 PM
Press Office Open (Old Town A)

10:00 AM - 10:30 AM
Coffee Break (Harbor A-H)

10:00 AM - 7:00 PM
Industry Theater Open (Harbor I)

10:00 AM - 7:15 PM
Exhibit Hall Open (Harbor A-H) Poster Halls Open (Seaport/Harbor/Regatta/Coronado Foyers)

10:30 AM - 12:30 PM
PLENARY SESSION (Seaport A-E) (ALL)

12:30 PM - 2:00 PM
Lunch Break
International Pediatric Heart Failure Registry Meeting (Old Town B) JHLT Editorial Board Lunch Meeting (Gaslamp A-C) Mechanical Circulatory Support Scientific Council Meeting (Grand Hall A) Pharmacy and Pharmacology Scientific Council Meeting (Seaport F-H) Pulmonary Transplantation Scientific Council Meeting (Grand Hall C)

2:00 PM - 3:30 PM
ORAL SESSION 13: Contemporary LVAD Trials - Same Old Song or New Tune? (Seaport A-E) (MCS, HF, HTX, NHSAH)

ORAL SESSION 14: Measure for Measure: In- and Ex-Vivo Cellular and Molecular Approaches for Thoracic Organ Tailoring (Grand Hall A) (BSTR, HF, HTX, LTX, MCS, NHSAH, PATH, PEDS, PHARM)

ORAL SESSION 15: Therapies and Monitoring After Heart Transplantation (Grand Hall B) (HTX, BSTR, NHSAH, PHARM)

ORAL SESSION 16: The Rise of the Machines: ECLS and EVLP in Lung Transplantation (Grand Hall C) (LTX, BSTR, EEP, ID, HTX, MCS, NHSAH, PATH, PHARM)

ORAL SESSION 17: What’s Up Next in Pulmonary Hypertension Research? (Grand Hall D) (PH, BSTR, HF, LTX)

ORAL SESSION 18: Contemporary Challenges in Pediatric Heart Transplant (Seaport F-H) (PEDS, HTX, PATH)

ORAL SESSION 19: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best (Coronado A-C) (ALL)

3:30 PM - 4:00 PM
Coffee Break (Harbor A-H) 2018 Symposium Planning Committee Meeting (Hillcrest A-D)

4:00 PM - 6:00 PM
SYMPOSIUM 17: To Pulse or Not To Pulse? That is the Question (Seaport A-E) (ALL)
SYMPOSIUM 18: Weeding Out Fact from Fiction - the Highs and Lows of Marijuana Use in Transplant (Grand Hall A)  
(PHARM, ALL)

SYMPOSIUM 19: Cardiogenic Shock: Types, Teams and Tactics (Grand Hall B)  
(HF, HTX, MCS)

SYMPOSIUM 20: ECMO in Lung Transplantation: Sensational Success or Fantastic Failure? (Grand Hall C)  
(LTX, ALL)

SYMPOSIUM 21: Cardiopulmonary Hemodynamics, the Right Ventricle, and the Kidney: Connecting All the Dots (Grand Hall D)  
(PH, HF, HTX, LTX, MCS)

SYMPOSIUM 22: Let's Get Personal! Precision Diagnostics in Thoracic Transplantation (Seaport F-H)  
(PATH, ALL)

SYMPOSIUM 23: Taming of the Shrew: Mycobacterium Abscessus in Lung Transplantation (Coronado A-C)  
(ID, ALL)

6:00 PM - 6:15 PM  
Break (Harbor A-H)

6:00 PM - 7:00 PM  
Past President's Meeting (Gaslamp D)

6:15 PM - 7:15 PM  
Wine & Cheese Reception (Harbor A-H)  
Council Networking Receptions:  
- Mechanical Circulatory Support (Seaport Terrace)  
- Nursing, Health Sciences & Allied Health (Coronado Terrace)  
- Pharmacy and Pharmacology (Coronado Terrace)  
- Pulmonary Hypertension (Harbor Terrace)  
- Pulmonary Transplantation (Harbor Terrace)

MODERATED POSTER SESSION 2:  
- Economics, Ethics, Public Policy (Coronado Foyer)  
- Heart Transplantation (Regatta Foyer)  
- Lung Transplantation (Harbor Foyer)  
- Mechanical Circulatory Support (Seaport Foyer)  
- Nursing, Health Sciences, Allied Health (Coronado Foyer)  
- Pharmacy and Pharmacology (Coronado Foyer)  
- Pulmonary Hypertension (Harbor Foyer)
MINI ORAL SESSION 7: Factors that Drive Success in MCS (Grand Hall A)
(MCS, EEP, HF, NHSAH)

MINI ORAL SESSION 8: Infections, Induction and IVIG (Grand Hall B)
(HTX, EEP, ID, MCS)

MINI ORAL SESSION 9: Novel Strategies and Mechanisms in Lung Preservation, Heart Failure and Assist Devices
(Grand Hall C)
(BSTR, HTX, ID, LTX, MCS, PEDS, PHARM)

MINI ORAL SESSION 10: Challenges in Lung Transplantation (Grand Hall D)
(LTX, EEP, ID, NHSAH, PATH, PHARM)

MINI ORAL SESSION 11: Outcomes in MCS (Seaport F-H)
(MCS, HF, HTX)

MINI ORAL SESSION 12: Hot Topics in Pediatric Heart Transplantation (Coronado A-C)
(PEDS, BSTR, HTX)

7:15 PM - 8:15 PM
Poster Session 2 Removal (Seaport/ Harbor/ Regatta/ Coronado Foyers)

8:00 PM – 9:30 PM
ISHLT President's Cocktail Reception (USS Midway Museum)

FRIDAY, APRIL 7, 2017

6:00 AM – 7:00 PM
Speaker Ready Room Open (Balboa ABC)

7:00 AM - 10:00 AM
Poster Session 3 Mount (Seaport/ Harbor/ Regatta/ Coronado Foyers)

7:00 AM – 5:45 PM
Registration Open (Palm Foyer)

7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 7: Getting to the Heart of Muscular Dystrophies (Grand Hall A)
(ALL)

SUNRISE SYMPOSIUM 8: Live Long and Prosper: Thriving After Pediatric Transplantation (Grand Hall B)
(PEDS, EEP, HF, HTX, LTX, MCS, NHSAH, PHARM)

SUNRISE SYMPOSIUM 9: Mixed Rejection (MR) of the Cardiac Allograft: The Next Frontier (Grand Hall C)
(PATH, BSTR, HF, HTX)

SUNRISE SYMPOSIUM 10: Contrasts and Similarities in Children and Adults: IPAH, Portopulmonary Hypertension, and Perioperative Management (Grand Hall D)
(PH, BSTR, HF, LTX, NHSAH, PEDS, PHARM)

SUNRISE SYMPOSIUM 11: There is No Such Thing as Perfect: Selecting Recipients for Lung Transplantation
(Seaport F-H)
(LTX, ID, NHSAH, PEDS)
SUNRISE SYMPOSIUM 12: HIV and Transplantation: It Isn't Going Away... (Coronado A-C)
(PHARM, HTX, ID, LTX, NHSAH, PEDS, PH)

8:00 AM - 9:30 AM
ORAL SESSION 20: New and Improving? Evolving Outcomes with MCS (Seaport A-E)
(MCS, EEP, HF, HTX, NHSAH)

ORAL SESSION 21: New Fixes for an Old Problem: Preventing, Diagnosing, and Treating Pump Thrombosis
(Grand Hall A)
(MCS, HF, NHSAH, PHARM)

ORAL SESSION 22: Does Risk Reap Reward? Expanding the Heart Donor Pool (Grand Hall B)
(HTX, BSTR)

ORAL SESSION 23: Choosing Right: Lung Recipient Selection and Management (Grand Hall C)
(LTX, BSTR, EEP, NHSAH, PHARM)

ORAL SESSION 24: An Amalgamation of Support in Heart Failure (Grand Hall D)
(HF, MCS, NHSAH, PHARM)

ORAL SESSION 25: Improving Outcomes in Pediatric Lung Transplantation (Seaport F-H)
(PEDS, ID, LTX)

ORAL SESSION 26: Philip K. Caves Award Candidate Presentations (Coronado A-C)
(ALL)

9:00 AM - 7:00 PM
Press Office Open (Old Town A)

9:30 AM - 10:00 AM
Coffee Break (Harbor A-H)
Annual Business Meeting (Seaport A-E)

9:30 AM - 4:00 PM
Exhibit Hall Open (Harbor A-H)
Industry Theater Open (Harbor I)

9:30 AM - 6:45 PM
Poster Halls Open (Seaport/Harbor/Regatta/Coronado Foyers)

10:00 AM - 11:30 AM
ORAL SESSION 27: The Leaking Gut - New Strategies for GI Bleeding in MCS (Seaport A-E)
(MCS, HF, NHSAH, PHARM)

ORAL SESSION 28: The Heart of the Matter: Cardiac Substrate in MCS Therapy (Grand Hall A)
(MCS, HF)

ORAL SESSION 29: Donor Utilization and Allocation in Heart Transplantation: Lessons to Learn (Grand Hall B)
(HTX, HF)

ORAL SESSION 30: Novel Mechanisms in Chronic Lung Allograft Dysfunction (Grand Hall C)
(LTX, BSTR, ID, PATH, PHARM)

ORAL SESSION 31: Saved by the Bell: Overcoming Adherence and Frailty (Grand Hall D)
(NHSAH, ALL)

ORAL SESSION 32: The Tell Tale Heart: From Signals to Biomarkers (Seaport F-H)
(BSTR, HF, HTX, MCS, NHSAH, PATH, PEDS, PH, PHARM)

Oral Session 33: PATH to Better Outcomes: Diagnostics in Heart and Lung Transplantation (Coronado A-C)
(PATH, BSTR, HTX, LTX, PEDS)

**11:30 AM - 1:30 PM**
Lunch Break
Basic Science and Translational Research Scientific Council Meeting (Seaport F-H)
DCD Registry Committee Lunch Meeting (Gaslamp D)
Heart Failure and Transplantation Scientific Council Meeting (Grand Hall B)
IMACS Users Group Meeting (Gaslamp A-C)
Pathology Scientific Council Meeting (Coronado A-C)

**1:30 PM - 3:30 PM**
SYMPOSIUM 24: Aiming Off Target: Non-Cardiac Consequences of LVAD Support (Seaport A-E)
(MCS, BSTR, HF)

SYMPOSIUM 25: Dealing with Antibodies Before and After Heart Transplant: Do We Have New Arrows in our Quiver? (Grand Hall A)
(ALL)

SYMPOSIUM 26: Making Every Heart Count (Grand Hall B)
(HTX, EEP, HF, HTX)

SYMPOSIUM 27: Bench to Bedside: How Advances in Immunology Shape the Care of Today’s Lung Transplant Recipients (Grand Hall C)
(LTX, BSTR, HTX, ID, NHSAH, PATH, PEDS, PHARM)

SYMPOSIUM 28: Great Debates in Pulmonary Hypertension (Grand Hall D)
(PH, ALL)

SYMPOSIUM 29: How to Mend a Broken Heart: Approaches for Cardiac Regeneration (Seaport F-H)
(BSTR, HF, HTX, PATH, PHARM)

SYMPOSIUM 30: E-Health, Wearables, Social Media and Big Data in Transplantation: Fancy Toys or True Care Innovations? (Coronado A-C)
(NHSAH, ALL)

**3:30 PM - 4:00 PM**
Coffee Break (Harbor A-H)

**4:00 PM - 5:30 PM**
ORAL SESSION 34: Short-Term MCS for Shock: New Paradigms (Seaport A-E)
(MCS, HF, HTX, NHSAH)

ORAL SESSION 35: Heart Failure in MCS (Grand Hall A)
(MCS, HF, HTX, PH)

ORAL SESSION 36: CAV: New Insights to an Old Problem (Grand Hall B)
(HTX, BSTR, PATH, PHARM)

ORAL SESSION 37: Impact of Donor Characteristics on Lung Transplant Outcomes (Grand Hall C)
(LTX, BSTR, EEP, MCS, NHSAH)
ORAL SESSION 38: The Nightmare of Primary Cardiac Allograft Dysfunction (Grand Hall D)
(HTX, MCS, PHARM)

ORAL SESSION 39: Early Career Scientist Award in Transplantation Finalist Presentations (Seaport F-H)
(BSTR, HTX, ID, LTX, PATH, PEDS, PHARM)

ORAL SESSION 40: Drugs, Bleeding and Enzymes ... Oh My! (Coronado A-C)
(PHARM, HTX, ID, LTX, MCS, NHSAH)

5:30 PM - 5:45 PM
Break (Seaport Foyer)

5:45 PM - 6:45 PM
Wine and Cheese Reception (Seaport/Harbor/Regatta/Coronado Foyers)
Council Networking Receptions:
Basic Science and Translational Research (Harbor Terrace)
Pathology (Harbor Terrace)

MODERATED POSTER SESSION 3:
Basic Science and Translational Research (Harbor Foyer)
Heart Transplantation (Coronado Foyer)
Junior Faculty Clinical Case Reports (Coronado Foyer)
Mechanical Circulatory Support (Seaport Foyer)
Pathology (Harbor Foyer)
Lung Transplantation (Regatta Foyer)

MINI ORAL SESSION 13: Controversies in Heart Transplantation (Grand Hall A)
(HTX, MCS)

MINI ORAL SESSION 14: Recipient Risk Factors Affecting Outcome after Lung Transplantation (Grand Hall B)
(LTX, BSTR, EEP, ID, NHSAH, PATH, PHARM)

MINI ORAL SESSION 15: Pediatric Heart Failure, MCS, and Peri-Transplant Issues (Grand Hall C)
(PEDS, HF, HTX, MCS)

MINI ORAL SESSION 16: Assessing and Managing the Failing Right Ventricle (Grand Hall D)
(PH, BSTR, HF, HTX, LTX, PHARM)

MINI ORAL SESSION 17: Progress in MCS Outcomes (Seaport F-H)
(MCS, HF, HTX, ID, NHSAH, PHARM)

MINI ORAL SESSION 18: Patient Centered Outcomes in Advanced Heart and Lung Disease (Coronado A-C)
(NHSAH, ALL)

6:45 PM - 7:45 PM
Poster Session 3 Removal (Seaport/Harbor/Regatta/Coronado Foyers)

SATURDAY, APRIL 8, 2017

6:00 AM - 1:30 PM
Speaker Ready Room Open (Balboa ABC)
7:00 AM - 12:00 PM
Registration Open (Palm Foyer)

7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 13: Mechanical Circulatory Support - The Interface of Design and Outcome (Grand Hall A) (MCS, BSTR, EEP, HF, HTX)

SUNRISE SYMPOSIUM 14: The Tsunami of Adult Congenital Heart Disease (ACHD) Patients Who Need Advanced Therapies: Are We Prepared? (Grand Hall B) (HTX, HF, LTX, MCS, PEDS, PH)

SUNRISE SYMPOSIUM 15: Extracorporeal Photopheresis: Shedding Light on Rejection? (Grand Hall C) (LTX, BSTR, HTX, ID, NHSAH, PATH, PEDS, PHARM)

SUNRISE SYMPOSIUM 16: Pregnant - Scared? So Are We.... Management of Pregnancy in Our Complex Patients (Seaport F-H) (PHARM, HTX, LTX, MCS, NHSAH, PEDS)

SUNRISE SYMPOSIUM 17: Living in a 'Bacterial' World: Microbiome in Thoracic Transplantation (Coronado A-C) (BSTR, ALL)

8:00 AM - 9:30 AM
ORAL SESSION 41: The Rhythm is Going to Get You: EP Issues in MCS (Seaport A-E) (MCS, HF, NHSAH)

ORAL SESSION 42: The Weighting Game: Impact of Obesity, Age, and Other Comorbidities in MCS (Grand Hall A) (MCS, HF, HTX, NHSAH)

ORAL SESSION 43: In the Mix of Heart Failure (Grand Hall B) (HF, BSTR, NHSAH, PHARM)

ORAL SESSION 44: Optimizing Early Outcomes after Lung Transplantation (Grand Hall C) (LTX, BSTR, ID, PATH, PHARM)

ORAL SESSION 45: Heart Transplant in Special Populations (Grand Hall D) (HTX, HF, MCS)

ORAL SESSION 46: Rogue One: A Graft Wars Story of Rejection and Tolerance (Seaport F-H) (BSTR, HF, HTX, LTX, PATH, PEDS, PHARM)

9:30 AM - 9:45 AM
Coffee Break (Seaport Foyer)

9:45 AM - 11:45 AM
PLENARY SESSION (Seaport A-E) (ALL)

11:45 AM - 12:00 PM
Coffee Break (Seaport Foyer)

12:00 PM - 1:30 PM
ORAL SESSION 47: Not the Usual Suspects: Driving Outcomes in MCS (Seaport A-E) (MCS, HF, HTX, NHSAH)

ORAL SESSION 48: Seeing the Patient Beyond the Device (Grand Hall A) (MCS, HF, NHSAH)

ORAL SESSION 49: Antibodies and Other Determinants of Cardiac Rejection: Let's ROCK and Rho (Grand Hall B) (HTX, BSTR, EEP, PEDS, PHARM)
ORAL SESSION 50: Influencing Long-term Outcomes in Lung Transplantation (Grand Hall C)
(LTX, BSTR, ID, NHSAH, PEDS, PHARM)

ORAL SESSION 51: Optimizing Outcomes After Heart Transplantation: Predictors and Risk Scores (Grand Hall D)
(HTX, MCS, PATH)

ORAL SESSION 52: Does Size Matter? Center Volume, Urgency Status and Managing Complications (Seaport F-H)
(EEP, HF, HTX, LTX, MCS, NHSAH, PEDS, PHARM)

ORAL SESSION 53: Getting to the Heart of the Matter: Psychosocial Factors Predict Outcomes in Transplant and MCS (Coronado A-C)
(NHSAH, ALL)

12:00 PM - 6:00 PM
ISHLT Board of Directors Meeting (America’s Cup A-D)
Wednesday, April 05, 2017

8:00 AM - 10:00 AM
SYMPOSIUM 01: Joint ISHLT/ICCAC Symposium: Besides the Surgery - How to Make VAD Patients Successful

Location:
Seaport A-E

Target Audience:
MCS, HF, HTX, NHSAH

Chairs:
Ivan Netuka, MD, PhD, and Thomas Schlöglhofer, BSc

Session Summary: This session, supported by a collaborative effort with the International Consortium of Circulatory Assist Clinicians (ICCAC), is designed to discuss questions frequently asked by MCS Teams around the world regarding multidisciplinary program structure, practice guidelines, VAD education including simulation labs, cost-effectiveness and international aspects in care delivery from a program perspective, and with patients, families, and staff caring for them.

8:00 AM
Multidisciplinary Approaches to Optimize VAD Patient Management in High Volume Centers
Friedrich Kaufmann, MSc, German Heart Institute, Berlin, Germany

8:12 AM Q&A

8:17 AM
Caring for the Pediatric VAD Patient - They Aren’t Just Small Adults
Jodie Lantz, MSN, RN, PCNS-BC, Children’s Health Dallas, Dallas, TX, USA

8:29 AM Q&A

8:34 AM
Keep Them at Home: Interventions to Prevent Readmission
Lori Edwards, MSN, Inova Fairfax Hospital, Falls Church, VA, USA

8:46 AM Q&A

8:51 AM
Measuring and Managing Blood Pressure in CF-LVAD recipients
Brent C Lampert, DO, Ohio State University, Columbus, OH, USA

9:03 AM Q&A

9:08 AM
Echocardiography in LVAD Recipients: How and What to Measure?
Peter J Bergin, MBBS, FRACP, Alfred Hospital, Melbourne, Australia

9:20 AM Q&A

9:25 AM
Optimizing Unloading with Right Heart Catheterization Ramp Studies
Nir Uriel, MD, University of Chicago, Chicago, IL, USA

9:37 AM Q&A

9:42 AM
Do We Need Antiplatelet Drugs and Anticoagulants to Manage LVAD Patients?
Haifa Lyster, MSc, Royal Brompton Harefield Hospital, Middlesex, United Kingdom

9:54 AM Q&A
8:00 AM - 10:00 AM
SYMPOSIUM 02: When Should We Call It Quits? The Efficacy of Interventions to Ameliorate Psychosocial Risk Factors

**Location:**
Grand Hall A

**Target Audience:**
HTX, HF, MCS, NHSAH

**Chairs:**
Lavanya Bellumkonda, MD, and Jane MacIver, RN, NP, PhD

**Session Summary:** This session will start by briefly reviewing the literature on psychosocial risk factors including: psychiatric illness, poor social support, medical non-adherence and substance abuse. The majority of the presentations will, however, focus on the interventions available to mitigate the risks associated with each variable and the efficacy of those interventions. Thus, the focus is how to use the psychosocial assessment as a means of problem identification for intervention rather than as a gate keeping function. A panel discussion with all speakers will conclude this session.

8:00 AM
*The Impact of Psychiatric Risk Factors on Outcomes in Heart Failure, MCS and Cardiothoracic Transplant Patients*
Heike Spaderna, PhD, University of Trier, Trier, Germany

8:15 AM
*The Efficacy of Interventions for Psychiatric Risk Factors in Cardiothoracic Transplantation and MCS*
Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada

8:30 AM
*It Takes a Village: Social Support and Social Determinants of Health in MCS and Cardiothoracic Transplantation as Potential Targets for Intervention*
Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA

8:45 AM
*When Do We Call It Quits: Intervention Strategies and Outcomes for Medical Non-Adherence*
Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

9:00 AM
*Are All Substances Made Equal?*
Andrea DiMartini, MD, University of Pittsburgh, Pittsburgh, PA, USA

9:15 AM
*Case Presentation (Part 1): The Good, The Bad And The Ugly*
Jay Baumwol, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia

9:25 AM **Q&A**

9:30 AM
*Case Presentation (Part 2): The Good, The Bad And The Ugly*
Gillian Coult, BSW, Alfred Hospital, Melbourne, Australia

9:40 AM **Q&A**

9:45 AM **Panel Discussion**

Wednesday, April 5
8:00 AM - 10:00 AM

SYMPOSIUM 03: Primary Graft Dysfunction (PGD) and Vasoplegia After Heart Transplantation: Sink or Swim

Location:
Grand Hall B

Target Audience:
HTX, HF, MCS

Chairs:
Scott Silvestry, MD, and Hermann Reichenspurner, MD, PhD

Session Summary: The session goals are to review the existing and updated knowledge on primary graft dysfunction (PGD) and vasoplegia after heart transplantation. The presentations include: review of the published literature and ISHLT 2014 PGD definitions; the UK prospective PGD study; donor, recipient, and surgical risk factors; as well as experiences with post-transplant vasoplegia, with possible lessons learned from non-transplant heart surgery. There will be a 30-minute panel discussion at the end.

8:00 AM
Review of the Published Literature and the ISHLT 2014 PGD Definition
Jon A. Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

8:15 AM
Review of Risk Factors for PGD: Donor, Recipient, and Surgical Procedure
Jennifer Cook, MD, University of Arizona, Tucson, AZ, USA

8:30 AM
First Prospective Observational Study on PGD: UK The Heart Evaluation and Retrieval for Transplantation Study
Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

8:45 AM
Vasoplegia after Adult Heart Transplantation and MCS Surgery
Maria M Patarroyo Aponte, MD, Allegheny General Hospital, Pittsburgh, PA, USA

9:00 AM
Severe PGD and Post-Operative Vasoplegia: Complications on the Same Spectrum or Different Entities?
Hiroo Takayama, MD, Columbia University, New York, NY, USA

9:15 AM
What Can We Learn from Non-Transplant Cardiac Surgery?
Paul J Mohacsi, MD, University Hospital, Bern, Switzerland

9:30 AM Panel Discussion
8:00 AM - 10:00 AM
SYMPOSIUM 04: Thinking Outside the Box: Extra-Pulmonary Management in Lung Transplantation

Location:
Grand Hall C

Target Audience:
LTX, BSTR, ID, NHSAH, PATH, PEDS, PHARM, PH

Chairs:
Adrian C Lawrence, MD, and Helen Whitford, MBBS, FRACP

Session Summary: Gastrointestinal complications, extra-pulmonary factors or concurrent systemic disorders may compromise long-term outcome following lung transplantation. This session highlights new paradigms of disease understanding, diagnosis, treatment, prevention and possibilities for investigational trial design.

8:00 AM
Gastro-Intestinal Dysmotility in Thoracic Organ Transplantation Revisited: Importance, Evaluation, Treatment
Frank D'Ovidio, MD, Columbia University, New York, NY, USA

8:20 AM Q&A

8:24 AM
Gastro-Intestinal Malignancies in Thoracic Organ Transplantation: Collateral Damage?
Monique Malouf, MD, St. Vincent's Hospital, Sydney, Australia

8:44 AM Q&A

8:48 AM
New Lungs - Old Sinuses: Friends or Foes?
Joseph M. Pilewski, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

9:08 AM Q&A

9:12 AM
Lung Transplantation in Systemic Disorders: Need for a Holistic Approach
Joseph P Lynch, MD, UCLA Medical Center, Los Angeles, CA, USA

9:32 AM Q&A

9:36 AM
Pregnancy After Thoracic Organ Transplantation: Unwanted But Unavoidable?
Mitesh Thakrar, MD, Alberta Lung Transplant Program, Calgary, AB, Canada

9:56 AM Q&A
SYMPOSIUM 05: Joint ISHLT/PHA Symposium: PH and Transplant: Where Do We Go From Here?

Location:
Grand Hall D

Target Audience:
PH, HF, HTX, LTX, MCS, NHSAH, PEDS

Chairs:
Oksana A. Shlobin, MD, and Karen Fagan, MD

Session Summary: Lung transplantation is a viable treatment option for Group I pulmonary arterial hypertension (PAH). In addition, the presence of a secondary forms of PH (Group 2, or 3) in patients who require heart or lung transplant confers a high risk of complications. This symposium, supported by a collaborative effort with the Pulmonary Hypertension Association (PHA), will address various aspects of lung transplantation in adult and pediatric patients with different forms of PH.

8:00 AM
Transplantation for PH in the Era of LAS
Roham Zamanian, MD, Stanford University, Stanford, CA, USA

8:15 AM Q&A

8:20 AM
Effect of Non-Group 1 Pulmonary Hypertension on Lung Transplantation
Jorn Carlsen, MD, DMSc, Copenhagen University Hospital, Copenhagen, Denmark

8:35 AM Q&A

8:40 AM
Saving the Lung: Liver Transplant in Portopulmonary Hypertension
Sonja Bartolome, MD, UT Southwestern Medical Center, Dallas, TX, USA

8:55 AM Q&A

9:00 AM
Oops: Pregnancy in Pulmonary Hypertension
Valerie McLaughlin, MD, University of Michigan, Ann Arbor, MI, USA

9:15 AM Q&A

9:20 AM
Challenging Choices: Switching between IV and Oral Prostanoid Therapy
Joel Wirth, MD, Maine Medical Center, Portland, ME, USA

9:35 AM Q&A

9:40 AM
Quality of Life is Most Important: Patient Related Outcomes in PH
Mardi Gomberg-Maitland, MD, Inova Heart and Vascular Institute, Falls Church, VA, USA

9:55 AM Q&A
8:00 AM - 10:00 AM
SYMPOSIUM 06: The Failing Fontan - Where Do We Go From Here?

Location:
Seaport F-H

Target Audience:
PEDS, EEP, HF, HTX

Chairs:
Thomas Moller, MD, PhD, and Steven Kindel, MD

Session Summary: The aim is to discuss the care of the Fontan patient with heart failure across the spectrum, from pre-transplant medical management to mechanical support and heart transplantation. Timing of transplantation and listing, multi-organ transplantation and listing, and listing policies will all be discussed. Finally, a difficult case will be presented to the expert speaker panel at the end of the session.

8:00 AM
Sustainable Palliation: Optimizing Fontan Patients Prior to Heart Transplant
Jack Rychik, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

8:15 AM Q&A

8:20 AM
Call for Help! Surgical Options for End-Stage Fontan Failure
Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

8:35 AM Q&A

8:40 AM
Do You Want to List Too Early or Too Late? How to Determine When Fontan Patients Should be Listed for Transplant
Claire Irving, MBChB, MRCPCH, MD, Children’s Hospital at Westmead, Sydney, Australia

8:55 AM Q&A

9:00 AM
It’s Not JUST the Heart: Multi-Organ Transplantation in Fontan Patients
Daniel N Bernstein, MD, Stanford University, Stanford, CA, USA

9:15 AM Q&A

9:20 AM
Will Anybody Still Transplant My Patient? Programmatic Issues With Taking On Complex Fontan Patients
Richard Kirk, FRCP, FRCPCH, UT Southwestern Medical Center, Dallas, TX, USA

9:35 AM Q&A

9:40 AM
Case Presentation - The Failing Fontan Patient
Kathleen Simpson, MD, Washington University and Saint Louis Children's Hospital, St. Louis, MO, USA

9:50 AM Panel Discussion
8:00 AM - 10:00 AM
SYMPOSIUM 07: Joint ISHLT/ESCMID Symposium: Ongoing Challenges in Transplant Infectious Diseases

Location:
Coronado A-C

Target Audience:
ID, HTX, LTX, MCS, PHARM

Chairs:
Lara Danziger-Isakov, MD, MPH, and Oriol Manuel, MD

Session Summary: This session, supported by a collaborative effort with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), will provide important insight on relevant issues surrounding the care of thoracic organ transplant candidates and recipients and patients on mechanical circulatory support with infections.

8:00 AM
Non-Cultural Methods for Diagnosis and Prevention of Invasive Fungal Infections: Are We There Yet?
Barbara Alexander, MD, Duke University, Durham, NC, USA

8:15 AM Q&A

8:20 AM
Role of Inhaled Antimicrobials in the Era of Multidrug Resistance
Benoit Guery, MD, University Hospital Vaudois, Lausanne, Switzerland

8:35 AM Q&A

8:40 AM
Infection in Thoracic Organ Transplant Recipients on ECMO
Nicolas Mueller, MD, University Hospital Zurich, Zurich, Switzerland

8:55 AM Q&A

9:00 AM
Hepatitis C in Donor and Thoracic Organ Transplant Candidates and Recipients: A New Horizon
Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy

9:15 AM Q&A

9:20 AM
Experience in HIV Infection in Thoracic Organ Transplantation and MCS
Shirish Huprikar, MD, Mount Sinai Medical Center, New York, NY, USA

9:35 AM Q&A

9:40 AM
EBV and Anellovirus Viremia as Markers of Risk of Infection in Lung Transplant Recipients
José María Aguado, MD, Hospital 12 de Octubre, Madrid, Spain

9:55 AM Q&A
10:30 AM - 12:30 PM
OPENING PLENARY SESSION

Location: Seaport A-E

Target Audience: ALL

Chairs: Jeffrey J Teuteberg, MD, and Maryl R Johnson, MD

10:30 AM
Welcome/Program Chair Report
Jeffrey J Teuteberg, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

10:35 AM
Thoracic Registry Report
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

10:55 AM
MCSD Registry Reports
James K Kirklin, MD, University of Alabama, Birmingham, AL, USA

11:05 AM
President’s Report
Maryl R Johnson, MD, University of Wisconsin School of Medicine, Madison, WI, USA

11:20 AM (1) The Treatment of Patients with Advanced Heart Failure Ineligible for Cardiac Transplantation with the HeartWare Ventricular Assist Device: Results of the ENDURANCE Supplement Trial; C. A. Milano¹, J. G. Rogers¹, A. J. Tatooles², G. Bhat³, M. S. Slaughter⁴, E. J. Birks⁴, N. A. Mokadam⁵, C. Mahr⁶, J. S. Miller⁶, V. Jeevanandam⁷, K. Leadley⁸, K. D. Aaronson⁹, F. D. Pagani⁹. ¹Duke University Medical Center, Durham, NC, ²Advocate Christ Medical Center, Downers Grove, IL, ³Advocate Health Care, Oak Lawn, IL, ⁴University of Louisville, Louisville, KY, ⁵University of Washington, Seattle, WA, ⁶Emory Healthcare, Atlanta, GA, ⁷University of Chicago, Chicago, IL, ⁸HeartWare, Framingham, MA, ⁹University of Michigan Medical Center, Ann Arbor, IL

11:35 AM
Interactive Discussant
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

11:40 AM (2) The Impact of Age, Sex, Therapeutic Intent and Severity of Advanced Heart Failure on Outcomes in the Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with Heartmate 3 (Momentum 3) Pivotal Trial; D. Goldstein¹, M. R. Mehra², Y. Naka³, C. T. Salerno⁴, N. Uriel⁵, D. Dean⁶, A. Itoh⁷, F. D. Pagani⁸, E. R. Skipper⁹, G. Bhat¹⁰, N. Raval¹¹, B. A. Bruckner¹², J. Estep¹², R. Cogswell¹³, C. A. Milano¹⁴, L. Fendelander¹⁵, J. B. O’Connell¹⁶, J. Cleveland¹⁷. ¹Montefiore Medical Center, Bronx, NY, ²Brigham and Women’s Hospital, Boston, MA, ³Columbia University Medical Center, New York, NY, ⁴St.Vincent’s Hospital, Indianapolis, IN, ⁵University of Chicago Medical Center, Chicago, IL, ⁶Piedmont Hospital, Atlanta, GA, ⁷Washington University School of Medicine, St.Louis, MO, ⁸University of Michigan Medical Center, Ann Arbor, MI, ⁹Carolina’s Medical Center, Charlotte, NC, ¹⁰Advocate Christ Medical Center, Chicago, IL, ¹¹Florida Hospital, Orlando, FL, ¹²Houston Methodist Hospital, Houston, TX, ¹³University of Minnesota Medical Center, Minneapolis, MN, ¹⁴Duke University Medical Center, Durham, NC, ¹⁵St.Jude Medical, Burlington, MA, ¹⁶St.Jude Medical, Pleasanton, CA, ¹⁷University of Colorado Medical Center, Denver, CO

11:55 AM
Interactive Discussant
Jan D Schmitto, MD, PhD, MBA, Hannover Medical School, Hannover, Germany

12:00 PM
Pioneer Award Recipient Lecture: Standing on the Shoulders of Giants
Stuart W Jamieson, MB, FRCS, UC San Diego Health System, La Jolla, CA, USA
2:30 PM - 4:00 PM
ORAL SESSION 01: Too Thick or Too Thin? Bleeding and Thrombosis in MCS

Location:
Seaport A-E

Target Audience:
MCS, HF, NHSAH, PHARM

Chairs:
Antonio Loforte, MD, and Nahush A. Mokadam, MD


2:45 PM (4) The Effect of Pre-Existing Hypercoagulable Disorders on Outcomes in Patients with LVADs; S. Adatya1, G. Egnaczyk2, J. N. Katz3, A. Brieke4, J. Stulak5, S. Nathan6, J. D. Rich7, S. Emani8, A. Kilic9, J. Ransom10, E. C. DePasquale11, D. Crandall12, D. J. Farrar12, K. Sundareswaran12, N. Uriel13. 1Advanced Heart Failure, Transplant and Mechanical Support, University of Chicago Medical Center, Chicago, IL, 2Christ Hospital, Cincinnati, OH, 3Division of Cardiology, University of North Carolina, Chapel Hill, NC, 4University of Colorado School of Medicine, Denver, CO, 5Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 6Memorial Hermann – Texas Medical Center, Houston, TX, 7Northwestern University Feinberg School of Medicine, Chicago, IL, 8Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, OH, 9Division of Cardiac Surgery, Ohio State University Medical Center, Columbus, OH, 10Baptist Health Heart and Transplant Institute, Little Rock, AR, 11Ronald Reagan UCLA Medical Center, Los Angeles, CA, 12St. Jude Medical, Pleasanton, CA, 13University of Chicago Medical Center, Chicago, IL


3:15 PM (6) Platelet Membrane-Related Morphologic Alterations: An Early Marker of Supra-Physiologic Shear-Mediated Platelet Activation Associated with VADs; A. Dimasi1, M. Rasponi1, F. Consolo1, A. Redaelli1, M. Slepian2. 1Politecnico di Milano, Milano, Italy, 2University of Arizona, Tucson, AZ


3:45 PM (8) Managing Anticoagulation in LVAD Patients: The Harefield Experience; R. Hards, G. Edwards, C. Kavanagh, M. Hedger, A. R. Simon. Transplant and Mechanical Circulatory Support, Harefield Hospital, Uxbridge, United Kingdom
2:30 PM - 4:00 PM
ORAL SESSION 02: Engineering for Perfection in MCS

Location:
Grand Hall A

Target Audience:
MCS, HF, NHSAH

Chairs:
Shashank S Desai, MD, and Sanem Nalbantgil, MD

2:30 PM (9) **Mechano-Acoustic Detection of Dysfunction in Continuous Flow VADs Utilizing Stretchable Electronic Systems**; Y. Liu¹, K. R. Ammann², J. A. Rogers¹, M. J. Slepian². ¹University of Illinois, Urbana-Champaign, IL, ²University of Arizona, Tucson, AZ

2:45 PM (10) **Virtual Implantation of the Infant Jarvik 2015 for Eligibility Criteria Establishment**; J. R. Ryan¹, J. Teal², S. Pophal³, J. Nigro³, I. Adachi⁴, R. Jaquiss⁵, D. Frakes⁶, R. Jarvik⁷. ¹Cardiac 3D Print Lab, Phoenix Children's Hospital, Phoenix, AZ, ²Jarvik Heart, New York, NY, ³Phoenix Children's Hospital, Phoenix, AZ, ⁴Texas Children's Hospital, Houston, TX, ⁵Duke University School of Medicine, Durham, NC, ⁶Arizona State University, Tempe, AZ, ⁷National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

3:00 PM (11) **A Novel, Implantable Device for Right-Side Mechanical Circulatory Support**; J. R. Stanfield¹, J. W. Long². ¹University of Utah, Oklahoma City, OK, ²INTEGRIS, Oklahoma City, OK

3:15 PM (12) **Pulsatile Outflow in Cows Supported Long-Term with the BiVACOR Rotary TAH**; W. E. Cohn¹, F. Arabia², D. L. Timms³, N. Greatrex³, M. Kleinheyer³, F. Nestler³, S. Diab¹, O. Frazier¹. ¹Texas Heart Institute, Houston, TX, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³BiVACOR Inc., Houston, TX

3:30 PM (13) **Primary Biventricular Durable Ventricular Assist Devices from Experience North American Centers: A Cautionary Tale**; P. Shah¹, R. Ha², R. Singh³, E. Adler⁴, M. Brambatti⁴, S. Kidambi², D. Banerjee⁵, V. D. Pretorius⁶. ¹Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, ²Cardiothoracic Surgery, Stanford University, Palo Alto, CA, ³Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, VA, ⁴Cardiovascular Medicine, University of California San Diego, La Jolla, CA, ⁵Cardiovascular Medicine, Stanford University, Palo Alto, CA, ⁶Cardiothoracic Surgery, University of California San Diego, La Jolla, CA

2:30 PM - 4:00 PM
ORAL SESSION 03: Moving DCD Forward: Thinking Inside the Box

Location:
Grand Hall B

Target Audience:
HTX, BSTR, MCS

Chairs:
Maryjane Farr, MD, and Kumud K Dhital, MD, PhD

2:30 PM (15) 12 Hour Hypothermic Oxygenated Machine Perfusion Preserves the Quality of Donor Hearts: A Biomarker Analysis; S. G. Michel¹, M. L. Madariaga², S. M. Labbe³, E. Dupre³, L. M. Anderson⁴, K. Shanmugarajah⁵. ¹Cardiac Surgery, Ludwig Maximilian University, Muenchen, Germany, ²Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ³IPS Therapeutique, Sherbrooke, QC, Canada, ⁴Paragonix Technologies, Inc., Braintree, MA, ⁵Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom


2:30 PM - 4:00 PM
ORAL SESSION 04: Donor Lung Allocation Strategies

Location:
Grand Hall C

Target Audience:
LTX, EEP, NHSAH

Chairs:
Dirk E Van Raemdonck, MD, and Laveena Chhatwani, MD

2:30 PM (21) What Effect Does Rate of Change in LAS Have on Lung Transplant Outcomes?:
A. Aretakis1, C. Towe2, M. Schecter2, D. L. Morales1, R. Bryant, III1, F. Zafar1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Pulmonology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

2:45 PM (22) Lung Allocation Score Implementation Narrowed Racial/Ethnic Disparities in Adult Lung Transplantation Outcomes:
B. Lim, J. Lasky, C. Schaufler, Y. Suzuki, D. Mallem, M. Molina, C. A. Bermudez, J. M. Diamond, J. D. Christie, E. Cantu. University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

3:00 PM (23) Objective Donor Scoring System for Lung Transplantation:
W. M. Whited, J. R. Trivedi, V. H. van Berkel, M. P. Fox. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

3:15 PM (24) Is There a Rationale for an “Old-for-Old” Program in Lung Transplantation? A Comparative Study Using the International Society of Heart and Lung Transplantation Database:
A. M. Bernhardt1, A. P. Levin2, J. Stehlik3, C. Benden4, L. Edwards5, F. M. Wagner1, H. Reichenspurner1. 1Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, 2Columbia University Medical Center, New York City, NY, 3University of Utah School of Medicine, Salt Lake City, UT, 4University Hospital Zurich, Zurich, Switzerland, 5United Network for Organ Sharing, Richmond, VA

3:30 PM (25) Are Donors with Pulmonary Arterial Embolism the Better Donors for Lung Transplantation?:
W. Sommer1, H. Kirschner2, F. Ius1, J. Salman1, T. Siemeni1, M. Avsar1, C. Kuehn1, M. Kaufmann2, M. Greer3, J. Gottlieb3, A. Rahmel4, T. Welte3, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, 2Deutsche Stiftung Organtransplantation, Region Nord, Germany, 3Respiratory Medicine, Hannover Medical School, Hannover, Germany, 4Deutsche Stiftung Organtransplantation, Frankfurt, Germany

3:45 PM (26) Use of Drug Intoxicated Donors for Lung Transplant: Impact on Survival Outcomes:
W. M. Whited, J. R. Trivedi, M. P. Fox, V. H. van Berkel. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

Wednesday, April 5
2:30 PM - 4:00 PM
ORAL SESSION 05: Registries and Risk Scores in Pulmonary Hypertension: Updates, Lessons Learned, and Practice Changes

Target Audience: PH, HF, HTX, LTX, NHAH, PEDS, PHARM

Chairs: Ioana R Preston, MD, and Tanya J. McWilliams, MD, PhD

2:30 PM (27) Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients: R. L. Benza, C. G. Elliott, H. W. Farber, A. J. Foreman, A. E. Frost, M. Gomberg-Maitland, M. D. McGoon, D. J. Pasta, M. Selej, R. P. Frantz. 1Allegheny General Hospital, Pittsburgh, PA, 2Intermountain Medical Center and the University of Utah, Salt Lake City, UT, 3Boston University School of Medicine, Boston, MA, 4ICON Clinical Research, San Francisco, CA, 5Houston Methodist Lung Center, Weill-Cornell, Institute for Academic Medicine, Houston, TX, 6Inova Fairfax Hospital, Falls Church, VA, 7Mayo Clinic, Rochester, MN, 8Actelion Pharmaceuticals US, Inc., South San Francisco, CA

2:45 PM (28) Preliminary Data from the USA CTEPH Registry: K. M. Kerr, W. R. Auger, R. L. Benza, R. N. Channick, K. Chin, R. D. Davis, C. G. Elliott, A. Z. LaCroix, M. M. Madani, V. V. McLaughlin, M. H. Park, V. F. Tapson. 1Univ California San Diego, La Jolla, CA, 2University of Pittsburgh, Pittsburgh, PA, 3Massachusetts General Hospital, Boston, MA, 4University of Texas Southwestern, Dallas, TX, 5Florida Hospital, Orlando, FL, 6Intermountain Healthcare, Salt Lake City, UT, 7University of Michigan, Ann Arbor, MI, 8Houston Methodist Hospital, Houston, TX, 9Cedars-Sinai Medical Center, Los Angeles, CA

3:00 PM (29) REVEAL Risk Score in Patients with Chronic Thromboembolic Pulmonary Hypertension Receiving Riociguat: R. L. Benza, H. W. Farber, A. Frost, E. Grüning, M. Hoeper, D. Busse, C. Meier, S. Nikkhø, H. Ghofrania. 1Allegheny Gen Hosp, Pittsburgh, PA, 2Pulmonary Center, Boston University School of Medicine, Boston, MA, 3Houston Methodist Lung Center and Institute of Academic Medicine, Houston, TX, 4Centre for Pulmonary Hypertension, Thoracixclinic at the University Hospital Heidelberg, Heidelberg, Germany, 5Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany, 6Chrestos Concept GmbH & Co, Essen, Germany, 7Global Medical Affairs, Bayer Pharma AG, Berlin, Germany, 8Global Clinical Development, Bayer Pharma AG, Berlin, Germany, 9University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, Member of the German Center, University Hospital Giessen and Marburg, Giessen, Germany

3:15 PM (30) OPUS Registry: Safety and Tolerability of Macitentan in a Real-World Setting: N. H. Kim, M. Brand, K. M. Chin, R. N. Channick, M. Selej, V. V. McLaughlin. 1University of California, San Diego, La Jolla, CA, 2Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 3UT Southwestern Medical Center, Dallas, TX, 4Massachusetts General Hospital, Boston, MA, 5Actelion Pharmaceuticals US Inc, South San Francisco, CA, 6University of Michigan, Ann Arbor, MI

3:30 PM (31) Orthotopic Heart Lung Transplantation Improving Outcomes Over Time: E. Nagy, L. B. Edwards, A. Y. Kucheryavaya, J. Stehlik, R. D. Yusen, L. H. Lund. 1Dept. of Cardiology, Karolinska University Hospital; Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Research Department, United Network for Organ Sharing, Richmond, VA., International Society for Heart and Lung Transplantation Registry, Dallas, Texas., Dallas, TX, 3Research Department, United Network for Organ Sharing, Richmond, VA., International Society for Heart and Lung Transplantation Registry, Dallas, Texas., Dallas, TX, 4University of Utah School of Medicine, Division of Cardiovascular Medicine, Salt Lake City, Utah, USA, Salt Lake City, UT, 5Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA., 6Division of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.

3:45 PM (32) Orthotopic Heart-Lung Transplantation: Outcomes and Predictors of Outcomes in Recipients with Eisenmenger Syndrome, Other Congenital Etiologies, and Idiopathic Pulmonary Arterial Hypertension: E. Nagy, L. B. Edwards, A. Y. Kucheryavaya, J. Stehlik, R. D. Yusen, L. H. Lund. 1Department of Cardiology, Karolinska University Hospital, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Research Department, United Network for Organ Sharing, Richmond, VA., International Society for Heart and Lung Transplantation Registry, Dallas, Texas., Dallas, TX, 3University of Utah School of Medicine, Division of Cardiovascular Medicine, Salt Lake City, Utah, USA., Salt Lake City, UT, 4Divisions of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA., 5Division of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA., 6Division of Pulmonary and Critical Care Medicine and General Medical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
2:30 PM - 4:00 PM
ORAL SESSION 06: Pediatric Heart Failure: Diagnosis, Management, and Confronting Risk

Location: Seaport F-H
Target Audience: PEDS, HF, HTX
Chairs: Ashwin K Lal, MD, and Shigetoyo Kogaki, MD

2:30 PM (33) **Distinct Disease Mechanisms Govern the Progression of Pediatric and Adult Dilated Cardiomyopathy**; M. Patel1, C. Schneider2, J. Mohan2, C. Canter1, T. Jeffrey3, K. J. Lavine2, 1Pediatrics, Washington University, St Louis, MO, 2Cardiology, Washington University, St Louis, MO, 3Pediatrics, University of Tennessee Health Center, Memphis, TN

2:45 PM (34) **Diagnostic Errors at First Presentation of Heart Failure in Children**; K. Puri1, H. Singh2, S. W. Denfield1, A. G. Cabrera1, W. J. Dreyer1, J. F. Price1. 1Cardiology, Baylor College of Medicine/Texas Children’s Hospital, Houston, TX, 2Medicine Health Services Research, Baylor College of Medicine, Houston, TX

3:00 PM (35) **Hemodynamics of the Pediatric Failing Fontan**; J. C. Dykes1, D. B. McElhinney2, D. Bernstein1, M. R. Chrisant3, S. Chen1, K. P. Daly4, R. K. Ameduri5, K. R. Knecht6, M. E. Richmond7, K. Y. Lin8, S. Urschel9, J. Simmonds10, K. E. Simpson11, C. S. Almond1, S. Chen1. 1Pediatrics, Stanford University, Palo Alto, CA, 2Cardiothoracic Surgery, Stanford University, Palo Alto, CA, 3Pediatrics, Joe DiMaggio Children's Hospital, Fort Lauderdale, FL, 4Pediatrics, Harvard University, Boston, MA, 5Pediatrics, University of Minnesota, Minneapolis, MN, 6Pediatrics, University of Arkansas for Medical Sciences, Arkansas, AR, 7Pediatrics, Columbia University Medical Center, New York, NY, 8Pediatrics, University of Pennsylvania, Philadelphia, PA, 9Pediatrics, University of Alberta, Edmonton, AB, Canada, 10Pediatrics, Great Ormond Street Hospital, London, United Kingdom, 11Pediatrics, Washington University School of Medicine, St. Louis, MO

3:15 PM **Assist Device Therapy for Myocarditis - Analysis from the German Multi-Centre Prospective Myocarditis Registry in Pediatric Patients:** "Mykke"; S. Schubert1, F. Degener2, B. Opge-Rhein2, F. Schmidt4, A. Weigel5, R. Wagner6, T. Mir7, A. Rentzsch8, E. z. Knyphausen9, K. Papkostas10, G. Wiegand11, B. Rüf12, T. Hannes13, K. Reineker14, D. Kiski15, M. Khaili16, M. Steinmetz17, G. Fischer18, T. Pickardt19, D. Messroghli20, O. O. MYKKE Consortium21. 1Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin and DZHK, Berlin, Germany, 2Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, 3Pediatric Cardiology, Charité Universitätsmedizin Berlin, Berlin, Germany, 4Pediatric Cardiology, Medizinische Hochschule Hannover, Hannover, Germany, 5Pediatric Cardiology, Universitätsklinikum Erlangen, Erlangen, Germany, 6Pediatric Cardiology, Herzzentrum Leipzig, Leipzig, Germany, 7Pediatric Cardiology, Univeristäres Herzzentrum Hamburg, Hamburg, Germany, 8Pediatric Cardiology, Universitätsklinikum des Saarlandes, Homburg, Germany, 9Congenital Heart Disease, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, 10Structural Heart Disease/Pediatric Cardiology, Klinikum Links der Weser, Bremen, Germany, 11Pediatric Cardiology, Universitätsklinikum Tübingen, Tübingen, Germany, 12Congenital Heart Disease/Pediatric Cardiology, 12Deutsches Herzzentrum und Technische Universität München, München, Germany, 13Pediatric Cardiology, Uniklinik Köln, Cologne, Germany, 14Congenital Heart Disease/Pediatric Cardiology, Universitäts-Herzzentrum Freiburg Bad Krozingen, Freiburg, Germany, 15Pediatric Cardiology, Universitätsklinikum Münster, Münster, Germany, 16Pediatric Cardiology, Universitätsklinik Gießen, Giessen, Germany, 17Pediatric Cardiology and Intensive Care, Universitätsmedizin und Kinderherzklínik Göttingen, Göttingen, Germany, 18Clinic for Pediatric Cardiology, Universitätskliniken Schleswig-Holstein, Kiel, Germany, 19Kompetenzzentrum für angeborene Herzfehler, Berlin, Germany, 20Cardiology, Deutsches Herzzentrum Berlin & DZHK, Berlin, Germany, 21Multicenter, Germany, Germany

3:30 PM (37) **Renal Dysfunction as a Relative Contraindication to Pediatric Heart Transplantation**; I. Wilmot, R. Rizwan, F. Zafar, D. Hooper, T. D. Ryan, C. Chin. Cardiology, Cincinnati Children’s Hospital All Children’s Hospital, Cincinnati, OH

3:45 PM (38) **The Impact of Tracheostomy on Pediatric Heart Transplant Outcomes: A Multi-Institutional Analysis**; J. A. Spinner1, S. W. Denfield1, K. Puri1, S. A. Morris1, B. S. Moffett2, J. F. Price1, W. J. Dreyer1, A. G. Cabrera1. 1Pediatrics, Baylor College of Medicine, Houston, TX, 2Pain Medicine, Texas Children's Hospital, Houston, TX

Wednesday, April 5
2:30 PM - 4:00 PM
ORAL SESSION 07: Cutting Edge Updates in Infectious Diseases

Location:
Coronado A-C

Target Audience:
ID, ALL

Chairs:
Karen Doucette, MD, MSc, and Stephanie M Pouch, MD

2:30 PM (39) Clinical Risk Factors for Invasive Aspergillosis in Lung Transplant Recipients: Results of an International Cohort Study; C. Aguilar1, B. Hamandi2, C. Fegbeutel3, F. P. Silveira4, E. A. Verschuuren5, P. Ussetti6, P. V. Chin-Hong7, A. Sole8, C. Holmes-Liew9, E. M. Billaud10, P. A. Grossi11, O. Manuel12, D. J. Levine13, R. G. Barbers14, D. Hadjiliadis15, L. Singer16, S. Husain1. 1Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 2Department of Pharmacy, University Health Network, Toronto, ON, Canada, 3Hannover Medical School, Hannover, Germany, 4University of Pittsburgh, Pittsburgh, PA, 5University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 6Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, 7University of California, San Francisco, San Francisco, CA, 8University and Polytechnic Hospital La Fe, Universidad de Valencia, Valencia, Spain, 9Royal Adelaide Hospital, Adelaide, Australia, 10APHP Hopital Européen G Pompidou, Paris, France, 11University of Insubria, Varese, Italy, 12University Hospital of Lausanne, Lausanne, Switzerland, 13University of Texas Health Science Center San Antonio, San Antonio, TX, 14KECK Medical Center of University of Southern California, Los Angeles, CA, 15University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA, 16Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

2:45 PM (40) Aspergillus Galactomannan Detection in Exhaled Breath Condensate for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients; A. Bhimji1, A. Bhaskaran1, L. G. Singer2, D. Kumar1, A. Humar1, R. Pavan1, C. Rotstein1, S. Keshavjee2, T. Mazzulli3, S. Husain1. 1Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 2Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, 3Mount Sinai Hospital, Toronto, ON, Canada

3:00 PM (41) Impact of Cytomegalovirus and Its Prevention Strategies on Survival in Thoracic Transplant Recipients; J. K. Preiksaitis, C. A. Mabilangan, C. Cervera. Medicine, University of Alberta, Edmonton, AB, Canada

3:15 PM (42) Invasive Mycobacterium abscessus Infection in Heart Transplant Recipients; E. K. Maziarz1, A. W. Baker1, C. B. Patel2, P. Patel2, C. A. Milano3, J. N. Schroder3, M. A. Daneshmand3, B. D. Alexander4, C. R. Wolfe1. 1Division of Infectious Diseases and International Health, Duke University, Durham, NC, 2Division of Cardiology, Duke University, Durham, NC, 3Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC

3:30 PM (43) Clinical and Microbiologic Characteristics of Infections in Left Ventricular Assist Device Recipients; M. Bradbury1, S. Phillips1, J. Stulak2, K. Abdullah1, C. T. Salerno3, S. Maltais2, S. M. Dunlay2, T. F. Dardas4, K. Aaronson5, F. D. Pagani5, J. A. Cowger3, P. Shah1. 1Inova Heart and Vascular Institute, Falls Church, VA, 2Mayo Clinic, Rochester, MN, 3St. Vincent Heart Center of Indiana, Indianapolis, IN, 4University of Washington, Seattle, WA, 5University of Michigan Health System, Ann Arbor, MI

3:45 PM (44) Potential Posaconazole Sequestration During Extracorporeal Membrane Oxygenation: Results from an Ex-Vivo Experiment; H. Lyster1, T. Pitti1, O. Maunz1, D. Garcia Saez1, J. Tiller1, N. Leaver1, J. Roberts2, K. Shekar3, D. Brown4, J. Mills4, M. Carby1, A. Simon1, A. Reed1. 1Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, 2The University of Queensland, Brisbane, Australia, 3The Prince Charles Hospital, Brisbane, Australia, 4University of Portsmouth, Portsmouth, United Kingdom
4:30 PM - 6:00 PM
ORAL SESSION 08: Bugs and Devices: A Bad Combination

Location:
Seaport A-E

Target Audience:
MCS, ID, NHSAH, PHARM

Chairs:
Simon Maltais, MD, PhD, and Orla Morrissey, MD

4:30 PM (45) Epidemiology of Bloodstream Infections in MCSD Recipients in the IMACS Registry: S. Aslam1, R. Xie2, V. Chu3, J. Cowger4, S. Schueler5, T. de By6, K. Gould5, O. Morrissey7, L. Lund8, S. Martin9, D. Goldstein10, M. Hannan11. 1Univ. of CA, San Diego, San Diego, CA, 2Univ. of Alabama, Birmingham, AL, 3Duke University, Durham, NC, 4St Vincent Heart Center of Indiana, Indianapolis, IN, 5Freeman Hospital, Newcastle upon Tyne, United Kingdom, 6Euromacs, Berlin, Germany, 7Alfred Hospital, Melbourne, Australia, 8Karolinska Institute, Stockholm, Sweden, 9Geisinger Health System, Danville, PA, 10Montefiore Medical Center, New York, NY, 11Mater Misericordiae University Hospital, Dublin, Ireland

4:45 PM (46) The Epidemiology of Infection in MCS from the IMACS Database: January 2013 to December 2015: M. M. Hannan1, R. Xie2, J. A. Cowger3, S. Schueler4, T. M. de By5, A. I. Dipchand6, V. H. Chu7, R. S. Cantor8, C. Koval8, T. Krabatsch9, C. Hayward10, J. K. Kirklin10. 1Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland, 2The James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO), UAB, Birmingham, AL, 3St Vincent Heart Center of Indiana, Indianapolis, IN, 4Newcastle Freeman Hospital, Newcastle upon Tyne, United Kingdom, 5EUROMACS, Berlin, Germany, 6Hospital for Sick Children, Toronto, ON, Canada, 7Division of Infectious Diseases, Duke University Medical Center, Durham, NC, 8Cleveland Clinic, Cleveland, OH, 9Deutsches Herzzentrum, Berlin, Germany, 10St Vincent's Hospital, Sydney, Australia

5:00 PM (47) Epidemiology of Fungal Infections (FI) in Mechanical Circulatory Support Device (MCSD) Recipients: Analysis of IMACS Registry 2013-2015: O. Morrissey1, R. Xie2, J. Chaeneman3, S. Husain4, M. Mooney5, T. Nakatani6, R. Kormos7, M. Gómez-Bueno8, S. Aslam9, Y. Pya10, M. Hannan11. 1Infectious Diseases, Alfred Health, Melbourne, Australia, 2The James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO/UAB), Birmingham, AL, 3Medicine, University of California, Los Angeles, Los Angeles, CA, 4Infectious Diseases, University Health Network, Toronto, ON, Canada, 5Sentara Norfolk Transplant Center/EVMS, Norfolk, VA, 6Maki Hospital, Osaka, Japan, 7Surgery, University of Pittsburgh, Pittsburgh, PA, 8Cardiology, Hospital Univ. Puerta de Hierro. Majadahonda, Madrid, Spain, 9Infectious Diseases, University of California, San Diego, San Diego, CA, 10National Research Cardiac Surgery Center, Astana, Kazakhstan, 11Microbiology, Mater Misericordiae University Hospital, Dublin, Ireland

5:15 PM (48) Risk Factors and Mortality for Sepsis in Left Ventricular Assist Device Recipients: P. S. Joy1, G. Kumar2, J. K. Bham1, L. M. Cadaret1. 1University of Iowa, Iowa City, IA, 2Northeast Georgia Health System, Gainesville, GA

5:30 PM (49) Supporting Imaging Modalities for Improving Diagnosis of Infection in Patients on CF-LVAD: A Single-Center Experience Including 61 Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomographies: A. M. Dell'Aquila1, N. Avramovic2, A. Motekallemi1, M. Scherer1, J. R. Sindermann1, C. Wenning1. 1Department of Thoracic and Cardiovascular Surgery, University Hospital Münster, Münster, Germany, 2Department of Nuclear Medicine, University Hospital Münster, Münster, Germany

5:45 PM (50) Hepatitis C Virus Infection Does Not Impact Survival Following Continuous-Flow Left Ventricular Assist Device Implantation: A. Pendyal1, J. M. Gelow. Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR
4:30 PM - 6:00 PM
ORAL SESSION 09: MCS Surgery: Does Nuance Make a Master?

Location:
Grand Hall A

Target Audience:
MCS, HF, NHSAH

Chairs:
Nader Moazami, MD, and Diyar Saeed, MD

4:30 PM (51) A Novel Technique of Temporary Right Ventricular Assist Device (RVAD) Placement During Durable Left Ventricular Assist Device (LVAD) Implant to Allow Early Ambulation and Bedside Percutaneous Removal; G. Zanotti1, T. B. Reece1, D. Fullerton1, J. Cleveland1, A. Babu2. 1Cardiothoracic Surgery, University of Colorado, Aurora, CO, 2Cardiothoracic Surgery, ST. Thomas Hospital, Nashville, TN


5:00 PM (53) Surgical Strategy to Support Right Ventricle with HVAD RVAD: Right Atrial vs Right Ventricular Diaphragmatic Surface Cannulation; Y. Shudo, R. V. Ha, O. Reinhartz, J. Woo, J. Boyd, C. Almond, D. N. Rosenthal, S. Chen, K. Maeda. Stanford University, Stanford, CA

5:15 PM (54) Should Prophylactic Tricuspid Valve Surgery Be Considered in Patients with Atrial Fibrillation Undergoing LVAD Implantation?; S. Maltais1, V. Tchantchaleishvili1, R. C. Daly1, D. L. Joyce1, L. D. Joyce1, S. S. Kushwaha2, J. M. Stulak1. 1Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

5:30 PM (55) Outcomes of Multiple Concomitant Valve Procedures in Patients Receiving Continuous-Flow Left Ventricular Assist Device; J. Han1, H. Takayama1, P. A. Kurlansky1, A. R. Garan2, M. Yuzefpolskaya2, V. K. Topkara2, P. C. Colombo2, Y. Naka1, K. Takeda1. 1Division of Cardiovascular Surgery, Columbia University Medical Center, New York, NY, 2Division of Cardiology, Columbia University Medical Center, New York, NY

5:45 PM (56) First-in-Human (FIH) Experience with the Intravascular Ventricular Assist System iVAS a Novel Approach to Mechanical Circulatory Support; V. Jeevanandam1, D. Onsager1, T. Song1, T. Ota1, C. Juricek1, T. Lammy1, V. Kagan1, H. Costantini1, G. Sayer2, S. Adatya2, G. Kim2, N. Uriel2. 1CT Surgery, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL
Wednesday, April 5

4:30 PM - 6:00 PM
ORAL SESSION 10: Movement on the Heart Transplant Wait List: VADS, Exceptions and Antibodies

Location: Grand Hall B

Target Audience: HTX, EEP, MCS, NHSAH

Chairs: Mark J Zucker, MD, and Tahir Yagdi, MD

4:30 PM (57) Trends in 1A Listing Exceptions in Heart Transplant (HT) Recipients Bridged by Left Ventricular Assist Device (LVAD) Type; A. Salimbangon1, J. A. Cowger2, D. Vucicevic1, L. Honoris1, A. Iyengar1, S. Shah1, E. Moreno1, A. Chang1, L. Reardon1, K. Pandya2, M. C. Deng1, A. Ardehali1, E. C. DePasquale1. 1UCLA, Los Angeles, CA, 2St Vincent Heart Center, Indianapolis, IN, 3UC Davis, Sacramento, CA

4:45 PM (58) Left Ventricular Assist Device Is Protective Against Cardiac Transplant Delisting for Medical Unsuitability; R. Cogswell1, S. Duval1, J. Schultz1, C. Martin1, K. Liao2, R. John2. 1Cardiology, University of Minnesota, Minneapolis, MN, 2Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

5:00 PM (59) Age Dependent Risk of LVAD Used as a Bridge to Transplant and of Comorbidities on Post-Transplant Survival: An Analysis of ISHLT Registry; M. Masetti1, A. R. Wilk2, F. Grigioni1, A. Russo1, L. B. Edwards2, L. H. Lund3, J. Stehlik4, L. Potena1. 1Heart Transplant Program, DIMEC, S.Orsola Hospital, University of Bologna, Bologna, Italy, 2United Network for Organ Sharing, Richmond, VA, 3Karolinska Institute, Department of Medicine, and Karolinska University Hospital, Department of Cardiology, Stockholm, Sweden, 4Utah Transplant Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program, University of Utah School of Medicine, Salt Lake City, UT

5:15 PM (60) Impact of Sensitization and 4S Prioritization on Heart Transplantation Waiting Times in Canada; N. Aleksova1, H. J. Ross2, L. M. Mielniczuk1, R. A. Davies1, E. Stadnick1, S. Chih1. 1University of Ottawa Heart Institute, Ottawa, ON, Canada, 2University Health Network, Toronto, ON, Canada

5:30 PM (61) Revealing a New Mode of Sensitization Induced by Mechanical Circulatory Support Devices (MCS): Impact of Anti-AT1R Antibodies; X. Zhang1, J. Mirocha2, T. Aintablian3, J. Moriguchi4, F. Arabia5, J. A. Kobashigawa4, N. L. Reinsmoen1. 1HLA and Immunogenetics Laboratory, Cedars-Sinai Health System, Los Angeles, CA, 2Biostastic Core, Cedars-Sinai Health System, Los Angeles, CA, 3California Heart Center, Los Angeles, CA, 4Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, 5Cardiovascular Surgery, Cedars Sinai Medical Center, Los Angeles, CA

5:45 PM (62) Trends in 1A Listing Exceptions in Heart Transplant (HT) Recipients Bridged with Mechanical Circulatory Support (MCS); E. C. DePasquale1, J. A. Cowger2, L. Honoris1, D. Vucicevic1, S. Shah1, A. Iyengar1, A. Salimbangon1, E. Moreno1, A. Chang1, L. Reardon1, K. Pandya2, M. Deng1, A. Ardehali1. 1UCLA, Los Angeles, CA, 2St Vincent Heart Center, Indianapolis, IN, 3UC Davis, Sacramento, CA
4:30 PM - 6:00 PM
ORAL SESSION 11: Improving Prognosis in Chronic Lung Allograft Dysfunction

Location:
Grand Hall C

Target Audience:
LTX, BSTR, EEP, ID, NHSAH, PATH, PHARM

Chairs:
Ramsey R Hachem, MD, and Erika D Lease, MD

4:30 PM (63) Correlation Between Microbial Diversity, Lung Inflammation, and Chronic Lung Allograft Dysfunction; L. Levy1, A. Tigert2, T. Saito3, K. Boonstra2, J. Prescod4, D. Hwang2, S. Keshavjee2, S. Juvet2, B. Coburn4, T. Martinu2. 1Toronto Lung Transplant Program, Toronto, ON, Canada, 2Toronto General Hospital, University Health Network, Toronto, ON, Canada, 3Kansai Medical University, Hirakara, Japan, 4Toronto General Research Institute, Toronto, ON, Canada

4:45 PM (64) Lung Bile Acid Correlation with Inflammation, Infection, CLAD and Survival; M. Ahmed1, R. Zamel2, D. Nakajima3, W. Klement3, M. Cypel2, J. Todd4, S. Weigt5, M. Liu2, L. Singer1, S. Keshavjee2, T. Martinu1. 1Medicine, Toronto Lung Transplant Program, Toronto, ON, Canada, 2Thoracic Surgery, Toronto Lung Transplant Program, Toronto, ON, Canada, 3Toronto Lung Transplant Program, Toronto, ON, Canada, 4Medicine, Duke University, Durham, NC, 5Medicine, UCLA, Los Angeles, CA

5:00 PM (65) Matrix Metalloproteinase-7 May Be a Biomarker of Early Chronic Lung Rejection; J. Jaffar1, T. Phan1, M. Stewart2, B. Levey2, M. Paraskeva2, G. Snell2, G. Westall1. 1The Alfred Hospital/Monash University, Melbourne, Australia, 2The Alfred Hospital, Melbourne, Australia

5:15 PM (66) The Impact of De Novo Donor-Specific Antibodies on Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome; E. Miyamoto, T. Martinu, W. Klement, S. Juvet, S. Keshavjee, K. Tinckam, J. Tikkanen. Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

5:30 PM (67) Role of Complement-Binding Anti-HLA Antibodies Detection as Early Predictor of Chronic Lung Dysfunction After Lung Transplantation; O. Brugière1, A. Roux2, J. Le Pavec3, D. Sroussi4, F. Parquin5, P. Pradère6, C. Dupin1, V. Bunel1, G. Mourin1, G. Jebra1, G. Thabut1, G. Dauriat1, Y. Castier1, P. Mordant1, B. Lortat Jacob1, S. Jean-Baptiste1, H. Mal1, C. Suberbielle1, J. Taupin1. 1Hôpital Bichat, Paris, France, 2Hôpital Foch, Suresnes, France, 3Hôpital Marie Lannelongue, Le Plessis Robinson, France

5:45 PM (68) Immunophenotyping Pre Total Lymphoid Irradiation for BOS After Lung Transplantation May Predict Response to Therapy; B. Schmack1, F. Cano Romero2, J. Hester2, V. Durrant3, S. Soresi4, D. Garcia Saez1, B. Zych1, O. Ananiadou1, A. R. Simon1, M. Carby4, A. Reed4, J. Smith3. 1Department of Cardiothoracic Transplantation & Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, 2Nuffield Department of Surgical Science, University of Oxford, Oxford, United Kingdom, 3Tissue Typing Service, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, 4Department of Respiratory and Transplant Medicine, Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom
4:30 PM - 6:00 PM  
**ORAL SESSION 12: Innovation in Pediatric MCS**

**Location:**  
Seaport F-H

**Target Audience:**  
PEDS, MCS

**Chairs:**  
Kristine J Guleserian, MD, and Oliver Miera, MD

---

4:30 PM (69) *Reverse Remodeling After Placement of Pulsatile and Continuous Flow Left Ventricular Assist Device in Children with End-Stage Idiopathic Dilated Cardiomyopathy;* J. Kasten¹, P. Punjwani², S. Zhang³, D. Rakheja¹, B. B. Das². ¹Department of Pathology, UT Southwestern Med Ctr, Dallas, TX, ²Division of Pediatric Cardiology, UT Southwestern Med Ctr, Dallas, TX, ³Department of Clinical Science Research, UT Southwestern Med Ctr, Dallas, TX

---


---

5:00 PM (71) *Post-Transplant Outcomes in Pediatric VAD Patients: A Pedimacs-PHTS Linkage Study;* D. L. Sutcliffe¹, E. Pruitt², R. S. Cantor², J. Godown³, J. Lane⁴, M. W. Turrentine⁵, S. P. Law⁶, J. L. Lantz⁷, D. C. Naffel⁸, J. K. Kirklin⁵, D. Bernstein⁷, E. D. Blume⁸. ¹Pediatric Cardiology, Children's Health Dallas, UT Southwestern, Dallas, TX, ²Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric Cardiology, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN, ⁴Pediatric Critical Care, Phoenix Children’s Hospital, Phoenix, AZ, ⁵Cardiac Surgery, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Cardiology, Columbia University-Morgan Stanley Children’s Hospital of New York Presbyterian, New York, NY, ⁷Pediatric Cardiology, Children's Health Dallas, Dallas, TX, ⁸Pediatric Cardiology, Lucile Packard Children’s Hospital at Stanford, Palo Alto, CA, ⁹Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA

---

5:15 PM (72) *In Vitro Examination of the VentiFlo™ True Pulse Pump for Failing Fontan Support;* P. M. Trusty¹, M. Tree², J. P. Naber³, K. Maher³, A. P. Yoganathan¹, S. Deshpande¹. ¹BME, Georgia Institute of Technology, Atlanta, GA, ²ME, Georgia Institute of Technology, Atlanta, GA, ³Design Mentor, Pelham, NH

---

5:30 PM (73) *Outcome of a Continous Flow Pump (Jarvik 2000) as Bridge to Transplantation or Destination Therapy in Pediatric Patients;* G. Perri¹, S. Filippelli¹, G. Testa¹, F. Iodice¹, R. Adoriso¹, R. Iacobelli¹, A. Di Molfetta¹, M. Massetti², A. Amodeo¹. ¹Bambino Gesù Children Hospital, Rome, Italy, ²Catholic University of Sacred Heart, Rome, Italy

---

5:45 PM (74) *Compassionate Deactivation of Ventricular Assist Devices in Children: A Survey of Pediatric VAD Clinicians’ Perspectives and Practices;* B. D. Kaufman¹, S. A. Hollander¹, S. H. Chen¹, D. Bernstein¹, D. N. Rosenthal¹, C. Almond¹, J. M. Murray¹, A. M. Burgart², H. J. Cohen¹, J. N. Kirkpatrick³, E. D. Blume⁴. ¹Pediatrics, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, ²Pediatric Anesthesia, Biomedical Ethics, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, ³Bioethics and Humanities, Medicine, University of Washington Medical Center, Seattle, WA, ⁴Pediatrics, Boston Children’s Hospital, Harvard Medical School, Boston, MA
4:30 PM - 6:00 PM
SYMPOSIUM 08: ECMO in Pre-Capillary PH: What is the Best Option for My Patient?

Location:
Grand Hall D

Target Audience:
PH, HF, LTX, PEDS, PH

Chairs:
Ellie Fadel, MD, and Corey E Ventetuolo, MD

Session Summary: ECMO options in patients with pre-capillary PH are multiple. They include peripheral VA ECMO through the lower or upper body, central ECMO, VV ECMO, or the new option of oxyRVAD. The indications depend on the patient conditions and underlying cause of PH. This symposium presents an overview of the different options and their application according to the sub-group of patients. There will be a focus on pediatric patients with PAH, adult patients with PAH, IPF-PH patients, and CTEPH patients. A panel discussion with all speakers will conclude this session.

4:30 PM
Peripheral vs. Central: ECMO in PAH Patients
Elie Fadel, MD, Hospital Marie Lannelongue, Le Plessis Robinson, France

4:50 PM
OxyRVAD: Who is a Candidate?
Charles Hoopes, MD, University of Alabama, Birmingham, AL, USA

5:10 PM
ECMO in Pediatric Patients with PAH: What are the Particularities?
Pirooz Eghtesady, MD, St. Louis Children's Hospital, St Louis, MO, USA

5:30 PM
ECMO in Non-PAH Pulmonary Hypertension: Clots and Scars
Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

5:50 PM
Panel Discussion
SYMPOSIUM 09: JHLT at ISHLT: The Year in a Capsule

Location:
Coronado A-C

Target Audience:
ALL

Chairs:
Duane Davis, MD, MBA, and Martin Schweiger, MD, PhD

Session Summary: This session will highlight the most impactful publications in JHLT over the past year. Following the presentation of each publication by a member of the Junior Faculty and Trainee Council a senior editorial consultant of the JHLT will relate the presented articles to the greater body of published literature and discuss how they advance our understanding of the field.

4:30 PM
Introduction and Recognition of Top Papers of the Year
Patricia Uber, PharmD, Virginia Commonwealth University, Richmond, VA, USA

4:40 PM
Highlights of Heart Transplantation and Mechanical Circulatory Support
Agnieszka Ciarka, MD, Catholic University of Leuven, Leuven, Belgium

4:55 PM
Senior Editor Perspective: Heart Transplantation and Mechanical Circulatory Support
Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

5:00 PM
Highlights of Lung Transplantation and Pulmonary Hypertension
Hrishikesh S Kulkarni, MD, Washington University School of Medicine, St. Louis, MO, USA

5:15 PM
Senior Editor Perspective: Lung Transplantation and Pulmonary Hypertension
Andrew J Fisher, FRCP, PhD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:20 PM
Highlights of Pediatric Heart and Lung Transplantation
Erin Albers, MD, Seattle Children's Hospital, Seattle, WA, USA

5:35 PM
Senior Editor Perspective: Pediatric Heart and Lung Transplantation
Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada

5:40 PM
Highlights of Infectious Diseases
Saima Aslam, MD, MS, UCSD Medical Center, San Diego, CA, USA

5:55 PM
Senior Editor Perspective: Infectious Diseases
Margaret Hannan, MD, Mater Misericordiae University Hospital, Dublin, Ireland
6:15 PM - 7:15 PM
MINI ORAL SESSION 1: Complicating Factors in MCS

Location:
Grand Hall A

Target Audience:
MCS, HF, HTX, NHSAH, PHARM

Chairs:
Dipanjan Banerjee, MD, and Sung Ho Jung, MD

6:15 PM (75) Preoperative Screening for Anti-Platelet Factor 4/Heparin Antibodies Does Not Accurately Predict Heparin-Induced Thrombocytopenia Post VAD; J. D. Plamenac1, J. Kumar1, G. Lee2, D. Yu3, Y. Toyoda4, R. Alvarez5, E. Hamad3. 1Internal Medicine, Temple University Hospital, Philadelphia, PA, 2Department of Internal Medicine, University of California, Irvine School of Medicine, Irvine, CA, 3Department of Clinical Sciences, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 4Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA, 5Section of Cardiology, Temple University Hospital, Philadelphia, PA

6:20 PM (76) The Effect of Infections in VAD Recipients on Survival and Risk of Thromboembolism; S. B. Katugaha1, M. Gibreal2, A. C. Carter3, J. A. Cowger3, C. T. Salerno4, S. Maltais5, S. Dunlay6, T. F. Dardas2, K. D. Aaronson7, F. D. Pagani8, J. Stulak5, P. Shah3. 1Infectious Diseases, Inova Heart and Vascular Institute, Falls Church, VA, 2Infectious Diseases, George Washington University Hospital, Washington, DC, 3Infectious Diseases, INOVA Fairfax Hospital, Annandale, VA, 4St. Vincent Heart Center of Indiana, Indianapolis, IN, 5Mayo Clinic, Rochester, MN, 6Department of Cardiovas Med, Mayo, Rochester, MN, 7University of Washington, Seattle, WA, 8University of Michigan Health System, Ann Arbor, MI, 9Inova Heart and Vascular Institute, Falls Church, VA

6:25 PM (77) Driveline Site Is Not a Predictor of Infection Following Ventricular Assist Device Implantation; J. G. Luc1, B. Martin1, R. MacArthur1, A. R. Bates2, H. Buchholz1, D. H. Freed1, J. Conway2. 1Surgery, University of Alberta, Edmonton, AB, Canada, 2Anesthesiology and Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, 3Pediatrics, University of Alberta, Edmonton, AB, Canada

6:30 PM (78) The Impact of LVAD Related Infections on Post Cardiac Transplant Outcomes: A Systematic Review; D. Chaha1, A. J. Wright2, M. Toma3. 1University of British Columbia, Vancouver, BC, Canada, 2Division of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada, 3Division of Cardiology, University of British Columbia, Vancouver, BC, Canada

6:35 PM (79) Bloodstream Infection in Patients with LVAD and CIED; M. Gibreal4, S. Katugaha2, K. Abdullah3, J. Stulak4, J. A. Cowger5, C. Salerno5, S. Maltais5, S. M. Dunlay4, T. F. Dardas2, K. D. Aaronson7, F. D. Pagani8, P. Shah3. 1Cardiovascular Disease, George Washington University, Washington, DC, 2Infectious Diseases, Inova Heart and Vascular Institute, Falls Church, VA, 3Inova Heart and Vascular Institute, Falls Church, VA, 4Cardiovascular Disease, Mayo Clinic, Rochester, MN, 5St. Vincent Heart Center of Indiana, Indianapolis, IN, 6Mayo Clinic, Rochester, MN, 7Cardiovascular Disease, University of British Columbia, Vancouver, BC, Canada

6:40 PM (80) Antimicrobial Surgical Prophylaxis in MCS Implant Surgery and Surgical Site Infection, IMACS January 2013 to December 2015; M. M. Hannan1, R. Xie2, S. Kusne3, C. Merry4, P. Grossi5, V. Stosor6, C. Sivathasan7, M. Mehra8, U. Jorde9, I. Netuka10, S. Huprikar11, J. K. Kirklin2. 1Mater Misericordiae University Hospital, Dublin, Ireland, 2The James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO) UAB, Birmingham, AL, 3Mayo Clinic, Scottsdale, AZ, 4Fiona Stanley Hospital, Perth, Australia, 5University of Insubria, Varese, Italy, 6Northwest University, Chicago, IL, 7National Heart Centre, Singapore, Singapore, 8Brigham and Womens Hospital, Boston, MA, 9Albert Einstein College of Medicine, New York, NY, 10Cardiothoracic Surgery, Prague, Czech Republic, 11The Mount Sinai Hospital, New York, NY

6:45 PM (81) Frequency and Risk Factors for Acquired Infections During ECMO; N. Selcuk, M. Sargin, M. E. Mete, S. B. Erdogan, M. Bastopçu, S. Ocalmaz, G. Orhan, S. A. Aka. Cardiovascular Surgery, Siyami Ersek Hospital, Istanbul, Turkey

6:50 PM (82) Increased Rate of Pump Thrombosis and Cardioembolic Events Following Ventricular Tachycardia Ablation in Patients Supported with Left Ventricular Assist Devices; J. Grinstein1, A. R. Garan2, E. Flatley3, G. H. Kim1, X. Mai2, N. Sarswat1, S. Kalantari1, S. Adatya1, J. Raikhelkar1, G. Sayer1, A. Oesterle1, V. Jeewanandam1, J. Moss3.
N. Uriel1, 1University of Chicago, Chicago, IL, 2Columbia University, New York, NY, 3University of California San Francisco, San Francisco, CA

6:55 PM (83) Neurological Complications in Patients Supported with Continuous Flow Left Ventricular Assist Devices - Comparative Analysis of HeartMate II and HeartWare Devices; M. Kawabori, C. Kurihara, T. Sugiura, L. Cunningham, A. Civitello, W. E. Cohn, O. H. Frazier, J. Morgan. Texas Heart Institute, Baylor College of Medicine, Houston, TX

7:00 PM (84) Impact of Body Mass Index on Outcomes After Left Ventricular Assist Device Placement: Evidence from a Meta-Analysis; A. Vallakati, S. Emani, W. T. Abraham. Cardiovascular Diseases, The Ohio State University, Columbus, OH

7:05 PM (85) Effect of Preoperative Atrial Fibrillation on Patients with Undergoing Implantation of Long-Term Continuous Flow Ventricular Assist Devices; C. Kurihara, M. Kawabori, T. Sugiura, W. E. Cohn, A. B. Civitello, O. Frazier, J. A. Morgan. Baylor College of Medicine, Houston, TX

6:15 PM - 7:15 PM
MINI ORAL SESSION 2: Donor Evaluation and Management: DBD and DCD

Location:
Grand Hall B

Target Audience:
HTX, EEP, MCS

Chairs:
Hannah Copeland, MD, and Alexander M Bernhardt, MD


6:20 PM (88) Performing Coronary Angiography in High Risk Cardiac Donors Does Not Affect Renal Function in Kidney Recipients; M. Lesouhaitier1, C. Legeai2, E. Savoye3, C. Cantrelle4, I. Pipien2, M. Macher3, C. Vigneau4, R. Dorent2. 1CHU Rennes, Rennes, France, 2Agence de la Biomédecine, Saint-Denis, France


6:30 PM (90) Does Distance from Donor Hospital Impact Survival in Heart Transplant Recipients?; Y. Ravi1, E. M. Stock2, S. K. Lella3, J. V. Balasubramanian4, S. Emani5, C. B. Sai-Sudhakar1. 1Cardiac Surgery, Scott & White, Texas A&M, Temple, TX, 2Center for Applied Health Research, US Department of Veteran Affairs, Perry Point, MD, 3Texas A&M Health Science Centre College of Medicine, Temple, TX, 4Cardiology, Sri Ramachandra University, Chennai, India, 5Internal Medicine, The Ohio State University, Columbus, OH


6:40 PM (92) Ischemia Time and the Eurotransplant Heart Donor Score as Predictors for Primary Graft Dysfunction; T. Haberl1, J. Riebandt1, A. Z. Alabadi-Zuckermann1, D. Wiedemann1, R. Moayedifar1, E. Osorio1, D. Hutschala2, G. Lauffer1, A. Zuckermann1. 1Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department of Anesthesiology and Pain Care, Medical University of Vienna, Vienna, Austria

6:45 PM (93) Comparison of Functional and Metabolic Assessment of Integrity of Human Donor Hearts: Possible Application for Donation After Circulatory Death; P. Bhaskaran1, R. Ou1, S. Perera2, F. L. Rosenfeldt1. 1Department of Surgery, Monash University, Melbourne, Australia, 2Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia

6:50 PM (94) Predicting Progression to Cessation of Circulation in the Pathway of Organ Donation After Circulatory Death; M. S. Fulton1, M. Connellan2, M. Harkess2, K. Dhitai2. 1Faculty of Medicine, University of New South Wales, Sydney, Australia, 2Heart and Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia

6:55 PM (95) Ex-Vivo Perfusion of a Human Heart Recovered from a DCD Donor for 13 Hours on Organ Care System Platform; J. W. Smith1, R. J. Madathil1, J. D. Pal1, J. Hersmensen1, C. Mahr2, R. L. Romig1, T. M. Arneberg3, N. A. Mokadam1. 1Cardiothoracic Surgery, University of Washington, Seattle, WA, 2Cardiology, University of Washington, Seattle, WA, 3Clinical Engineering, Transmedics, Inc., Andover, MA

7:00 PM (96) Outcome After Warm Machine Perfusion (WMP) Recovery of Marginal Brain Dead (MBD) and Donation After Circulatory Death (DCD) Heart Transplantation; H. Chew1, C. Cheong2, M. Fulton2, M. Shah1, A. Doyle3, L. Gao3, J. Villanueva3, C. Soto4, M. Hicks5, M. Connellan1, E. Granger1, P. Jansz1, P. Spratt1, C. Hayward6, A. Keogh8, E. Kotyraf9, A. Jabbar9, K. Dhitai1, P. Macdonald9. 1Cardiothoracic Surgery, St Vincent's Hospital, Darlinghurst, Australia, 2Clinical School, St Vincent's Hospital, Darlinghurst, Australia, 3Cardiac Transplantation Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, Australia, 4Cardiac Perfusion, St Vincent's Hospital, Darlinghurst, Australia, 5Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, Australia, 6Heart Lung Clinic, St Vincent's Hospital, Darlinghurst, Australia

Wednesday, April 5
7:05 PM (97) Transition of DCD Heart Transplantation from Research to a Clinical Programme - Challenges and Lessons Learned; M. Berman, E. Pavlushkov, H. Doshi, S. Balasubramanian, D. White, S. Claydon, H. Ballantyne, C. Ellis, S. Tsui. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

7:10 PM (98) Post-Transplant Assessment of DCD Cardiac Allografts with MRI; E. Pavlushkov¹, A. Page¹, S. Messer¹, A. Kydd¹, K. Tweed², Y. Abu-Omar¹, A. Ali¹, M. Berman¹, P. Catarino¹, J. Dunning¹, D. Jenkins¹, C. Lewis³, J. Parameshwar³, S. Pettit³, C. Sudarshan¹, S. Tsui¹, S. Large¹. ¹Cardiothoracic Transplantation, Papworth Hospital, Cambridge, United Kingdom, ²Radiology, Papworth Hospital, Cambridge, United Kingdom, ³Transplant Cardiology, Papworth Hospital, Cambridge, United Kingdom
6:15 PM - 7:15 PM
MINI ORAL SESSION 3: Wretched Strangers: Mechanisms of Thoracic Organ Infection, Rejection and Tolerance

Location:
Grand Hall C

Target Audience:
BSTR, EEP, HF, HTX, ID, LTX, PATH, PEDS, PHARM, PH

Chairs:
Stephen C Juvet, MD, PhD, FRCPC, and Michael G Ison, MD MS


6:20 PM (100) Cis-Binding of the Inhibitory Molecule CD22 to CD22 Ligand (CD22L) Controls Activation of Human CD27+IgM+ B Cells; E. Dijke, K. Derkatz, J. Pearcey, F. Wong, B. Motyka, L. West. Pediatrics/Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada

6:25 PM (101) The Degree of CMV-Specific T Cell Response Is Related with Infection Complications in Heart Transplant Recipients; J. Youn1, J. Lee2, S. Han1, S. Kang3, E. Shin2. 1Hallym University, Gyeonggido, Korea, Republic of, 2KAIST, Daejeon, Korea, Republic of, 3Yonsei University, Seoul, Korea, Republic of


6:35 PM (103) Airway-Centered Inflammation Induced by Lipopolysaccharide (LPS) Leads to BOS-Like Phenotype of CLAD in Rat Lung Transplantation; A. Takahagi1, M. Sato2, T. Chen-Yoshikawa1, A. Yoshizawa1, K. Ohata1, M. Saito1, R. Okabe1, F. Gochi1, H. Yamagishi1, M. Hamaji1, H. Motoyama1, K. Hijiya1, A. Aoyama1, H. Date1. 1Thoracic Surgery, Kyoto University Graduate School, Kyoto, Japan, 2Thoracic Surgery, the University of Tokyo, Tokyo, Japan


6:45 PM (105) Nitric Oxide Producing Eosinophils Play a Critical Role in Lung Allograft Acceptance; O. O. Onyema1, Y. Guo1, A. E. Gelman2, D. Kreisel2, J. J. Lee2, A. S. Krupnick1. 1Department of Surgery, University of Virginia, Charlottesville, VA, 2Department of Surgery, Washington University, St Louis, MO, 3Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ

6:50 PM (106) Tolerance Induction by Myeloid Progenitor Cells: Matching Requirements and Expanded Model; Y. Li1, A. Sedello2, T. Fong2, J. Domen1. 1Cardiac Surgery, Children’s Mercy Hospital and Clinics, Kansas City, MO, 2Cellerant Therapeutics, San Carlos, CA

6:55 PM (107) Blood Group A-Antigen Specific Tolerance Following Exposure to A-Antigen in Infant Mice; B. Motyka1, Y. Wang2, B. Lamarche2, I. Adam1, J. Pearcey1, K. Tao3, C. W. Cairo4, P. J. Cowan5, L. J. West1. 1Dept Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, 2Dept Pediatrics, University of Alberta, Edmonton, AB, Canada, 3Dept Pediatrics, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, 4Dept Chemistry, Alberta Glycomics Centre, University of Alberta, Edmonton, AB, Canada, 5Immunology Research Centre, St Vincent’s Hospital, Melbourne, Australia

Wednesday, April 5
7:00 PM (108) Effect of Perioperative Treatment with Adenosine A2A Receptor Agonist on Pulmonary Allograft Survival in MHC-Inbred CLAWN Miniature Swine; H. Sahara, M. Sekijima, T. Murokawa, Y. Ariyoshi, T. Iwanaga, Y. Ichinari, A. Shimizu, K. Yamada. Division of Organ Replacement of Xenotransplantation Surgery, Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan

7:05 PM (109) The Microbiome of the Respiratory Tract After Heart Transplantation; H. Joyce, M. Hong, M. Workentine, A. Pinto, S. Hirot, M. Surette, S. C. Greenway. 1University of Calgary, Calgary, AB, Canada, 2McMaster University, Hamilton, ON, Canada

7:10 PM (110) Lower Pre-Transplant Memory Class-Switched B Cell Levels Are Associated with a High Risk of Severe Infection After Heart Transplantation; L. Calahorra, E. Sarmiento, A. Gallego, S. Garcia, E. Zatarain, I. Sousa, M. Valerio, R. Lerma, J. Navarro, N. Lanio, J. Carbone. 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Microbiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain
6:15 PM - 7:15 PM
MINI ORAL SESSION 4: Allocation, Bridging and Lung Allograft Assessment Strategies

Location:
Grand Hall D

Target Audience:
LTX, BSTR, EEP, ID, MCS, NHSAH, PATH, PHARM

Chairs:
Hiroshi Date, MD, and Clemens Aigner, MD

6:15 PM (111) Lung Allocation Score Is Not Created Equal: For a Given LAS, Waitlist Survival Varies by Diagnosis Among Lung Transplant Registrants; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University, Baltimore, MD, ²Department of Medicine, Johns Hopkins University, Baltimore, MD

6:20 PM (112) Lung Allocation Score Does Not Accurately Predict Post-Transplant Survival Among Cystic Fibrosis Lung Transplant Recipients; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

6:25 PM (113) Lung Allocation Score Does Not Predict Survival Among Idiopathic Pulmonary Fibrosis Lung Transplant Recipients; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University, Baltimore, MD, ²Department of Medicine, Johns Hopkins University, Baltimore, MD

6:30 PM (114) Lung Transplant Experience with Public Health Services Increased Risk Donors: Recipient Outcomes and Incidence of Transmission and Conversion; C. A. Bermudez¹, M. R. Molina¹, A. M. Thomasson², E. Blumberg³, J. Lee⁴, L. Gardo⁵, V. Ahya⁶, N. Blumenthal⁶, E. Cantu⁷, J. D. Christie⁷, A. Courtwright⁷, J. Diamond⁷, J. Golato⁸, D. Hadjiladis⁹, E. J. Hobson⁹, N. Patel⁹, M. Porteous⁹, M. Crespo⁹. ¹Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Penn Transplant Statistician, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Infectious Disease Transplantation/Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Department of Pulmonary, Allergy & Critical Care Division, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Penn Performance Improvement Outcomes Specialist, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁶Penn Transplant Center Lung Program, Hospital of the University of Pennsylvania, Philadelphia, PA

6:35 PM (115) Contemporary Outcomes of ECMO Used as Bridge to Lung Transplantation; A. H. Hakim¹, U. Ahmad¹, K. McCurry¹, D. R. Johnston¹, G. Pettersson¹, M. Budev², S. Murthy¹, E. H. Blackstone¹, M. Z. Tong¹. ¹Cardio-Thoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH, ²Pulmonary Medicine, Cleveland Clinic Foundation, Cleveland, OH

6:40 PM (116) Mechanical Ventilation and Extracorporeal Membrane Oxygenation (ECMO) as a Combined Bridging Strategy to Lung Transplantation: Significant Gains in Survival; A. L. Du¹, J. Hayanga², J. D’Cunha², M. Tuft³, M. Morrell³, N. Shigemura³. ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Division of Cardiothoracic Transplantation, Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA

6:45 PM (117) Risk Factors for Intraoperative Extracorporeal Circulatory Support in Patients Undergoing Lung Transplantation for Pulmonary Fibrosis; F. Ius¹, J. Salman¹, W. Sommer¹, C. Kühn¹, M. Avsar¹, T. Siemeni¹, D. Böthig¹, M. Greer², N. Schwert³, J. Gottlieb³, T. Welte², A. Haverich¹, G. Warnecke¹, I. Tudorache³. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, ³Department of Paediatrics, Hannover Medical School, Hannover, Germany

6:50 PM (118) The Effect of Left-To-Right Shunt Using Veno-Arterial-Veno Extracorporeal Membrane Oxygenation (ECMO) on Oxygenation of Proximal Ascending Aorta in Lung Transplantation Patients; N. Kim¹, J. G. Lee². S.
6:55 PM (119) Development of a Donor Lung Discard Score to Prompt Assessment for Ex-Vivo Lung Perfusion Reconditioning; C. Legeai1, C. Picard2, C. Pison3, E. Sage2, O. Mercier4, O. Huot1, R. Dorent1. 1Agence de la Biomédecine, Saint-Denis, France, 2Hôpital Foch, Suresnes, France, 3CHU de Grenoble, Grenoble, France, 4Hôpital Marie-Lannelongue, Le Plessis Robinson, France

7:00 PM (120) Important Implication in Evaluation of Donor Lungs in Single Lung Ex Vivo Lung Perfusion; H. Niikawa1, T. Okamoto2, K. Ayyat1, Y. Itoda1, K. R. McCurry2. 1Pathobiology, Cleveland Clinic, Cleveland, OH, 2Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

7:05 PM (121) Comparison of Two Strategies for Experimental Ex-Vivo Lung Perfusion - Cellular Solution and Open Atrium versus Acellular Solution and Closed Atrium; T. Nilsson1, J. Gielis2, C. Hansson3, A. Wallinder3, A. Laffin3, S. Ricksten,1 G. Dellgren3. 1Dept of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden, 2Department of Thoracic Surgery, Antwerp Surgical Training and Anatomy Research Centre, Antwerp University, Antwerp, Belgium, 3Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

MINI ORAL SESSION 5: The Hardware of MCS

Target Audience: MCS, HF, NHSAH

Chairs: David A Baran, MD, and Melana Yuzefpolskaya, MD

6:15 PM (123) Evaluation of a Virtual Implant Technique to Optimise Implantation of a Bioprosthetic Total Artificial Heart; C. Latrémouille1, J. C. Rousse2, M. Kindo3, P. Leprince4, D. Duveaux5, B. Tchakgarian6, J. C. Perles6, P. Jansen6, A. Carpentier1. 1Cardiovascular Surgery, Hôpital Européen Georges Pompidou, APHP, Université Paris Descartes-Sorbonne Paris Cité, Paris, France, 2Cardiovascular Surgery, Hôpital Guillaume et René Laennec, Université de Nantes, Saint-Herblain, France, 3Cardiovascular Surgery, Nouvel Hôpital Civil, Université de Strasbourg, Strasbourg, France, 4Cardiovascular Surgery, Groupe Hospitalier Pitié-Salpêtrière, APHP, Université Pierre et Marie Curie, Paris, France, 5Cardiovascular Surgery, Faculté de Médecine, Université de Nantes, Nantes, France, 6Carmat SA, Vélizy-Villacoublay, France

6:20 PM (124) Performance of a Novel Shuttling Total Artificial Heart on a on a Mock Circulatory Loop; R. Wampler1, J. Glynn2, S. Withers2, B. Hull3, M. Slaughter2, A. Starr1, H. K. Song1. 1Cardiothoracic Surgery, Oregon Health & Science University, Portland, OR, 2Oregon Heart, Inc, Portland, OR, 3Cardiothoracic Surgery, University of Louisville, Louisville, KY

6:25 PM (125) Increased Right Ventricular Afterload Is Associated with Poor Survival Among Patients Receiving Biventricular Impella (BiPella) Support for Cardiogenic Shock; M. Esposito1, S. Kuchibhotla1, B. Catalina1, O. Ryan1, R. Pedicini1, M. Andrew1, S. Annamalai1, G. Mark2, M. Kiernan1, D. T. Pham3, M. Anderson4, D. Morris5, G. Batsides6, R. Danny7, N. K. Kapur1. 1Cardiology, Tufts Medical Center, Boston, MA, 2Cardiology, Sacred Heart Medical Group, Pensacola, FL, 3Cardiology, Northwestern Memorial Hospital, Chicago, IL, 4Cardiothoracic Surgery, Einstein Medical Center, Philadelphia, PA, 5Cardiology, Einstein Medical Center, Philadelphia, PA, 6Cardiothoracic Surgery, Robert Wood Johnson University Hospital, New Brunswick, NJ, 7Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA


6:50 PM (130) Durable Left Ventricular Assist Device Therapy to Reduce Transpulmonary Gradient in Adult Congenital Heart Disease to Facilitate Heart Transplant; A. Woods, G. MacGowan, N. Robinson-Smith, L. Kenny, A. Hasan, S. Schueler. Cardiothoracic, Newcastle upon Tyne NHS Foundations Trust, Newcastle upon Tyne, United Kingdom

6:55 PM (131) Association Between the Use of Invasive Hemodynamic Monitoring and Outcomes with Percutaneous Left Ventricular Support: A Call for Standardization?; J. J. Teuteberg1, W. O'Neill2. 1University of Pittsburgh, Pittsburgh, PA, 2Henry Ford, Detroit, MI
7:00 PM (132) Analysis of Right Ventricular (RV) Regional and Global Systolic Function by Gated Blood Pool SPECT (GBPS) in Patients Undergoing Left Ventricular Assist Device (LVAD) Implantation; C. B. Link, A. Nayak, P. Soman, M. A. Simon, J. J. Teuteberg, L. Lagazzi, A. Althouse, R. Kormos. HVI, UPMC, Pittsburgh, PA

7:05 PM (133) Emerging Science of Hemocompatibility as Applied to VAD Design and Pre-Clinical Evaluation; J. W. Long¹, T. Snyder², J. R. Stanfield³. ¹Integris Health, Oklahoma City, OK, ²VADovations, Oklahoma City, OK, ³University of Utah, Oklahoma City, OK

MINI ORAL SESSION 6: Therapeutics in Advanced Heart and Lung Disease

Location: Coronado A-C

Target Audience: PHARM, HTX, ID, LTX, MCS, NHSAH

Chairs: Douglas L. Jennings, PharmD, and Amanda Ingemi, PharmD

6:15 PM (135) Combination Abbreviated Inhaled Ribavirin and Oral Ribavirin Therapy for Respiratory RNA Viruses in Lung Transplant; A. T. Logan¹, S. Kapadia², E. Schwaiger², T. Haddad³, K. Patel². ¹Department of Pharmacy, Tampa General Hospital, Tampa, FL, ²Department of Pulmonary Critical Care, University of South Florida, Tampa, FL, ³Department of Pulmonary Critical Care, Tampa General Hospital, Tampa, FL

6:20 PM (136) Single-Center Experience with Epstein-Barr Virus Screening in Lung Transplant Recipients to Identify Patients with Post-Transplant Lymphoproliferative Disorder; D. Owen¹, K. Dawson¹, B. Pierce¹, A. Goodarzi², N. Sinha², J. Youssef², T. Kaleekal². ¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX, ²J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX

6:25 PM (137) Infectious Complications Following Rituximab in Lung Transplantation: A Propensity-Matched Cohort; J. Rago¹, K. B. Bain², K. A. Fester², T. A. Horwede², J. I. Melarago³, C. A. Witt⁴, R. R. Hachem⁵. ¹Pharmacy, Methodist Dallas Medical Center, Dallas, TX, ²Pharmacy, Barnes Jewish Hospital, St. Louis, MO, ³Pharmacy, University of Rochester Medical Center, Rochester, NY, ⁴Pulmonary and Critical Care Medicine, Washington University, St. Louis, MO

6:30 PM (138) Comparative Efficacy of Azathioprine versus Mycophenolate in Lung Transplant Recipients; M. A. Olson¹, K. B. Bain¹, K. A. Fester¹, C. Chen², R. R. Hachem³. ¹Pharmacy, Barnes Jewish Hospital, St. Louis, MO, ²Internal Medicine, UT Southwestern, Dallas, TX, ³Pulmonary and Critical Care Medicine, Washington University, St. Louis, MO

6:35 PM (139) Characterization of Unfractionated Heparin Dosing Requirements in Cystic Fibrosis; K. B. Bain¹, B. R. Tellor¹, K. A. Fester¹, R. D. Yusen². ¹Pharmacy, Barnes Jewish Hospital, St. Louis, MO, ²Pulmonary and Critical Care Medicine, General Medical Science, Washington University School of Medicine, St. Louis, MO

6:40 PM (140) Four Factor Prothrombin Complex Concentrate and the Risk of Thrombosis in Continuous Flow LVAD; J. Rimsans¹, A. Levesque¹, R. Nashett¹, H. Badreddin¹, E. Lyons², K. Sylvester¹, G. C. Stewart², J. M. Connors³. ¹Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, ²Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, ³Division of Hematology, Brigham and Women's Hospital, Boston, MA

6:45 PM (141) Four-Factor Prothrombin Complex Concentrate for Bleeding in Patients with LVADs; B. Tellor¹, J. Shuster¹, T. Human¹, S. LaRue², J. Vadder², K. Balsara³. ¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Int Med - Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, ³Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO


6:55 PM (143) PDE5i Initiation in Patients with Right Ventricular Dysfunction Post-LVAD Does Not Improve Right Ventricular Function; J. E. Shuster¹, K. Roberts¹, S. LaRue², B. Tellor¹. ¹Barnes-Jewish Hospital, Saint Louis, MO, ²Washington University in Saint Louis, Saint Louis, MO

7:00 PM (144) Effect of ABCB1 Haplotypes on Tacrolimus Disposition in Heart Transplant Recipients; K. Oreschak¹, K. M. Deininger¹, A. V. Ambardekar¹, R. L. Page II¹, J. Lindenfeld³, C. L. Aquilante¹. ¹University of Colorado, Aurora, CO, ²Vanderbilt University, Nashville, TN

7:10 PM (146) *The Risks and Rewards of Desensitization Therapies for Heart Transplant Candidates*; C. Carson, C. T. Doligalski. Tampa General Hospital, Lutz, FL
Thursday, April 06, 2017

7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 01: Walk With Me: Exercise Physiology in the LVAD Patient

Location:
Grand Hall A

Target Audience:
MCS, ALL

Chairs:
Christopher S Hayward, MD, and Jorge Silva Enciso, MD

Session Summary: Ventricular assist devices improve functional class and quality of life due to its impact on exercise capacity. Long-term LVAD support is associated with improved central hemodynamics and exercise performance. Although, the maximal effects on functional performance continue to be marginal, pump flow changes and cardiac output augmentation does occur during exercise. Understanding the basis of exercise physiology in LVAD patients may allow for future interventions to enhance exercise performance.

7:00 AM  
Invasive Exercise Hemodynamic Evaluation in LVAD Patients
David M Kaye, MD, PhD, Alfred Hospital, Melbourne, Australia

7:10 AM Q&A

7:15 AM  
Factors Influencing Exercise Performance in LVAD Patients
Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD, USA

7:25 AM Q&A

7:30 AM  
Pulsatility and Exercise Performance in Continuous vs. Pulsatile Flow
Christopher S Hayward, MD, St. Vincent's Hospital, Sydney, Australia

7:40 AM Q&A

7:45 AM  
Right Ventricular Function During Exercise in LVAD Patients
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

7:55 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 02: Chagasic Cardiomyopathy: Lessons To Be Learned

Location:
Grand Hall B

Target Audience:
HF, HTX, ID, MCS

Chairs:
Alejandro M Bertolotti, MD, and Stanley Martin, MD

Session Summary: The cardiac form of Chronic Chagas Disease is responsible for inability to work, low quality of life and death among infected individuals. Chagas disease currently affects approximately 8 – 11 million people in South America, Central America and Mexico, and approximately 80 million people are at risk for contracting the illness. Although an estimated 300,000 persons with Chagas disease live in the USA, little is known about the burden of Chagasic heart disease. A 12-minute panel discussion with all speakers will conclude this session.

7:00 AM
Chronic Chagas Disease and Chagasic Cardiomyopathy
Anna K Sa, MD, Pro Cardiac Hospital, Rio de Janeiro, Brazil

7:12 AM
Arrhythmic Storm as the First and Last Manifestation of Chagas Disease
Fabiana G Marcondes-Braga, MD, PhD, Heart Institute, Sao Paulo, Brazil

7:24 AM
Heart Transplant in Chagasic Cardiomyopathy: How to Manage Immunosuppression
Fernando Bacal, MD, PhD, University of Sao Paulo, Sao Paulo, Brazil

7:36 AM
Reactivation of Chagas Post-Transplant: Diagnosis and Pharmaceutical Management
Lisa Peters, PharmD, MedStar Washington Hospital Center, Washington, DC, USA

7:48 AM Panel Discussion
SUNRISE SYMPOSIUM 03: Lifecycle Journey of Thrombosis in Mechanical Circulatory Support Patients

Location:
Grand Hall C

Target Audience:
PHARM, HF, HTX, MCS, NHSAH

Chairs:
Stephan Schueler, MD, PhD, FRCS, and Christina T. Doligalski, PharmD, BCPS

Session Summary: This lifecycle journey is an enduring case with 3 defined points. The time points discussed include implantation and management strategies that influence thrombotic risk; management of anticoagulation including review of current therapy, potential novel therapies and appropriate monitoring; the anatomy of the clot and potential mechanisms of thrombosis in MCS.

7:00 AM
Lifecycle Journey Case Presentation
Christina T Doligalski, PharmD, BCPS, Tampa General Hospital, Tampa, FL, USA

7:03 AM
Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria

7:18 AM
Lifecycle Journey Case Update
Christina Doligalski

7:19 AM
Prevention of Thrombosis in Mechanical Support: Where are we going?
Ed Horn, PharmD, Allegheny General Hospital, Pittsburgh, PA, USA

7:34 AM
Lifecycle Journey Case Update
Christina Doligalski

7:35 AM
What Pathology Can Tell Us About Mechanisms of Thrombosis
Lisa Baumann Kreuziger, MD, Medical College of Wisconsin, Milwaukee, WI, USA

7:50 AM Panel Discussion
SUNRISE SYMPOSIUM 04: Completing the Picture: Patient Reported Outcomes (PROs) as an Essential Source of Information in Evaluating Transplantation Outcomes

Location:
Grand Hall D

Target Audience:
NHSAH, ALL

Chairs:
Maria R. Molina, MSN, CRNP, CCRN, and James Kirklin, MD

Session Summary: Patient Reported Outcomes (PRO) are increasingly used to capture the outcomes of transplant recipients and living donors and have become an inherent part of the evaluation of transplant programs’ quality assessment and performance improvement. PROs drive patient centered outcomes research (PCOR). The aim of this session is to explain the concept of patient reported outcomes, how PROs measures are developed and how PROs are assessed to successfully perform PCOR. Further it will provide a number of examples on the use of PROs in clinical practice, research, and quality assessment and performance.

7:00 AM
The Crucial Importance of PROs for Transplant Evaluation from a Clinical, Research and Quality Assurance Perspective
Linda Ohler, MSN, FAAN, George Washington University, Washington, DC, USA

7:15 AM Q&A

7:20 AM
State of the Art Development of PRO Assessments for Patient Centered Outcomes Research (PCOR)
Sabina M De Geest, RN, PhD, University of Basel, Basel, Switzerland

7:35 AM Q&A

7:40 AM
PROs in Pediatric Transplant Patients: Special Issues
Kathleen L Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA

7:55 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 05: Upcoming Opportunities and Challenges in Pediatric Lung Transplantation

Location:
Seaport F-H

Target Audience:
PEDS, HF, LTX, MCS, PEDS, PH

Chairs:
Marc G. Schecter, MD, and Christian Benden, MD, FCCP

Session Summary: Over recent years, outcomes after lung transplantation in children have improved. Against this background, new challenges arise and new opportunities come up. At this symposium, selection criteria and bridging strategies to lung transplantation for critically ill neonates are discussed, and overall changing indications for pediatric lung transplantation given the decreasing number of children with cystic fibrosis referred for it. In addition, alternative approaches to lung transplant such as Potts-shunts in children with severe pulmonary arterial hypertension are reviewed, and strategies debated to increase the donor pool, for example ABO incompatible lung transplantation in smaller children.

7:00 AM
Bridge over Troubled Water: ECMO for the Critically Ill Newborn as a Bridging Strategy to Transplantation - Who is the Right Candidate?
Stuart C Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA

7:12 AM Q&A

7:15 AM
New Kids on the Block: Is There a Change of Indications for Pediatric Lung and Heart-Lung Transplantation?
Bart L. Rottier, MD, University Medical Center Groningen, Groningen, Netherlands

7:27 AM Q&A

7:30 AM
ABO Incompatible Lung Transplantation in Infants and Small Children to Expand the Donor Pool: Where is the Age Limit and What Has To Be Considered?
Melinda P. Solomon, MD, FRCPC, Hospital for Sick Children, Toronto, ON, Canada

7:42 AM Q&A

7:45 AM
Potts-Shunt in Children with Severe PAH: A Promising Procedure To Avoid Lung Transplantation?
Maria C Gazzaneo, MD, Texas Children's Hospital, Houston, TX, USA

7:57 AM Q&A
Session Summary: Respiratory viruses following lung transplantation are a common occurrence and can range from the common cold to fulminant respiratory failure. Respiratory viruses have also been implicated in the development of Chronic Lung Allograft Dysfunction (CLAD), the most significant cause of mortality following lung transplantation. Available therapies are limited, however, as is the data supporting their use. Improved understanding of the host response to respiratory viruses may help contribute to the novel therapeutics.
8:00 AM - 10:00 AM
SYMPOSIUM 10: Antibodies in Mechanical Circulatory Support: The Phantom Menace

Location:
Seaport A-E

Target Audience:
MCS, BSTR, HF, HTX, PEDS, PHARM

Chairs:
Jon A. Kobashigawa, MD, and Andreas Zuckermann, MD

Session Summary: As the number of patients requiring mechanical circulatory support (MCS) increases, allosensitization in this population presents a special challenge as it limits options for transplantation. This session will discuss the nature of sensitization in MCS patients, epidemiology, risk of the sensitized MCS patient, therapeutic options and post-transplant management. A 20-minute panel discussion with all speakers will conclude this session.

8:00 AM
Is the MCS Device Immunomodulatory?
Elaine F Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA

8:20 AM
Sensitization in the Pediatric MCS Population
Francesco Parisi, MD, Bambino Gesù Pediatric Hospital, Rome, Italy

8:40 AM
Approach to the Sensitized MCS Patient: Desensitization and Other Strategies
Jignesh K. Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

9:00 AM
Epidemiology and Risk of the Sensitized MCS Patient
Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

9:20 AM
What Happens to the Antibodies After Heart Transplant?
Howard Eisen, MD, Drexel University, Philadelphia, PA, USA

9:40 AM Panel Discussion
8:00 AM - 10:00 AM
SYMPOSIUM 11: Not CAVing to CLADtastrophe: Emerging Mechanisms of Chronic Heart and Lung Allograft Disease

Location:
Grand Hall A

Target Audience:
BSTR, HTX, LTX, PATH, PHARM

Chairs:
Elizabeth H Hammond, MD, and Christopher H. Wigfield, MD, FRCS

Session Summary: In this session, we will examine factors which have been recently implicated in coronary artery vasculopathy and chronic lung allograft dysfunction. Donor and recipient innate immune responses, autoimmune responses triggered by alloimmunity, and the pivotal role of endothelium and micro-vasculature will be explored. The goal of the session is to identify new pathologic and molecular targets for treatment in both Cardiac Allograft Vasculopathy (CAV) and Chronic Lung Allograft Dysfunction (CLAD). Importantly, this session will examine parallels between chronic processes in the transplanted heart and lung and bring together research and clinical experts in lung and heart transplantation.

8:00 AM
Pivotal Role of the Endothelium in CAV
Daniel Jane-Wit, MD, PhD, Yale School of Medicine, New Haven, CT, USA

8:15 AM Q&A

8:20 AM
Critical Effect of Airway Microvasculature on CLAD Development
Mark R. Nicolls, MD, Stanford University, Stanford, CA, USA

8:35 AM Q&A

8:40 AM
DAMPs, PAMPs and Innate Immunity in CAV
Joren C Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA, USA

8:55 AM Q&A

9:00 AM
DAMPs, PAMPs, and Innate Immunity in CLAD
Scott M. Palmer, MD, MHS, Duke University, Durham, NC, USA

9:15 AM Q&A

9:20 AM
Antibodies in CAV: the Role of Autoimmunity in Alloimmunity
Christine M Lin, MD, University of Colorado, Denver, CO, USA

9:35 AM Q&A

9:40 AM
Antibodies and B Cells in Pathogenesis of CLAD
Masaaki Sato, MD, University of Tokyo, Tokyo, Japan

9:55 AM Q&A
SYMPOSIUM 12: A Tale of Two Organs: Selecting and Managing Multi-Organ Transplant Recipients

Location: Grand Hall B

Target Audience: HTX, ALL

Chairs: Teresa De Marco, MD, and Jose Gonzalez-Costello, MD

Session Summary: This session will use a combination of lectures and debates to highlight treatment options for patients who have primary thoracic organ failure and secondary end-organ dysfunction. Appropriate selection and management of multi-organ recipients will be discussed. In addition, speakers will address unique challenges faced in multi-organ transplantation, including a review of the policies and ethical considerations in allocating multiple organs to a single individual. A 15-minute panel discussion will conclude this session.

8:00 AM
Heart-Lung Transplantation: How Bad Do The Ventricles Have To Be?
John J Dunning, FRCS, Papworth Hospital, Cambridge, United Kingdom

8:15 AM
DEBATE (PRO): Heart Transplant Candidates with Vulnerable Kidneys Should Undergo Combined Heart-Kidney Transplantation
Eugene C DePasquale, MD, UCLA David Geffen School of Medicine, Los Angeles, CA, USA

8:30 AM
DEBATE (CON): Heart Transplant Candidates with Vulnerable Kidneys Should Undergo Combined Heart-Kidney Transplantation
Marcelo Cantarovich, MD, McGill University Health Centre, Montreal, QC, Canada

8:45 AM
DEBATE (PRO): Heart Transplant Candidates with Bridging Fibrosis Should Undergo Combined Heart-Liver Transplantation
Sudhir S Kushwaha, MD, Mayo Clinic, Rochester, MN, USA

9:00 AM
DEBATE (CON): Heart Transplant Candidates with Bridging Fibrosis Should Undergo Combined Heart-Liver Transplantation
Charles E. Canter, MD, St Louis Children's Hospital, St. Louis, MO, USA

9:15 AM
Thoracic and Abdominal Tug of War: Management of the Multi-Organ Transplant Recipient
Richard C Daly, MD, Mayo Clinic, Rochester, MN, USA

9:30 AM
Ethical Principles in Allocating Multiple Organs to One Recipient
Heather J Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada

9:45 AM Panel Discussion
8:00 AM - 10:00 AM
SYMPOSIUM 13: Lung Allocation Scores (LAS): Making the Complex Simple, or Just the Simple Complex?

Location:
Grand Hall C

Target Audience:
LTX, ALL

Chairs:
Kevin M. Chan, MD, and Allan Glanville, MBBS, MD, FRACP

Session Summary: This symposium highlights the lung allocation systems employed worldwide, describes changes in US lung allocation since the implementation of the LAS, reviews the results of the LAS by Eurotransplant, describes early results of the LAS revision, and discusses controversies on allocation equality raised by the LAS.

8:00 AM
Who Needs LAS Anyway? Lung Allocation Around the World
Are Martin Holm, MD, Oslo University Hospital, Oslo, Norway

8:20 AM Q&A

8:24 AM
Lung Allocation Score: the Changing Landscape of Lung Transplantation in the USA
Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC, USA

8:44 AM Q&A

8:48 AM
Modification of the USA LAS Model 2015: Early Results
Kevin M Chan, MD, University of Michigan, Ann Arbor, MI, USA

9:08 AM Q&A

9:12 AM
LAS in Eurotransplant: Towards a Uniform Approach?
Jacqueline Smits, MD, PhD, Eurotransplant International Foundation, Leiden, Netherlands

9:32 AM Q&A

9:36 AM
LAS Controversies: Improving Equity in Organ Allocation?
Selim Arcasoy, MD, MPH, Columbia University, New York, NY, USA

9:56 AM Q&A
8:00 AM - 10:00 AM
SYMPOSIUM 14: Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Current Controversies and New Directions

Location:
Grand Hall D

Target Audience:
PH

Chairs:
William Auger, MD, and C. Dario Vizza, MD

Session Summary: This symposium will review some of the key questions and controversial topics in patients with CTEPH in the preoperative and postoperative period.

8:00 AM
Out-of-Proportion Pulmonary Vascular Resistance (PVR): Operative Suitability and Perioperative Considerations
Marc de Perrot, MD, University of Toronto, Toronto, ON, Canada

8:15 AM Q&A

8:20 AM
Medical Therapy for CTEPH as "Bridge" to Surgery: Right or Wrong?
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA

8:35 AM Q&A

8:40 AM
The Right Ventrical (RV) in CTEPH: How to Assess Before and After Pulmonary Endarterectomy
Paul Forfia, MD, Temple University, Philadelphia, PA, USA

8:55 AM Q&A

9:00 AM
Chronic Thromboembolic Disease Without PH at Rest: Treat or Not?
John Granton, MD, University of Toronto, Toronto, ON, Canada

9:15 AM Q&A

9:40 AM
Is Balloon Pulmonary Angioplasty (BPA) an Alternative or Complementary to PEA?
Hiromi Matsubara, MD, PhD, Okayama Medical Center, Okayama, Japan

9:55 AM Q&A
8:00 AM - 10:00 AM
SYMPOSIUM 15: HLA, AMR and DSA - Approaching Antibodies in Kids

Location:
Seaport F-H

Target Audience:
ALL

Chairs:
Steven A. Webber, MBChB, and Robert G. Weintraub, FRACP, FACC

Session Summary: The goal of this symposia is to educate transplant clinicians in the use of antibody testing in the assessment of patients who are candidates for transplant, and for assessment and treatment of Antibody Mediated Rejection (AMR) after transplant. The session will start with basic science background principles in HLA antibodies, and end with a case of an allosensitized patient, with a forum discussion by the experts.

8:00 AM
Back to the Basics: HLA Antibodies, Donor-Specific Antibodies, and How to Measure Them
Anat Roitberg-Tambur, DMD/PhD, Northwestern University, Chicago, IL, USA

8:15 AM Q&A

8:20 AM
Before Transplant: Why the PRA Matters
Anne Dipchand, MD, Hospital for Sick Children, Toronto, ON, Canada

8:35 AM Q&A

8:40 AM
Before Transplant: Why the PRA Doesn't Matter Anymore
Brian Feingold, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

8:55 AM Q&A

9:00 AM
After Transplant: What To Do With New DSA?
Matthew Fenton, MRCPCH, Great Ormond Street Hospital for Children, London, United Kingdom

9:15 AM Q&A

9:20 AM
After Transplant: How to Diagnose and Treat AMR in Kids
Melanie D. Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA

9:35 AM Q&A

9:40 AM
Case Presentation: Managing an Allosensitized Patient to Transplant
Ching Kit Chen, MBBS, MRCPCH, KK Women’s and Children's Hospital, Singapore, Singapore

9:50 AM Panel Discussion
8:00 AM - 10:00 AM
SYMPOSIUM 16: "Around the World in 80 Days": Infectious Challenges in Cardiothoracic Transplantation

Location:
Coronado A-C

Target Audience:
ID, HF, HTX, LTX

Chairs:
Saima Aslam, MD, MS, and Shahid Husain, MD, MS

Session Summary: The rise of cardiothoracic (CT) transplantation in emerging countries has led to unique infectious challenges. The goal of the symposium is to understand the impact of locally endemic infections such as Zika virus, hepatitis B, and tuberculosis on CT transplant recipients in different areas of the world. The presentations will cover the scope of the problem, management strategies, outcomes and travel advice.

8:00 AM
Perspective on Zika Virus and Other Emerging Infections from Latin America
Silvia V Campos, MD, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil

8:20 AM Q&A

8:24 AM
Hepatitis B and Thoracic Transplantation
Emily A Blumberg, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

8:44 AM Q&A

8:48 AM
Screening and Management of Latent Tuberculosis
Subramanian Swaminathan, MD, MNAMS, Global Hospitals, Chennai/Bengaluru, India

9:08 AM Q&A

9:12 AM
Treatment of Tuberculosis
Amparo Sole, MD, PhD, Hospital Universitario la Fe, Valencia, Spain

9:32 AM Q&A

9:36 AM
Travel Advice for the Immunocompromised Traveler: Prophylaxis, Vaccination, and Other Preventive Measures
Stephanie Pouch, MD, The Ohio State University, Columbus, OH, USA

9:56 AM Q&A
10:30 AM - 12:30 PM
PLENARY SESSION

Location:
Seaport A-E

Target Audience:
ALL

Chairs:
Hermann Reichenspurner, MD, PhD, and David O. Taylor, MD

10:30 AM
Putting an End to Transplantation? Translating the Promise of Stem Cell Therapy into Practice
Brenda Ogle, PhD, University of Minnesota, Minneapolis, MN, USA

10:50 AM (147) Impella RP Post Approval Study: First Multi-Center, Prospective Post Market Approval Results for the Impella RP in Patients with Right Ventricular Failure; M. Anderson¹, L. Morris¹, D. Tang², G. Batsides³, A. Kirtane⁴, I. Hanson⁵, P. Meraj⁶, N. Kapur⁷, W. O'Neill⁸. ¹Einstein Healthcare Network, Philadelphia, PA, ²Virginia Commonwealth University, Richmond, VA, ³Rutgers / Robert Wood Johnson, New Brunswick, NJ, ⁴Columbia Presbyterian University Hospital, New York, NY, ⁵William Beaumont, Royal Oak, MI, ⁶Northwell Health, Manhasset, NY, ⁷Tufts University, Boston, MA, ⁸Henry Ford, Detroit, MI

11:05 AM
Interactive Discussant
Martin Strueber, MD, MSU College of Human Medicine, East Lansing, MI, USA

11:10 AM
Tweets, Texts, and Posts: Does Social Media Improve or Complicate Communication in Medicine?
Dorry Segev, MD, PhD, Johns Hopkins School of Medicine, Baltimore, MD, USA

11:30 AM
Share and Share Alike: Optimizing Organ Allocation in an Era of Increasing Need
Sommer Gentry, PhD, USA Naval Academy, Annapolis, MD, USA

11:50 AM (148) Early Graft Injury Measured by Donor-Derived Cell-Free DNA Predicts Early Mortality in Lung Transplant Recipients; S. Agbor-Enoh¹, I. Tunc², I. De Vlaminck³, A. Davis¹, S. Gorham¹, M. Jang¹, K. Cuttin¹, U. Fidelii⁴, A. Marishta¹, J. Wylie¹, H. Luikart⁵, K. Khush⁶, H. Valantine¹. ¹Laboratory of Transplant Genomics, National Heart, Lung and Blood Institute, Bethesda, MD, ²Informatics and Computation Biology Core, National Heart, Lung and Blood Institute, Bethesda, MD, ³Cornell University, Itheca, NY, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵Laboratory of Transplant Genomics, Stanford University School of Medicine, Palo Alto, CA

12:05 PM
Interactive Discussant
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

12:10 PM
Metabolomics: New Tools to Understand Rejection
Brendan Keating, PhD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
2:00 PM - 3:30 PM
ORAL SESSION 13: Contemporary LVAD Trials - Same Old Song or New Tune?
Location: Seaport A-E
Target Audience: MCS, HF, HTX, NHSAH
Chairs: Jeffrey J Teuteberg, MD, and Francis D Pagani, MD, PhD

2:00 PM (149) Hemocompatibility Related Outcomes in the Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with Heartmate 3 (Momentum 3) Pivotal Trial: N. Uriel1, P. C. Colombo2, J. Cleveland3, J. Long4, C. T. Salerno5, D. Goldstein6, C. Patel7, G. Ewald8, A. J. Tatooles9, S. Silvestry10, R. John11, C. Caldeira12, V. Jeevanandan13, A. J. Boyle14, K. S. Sundareswaran14, P. Sood15, M. R. Mehra16, 1University of Chicago Medical Center, Chicago, IL, 2Columbia University Medical Center, New York, NY, 3University of Colorado Medical Center, Denver, CO, 4Integris Baptist Medical Center, Oklahoma City, OK, 5St.Vincent’s Hospital, Indianapolis, IN, 6Montefiore Medical Center, Bronx, NY, 7Duke University Medical Center, Durham, NC, 8Washington University School of Medicine, St. Louis, MO, 9Advocate Christ Medical Center, Chicago, IL, 10Florida Hospital, Orlando, FL, 11University of Minnesota Medical Center, Minneapolis, MN, 12Tampa General Hospital, Tampa, FL, 13Thomas Jefferson University, Philadelphia, PA, 14St.Jude Medical, Pleasanton, CA, 15St.Jude Medical, Burlington, MA, 16B Brigham and Women’s Hospital, Boston, MA

2:15 PM (150) ENDURANCE Destination Therapy Trial Outcomes as Stratified by Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Classification: S. V. Pamboukian1, F. D. Pagani2, J. J. Teuteberg3, R. L. Kormos4, C. C. Caldeira5, C. H. Selzmann5, J. K. Kirklin1, B. B. Reid6, E. C. McGee7, C. A. Milano8, J. G. Rogers9, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Michigan Medical Center, Ann Arbor, MI, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Tampa General Hospital, Tampa, FL, 5University of Utah, Salt Lake City, UT, 6Intermountain Heart Institute, Murray, UT, 7Loyola University Medical Center, Maywood, IL, 8Duke University Medical Center, Durham, NC

2:30 PM (151) HeartMate 3 Fully Magnetically Levitated Left Ventricular Assist Device for the Treatment of Advanced Heart Failure - CE Mark Study 2-Year Results: J. D. Schmitto1, Y. Pya2, D. Zimpfer3, T. Krabatsch4, J. Garbade5, V. Rao6, M. Morshuis7, F. Beyersdorf8, S. Marasco9, P. Sood10, L. Damme10, I. Netuka11, 1Hannover Medical School, Hannover, Germany, 2National Research Cardiac Surgery Center, Astana, Kazakhstan, 3University of Vienna, Vienna, Austria, 4German Heart Center, Berlin, Germany, 5Heart Center Leipzig, Leipzig, Germany, 6Toronto General Hospital, Toronto, ON, Canada, 7Thoracic and Cardiovascular Surgery Clinic, Bad Oeynhausen, Germany, 8University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany, 9The Alfred Hospital, Melbourne, Australia, 10St. Jude Medical Inc., St. Paul, MN, 11Institute for Clinical and Experimental Medicine, Prague, Czech Republic

2:45 PM (152) A Prospective, Controlled, Un-Blinded, Multi-Center Clinical Trial to Evaluate the Thoracotomy Implant Technique of the HVAD System in Patients with Advanced Heart Failure: Results of the LATERAL Trial: M. R. Danter1, E. C. McGee2, M. Strueber3, S. Maltais4, N. A. Mokadam5, G. M. Weisenthaler6, K. Leadley7, S. W. Boyce8, A. Cheung9, 1Vanderbilt University Medical Center, Nashville, TN, 2Loyola University Medical Center, Maywood, IL, 3Spectrum Health, Grand Rapids, MI, 4Mayo Clinic, Rochester, MN, 5University of Washington, Seattle, WA, 6University of California San Francisco, San Francisco, CA, 7HeartWare, Framingham, MA, 8MedStar Health, Washington, DC, 9University of British Columbia, Vancouver, BC, Canada

3:00 PM (153) Quality of Life and Functional Capacity Assessment in the Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with Heartmate 3 (Momentum 3) Pivotal Trial: J. A. Cowger1, Y. Naka2, K. Aaronson3, D. Horstmannhoff4, S. Gulati5, D. Rinde-Hoffman6, S. Pinney7, S. Adatya8, D. J. Farrar9, U. P. Jorde10, 1St.Vincent’s Hospital, Indianapolis, IN, 2Columbia University Medical Center, New York, NY, 3University of Michigan Medical Center, Ann Arbor, MI, 4Integris Baptist Medical Center, Oklahoma City, OK, 5Carolinas Medical Center, Charlotte, NC, 6Tampa General Hospital, Tampa, FL, 7Mt.Sinai Hospital, New York, NY, 8University of Chicago Medical Center, Chicago, IL, 9St.Jude Medical, Pleasanton, CA, 10Montefiore Medical Center, Bronx, NY

3:15 PM (154) Impact of Adherence to Standard Practice Guidelines for Patients Receiving a Left Ventricular Assist Device - Insights from the PREVENT Study: J. N. Katz1, S. Emani2, G. Egnaczyk3, E. Adler4, J. Chinn5, P. Shah6, A. Brieki7, M. Keebler8, S. Nathan9, I. Gregoric9, D. Crandall10, D. J. Farrar10, K. S. Sundareswaran10, S. Maltais11, 1Division of Cardiology, University of North Carolina, Chapel Hill, NC, 2Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, OH, 3Christ Hospital, Cincinnati, OH, 4Division of Cardiovascular Medicine, University of California - San Diego, San Diego, CA, 5Sutter Medical Center, Sacramento, CA, 6Inova Heart and Vascular Institute, Falls Church, VA, 7University of Colorado School of Medicine, Denver, CO, 8Vanderbilt Heart and Vascular Institute, Vanderbilt University, Nashville, TN, 9Memorial Hermann – Texas Medical Center, Houston, TX, 10St. Jude Medical, Pleasanton, CA, 11Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN

Thursday, April 6
2:00 PM - 3:30 PM

ORAL SESSION 14: Measure for Measure: In- and Ex-Vivo Cellular and Molecular Approaches for Thoracic Organ Tailoring

Location:
Grand Hall A

Target Audience:
BSTR, HF, HTX, LTX, MCS, NHSAH, PATH, PEDS, PHARM

Chairs:
Simon Pecha, MD, and Lori J West, MD, DPhil

2:00 PM (155) Advanced Theranostics in Ex-Vivo Lung Bioengineering; B. A. Guenthart, J. D. O’Neill, G. Vunjak-Novakovic, M. Bacchetta. 1Thoracic Surgery, Columbia University, New York, NY; 2Biomedical Engineering, Columbia University, New York, NY


2:30 PM (157) Hypoxia Inducible Factor 1 Alpha Mediates Apoptotic Cell Death in the DCD Heart Following Prolonged Exposure to Warm Ischemia; A. A. Ali, P. Downey, A. Zalewski, K. J. Clerkin, I. George, P. C. Colombo, S. Messer, S. R. Large, Z. A. Ali. 1Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom; 2Cardiology, Columbia University, New York, NY

2:45 PM (158) Extending the Boundaries of DCD Heart Transplantation: Improved Functional Recovery of DCD Hearts Exposed to Prolonged Warm Ischemia by Inhibition of Histone Deacetylase; A. A. Ali, P. Downey, A. Zalewski, K. J. Clerkin, I. George, P. C. Colombo, S. Messer, S. Large, Z. A. Ali. 1Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom; 2Cardiology, Columbia University, New York, NY

3:00 PM (159) Donor Organ Pretreatment with a Gap and Tight Junction Stabilizing Peptide Prevents IRI in a Mouse Lung Transplant Model; Q. Cheng, K. Patel, P. Zhu, L. Rucker, P. Allen, C. Vasu, S. Nadig, C. Atkinson. 1Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC; 2Department of Surgery, Tongji Hospital, Wuhan, China

3:15 PM (160) Normothermic Donor Lung Preservation Using the Organ Care System Significantly Reduces Ischemia/Reperfusion Injury by Promoting Cytokine Antagonists; B. Wiegmann, C. Falk, M. Seyda, C. Neudoerfl, C. Kühn, I. Tudorache, M. Avsar, A. Haverich, G. Wamecke. 1Dpt. for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany; 2Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
2:00 PM - 3:30 PM
ORAL SESSION 15: Therapies and Monitoring After Heart Transplantation

Location:
Grand Hall B

Target Audience:
HTX, BSTR, NHSAH, PHARM

Chairs:
Todd F Dardas, MD, and Mustafa Toma, MD

2:00 PM (165) Metformin Treatment After Heart Transplantation Is Associated with Reduced Malignancy Rate; Y. Peled¹, J. Lavee¹, E. Raichlin², M. Katz¹, M. Arad¹, Y. Shemesh¹, Y. Kassif¹, E. Asher¹, D. Elian¹, Y. Har-Zahav¹, N. Shlomo¹, D. Freimark¹, I. Goldenberg¹, R. Klempfner¹. ¹Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel, ²University of Nebraska Medical Center, Omaha, NE

2:15 PM (162) High Sensitivity Troponin Assays Can Decrease the Frequency of Endomyocardial Biopsy After Heart Transplantation; S. Fitzsimons¹, J. Parameshwar¹, N. Mills², S. Pettit¹. ¹Transplant Unit, Papworth Hospital, Papworth, United Kingdom, ²BHF Centre for Cardiovascular Sciences, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom


2:45 PM (164) Effect of Donor Simvastatin Treatment on Cardiac Allograft Ischemia-Reperfusion Injury - 30-Day Analysis of a Randomized Prospective Single-Center Clinical Trial; A. I. Nykanen¹, E. Holmström², S. Syrjäla², J. Jokinen¹, R. Krebs², K. B. Lemström¹. ¹Cardiac Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ²University of Helsinki, Helsinki, Finland

3:00 PM (161) Analysis of Donor-Derived Cell-Free DNA with 3-Year Outcomes in Heart Transplant Recipients; M. Crespo-Leiro¹, D. Hiller², R. Woodward², M. Grskovic³, C. Marchis³, M. Song², J. Collins³, A. Zuckermann³. ¹Hospital Universitario de A Coruña, La Coruña, Spain, ²CareDx, Brisbane, CA, ³Medical University of Vienna, Vienna, Austria

3:15 PM (166) Does Induction Therapy for Heart Transplant Recipients on Tacrolimus/Mycophenolate/Prednisone Improve Survival in the Current Allocation Era?; A. A. Amin¹, V. K. Ariyamuthu², M. A. Urey¹, F. G. Araj¹, M. H. Drazner¹, P. P. Mammen¹, B. Tanriover². ¹Cardiology, UT Southwestern, Dallas, TX, ²Nephrology, UT Southwestern, Dallas, TX
2:00 PM - 3:30 PM
ORAL SESSION 16: The Rise of the Machines: ECLS and EVLP in Lung Transplantation

Location:
Grand Hall C

Target Audience:
LTX, BSTR, EEP, ID, LTX, MCS, NHSAH, PATH, PHARM

Chairs:
Goran Dellgren, MD, PhD, and Marc De Perrot, MD

2:00 PM (167) **ECLS Bridge to Lung Transplantation: A Review of Our Institutional Experience**; A. Benazzo, G. Tukora, S. Schwarz, K. Hoetzenecker, B. Moser, J. Matilla Sigueenza, S. Taghavi, P. Jaksch, W. Klepetko, G. Lang. Thoracic Surgery, Medical University of Vienna, Vienna, Austria


2:30 PM (169) **Enhanced Organ Procurement with Resuscitation of Highly Marginal Donors with the Vivoline Ex Vivo Lung Perfusion System**; C. Divithotawela, D. C. Chambers, S. Yerkovich, P. Hopkins. Queensland Lung Transplant Service, The Prince Charles Hospital, Chermside, Australia


3:00 PM (171) **Improved Outcomes with Negative Pressure Ventilation (NPV) During Normothermic Ex Vivo Lung Perfusion**; N. Aboelnazar1, S. Himmat1, S. Hatami1, C. W. White2, D. H. Freed3, J. Nagendran3. 1Experimental Surgery, University of Alberta, Edmonton, AB, Canada, 2Cardiac Surgery Resident, University of Alberta, Edmonton, AB, Canada, 3Division of Cardiac Surgery, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada

3:15 PM (172) **High Levels of Cytokines in the Perfusate During Ex-Vivo Lung Perfusion Correlates with Persistence of Poor Graft Function After Lung Transplantation Using Reconditioned Grafts**; M. Boffini, V. Fanelli, E. Simonato, D. Ricci, P. Solidoro, P. Lausi, C. Barbero, L. Brazzi, M. Rinaldi. Surgical Sciences Department, University of Turin, Turin, Italy
2:00 PM - 3:30 PM
ORAL SESSION 17: What's Up Next in Pulmonary Hypertension Research?

Location:
Grand Hall D

Target Audience:
PH, BSTR, HF, LTX

Chairs:
Dana P McGlothlin, MD, and David L Joyce, MD

2:00 PM (173) Human Right Ventricular Myofilaments Exhibit Directionally Opposite Changes in Maximal Force and Calcium Sensitivity in Systemic Sclerosis-Associated versus Idiopathic Pulmonary Arterial Hypertension; S. Hsu1, J. A. Kirk2, C. J. Mullin3, M. Mukherjee1, T. M. Kolb3, R. L. Damico3, S. C. Mathai3, A. A. Shah4, F. M. Wigley5, K. B. Margulies5, P. M. Hassoun3, R. J. Tedford1, D. A. Kass1. 1Cardiology, Johns Hopkins University, Baltimore, MD, 2Cell and Molecular Physiology, Loyola University Chicago Stritch School of Medicine, Chicago, IL, 3Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, 4Rheumatology, Johns Hopkins University, Baltimore, MD, 5Cardiology, University of Pennsylvania School of Medicine, Philadelphia, PA

2:15 PM (174) In-Vivo Study of a Novel Long-Term Lung Support Device for PAH, Bridge-to-Transplant and Bridge-to-Candidacy; R. Borchardt1, S. Sonntag1, P. Ritter1, F. Boehning1, S. Groß-Hardt1, F. Hesselmann1, U. Steinseifer2, T. Verbelen3, B. Meyns3, T. Kaufmann1. 1enmodes GmbH, Aachen, Germany, 2Dept. of Cardiovascular Engineering, Institute of Applied Medical Engineering, RWTH Aachen University, Aachen, Germany, 3Dept. of Cardiovascular Science, KU Leuven, Leuven, Belgium

2:30 PM (175) Lung Allocation Score Is Not Predictive of Post-Transplant Survival Among Pulmonary Hypertension Lung Transplant Recipients; H. Maredia1, M. Bowring1, A. Massie1, S. Oyetunji1, C. Merlo2, R. Higgins1, D. Segev1, E. Bush1. 1Department of Surgery, Johns Hopkins University, Baltimore, MD, 2Department of Medicine, Johns Hopkins University, Baltimore, MD

2:45 PM (176) Surgical Series of 370 Cases of Pulmonary Thromboendarterectomy: Experience from the Indian Subcontinent; V. Shetty, J. Punnen, D. P. Shetty. Cardiac Surgery, Narayana Institute of Cardiac Sciences, Bangalore, India

3:00 PM (177) Implications of PAP Changes from Right Heart Catheterization to Lung Transplantation; S. Biswas Roy1, R. Panchanathan2, E. Todd1, P. Kang1, R. Walia1, R. M. Bremner1, M. A. Smith4. 1Norton Thoracic Institute; St. Joseph's Hospital and Medical Center, Phoenix, AZ, 2University of Arizona Medical School, Phoenix, AZ, 3University of Arizona College of Public Health, Phoenix, AZ, 4Norton Thoracic Institute, Phoenix, AZ

3:15 PM (178) Incremental Benefit of Cardiopulmonary Exercise Testing for the Prediction of Outcome in Stable Prevalent Pulmonary Arterial Hypertension Patients; R. Badagliacca1, S. Papa1, R. Poscia1, G. Valli1, B. Pezzuto1, G. Manzi1, P. Palange2, F. Fedele1, C. D. Vizza1. 1Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy, 2Clinical Medicine, Sapienza University of Rome, Rome, Italy
2:00 PM - 3:30 PM
ORAL SESSION 18: Contemporary Challenges in Pediatric Heart Transplant

Location:
Seaport F-H

Target Audience:
PEDS, HTX, PATH

Chairs:
Steven C Greenway, MD, and Tajinder P Singh, MD, MSc

2:00 PM (179) Pediatric Marginal Donor Hearts: National Use and Center-Specific Variability; A. K. Morrison¹, D. Tumin², D. Hayes, Jr.³, C. Phelps¹, J. Tobias², R. J. Gajarski¹, D. Nandi¹. ¹The Heart Center, Nationwide Children’s Hospital, Columbus, OH, ²Department of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, Columbus, OH, ³Section of Pulmonary Medicine, Nationwide Children’s Hospital, Columbus, OH

2:15 PM (180) Hearts Transplanted After Circulatory Death in Children: Analysis of the International Society for Heart and Lung Transplantation Registry; J. Kleinmahon¹, S. Patel¹, S. Auerbach¹, J. Stehlik², J. Rossano³, M. Everitt¹. ¹Cardiology, Children’s Hospital Colorado, Denver, CO, ²Cardiology, University of Utah Hospital, Salt Lake City, UT, ³Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA

2:30 PM (181) Use of Decellularized Cryopreserved Allografts During Single Ventricle Reconstruction Results in Lower HLA Sensitization Than Standard Allograft; H. M. Lim¹, J. Friedland-Little², S. Yu¹, R. E. Lowery¹, R. J. Gajarski³, R. G. Ohye⁴, K. R. Schumacher¹. ¹Department of Pediatric Cardiology, University of Michigan, C.S Mott Children’s Hospital, Ann Arbor, MI, ²Department of Pediatric Cardiology, Seattle Children’s Hospital, Seattle, WA, ³Department of Pediatric Cardiology, Nationwide Children’s Hospital, Columbus, OH, ⁴Department of Cardiac Surgery, University of Michigan, C.S Mott Children’s Hospital, Ann Arbor, MI

2:45 PM (182) Impact of Newly Detected Donor Specific Anti-HLA Antibody in the First Year After Pediatric Heart Transplantation; A. I. Dipchand¹, S. Webber², K. Much³, B. Feingold⁴, C. Bentlejewski⁵, E. D. Blume⁶, R. Shaddy⁷, C. Canter⁸, J. Lamour⁹, W. Mahle¹⁰, W. Zuckerman¹¹, H. Diop¹², Y. Morrison¹³, B. Armstrong³, D. Ikle³, J. Odim³, A. Zeevi¹⁴, T. CTOTC-04 Investigators¹³. ¹Hosp for Sick Children, Toronto, ON, Canada, ²Vanderbilt Univ, Nashville, TN, ³Rho, Chapel Hill, NC, ⁴Children’s Hospital of Pittsburgh, Pittsburgh, PA, Canada, ⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ⁶Children’s Hospital Boston, Boston, MA, Canada, ⁷Children’s Hospital of Philadelphia, Philadelphia, PA, ⁸St Louis Children’s Hospital, St Louis, MO, ⁹Montefiore Children’s Hospital, New York, NY, ¹⁰Children’s Healthcare of Atlanta, Atlanta, GA, ¹¹Children’s Hospital of New York, New York, NY, ¹²NIAID, Bethesda, MD, Canada, ¹³NIAID, Bethesda, MD, ¹⁴Univ of Pittsburgh, Pittsburgh, PA

3:00 PM (183) HLA Eplet Mismatching Is Associated with Increased Risk of Graft Loss in Pediatric Heart Transplant Recipients; E. Albers¹, N. Jorgensen², J. Friedland-Little¹, B. Hong¹, M. Kemna¹, P. Warner³, Y. Law¹. ¹Seattle Children’s Hospital, Seattle, WA, ²University of Washington, Seattle, WA, ³Bloodworks Northwest, Seattle, WA

3:15 PM (184) Predicting Cardiac Allograft Vasculopathy Using Circulating Vascular Endothelial Growth Factor in Pediatric Heart Transplant Recipients; K. Watanabe, S. D. Miyamoto, S. J. Nakano. School of Medicine, University of Colorado Denver, Aurora, CO
2:00 PM - 3:30 PM
ORAL SESSION 19: Junior Faculty Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best

**Location:** Coronado A-C
**Target Audience:** ALL
**Chairs:** Duane Davis, MD, MBA, and Hirsch S Mehta, MD

2:00 PM (185) **Driving an Electric Car Before You’re Old Enough To Get A Licence;** D. S. Burstein¹, D. Nandi², J. W. Gaynor¹, J. W. Rossano¹. ¹Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Cardiology, Nationwide Children's Hospital, Columbus, OH

2:05 PM **Expert Senior Discussant (Pediatric Transplantation)**
Elfriede Pahl, MD, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA

2:09 PM **Moderated Discussion**

2:15 PM (186) **Doing Your Best to Keep the Germs Away;** T. Sam¹, S. Wada², S. M. Joseph³, J. F. Trotter¹, S. K. Asrani¹, B. Lima³, G. Gonzalez-Stawinski³, S. A. Hall³, R. L. Gottlieb³. ¹Baylor Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Dallas, TX, ²Transplant Infectious Diseases, Baylor University Medical Center, Dallas, Dallas, TX, ³Baylor Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Dallas, TX

2:20 PM **Expert Senior Discussant (Infectious Diseases)**
Stanley I. Martin, MD, Geisinger Health System, Danville, PA, USA

2:24 PM **Moderated Discussion**

2:30 PM (187) **When Phoning It In Becomes the New Normal;** R. J. Cogswell¹, T. B. Freitag¹, C. A. Lilla², R. John³. ¹Cardiology, University of Minnesota, Minneapolis, MN, ²Nursing, Fairview - University of Minnesota Medical Center, Minneapolis, MN, ³Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

2:35 PM **Expert Senior Discussant (Mechanical Circulatory Support)**
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

2:39 PM **Moderated Discussion**

2:45 PM (188) **The Logistics of Staffing Clinic From Home;** S. Airhart¹, C. Walters¹, N. Verlinden¹, P. Correa¹, V. Franco², A. Raina¹, R. Benza¹. ¹Allegheny General Hospital, Pittsburgh, PA, ²Ohio State University, Columbus, OH

2:50 PM **Expert Senior Discussant (Pulmonary Hypertension)**
Myung H. Park, MD, Houston Methodist, Houston, TX, USA

2:54 PM **Moderated Discussion**

3:00 PM (189) **Safety During a Transition of Power;** Y. Peled, Y. Har-Zahav, Y. Kassif, Y. Shemesh, D. Freimark, J. Lavee. ¹Sheba Medical Center and Tel Aviv University, Tel Aviv, Tel Aviv, Israel

3:05 PM **Expert Senior Discussant (Heart Failure/Transplantation)**
Steven SL Tsui, MD, FRCS, Papworth Hosp NHS Trust, Cambridge, United Kingdom

3:09 PM **Moderated Discussion**

3:15 PM (190) **How It Feels to Get Rejected Quickly;** G. L. Calligaro¹, N. Watson², M. Malouf¹, M. Plit¹, M. R. Qiu³, T. Shein³, M. Benzimra¹, A. Rigby¹, A. R. Glanville¹, A. Havryk¹. ¹Lung Transplantation, St. Vincent's Hospital, Sydney, Australia, ²Tissue Typing Laboratory, Australian Red Cross, Sydney, Australia, ³Anatomical Pathology, St. Vincent's Hospital, Sydney, Australia

3:20 PM **Expert Senior Discussant (Lung Failure/Transplantation)**
Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

3:24 PM **Moderated Discussion**
SYMPOSIUM 17: To Pulse or Not To Pulse? That is the Question

Location:
Seaport A-E

Target Audience:
ALL

Chairs:
Paolo Colombo, MD, and Bart Meyns, MD, PhD

Session Summary: Human evolution has favored a pulsatile heart pump as the optimal way for organ perfusion. CF-LVAD physiology, with low to no pulsatility, has challenged that widely accepted notion. Although the present technology had been rapidly adapted, we are still hampered by morbidities that limit the expansion into the less sick group. Are we missing the pulse? Thus, methods to generate pulsatility and possibly create a hybrid between the man-made and mankind are presently being explored. A 15-minute panel discussion with all speakers will conclude this session.

4:00 PM
**Physiologic and Clinical Impact of Pulsatile vs. Nonpulsatile Flow on Blood Vessels and Vital Organs**
Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA

4:15 PM
**Physiologic and Clinical Impact of Pulsatile vs. Nonpulsatile Flow on the Brain**
William K Cornwell, MD, University of Colorado, Denver, CO, USA

4:30 PM
**Best Strategies to Measure Arterial Pulsatility and Tissue Perfusion in CF-LVAD Patients**
Melana Yuzefpolskaya, MD, Columbia University, New York, NY, USA

4:45 PM
**Design and Rationale for New Pulsatile Technology**
Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

5:00 PM
**Hemodynamic Effects of Counterpulsation**
Navin K Kapur, MD, Tufts Medical Center, Boston, MA, USA

5:15 PM
**Long-term Ambulatory Counterpulsation Using iVAS**
Val Jeevanandam, MD, University of Chicago Medicine, Chicago, IL, USA

5:30 PM
**The Pulse of Life - A Scientific and Existential Perspective**
Mandeep Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital / Harvard Medical School, Boston, MA, USA

5:45 PM **Panel Discussion**
SYMPOSIUM 18: Weeding Out Fact from Fiction - the Highs and Lows of Marijuana Use in Transplant

Location:  
Grand Hall A

Target Audience:  
PHARM, ALL

Chairs:  
Adam Cochrane, PharmD, and Vincent G. Valentine, MD

Session Summary: Increasing prevalence of medicinal and recreational cannabis use among transplant recipients has sparked discussion on the legal and safety ramifications of cannabis use in this patient population. This symposium will discuss the pharmacology of cannabis as well as explore the data surrounding the legal ramifications and risk/benefits of cannabis use in transplantation.

4:00 PM
*The Pharmacology of a Weed: Clinical Pharmacology of Cannabis and Cannabinoids*
Robert L Page, PharmD, MSPH, University of Colorado, Denver, CO, USA

4:15 PM Q&A

4:20 PM
*Cannabis: Wonder-Drug or Devil’s Weed? The Psychosocial Impact of Cannabis Use Post-Transplant*
Patrick Smith, PhD, Duke University Medical Center, Durham, NC, USA

4:35 PM Q&A

4:40 PM
*Cannabis Use and Graft Function: What Do We Know?*
Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Toronto, ON, Canada

4:55 PM Q&A

5:00 PM
*But the Government Says I Can⋯ Regulatory Implications of Legalizing Cannabis*
Lorriana E Leard, MD, UCSF Medical Center, San Francisco, CA, USA

5:15 PM Q&A

5:20 PM
*DEBATE (PRO): Cannabis Use Pre-Transplant - Don’t Judge Me!*
Martin Zamora, MD, University of Colorado, Denver, CO, USA

5:35 PM
*DEBATE (CON): Cannabis Use Pre-Transplant - Don’t Judge Me!*
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, Netherlands

5:50 PM
*DEBATE REBUTTAL (PRO)*
Martin Zamora

5:55 PM
*DEBATE REBUTTAL (CON)*
Erik Am Verschuuren
4:00 PM - 6:00 PM
SYMPOSIUM 19: Cardiogenic Shock: Types, Teams and Tactics

Location:
Grand Hall B

Target Audience:
HF, HTX, MCS

Chairs:
Lynn R Punnoose, MD, and Marian Urban, MD

Session Summary: Cardiogenic shock encompasses a broad clinical spectrum, including acute MI, primary RV failure and biventricular failure. This session will incorporate individual presentations describing (1) the spectrum and prevalence of cardiogenic shock subtypes, (2) national and international approaches to management and temporary mechanical support selection, and (3) the interdisciplinary approach to device management involving heart failure, interventional, critical care and imaging cardiologists.

4:00 PM
Phenotypes of Cardiogenic Shock: How to Move Beyond Anecdotes to Estimate Subtype Prevalence
Shelley A. Hall, MD, Baylor University Medical Center, Dallas, TX, USA

4:15 PM Q&A

4:20 PM
Hemodynamics of Temporary MCS: Do They Help Guide Device Selection? What If You Don't Have Them?
Gabriel Sayer, MD, University of Chicago, Chicago, IL, USA

4:35 PM Q&A

4:40 PM
The Use of SHOCK Teams in Hospitals with Advanced Heart Failure Care
Jose N Nativi, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

4:55 PM Q&A

5:00 PM
Refractory Ventricular Tachycardia (VT) with Hemodynamic Compromise: Temporary Device Choice and Ablative Options
A Reshad Garan, MD, Columbia University, New York, NY, USA

5:15 PM Q&A

5:20 PM
Weaning Temporary Mechanical Circulatory Support: Echocardiographic vs. Hemodynamic Parameters - This Is How We Do It
Jamie L Kennedy, MD, University of Virginia Health System, Charlottesville, VA, USA

5:35 PM Q&A

5:40 PM
Weaning Temporary Mechanical Circulatory Support: Echocardiographic vs. Hemodynamic Parameters - This Is How WE Do It
Evgenij V Potapov, MD, PhD, Berlin Heart Center, Berlin, Germany

5:55 PM Q&A
4:00 PM - 6:00 PM
SYMPOSIUM 20: ECMO in Lung Transplantation: Sensational Success or Fantastic Failure?

Location:
Grand Hall C

Target Audience:
LTX, ALL

Chairs:
Erika Berman Rosenzweig, MD, and Reda E. Girgis, MD

Session Summary: This symposium gives a state-of-the art overview of current ECMO technology, including cannulation strategies, patient selection, peri-operative and program management.

4:00 PM
ECMO Technique: Configuration, Cannulae, Complications
Martin Strueber, MD, Michigan State University College of Human Medicine, East Lansing, MI, USA

4:20 PM Q&A

4:24 PM
ECMO Candidate Selection for Elective ECMO
Clemens Aigner, MD, Universität Duisburg-Essen, Essen, Germany

4:44 PM Q&A

4:48 PM
ECMO as Urgent Bridge to Transplant
Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany

5:08 PM Q&A

5:12 PM
Post-Operative ECMO for Rescue Therapy
Göran Dellgren, MD, Sahlgrenska University Hospital, Göteborg, Sweden

5:32 PM Q&A

5:36 PM
ECMO Program Management: Bridge over Troubled Water?
David Michael McMullan, MD, Seattle Children’s Hospital, Seattle, WA, USA

5:56 PM Q&A
SYMPOSIUM 21: Cardiopulmonary Hemodynamics, the Right Ventricle, and the Kidney: Connecting All the Dots

Location:
Grand Hall D

Target Audience:
PH, HF, HTX, LTX, MCS

Chairs:
Ryan J Tedford, MD, and Marco Guazzi, MD, PhD

Session Summary: This symposium reviews hot topics in hemodynamic assessment and management of patients with pulmonary hypertension including measures of pulmonary vascular compliance, the emerging role of right ventricular reserve assessment, and the interaction between right heart and kidney function. In the final two talks, the speakers debate the need for provocative testing in patients meeting hemodynamic criteria for Group I PAH but who have all least some phenotypic characteristics of group II PH. A panel discussion with all speakers will conclude this session.

4:00 PM
*Forget About Pulmonary Vascular Resistance (PVR), Only Pulmonary Vascular Compliance Matters*
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, USA

4:20 PM
*No Time to Rest: The Importance of Right Ventricular Reserve in Pulmonary Hypertension*
Ryan J. Tedford, MD, Johns Hopkins, Baltimore, MD, USA

4:40 PM
*The Cardiorenal Syndrome in Right Heart Failure: Just Central Venous Pressure (CVP) or More to the Story?*
Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA

5:00 PM
*Case Presentation: Age >65, mPAP>25mmHg, Borderline Pulmonary Artery Wedge Pressure (PAWP)*
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN, USA

5:05 PM
*DEBATE (PRO): It is Essential to Unmask PH due to Left Heart Disease (LHD) with Volume Loading and/or Exercise Testing*
Marc A. Simon, MD, University of Pittsburgh, Pittsburgh, PA, USA

5:25 PM
*DEBATE (CON): It is Essential to Unmask PH due to Left Heart Disease (LHD) with Volume Loading and/or Exercise Testing*
Susanna Mak, MD, PhD, Mount Sinai Hospital, Toronto, ON, Canada

5:45 PM *Panel Discussion*
4:00 PM - 6:00 PM
SYMPOSIUM 22: Let's Get Personal! Precision Diagnostics in Thoracic Transplantation

Location:
Seaport F-H

Target Audience:
PATH, ALL

Chairs:
Patrick Bruneval, MD, and Sean Agbor-Enoh, MD

Session Summary: In recent years, methodologies of precision medicine have been applied to the study of post-transplant pathobiology. Basic molecular mechanisms involved in acute and chronic allograft rejection have been uncovered, and novel molecular tools for the non-invasive monitoring of heart and lung transplantation have been discovered. This symposium brings together state-of-the-art scientific speakers who lead the field as we make a transition to personalized transplant care.

4:00 PM
*Precision Medicine: Applying Circulating Cell-Free DNA to Monitor Transplant Health Outcomes*
Hannah Valantine, MD, National Institutes of Health, Bethesda, MD, USA

4:15 PM Q&A

4:20 PM
*How to Use the Virome to Monitor Post-Transplant Immune Status*
Iwijn De Vlaminck, PhD, Cornell University, Ithaca, NY, USA

4:35 PM Q&A

4:40 PM
*Tissue and Circulating Long-Noncoding RNA and MicroRNA in Thoracic Transplantation*
Howard J Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, USA

4:55 PM Q&A

5:00 PM
*Transcriptomic Analysis of Endomyocardial Biopsies for Precision Diagnosis*
Jean-Paul Duong Van Huyen, MD, Hospital Necker, Paris, France

5:15 PM Q&A

5:20 PM
*Next Generation Sequencing and Signatures: Applications in Transplant Diagnostics*
Bruce McManus, MD, PhD, St. Paul's Hospital, Vancouver, BC, Canada

5:35 PM Q&A

5:40 PM
*The Future of Precision Medicine: Genome Editing Using CRISPR/Cas9 Technology*
Christof Fellmann, PhD, University of California, Berkeley, CA, USA

5:55 PM Q&A
SYMPOSIUM 23: Taming of the Shrew: Mycobacterium Abscessus in Lung Transplantation

Location:
Coronado A-C

Target Audience:
ID, ALL

Chairs:
Jens Gottlieb, MD, and Me-Linh Luong, MD

Session Summary: Mycobacterium abscessus is increasingly isolated pre- and post-lung transplant (LT). It causes a wide spectrum of infection including disseminated post-LT. Pre-LT isolation is a risk for post-LT infection and patient-to-patient transmission may occur. It is resistant to many antibiotics. Prolonged combination therapy is required and side-effects are frequent. Thus, many centers consider M. abscessus a contra-indication to LT. Good outcomes appear linked to aggressive peri-operative management. A 10-minute panel discussion with all speakers will conclude this session.

4:00 PM
Epidemiology and Modes of Transmission
Cameron Wolfe, MD, Duke University, Durham, NC, USA

4:15 PM Q&A

4:20 PM
Clinical Manifestations, Diagnosis and Antimicrobial Susceptibility
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

4:35 PM Q&A

4:40 PM
Management of M. Abscessus in the Lung Transplant Candidate: Preparation for Transplantation
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

4:55 PM Q&A

5:00 PM
Antimicrobial Therapy of M. Abscessus: Current and Novel Agents
Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland

5:15 PM Q&A

5:20 PM
DEBATE (PRO): Patients with M. Abscessus Can Be Safely Transplanted
Gregory I Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

5:35 PM
DEBATE (CON): Patients with M. Abscessus Can Be Safely Transplanted
Paul Corris, MB FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:50 PM Panel Discussion
6:15 PM - 7:15 PM
MINI ORAL SESSION 7: Factors that Drive Success in MCS

Target Audience:
MCS, EEP, HF, NHSAH

Chairs:
Andrew J Boyle, MD, and Maryse Palardy, MD


6:20 PM (192) A Survey of Non-Heart Failure Cardiologists’ Perception and Understanding of Left Ventricular Assist Device Therapy and Outcomes; A. Bitar1, K. Aaronson1, F. Paganii, P. Shah2, R. Singh2, T. Dardas3, N. Mokadam3, J. Stulak4, S. Dunlay4, C. Salerno5, J. Cowger5. 1University of Michigan Health System, Ann Arbor, MI, 2Inova Heart & Vascular Institute, Falls Church, VA, 3University of Washington, Seattle, WA, 4Mayo Clinic, Rochester, MN, 5St Vincent Heart Center of Indiana, Indianapolis, IN


6:30 PM (194) Effect of the Lavare Cycle on Pump Function, Aortic Valve Opening, Autonomic Function and Activity Outcomes in Continuous Flow LVAD Patients; R. Clifford1, Y. D. Kim1, D. Robson1, C. Gross2, F. Moscato2, H. Schima2, P. S. Macdonald2, P. Jansz2, C. S. Hayward3. 1Heart Failure and Transplant Unit, St Vincent’s Hospital, Sydney, Australia, 2Medical University of Vienna, Vienna, Austria

6:35 PM (195) Impact of Evaluation of Left Ventricular Apical Core Pathology Obtained at Time of LVAD Implantation; J. N. Schultz1, R. John2, C. M. Martin3, M. Pritzker3, E. Missov3, T. Thenappan3, R. Cogswell3. 1Department of Medicine, University of Minnesota, Minneapolis, MN, 2Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN, 3Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN

6:40 PM (196) Previous Cardiac Operations Do Not Significantly Influence Outcome After Minimally Invasive HVAD Implantation; D. Böthig, C. Feldmann, J. S. Hanke, S. V. Rojas, E. Deniz, G. Dogan, A. Haverich, J. D. Schmitto. Hannover Medical School, Hannover, Germany


6:50 PM (198) Circadian Variation of Blood Pressure and Hemodynamics in Outpatients with Heart Mate II; F. Castagna1, A. Pinsino1, E. J. Stöhr1, B. McDonnell2, M. Yuzefpolskaya1, M. Flannery1, D. L. Brunjes1, N. Akter1, R. T. Te-Frey1, M. F. Pineda1, E. Royzman1, V. K. Topkara1, A. R. Garan1, H. Takayama1, K. Takeda1, Y. Naka1, J. Cockcroft2, P. C. Colombo1. 1New York Presbyterian Hospital - Columbia University Medical Center, New York, NY, 2Cardiff Metropolitan University, Cardiff, United Kingdom

6:55 PM (199) Resting Oxygen Consumption Index Is Reduced in LVAD Patients Compared to Controls and Published Estimations of Oxygen Consumption; T. Cascino, G. Grafton, T. M. Koelling. University of Michigan, Ann Arbor, MI

7:00 PM (200) Postoperative Vasoplegia Is Strongly Associated with Short and Long Term Outcomes in Patients Receiving Left Ventricular Assist Device (LVAD) Therapy; B. Lima1, S. A. Hall2, G. V. Gonzalez-Stawinski1, J. Collier1, K. Tecson2, P. Kale2, S. Still3, A. Sheikh1, R. Baxter1, S. M. Joseph2. 1Cardiac Surgery, Baylor University Medical Center, Dallas, TX, 2Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX

Thursday, April 6
7:05 PM (201) Obesity Increases Risk of Thromboembolic Event After LVAD Implant? An Analysis by Devices; H. TOEG¹, J. Stulack², S. Dunlay², C. Salerno³, J. Cowger², P. Shah⁴, R. Singh⁴, T. Dardas⁵, K. Aaronson⁶, F. Pagani⁶, S. Maltais⁷. ¹University of Ottawa Heart Institute, Ottawa, ON, Canada, ²Mayo Clinic, Rochester, MN, ³St Vincent Heart Center of Indiana, Indianapolis, IN, ⁴Inova Heart and Vascular Institute, Falls Church, VA, ⁵University of Washington, Seattle, WA, ⁶University of Michigan Medical Center, Ann Arbor, MI, ⁷Cardiac Surgery, Mayo Clinic, Rochester, MN

7:10 PM (202) Left Ventricular Assist Device Implantation in Marijuana Users; P. S. Joy¹, G. Kumar², J. K. Bhama¹, L. M. Cadaret¹. ¹University of Iowa, Iowa City, IA, ²Northeast Georgia Health System, Gainesville, GA
6:15 PM - 7:15 PM
MINI ORAL SESSION 8: Infections, Induction and IVIG

Location:
Grand Hall B

Target Audience:
HTX, EEP, ID, MCS

Chairs:
Javier Segovia, MD, PhD, and Valentina Stosor, MD

6:15 PM (203) Treatment with IV Antibiotics Immediately Pre-Transplant Is Associated with Increased Mortality in Heart Transplant Recipients; D. Vucicevic, L. Honoris, M. Moore, L. Sweet, A. Salimbangon, A. Chang, E. Moreno, K. Pandya, A. Iyengar, S. Shah, B. Kubak, A. Ardehali, M. Deng, E. DePasquale. 1Department of Cardiology, UCLA, Los Angeles, CA, 2Department of Cardiology, UC Davis, Davis, CA, 3Department of Infectious Diseases, UCLA, Los Angeles, CA, 4Department of Cardiothoracic Surgery, UCLA, Los Angeles, CA

6:20 PM (204) More Inactive Time on Heart Transplant List Results in Increased Post Transplant Mortality; D. Vucicevic, L. Honoris, A. Salimbangon, A. Chang, E. Moreno, K. Pandya, A. Iyengar, S. Shah, M. Moore, L. Sweet, M. Deng, A. Ardehali, E. DePasquale. 1Department of Cardiology, UCLA, Los Angeles, CA, 2Department of Cardiology, UC Davis, Davis, CA, 3Department of Cardiothoracic Surgery, UCLA, Los Angeles, CA

6:25 PM (205) Sternal Wound Infection Post Orthotropic Heart Transplantation; H. Fernando, A. Leet. Cardiology, Alfred Hospital, Prahran, Australia


6:35 PM (207) Potential Intravenous Immunoglobulin Mediated Protection Against Severe Infections in a Randomized Clinical Trial in Solid Organ Transplantation; E. Sarmiento, I. Ezzahouri, J. Montanchez, L. Calahorra, S. Garcia-Jimenez, I. Sousa-Casasnovas, E. Zatarain, P. Navas, M. Rodriguez-Ferrero, M. Salcedo, M. Valero, J. Navarro, E. Bouza, J. Carbone. 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Nephrology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 4Hepatology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 5Microbiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

6:40 PM (208) Rituximab Induction and Risk of Cardiac Allograft Vasculopathy, Rejection and Death; A. Vidic, R. Starling, L. B. Edwards, A. E. Toll, P. Heeger, L. H. Lund, S. G. Drakos, A. G. Kfouri, M. H. Sayegh, A. K. Chandraker, J. Stehlik. 1University of Utah School of Medicine, Salt Lake City, UT, 2Cleveland Clinic Foundation, Cleveland, OH, 3United Network for Organ Sharing, Richmond, VA, 4Icahn School of Medicine at Mount Sinai, New York, NY, 5Karolinska University Hospital, Stockholm, Sweden, 6Intermountain Medical Center, Salt Lake City, UT, 7Brigham and Women's Hospital, Harvard Medical School, Boston, MA

6:45 PM (209) Induction with Basilixumab or Thymoglobulin for Adult Heart Transplantation Transplantation; S. G. Al-Kindi, B. Dhakal, C. Elamm, B. Sareyyupoglu, G. H. Oliveira, M. Ginwalla. University Hospitals Cleveland Medical Center, Cleveland, OH

6:50 PM (210) First Outbreak of Pneumocystis jirovecii Pneumonia in Heart Transplantation Recipients; E. Ammirati, G. Veronese, M. C. Moioli, R. Baldan, C. Orcese, G. De Rezende, S. Veronese, E. Perina, G. Masciocco, G. Travi, M. Puoti, M. G. Mondino, M. Cipriani, D. M. Cirillo, M. Frigerio. 1De Gasperis CardioCenter, Niguarda Hospital, Milan, Italy, 2Infectious Diseases, Niguarda Hospital, Milan, Italy, 3Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, 4Pathology, Niguarda Hospital, Milan, Italy, 5Cardiothoracic Anesthesia and Intensive Care, Niguarda Hospital, Milan, Italy

7:00 PM (212) *The Prevalence of Hepatitis E Virus Serum Antibodies and RNA in Heart Transplant Recipients*; K. Okamura¹, K. Nawata¹, M. Kimura¹, O. Kinoshita¹, A. Masuzawa¹, H. Yamauchi¹, Y. Hirata¹, Y. Owada², Y. Oshiro², H. Okamoto³, N. Ohkohchi², M. Ono¹.¹Cardiac Surgery, The University of Tokyo Hospital, Bunkyo-ku Tokyo, Japan, ²Surgery, University of Tsukuba, Tsukuba Ibaraki, Japan, ³Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke Tochigi, Japan


7:10 PM (214) *Coccidiomycosis - Screening and Prophylaxis for Thoracic Transplant Recipients in Endemic Areas*; A. Colon, S. Pophal, S. Zangwill. Pediatric Cardiac Transplant, Phoenix Children's Hospital, Phoenix, AZ
6:15 PM - 7:15 PM
MINI ORAL SESSION 9: Novel Strategies and Mechanisms in Lung Preservation, Heart Failure and Assist Devices

Location:
Grand Hall C

Target Audience:
BSTR, HTX, ID, LTX, MCS, PEDS, PHARM

Chairs:
Marcelo Cypel, MD, and Desiree Robson, RN BSc (Hons)


6:20 PM (216) Thermographic Evaluation During Ex Vivo Lung Perfusion for Detecting Regional Graft Damage: H. Motoyama, T. F. Chen-Yoshikawa, K. Hijiya, S. Tanaka, E. Miyamoto, M. Takahashi, K. Ohata, A. Aoyama, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

6:25 PM (217) Surfactant Metabolism During Normothermic Ex Vivo Lung Perfusion: L. Thakuria1, R. Romano1, V. Goss2, G. Koster2, P. Townsend2, A. Popov1, F. de Robertis1, T. Pitt1, M. Carby1, A. Simon1, N. Marczin1, M. Griffiths3, A. Postle4, A. Reed1. 1Dept of Transplantation, Harefield Hospital, Harefield, United Kingdom, 2University of Southampton, Southampton, United Kingdom, 3National Heart Lung Institute, Imperial College London, Harefield, United Kingdom

6:30 PM (218) Sphingosine-1-Phosphate Attenuates Lung Injury in Murine Model of Ex Vivo Lung Perfusion: J. H. Mehaffey1, E. J. Charles1, R. B. Hawkins1, S. A. Schubert1, Y. Kharel2, C. G. Tribble1, V. E. Laubach1, K. Lynch2, A. Sharma2, I. L. Kron1. 1Surgery, University of Virginia, Charlottesville, VA, 2Pharmacology, University of Virginia, Charlottesville, VA

6:35 PM (219) Anti-Inflammatory Effect of Mesenchymal Stem Cells Facilitates Lung Preservation: N. A. Pacienza1, D. Santa-Cruz1, M. Marcos2, O. Robledo2, G. Lemus2, A. Bertolotti3, G. Yannarelli1. 1Laboratorio de Regulación Génica y Células Madre, IMETTYB, Universidad Favaloro-CONICET, Ciudad Autonoma de Buenos Aires, Argentina, 2Departamento de Cirugía, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, La Plata, Argentina, 3Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Ciudad Autonoma de Buenos Aires, Argentina


6:45 PM (221) Implantation of Spontaneously Beating Human iPS Cell-Derived Engineered Heart Tissue Does Not Provokes Ventricular Arrhythmias in a Guinea Pig Infarction Model: S. Pecha1, K. Breckwoldt2, M. Roehl3, A. Hansen3, A. Schwoerer4, H. Ehmke4, H. Reichenspurner1, T. Eschenhagen3. 1Cardiovascular Surgery, Univ Hospital Hamburg, Hamburg, Germany, 2Experimental Pharmacology and Toxicology, Univeristy Hospital Hamburg Eppendorf, Hamburg, Germany, 3Experimental Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, Hamburg, Germany, 4Physiology, University Hospital Hamburg Eppendorf, Hamburg, Germany


6:55 PM (223) An Integrated Analysis of Metabolomics After Left Ventricular Assist Device Implantation: B. Fine1, A. Marx1, V. Topkara1, E. A. Gomez2, G. Vinjak-Novakovic3, P. Colombo1. 1Department of Medicine, Columbia University, New York, NY, 2Department of Neurology, Columbia University, New York, NY, 3Department of Biomedical Engineering, Columbia University, New York, NY

F. Rueter¹, M. Grapow¹, O. Reuthebuch¹, F. Eckstein¹, F. Beyersdorf⁶, M. Siepe⁶, O. Schilling². ¹Cardiac Surgery, University Hospital Basel, Basel, Switzerland, ²IMMZ, University of Freiburg, Freiburg, Germany, ³IMMZ, Freiburg, Germany, ⁴Biology, University of Freiburg, Freiburg, Germany, ⁵ZBSA, University of Freiburg, Freiburg, Germany, ⁶Cardiac Surgery, Heart Centre Freiburg University, Freiburg, Germany

7:05 PM (225) Neopterin Elevation and Survival Following Left Ventricular Assist Device Implantation; M. M. Lander¹, M. Mercurio², K. Hanley-Yanez², M. S. Sharbaugh¹, A. D. Althouse¹, M. A. Simon¹, J. J. Teuteberg¹, L. Lagazzi¹, C. M. Sciortino¹, C. McTiernan¹, R. Kormos¹, D. M. McNamara¹. ¹Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh Medical Center, Pittsburgh, PA

7:10 PM (226) Reduced PF4 and C6orf25 Gene Copies Prior to LVAD in Patients with Thromboembolic Events; G. H. Kim¹, G. Sayer¹, D. Rodgers¹, R. Woodward², P. Arnold², N. Sarswat¹, J. Grinstein¹, S. Kalantari¹, S. Adatya¹, J. Yee², T. Ota¹, V. Jeevanandam¹, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²CareDx, Inc, Brisbane, CA
6:15 PM - 7:15 PM
MINI ORAL SESSION 10: Challenges in Lung Transplantation

Location:
Grand Hall D

Target Audience:
LTX, EEP, ID, NHSAH, PATH, PHARM

Chairs:
Erik Am Verschuuren, MD, PhD, and Barbara C Cahill, MD

6:15 PM (227) Improved Survival After Lung Transplantation for Adults Requiring Pre-Operative Invasive Mechanical Ventilation: A National Cohort Study; B. C. Hamilton¹, G. R. Dincheva², J. A. Golden³, S. R. Hays³, L. E. Leard³, R. Shah³, M. E. Kleinhenz³, T. Deuse², B. Trinh³, M. Brznzinski³, M. A. Matthey³, J. P. Singer³, J. Kukreja³.
¹Department of Surgery, UCSF, San Francisco, CA, ²Department of Surgery, Division of Cardiothoracic Surgery, UCSF, San Francisco, CA, ³Department of Medicine, Pulmonary and Critical Care, UCSF, San Francisco, CA, ⁴Department of Anesthesia, UCSF, San Francisco, CA, ⁵Department of Medicine and Anesthesia, Cardiovascular Research Institute, UCSF, San Francisco, CA

6:20 PM (228) Simultaneous or Sequential Lung-Kidney Transplantation Confers Superior Survival in Renal-Failure Patients Undergoing Lung Transplantation: A National Analysis; B. A. Yerokun¹, M. S. Mulvihill¹, A. A. Osho², M. G. Hartwig¹. ¹Duke University Medical Center, Durham, NC, ²Massachusetts General Hospital, Boston, MA

6:25 PM (229) De Novo Solid Organ Malignancies After Lung Transplantation: A 25-Year Single Center Experience; R. Waseda¹, M. Hoda², A. Benazzo², P. Jaksch², T. Klikovits², G. Lang², S. Taghavi², W. Klepetko². ¹Fukuoka University, Fukuoka, Japan, ²Medical University of Vienna, Vienna, Austria

6:30 PM (230) Post-Transplant Lymphoproliferative Disorder After Lung Transplantation: 10-Year Experience at Duke University; L. Zaffiri¹, C. Frankel¹, E. N. Pavlisko¹, S. M. Palmer¹, L. D. Snyder¹. ¹Pulmonary and Critical Care, Duke University, Durham, NC, ²Pathology, Duke University, Durham, NC

6:35 PM (231) NonTuberculous Mycobacteria Infection and Lung Transplantation in Cystic Fibrosis: A Worldwide Survey of Clinical Practice; M. Brodlie¹, A. Tissot¹, M. F. Thomas¹, P. A. Corris¹. ¹Paediatric Respiratory Medicine, Freeman Hospital/Great North Children's Hospital/Newcastle University, Newcastle upon Tyne, United Kingdom, ²Respiratory Medicine, Centre Hospitalier Universitaire de Nantes, Nantes, France, ³Respiratory Medicine, Freeman Hospital/Newcastle University, Newcastle upon Tyne, United Kingdom

6:40 PM (232) Preoperative Functional Independence and Employment Status Are Associated with Improved Long Term Survival After Lung Transplantation; A. A. Osho¹, N. Lamba¹, S. Hirji³, M. Mulvihill³, B. Yerokun⁴, M. Bishawi⁶, P. Spencer⁶, M. Villavicencio-Theoduloz¹, M. Hartwig⁴. ¹Surgery, Massachusetts General Hospital, Boston, MA, ²School of Medicine, Harvard University, Boston, MA, ³Surgery, Brigham and Women's Hospital, Boston, MA, ⁴Surgery, Duke University Hospital, Durham, NC

6:45 PM (233) Perceived Cognitive Difficulties and Quality of Life following Lung Transplantation; P. J. Smith, J. A. Blumenthal, L. D. Snyder, S. Rivelli, S. M. Palmer. Duke University Medical Center, Durham, NC

6:50 PM (234) Towards Accurate Death Classification Following Lung Transplantation: The Alfred Cohort; K. Levin, G. Snell, M. Paraskeva. Department of General Respiratory and Lung Transplantation, The Alfred Hospital, Melbourne, Australia


7:00 PM (236) Cytokine Profiles of Aspergillus Isolation in Lung Transplant Recipients (LTR); O. Morrissey¹, G. Westall², R. Ffrench³, T. Edgell⁴, Y. Cristiano⁵, T. Phan⁵, B. Levvey², G. Snell², H. de Silva². ¹Infectious Diseases, Alfred Health, Melbourne, Australia, ²Respiratory Medicine, Alfred Health, Melbourne, Australia, ³Burnet Institute, Melbourne, Australia, ⁴Hudson Institute, Melbourne, Australia, ⁵Immunology and Pathology, Monash University, Melbourne, Australia
7:05 PM (237) **A. fumigatus CYP51A Mutations in Lung Transplant Recipients;** F. Cheema¹, L. McTaggart², L. G. Singer³, D. Kumar¹, A. Humar¹, C. Rotstein¹, S. Keshavjee³, J. Kus², T. Mazzulli³, S. Husain¹. ¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Public Health Ontario, Toronto, ON, Canada, ³Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada.

7:10 PM (238) **Ribavirin Efficacy in Upper and Lower Respiratory Tract Paramyxovirus Infection and Lower Respiratory Tract Paramyxovirus Infection;** A. E. Zwart de¹, A. Riezebos-Brilman², J. C. Alffenaar³, W. Bij van der¹, M. E. Erasmus⁴, E. A. Verschuuren¹. ¹Dept of Pulmonary Disease and Tuberculosis, Univ Med Centre Groningen, University of Groningen, Groningen, Netherlands, ²Dept of Medical Microbiology, Univ Med Centre Utrecht, Utrecht, Netherlands, ³Dept of Clinical Pharmacy and Farmacology, Univ Med Centre Groningen, University of Groningen, Groningen, Netherlands, ⁴Dept of Cardiothoracic Surgery, Univ Med Centre Groningen, University of Groningen, Groningen, Netherlands.
MINI ORAL SESSION 11: Outcomes in MCS

Location:
Seaport F-H

Target Audience:
MCS, HF, HTX

Chairs:
Paul J Mohacsi, MD, and Daniel J Goldstein, MD


6:20 PM (240) Acute Kidney Injury Is Highly Frequent Early After LVAD Implantation, with High Morbidity and Mortality Rates: A Multi-Centre Study; R. Muslem1, K. Caliskan1, S. Akin1, D. A. Hesselink2, G. J. Whitman3, R. J. Tedford4, A. J. Bogers5, O. C. Manintveld6, S. D. Russell4. 1Cardiology, Erasmus MC, Rotterdam, Netherlands, 2Nephrology, Erasmus MC, Rotterdam, Netherlands, 3Cardiothoracic Surgery, Johns Hopkins School of Medicine, Baltimore, MD, 4Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, 5Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands


(243) PROMOTED TO ORAL

6:35 PM (1101) Utilisation of Hospital in the Home (HITH) by Heart and Lung Transplant Units at a Tertiary Transplant Hospital - The Alfred Health HITH Experience; A. Fuller1, D. Loader2, O. Strubel2, S. Lang2, D. Ferraro2, C. James2, B. Wallis3, P. Bergin3, G. Snell4. 1Infectious Diseases, Alfred Hospital, Melbourne, Australia, 2HITH, Alfred Hospital, Melbourne, Australia, 3Heart Transplantation, Alfred Hospital, Melbourne, Australia, 4Lung Transplantation, Alfred Hospital, Melbourne, Australia

6:40 PM (244) Pulmonary Artery Pulsatility Index Predicts RV Failure, Duration of Inotropes and Death After LVAD Implantation in a Large, High Acuity Cohort; J. D. Moreno, L. Adamo, D. S. Raymer, C. T. Sparrow, B. R. Pierce, S. J. LaRue. Medicine, Washington University in St. Louis, St. Louis, MO

6:45 PM (245) Recurrent Falls in Patients with CF-LVAD’s Are Associated with Major Morbidity and Mortality; J. K. Wong1, A. Forrest1, S. Sherazi2, L. Chen2, J. Alexis2, S. M. Friedman3, J. M. Lehoux1, H. T. Massey1, S. M. Prasad1, P. A. Knight1. 1Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY, 2Division of Cardiology, University of Rochester Medical Center, Rochester, NY, 3Department of Medicine, University of Rochester Medical Center, Rochester, NY

6:50 PM (246) Outcomes in Patients Bridged to Long-Term Continuous Flow Left Ventricular Assist Devices Using Short-Term Mechanical Circulatory Support; C. Kurihara, M. Kawabori, T. Sugiura, W. E. Cohn, A. B. Civitello, O. Fraizer, J. A. Morgan. Baylor College of Medicine, Houston, TX

6:55 PM (247) Right Ventricular Dysfunction Augments Risk of Adverse Outcomes in Patients with Refractory Ventricular Arrhythmias Prior to Left Ventricular Assist Device Implantation; R. A. Chhana, C. T. Sparrow2, P. K. Rao2, M. E. Nassif2, E. Novak2, S. J. LaRue2, J. D. Schilling2. 1Department of Medicine, Washington University, St Louis, MO, 2Department of Medicine, Division of Cardiology, Washington University, St Louis, MO

7:00 PM (248) Similar One-Year Survival with Acute Mechanical Circulatory Support Compared to Durable Mechanical Circulatory Support Use Prior to Orthotopic Heart Transplantation: A Single Center Experience; D.
Zisa, C. Davila, S. Patel, K. Morine, M. Esposito, M. Kiernan, D. DeNofrio, N. Kapur. CardioVascular Center, Tufts Medical Center, Boston, MA


7:10 PM (250) The Hemodynamic Effects of Concomitant Mitral Valve Repair and Left Ventricular Assist Device Implantation; J. Nnanabu1, D. Rodgers1, N. Sarswat1, J. Raikhelkar1, S. Adatya1, G. H. Kim1, D. Medvedofsky1, T. Ota1, T. Song1, D. Burkhoff2, R. M. Lang1, V. Jeevanandam1, G. Sayer1, N. Uriel1. 1University of Chicago, Chicago, IL, 2HeartWare International, Inc, Framingham, MA
MINI ORAL SESSION 12: Hot Topics in Pediatric Heart Transplantation

Location: Coronado A-C

Target Audience: PEDS, BSTR, HTX

Chairs: Steven D Zangwill, MD, and Anne I Dipchand, MD

6:15 PM (251) Reduced Naive Regulatory T-Cells and B-10 Cells in Thymectomized Children Predispose for Allergic Disorders After Heart Transplantation: T.-B. Kim1, N. Avdimiret2, L. Ionescu3, I. M. Larsen1, B. Motyka1, L. J. West1, S. Urschel1. 1Pediatrics, University of Alberta, Edmonton, AB, Canada, 2Pediatrics, Hospital for Sick Children, Toronto, ON, Canada


6:30 PM (254) Refinement of Automated Whole Slide Image Analysis in Pediatric Heart Transplants: A. K. Bhatia1, L. Tong2, R. Hoffman3, P. Wu3, H. R. Hassanzadeh4, M. D. Wang2, S. R. Deshpande5. 1Pediatric Cardiology, Standford University, Stanford, CA, 2Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 3Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 4Computational Science and Engineering, Georgia Institute of Technology, Atlanta, GA, 5Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA

6:35 PM (255) Use of Two Dimensional Speckle Tracking Echocardiography for the Detection of Acute Rejection in Pediatric Heart Transplant Recipients: A Prospective Study: K. Engelhardt1, M. Sorenson2, B. Das3, T. Zellers3, M. Lemler3. 1University of Texas Southwestern, Dallas, TX, 2Pediatrics, University of Texas Southwestern, Dallas, TX, 3Pediatric Cardiology, University of Texas Southwestern, Dallas, TX

6:40 PM (256) Left Atrial Function During the First Year After Pediatric Heart Transplantation: F. I. Lunze1, S. D. Colan1, N. Rifai2, K. Gauvreau1, M. A. Molloy1, K. Veljkovic3, P. Kavsak4, K. Adeli1, E. D. Elizabeth D. Blume1, T. P. Singh1. 1Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, 2Clinical Biochemistry, Boston Children's Hospital, Harvard Medical School, Boston, MA, 3Departments of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, 4Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, 5Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON

6:45 PM (257) Post-Transplant Outcomes of Children with Donor-Recipient Race Mismatch in the USA: An Analysis of the UNOS Database: A. G. Cabrera1, J. F. Price1, I. Adachi2, B. Elias2, S. W. Denfield1, W. J. Dreyer1, H. P. Tunuguntla1, N. J. Rodgers1, A. Jeewa1. 1Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 2Surgery, Baylor College of Medicine/Texas Children's Hospital, Houston, TX

6:50 PM (258) Japanese Registry for Pediatric Heart Transplantation: The First Report 2017: N. Fukushima1, M. Ono2, S. Kogaki3, Y. Sawa4. 1Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan, 2Department of Cardiac Surgery, University of Tokyo, Tokyo, Japan, 3Department of Pediatrics, Osaka University, Suita, Japan, 4Department of Cardiovascular Surgery, Osaka University, Suita, Japan


7:00 PM (260) Psychosocial Determinants of Health in Young Heart Transplant Recipients: Thinking Outside the Box: N. R. Dempster1, R. Gajarski2, L. Fisher2, H. Missler2, T. Cole3, D. Nandi2. 1Department of Psychology and...
Neuropsychology, Nationwide Children’s Hospital, Columbus, OH, \(^2\)Department of Cardiology, Nationwide Children’s Hospital, Columbus, OH, \(^3\)Department of Social Work, Nationwide Children’s Hospital, Columbus, OH

7:05 PM (261) Recovery of Microcirculation and Tissue Oxygenation After Pediatric Heart Transplantation: New Insight into an Old Problem; D. Gupta\(^1\), D. Lopez-Colon\(^1\), B. A. Pietra\(^1\), M. S. Bleiweis\(^1\), F. J. Fricker\(^1\), R. S. Samraj\(^2\). \(^1\)Congenital Heart Center, Department of Pediatrics, University of Florida, Gainesville, FL, \(^2\)Pediatric Critical Care Medicine, Department of Pediatrics, University of Florida, Gainesville, FL

7:10 PM (262) Safety Problems Associated with Extemporaneously-Prepared Liquid Tacrolimus in US Children After Heart Transplantation; N. McDonald\(^1\), J. Lee\(^1\), E. Pahl\(^2\), J. Rosanno\(^3\), K. Daly\(^4\), A. J. Burnette\(^5\), C. Hartman\(^6\), H. Bastardi\(^7\), V. Peiris\(^8\), C. Almond\(^9\). \(^1\)Heart Transplant, Lucile Packard Childrens Hospital, Palo Alto, CA, \(^2\)Heart Transplant, Lurie Children’s Hospital, Chicago, IL, \(^3\)Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, \(^4\)Cardiology, Boston Children's Hospital, Boston, MA, \(^5\)Heart Transplant, Medical University of South Carolina, Columbia, SC, \(^6\)Heart Transplant, Children National Health System, Washington, DC, \(^7\)Heart Transplant, Boston Children's Hospital, Boston, MA, \(^8\)US Food and Drug Administration, Silver Spring, MD, \(^9\)Heart Transplant, Stanford Hospital, Palo Alto, CA
Friday, April 07, 2017

7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 07: Getting to the Heart of Muscular Dystrophies

Location:
Grand Hall A

Target Audience:
ALL

Chairs:
Forum Kamdar, MD, PhD, and Takeshi Nakatani, MD, PhD

Session Summary: Neuromuscular disorders result in significant skeletal muscle weakness and increasingly severe cardiomyopathy. The objectives of this session are to identify cardiomyopathy as a common sequela of neuromuscular disorders, review current medical therapies for treating heart failure in this unique population, and discuss the use of advanced heart failure therapies such as cardiac transplantation and LVADs for pediatric and adult patients with end-staged neuromuscular cardiomyopathy.

7:00 AM
Heart Failure in Muscular Dystrophies: No Longer Just a Skeletal Muscle Disorder
Forum Kamdar, MD, PhD, University of Minnesota Medical Center, Minneapolis, MN, USA

7:10 AM Q&A

7:15 AM
Heart Failure Medical Treatment for Muscular Dystrophy: When and How to Treat
Denis Duboc, MD, CHU Paris Centre, Hospital Cochin, Paris, France

7:25 AM Q&A

7:30 AM
Mechanical Circulatory Support in Muscular Dystrophy Cardiomyopathy
Antonio Amodeo, MD, Bambino Gesu Pediatric Hospital, Rome, Italy

7:40 AM Q&A

7:45 AM
Cardiac Transplantation in Muscular Dystrophies
Jeffrey Towbin, MD, Le Bonheur Children's Hospital, Memphis, TN, USA

7:55 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 08: Live Long and Prosper: Thriving After Pediatric Transplantation

Location:
Grand Hall B

Target Audience:
PEDS, EEP, HF, HTX, LTX, MCS, NHSAH, PHARM

Chairs:
Caron L Burch, MSN, and Estela Azeka, MD

Session Summary: The session will focus on the psychosocial, behavioral challenges as well as communication and developmental issues in pediatric transplant patients. Specific attention will be given to adolescence and models for transition.

7:00 AM
Neurodevelopmental Outcomes after Pediatric Cardiothoracic Transplant
Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada

7:10 AM Q&A

7:15 AM
Keep Moving! Physical Exercise and Competitive Sports After Pediatric Transplantation
Kari Nytroen, PhD, Oslo University Hospital Rikshospitalet, Oslo, Norway

7:25 AM Q&A

7:30 AM
Nobody Understands Me! Communication Strategies to Reach Teenagers and Young Adults
Melissa Cousino, PhD, University of Michigan Transplant Center, Ann Arbor, MI, USA

7:40 AM Q&A

7:45 AM
Transitioning to Adult Care: Does Anything Work?
Jonathan N Johnson, MD, Mayo Clinic, Rochester, MN, USA

7:55 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 09: Mixed Rejection (MR) of the Cardiac Allograft: The Next Frontier

Location:
Grand Hall C

Target Audience:
PATH, BSTR, HF, HTX

Chairs:
Gerald J. Berry, MD, and Marny Fedrigo, MD, PhD

Session Summary: Cellular rejection and antibody mediated rejection are well-characterized. These two forms of rejection are most often considered separately, if not mutually exclusive. Increasingly, an overlap in features of these two rejection patterns is being noted (coined "mixed rejection"). Insights into the immune mechanisms of rejection may be gleaned from a better understanding of mixed rejection. A panel discussion with all speakers will conclude this session.

7:00 AM
T- and B-cell Immunity in Mixed Rejection: Time to Tango
Anne Halpin, MSc, University of Alberta, Edmonton, AB, Canada

7:15 AM
Is the Pathology of Mixed Rejection More Than Just ACR + AMR? See for Yourself
Dylan Miller, MD, Intermountain Central Laboratory, Salt Lake City, UT, USA

7:30 AM
Clinical Insights into the Behavior of Mixed Rejection in Heart Transplantation
A. G Kfoury, MD, FACC, Intermountain Medical Center, Murray, UT, USA

7:45 AM Panel Discussion
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 10: Contrasts and Similarities in Children and Adults: IPAH, Portopulmonary Hypertension, and Perioperative Management

Location:
Grand Hall D

Target Audience:
PH, BSTR, HF, LTX, NHSAH, PEDS, PHARM

Chairs:
Jean-Luc Vachiery, MD, and Brian Feingold, MD

Session Summary: This symposium will provide attendees with details on current management of pulmonary arterial hypertension (PAH) in adults and children. Three different clinical scenarios are discussed: idiopathic PAH, portopulmonary PAH, and perioperative PAH care. A panel discussion with all speakers will conclude this session.

7:00 AM
New Treatment Paradigms in IPAH Management in Children: How do we extrapolate data from Adults?
Erika Berman Rosenzweig, MD, Columbia University, New York, NY, USA

7:15 AM
Challenges in Portopulmonary hypertension: Different in Children?
Michel De Pauw, MD, Ghent University Hospital, Ghent, Belgium

7:30 AM
Peri-operative Management of Infants, Children, and Adolescents with Pulmonary Vascular Disease: “Tried as an Adult”?
Ernestina Melicoff-Portillo, MD, Baylor College of Medicine, Houston, TX, USA

7:45 AM Panel Discussion
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 11: There is No Such Thing as Perfect: Selecting Recipients for Lung Transplantation

Location:
Seaport F-H

Target Audience:
LTX, ID, NHSAH, PEDS

Chairs:
Rupal Shah, MD, and Daniel C. Chambers, MBBS, MRCP, FRACP, MD

Session Summary: Selection of lung transplant recipients is challenging, often due to limitations of current selection criteria. This sunrise symposium highlights cutting edge research and practical knowledge on physiologic factors, psychological features and non-standard, controversial or rare transplant indications to assist in selecting lung transplant recipients.

7:00 AM
Identifying the Right Candidate: Body Composition, Physiologic Frailty and Age
Jonathan P Singer, MD, MS, UCSF Medical Center, San Francisco, CA, USA

7:17 AM Q&A

7:20 AM
Psychological and Neurocognitive Frailty: Effect on Transplant Outcomes
James A Blumenthal, PhD, Duke University Medical Center, Durham, NC, USA

7:37 AM Q&A

7:40 AM
“Extended Criteria” Recipients: How Far Should We Go?
Jens Gottlieb, PhD, Hannover Medical School, Hannover, Germany

7:57 AM Q&A
**7:00 AM - 8:00 AM**
**SUNRISE SYMPOSIUM 12: HIV and Transplantation: It Isn't Going Away...**

**Location:**
Coronado A-C

**Target Audience:**
PHARM, HTX, ID, LTX, NHSAH, PEDS, PH

**Chairs:**
Patricia Uber, PharmD, and Joanna M. Schaenman, MD, PhD

**Session Summary:** This session will review end-stage heart and lung diseases associated with HIV and discuss key infectious diseases and pharmacotherapy management considerations in both the transplant and post-transplant phases of care. Lastly, HIV to HIV transplantation in the cardio-thoracic population will be discusses.

**7:00 AM**
**The ART and Science of HIV Associated Cardiomyopathy**
Marco Masetti, MD, Malpighi University Hospital, Bologna, Italy

**7:10 AM**  **Q&A**

**7:15 AM**
**HIV Associated Pulmonary Arterial Hypertension: True, True and Related**
Robert Frantz, MD, Mayo Clinic, Minneapolis, MN, USA

**7:25 AM**  **Q&A**

**7:30 AM**
**HIV: the ID Perspective on the Donor and Recipient**
Valentina Stosor, MD, Northwestern University, Chicago, IL, USA

**7:40 AM**  **Q&A**

**7:45 AM**
**A Delicate Balance: Management of Transplant Meds, HIV Meds, and ID Prophylaxis Meds**
Christine Hui, PharmD, UCSF Medical Center, San Francisco, CA, USA

**7:55 AM**  **Q&A**
8:00 AM - 9:30 AM
ORAL SESSION 20: New and Improving? Evolving Outcomes with MCS

Location:
Seaport A-E

Target Audience:
MCS, EEP, HF, HTX, NHSAH

Chairs:
Claudius Mahr, DO, and Patricia P Chang, MD

8:00 AM (263) Clinical Outcomes with Heartmate 3 as Treatment for Advanced HF: First Data from the European ELEVATE Registry; F. Gustafsson1, M. Morshuis2, D. Zimpfer3, J. Lavee4, T. Krabatsch5, S. Shaw6, D. Saeed7, L. Damme8, J. Garbade9, J. Rigshospitalet, Copenhagen, Denmark, 2HDZ NRW, Bad Oeynhausen, Germany, 3Medical University Vienna, Vienna, Austria, 4Sheba Medical Center, Ramat Aviv, Israel, 5Deutsches Herz Zentrum, Berlin, Germany, 6Wythenshawe Hospital, Manchester, United Kingdom, 7Heinrich-Heine Universität Düsseldorf, Dusseldorf, Germany, 8St Jude Medical, Zaventem, Belgium, 9Herzzentrum Leipzig GmbH, Leipzig, Germany


8:30 AM (265) Five-Year Outcome in Patients Treated with Heart Transplantation with Advanced Age Donors versus Patients on Waiting List for Heart Transplantation Implanted with Left Ventricular Assist Device; E. Ammirati, M. Cipriani, E. Perna, M. Varrenti, T. Colombo, A. Garascia, A. Cannata, G. Pedrazzini, F. Milazzo, F. Oliva, M. P. Gagliardone, C. F. Russo, M. Frigerio. De Gasperis CardioCenter, Niguarda Hospital, Milan, Italy

8:45 AM (266) Which INTERMACS 4-7 Patients Are at Low Risk for Mortality at One Year? Insights from the INTERMACS Database; J. J. Teuteberg1, A. D. Althouse1, M. Shullo1, N. Kunz1, K. Lockard1, E. Dunn1, L. Lagazzi1, C. Sciortino1, J. Cowger2, S. Joseph3, R. L. Kormos1. 1University of Pittsburgh, Pittsburgh, PA, 2St. Vincent, Indianapolis, IN, 3Baylor Medical Center, Houston, TX

9:00 AM (267) Outcomes of Jarvik 2000 LVAD as a Bridge to Heart Transplantation: Data from the Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS); H. Kohno1, G. Matsumiya1, Y. Sawa2, M. Ono3, Y. Saiki4, A. Shiose5, K. Yamazaki6, Y. Matsui7, H. Niinami8, H. Matsuda9, S. Kitamura10, T. Nakatani11, S. Kyo12. 1Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba, Japan, 2Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 3Cardiac Surgery, The University of Tokyo, Tokyo, Japan, 4Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, 5Cardiovascular Surgery, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan, 6Cardiovascular Surgery, Tokyo Women's Medical University Hospital, Tokyo, Japan, 7Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 8Cardiovascular Surgery, Saitama Medical University International Medical Center, Hidaka, Japan, 9Higashi-Takarazuka Satoh Hospital, Takarazuka, Japan, 10National Cerebral and Cardiovascular Center, Osaka, Japan, 11Maki Health Care Group, Maki Hospital, Osaka, Japan, 12Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan

9:15 AM (268) Effects of Hospital Characteristics on In-Hospital Mortality and Hospitalization Costs for Mechanical Circulatory Support Device (MCSD) Therapy: Results from the National (Nationwide) Inpatient Sample (NIS); L. Sridharan1, R. Givens1, A. R. Garan1, M. Yuze81polskaya1, K. Takeda2, F. Latif3, S. Restaino3, J. Haythe4, M. Maurer5, D. M. Mancini5, M. Farr1, Y. Naka2, P. C. Colombo1, V. Topkara1. 1Cardiology, Columbia University, New York, NY, 2Cardiothoracic Surgery, Columbia University, New York, NY, 3Cardiology, Mount Sinai, New York, NY

Friday, April 7
ORAL SESSION 21: New Fixes for an Old Problem: Preventing, Diagnosing, and Treating Pump Thrombosis

Location:
Grand Hall A

Target Audience:
MCS, HF, NHSAH, PHARM

Chairs:
Evgenij V Potapov, MD, PhD, and Allen Cheng, MD

8:00 AM (269) Management and Outcomes of LVAD Thrombosis: A Systematic Review and Meta-Analysis; V. Tchantchaleishvili1, J. G. Luc2, K. Phan3, S. M. Dunlay4, S. Maltais1, J. M. Stulak1. 1Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 3Faculty of Medicine, University of Sydney, Sydney, Australia, 4Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

8:15 AM (270) Novel Techniques of Sound Wave Analysis Can Detect Ventricular Assist Device Thrombosis; M. Bran Pouyan1, L. Blazquez Arroyo2, S. Hersek1, M. Jannmohamed2, T. De Marco2, G. M. Wieselthaler3, V. N. Selby2, O. T. Inan1, L. Klein2. 1School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, 2Cardiology, University of California, San Francisco, CA, 3Cardiac Surgery, University of California, San Francisco, CA

8:30 AM (271) Apixaban in Mechanical Circulatory Support - Evaluation in a Mock Circulatory Loop with Human Blood; S. Rao1, D. Connor2, N. Kerr3, J. Joseph4, P. Jansz1, C. Hayward1. 1Heart Transplant, St Vincent's Hospital, Darlinghurst, Australia, 2St Vincent's Centre for Applied Medical Research, Darlinghurst, Australia, 3St Vincent's Hospital, Darlinghurst, Australia, 4Heamatology, St Vincent's Hospital, Darlinghurst, Australia

8:45 AM (272) Left Atrial Appendage Occlusion Is Associated with Decreased Thromboembolic Events in LVAD Patients; A. Deshmukh, A. Bhatia, N. Sarswat, S. Adatya, G. Kim, G. Sayer, C. Ozcan, T. Ota, V. Jeevanandam, N. Uriel. University of Chicago, Chicago, IL

9:00 AM (273) Trends in Serum Lactate Dehydrogenase During HeartMate II Left Ventricular Assist Device Support and Its Relation to Clinical Outcomes: Insights from the PREVENT Study; T. Thenappan1, J. Stulak2, R. Agarwal3, S. Maltais2, P. Shah4, P. Eckman5, S. Emani6, J. Katz7, I. Gregoric8, M. Keebler9, N. Uriel10, E. Adler11, J. Chuang12, D. Farrar12, K. Sundareswaran12, R. John1. 1University of Minnesota, Minneapolis, MN, 2Mayo Clinic, Rochester, MN, 3Allegheny General Hospital, Pittsburgh, PA, 4Inova Heart and Vascular Institute, Falls Church, VA, 5Minneapolis Heart Institute, Minneapolis, MN, 6Ohio State University Medical Center, Columbus, OH, 7University of North Carolina, Chapel Hill, NC, 8Memorial Hermann - Texas Medical Center, Houston, TX, 9Vanderbilt University, Nashville, TN, 10University of Chicago Medical Center, Chicago, IL, 11University of California San Diego Medical Center, La Jolla, CA, 12St. Jude Medical, Pleasanton, CA

9:15 AM (274) Sildenafil Reduces Risk of Ischemic Stroke and Pump Thrombosis with Ongoing Low Level Hemolysis During Heart Mate II Support; O. Saeed1, S. Rangasamy1, A. Luke1, S. P. Patel1, D. B. Sims1, J. Shin1, M. Reyes Gil2, M. J. Sleipn3, H. H. Billett3, D. J. Goldstein4, U. P. Jorde1. 1Medicine (Cardiology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 2Medicine (Hematology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 3Medicine (Cardiology), University of Arizona, Tucson, AZ, 4Surgery (Cardiothoracic), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
8:00 AM - 9:30 AM
ORAL SESSION 22: Does Risk Reap Reward? Expanding the Heart Donor Pool

Location:
Grand Hall B

Target Audience:
HTX, BSTR

Chairs:
Mahazarin B Ginwalla, MD, and Paul Christian Schulze, MD, PhD

8:00 AM (275) Outcomes for Donor Hearts with Low Ejection Fraction That Improve During Donor Management: S. Madan1, O. Saeed1, P. Vlismas1, I. Katsa2, S. R. Patel1, J. Shin1, D. Sims1, D. Goldstein3, U. P. Jorde1. 1Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, 2Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, New York, NY, 3Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY

8:15 AM (276) Center for Disease Control High Risk Donor Use in Heart Transplantation: Current Trends: A. Iyengar1, D. Vucicevic2, E. Adams1, C. Eisenring3, L. Reardon2, M. Deng3, A. Ardehali3, E. DePasquale3. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2Department of Cardiology, University of California - Los Angeles, Los Angeles, CA, 3Department of Cardiac Surgery, University of California - Los Angeles, Los Angeles, CA


9:00 AM (279) Close to the Heart: Increasing Geographic Distance from Transplanting Center Associated with Increased Incidence of Graft Failure and Mortality Following Heart Transplant: T. Khuu1, B. Chen1, M. Cadeiras2. 1UCLA, Los Angeles, CA, 2Medicine, UCLA, Los Angeles, CA

9:15 AM (280) Prediction of Waitlist Mortality in Adult Heart Transplant Candidates: The Candidate Risk Score: C. Jasseron1, C. Legeai1, C. Jacquelinet1, P. Leprince2, C. Cantrelle1, B. Audry1, R. Porcher3, O. Bastien1, R. Dorent1. 1Direction Prélèvement Greffe Organes-Tissus, Agence de la Biomédecine, Saint-Denis La Plaine, France, 2Service de Chirurgie Cardio-Vasculaire, Hôpital de la Pitié Salpêtrière, Paris, France, 3Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Paris, France
8:00 AM - 9:30 AM
ORAL SESSION 23: Choosing Right: Lung Recipient Selection and Management

Location: Grand Hall C

Target Audience: LTX, BSTR, EEP, NHSAH, PHARM

Chairs: Roger D. Yusen, MD, MPH, and Marie M Budev, DO, MPH

8:00 AM (281) The Lung Transplant Risk Model - A Nationally Validated Tool for Pre-Transplant Risk Assessment
E. Y. Chan1, D. T. Nguyen2, N. Sinha3, T. S. Kaleekal4, A. Goodarzi5, J. G. Youssef6, B. A. Bruckner7, E. E. Suarez8, S. A. Scheinin9, E. A. Graviss10, A. O. Gaber11. 1Division of Thoracic Surgery, Department of Surgery, Houston Methodist Hospital, Houston, TX, 2Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, 3Division of Transplant Pulmonology, Department of Medicine, Houston Methodist Hospital, Houston, TX, 4Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, 5Department of Surgery, Houston Methodist Hospital, Houston, TX

8:15 AM (282) Underutilization of Lung Transplant Referral Among Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF)
L. Paoletti1, S. Palmer2, E. Yow3, M. L. Neely3, V. Gameran4, T. Whelan1. 1Medical University of South Carolina, Charleston, SC, 2Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, 3Duke Clinical Research Institute, Durham, NC, 4Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

8:30 AM (283) Cost and Readmission of Single and Double Lung Transplantation in the U.S. Medicare Population

8:45 AM (284) Technique and Outcomes of Less Invasive Lung Retransplantation
W. Sommer1, F. Ius1, C. Kuehn1, M. Avsar1, J. Salman1, T. Siemen1, J. Gottlieb2, N. Schwerk2, A. Haverich2, I. Tudorache1, G. Warnecke1. 1Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, 2Respiratory Medicine, Hannover Medical School, Hannover, Germany, 3Pediatric Respiratory Medicine, Hannover Medical School, Hannover, Germany

9:00 AM (285) Functions of Inverted Grafts Are Satisfactory Compared with Non-Inverted Grafts in Living-Donor Lobar Lung Transplantation
H. Kayawake, T. F. Chen-Yoshikawa, Y. Goda, H. Oda, S. Ueda, H. Motoyama, M. Hamaji, K. Hijiya, A. Aoyama, H. Date. Department of Thoracic Surgery, Kyoto University, Kyoto, Japan

9:15 AM (286) A Comparison of Propofol Based Total Intravenous Anesthesia and Sevoflurane Based Balanced Anesthesia on Renal Protection During Lung Transplantation Under Extracorporeal Membrane Oxygenation - A Prospective, Randomized Trial
N. Kim1, J. G. Lee2, S. Lee2, K. S. Nam2, J. W. Shu2, H. C. Paik2, Y. C. Yoo1. 1Anesthesiology, Yonsei University, Seoul, Korea, Republic of, 2Thoracic and Cardiovascular Surgery, Yonsei University, Seoul, Korea, Republic of
8:00 AM - 9:30 AM
ORAL SESSION 24: An Amalgamation of Support in Heart Failure

Location:
Grand Hall D

Target Audience:
HF, MCS, NHSAH, PHARM

Chairs:
Savitri Fedson, MD, and Navin K Kapur, MD

8:00 AM (287) MitraClip Therapy for Patients with End-Stage Heart Failure: A Durable Option?

8:15 AM (288) Percutaneous Axillary Balloon Pumps: Outcomes of Extended Support

8:30 AM (289) Predictors of Hemodynamic Stabilization Following Intra-Aortic Balloon Pump Implantation for Cardiogenic Shock
C. Juricek1, T. Imamura2, H. Costantini1, V. Kagan1, T. Song1, D. Onsager1, T. Ota1, S. Adatya2, G. Kim2, N. Sarswat2, G. Sayer2, V. Jeevanandam1, N. Uriel2. 1CT Surgery, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL

8:45 AM (290) The ASA Score - A Simple Way to Predict Outcome of Non-Transplant Eligible Patients Receiving Palliative Inotropic Therapy
E. Achu1, D. A. Baran1, A. Harhash2, M. J. Zucker1, J. Crincoli1, M. Rovner2, M. Mody1, Z. Port1, A. Hussein2, S. Kapoor1, J. Pieretti1, C. Gidea1, M. Goldschmidt2. 1Newark Beth Israel Medical Ctr, Newark, NJ, 2Morristown Medical Center, Morristown, NJ

9:00 AM (291) Tolerability of High Dose Continuous Outpatient Milrinone: Time to Re-Evaluate?
A. Harhash1, E. Achu2, M. J. Zucker2, M. Goldschmidt1, M. Rovner1, J. Crincoli2, A. Hussein1, J. Pieretti2, C. Gidea2, M. Mody2, Z. Port2, S. Kapoor2, D. A. Baran2. 1Morristown Medical Center, Morristown, NJ, 2Newark Beth Israel Medical Ctr, Newark, NJ

9:15 AM (292) Seattle Heart Failure Model Predicted One-Year Mortality of 20% or More Is Associated with a Poor Prognosis in Patients Referred for Heart Transplant Assessment
P. Narayan, S. Drew, A. Bin Mohd Ghazi, C. Lewis, J. Parameshwar, J. Pettit. Transplant Unit, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
8:00 AM - 9:30 AM
ORAL SESSION 25: Improving Outcomes in Pediatric Lung Transplantation

Location: Seaport F-H

Target Audience: PEDS, ID, LTX

Chairs: Carol K Conrad, MD, and Malcolm Brodlie, BSc (Hons), MB ChB, PhD, MRCPCH

8:00 AM (293) Long-Term Outcomes After Living-Donor Lobar Lung Transplantation Using a Single Donor; S. Ueda, T. F. Chen-Yoshikawa, H. Motoyama, M. Hamaji, K. Hijiya, A. Aoyama, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

8:15 AM (294) Respiratory Viral Infections in Pediatric Lung Transplant Recipients Are Not Associated with BOS, Retransplant or Death; S. C. Sweet¹, R. Buller¹, H. Chin², C. Conrad³, A. Faro⁴, S. Goldfarb⁵, D. Hayes⁶, P. Heeger⁷, D. Ikle⁸, K. Kesler⁹, E. Melicoff-Portillo⁸, T. Mohanakumar⁹, M. Schecter¹⁰, G. Storch¹¹, G. Visner¹¹, N. Williams¹², L. Danziger-Isakov¹⁰. ¹Washington University, St. Louis, MO, ²Rho, Inc., Chapel Hill, NC, ³Lucille Packard Children’s Hospital, Palo Alto, CA, ⁴Cystic Fibrosis Foundation, Bethesda, MD, ⁵Children’s Hospital of Philadelphia, Philadelphia, PA, ⁶Nationwide Children’s Hospital, Columbus, OH, ⁷Mount Sinai School of Medicine, New York, NY, ⁸Texas Children’s Hospital, Houston, TX, ⁹St. Joseph’s Hospital & Medical Center, Phoenix, AZ, ¹⁰Cincinnati Children’s Hosp Med Ctr, Cincinnati, OH, ¹¹Boston Children’s Hospital, Boston, MA, ¹²National Institutes of Health, Bethesda, MD

8:30 AM (295) Autotransplantation of the Left Lung for the Treatment of Recurrent Life Threatening Pulmonary Hemorrhage Related to Pulmonary Vascular Malformation: A Novel Treatment Approach & a Unique Chance to Study Ischemia/Reperfusion Injury; C. Falk¹, I. Tudorache², C. Mueller³, W. Sommer⁴, K. Daemen⁴, J. Keil⁴, C. Neudörfl⁴, G. Hansen³, A. Haverich⁴, G. Warnecke³, I. Tudorache⁴. ¹Institute of Transplant Immunology, IFB-Tx, Hannover Medical School, Hannover, Germany, ²Cardiac-, Thoracic-, Trasplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ³Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁴Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

8:45 AM (296) Risk and Outcomes of Pulmonary Fungal Infection in Pediatric Lung Transplant; E. Ammerman¹, L. Danziger-Isakov², G. A. Storch², M. Fenchel¹, C. Conrad³, D. Hayes⁴, A. Faro⁵, S. Goldfarb⁶, K. Kesler⁶, E. Melicoff-Portillo⁷, M. Schecter⁸, G. Visner⁸, N. Williams⁸, S. C. Sweet⁹. ¹Children’s Hosp Med Ctr, Cincinnati, OH, ²Washington University/St. Louis Children’s Hospital, St. Louis, MO, ³Lucille Packard Children’s Hospital at Stanford University, Palo Alto, CA, ⁴Nationwide Children’s Hospital, Columbus, OH, ⁵Children’s Hospital of Philadelphia, Philadelphia, PA, ⁶Rho, Inc, Chapel Hill, NC, ⁷Texas Children’s Hospital, Houston, TX, ⁸Harvard Medical School/Boston Children’s Hospital, Boston, MA, ⁹National Institute of Allergy and Infectious Diseases, Bethesda, MD

9:00 AM (297) Anellovirus Can Be Used to Predict Short- and Long-Term Outcomes in Pediatric Lung Transplant Recipients; J. Blatter¹, S. Sweet¹, C. Conrad², L. A. Danziger-Isakov³, A. Faro⁴, S. B. Goldfarb⁵, D. Hayes, Jr.⁶, E. Melicoff⁷, M. Schecter⁸, G. Storch⁹, G. A. Visner⁹, N. M. Williams¹⁰. ¹Department of Pediatrics, Washington University School of Medicine in St. Louis, Saint Louis, MO, ²Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, ³Division of Infectious Diseases, Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ⁴Cystic Fibrosis Foundation, Bethesda, MD, ⁵Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, ⁶Department of Pediatrics, The Ohio State University, Columbus, OH, ⁷Department of Pediatrics, Baylor College of Medicine, Houston, TX, ⁸Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ⁹Department of Pathology and Immunology, Department of Molecular Biology, Washington University School of Medicine in St. Louis, Saint Louis, MO

9:15 AM (298) Extracorporeal Life Support in Pediatric Lung Transplant: A Single Center Experience; R. D. Vanderlaan¹, M. Cypel², H. Grassmann³, O. Honjo⁴, T. Humph⁵, C. A. Caldarone⁶, M. Solomon⁷, R. Casas⁷, S. Azad⁸, A. Gueguerian⁹, S. Keshavjee². ¹Cardiac Surgery, University of Toronto, Toronto, ON, Canada, ²Thoracic Surgery, Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Respiratory Medicine, Lung Transplant Program, Hospital for Sick Children, Toronto, ON, Canada, ⁴Cardiovascular Surgery, Hospital for Sick Children, Toronto, ON, Canada, ⁵Cardiology, Hospital for Sick Children, Toronto, ON, Canada, ⁶Critical Care Medicine, Hospital for Sick Children, Toronto, ON, Canada

Friday, April 7
8:00 AM - 9:30 AM
ORAL SESSION 26: Philip K. Caves Award Candidate Presentations

Location:
Coronado A-C

Target Audience:
ALL

Chairs:
Stephan M. Ensminger, MD, DPhil, and Daniel Kreisel, MD, PhD

8:00 AM (299) **Donor-Derived Non-Classical Monocytes Recruit Recipient Neutrophils and Mediate Primary Lung Allograft Dysfunction**; S. Chiu¹, Z. Zheng¹, M. Akbarpour¹, R. Fernandez¹, A. McQuattie-Pimentel¹, P. Reyfman¹, K. Anekalla¹, D. Kreisel², H. Perlman¹, G. S. Budinger¹, A. Misharin¹, A. Bharat¹. ¹Northwestern University, Chicago, IL, ²Washington University, St. Louis, MO

8:15 AM (300) **Extracorporeal Photopheresis Inhibits the Development of Obliterative Airway Disease and Promotes the Expansion of Intragraft Retinoic Acid-Producing CD103⁺ Dendritic Cells and Tregs**; Z. Liu¹, F. Liao¹, X. Lin¹, K. A. Toth¹, X. Wang², J. Zhu¹, D. Scozzi¹, A. S. Krupnick³, D. Kreisel¹, R. Hachem⁴, J. M. Green⁵, A. E. Gelman¹. ¹Department of Surgery, Washington University in St. Louis, St. Louis, MO, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Surgery, University of Virginia, Charlottesville, VA, ⁴Division of Pulmonary and Critical Care Medicine, Washington University in St. Louis, St. Louis, MO, ⁵Division of Biology and Biomedical Sciences, Washington University in St. Louis, St. Louis, MO

8:30 AM (301) **Increased Tumor Necrosis Factor-α Levels in Patients with Continuous-Flow Left Ventricular Assist Devices Mediate Vascular Instability and Are Associated with Higher Non-Surgical Bleeding**; C. E. Tabit¹, M. Coplan¹, P. Chen¹, V. Jeevanandam², N. Uriel¹, J. K. Liao¹. ¹Cardiology, The University of Chicago Medical Center, Chicago, IL, ²Surgery, The University of Chicago Medical Center, Chicago, IL

8:45 AM (302) **Induction of Persistent Lung Transplant Tolerance by IL-2 Complex-Stimulated Regulatory T Cells In Vivo**; Y. Yamada¹, D. Impellizzieri², T. Maeyashiki¹, K. Brüstle¹, L. Dubs¹, J. Jang¹, U. Karakus², J. Woyschak², I. Inci¹, W. Weder¹, O. Boyman², W. Jungraithmayr¹. ¹Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²Department of Immunology, University Hospital Zurich, Zurich, Switzerland

9:00 AM (303) **Ischaemic Reperfusion Injury and Allograft Rejection Following DCD Heart Transplantation: Early Results**; A. Page, M. Goddard, S. Messer, J. Dunning, J. Parameshwar, C. Lewis, A. Kydd, S. Pettit, Y. Abu-Omar, M. Berman, A. Ali, S. Tsui, S. Large. ¹Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

9:15 AM (304) **Utility of Droplet Digital PCR for the Detection of Aspergillus DNA in Bronchoalveolar Lavage and Exhaled Breath Condensate Samples from Lung Transplant Recipients**; A. Bhimji¹, L. G. Singer², D. Kumar¹, A. Humar¹, C. Rotstein¹, S. Keshavjee², T. Mazzulli³, S. Husain¹. ¹Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ³Mount Sinai Hospital, Toronto, ON, Canada
10:00 AM - 11:30 AM
ORAL SESSION 27: The Leaking Gut - New Strategies for GI Bleeding in MCS

Location:
Seaport A-E

Target Audience:
MCS, HF, NHSAH, PHARM

Chairs:
Jan F Gummert, MD, PhD, and Sarah Schettle, PA-C


10:15 AM (306) Incidence and Risk Factors of Late Bleeding in Patients Enrolled in the PREVENT Study; R. John1, M. Keebler2, J. Stulak3, S. Emani4, C. Klodell5, S. Nathan6, A. Briee7, N. Uriel8, J. Chin9, P. Eckman10, A. Nsair11, R. Agarwal12, T. Thenappan1, R. Adamson13, J. Chuang14, D. Farrar14, K. Sundareswaran14, J. Katz15. 1University of Minnesota, Minneapolis, MN, 2Vanderbilt University, Nashville, TN, 3Mayo Clinic, Rochester, MN, 4Ohio State University Medical Center, Columbus, OH, 5University of Florida, Gainesville, FL, 6Memorial Hermann - Texas Medical Center, Houston, TX, 7University of Colorado School of Medicine, Denver, CO, 8University of Chicago Medical Center, Chicago, IL, 9Sutter Medical Center, Sacramento, CA, 10Minneapolis Heart Institute, Minneapolis, MN, 11UCLA Medical Center, Santa Monica, CA, 12Allegheny General Hospital, Pittsburgh, PA, 13Sharp Memorial Hospital, San Diego, CA, 14St. Jude Medical, Pleasanton, CA, 15University of North Carolina, Chapel Hill, NC

10:30 AM (307) Predicting Recurrent GI Bleeding in Patients with CF-LVADs Using Pre-Implant Data; L. C. Lohmueller1, W. A. Alexander2, J. F. Antaki1. 1Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, 2HEMA Biologics, LLC, Louisville, KY

10:45 AM (308) Comparison of Gastrointestinal Bleeding Rates Between Axial Flow (HeartMate II) and Centrifugal (HeartWare) Flow Pumps at a Single Institution; M. Kawabori, C. Kurihara, T. Sugiura, L. Cunningham, A. B. Civitello, W. E. Cohn, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Baylor College of Medicine, Houston, TX

11:00 AM (309) Octreotide Reduces the Reoccurrence of Ventricular Assist Device Related Gastrointestinal Bleeding; K. B. Shah1, G. Sampath1, S. Emani2, M. K. Kanwar3, N. Uriel4, P. C. Colombo5, P. A. Uber1, M. L. Sears1, J. Chuang6, D. J. Farrar6, G. B. Smallfield1. 1Virginia Commonwealth Univ, Richmond, VA, 2Ohio State University, Columbus, OH, 3Allegheny General Hospital, Pittsburgh, PA, 4University of Chicago, Chicago, IL, 5Columbia University, New York, NY, 6St. Jude Medical, St. Paul, MN

10:00 AM - 11:30 AM
ORAL SESSION 28: The Heart of the Matter: Cardiac Substrate in MCS Therapy

Location:
Grand Hall A

Target Audience:
MCS, HF

Chairs:
Stuart D. Russell, MD, and Jennifer A Cowger, MD, MS

10:00 AM (311) Diurnal and Patient Activity Related Determinants of Aortic Valve Opening on Continuous Flow LVAD Support; R. Clifford¹, D. Robson¹, C. Gross², F. Moscato², H. Schima², P. S. Macdonald¹, P. Jansz¹, C. S. Hayward¹. ¹Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia, ²Medical University of Vienna, Vienna, Austria


10:30 AM (313) Echocardiography Accurately Tracks Left Ventricular Unloading in Patients Supported with a HeartMate II LVAD Undergoing Ramp Testing; L. Letarte¹, J. Amione-Guerra², A. Bhimaraj¹, B. Trachtenberg¹, A. Guha¹, G. Torre-Amione¹, M. H. Park¹, J. D. Estep¹. ¹Advanced Heart Failure and Transplant Cardiology, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Hospital, Houston, TX

10:45 AM (314) 3D Echocardiography and Shape Analysis Changes Following Left Ventricular Assist Device Implantation: The Effect of Unloading on Reverse Remodeling; G. Sayer¹, D. Medvedofsky¹, S. Adatya¹, N. Sarswat¹, G. H. Kim¹, E. Kruse¹, T. Ota², V. Jeevanandam², D. Burkhoff³, R. Lang¹, N. Uriel¹. ¹Medicine, University of Chicago, Chicago, IL, ²Cardiothoracic Surgery, University of Chicago, Chicago, IL, ³Medicine, Columbia University, New York, NY

11:00 AM (315) Prevalence of Myocardial Fibrosis by LVAD Apical Core Biopsy and Correlation with Other Markers of Myocardial Recovery; J. N. Schultz¹, R. John², C. M. Martin³, M. Pritzker³, E. Missov³, T. Thenappan³, R. Cogswell³. ¹Department of Medicine, University of Minnesota, Minneapolis, MN, ²Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN, ³Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN

10:00 AM - 11:30 AM
ORAL SESSION 29: Donor Utilization and Allocation in Heart Transplantation: Lessons to Learn

Location:
Grand Hall B

Target Audience:
HTX, HF

Chairs:
Joseph G Rogers, MD, and Marta Farrero Torres, MD, PhD

10:00 AM (317) Great Variability in Donor Heart Acceptance Practices Across the USA; K. Khush, R. Ball. Stanford University, Stanford, CA

10:15 AM (318) Supply and Demand: Disparities Across UNOS Regions; D. A. Baran¹, H. Copeland², G. Katlaps³, B. Dharmaraj¹, S. Kapoor¹, J. Piretti¹, C. Gidea¹, M. J. Zucker¹, T. Martin¹, M. Camacho¹, J. Copeland³. ¹Transplant Center, Newark Beth Israel Medical Ctr, Livingston, NJ, ²Dept of Cardiac Surgery, Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, VA, ³McGuire VA Medical Center, Richmond, VA

10:30 AM (319) Is There an Optimal Acceptance Rate for Adult Transplant Centers?; Y. Radzi¹, F. Zafar¹, R. Rizwan¹, C. Park¹, J. Tweddell¹, A. Simeone², L. Louis IV, D. Morales¹. ¹Division of Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, OH, ²Division of Cardiac Surgery, University of Cincinnati, Cincinnati, OH


11:00 AM (321) The New Heart Allocation System: Implications on Patients with Restrictive Cardiomyopathy in the UNOS Registry; L. Sridharan², R. Givens¹, K. Takeda², A. R. Garan¹, M. Yuzefpolskaya¹, F. Latif¹, S. Restaino¹, J. Haythe¹, J. Ginns¹, D. Mancini², Y. Naka², P. Colombo¹, M. Maurer², H. Takayama², V. K. Topkara¹. ¹Cardiology, Columbia University, New York, NY, ²Cardiothoracic Surgery, Columbia University, New York, NY, ³Cardiology, Mount Sinai, New York, NY

11:15 AM (322) Effect of Left Ventricular Dysfunction on Utilization of Donor Hearts; D. Tryon¹, N. W. Hasaniya¹, L. L. Bailey¹, D. S. Juma², B. Jabò², A. J. Razzouk¹, D. G. Rabkin¹. ¹Cardiovascular and Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA, ²School of Public Health, Research Consulting Group, Loma Linda University Medical Center, Loma Linda, CA

Friday, April 7
10:00 AM - 11:30 AM
ORAL SESSION 30: Novel Mechanisms in Chronic Lung Allograft Dysfunction

Location:
Grand Hall C

Target Audience:
LTX, BSTR, ID, PATH, PHARM

Chairs:
Mark Greer, MB Bch, and David Weill, MD

10:00 AM (323) Decreased Donor PBMC and Allograft Telomere Length Are Associated with Shorter CLAD-Free Survival; H. E. Faust¹, J. A. Golden², R. Rajalingam³, A. S. Wang³, G. Green², S. R. Hays², J. Kukreja³, J. P. Singer², P. J. Wolters², J. R. Greenland³. ¹Medicine, Perelman School of Medicine, Philadelphia, PA, ²Medicine, U. California SF, San Francisco, CA, ³Surgery, U. California SF, San Francisco, CA

10:15 AM (324) Novel Mechanism for the Increased Risk for Chronic Lung Allograft Dysfunction by Respiratory Viral Infections Following Human Lung Transplantation; M. Gunasekaran¹, A. Limaye², M. Sharma¹, S. Bansal¹, R. Walia¹, M. Smith¹, R. M. Bremner¹, T. Mohanakumar¹. ¹St. Joseph's Hospital & Medical Center, Phoenix, AZ, ²University of Washington, Seattle, WA


10:45 AM (326) Antibodies to Human Leukocyte Antigen Class I and Lung Associated Self-Antigens, K-alpha-1 Tubulin and Collagen V Induces Exosomes Containing Self-Antigens from Human Primary Airway Epithelial and Endothelial Cells; M. Gunasekaran², M. Sharma¹, S. Bansal¹, R. Walia¹, R. M. Bremner¹, M. Smith¹, T. Mohanakumar². ¹St. Joseph's Hospital & Medical Center, Phoenix, AZ, ²St. Joseph's, Phoenix, AZ

11:00 AM (327) Exosomes Isolated from Lung Transplant Recipients Diagnosed with Bronchiolitis Obliterans Syndrome, But Not Stable, Can Induce Immune Responses to Lung Associated Self-Antigens, K-alpha-1 Tubulin and Collagen V; M. Gunasekaran, M. Sharma, S. Bansal, R. Walia, M. Smith, R. M. Bremner, T. Mohanakumar. St. Joseph's Hospital & Medical Center, Phoenix, AZ

11:15 AM (328) Increasing Frequency of CD127low Regulatory T Cells Early After Lung Transplantation Is Associated with Freedom from Chronic Lung Allograft Rejection and Survival in 503 Patients; F. Ius¹, J. Salman¹, A. Knöfel¹, T. Nakagiri¹, W. Sommer¹, T. Siemeni¹, C. Kühn¹, M. Avsar¹, D. Böthig¹, T. Welte², A. Haverich¹, I. Tudorache¹, G. Warnecke¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
10:00 AM - 11:30 AM
ORAL SESSION 31: Saved by the Bell: Overcoming Adherence and Frailty

Location:
Grand Hall D

Target Audience:
NHSAH, ALL

Chairs:
Meloneya Hubbard, MSN, CRNP, CCTC, and Christiane Kugler, PhD

10:00 AM (329) The Use of Transplant Medicines IT Tool in Supporting Patients’ Knowledge of Immunosuppressant Medications; L. Alsarraf1, R. Betmouni1, N. Bidad2, A. Reed1, O. Dar1, A. Simon1, H. Lyster1, 1Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom, 2University College London, London, United Kingdom

10:15 AM (330) Practice Patterns to Improve Pre- and Post-Transplant Medication Adherence in Heart Transplant Centers: A Secondary Data Analysis of the International Bright Study; S. M. De Geest. Public Health, University of Basel, Basel, Switzerland

10:30 AM (331) A Trajectory Analysis of Adherence to Recommended Exercise Following Lung Transplantation; M. Alrawashdeh, J. Choi, A. DeVito Dabbs. School of Nursing, University of Pittsburgh, Pittsburgh, PA

(332) WITHDRAWN

10:45 AM (448) FOCUS for Pediatric Heart Transplant: A Trauma-Informed, Family-Centered, Resilience Enhancing Intervention; K. Wijesekera1, N. D. Emerson1, M. S. Cortez1, J. Alejos2, P. Lester1. 1Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA, 2Pediatric Cardiology, UCLA, Los Angeles, CA

11:00 AM (333) Quadriceps Strength Predicts Estimates of Physical Activity Post-Heart Transplantation; R. L. Kelly1, J. R. Walsh1, J. D. Paratz2, S. T. Yerkovich3, S. McKenzie3, N. R. Morris2. 1Physiotherapy Department, The Prince Charles Hospital, Chermside, Australia, 2School of Allied Health Sciences, Griffith University, Gold Coast, Australia, 3School of Medicine, The University of Queensland, Brisbane, Australia

11:15 AM (334) Increased Perceived Stress and Fatigue are Associated with Worse Quality of Life in Patients with a Left Ventricular Assist Device; M. A. Abshire1, P. M. Davidson1, S. Desai2, C. Budhathoki1, S. D. Russell1, C. Dennison Himmelfarb1. 1Johns Hopkins University, Baltimore, MD, 2Inova Fairfax Hospital, Falls Church, VA
10:00 AM - 11:30 AM
ORAL SESSION 32: The Tell Tale Heart: From Signals to Biomarkers

Location:
Seaport F-H

Target Audience:
BSTR, HF, HTX, MCS, NHSAH, PATH, PEDS, PH, PHARM

Chairs:
Kyung-Hee Kim, MD, and Tomoko S Kato, MD, PhD

10:00 AM (335) Complementary Intragraft and Peripheral Blood Mononuclear Cell Gene Co-Expression Network Analysis of ISHLT Driven versus Unsupervised Molecular Classification; E. Chang¹, G. Fishbein¹, M. Bakir¹, D. Liem¹, S. Litovsky², J. Tallaj¹, G. Bondar¹, E. Reed¹, M. Deng¹, E. Tabak³, M. Cadeiras¹. ¹Medicine, UCLA, Los Angeles, CA, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Courant Institute of Mathematical Sciences, New York University, New York, NY

10:15 AM (336) Pre-Transplant Serum Exosome and Functional Analysis in Primary Graft Dysfunction; B. Fine¹, E. Zorn¹, E. Chen², G. Vunjak-Novakovic³, P. Colombo¹. ¹Medicine, Columbia University, New York, NY, ²Pharmacology, Columbia University, New York, NY, ³Biomedical Engineering, Columbia University, New York, NY

10:30 AM (337) Antibody Response to Non-Self Blood Group A-Antigen Is Dependent on CD4 T Cells and Co-Engagement with Foreign Protein; I. Adam¹, B. Motyka¹, J. Pearcey¹, K. Tao¹, P. J. Cowan², L. J. West¹. ¹Dept. Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, ²Immunology Research Centre, St Vincent's Hospital, University of Melbourne, Melbourne, Australia

10:45 AM (338) Gene Expression in Pediatric Myocardium: Pulsatile- vs. Continuous-Flow VAD Support; I. Adachi¹, M. Zhang², S. Burki³, D. L. Morales³, A. Jeewa⁴, D. Kearney⁵, L. Wadhwa⁴, C. D. Fraser, Jr.¹, J. F. Martin⁶. ¹Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, ²Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, ³Congenital Heart Surgery, Cincinatti Children's Hospital, Cincinnati, OH, ⁴Pediatric Cardiology, Texas Children's Hospital, Houston, TX, ⁵Pathology, Texas Children's Hospital, Houston, TX, ⁶Molecular Physiology and Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX

11:00 AM (339) PPARgamma Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells; L. Calvier¹, P. Chouvarine¹, M. M. Mozes², G. Hansmann¹. ¹Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany, ²Pathophysiology, Semmelweis University, Budapest, Hungary

11:15 AM (340) Voltage-Gated Ca²⁺ Influx into Coronary Artery Smooth Muscle Is Decreased in Ischemic versus Non-Ischemic Cardiomyopathy - The First Evidence from Human Transplant Cardiectomy Samples; R. J. Chen¹, M. Alloosh², J. K. Badin², M. Sturek², I. Wang³, T. Wozniak³, Z. A. Hashmi¹. ¹Cariothoracic Transplantation Surgery, Indiana University - Methodist Hospital, Indianapolis, IN, ²Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN
ORAL SESSION 33: PATH to Better Outcomes: Diagnostics in Heart and Lung Transplantation

Location: Coronado A-C

Target Audience: PATH, BSTR, HTX, LTX, PEDS

Chairs: Martin J Goddard, FRCS MRCPa, and Robert F. Padera, MD, PhD

10:00 AM (341) Widening of Alveolar Septa in Transbronchial Biopsies with Antibody-Mediated Rejection (AMR): Preliminary Data from Multicenter Pilot Study; F. Calabrese¹, S. Hirschi², M. Chenard², M. Montero-Fernandez³, D. Neil⁴, W. Timens⁵, E. Verbeken⁶, E. Perissinotto⁷, F. Lunardi¹, E. Cozzi⁷, D. J. Levine⁶, M. Goddard³. ¹University of Padova, Padova, Italy, ²University of Strasbourg, Strasbourg, France, ³Royal Brompton & Harefield NHS, London, United Kingdom, ⁴Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁵University of Groningen, Groningen, Netherlands, ⁶University of Leuven, Leuven, Belgium, ⁷Padova University Hospital, Padova, Italy, ⁸University of Texas Health Science Center, San Antonio, TX, ⁹Papworth Hospital, Papworth, United Kingdom

10:15 AM (342) Prospective Study of Histopathologic Features of Cardiac Antibody-Mediated Rejection and Correlation with Donor Specific Antibodies and Graft Dysfunction; A. C. Roden¹, J. J. Maleszewski¹, P. Lin², S. M. Jenkins², M. Gandhi², N. Pereira², M. Aubry¹. ¹Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN

10:30 AM (343) Endothelial Cell Activation in a Mouse Model of Cardiac Antibody-Mediated Rejection; M. Racape¹, J. Duong Van Huyen¹, C. Chen², A. Loupy¹, O. Thaunat², P. Brunet¹. ¹U970, INSERM-University Paris Descartes, Paris, France, ²U1111, INSERM-University Lyon 1 Claude Bernard, Lyon, France

10:45 AM (344) Liquid Biopsies: Non-Invasive Rejection Detection After Heart Transplantation; L. Hofste¹, A. Vink¹, J. van Kuik¹, E. Siera-de Koning¹, F. Ahmadi¹, N. de Jonge², R. de Weger¹, M. Huibers¹. ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands

11:00 AM (345) Changes in Myocardial Microvascularisation After Heart Transplantation and During Cardiac Allograft Vasculopathy; M. Huibers¹, F. van Pijpen¹, H. Kirkels², N. de Jonge², A. Vink¹, R. de Weger¹. ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands

11:15 AM (346) Late Graft Dysfunction After Pediatric Heart Transplantation Is Associated with Fibrosis and Decreased Capillary Density by Automated, Whole-Slide Imaging; B. Feingold¹, J. Picarsic², A. Lesnink³, M. Wood-Trageser³, B. Popp³, A. J. Demetris³. ¹Pediatric Cardiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pathology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pathology, University of Pittsburgh, Pittsburgh, PA
1:30 PM - 3:30 PM
SYMPOSIUM 24: Aiming Off Target: Non-Cardiac Consequences of LVAD Support

Location:
Seaport A-E

Target Audience:
MCS, BSTR, HF

Chairs:
Mustafa Toma, MD, and Emma Birks, MD, PhD

Session Summary: The relevance of non-cardiac consequences of LVAD support is being increasingly recognized. Many of these "off-target-organ" effects have largely driven the morbidity and mortality of LVAD-supported patients, and these will become more relevant with the rise of the destination therapy population. In this symposium, each speaker will discuss alterations in a different organ system with LVAD support and future directions for research and technologic development to address these alterations.

1:30 PM
Continuous-Flow Effects on the Systemic Vasculature and Endothelium
Amrut V Ambardekar, MD, University of Colorado, Aurora, CO, USA

1:45 PM Q&A

1:50 PM
LVAD Effects on Skeletal Musculature and Exercise Capacity
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark

2:05 PM Q&A

2:10 PM
Renal Function with LVAD Support
Meredith A Brisco, MD MSCE, Temple University, Philadelphia, PA, USA

2:25 PM Q&A

2:30 PM
Hematologic Perturbations Caused by Mechanical Support
Anna L Meyer, MD, Leipzig Heart Center, Leipzig, Germany

2:45 PM Q&A

2:50 PM
Neuropsychological Function in Long-term LVAD Patients
Ralph Petrucci, MD, Drexel University College of Medicine, Philadelphia, PA, USA

3:05 PM Q&A

3:10 PM
Gastrointestinal Physiologic Changes Associated With Continuous-Flow Pumps
Brian Houston, MD, Medical University of South Carolina, Charleston, SC, USA

3:25 PM Q&A
1:30 PM - 3:30 PM
SYMPOSIUM 25: Dealing with Antibodies Before and After Heart Transplant: Do We Have New Arrows in our Quiver?

Location:
Grand Hall A

Target Audience:
ALL

Chairs:
Michael Shullo, PharmD, and Luciano Potena, MD, PhD

Session Summary: This session will provide an overview of the current management strategies for sensitized patients pre- and post-transplant by discussing desensitization pharmacotherapy, long-term management and monitoring, key challenges and strategies, immunogenetic and non-HLA considerations, and possible downstream implications on target cells, incorporating the newest research-based evidence supplemented with experience from seasoned multidisciplinary clinicians.

1:30 PM
Overview of the Management of the Sensitized Heart Transplant Candidate and Recipient
Monica Colvin, MD, University of Michigan, Ann Arbor, MI, USA

1:45 PM Q&A

1:50 PM
Strategies for Desensitization of the Heart Transplant Candidate
Laura M. Lourenco, PharmD, University of Chicago Medicine, Chicago, IL, USA

2:05 PM Q&A

2:10 PM
Downstream Implications of Desensitization
Rajalingam Raja, PhD, UCSF Medical Center, San Francisco, CA, USA

2:25 PM Q&A

2:30 PM
DEBATE (PRO): No Time to Wait: Proceed to Heart Transplant with Low Level Donor Specific Antibodies
Barbara Pisani, MD, Wake Forest Medical Center, Winston-Salem, NC, USA

2:45 PM
DEBATE (CON): No Time to Wait: Proceed to Heart Transplant with Low Level Donor Specific Antibodies
Lee R. Goldberg, MD, MPH, University of Pennsylvania, Philadelphia, PA, USA

3:00 PM
DEBATE (PRO): Asymptomatic Donor Specific Antibodies After Transplant: Everyone Should Be Treated
Sharon Chih, MD, University of Ottawa Heart Institute, Ottawa, ON, Canada

3:15 PM
DEBATE (CON): Asymptomatic Donor Specific Antibodies After Transplant: Everyone Should Be Treated
Palak Shah, MD, MS, Inova Fairfax Hospital, Falls Church, VA, USA
1:30 PM - 3:30 PM
SYMPOSIUM 26: Making Every Heart Count

Location:
Grand Hall B

Target Audience:
HTX, EEP, HF, HTX

Chairs:
Kiran K. Khush, MD, and Jason W Smith, MD

Session Summary: This symposium focuses on donor heart utilization, from use of expanded criteria donors to improved stewardship of donor hearts, reducing waste of potentially usable hearts and breaking open the doors of DCD heart procurement.

1:30 PM
Is The Expanded Criteria Donor the New Standard Criteria Donor?
Andre R Simon, MD, PhD, Harefield Hospital, London, United Kingdom

1:45 PM Q&A

1:50 PM
Can We Revive the DCD Heart?
Stephen Large, FRCS, Papworth Hospital, Cambridge, United Kingdom

2:05 PM Q&A

2:10 PM
Resource Stewardship in Donor Selection
Michael Pham, MD, California Pacific Medical Center, San Francisco, CA, USA

2:25 PM Q&A

2:30 PM
The Public Health Service (PHS) Increased Risk Donor: What Is the Real Risk of Infection?
Michael Ison, MD, Northwestern University, Chicago, IL, USA

2:45 PM Q&A

2:50 PM
Evaluation of the Heart at Time of Donor Procurement
William E Stansfield, MD, Toronto General Hospital, Toronto, ON, Canada

3:05 PM Q&A

3:10 PM
Getting The Heart Home - How to Procure the Donor Heart
Hannah Copeland, MD, VA McGuire Medical Center/Virginia Commonwealth University, Richmond, VA, USA

3:25 PM Q&A
1:30 PM - 3:30 PM
SYMPOSIUM 27: Bench to Bedside: How Advances in Immunology Shape the Care of Today’s Lung Transplant Recipients

Location:
Grand Hall C

Target Audience:
LTX, BSTR, HTX, ID, NHSAH, PATH, PEDS, PHARM

Chairs:
Ciara M Shaver, MD, and Andrew J Fisher, PhD FRCP

Session Summary: Recent advances in immunology have important implications for modern day clinical care. This session will highlight some important scientific advances in genomics and immunology with direct applicability to clinical issues including immunosuppression, graft surveillance, drug dosing, and antibody mediated rejection. This session will help to bridge the gap between translational immunology research and current clinical practice.

1:30 PM
The Immunobiology of Lung Transplantation: From Bench to Bedside
Rebecca A Shilling, MD, University of Chicago, Chicago, IL, USA

1:50 PM Q&A

1:54 PM
The Quest for Biomarkers for Acute and Chronic Lung Rejection: Where Are We Now?
John R Greenland, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

2:14 PM Q&A

2:18 PM
Tackling the Immune System: Novel Biologicals and Immunomodulators in Lung Transplant Recipients
Stephen Juvet, MD, PhD, Toronto General Research Institute, Toronto, ON, Canada

2:38 PM Q&A

2:42 PM
Antibody-Targeted Therapies in Lung Transplantation: When and How to Use?
Ramsey R Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA

3:02 PM Q&A

3:06 PM
Targeting Non-Immune Cells: Novel Treatment Options in Lung Transplantation
Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

3:26 PM Q&A
1:30 PM - 3:30 PM
SYMPOSIUM 28: Great Debates in Pulmonary Hypertension

Location:
Grand Hall D

Target Audience:
PH, ALL

Chairs:
Teresa De Marco, MD, FACC, and Paul A Corris, MB FRCP

Session Summary: The diagnosis and management of pulmonary hypertension is steadily being refined by ongoing investigations in the field. However, knowledge gaps and challenges still remain. This session will explore in case and debate format controversial diagnostic and management dilemmas beyond accepted practice. Topics include adding additional Pulmonary Arterial Hypertension (PAH) specific therapy in a stable patient, treatment of borderline pulmonary hypertension, and managing pulmonary hypertension complicated by Interstitial Lung Disease (ILD).

1:30 PM
Case Presentation: To Treat or Not To Treat...Interstitial Lung Disease (ILD)-PH
Christopher King, MD, FACP, FCCP, Inova Fairfax Hospital, Falls Church, VA, USA

1:35 PM
DEBATE (PRO): Pulmonary Hypertension Due to Lung Disease Should Be Treated with PAH Specific Therapies
Steven D. Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

1:50 PM
DEBATE (CON): Pulmonary Hypertension Due to Lung Disease Should Be Treated with PAH Specific Therapies
Marius Hoeper, MD, Hannover Medical School, Hannover, Germany

2:05 PM
Case Presentation: To Treat or Not To Treat...Borderline PAH
Thenappan Thenappan, MD, University of Minnesota, Minneapolis, MN, USA

2:10 PM
DEBATE (PRO): “Borderline” PAH Should Be Treated with PAH Specific Therapy
Bradley Maron, MD, Brigham and Women’s Hospital, Boston, MA, USA

2:25 PM
DEBATE (CON): “Borderline” PAH Should Be Treated with PAH Specific Therapy
Jean-Luc Vachiery, MD, Erasme University Hospital - ULB, Brussels, Belgium

2:40 PM
Case Presentation: “I'm doing fine Doc, do I really need another pill?”
Roberto Badagliacca, MD, University of Rome Sapienza, Rome, Italy

2:45 PM
DEBATE (PRO): My Patient with PAH is Clinically Stable on Monotherapy: I Should Escalate to Dual or Triple Therapy
Rogerio Souza, MD, University of Sao Paulo, Sao Paulo, Brazil

3:00 PM
DEBATE (CON): My Patient with PAH is Clinically Stable on Monotherapy: I Should Escalate to Dual or Triple Therapy
Veronica Franco, MD, Ohio State University, Columbus, OH, USA

3:15 PM Panel Discussion
1:30 PM - 3:30 PM
SYMPOSIUM 29: How to Mend a Broken Heart: Approaches for Cardiac Regeneration

Location:
Seaport F-H

Target Audience:
BSTR, HF, HTX, PATH, PHARM

Chairs:
Lori West, MD, DPhil, and Daniel TS Reichart, MD

Session Summary: This session provides an overview of mechanisms of heart failure and different experimental approaches for cardiac regeneration. Implications for multipotent stem cell therapies are presented, followed by cell independent strategies to cardiac regeneration. Furthermore, the potential of pluripotent stem cells and stem cell-derived cardiomyocytes, as well as myocardial tissue engineering approaches, will be discussed.

1:30 PM
Mechanisms of Heart Failure and Experimental Therapeutic Options
Claudius Mahr, DO, University of Washington, Seattle, WA, USA

1:45 PM Q&A

1:50 PM
Multipotent Stem Cells and Cardiac Progenitors in Clinical Trials
Joshua Hare, MD, Miller School of Medicine, Miami, FL, USA

2:05 PM Q&A

2:10 PM
MicroRNAs and Cell Independent Strategies for Cardiac Regeneration
Pradeep Mammen, MD, UT Southwestern Medical Center, Dallas, TX, USA

2:25 PM Q&A

2:30 PM
Cardiac Cell Injection for Heart Failure: Pluripotent Stem Cells (PSC) and Stem Cell-Derived Cardiomyocytes
Tobias Deuse, MD, PhD, UCSF Medical Center, San Francisco, CA, USA

2:45 PM Q&A

2:50 PM
Myocardial Tissue Engineering: Where Are We Now and Where Are We Heading?
Simon Pecha, MD, University Heart Centre Hamburg, Hamburg, Germany

3:05 PM Q&A

3:10 PM
Pluripotent Stem Cells: Hurdles and Perspectives on the Way to Clinical Application
Doris Taylor, MD, Texas Heart Institute, Houston, TX, USA

3:25 PM Q&A
1:30 PM - 3:30 PM
SYMPOSIUM 30: E-Health, Wearables, Social Media and Big Data in Transplantation: Fancy Toys or True Care Innovations?

Location:
Coronado A-C

Target Audience:
NHSAH, ALL

Chairs:
Deborah Page, NP, and Steve Ivulich, PharmD

Session Summary: The purpose of this symposium is to discuss the state-of-the-art of e-health technology (telemedicine, telehealth and interactive health technology applications) in delivering care (e.g. long-distance care, self-management support) in end-stage organ disease, LVAD and transplantation. In addition, interactive communication options via social media for public involvement as well as research dissemination will be reviewed. Moreover the value of big data for transplantation will be explored.

1:30 PM
*The Many Faces of E-health: An Overview*
Fabienne Dobbels, MSc, PhD, University of Leuven, Leuven, Belgium

1:45 PM Q&A

1:50 PM
*The Importance of Involving End-Users When Designing Interactive Health Technology Applications for Self-Management Support*
Annette Devito-Dabbs, PhD, RN, ACNS-BC, FAAN, University of Pittsburgh School of Nursing, Pittsburgh, PA, USA

2:05 PM Q&A

2:10 PM
*The ABCs of Social Media*
Mary N. Walsh, MD, St. Vincent Hospital, Indianapolis, IN, USA

2:25 PM Q&A

2:30 PM
*Closer to the Heart: The Impact of Distance to Care and Remote Care*
Tam Khuu, PharmD, UCLA Medical Center, Los Angeles, CA, USA

2:45 PM Q&A

2:50 PM
*Big Data: Big Impact*
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

3:05 PM Q&A

3:10 PM
*New Ethical and Legal Challenges Surrounding E-health in Transplantation*
JiYeon Choi, PhD, RN, University of Pittsburgh School of Nursing, Pittsburgh, PA, USA

3:25 PM Q&A
4:00 PM - 5:30 PM
ORAL SESSION 34: Short-Term MCS for Shock: New Paradigms

Location:
Seaport A-E

Target Audience:
MCS, HF, HTX, NHAH

Chairs:
Ashish S. Shah, MD, and Pascal N. Leprince, MD, PhD

4:00 PM (347) Extra Corporeal Membrane Oxygenation (ECMO) as a Bridge to Adult Heart Transplantation: Bridge to Bridge Strategy vs Direct ECMO Bridge Strategy (UNOS Analysis); B. Hannawi¹, J. Estep¹, D. Nguyen², E. Graviss², B. Trachtenberg¹, A. Bhimaraj¹, M. Park¹, B. A. Bruckner³, A. Guha¹. ¹Cardiovascular Disease, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Research Institute, Houston, TX, ³Houston Methodist Hospital, Houston, TX


4:30 PM (349) Incidence and Outcomes of Acute Circulatory Support Prior to Heart Transplantation; D. Ouyang, G. Gulati, R. Ha, D. Banerjee. Medicine, Stanford, Palo Alto, CA

4:45 PM (350) Clinical Outcomes and Left Ventricular Unloading with Intra-Aortic Balloon Pump During Extracorporeal Life Support; S. Tepper, M. F. Masood, M. Baltazar Garcia, M. Pisani, A. Ahmed, A. Khan, A. Itoh. Washington University School of Medicine in St. Louis, Saint Louis, MO

5:00 PM (351) Contemporary ECMO Therapy for Postcardiotomy Shock: From REgiStry for Cardiogenic Shock: Utility and Efficacy of Device Therapy (RESCUE); H. Takayama¹, J. Han¹, M. Baltazar-Garcia², M. Lucas³, M. Kai⁴, M. Camacho⁵, B. Sun⁶, D. Ranney⁷, M. A. Daneshmand⁷, A. Itoh². ¹Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, ²Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, MO, ³Department of Cardiothoracic Surgery, University of Colorado, Denver, CO, ⁴Department of Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY, ⁵Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ, ⁶Minneapolis Heart Institute, Minneapolis, MN, ⁷Division of Cardiothoracic Surgery, Duke University Medical Center, Durham, NC

**ORAL SESSION 35: Heart Failure in MCS**

**4:00 PM - 5:30 PM**

**Location:**
Grand Hall A

**Target Audience:**
MCS, HF, HTX, PH

**Chairs:**
Ahmet Kilic, MD, and Anna L Meyer, MD

---

**4:00 PM (353) Does Inotrope Dependence Make a Difference in Outcome in Patients Receiving Left Ventricular Assist Device? Comparison Between INTERMACS Profiles 3 vs 4/5 from the INTERMACS Registry;**
S. M. Joseph1, S. A. Hall1, B. Lima1, J. O. Robertson2, D. C. Naftel3, S. Myers3, J. K. Kirklin4, S. C. Silvestry5. 1Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX, 2Washington University, St. Louis, MO, 3University of Alabama, Birmingham, AL, 4Surgery, University of Alabama, Birmingham, AL, 5Surgery, Florida Hospital Center, Orlando, FL

**4:15 PM (354) Vasoactive-Inotropic Score Is Associated with In-Hospital Mortality in Continuous Flow Left Ventricular Assist Device Patients;**
J. Han1, H. Takayama1, P. A. Kurlansky1, A. R. Garan2, M. Yuzefpolskaya2, V. K. Topkara2, P. C. Colombo2, Y. Naka1, K. Takeda1. 1Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 2Division of Cardiology, Columbia University Medical Center, New York, NY

**4:30 PM (355) The Duration of Inotropic Support and Survival After Left Ventricular Assist Device;**
E. Grandin1, D. Mooney1, K. Kennedy2, M. S. Kiernan3, R. D. Kociol1, J. J. Teuteberg4, F. D. Pagani5, A. C. Gaffey6, P. Atluri7, E. Y. Birati8, S. Myers9, D. Naftel9, G. Oliveira10, K. E. Simpson11, R. W. Yeh1, J. K. Kirklin12, R. L. Kormos13, J. Rame8. 1Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, 2Mid America Heart Institute, St. Luke's Hospital, Kansas City, MO, 3Division of Cardiovascular Medicine, Tufts Medical Center, Boston, MA, 4Division of Cardiovascular Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Division of Cardiovascular Surgery, University of Michigan, Ann Arbor, MI, 6Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 7Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 8Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 9INTERMACS, University of Alabama at Birmingham, Birmingham, AL, 10Division of Cardiovascular Medicine, University Hospitals Case Medical Center, Cleveland, OH, 11Division of Pediatric Cardiology, St. Louis Children's Hospital, St. Louis, MO, 12Division of Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL, 13Division of Cardiovascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

**4:45 PM (356) The Incidence of Early and Late Clinical Right Heart Failure and the Impact on Survival After Continuous Flow Mechanical Support: Insights from the New INTERMACS Definition of Right Heart Failure;**
J. J. Teuteberg1, G. Studdard2, F. Pagani3, M. Kiernan4, G. Oliveria5, E. Rame6, P. Atluri7, A. Gaffey8, E. W. Grandin9, J. Kirklin10, S. Myers11, C. Collum12, R. L. Kormos13. 1University of Pittsburgh, Pittsburgh, PA, 2University of Alabama, Birmingham, Birmingham, AL, 3University of Michigan, Ann Arbor, MI, 4Tufts Medical Center, Boston, MA, 5Case Western, Cleveland, OH, 6University of Pennsylvania, Philadelphia, PA, 7Beth Isreal Deaconess, Boston, MA

**5:00 PM (357) Normalization of Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure in Response to Speed Change Predicts Better Outcome in Patients with Left Ventricular Assist Devices;**
T. Imamura1, G. Sayer1, S. Adatya1, G. Kim1, J. Raikhelkar1, T. Ota1, T. Song1, C. Juricek1, V. Kagan1, D. Rodgers1, V. Jeevanandam1, D. Burkhoff2, N. Uriel1. 1University of Chicago, Chicago, IL, 2University of Columbia, New York, NY

**5:15 PM (358) Effect of Transplant Rates on Benefit of Left Ventricular Assist Device versus Inotrope Support;**
J. C. Robertson1, K. D. Aarsonson2, A. Basu1, L. Kessler1, C. Mahr3, N. A. Mokadam4, T. Dardas3. 1Health Services, University of Washington, Seattle, WA, 2Internal Medicine, University of Michigan, Ann Arbor, MI, 3Medicine, University of Washington, Seattle, WA, 4Surgery, University of Washington, Seattle, WA
4:00 PM (359) **Sirolimus-Based Immunosuppression Mitigates Progression of Cardiac Allograft Vasculopathy and Improves Cardiac Outcomes After Heart Transplantation: A Single Center 15-Year Follow-Up Study**


4:45 PM (361) **Atheroprotective Effect of IgM Anti-Phosphorylcholine Natural Antibodies in Heart Transplant Patients**

C. A. Labarrere1, J. W. Hardin2, B. R. Jaeger3, D. L. Bhatt4, G. S. Kassab1. *California Medical Innovations Institute, San Diego, CA,* 2Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, 3Medical Care Center, Laboratory Dr. Stein and Colleagues, Mönchengladbach, Germany, 4Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

4:50 PM (362) **IgM Anti-Phosphorylcholine, Inflammation and Thrombosis: Effects on Heart Transplant Outcomes**

C. A. Labarrere1, J. W. Hardin2, B. R. Jaeger3, D. L. Bhatt4, G. S. Kassab1. *California Medical Innovations Institute, San Diego, CA,* 2Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, 3Medical Care Center, Laboratory Dr. Stein and Colleagues, Mönchengladbach, Germany, 4Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA

5:00 PM (363) **Early Changes in the Coronary Microstructure After Heart Transplantation: A Prospective Optical Coherence Tomography Study**

T. S. Clemmensen1, N. R. Holm1, H. Eiskjær1, B. B. Løgstrup1, J. Dijkstra2, C. J. Terkelsen1, M. Maeng1, E. H. Christiansen1, S. H. Poulsen1. *Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark,* 2Division of Image Processing, Leiden University Medical Centre, Leiden, Netherlands

5:15 PM (364) **Markers of Intermediate-Term Risk After Heart Transplant - Results of the CTOT-18 Study**

J. Stehlik1, B. Armstrong2, D. A. Baran3, A. Chandraker4, N. D. Bridges5, T. DeMarco6, E. Feller7, M. Givertz8, R. Gordon6, P. S. Heeger9, A. Heroux10, J. Hunt11, D. N. Ikle2, A. G. Kfoury12, J. C. Madsen13, Y. R. Morrison5, S. P. Pinney14, R. C. Starling15, .. for CTOT-18 Investigators1. *University of Utah School of Medicine, Salt Lake City, UT,* 2Rho Federal Systems Division, Chapel Hill, NC, 3Newark Beth Israel Medical Center, Newark, NJ, 4Brigham & Women’s Hospital, Boston, MA, 5DAIT, NIAID, NIH, Bethesda, MD, 6UCSF, San Francisco, CA, 7University of Maryland, Baltimore, MD, 8Northwestern University, Chicago, IL, 9Mount Sinai School of Medicine, New York, NY, 10Loyola University School of Medicine, Maywood, IL, 11Medical City Dallas Hospital, Dallas, TX, 12Intermountain Medical Center, Salt Lake City, UT, 13Massachusetts General Hospital, Boston, MA, 14Mount Sinai School of Medicine, Salt Lake City, UT, 15The Cleveland Clinic Foundation, Cleveland, OH
4:00 PM - 5:30 PM
ORAL SESSION 37: Impact of Donor Characteristics on Lung Transplant Outcomes

Location:
Grand Hall C

Target Audience:
LTX, BSTR, EEP, MCS, NHSAH

Chairs:
Arne Neyrinck, MD, PhD, and Cassie C Kennedy, MD

(365) WITHDRAWN

4:00 PM (409) Making a Case for EPLET Matching...Eplet Matching Is Associated with Improved Baseline Spirometry and Reduced Risk of CLAD Following Lung Transplantation; M. Paraskeva¹, D. C. Walton², S. J. Hiho², J. Fuller³, L. S. Cantwell², G. P. Westall¹, G. I. Snell¹. ¹Lung Transplant Service, Alfred Hospital, Melbourne, Australia, ²Victorian Transplantation and Immunogenetics Service, Australian Red Cross Blood Service, Melbourne, Australia, ³Monash University, Melbourne, Australia

4:15 PM (366) 10 Years Experience with Maastricht Category III Donation After Circulatory Death (DCD) in Lung Transplantation (LTX) - Analysis of Early and Long-Term Results in Large Single-Centre Cohort; B. Zych¹, D. Garcia-Saez¹, O. Ananiadou¹, P. N. Mohite¹, L. Fazedas¹, M. Husain¹, B. Schmack¹, F. De Robertis¹, A. F. Popov¹, T. Bahrami¹, N. Marczin², A. Reed¹, M. Carby¹, A. R. Simon¹. ¹Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital. Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom, ²Department of Anaesthesia and Intensive Care, Harefield Hospital. Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom

4:30 PM (367) Extended Donation After Circulatory Death (DCD) Cat 3 Lung Donor Agonal and Post-Mortem Warm Ischemic Times (WIT) Do Not Affect Early Mortality; B. Levvey¹, L. Edwards², A. Robinson², S. Keshavjee³, M. Erasmus⁴, A. Glanville⁵, P. Hopkins⁶, M. Musk⁷, A. Patterson⁸, M. Hertz⁹, F. D'Ovidio¹⁰, K. McCurry¹¹, P. Camp¹², B. Carrió², J. Stehlik¹³, D. Van Raemdonck¹⁴, G. Snell¹. ¹Alfred Hospital, Melbourne, Australia, ²UNOS, Richmond, VA, ³Toronto General Hospital, Toronto, ON, Canada, ⁴Universitair Medisch Centrum Groningen, Groningen, Netherlands, ⁵St Vincent's Hospital, Sydney, Australia, ⁶Prince Charles Hospital, Brisbane, Australia, ⁷Lung Transplant Program, Fiona Stanley Hospital, Perth, Australia, ⁸Barnes-Jewish Hospital, St Louis, MO, ⁹Fairview Medical Centre-University of Minnesota, Minneapolis, MN, ¹⁰Columbia Presbyterian Medical Center, New York, NY, ¹¹The Cleveland Clinic Foundation, Cleveland, OH, ¹²B Brigham and Womens Hospital, Boston, MA, ¹³University of Utah, Salt Lake City, UT, ¹⁴UZ Gasthuisberg Leuven, Leuven, Belgium

4:45 PM (368) Lessons Learned from the First Clinical Trial to Compare Outcomes of Lungs Transplanted from Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs) Assessed by Ex-Vivo Lung Perfusion (EVLP) and CT Scan and Lungs Transplanted from Conventional Donors (CONV); T. M. Egan¹, J. Blackwell¹, B. Haithcock¹, J. Long¹, K. Birchard², J. Lobo³, S. Masuoodi¹, J. Requard III⁴, C. Thys⁵. ¹Surgery, U. North Carolina Sch Med, Chapel Hill, NC, ²Radiology, U. North Carolina Sch Med, Chapel Hill, NC, ³Medicine, U. North Carolina Sch Med, Chapel Hill, NC, ⁴Lung Banks of America, Chapel Hill, NC, ⁵Carolina Donor Services, Durham, NC

5:00 PM (369) An In Situ Donor Derived Panel of Innate Immune Transcripts Predicts Primary Graft Dysfunction in Lung Transplant Recipients; T. J. Carter¹, Y. Suzuki¹, J. Lasky¹, C. Schaufler¹, B. Lim¹, D. Mallem¹, C. A. Bermudez¹, J. M. Diamond², J. D. Christie³, X. Yu⁴, R. Feng⁴, E. Cantu¹. ¹Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania, Philadelphia, PA, ³Pulmonary, Allergy, and Critical Care Division; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA

5:15 PM (370) Donor-Derived Cell-Free DNA Associates with Rejection in Lung Transplantation Using Clinical-Grade Targeted Next-Generation Sequencing; K. K. Khush¹, J. F. Beausang¹, R. N. Woodward², D. Lew², J. Sninsky², I. De Vlaminck³, C. Strehl³, H. Luikart¹, M. Nicolls¹, D. Weill³. ¹Stanford University, Stanford, CA, ²CareDx, Brisbane, CA, ³Cornell University, Ithica, NY, ⁴Florida International University, Miami, FL, ⁵Weill Consulting Group, Palo Alto, CA

Friday, April 7
4:00 PM - 5:30 PM
ORAL SESSION 38: The Nightmare of Primary Cardiac Allograft Dysfunction

Location:
Grand Hall D

Target Audience:
HTX, MCS, PHARM

Chairs:
Feras Khaliel, MD, PhD, and Maria G Crespo-Leiro, MD

4:00 PM (371) Does the New ISHLT Primary Graft Dysfunction (PGD) Grading Scale in Heart Transplantation Predict Outcome; J. Patel, M. Kittleson, T. Aintablian, R. Levine, M. Curry, A. Hage, D. Geft, D. Chang, L. Czer, D. Ramzy, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

4:15 PM (372) The Incidence and Outcome of Primary Graft Dysfunction After Adult Heart Transplantation in the United Kingdom; S. Avtaar Singh¹, N. R. Banner², S. Rushton³, N. Al-Attar¹. ¹Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, ²Golden Jubilee National Hospital, Glasgow, United Kingdom, ³Statistics, National Health Service Blood and Transplant (NHSBT), Bristol, United Kingdom


4:45 PM (374) Risk of Early Graft Failure Following Heart Transplantation with Durable Continuous Flow vs. Pulsatile Flow Mechanical Circulatory Support; K. J. Clerkin¹, D. M. Mancini², J. Stehlik³, M. A. Clark⁴, L. B. Edwards⁴, L. H. Lund⁵. ¹Cardiology, Columbia University Medical Center, New York, NY, ²Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Cardiology, University of Utah School of Medicine, Salt Lake City, UT, ⁴United Network for Organ Sharing, Richmond, VA, ⁵Karolinska Institutet (Department of Medicine) and Karolinska University Hospital (Department of Cardiology), Stockholm, Sweden

5:00 PM (375) Donor Predicted Heart Mass Is Superior to Total Body Weight in Predicting Primary Graft Dysfunction in Undersized Donors; T. A. Gong, G. Gonzalez-Stawinski, S. M. Joseph, P. P. Kale, J. C. MacHannaford, A. Rafael, G. Saracino, S. A. Hall, B. Lima. Advanced Heart Failure and Transplant, Baylor University Medical Center, Dallas, TX

5:15 PM (376) Assessing Risk of Primary Graft Dysfunction in Heart Transplantation (HT); S. Shah¹, D. Cruz², M. Deng², A. Ardeshi², E. C. DePasquale². ¹David Geffen School of Medicine, Los Angeles, CA, ²UCLA Department of Cardiology, Los Angeles, CA
4:00 PM - 5:30 PM
ORAL SESSION 39: Early Career Scientist Award in Transplantation Finalist Presentations

Location:
Seaport F-H

Target Audience:
BSTR, HTX, ID, LTX, PATH, PEDS, PHARM

Chairs:
Sonja Schrepfer, MD, PhD, and Edward Cantu, MD

4:00 PM (377) Transplanting the Human Respiratory Virome; A. B. Mitchell¹, B. Mourad¹, M. A. Malouf², M. Benzimra², L. C. Morgan³, B. G. Oliver¹, A. R. Glanville¹. ¹Molecular Biology, University of Technology, Sydney, Australia, ²Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ³Thoracic Medicine, Concord Clinical School, University of Sydney, Sydney, Australia, ⁴Thoracic Medicine, St Vincent's Hospital, Sydney, Australia

4:15 PM (378) Differential Modulation of the IL-17A Pathway in Restrictive Allograft Syndrome (RAS) versus Bronchiolitis Obliterans Syndrome (BOS); A. Tigert¹, T. Saito², L. Levy¹, G. Zehong¹, K. Boonstra¹, S. Keshavjee¹, S. Juvet¹, T. Martinu¹. ¹Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada, ²Department of Thoracic Surgery, Kansai Medical University, Hirakata, Japan

4:30 PM (379) Splenic Monocytes Promote Neutrophil Extravasation into Lung Grafts via a TLR9-IL1β-Dependent Pathway; H. Hsiao¹, T. Takahashi¹, Y. Liu¹, D. Scozzi¹, W. Li¹, A. S. Krupnick², A. E. Gelman², D. Kreisel¹. ¹Surgery, Washington University in Saint Louis, Saint Louis, MO, ²Surgery, University of Virginia, Charlottesville, VA, ³Pathology and Immunology, Washington University in Saint Louis, Saint Louis, MO

4:45 PM (380) Validation of microRNA Profiling in Different Types of Rejection Previously Identified with NGS Technology in Formalin Fixed EMBs; A. Di Francesco¹, M. Fedrigo², F. De Pascale³, C. Castellani², G. Feltrin², G. Toscano², A. Fraiese², E. Benazzi⁴, A. Nocco³, G. Thiene³, M. Valente³, G. Valsecchi³, G. Gerosa³, A. Angelini². ¹University of Padova, Padova, Italy, ²Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ³CRIIBI Biotechnology Centre, University of Padova, Padova, Italy, ⁴Organ and Tissue Transplantation Immunology, Fondazione I.R.C.C.S. Cà Granda Ospedale Maggiore Policlinico, Milano, Italy

5:00 PM (381) Molecular Profiling of Endomyocardial Biopsies and Clinical Phenotype of Graft Dysfunction: Taking Rejection Diagnosis Beyond Pathological Findings; L. Borgese¹, A. Gaudenzi¹, V. Agostini², M. Masetti¹, B. Corti², J. Reeve³, F. Grigioni¹, O. Leone², P. Halloran³, L. Potena¹. ¹Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, ²Pathology, University of Bologna, Bologna, Italy, ³ATAGC, University of Alberta, Edmonton, AB, Canada
4:00 PM - 5:30 PM
ORAL SESSION 40: Drugs, Bleeding and Enzymes ... Oh My!

Location:
Coronado A-C

Target Audience:
PHARM, HTX, ID, LTX, MCS, NHSAH

Chairs:
Walter Uber, PharmD, and Rochelle M Gellatly, PharmD

4:00 PM (382) Impact of Angiotensin II Inhibitors on the Incidence of Gastrointestinal Bleeds After Left Ventricular Assist Device Placement; M. Converse, M. Sobhanian, A. Mardis, D. Taber, W. Uber, H. Meadows, B. Houston, N. Patel, A. Vanbakel. Pharmacy, Medical University of South Carolina, Charleston, SC

4:15 PM (383) Evaluation of Prothrombin Complex Concentrate in Warfarin Reversal Prior to Heart Transplantation in Patients with Durable Mechanical Circulatory Support; C. I. Konopka1, E. T. Horn1, S. Murali2, R. L. Benza2, R. J. Moraca3, S. H. Bailey3. 1Department of Pharmacy, Allegheny General Hospital, Pittsburgh, PA, 2Division of Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, PA, 3Division of Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA

4:30 PM (384) Stimulated T-Cell Interferon Gamma Responses as a Biomarker of Immune Function; S. Yogakanthi1, A. Y. Peleg2, E. Paul3, Y. Cristiano1, G. Snell1, G. Westall1. 1Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital & Monash University, Melbourne, Australia, 2Department of Infectious Diseases, Alfred Hospital & Monash University, Melbourne, Australia, 3Department of Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia

4:45 PM (385) Impact of CYP3A5, CYP3A4, and ABCB1 Genotypes on Lung Transplant Recipient Early Clinical Outcomes; D. R. Calabrese1, R. Boettger2, K. Dewey2, C. Hui2, D. Torgerson1, H. Faust3, R. Rajalingam4, S. Hays1, J. Singer1, R. Shah1, L. Leard1, J. Kukreja4, J. Golden4, J. Greenland5. 1Department of Medicine, University of California San Francisco, San Francisco, CA, 2Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, 3Department of Medicine, University of Pennsylvania Health System, Philadelphia, PA, 4Department of Surgery, University of California San Francisco, San Francisco, CA, 5Medical Service, Veterans Affairs Medical Center, San Francisco, CA

5:00 PM (386) Tacrolimus Dosing Requirements Are Reduced in Heart Transplant Recipients with Severe Primary Graft Dysfunction on ECMO Support; N. Breslin, D. Salerno, N. Jandovitz, D. Tsapepas, S. Restaino, F. Latif, P. Colombo, M. Farr, D. L. Jennings. New York Presbyterian Columbia Irving Medical Center, New York, NY

5:15 PM (387) Relationship Between Patient-Perceived Treatment Burden and Medication Adherence in Heart Transplant Recipients; K. M. Deininger1, J. D. Hirsch2, S. A. Graveline2, A. A. Feist2, S. M. Smith2, J. A. Reich1, J. LaFleur4, A. V. Ambardekar1, J. Lindenfeld5, C. L. Aquilante1. 1University of Colorado, Aurora, CO, 2University of California San Diego, La Jolla, CA, 3University of Florida, Gainesville, FL, 4University of Utah, Salt Lake City, UT, 5Vanderbilt University, Nashville, TN

Friday, April 7
MINI ORAL SESSION 13: Controversies in Heart Transplantation

Location: Grand Hall A

Target Audience: HTX, MCS

Chairs: William Stansfield, MD, and Susan Woodley Restaino, MD

5:45 PM - 6:45 PM

5:45 PM (388) Cardiac Transplantation in Patients Supported with Extracorporeal Membrane Oxygenation (ECMO): Early and Mid-Term Results; P. Noly1, E. Flecher2, M. Hebert1, M. Mauduit2, Y. Lamarche1, J. Verhoye2, M. Carrier1. 1Cardiac Surgery, Montreal Heart Institute, Montreal, QC, Canada, 2Cardiac Surgery, Rennes Hospital, Rennes, France

5:50 PM (389) Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Heart Transplantation: Impact on Post Transplantation Outcomes; A. C. Gaffey1, C. W. Chen1, J. J. Chung1, L. R. Goldberg2, C. A. Bermudez3, M. A. Acker1, P. Atli1. 1Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Department of Medicine, University of Pennsylvania, Philadelphia, PA

5:55 PM (390) Trends in Combined Heart-Kidney Transplantation and Impact on Patient Survival; D. Vucicevic1, L. Honoris1, A. Salimbangon1, A. Chang1, E. Moreno1, M. Moore1, L. Sweet1, S. Shah1, A. Iyengar1, K. Pandya2, A. Ardehali3, M. Deng1, E. DePasquale1. 1Department of Cardiology, UCLA, Los Angeles, CA, 2Department of Cardiology, UC Davis, Davis, CA, 3Department of Cardiothoracic Surgery, UCLA, Los Angeles, CA

6:00 PM (391) Simultaneous Kidney-Heart Transplantation is Superior to Sequential Heart-Kidney Transplantation in Renal Failure Heart Transplant Candidates; M. S. Mulvihill1, B. A. Yerokun1, P. Patel2, J. G. Rogers2, C. A. Milano3, C. B. Patel4, M. G. Hartwig1. 1Department of Surgery, Duke University, Durham, NC, 2Department of Medicine, Duke University, Durham, NC

6:05 PM (392) Attenuation of Cardiac Allograft Vasculopathy in Dual Organ Transplantation; K. J. Clerkin1, S. W. Restaino1, F. Latif1, M. A. Farr1, E. Zorn2, D. M. Mancini3, K. Takeda4, H. Takayama4, Y. Naka4, P. C. Colombo5, V. K. Topkara1. 1Cardiology, Columbia University Medical Center, New York, NY, 2Immunology, Columbia University Medical Center, New York, NY, 3Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, 4Cardiac Surgery, Columbia University Medical Center, New York, NY

6:10 PM (393) Impact of Cardiac Allograft Vasculopathy and Treated Rejection on Sudden Cardiac Death in Patients Receiving a Cardiac Transplant. An Analysis of the ISHLT Registry Data; A. C. Alba1, C. S. Fan2, C. Manihiot2, A. I. Dipchand3, J. Stehlik4, H. J. Ross1. 1Toronto General Hospital - University Health Network, Toronto, ON, Canada, 2The Hospital for Sick Children - University of Toronto, Toronto, ON, Canada, 3Heart Transplant Program, The Hospital for Sick Children - University of Toronto, Toronto, ON, Canada, 4University of Utah School of Medicine, Salt Lake City, UT

6:15 PM (394) Positron Emission Tomography Is Associated with the Presence of Cardiac Allograft Vasculopathy on Coronary Angiography; M. C. Konerman1, J. J. Lazarus1, R. L. Weinberg1, M. Ghannam1, A. Saleh1, H. Yun1, V. M. Moles1, S. L. Hummel1, R. V. Shah2, J. R. Corbett3, K. D. Aaronson1, M. M. Colvin1, T. M. Koelling1, V. L. Murthy1. 1University of Michigan, Ann Arbor, MI, 2Beth Israel Deaconess Medical Center, Boston, MA

6:20 PM (395) Highly Automated Analysis of Intimal and Medial Thickness in Heart-Transplant Coronary OCT Facilitates Longitudinal Studies of CAV Progression; Z. Chen1, A. Wahle1, Z. Guo1, H. Zhang1, V. Karmazin2, A. Tomasek3, H. Bedanova3, J. J. Lopez4, T. Kovarnik5, M. Pazdemnik2, M. Sonka1. 1University of Iowa, Iowa City, IA, 2IKEM, Prague, Czech Republic, 3Cardiovascular and Transplantation Surgery, Brno, Czech Republic, 4Loyola University, Chicago, IL, 5Charles University, Prague, Czech Republic

6:25 PM (396) Strategies to Reduce Tricuspid Regurgitation After Heart Transplant; K. Carl1, A. M. Borkon1, S. Aggarwal1, K. Allen1, R. Davis1, A. Pak1, E. Thompson1, J. Wang2, A. Kao3, A. Magalski3, S. Lawhorn3, T. Khumari3, B. Austin1. 1Cardiovascular Surgery, Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, 2Biostatistics,

6:35 PM (398) MRI Findings in Late Cardiac Allograft Failure; M. Hyden, E. Raichlin. Cardiology, UNMC, Omaha, NE

6:40 PM (399) A Comparison of Two-Dimensional Echocardiography Parameters with Cardiac Magnetic Resonance Imaging in the Assessment of Right Ventricular Function Post Orthotopic Heart Transplantation; M. Hyden, R. K. Anchan, R. High, S. Saxena. Department of Internal Medicine, Nebraska Medicine, Omaha, NE
MINI ORAL SESSION 14: Recipient Risk Factors Affecting Outcome after Lung Transplantation

Location: Grand Hall B

Target Audience: LTX, BSTR, EEP, ID, NHSAH, PATH, PHARM

Chairs: Peter M Hopkins, FRACP, and Cynthia J. Gries, MD, MSc

5:45 PM (400) How Old Is Old to Have a Lung Transplantation - Results from a Single Center: Y. Toyoda¹, J. Gomez-Abraham¹, S. Keshavamurthy¹, T. Yoshizumi¹, H. Zhao², F. Cordova³, S. Kartik¹, A. J. Mamary², G. Griner¹, A. Kashem¹. ¹Cardiovascular Surgery, Temple University, Philadelphia, PA, ²Department of Clinical Science and Statistics, Temple University, Philadelphia, PA, ³Thoracic and Pulmonary Medicine, Temple University, Philadelphia, PA

5:50 PM (401) Preexisting Coronary Artery Disease Is Associated with Higher Morbidity in Patients Undergoing Lung Transplantation: S. Biswas Roy¹, M. Olson², D. Harned³, P. Kang², R. Panchanathan³, A. Hashimi³, J. Huang¹, H. Abdelazek¹, V. Patel¹, A. Omar³, R. M. Bremer¹, M. A. Smith¹, R. Walia¹, A. V. Kalya¹. ¹Norton Thoracic Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ, ²Grand Canyon University, Phoenix, AZ, ³University of Arizona College of Public Health, Phoenix, AZ, ⁴University of Arizona Medical School, Phoenix, AZ

5:55 PM (402) Prognostic Factors in Lung Transplantation After Hematopoietic Stem Cell Transplantation: T. F. Chen-Yoshikawa¹, S. Sugimoto², T. Shiraiishi³, M. Minami⁴, Y. Matsuda⁵, M. Chida⁶, S. Maeda⁶, A. Aoyama¹, Y. Okada⁵, M. Okumura⁴, A. Iwasaki³, S. Miyoshi², T. Oto², H. Date¹. ¹Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, ³Thoracic Surgery, Fukuoka University Hospital, Fukuoka, Japan, ⁴General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ⁵Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, ⁶General Thoracic Surgery, Graduate School of Medicine, Dokkyo Medical University, Mibu, Japan, ⁷Organ Transplant Center, Okayama University Hospital, Okayama, Japan

6:00 PM (403) Lung Volumes Pre and Post Transplant: The Frustrum Model: S. Park, W. Ring, M. A. Wait. Thoracic & Cardiovascular Surgery, UT Southwestern Medical Center, Dallas, TX

6:05 PM (404) Impact of Acute Respiratory Syncytial Virus Infection on the Lung Function of Lung Transplant Recipients: What Happens?: H. Lafoeste¹, C. Picard¹, L. Beaumont¹, E. Farfour², S. De Miranda¹, B. Douvry¹, A. Hamid¹, N. Carlier¹, D. Grenet¹, F. Parquin³, E. Sage³, A. Roux¹. ¹Respiratory Medicine, Foch Hospital, Suresnes, France, ²Microbiology Department, Foch Hospital, Suresnes, France, ³Thoracic Surgery, Foch Hospital, Suresnes, France

6:10 PM (405) Post-Lung Transplant Esophageal Impedance/pH Studies Do Not Predict Onset of RAS or BOS Phenotypes: O. M. Crespin¹, T. Martinu², J. Tikkanen², W. Klement², A. Okraine¹, L. Liu³, M. Cype³, S. Keshavjee², G. E. Darling³, J. C. Yeung³. ¹Division of General Surgery, University of Toronto, Toronto, ON, Canada, ²Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada, ³Division of Gastroenterology, University of Toronto, Toronto, ON, Canada, ⁴Division of Thoracic Surgery, University of Toronto, Toronto, ON, Canada

6:15 PM (406) Prevalence and Predictors of Severe Bronchial Complications Following Lung Transplantation: K. Narm, S. Lee, J. Suh, J. Lee, A. Kim, H. Paik. Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of

6:20 PM (407) Repertoire Analysis of De Novo Non-HLA Antibodies Associated with Chronic Lung Allograft Rejection Following Human Lung Transplantation: D. Nayak, R. Walia, R. Bremer, M. Smith, T. Mohanakumar. St. Joseph's Hospital & Medical Center, Phoenix, AZ

6:25 PM (408) Early Elevation of Anti-HLA Immunoglobulin M Level Is Associated with Subsequent Lung Transplant Rejection and Worse Outcomes: K. Miyahara, K. Miyoshi, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, T. Oto. Department of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama-shi,Okayama prefecture, Japan

6:30 PM (409) MOVED TO ORAL SESSION 37

Friday, April 7
6:35 PM (410) The Histomorphological Spectrum of Restrictive Chronic Lung Allograft Dysfunction (rCLAD): Implications for Its Etiopathogenesis and Evidence for Prognostic Patterns of Fibrosis; J. H. von der Thüsen¹, E. Vandermeulen², R. Vos², B. Weynand³, E. Verbeke², S. E. Verleden². ¹Department of Pathology, Erasmus MC, Rotterdam, Netherlands, ²Lung Transplant Unit, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium, ³Department of Pathology, UZ Gasthuisberg, Leuven, Belgium

6:40 PM (411) Can Lymphocytes Subtypes in Broncoalveolar Lavage Predict the Response to the Extracorporeal Photopheresis?; M. Aguilar Perez¹, R. Castejón Diaz², S. Aguado Ibañez¹, R. Laporta Hernandez¹, M. T. Lazaro Carrasco De La Fuente¹, P. Minguez Clemente¹, J. L. Bueno Cabrera¹, P. Ussetti Gil¹. ¹Pulmonary Department, Universitary Puerta de Hierro Majadahonda Hospital, Madrid, Spain, ²Internal Medicine Department, University Puerta de Hierro Majadahonda Hospital, Madrid, Spain
5:45 PM - 6:45 PM
MINI ORAL SESSION 15: Pediatric Heart Failure, MCS, and Peri-Transplant Issues

Location:
Grand Hall C

Target Audience:
PEDS, HF, HTX, MCS

Chairs:
Ranny Goldwasser, MD, and Janet N Scheel, MD

5:45 PM (412) Risk Factors for Death or Heart Transplant for Patients with Right Ventricular Dysfunction After the Norwood Procedure: A Secondary Analysis of the Single Ventricle Reconstruction Trial; E. Jean-St-Michel1, J. M. Meza2, J. Coles3, J. Maguire4, B. W. McRindle5. 1Paediatrics, Hospital for Sick Children, Toronto, ON, Canada, 2Congenital Heart Surgeons’ Society Data Center, Hospital for Sick Children, Toronto, ON, Canada, 3Surgery, Hospital for Sick Children, Toronto, ON, Canada


5:55 PM (414) Weaning from Ventricular Assist Devices in Children: Predictors for Recovery and Long-Term Follow Up; O. Miera1, M. Germann1, M. Cho2, M. Yigitbasi1, M. Musci2, J. Photiadis2, F. Berger1, K. R. Schmitt1. 1Congenital Heart Disease / Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, 2Surgery for Congenital Heart Disease / Pediatric Cardiac Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

6:00 PM (415) Mechanical Circulatory Support (MCS) in Infants with Congenital Heart Disease Listed for Heart Transplant- A PHTS Multicenter Experience; J. Conway1, E. Pruitt2, R. Spicer3, D. Gupta4, M. McCulloch5, A. Asante-Korang6, D. T. Eulrich7, J. Kirlin8, E. Pahl9, 1Stollery Children’s Hospital, Edmonton, AB, Canada, 2University of Alabama at Birmingham, Birmingham, AL, 3The Children’s Hospital and Medical Center, Omaha, NE, 4University of Florida, Shands Hospital, Gainesville, FL, 5Nemours Cardiac Center, Wilmington, DE, 6John Hopkins All Children’s Institute, St. Petersburg, FL, 7University of Alberta, Edmonton, AB, Canada, 8Ann & Robert H Lurie Children’s Hospital of Chicago, Chicago, IL

6:05 PM (416) Post-Transplant Outcomes of Patients Supported with the Berlin Heart EXCOR as a Bridge to Transplantation: A Multi-Institutional Study; A. Jeewa1, M. Imamura2, C. Canter3, R. Niebler4, C. VanderPluym5, D. Rosenthal6, J. K. Kirklin7, M. Tresler7, M. McMullan8, V. Morell9, M. Turrentine10, R. Ameduri11, K. Nguyen12, K. Kanter13, J. Conway14, R. Gajarski15, C. D. Fraser Jr16. 1The Hospital for Sick Children, Toronto, ON, Canada, 2Arkansas Children’s Hospital, Little Rock, AR, 3St. Louis Children’s Hospital, St. Louis, MO, 4Children’s Hospital of Wisconsin, Milwaukee, WI, 5Boston Children’s Hospital, Boston, MA, Canada, 6Lucile Packard Children’s Hospital at Stanford, Palo Alto, CA, 7University of Alabama at Birmingham, Birmingham, AL, 8Seattle Children’s Hospital, Seattle, WA, 9Children’s Hospital of Pittsburgh, Pittsburgh, PA, 10Riley Hospital for Children, Indianapolis, IN, 11University of Minnesota, Minneapolis, MN, 12Mount Sinai Medical Center, New York, NY, 13Children’s Healthcare of Atlanta, Atlanta, GA, 14The Stollery Children’s Hospital, Edmonton, AB, Canada, 15Nationwide Children’s Hospital, Columbus, OH, 16Texas Children’s Hospital, Houston, TX

6:10 PM (417) Development of Miniature, Implantable Pediatric Ventricular Assist Device; P. D. Wearden1, T. A. Snyder2, J. R. Stanfield3, P. Coghill4, D. Crompton5, S. E. Olia5, S. Ye6, M. V. Kameneva6, W. R. Wagner6, J. W. Long7. 1Nemours Cardiac Center, Nemours Children’s Hospital, Orlando, FL, 2INTEGRIS Advanced Cardiac Care, INTEGRIS Baptist Medical Center, Oklahoma City, OK, 3VADovations, Oklahoma City, OK, 4University of Pittsburgh, Pittsburgh, PA, 5Bioengineering, University of Pittsburgh, Pittsburgh, PA, 6McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA

6:15 PM (418) Initial In Vitro Testing of a Pediatric Continuous-Flow Total Artificial Heart; K. Fukamachi, D. J. Horvath, J. H. Karimov, G. Sunagawa, N. Byram, B. D. Kuban, S. Gao, R. Dessoffy, N. Moazami. Cleveland Clinic Foundation, Cleveland, OH
6:20 PM (419) **Predictors of Long Ischemic Time in Pediatric Heart Transplantation;** F. Zafar¹, T. Weiss¹, I. Wilmot², T. D. Ryan², C. Chin², R. Bryant¹, D. L. Morales¹. ¹Cardiothoracic Surgery, Children’s Hospital Med Ctr Texas Children’s Hospital, Cincinnati, OH, ²Cardiology, Children’s Hospital Med Ctr Texas Children’s Hospital, Cincinnati, OH

6:25 PM (420) **Does Distance Matter in Pediatric Heart Transplantation?;** M. J. Bock¹, S. Malerba², I. D. Lytrivi³. ¹Pediatric Cardiology, Loma Linda University Children’s Hospital, Loma Linda, CA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Pediatric Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY

6:30 PM (421) **The Virtual Heart Transplant - The Next Step in Size Matching for Pediatric Heart Transplantation;** J. D. Plasencia¹, J. R. Ryan², S. S. Park³, J. J. Nigro³, D. H. Frakes¹, S. G. Pophal³, S. D. Zangwill³. ¹School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, ²Cardiac 3D Print Lab, Phoenix Children’s Hospital, Phoenix, AZ, ³Cardiology, Phoenix Children’s Hospital, Phoenix, AZ

6:35 PM (422) **Systemic Venous Reconstructions During Pediatric Heart Transplantation;** F. Altin¹, B. Alsoufi², K. Kanter², S. R. Deshpande³. ¹Cardiothoracic Surgery, Emory University Children’s Healthcare of Atlanta, Atlanta, GA, ²Cardiothoracic Surgery, Emory University, Atlanta, GA, ³Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA

6:40 PM (423) **Transplantation in Adults with Congenital Heart Disease: A Special Exception;** J. D. Sparks¹, C. Alexander¹, A. Lenneman², J. Trivedi³, M. Slaughter³. ¹Pediatrics, University of Louisville, Louisville, KY, ²Medicine, University of Louisville, Louisville, KY, ³Cardiothoracic Surgery, University of Louisville, Louisville, KY
5:45 PM - 6:45 PM
MINI ORAL SESSION 16: Assessing and Managing the Failing Right Ventricle

Location:
Grand Hall D

Target Audience:
PH, BSTR, HF, HTX, LTX, PHARM

Chairs:
Arezu Z. Aliabadi, MD, and Amrasha Raina, MD

5:45 PM (424) Switch from Bosentan to Macitentan in Adult Outpatients with Pulmonary Arterial Hypertension: A Real-World Study; M. T. Politi¹, N. A. Caruso², J. Lescano², J. M. Farina¹, D. N. Spagnuolo¹, R. Ferreyra¹, G. R. Bortman³, ¹Cardiology, Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina, ²Heart Transplant and Pulmonary Hypertension, Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina, ³Heart Transplant and Pulmonary Hypertension, Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina

5:50 PM (425) Impact of TPG on Six Month and One Year Waitlist Mortality During Listing for Heart Transplant; A. Guha, A. S. Cruz-Solbes, D. Nguyen, B. Trachtenberg, A. Bhimajri, E. Graviss, J. D. Estep, M. Park. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

5:55 PM (426) Preoperative Serum Markers of Liver Dysfunction Are Associated with Early Postoperative Mortality in Patients with Pulmonary Hypertension Undergoing Lung Transplantation; T. Kato¹, L. Donahoe¹, H. Oishi¹, J. Lopez¹, S. Azad¹, M. Cypel¹, M. de Perrot¹, A. Pierre¹, K. Yasufuku¹, T. Waddell¹, J. Granton², L. G. Singer³, K. Kaga⁴, Y. Matsui⁴, S. Keshavjee¹. ¹Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada, ²Respirology, University Health Network, Mount Sinai Hospital and Women's College Hospital, Toronto, ON, Canada, ³Medicine, University of Toronto, Toronto, ON, Canada, ⁴Cardiovascular and Thoracic Surgery, Hokkaido University, Sapporo, Japan

6:00 PM (427) Right Ventricular Longitudinal Strain versus Tricuspid Annular Plane Systolic Excursion in Patients with Chronic Thromboembolic Pulmonary Hypertension; A. G. Connelly¹, P. G. Chiles¹, W. R. Auger², D. G. Blanchard³, T. M. Fernandes⁴. ¹Department of Internal Medicine, UC San Diego, San Diego, CA, ²Division of Pulmonary, Critical Care & Sleep Medicine, UC San Diego, San Diego, CA, ³Division of Cardiovascular Medicine, UC San Diego, San Diego, CA

6:05 PM (428) The Nuclear Orphan Receptors NR4A as Therapeutic Target in Pulmonary Arterial Hypertension; X. Nie, W. Mao, J. Tan, Y. Dai, J. Chen. Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China

6:10 PM (429) Right Ventricle on Fire: Interleukin-6 Is Independently Associated with Right Ventricular Function in Pulmonary Arterial Hypertension; K. Prins¹, L. Rose¹, S. L. Archer², A. Sharma³, M. Pritzker¹, T. Thenappan¹. ¹Medicine- Cardiology, University of Minnesota, Minneapolis, MN, ²Medicine- Cardiology, Queens University, Kinston, ON, Canada

6:15 PM (430) Doppler Echocardiography Provides a Reliable Estimate of Elevated Pulmonary Vascular Resistance in Patients with Advanced Lung and Liver Disease; J. Svetlichnaya, M. Manicardi, V. Selby, L. Klein, M. Janmohamed, T. De Marco. University of California San Francisco, San Francisco, CA

6:20 PM (431) Transendocardial CD34+ Cell Therapy Improves Right Ventricular Function in Dilated Cardiomyopathy Patients; S. Friliak¹, G. Poglajen¹, G. Zemljic¹, A. Cerar¹, M. Bervar¹, R. Okrajsek¹, M. Jakic¹, F. Haddad², B. Vrtovec¹. ¹Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, ²Stanford Cardiovascular Institute, Stanford, CA

6:25 PM (432) Should We Amplify Cardiac Response Criteria in Patients with Cardiac Light-Chain Amyloidosis Treated with Bortezomib?; J. Vázquez, A. Durante, F. Hernández, V. Moñivas Palomero, S. Mingo, I. Sayago, P. García Pavía, L. Alonso-Pulpoñ, J. Segovia Cubero. Cardiology, Hospital Puerta de Hierro, Madrid, Spain

6:30 PM (433) Beta Blocker Use in Patients with LVADs Is Associated with Lower proBNP and Is Not Associated with Heart Failure Hospitalizations or an Increase in Adverse Events; G. Vaidya, B. C. Salgado, J. Pillarellia, C. L. Dunbar-Matos, R. Vijayakrishnan, A. Lenneman, M. S. Slaughter, E. Birks, D. Abramov. Division of Cardiovascular Medicine, University of Louisville, Louisville, KY

Friday, April 7
6:35 PM (434) Painting Profiles of Ambulatory Advanced Heart Failure: A Report from the REVIVAL Registry; M. M. Kittleson, P. Shah, A. Lala, R. McLean, S. Pamboukian, D. Horstmanshof, J. Thibodeau, K. Shah, D. Lanfear, J. Teuteberg, W. Taddei-Peters, S. Khalatbari, L. Stevenson, D. Mann, K. Aaronson, G. Stewart, Cedars Sinai Hrt Inst, Los Angeles, CA, Inova Heart and Vascular Institute, Fairfax, VA, Mount Sinai Hospital, New York, NY, University of Pennsylvania, Philadelphia, PA, University of Alabama at Birmingham, Birmingham, AL, INTEGRIS Baptist Medical Center, Oklahoma City, OK, University of Texas Southwestern Medical Center, Dallas, TX, Virginia Commonwealth University, Richmond, VA, Henry Ford Hospital, Detroit, MI, University of Pittsburgh, Pittsburgh, PA, National Heart, Lung and Blood Institute, Bethesda, MD, University of Michigan, Ann Arbor, MI, Brigham and Women's Hospital, Boston, MA, Washington University School of Medicine, St. Louis, MO

5:45 PM - 6:45 PM
MINI ORAL SESSION 17: Progress in MCS Outcomes

Location:
Seaport F-H

Target Audience:
MCS, HF, HTX, ID, NHSAH, PHARM

Chairs:
Andre Vincentelli, MD, PhD, and Andrae Wasler, MD

5:45 PM (436) Inert Gas Rebreathing - A Helpful Tool in LVAD Patient Management: N. Reiss1, T. Schmidt1, S. Mommertz1, E. Deniz2, C. Feldmann2, S. Schulte-Eistrup1, D. Willemsen1, J. Schmitto. 1Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, 2Hannover Medical School, Hannover, Germany

5:50 PM (437) β-Blockers Use During Support with Continuous-Flow Left Ventricular Assist Device in Patients with and without Right Ventricular Dysfunction; M. Yin, A. Pekarek, K. Wittersheim, R. T. Cole, D. Gupta, R. Laskar, A. Smith, D. Vega, A. Morris. Emory University School of Medicine, Atlanta, GA

5:55 PM (438) Single Center Experience with “Lysis First” as Treatment Strategy of Device Thrombosis in the HeartWare HVAD; C. Heim, M. Konduweit, M. Weyand, R. Tandler. University of Erlangen Department of Cardiac Surgery, Erlangen, Germany

6:00 PM (439) Concomitant Valve Procedures Are Not Associated with Higher Perioperative Mortality; T. Sugiuara, C. Kurihara, M. Kawabori, W. E. Cohn, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Houston, TX

6:05 PM (440) Echocardiographic Predictors of Hemodynamics in Patients Supported with Left Ventricular Assist Devices; J. Grinstein1, E. Kruse1, S. Kalantari Tannenbaum1, D. Rodgers1, S. Adatya1, G. Sayer1, G. H. Kim1, N. Sarswat1, J. Raikhelkar1, V. Kagan1, H. Costantini1, D. Burkhoff2, V. Jeevanandarn1, R. Lang1, N. Uriel1. 1University of Chicago, Chicago, IL, 2Columbia University, New York, NY

6:10 PM (441) The Impact of Blood Pressure Control on the Development of Left Ventricular Distension with VA-ECMO: A Comparison of Vasodilation vs. Diuresis; J. Han1, H. Takayama1, D. Burkhoff2, M. L. Dickstein3. 1Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 2Division of Cardiology, Columbia University Medical Center, New York, NY, 3Division of Cardiothoracic Anesthesia, Columbia University Medical Center, New York, NY

6:15 PM (442) Novel Palliative Care Integration Program increases Days Alive and Out of Hospital and Reduces Inpatient Direct Costs Among Left Ventricular Assist Device Patients; S. Nakagawa1, J. M. Luna2, V. K. Topkara3, M. Yuzefpolskaya3, D. Vawdrey2, A. R. Garan3, H. Takayama4, K. Takeda4, P. C. Colombo3, Y. Naka4, C. D. Blinderman1. 1Adult Palliative Care Services, Department of Medicine, Columbia University Medical Center, New York, NY, 2Value Institute, NewYork-Presbyterian Hospital, New York, NY, 3Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY, 4Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY

6:20 PM (443) Radically Redesigned Approach to LVAD Adverse Event Management; M. Old Crow, S. Jones, N. Chelikani, M. El Banayosy, H. Setiadi, J. Long, D. Horstmannshof, K. Nelson. Advanced Cardiac Care, INTEGRIS Baptist Medical Center, Oklahoma City, OK

6:25 PM (444) The Anemic Stress Index - A Novel Index that Predicts Short and Long Term Mortality of Patients on Continuous Flow Ventricular Assist Devices; T. C. Hanff1, J. A. Mazurek1, E. W. Grandin2, A. Padegimas3, J. Howard4, R. Forde-McLean1, J. Wald1, M. A. Acker4, L. R. Goldberg1, P. Atluri1, J. E. Rame1, M. Jessup1, K. B. Margulies1, E. Y. Birati1. 1Cardiology, University of Pennsylvania, Philadelphia, PA, 2Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, 3Internal Medicine, University of Pennsylvania, Philadelphia, PA, 4Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

6:30 PM (445) First In Vitro Results of Local Pump Thrombus Lysis; E. Deniz1, C. Feldmann1, A. Stomps2, M. Avsar3, G. Dogan1, S. V. Rojas1, J. S. Hanke1, M. Ricklefs1, A. Haverich1, J. D. Schmitto. 1Department of Cardiothoracic-,
6:35 PM (446) LVAD Post-Implant Length of Stay Impacts Long Term Survival: An Intermacs Database Analysis; S. C. Silvestry1, S. M. Joseph2, S. L. Myers3, D. C. Naftel3, J. K. Kirklin4, S. Prasad5. 1Florida Hospital Transplant Institute, Orlando, FL, 2Center for Advanced Heart & Lung Disease, Baylor University Medical Center, Dallas, TX, 3Cardiovascular Thoracic Surgery Research, The University of Alabama at Birmingham, Birmingham, AL, 4Surgery, University of Alabama, Birmingham, AL, 5Surgery, University of Rochester, Rochester, NY

6:40 PM (447) Increased Risk of Bleeding Associated with VKORC1 Gene Polymorphism in Patients with Continuous Flow Left Ventricular Assist Devices (CF-LVAD); T. Alexy1, W. M. Schultz1, R. T. Cole1, S. R. Laskar1, A. Pekarek1, A. Duncan2, A. L. Smith1, D. J. Vega3, D. Q. Nguyen3, D. Gupta1. 1Cardiology, Emory University, School of Medicine, Atlanta, GA, 2Pathology, Emory University, School of Medicine, Atlanta, GA, 3Cardiothoracic Surgery, Emory University, School of Medicine, Atlanta, GA
5:45 PM - 6:45 PM
MINI ORAL SESSION 18: Patient Centered Outcomes in Advanced Heart and Lung Disease

Location:
Coronado A-C

Target Audience:
NHSAH, ALL

Chairs:
Maureen P. Flattery, RN, MS, NP, and Sabina De Geest, RN, PhD

5:45 PM (1095) **Quality of Life Outcomes Among Pediatric Lung Transplant Recipients**: T. Lazor¹, H. Grasemann², M. Solomon², S. J. Anthony¹. ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ²Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada

5:50 PM (449) **Is Lung Allocation Score Predictive of Survival Among COPD Lung Transplant Registrants and Recipients?**; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University, Baltimore, MD, ²Department of Medicine, Johns Hopkins University, Baltimore, MD

5:55 PM (450) **Upper Limb Rehabilitation After Lung Transplantation: A Randomised Controlled Trial**: L. M. Fuller¹, D. El-Ansary², B. Button¹, M. Corbett¹, G. Snell³, S. Marasco⁴, A. E. Holland¹. ¹Physiotherapy Department, Alfred Hospital, Melbourne, Australia, ²Faculty of Medicine, Dentistry & Health Sciences, Physiotherapy School, University of Melbourne, Melbourne, Australia, ³Lung Transplant Services, Alfred Hospital, Melbourne, Australia, ⁴Cardiothoracic Surgery Department, Alfred Hospital, Melbourne, Australia

6:00 PM (451) **Predictors for Peak Oxygen Uptake in De Novo Heart Transplant Recipients (the HITTS Study)**; K. Rold, M. Yardley, A. R. Authen, I. Grov, M. R. Kunzst, E. Bjørkelund, E. Gude, A. K. Andreassen, L. Gullesstad, K. Nytre. ¹Department of Cardiology, Oslo University Hospital, Oslo, Norway

6:05 PM (452) **Do LVAD Patients Need a Specific Diet to Control Weight?**; K. Vandersmissen¹, J. Driesen¹, K. Van den Bossche¹, W. Drooghe², S. Jacobs¹, L. Fresiello¹, F. Rega¹, K. Gerits¹, B. Meyns¹. ¹Department Cardiac Surgery, UZLeuven, Leuven, Belgium, ²Department of Cardiology, UZLeuven, Leuven, Belgium

6:10 PM (453) **Micronutrient Monitoring and Bone Health in Adults with Cystic Fibrosis Undergoing Lung Transplant**: G. L. Hubert¹, T. Tam Chung¹, C. Prosser², D. Lien³, J. Weinkauf³, N. Brown⁴, M. Goodvin⁵, K. Jackson¹, J. Tabak⁶, J. Salgado⁶, A. S. Alzaben⁶, D. R. Mager⁶. ¹Lung Transplant, University of Alberta Hospital, Alberta Health Services, Edmonton, AB, Canada, ²Laboratory Medicine, University of Alberta Hospital, Alberta Health Services, Edmonton, AB, Canada, ³Lung Transplant, Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Adult Cystic Fibrosis, Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Adult Cystic Fibrosis, University of Alberta Hospital, Alberta Health Services, Edmonton, AB, Canada, ⁶Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, AB, Canada

6:15 PM (454) **What Does First Person Authorization (FPA) Mean? Knowledge and Attitudes Among FPA Adults Rec: Brain Dead Donors (BDDs) and Controlled Donation After Circulatory Determination of Death (cDCDD)**

6:20 PM (455) **Patient and Clinician Perspectives on Usability and Acceptability of a Patient-Centered Decision Aid for Left Ventricular Assist Device Treatment**: K. M. Kostick¹, R. J. Volk², C. R. Bruce¹, S. A. McCurdy³, J. D. Estep⁴, J. S. Blumenthal-Barby¹. ¹Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, ²Department of Health Services Research, the M.D. Anderson Cancer Center, University of Texas, Houston, TX, ³School of Public Health, University of Texas, Houston, TX, ⁴Houston Methodist DeBakey Heart & Vascular Center and J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX

6:25 PM (456) **Most Survivors Are Glad to Have a VAD**: L. W. Stevenson¹, J. Lindenfeld², K. Grady³, J. Vader⁴, M. Givertz⁵, D. Naftel⁶, T. Baldwin⁶, S. Myers⁷, R. Kormos⁸, J. K. Kirklín⁸. ¹Cardiovascular Division, Brigham & Women's

1The Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai, New York, NY, 2University of Colorado at Denver, Denver, CO, 3Houston Methodist Research Institute, Houston, TX, 4University of Utah, Salt Lake City, UT, 5Cleveland Clinic Foundation, Cleveland, OH, 6Abington Memorial Hospital, Abington, PA, 7INTEGRIS Baptist Medical Center, Oklahoma City, OK, 8University of Texas Southwestern Medical Center, Dallas, TX, 9Virginia Commonwealth University, Richmond, VA, 10Henry Ford Hospital, Detroit, MI, 11University of Pittsburgh, Pittsburgh, PA, 12National Heart, Lung and Blood Institute, Bethesda, MD, 13University of Michigan, Ann Arbor, MI, 14Brigham and Women's Hospital, Boston, MA, 15Washington University School of Medicine, St. Louis, MO

6:35 PM (458) Does Functional Status at Listing and Time of Heart Transplant Influence Survival in Heart Transplant Recipients?; Y. Ravi1, E. Stock2, S. K. Lella3, J. V. Balasubramaniyan4, L. Copeland5, S. Emani6, C. B. Sai-Sudhakar1. 1Cardiac Surgery, Scott & White, Texas A&M, Temple, TX, 2Center for Applied Health Research, Veterans Affair, Perry Point, MD, 3College of Medicine, Texas A&M Health Science Centre, Temple, TX, 4Internal Medicine, Sri Ramachandra University, Chennai, India, 5Center for Applied Health Research, Scott & White, Texas A&M, Temple, TX, 6Internal Medicine, The Ohio State University, Columbus, OH

6:40 PM (459) Slow Gait Speed Linked to More Severe Disease but Not with Early Events in Ambulatory Advanced Heart Failure: Results from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry; A. V. Ambardekar1, J. Thibodeau2, A. DeVore3, M. Kittleson4, R. Forde-McLean5, M. Palardy6, M. Mountis7, L. Cadaret8, J. Teuteberg9, S. Pamboukian10, L. Stevenson11, R. Xie10, G. Stewart11. 1U Colorado, Aurora, CO, 2UTSW, Dallas, TX, 3Duke, Durham, NC, 4Cedars Sinai, Los Angeles, CA, 5U Pennsylvania, Philadelphia, PA, 6U Michigan, Ann Arbor, MI, 7Cleveland Clinic, Cleveland, OH, 8U Iowa, Iowa City, IA, 9U Pittsburgh, Pittsburgh, PA, 10UAB, Birmingham, AL, 11Brigham, Boston, MA
Saturday, April 08, 2017

7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 13: Mechanical Circulatory Support - The Interface of Design and Outcome

Location:
Grand Hall A

Target Audience:
MCS, BSTR, EEP, HF, HTX

Chairs:
Ulrich Steinseifer, PhD, and Robert L Kormos, MD

Session Summary: Despite the advance of mechanical circulatory support systems over the past decade they remain limited by the significant incidence of adverse events (AE). In this session approaches to understand and limit AE such as thrombosis, bleeding and infection will be addressed. Particularly, the role of system component interfaces, smart monitoring and alarms using pressure sensors and data mining techniques, and the “design thinking” paradigm for devices that embody multi-factorial challenges.

7:00 AM
**Interfaces and Mechanical Circulatory Support: Challenges and Opportunities for System and Outcome Improvement**
Marvin J Slepian, MD, University of Arizona, Tucson, AZ, USA

7:10 AM Q&A

7:15 AM
**Will Pressure Sensors Help in Making Smarter Pumps?**
Mark Slaughter, MD, University of Louisville, Louisville, KY, USA

7:25 AM Q&A

7:30 AM
**Anticipation of Adverse Events: Do the Data Speak For Themselves?**
Francesco Moscato, PhD, Medical University of Vienna, Vienna, Austria

7:40 AM Q&A

7:45 AM
**Design/Interconnected Thinking for Better Biomedical Devices**
J. Yasha Kresh, PhD, Drexel University College of Medicine, Philadelphia, PA, USA

7:55 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 14: The Tsunami of Adult Congenital Heart Disease (ACHD) Patients Who Need Advanced Therapies: Are We Prepared?

Location:
Grand Hall B

Target Audience:
HTX, HF, LTX, MCS, PEDS, PH

Chairs:
Heather J. Ross, MD, MHSc, FRCPC, and Sanem Nalbantgil, MD

Session Summary: A need exists for advanced therapies for Adult Congenital Heart Disease (ACHD) patients. The session will begin with the challenges of bringing ACHD patients to transplant. The session will also include talks on surgical planning and mechanical support options for these patients, accurate imaging evaluation, and treatment of pulmonary hypertension. We will discuss a team based approach to successful outcomes as well as dual organ transplantation and will end with a discussion of allocation in ACHD patients worldwide.

7:00 AM
How to Know When an Adult with Complex Congenital Heart Disease Needs Heart Transplantation
Heather J. Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada

7:15 AM Q&A

7:20 AM
Surgical Considerations for MCS and Heart Transplant ACHD
Martin Schweiger, MD, Children's Hospital, Zurich, Switzerland

7:35 AM Q&A

7:40 AM
Care of the ACHD Patient After MCS or Heart Transplant: The Challenge is Just Beginning
Jonathan Menachem, MD, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

7:55 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 15: Extracorporeal Photopheresis: Shedding Light on Rejection?

Location:
Grand Hall C

Target Audience:
LTX, BSTR, HTX, ID, NHSAH, PATH, PEDS, PHARM

Chairs:
Matthew R Morrell, MD, and Christian Benden, MD

Session Summary: This session will explore mechanisms of and clinical indications for extracorporeal photopheresis (ECP) with a goal to increase understanding of the possible benefits of ECP and adoption of this therapy in lung and heart transplant recipients.

7:00 AM
ECP: Everything Under the Sun
Jill Adamski, MD, PhD, Mayo Clinic Arizona, Phoenix, AZ, USA

7:17 AM Q&A

7:20 AM
ECP in Heart Transplantation: Have the Lights Gone Out?
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

7:37 AM Q&A

7:40 AM
ECP in Lung Transplantation: Light at the End of the Tunnel?
Mark Greer, MB Bch, Hannover Medical School, Hannover, Germany

7:57 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 16: Pregnant - Scared? So Are We.... Management of Pregnancy in Our Complex Patients

Location:
Seaport F-H

Target Audience:
PHARM, HTX, LTX, MCS, NHSAH, PEDS

Chairs:
Susan M Joseph, MD, and Christa Kirk, PharmD

Session Summary: Women of reproductive age account for over 1/3 of all SOT recipients. Most are advised to avoid pregnancy for several years post-transplant, if not altogether. However, as outcomes post-transplant continue to improve, more women are able to consider pregnancy. There are numerous risks to the transplant recipient, organ, and fetus. Hence, there is a great need for expertise in addressing family planning, fertility, contraception, and care during and after pregnancy.

7:00 AM
The Facts of Life: Pregnancy after Thoracic Organ Transplant
Robin Vos, MD, PhD, KU Leuven, Leuven, Belgium

7:10 AM Q&A

7:15 AM
Labor of Love: Pregnancy in the Heart Failure / Congenital Population
Leigh C Reardon, MD, UCLA Medical Center, Los Angeles, CA, USA

7:25 AM Q&A

7:30 AM
In the Mix: Orchestrating the Multidisciplinary Care of the Post-Transplant/MCS/Complex Congenital Pregnant Patient
Mary Canobbio, RN, FAAN, UCLA Medical Center, Los Angeles, CA, USA

7:40 AM Q&A

7:45 AM
Treating the Mother, Protecting the Baby: Drug Therapy During and After Pregnancy
Jennifer Eshelman, PharmD, Children's Hospital Colorado, Aurora, CO, USA

7:55 AM Q&A
7:00 AM - 8:00 AM
SUNRISE SYMPOSIUM 17: Living in a 'Bacterial' World: Microbiome in Thoracic Transplantation

Location:
Coronado A-C

Target Audience:
BSTR, ALL

Chairs:
Howard Eisen, MD, and Bryan Coburn, MD, PhD, FRCPC

Session Summary: The goal of this session is to explore the role of the microbiome in affecting posttransplant outcomes or in reflecting the extent of immunosuppression. Discussion will include an overview of the effect of the microbiome on health and disease followed by transplant specific considerations. Included in this is the question of whether changes in the bacterial or viral microbiome can be used to reflect the extent of immunosuppression, thus facilitating modulation of immunosuppression to improve outcomes.

7:00 AM
The Microbiome in Health and Disease
W. H. Wilson Tang, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

7:10 AM Q&A

7:15 AM
Microbiome in Transplantation
Maria-Luisa Alegre, MD PhD, University of Chicago, Chicago, IL, USA

7:25 AM Q&A

7:30 AM
The Microbiome and Immunosuppression in Heart Transplant
Kiran Khush, MD, MAS, Stanford University, Stanford, CA, USA

7:40 AM Q&A

7:45 AM
Microbiome in Lung transplantation and Gut-Lung Axis
Sangeeta M Bhorade, MD, Northwestern Memorial Hospital, Chicago, IL, USA

7:55 AM Q&A
8:00 AM - 9:30 AM
ORAL SESSION 41: The Rhythm is Going to Get You: EP Issues in MCS

Location:
Seaport A-E

Target Audience:
MCS, HF, NHSAH

Chairs:
Ayesha K. Hasan, MD, and Daniel Zimpfer, MD

8:00 AM (460) Cardiac Resynchronization Therapy Reduces Mortality and Cardiovascular Readmissions in Left Ventricular Assist Device Recipients; A. R. Garan1, X. Mai1, V. K. Topkara1, K. Takeda1, K. J. Clerkin1, R. Demmer1, M. Yuzefpolskaya1, H. Takayama1, Y. Naka1, J. Chyou2, H. M. Spotnitz1, N. Uriel1, J. Dizon1, P. C. Colombo1. 1Columbia University, New York, NY, 2SUNY Stonybrook, Stonybrook, NY, 3University of Chicago, Chicago, IL

8:01 AM (461) Survival Benefit of Implantable Cardioverter Defibrillator Therapy on Patients with Left Ventricular Assist Device; E. Simsek1, S. Nalbantgil1, E. Demir1, H. S. Kemal2, I. Mutlu3, P. Ozturk3, S. Ertugay3, C. Engin3, T. Yagdi3, M. Ozbaran3. 1Cardiology, Ege University School of Medicine, Izmir, Turkey, 2Cardiology, Near East University School of Medicine, Lefkosa, Cyprus, 3Cardiovascular Surgery, Ege University School of Medicine, Izmir, Turkey

8:30 AM (462) Impact of Cardiac Resynchronization Therapy (CRT) on Invasive Hemodynamics and Echocardiographic Parameters in Patients with Implanted Left Ventricular Assist Devices (LVADs); S. Adatya1, D. M. Tehrani1, N. Sarswat1, G. H. Kim1, J. Raikhelkar1, C. Juricek1, V. Kagan1, T. Ota1, D. Burkhoff2, G. Sayer1, V. Jeevanandam1, N. Uriel1. 1University of Chicago, Chicago, IL, 2Heartware International, Inc, Framingham, MA

8:45 AM (463) Right Ventricular Pacing Improves Functional Status and Quality of Life Compared to Biventricular Pacing in Left Ventricular Assist Device Patients; J. Grinstein1, D. Medvedofsky1, E. Flatley1, J. Moss2, D. Beiser1, S. Adata1, G. Sayer1, N. Sarswat1, J. Raikhelkar1, G. H. Kim1, V. Kagan1, W. Lee1, T. Ota1, V. Jeevanandam1, R. Lang1, N. Uriel1. 1University of Chicago, Chicago, IL, 2University of California San Francisco, San Francisco, CA

9:00 AM (464) Postoperative Atrial Fibrillation After Left Ventricular Assist Device Placement Increases Morbidity and Resource Utilization; R. B. Hawkins1, A. Guo1, J. Mehaffey1, C. Fonner2, A. Speir3, J. Rich2, M. Quader4, G. Allawadi1, L. Yarboro1. 1University of Virginia, Charlottesville, VA, 2Virginia Cardiac Services Quality Initiative, Falls Church, VA, 3INOVA Heart and Vascular Institute, Falls Church, VA, 4Virginia Commonwealth University, Charlottesville, VA

8:00 AM - 9:30 AM
ORAL SESSION 42: The Weighting Game: Impact of Obesity, Age, and Other Comorbidities in MCS

Location:
Grand Hall A

Target Audience:
MCS, HF, HTX, NHSAH

Chairs:
Theodoros Kofidis, MD, PhD, FRCS, and Brent C Lampert, DO

8:00 AM (466) Clinical Outcomes of Adults with Elevated Body Mass Index with Destination Therapy: An Analysis of INTERMACS Registry; A. Jaiswal\textsuperscript{1}, L. Myers\textsuperscript{2}, V. K. Topkara\textsuperscript{3}, P. C. Colombo\textsuperscript{3}, D. Baran\textsuperscript{4}, T. H. Le Jemtel\textsuperscript{1}. \textsuperscript{1}Cardiology, Tulane Heart and Vascular Institute, New Orleans, LA, \textsuperscript{2}Global Biostatistics and Data Science, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, \textsuperscript{3}Cardiology, Columbia University Medical Center-New York Presbyterian, New York, NY, \textsuperscript{4}Heart Transplantation, Newark Beth Israel Medical Center, Newark, NJ

8:15 AM (467) Impact of Morbid Obesity After Left Ventricular Assist Device Placement; L. Coyle, G. Yost, C. Gallagher, N. Graney, R. Siemeck, G. Bhat, A. Tatooles. Heart and Vascular Institute, Advocate Christ Medical Center, Oak Lawn, IL

8:30 AM (468) Factors Associated with Prolonged Survival in Destination Therapy LVAD Recipients; Y. Xia\textsuperscript{1}, S. Forest\textsuperscript{1}, P. Friedmann\textsuperscript{1}, L. Chou\textsuperscript{1}, S. Patel\textsuperscript{2}, U. Jorde\textsuperscript{3}, D. Goldstein\textsuperscript{1}. \textsuperscript{1}Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, \textsuperscript{2}Internal Medicine, Cardiology, Montefiore Medical Center, Bronx, NY, \textsuperscript{3}Medicine, Cardiology, Montefiore Medical Center, Bronx, NY

8:45 AM (469) How Old Is Too Old? The Influence of Advanced Age on VA-ECMO Outcomes; M. Salna\textsuperscript{1}, K. Takeda\textsuperscript{2}, P. Kurlansky\textsuperscript{2}, H. Ikegami\textsuperscript{2}, J. Han\textsuperscript{1}, S. Stein\textsuperscript{2}, V. Topkara\textsuperscript{3}, M. Yuzefpolskaya\textsuperscript{3}, P. C. Colombo\textsuperscript{3}, Y. Naka\textsuperscript{2}, A. R. Garan\textsuperscript{2}, H. Takayama\textsuperscript{2}. \textsuperscript{1}Columbia University College of Physicians and Surgeons, New York, NY, \textsuperscript{2}Surgery (Cardiothoracic), Columbia University Medical Center, New York, NY, \textsuperscript{3}Medicine (Cardiology), Columbia University Medical Center, New York, NY

9:00 AM (470) Proteinuria in Patients Receiving Left Ventricular Assist Devices Is Highly Associated with Renal Failure and Mortality; R. Muslem\textsuperscript{1}, K. Caliskan\textsuperscript{1}, S. Akin\textsuperscript{1}, D. A. Hesselink\textsuperscript{2}, G. Whitman\textsuperscript{3}, R. J. Tedford\textsuperscript{4}, A. J. Bogers\textsuperscript{5}, O. C. Manintveld\textsuperscript{1}, S. D. Russell\textsuperscript{4}. \textsuperscript{1}Cardiology, Erasmus MC, Rotterdam, Netherlands, \textsuperscript{2}Nephrology, Erasmus MC, Rotterdam, Netherlands, \textsuperscript{3}Cardiac Surgery, Johns Hopkins School of Medicine, Baltimore, MD, \textsuperscript{4}Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, \textsuperscript{5}Cardiac Surgery, Erasmus MC, Rotterdam, Netherlands

9:15 AM (471) Adverse Events After Device Implantation Are More Common in Obese Patients: An IMACS Registry Analysis; S. J. Forest\textsuperscript{1}, R. Xie\textsuperscript{2}, J. K. Kirklin\textsuperscript{2}, J. A. Cowger\textsuperscript{3}, Y. Xia\textsuperscript{1}, A. I. Dipchand\textsuperscript{1}, C. Shivathanan\textsuperscript{5}, C. Merry\textsuperscript{6}, L. H. Lund\textsuperscript{7}, R. Kormos\textsuperscript{8}, T. Nakatani\textsuperscript{9}, U. Jorde\textsuperscript{10}, D. J. Goldstein\textsuperscript{1}. \textsuperscript{1}Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY, \textsuperscript{2}The James and John Kirklin Institute for Research in Surgical Outcomes (KIRSO)/UAB, Birmingham, AL, \textsuperscript{3}St. Vincent Heart Center of Indiana, Indianapolis, IN, \textsuperscript{4}Hospital for Sick Children, Toronto, ON, Canada, \textsuperscript{5}National Heart Centre Singapore, Singapore, Singapore, \textsuperscript{6}Fiona Stanley Hospital, Perth, Australia, \textsuperscript{7}Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, \textsuperscript{8}Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, \textsuperscript{9}Maki Hospital, Osaka, Japan, \textsuperscript{10}Medicine, Montefiore Medical Center, Bronx, NY
8:00 AM - 9:30 AM
ORAL SESSION 43: In the Mix of Heart Failure

Location:
Grand Hall B

Target Audience:
HF, BSTR, NHSAH, PHARM

Chairs:
Ivan Knezevic, MD, and Michael M. Givertz, MD

8:00 AM (472) Exosome Signaling in Heart Failure; H. Basma, K. Dhar, D. R. Anderson, L. M. Smith, S. Rennard, B. D. Lowes. Internal Medicine, UNMC, OMAHA, NE

8:15 AM (473) The Effects of CD34+ Cell Therapy in Heart Failure with Preserved Ejection Fraction; B. Vrtovec1, G. Poglajen1, G. Zemljic1, S. Frljak1, A. Cerar1, R. Okrajsek1, M. Jaklic1, F. Haddad2. 1Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, 2Stanford Cardiovascular Institute, Stanford, CA

8:30 AM (474) Leukocyte Time-Dependent Biology and Outcomes in Advanced Heart Failure; G. Bondar1, M. Cadeiras1, N. Wisniewski1, A. Esmaeili1, G. Godoy1, J. Maque1, E. Chang1, M. Bakir1, S. Kupiec-Weglinski2, D. Chu1, T. Bao1, J. Hai1, R. Yee1, A. Li1, M. Rai1, D. Tran1, L. Madrigal1, R. Togashi1, P. Ping3, E. Reed4, M. Deng1. 1Medicine/Cardiology, David-Geffen Sch Med, Los Angeles, CA, 2Agriculture and Life Science, Cornell University, Ithaca, NY, 3Physiology, David-Geffen Sch Med, Los Angeles, CA, 4Pathology & Laboratory Medicine-Immunogenetics Center, David-Geffen Sch Med, Los Angeles, CA


9:00 AM (476) Abnormalities of Cardiolipin Synthesis and Remodeling in Heart Failure: A Cornerstone of Energy Deprivation; H. N. Sabbah. Henry Ford Health System, Detroit, MI

9:15 AM (477) Increased Right Ventricular Sympathetic Activity and Oxygen Consumption in Patients with Right Ventricular Dysfunction; A. Ahmadi, J. M. Renaud, S. Promislow, I. Burwash, G. Dwivedi, J. Zelt, R. A. deKemp, R. S. Beanlands, L. M. Mieleniczuk. University of Ottawa Heart Institute, Ottawa, ON, Canada
8:00 AM - 9:30 AM
ORAL SESSION 44: Optimizing Early Outcomes after Lung Transplantation

Location:
Grand Hall C

Target Audience:
LTX, BSTR, ID, PATH, PHARM

Chairs:
Hilary J Goldberg, MD, and Monique Malouf, FRACP

8:00 AM (478) Relationship of Early Lung Allograft Injury as Measured by Cell Free DNA with Donor and Recipient Characteristics; S. M. Pham1, S. Agbor-Enoh2, P. Shah3, I. Timofte4, S. Nathan5, J. Orens3, A. Brown5, S. Gorham5, K. Bhatti5, A. Marishta5, M. Jang2, Y. Yang6, U. Fidelii2, I. Tunc5, J. Zhu5, A. Iacono6, H. Valantine6. 1Surgery, University of Maryland, Baltimore, MD, 2NIH, Bethesda, MD, 3Johns Hopkins University, Baltimore, MD, 4Medicine, University of Maryland, Baltimore, MD, 5Inova, Fall Church, VA, 6University of Maryland, Baltimore, MD

8:15 AM (479) Cell-Free DNA in Human Ex-Vivo Lung Perfusate as a Potential Biomarker to Predict the Risk of Primary Graft Dysfunction (PGD) in Lung Transplantation; T. Kanou1, R. Zamel1, M. Chen1, D. Nakajima1, Y. Watanabe1, L. Ding1, S. Azad1, T. K. Waddell1, K. Nakahira2, A. M. Choi2, M. Cypel1, M. Liu1, S. Keshavjee1. 1Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, Toronto, ON, Canada, 2Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY

8:30 AM (483) Early CMV Management Post Lung Transplant(LTx): A 6-Year Review of Pre-Emptive Strategy for CMV; K. Santhanakrishnan, E. Karimi, N. Yonan, M. Alaloul, R. Venkateswaran, K. Heyes. Transplant Department, Wythenshawe Hospital, Manchester, United Kingdom

8:45 AM (481) Gene Expression Profiling of Bronchoalveolar Lavage Cells During Lung Allograft Acute Rejection; S. S. Weigt1, X. Wang1, V. Palchevskiy1, N. D. Patel1, D. J. Ross1, J. M. Reynolds2, P. Shah3, L. Singer4, M. Budev5, S. Palmer2, J. A. Belperio1. 1UCLA, Los Angeles, CA, 2Duke University, Durham, NC, 3Johns Hopkins, Baltimore, MD, 4University of Toronto, Toronto, ON, Canada, 5Cleveland Clinic, Cleveland, OH


8:00 AM - 9:30 AM
ORAL SESSION 45: Heart Transplant in Special Populations

Location:
Grand Hall D

Target Audience:
HTX, HF, MCS

Chairs:
Jacqueline M. Smits, MD, PhD, and Tobias Deuse, MD, PhD

8:00 AM (484) Heart Transplantation and Bridge with Mechanical Circulatory Support in Cardiac Sarcoidosis: An Analysis of the UNOS Registry; T. C. Crawford¹, J. T. Magruder¹, J. Grimm¹, A. Suarez Pierre¹, B. A. Houston², K. Mandal¹, K. J. Zehr¹, G. J. Whitman¹, R. J. Tedford³, S. D. Russell³, N. A. Gilotra¹. ¹Surgery, Johns Hopkins University, Baltimore, MD, ²Medicine, Medical University of South Carolina, Charleston, SC, ³Medicine, Johns Hopkins University, Baltimore, MD

8:15 AM (485) Survival After Heart Transplantation in Patients with Cardiac Sarcoidosis - A UNOS Registry Analysis; S. Madan¹, S. R. Patel¹, D. Sims¹, J. Shin¹, D. Goldstein², U. P. Jorde¹, O. Saeed¹. ¹Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, ²Cardiovascular and Thoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY

8:30 AM (486) Heart Transplantation in Muscular Dystrophy Patients: Is It a Viable Option?; R. Rizwan¹, J. L. Jefferies², R. Bryant III¹, G. A. Pettengill¹, T. D. Ryan², A. Lorts², C. Chin², F. Zafar¹, D. L. Morales¹. ¹Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

8:45 AM (487) The Effect of Pre-Heart Transplant Obesity on Post-Transplant Mortality: An Analysis of the ISHLT Registry Data; B. S. Doumouras¹, C. S. Fan², A. I. Dipchand², C. Manlhiot², J. Stehlik⁴, H. J. Ross¹, A. C. Alba¹. ¹Heart Failure and Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²CV Data Management Centre, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴University of Utah School of Medicine, Salt Lake City, UT

9:00 AM (488) Young African American Heart Transplant Recipients Have an Elevated Risk of Post-Transplant Mortality; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

8:00 AM - 9:30 AM
ORAL SESSION 46: Rogue One: A Graft Wars Story of Rejection and Tolerance

Location:
Seaport F-H

Target Audience:
BSTR, HF, HTX, LTX, PATH, PEDS, PHARM

Chairs:
Tereza Martinu, MD, PhD, and Stijn E Verleden, PhD

8:00 AM (490) Chronic Airway Fibrosis in Orthotopic Mouse Lung Transplantation Models - An Experimental Reappraisal; L. Dubs¹, Y. Yamada¹, J. Jang¹, T. Martinu², D. Kenkel³, K. Windirsch¹, I. Inci¹, B. Vanaudenaerde⁴, A. Boss³, W. Weder¹, W. Jungraithmayr¹. ¹Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²University of Toronto, Toronto, ON, Canada, ³Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ⁴Laboratory of Pneumology, Katholieke Universiteit Leuven, Leuven, Belgium

8:15 AM (491) Ischemia Reperfusion Injury Augments Acute and Chronic Rejection and Alloimmune-Dependent Intrapulmonary Lymphoid Neogenesis in a Mouse Orthotopic Lung Transplant Model; T. Watanabe¹, T. Martinu¹, H. Oishi², M. Horie³, D. Hwang¹, Z. Guan¹, M. Liu¹, S. Keshavjee¹, S. Juvet¹. ¹Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, ²Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, ³Cardiothoracic Division, Department of Medical Imaging, Time Resolved Imaging and Image Optimization, University Health Network, Toronto, ON, Canada

8:30 AM (492) Linking Chronic Lung Allograft Dysfunction with Early Immunologic Events in a Humanized Mouse Model; T. Siemeni¹, A. Knöfel¹, F. Ius¹, K. Jansson¹, J. Salman¹, W. Sommer¹, M. Avsar¹, C. Kühn¹, C. Falk², A. Haverich¹, G. Warnecke¹. ¹Hannover HTTG, Hannover, Germany, ²Institute of Transplant Immunology, Hannover, Germany

8:45 AM (493) Selective Reprogramming and Recapitulation of CD4 and CD8 T Cells in the Neonate to Induce Tolerance to Heart Transplants; R. A. Bascom, K. Tao, L. J. West. University of Alberta, Edmonton, AB, Canada

9:00 AM (494) Two Months Delayed Induction of Mixed Chimerism After Heart and Kidney Cotransplantation in Nonhuman Primates; K. Huh¹, W. Sommer¹, K. A. Robinson¹, X. Wu¹, J. T. Paster¹, I. Hanekamp¹, A. Dehndadi¹, T. Kawai¹, R. N. Smith², R. Colvin³, G. Benichou¹, J. Madsen¹. ¹Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Boston, MA, ²Department of Pathology, Massachusetts General Hospital, Boston, MA, ³Center for Transplantation Sciences, Department of Pathology, Massachusetts General Hospital, Boston, MA

9:15 AM (495) Generating Hypoimmunogenic Murine Induced Pluripotent Stem Cells by the Disruption of beta-2-Microglobulin; X. Hu¹, T. Deuse², N. Kooreman³, M. Alawi⁴, G. Tedashvili¹, H. Reichenspurner⁵, S. Schrepfer¹. ¹Surgery, TSI Lab, UCSF, San Francisco, CA, ²CT Surgery, UCSF, San Francisco, CA, ³Cardiovascular Medicine, Stanford University, Stanford, CA, ⁴Heinrich Pette, UKE, Hamburg, Germany, ⁵Cardiovascular Surgery, UHZ, Hamburg, Germany
9:45 AM - 11:45 AM
PLENARY SESSION

Location:
Seaport A-E

Target Audience:
ALL

Chairs:
Andrew J Fisher, PhD FRCP, and Christian Benden, MD FCCP

9:45 AM Awards Presentations

10:15 AM
Using the Financial Markets to Fund Early-Stage Drug Development
Roger M Stein, PhD, MIT Laboratory for Financial Engineering, Boston, MA, USA

10:40 AM (496) Advanced Therapy Utilization and Survival in Ambulatory Patients with Advanced Heart Failure: Results from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry; A. V. Ambardekar¹, M. Kittleson², M. Palardy³, M. Mountis⁴, R. Forde-McLean⁵, A. DeVore⁶, S. Pamboukian⁷, J. Thibodeau⁸, J. Teuteberg⁹, L. Cadaret¹⁰, R. Xie¹¹, L. Stevenson¹¹, G. Stewart¹¹, ¹U Colorado, Aurora, CO, ²Cedars, Los Angeles, CA, ³U Michigan, Ann Arbor, MI, ⁴Cleveland Clinic, Cleveland, OH, ⁵U Penn, Philadelphia, PA, ⁶Duke, Durham, NC, ⁷UAB, Birmingham, AL, ⁸UTSW, Dallas, TX, ⁹U Pitt, Pittsburgh, PA, ¹⁰U Iowa, Iowa City, IA, ¹¹Brigham, Boston, MA

10:55 AM
Interactive Discussant
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

11:00 AM
PRESIDENT’S DEBATE (PRO): We Must Take Greater Risks for the Sake of Our Patients!
Lori J West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

11:20 AM
PRESIDENT’S DEBATE (CON): We Must Take Greater Risks for the Sake of Our Patients!
Allan R Glanville, MBBS, MD, FRACP, St. Vincent's Hospital, Sydney, Australia
12:00 PM - 1:30 PM  
ORAL SESSION 47: Not the Usual Suspects: Driving Outcomes in MCS  

Location:  
Seaport A-E  

Target Audience:  
MCS, HF, HTX, NHSAH  

Chairs:  
Markus Johannes Barten, MD, PhD, and Maria M. Mountis, DO  

12:00 PM (497) The Effects of Patient Blood Pressure on the Occurrence of Serious Adverse Events in the ENDURANCE Trial; J. A. Cowger1, J. G. Rogers2, C. A. Milano2, J. J. Teuteberg3, N. A. Mokadam4, E. J. Birks5, S. W. Boyce6, K. D. Aaronson7, F. D. Pagani7. 1St. Vincent Heart Center, Indianapolis, IN, 2Duke University Medical Center, Durham, NC, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Washington, Seattle, WA, 5University of Louisville, Louisville, KY, 6MedStar Health, Washington, DC, 7University of Michigan Medical Center, Ann Arbor, IL  

12:15 PM (498) How Does the Pulse Pressure Impact on Cerebral Autoregulation Between Axial and Centrifugal LVAD?; M. Ono1, S. K. Singh2, K. K. Kibler1, B. R. Easley1, O. H. Frazier1, K. M. Brady1. 1Baylor College of Medicine, Houston, TX, 2Brigham & Women's Hospital, Boston, MA  

12:30 PM (499) The Hemodynamic Effects of Intravascular Ventricular Assist System (iVAS) in Advanced Heart Failure Patients Awaiting Heart Transplant; V. Jeevanandam1, D. Onsager1, T. Song1, B. Chung2, T. Ota1, C. Juricek1, T. Lammy1, N. Uriel3. 1CT Surgery, University of Chicago, Chicago, IL, 2University of Chicago, Chicago, IL, 3Cardiology, University of Chicago, Chicago, IL  

12:45 PM (500) Temporal Patterns of Adverse Events (AE) Occurring within 60 Days of LVAD Implantation: The Concept of the AE Cascade; J. O. Larsen1, A. D. Althouse2, J. J. Teuteberg3, C. M. Sciortino4, C. V. Nikas1, L. F. Lagazzi5, M. S. Sharbaugh6, S. U. Iturra1, N. M. Kunz2, E. M. Dunn2, K. L. Lockard2, R. L. Kormos4. 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA  

1:00 PM (501) Sex-Specific Outcome Disparities in Patients Receiving Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis; V. Blumer, R. Mendirichaga, S. Chaparro. University of Miami, Miami, FL  

1:15 PM (502) A Multi-Institutional Study of Mechanical Circulatory Support in Adult Congenital Heart Disease: Is This an Effective Therapy?; A. M. Cedars1, C. Vanderpluym2, D. Koehl3, R. Cantor3, J. K. Kirklin4. 1Cardiology, Baylor University Medical Center, Dallas, TX, 2Cardiology, Boston Children’s Hospital, Boston, MA, 3Kirklin Institute for Research in Surgical Outcomes, University of Alabama Birmingham, Birmingham, AL, 4Cardiothoracic Surgery, University of Alabama Birmingham, Birmingham, AL
12:00 PM - 1:30 PM
Location: Grand Hall A

Target Audience: MCS, HF, NHSAH

Chairs: Jennifer A. Beckman, MSN-FNP, RN, CHFN, and Samer S Najjar, MD

12:00 PM (503) Health-Related Quality of Life and Treatment Preferences in Ambulatory Heart Failure - Results from the REVIVAL Study: J. Stehlik1, M. Mountis2, D. Haas3, M. Palarzy4, A. Ambardekar5, J. Estep6, G. Ewald7, S. Russell8, S. Robinson9, U. Jorde10, N. Jeffries11, C. Spino4, J. T. Baldwin11, D. Mann7, G. Stewart12, K. Aaronson4. for the REVIVAL Investigators1. 1University of Utah School of Medicine, Salt Lake City, UT, 2Cleveland Clinic Foundation, Cleveland, OH, 3Abington Memorial Hospital, Abington, PA, 4University of Michigan, Ann Arbor, MI, 5University of Colorado, Denver, CO, 6Houston Methodist Research Institute, Houston, TX, 7Washington University School of Medicine, St. Louis, MO, 8The Johns Hopkins University School of Medicine, Baltimore, MD, 9University of Maryland, Baltimore, MD, 10Montefiore Medical Center, New York City, NY, 11National Heart, Lung and Blood Institute, Bethesda, MD, 12Brigham and Women's Hospital, Boston, MA

12:15 PM (504) Glad to Have a VAD Across Intermacs Profiles: F. Pagani1, M. Kittleson2, G. Stewart3, A. DeVore4, M. Brinkley5, S. Myers6, M. Miller6, D. Nattel6, J. J. Teuteberg7, L. W. Stevenson7, 1Cardiac Surgery, University of Michigan, Ann Arbor, MI, 2Brigham & Women's Hospital, Boston, MA, 3Cardiovascular Medicine, Brigham & Women's Hospital, Boston, MA, 4Cardiology, Duke University Medical Center, Durham, NC, 5Cardiology, Vanderbilt Medical Center, Nashville, TN, 6Cardiac Surgery, University of Alabama at Birmingham, Birmingham, AL, 7National Heart Lung and Blood Institute, Bethesda, MD, 8Cardiology, University of Pittsburgh, Pittsburg, PA

12:30 PM (505) Destination Therapy: Targeting & Refining Advance Care Planning: J. Woodburn1, L. L. Staley1, S. E. Wordingham2, J. Spadafore1, E. Boldea1, H. M. Ross1, D. E. Steidley3, O. E. Pajaro1. 1Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, 2Palliative Medicine, Mayo Clinic, Phoenix, AZ, 3Cardiology/Transplant, Mayo Clinic, Phoenix, AZ


1:00 PM (507) Reducing 30-Day Hospital Readmission Rate in Left Ventricular Assist Device Patients with a Structured Readmission Improvement Plan: D. B. Sims1, A. Luke2, S. Rangasamy1, E. Borukhov2, O. Saeed1, S. Murthy1, S. Patel1, J. J. Shin1, D. J. Goldstein2, U. P. Jorde1. 1Cardiology, Montefiore Medical Center, New York, NY, 2Cardiovascular and Thoracic Surgery, Montefiore Medical Center, New York, NY

1:15 PM (508) Impact of Patient Distance from VAD Implanting Center on Outcomes: J. A. Cowger1, P. Shah2, R. Singh3, K. D. Aaronson4, F. D. Pagani5, J. Stulak6, S. M. Dunlay7, T. F. Dardas8, N. A. Mokadam9, C. T. Salerno10, A. Ravichandran11. 1St. Vincent Heart Center of Indiana, Carmel, IN, 2Cardiovascular Medicine, Inova Heart & Vascular Institute, Falls Church, VA, 3Surgery, Inova Heart & Vascular Institute, Falls Church, VA, 4Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 5Cardiac Surgery, University of Michigan, Ann Arbor, MI, 6Cardiac Surgery, Mayo Clinic, Rochester, MN, 7Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 8Cardiovascular Medicine, University of Washington, Seattle, WA, 9Cardiovascular Surgery, University of Washington, Seattle, WA, 10Cardiac Surgery, St. Vincent Heart Center of Indiana, Carmel, IN, 11Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN
12:00 PM - 1:30 PM
ORAL SESSION 49: Antibodies and Other Determinants of Cardiac Rejection: Let's ROCK and Rho

Location:
Grand Hall B

Target Audience:
HTX, BSTR, EEP, PEDS, PHARM

Chairs:
Jignesh K. Patel, MD, PhD, and Catherine M. Murks, PhD, APN

12:00 PM (509) The Incidence of Donor-Specific Antibody in the Presence of Biopsy-Proven Antibody-Mediated Rejection After Heart Transplantation; S. Sana, J. Patel, M. Kittleson, T. Aintablian, M. Rafiei, D. Luthringer, X. Zhang, N. Reinsmoen, L. Czer. Cedars-Sinai Heart Institute, Los Angeles, CA


12:30 PM (511) Pre-Transplant Donor-Recipient Characteristics and the Relationship to Early Cardiac Allograft Injury Measured by Cell-Free DNA; P. Shah1, S. Agbor-Enoh2, A. Ulyanov3, S. Gorham2, U. Fidelis2, I. Tunc2, J. Zhu2, M. Jang2, Y. Yang2, K. Bhatti2, A. Marishta2, M. E. Rodrigo4, S. M. Pham5, K. B. Shah6, S. D. Russell7, E. Feller8, H. A. Valantine2. 1Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, 2Laboratory of Transplantation Genomics, NHLBI, Bethesda, MD, 3Bioinformatics, Inova Translational Medicine Institute, Falls Church, VA, 4Heart Failure and Transplantation, Washington Hospital Center, Washington, DC, 5Cardiothoracic Surgery, University of Maryland, Baltimore, MD, 6Cardiovascular Medicine, Johns Hopkins University, Baltimore, MD, 7Cardiovascular Medicine, University of Maryland, Baltimore, MD

12:45 PM (512) Identification and Validation of Non-HLA Antibodies in Cardiac Allograft Rejection; C. Butler1, N. Jiang2, P. Rao1, Y. Zheng1, D. Gjertson1, Q. Zhang1, M. Cadeiras1, M. Deng1, B. Ray2, E. Reed1. 1UCLA, Los Angeles, CA, 2Immucor, Inc., Stamford, CT

1:00 PM (513) Combined Heart and Liver Transplantation in Highly Sensitized Patients: Protection of the Cardiac Allograft from Antibody Mediated Rejection by Initial Liver Implantation; R. C. Daly, N. L. Pereira, T. Taner, M. J. Gandhi, J. K. Heimbach, J. A. Dearani, B. S. Edwards, S. S. Kushwaha. Mayo Clinic, Rochester, MN

12:00 PM - 1:30 PM
ORAL SESSION 50: Influencing Long-term Outcomes in Lung Transplantation

Location:
Grand Hall C

Target Audience:
LTX, BSTR, ID, NHSAH, PEDS, PHARM

Chairs:
Jason D Christie, MD, and Johanna M Kwakkel-van Erp, MD, PhD

12:00 PM (515) A Study of QuantiFERON-CMV-Directed CMV Prophylaxis versus Standard-of-Care to Reduce Late CMV Reactivation Following Lung Transplantation; G. P. Westall, Y. Cristiano, A. Peleg, M. Paraskeva, B. Levvey, H. Whitford, G. Snell. Alfred Hospital, Melbourne, Australia

12:15 PM (516) Regulation of KLRG1 Gene Expression by T-bet Correlates with Human Cytomegalovirus-Specific CD8+ T Cells Effector Function; A. Hoji1, I. Popescu1, M. Pipeling1, H. Mannem2, J. McDyer1. 1UPMC, Pittsburgh, PA, 2UVA, Charlottesville, VA

12:30 PM (517) Single Nucleotide Polymorphism in a Gene Involved in Mycophenolic Acid Metabolism Is Linked to Survival Post-Lung Transplantation; L. K. Tague1, D. Byers1, R. Hachem1, A. Gelman2. 1Internal Medicine, Pulmonary and Critical Care Medicine, Washington University in St. Louis, Saint Louis, MO, 2Cardiothoracic Surgery, Washington University in St. Louis, Saint Louis, MO

12:45 PM (518) Basiliximab for CNI Holiday in Lung Transplant Recipients with Acute Kidney Injury; U. Goswami1, R. Z. Brown2, K. D. Rudser2, M. I. Hertz1, J. R. Patil1, R. Tomic1, G. Loor3, J. M. Dunitz1. 1Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, MN, 2Biostatistics, University of Minnesota, Minneapolis, MN, 3Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

1:00 PM (519) Regional Variation in Lung Transplant Outcomes; W. M. Whited, J. R. Trivedi, M. P. Fox, V. H. van Berkel. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

1:15 PM (520) The Burden of Sinus Disease in Cystic Fibrosis Lung Transplant Recipients; L. Morlacchi1, M. Greer2, I. Tudorache3, F. Blasi1, T. Welte2, J. G. Mainz4, J. Gottlieb2. 1Department of Pathophysiology and Transplantation, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, 2Department of Respiratory Medicine, Lungentransplantation, Medizinische Hochschule Hannover, Hannover, Germany, 3Department of Cardiothoracic, Transplant and Vascular Surgery, Medizinische Hochschule Hannover, Hannover, Germany, 4Department of Paediatrics, CF-Center for Children and Adults, Jena University Hospital, Jena, Germany
12:00 PM - 1:30 PM
ORAL SESSION 51: Optimizing Outcomes After Heart Transplantation: Predictors and Risk Scores

Location:
Grand Hall D

Target Audience:
HTX, MCS, PATH

Chairs:
Shelley A Hall, MD, and George Javorsky, MBBS, FRACP

12:00 PM (521) Is the ISHLT-Suggested Inotrope Score a Predictor of In-Hospital Mortality After Heart Transplantation?: M. Wright, K. Takeda, C. Mauro, P. Kurlansky, J. Han, L. Truby, M. Salna, V. Topkara, A. R. Garan, M. Yuzefpolskaya, P. Colombo, Y. Naka, M. Farr, H. Takayama. Columbia University Medical Center, New York, NY

12:15 PM (522) GIMVECH: A Novel Risk Score for Stroke in the Perioperative Post Transplant Period: N. Nair, S. Yang, E. Gongora. Cardiology, Texas Tech Health Sciences Center, Lubbock, TX


1:15 PM (526) High-Risk and Low-Risk Donor/Recipient Characteristics and 90-Day Transplant Outcomes in LVAD versus Standard Recipients: M. Urban, N. Robinson-Smith, A. Woods, S. Schueler, G. Parry, G. MacGowan. Freeman Hospital, Newcastle upon Tyne, United Kingdom
ORAL SESSION 52: Does Size Matter? Center Volume, Urgency Status and Managing Complications

Location: Seaport F-H

Target Audience: EEP, HF, HTX, LTX, MCS, NHSAH, PEDS, PHARM

Chairs: Axel Rahmel, MD, and Jonathan P Singer, MD, MS

12:00 PM (527) Benefits of Specialized Thoracic Adapted Recovery (STAR) Team Model for Heart and Lung Transplantation; H. A. Tetteh1, P. Brandenhoff2, R. S. Higgins3. 1Department of Surgery, Uniformed Services University, Bethesda, MD, 2Department of Surgery, University of California San Francisco, San Francisco, CA, 3Department of Surgery, Johns Hopkins University, Baltimore, MD

12:15 PM (528) Should Heart Transplantation in High Risk Recipients Be Performed in High Volume Centers?; C. Legeai1, O. Bastien1, C. Jasseron1, C. Cantrelle1, S. Varnous2, L. Sebbag3, A. Belin4, R. Dorent5. 1Agence de la Biomédecine, Saint-Denis, France, 2Hôpital Pitié-Salpêtrière, Paris, France, 3CHU Lyon, Lyon, France, 4CHU Caen, Caen, France

12:30 PM (529) Effect of Broader Geographic Sharing of Donor Lungs on Regional Waitlist (WL) Mortality and Transplant Center Volume; J. Mooney1, L. Chhatwani1, J. Boyd2, G. S. Dhillon1. 1Medicine, Stanford University School of Medicine, Stanford, CA, 2Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA

12:45 PM (530) Use of Urgent Statuses to List Adult Heart Transplant Candidates Is Increasing; W. Parker1, M. Churpek1, S. Fedson2, E. Garrity1. 1Pulmonary and Critical Care, University of Chicago Medicine, Chicago, IL, 2Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX

1:00 PM (531) CANCELLED

1:15 PM (532) The Impact of Center VAD Operative Volumes on Outcomes After VAD Implant; J. A. Cowger1, J. M. Stulak2, P. Shah3, T. F. Dardas4, F. D. Pagan5, S. M. Dunlay6, K. D. Aaronson7, R. Singh8, N. A. Mokadam9, S. Maltais10, J. K. Kirklin11, C. T. Salerno12. 1Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN, 2Surgery, Mayo Clinic, Rochester, MN, 3Cardiovascular Medicine, Inova Heart & Vascular Institute, Fairfax, VA, 4Cardiovascular Medicine, University of Washington, Seattle, WA, 5Cardiac Surgery, University of Michigan, Ann Arbor, MI, 6Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 7Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 8Cardiovascular Medicine, Inova Heart & Vascular Institute, Falls Church, VA, 9Cardiovascular Surgery, University of Washington, Seattle, WA, 10Cardiac Surgery, Mayo Clinic, Rochester, MN, 11Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, 12Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN
8:00 AM - 9:30 AM
ORAL SESSION 53: Getting to the Heart of the Matter: Psychosocial Factors Predict Outcomes in Transplant and MCS

Location:
Coronado A-C

Target Audience:
NHSAA, ALL

Chairs:
Karen C. Uzark, PhD, PNP, and Kevin C Carney, MSN, CRNP, CCTC

(533) WITHDRAWN

12:00 PM (243) **Social and Clinical Characteristics Associated with Increased Short Term Mortality in Non-Inotrope Dependent Patients Undergoing Left Ventricular Assist Device Therapy: Results from InterMACS**; S. M. Joseph, R. L. Kormos, A. Althouse, J. Teuteberg, A. Cowger. Baylor University Medical Center, Dallas, TX, Surgery, University of Pittsburgh, Pittsburgh, PA, Interneal Medicine, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, St Vincent Medical Center, Indianapolis, IN


12:45 PM (536) **The Impact of Pre-LVAD Psychosocial Evaluations on Post-LVAD Outcomes**; M. Sobhanian, M. Converse, N. Patel, A. Mardis, D. Taber, B. Houston, B. Ramu, E. Serber, A. Agyemang, D. Heyward, W. Uber, H. Meadows. Medical University of South Carolina, Charleston, SC

1:00 PM (537) **Cognitive Function: A Significant Predictor of Quality of Life in Adults with an Implantable Ventricular Assist Device**; J. M. Casida, J. J. Yang, H. Craddock, P. Combs. School of Nursing, University of Michigan, Ann Arbor, MI, Heart Failure/Mechanical Circulatory Support, Washington University, Saint Louis, MO, VAD/Heart Failure, Jewish Hospital, Louisville, KY

1:15 PM (538) **Individual and Dyad Determinants of Patient Quality of Life and Caregiver Strain in Ventricular Assist Device Therapy**; J. T. Bidwell, J. O. Mudd, K. S. Lyons, K. L. Grady, J. M. Gelow, S. O. Hiatt, C. V. Chien, C. S. Lee. Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, School of Nursing, Oregon Health & Science University, Portland, OR, Feinberg School of Medicine, Northwestern University, Chicago, IL
Poster Session 1
Wednesday, April 05, 2017
6:15 PM - 7:15 PM

NOTE: Poster presenters and discussants will be present during the evening poster viewing session from 6:15 PM – 7:15 PM.

HEART FAILURE
(Seaport Foyer)

Poster Discussants: Maria Crespo-Leiro, MD (Spain), Savitri Fedson, MD (USA), Robert Gordon, MD (USA), George Javorsky, MBBS, FRACP (Australia), Catherine Murks, PhD, APN (USA), Sunu Thomas, MD (USA)

(539) Racial Differences in Receipt of Care by a Cardiologist During a Critical Heart Failure Admission; K. Breathett1, W. G. Liu2, L. A. Allen3, S. L. Daugherty1, I. V. Blair4, J. Jones4, G. K. Grunwald5, M. Moss5, T. H. Kiser6, E. Burnham6, R. W. Vandervier5, B. Clark5, E. F. Lewis6, S. Mazimba7, P. M. Ho6, P. Peterson9. 1Division of Cardiology, University of Colorado, Aurora, CO, 2Veteran Affairs Eastern Colorado Health Care System, Denver, CO, 3Division of Psychology and Neuroscience, University of Colorado, Boulder, CO, 4Department of Nursing, University of Colorado, Aurora, CO, 5Division of Pulmonary Sciences and Critical Care, University of Colorado, Aurora, CO, 6Division of Cardiology, Brigham and Women’s Hospital, Boston, MA, 7Division of Cardiology, University of Virginia Health System, Charlottesville, VA, 8Division of Cardiology, University of Colorado and Veteran Affairs Eastern Colorado Health Care System, Aurora, CO, 9Division of Cardiology, University of Colorado and Denver Health Medical Center, Aurora, CO

(540) Risk Factors Associated with Mortality in Broad HF Population; D. Weisshaar1, D. Lin2, L. Tucker3, J. Trammell1. 1Heart Transplant, Kaiser Permanente Northern California, Santa Clara, CA, 2Graduate Medical Education, Kaiser Permanente Northern California, Santa Clara, CA, 3Division of Research, Kaiser Permanente Northern California, Oakland, CA

(541) The REVIVAL Registry of Ambulatory Advanced Heart Failure: Baseline Characteristics; M. Palardy1, R. McLean2, S. Pamboukian3, M. M. Kittleton4, L. Warner Stevenson5, P. Shah6, G. Ewald7, S. Russell8, S. Robinson9, U. Jorde10, N. Jeffries11, C. Spino12, J. Baldwin13, D. L. Mann14, G. C. Stewart5, K. Aaronson1, F. REVIVAL Investigators. 1University of Michigan, Ann Arbor, MI, 2University of Pennsylvania, Philadelphia, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4Cedars-Sinai Heart Institute, Beverly Hills, CA, 5Brigham and Women’s Hospital, Boston, MA, 6Inova Heart and Vascular Institute, Falls Church, VA, 7Washington University School of Medicine, St. Louis, MO, 8The Johns Hopkins University School of Medicine, Baltimore, MD, 9University of Maryland, College Park, MD, 10Montefiore Medical Center, Bronx, NY, 11National Heart, Lung and Blood Institute, Bethesda, MD, 12Biostatistics Department, University of Michigan, Ann Arbor, MI, 13National Heart, Lung, and Blood Institute, Bethesda, MD, 14Washington University, St. Louis, MO

(542) Impact of Preoperative Extracorporeal Membrane Oxygenation Apply on Heart Transplantation; S. Lee, Y. Youn, H. Joo, J. Kim. Severance Cardiovascular Hospital, Seoul, Korea, Republic of

(543) Impact of a Comprehensive Heart Failure Self-Care Review; G. Mentzer4, K. Packard2, R. Holcomb3, J. Stachura4, S. Lawler1, G. Montoya5, A. Wardyn6. 1Cardiovascular, Nebraska Heart Institute, Lincoln, NE, 2Pharmacy, Creighton University, Omaha, NE, 3Cardiovascular Research, Nebraska Heart Institute, Lincoln, NE, 4Cardiovascular, CHI Health St. Elizabeth, Lincoln, NE, 5Pharmacy, Creighton University, Lincoln, NE, 6Wesleyan University, Lincoln, NE

(544) Marital Status Predicts Hospital Length of Stay in Patients with Congestive Heart Failure Exacerbation; V. Kataria, N. Yamani, M. Alimohamed, A. Silver, N. Saha, B. Mohamedali. Rush University Medical Center, Chicago, IL


(546) High-Risk Heart Failure Patients Can Be Successfully Identified by an Automated Search Algorithm Using Electronic Health Records; S. Emani1, R. Buchanan2, S. Zaidi3, D. Selsky4, A. M. Lai5. 1Division of Cardiology, Ohio State University, Columbus, OH, 2Gevity, Inc, Toronto, ON, Canada, 3Gevity, Inc., Toronto, ON, Canada, 4Capsenta, Austin, TX, 5Institute for Informatics, Washington University in St. Louis, St. Louis, MO
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>547</td>
<td>Trends in Palliative Care in Inpatient Advanced Heart Failure After Initiation of a Dedicated Palliative Care Team</td>
<td>M. A. Chandrasekhar, S. Mohammad, K. Walker, G. Ruiz, H. Groninger</td>
<td>Internal Medicine, Medstar Washington Hospital Center, Washington, DC, Medstar Washington Hospital Center, Washington, DC</td>
</tr>
<tr>
<td>548</td>
<td>The Age Paradox in Survival Among Patients with Systolic Heart Failure on ‘Destination’ Inotropic Therapy</td>
<td>G. G. Sokos, K. Cherukuri, R. Agarwal, A. Raina</td>
<td>Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA</td>
</tr>
<tr>
<td>549</td>
<td>Noninvasive Assessment of Lung Fluid Percentage in Advanced Heart Failure Patients</td>
<td>S. Adatya, T. Imamura, G. H. Kim, G. Sayer, D. Rodgers, J. Raikherkar, A. Nguyen, B. Chung, N. Sarswat, R. Abbo, D. Burkhoff, N. Uriel</td>
<td>University of Chicago, Chicago, IL, Sensible Medical, Netanya, Israel, Department of Medicine, Columbia University, New York, NY</td>
</tr>
<tr>
<td>550</td>
<td>Implementation of an Informed Consent Process for Advanced Heart Failure Therapies: Defining the Population and Process</td>
<td>C. H. Fine, J. Gelow, J. Davis, J. Mudd, V. Herbi</td>
<td>Internal Medicine, Oregon Health and Science, Portland, OR, Knight Cardiovascular Institute, Oregon Health and Science, Portland, OR</td>
</tr>
<tr>
<td>554</td>
<td>Treatment with Sacubitril/Valsartan Regarding Evaluation for Heart Transplantation</td>
<td>F. M. Strangl, M. Rybczinski</td>
<td>Klinik für Allgemeine und Interventionelle Kardiologie, Universitäres Herzzentrum Hamburg, Hamburg, Germany</td>
</tr>
<tr>
<td>555</td>
<td>Right Internal Jugular Access Is an Alternative to Femoral Access for CardioMEMS Implantation</td>
<td>R. S. Lewis, L. Wang, K. J. Spinelli, J. D. Remick, J. Paulson, J. Chappell, J. Abraham</td>
<td>Center for Advanced Heart Disease, Providence Heart and Vascular Institute, Portland, OR, Medical Data Research Center, Providence Heart and Services, Portland, OR, Regional Research Center, Providence Heart and Services, Portland, OR, McKenzie Heart, Lung and Vascular Center, McKenzie-Williams Medical Center, Springfield, OR</td>
</tr>
<tr>
<td>556</td>
<td>Heart Transplantation or Mechanical Circulatory Support May Be Safely Deferred for Two Years in Patients with Suppressed Natriuretic Peptide Levels</td>
<td>G. Whittaker, A. Kydd, C. Lewis, J. Parameshwar, S. J. Pettit</td>
<td>School of Medical Education, King's College London, London, United Kingdom, Transplant Unit, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>557</td>
<td>Baseline Hemodynamic Indices of Mixed Pulmonary Hypertension Do Not Predict Pressure Reduction in Patients with Chronic Heart Failure Implanted with CardioMEMS HF Sensor</td>
<td>A. M. Wolfson, L. Saxon, L. Grazette, H. Nazeer, D. Shavelle, R. Jermyn</td>
<td>Cardiology, University of Southern California, Los Angeles, CA, Cardiology, Hofstra School of Medicine at Northwell Health, Hempstead, NY</td>
</tr>
<tr>
<td>558</td>
<td>Worsening Renal Function in Patients with Low Output Decompensated Heart Failure Is Associated with 1-Year Mortality</td>
<td>J. Tsay, B. Lampert, B. Whitson, R. Hasson, R. Emanzi, A. Hasan, A. Kilic, S. Smith</td>
<td>The Ohio State University, Columbus, OH</td>
</tr>
<tr>
<td>559</td>
<td>Clinical Risk Factors of Advanced Systolic Heart Failure in Hypertrophic Cardiomyopathy</td>
<td>S. J. Lee, K. H. Kim, H. J. Jang, S. K. Hong</td>
<td>Cardiology, Sejong General Hospital, Bucheon, Korea, Republic of</td>
</tr>
<tr>
<td>560</td>
<td>Frailty Does Not Increase The Risk of Adverse Outcomes Following a Hospitalization for Heart Failure Decompensation</td>
<td>J. G. Durero Posada, H. Baranek, C. Pendrith, M. McDonald, H. Ross, S. Bhatia</td>
<td>Cardiology, University Health Network, Toronto, ON, Canada, Institute for Health System's Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada, Cardiology, Women's College Hospital, Toronto, ON, Canada</td>
</tr>
<tr>
<td>561</td>
<td>Predictors of Survival in Patients with Cardiac Amyloidosis</td>
<td>Y. Moayedi, J. P. Duero, F. Foroutan, A. C. Alba, H. J. Ross, D. Delgado</td>
<td>Medicine, University of Toronto, Toronto, ON, Canada, Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada</td>
</tr>
<tr>
<td>562</td>
<td>Nutritional Characteristics of Patient with Chagas Cardiomyopathy with Decompensated Heart Failure</td>
<td>L. C. Tavares, H. F. Moreira, C. B. Terhoch, S. H. Lage, M. T. Oliveira Junior, E. A. Bocchi, V. S. Issa</td>
<td>Department of</td>
</tr>
</tbody>
</table>
Heart Failure, Heart Institute (InCor) do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Department of Cardiopneumology, Heart Institute (InCor) do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Emergency Unit, Heart Institute (InCor) do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Buenos Aires, Argentina, Argentina, Buenos Aires, Argentina, Facultad de Ingenieria, Universidad de Buenos Aires, Buenos Aires, Argentina, Lewis (USA), Veli K Topkara, MD (USA), Krisl, PharmD (USA), Bruno M Meiser, MD (Germany), Sane

(563) Does Heart Failure with a Lower Ejection Fraction Mean Higher Costs? Insights from Data Analytics Across a Large Health Care System; C. B. Link1, S. Koscumb2, P. Lynch2, R. Ramani1, M. Shullo1, O. Marroquin1, J. J. Teuteberg1. 1HVI, UPMC, Pittsburgh, PA, 2Department of Clinical Analytics, UPMC, Pittsburgh, PA

(564) Outcomes and Characteristics of Patients with Critical Cardiogenic Shock Admitted to a Quaternary Heart Failure Unit in the UK; P. S. Chaggar1, E. McKay1, P. Foden2, S. G. Williams1, J. Barnard1, N. Yonan1, R. Venkateswaran1, S. M. Shaw1. 1The Transplant Unit, University Hospital of South Manchester, Manchester, United Kingdom, 2Medical Statistics, University Hospital of South Manchester, Manchester, United Kingdom

(565) Peak Oxygen Consumption as a Prognostic Marker in Patients with Cardiac Amyloidosis; Y. Moayedi1, J. G. Duero Posada1, D. H. Delgado1, F. Foroutan2, T. Schofield1, H. J. Ross1, A. C. Alba1. 1Medicine, University of Toronto, Toronto, ON, Canada, 2Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

(566) Predictors of Survival in Critical Cardiogenic Shock Admissions to a Quaternary Heart Failure Unit in the UK; P. M. Chaggar, E. McKay, S. G. Williams, J. Barnard, N. Yonan, R. Venkateswaran, S. M. Shaw. The Transplant Unit, University Hospital of South Manchester, Manchester, United Kingdom

(567) Frequency of Recovery and Relapse in Patients with Nonischemic Dilated Cardiomyopathy on Medical Therapy; K. Kim, S. Lee, S. Hong. Sejong General Hospital, Bucheon, Korea, Republic of

(568) Metabolomic Differences Between Patients with Advanced Heart Failure and Healthy Controls; B. Lima, E. Arning, C. Harmon, J. Felius, S. M. Joseph, G. V. Gonzalez-Stawinski, S. A. Hall, T. Bottiglieri. Baylor University Medical Center, Dallas, TX

(569) Peak Exercise Oxygen Consumption in Patients Hospitalized with Severe and Recurrent Heart Failure: Insights from ESCAPE; D. Cheeran1, M. Drazner1, W. Tang2, J. Grodin1. 1Cardiology, UT Southwestern, Dallas, TX, 2Cardiology, Cleveland Clinic, Cleveland, OH

(570) Utilizing Data Analytics to Identify Patients at Highest Risk of Heart Failure Readmission; C. B. Link1, S. Koscumb2, P. Lynch2, R. Ramani1, M. A. Shullo1, O. Marroquin1, J. J. Teuteberg1. 1HVI, UPMC, Pittsburgh, PA, 2Department of Clinical Analytics, UPMC, Pittsburgh, PA

(571) The Mortality of Cardiogenic Shock in Patients Admitted with Acute Decompensated Systolic Heart Failure; J. Kumar, C. Dillane, J. Plammenac, D. Schwartz. Temple University Hospital, Philadelphia, PA

(572) Endothelial Dysfunction in Heart Failure; A. Ali, R. Araujo-Gutierrez, A. S. Cruz-Solbes, C. Uribe, K. A. Youker, A. Bhimaraj. DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

HEART TRANSPLANTATION
(Seaport Foyer)

Poster Discussants: Sean Agbor-Enoh, MD (USA), Robert J Chen, MD, MPH (Taipei), Vlad Cotarlan, MD (USA), Jill C Kristl, PharmD (USA), Bruno M Meiser, MD (Germany), Sanem Nalbantgil, MD (Turkey), Susan Woodley Restaino, MD (USA), Veli K Topkara, MD (USA)

(573) Normothermic Ex Vivo Heart Perfusion in Argentina; L. G. Berra1, S. Berra2, M. L. Berra3, A. Irusta4, M. A. Lewis5. 1Heart Transplant Department, Hospital Garrahan Argentina, Buenos Aires, Argentina, 2Control Department - Facultad de Ingenieria, Universidad de Buenos Aires, Buenos Aires, Argentina, 3Clinical Department, Hospital Posadas Argentina, Buenos Aires, Argentina, 4Biomaterials, Lew Supplies and Innovations, Buenos Aires, Argentina, 5Medical Research, Lew Supplies and Innovations, Buenos Aires, Argentina

(574) Acute Cellular Rejection (ACR) ± Antibody Mediated Rejection (AMR) - Double Trouble or Overrated?; J. Goekler, A. Zuckermann, E. Osorio, K. Uyanik-Uenal, G. Lauffer, A. Aliabadi-Zuckermann. Medical University Vienna, Vienna, Austria
(575) Cytomegalovirus Infection and Rejection May Cause Myocardial Tissue Alterations Detectable at Cardiac Magnetic Resonance at One Year Follow-Up After Heart Transplant; P. Pedrotti¹, P. Campadello¹, G. Maschio¹, R. Facchetti², A. Milazzo², G. Quattrochi², M. P. Gagliardone¹, C. F. Russo¹, C. Giannattasio², M. Frigerio¹. ¹Dipartimento Cardiotoracovascolare A. De Gasperis, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, ²Dipartimento di Medicina Clinica e Prevenzione, Università degli Studi Milano Bicocca, Milan, Italy


(577) Stratifying MELD-XI by Cardiomyopathy; E. Adams, N. J. Jackson, A. Iyengar, L. C. Reardon. David Geffen School of Medicine, UCLA, Los Angeles, CA

(578) Factor VIII Administration in Cardiopulmonary Bypass and Its Impact on Thromboembolic Events and Post-Transplant Outcomes; R. Winstead¹, K. Pandya¹, J. Flynn¹, G. Davis¹, A. Sieg¹, M. Guqlin¹, G. Klink², R. Evans¹. ¹University of Kentucky Healthcare, Lexington, KY, ²University of Kentucky College of Pharmacy, Lexington, KY

(579) WITHDRAWN

(580) Changes and Relationship Between Invasive Hemodynamic and Brain Natriuretic Peptide During the Early to Late Phase of First Year After Heart Transplantation; T. S. Clemmensen, H. Eiskjaer, B. B. Logstrup, S. H. Poulsen. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark

(581) Bridge-to-Transplant LVAD or Primary Heart Transplantation in Young Patients? Both Offer Similar Mid-Term Survival; M. James, K. Takeda, P. Kurlansky, M. Ando, C. Lee, J. Han, M. Wright, V. Topkara, A. R. Garan, M. Yuzefpolskaya, M. Farr, P. Colomb, Y. Naka, H. Takayama. Columbia University Medical Center, New York, NY

(582) Results of Adult Heart Transplant While Supported on Extra-Corporeal Membrane Oxygenator Support: Evidence from a National Registry; S. Deo¹, M. Zacharias², R. Benatti², M. Robinson², C. Elamm³, B. Sareyuppyoglu¹, B. Medallion¹, Y. Elgudin¹, G. Oliveira², S. Park¹, E. Ginwalla². ¹Cardiac Surgery, University Hospitals, Cleveland, OH, ²Cardiology, University Hospitals, Cleveland, OH, ³Cardio, University Hospitals, Cleveland, OH


(584) Pre- and Post-Transplant Renal Dysfunction in Cardiac Transplant Recipients: A Retrospective Single Center Analysis; K. L. Freystaetter¹, G. A. Bohmig², A. Aliabadi-Zuckermann¹, A. Kaider³, R. Moayedifar¹, E. Osorio¹, K. Uyanik-Uenal¹, G. Laufer¹, A. Zuckermann¹. ¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ³Center for Medical Statistics, Informatics and Intelligent Systems, Section for Clinical Biometrics, Medical University of Vienna, Vienna, Austria

(585) Does a History of Malignancy Affect Long-Term Survival in Heart Transplant Recipients?; Y. Ravi¹, E. M. Stock², S. K. Lella³, J. V. Balasubramaniyan⁴, L. A. Nikloïdis⁵, L. M. Copeland⁶, S. Emani⁷, C. B. Sai-Sudhakar¹. ¹Cardiac Surgery, Scott & White, Texas A&M, Temple, TX, ²Center for Applied Health Research, Veterans Health System, Perry Point, MD, ³College of Medicine, Scott & White, Texas A&M, Temple, TX, ⁴Center for Applied Health Research, Scott & White, Texas A&M, Temple, TX, ⁵Division of Cardiology, Veterans Health System, Brighton, CO, ⁶Medical University of Kentucky College of Pharmacy, Lexington, KY, ⁷Department of Cardiology, Clinical Sciences, Lund University, Sweden

(586) Improved Quality, Increased Volume, and Better Outcomes Using a Specialized Thoracic Adapted Recovery (STAR) Model for Heart Transplantation; H. A. Tetteh¹, E. J. Molina², J. M. Block², C. C. Shults². ¹Department of Surgery, Uniformed Services University, Bethesda, MD, ²MedStar Heart Institute, MedStar Washington Hospital Center, Washington, DC

(587) L-Arginine and Methylarginines Prior to and After Heart Transplantation; J. Lundgren¹, A. Sandqvist², M. Hedeland³, U. Bondesson⁴, G. Wikström⁵, G. Rådegran¹. ¹Cardiology, Clinical Sciences, Lund University, Sweden,

(589) Clinical Usefulness of Cardiac Magnetic Resonance Imaging After Heart Transplantation; G. Poglajen, A. Cerar1, R. Zbacnik, G. Zemljii, S. Frijak1, J. Ksela, I. Knezevic, P. Berden, B. Vrtovec. Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia; Institute of Radiology, University Medical Center Ljubljana, Ljubljana, Slovenia; Dept. of Cardiovascular Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia

(590) Clinical Outcome and Hemodynamic Function Following the Use of Size-Mismatched Donor Hearts for Orthotopic Heart Transplantation; A. A. Ali, W. Watson, N. Nwaejike, A. Page, J. Schroder, C. Milano. Cardiac Surgery, Papworth Hospital, Cambridge, United Kingdom; Cardiothoracic Surgery, Duke University Medical Center, Durham, NC

(591) De Novo Donor Specific Antibodies (dnDSA) Is Associated with Cardiac Allograft Hypertrophy After Heart Transplantation (HT); N. L. Pereira, M. Jesus Valero, M. Wong, S. Kushwaha, B. Smith, W. Kremers, M. Gandhi, D. Richard. Mayo Clinic, Rochester, MN

(592) Very Long-Term Outcomes of Combined Heart-Lung Transplantation: A Single-Center 26-Year Experience and Current Strategies for Follow-Up; V. J. Gonzalez, E. G. Jernigan, P. D. Strassle, J. S. Nelson. University of North Carolina at Chapel Hill, Chapel Hill, NC; Cardiothoracic Surgery, Duke University Medical Center, Durham, NC


(594) Influence of the MELD-XI (Model of End-Stage Liver Disease Excluding INR) on Heart Transplant Outcomes; A. Loforte, M. Gremonini, M. Cefarelli, G. Jafrafrancesco, E. Pilato, L. Potena, M. Masetti, F. Grigioni, G. Marinelli. Cardiovascular Surgery and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy; Cardiothoracic Surgery and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy

(595) Influence of Pulmonary Vascular Resistance and Pulmonary Elastance on Postoperative Recovery Parameters After Heart Transplant an Analysis of 88 Cases; B. Komarakshi, R. Ratnaigiri, K. Suresh Rao, M. Tanguturu. Cardiac Surgery, Fortis Malar Hospital, Chennai, India; Cardiology, Fortis Malar Hospital, Chennai, India; Cardiac Anesthesia & Critical Care, Fortis Malar Hospital, Chennai, India; Cardiac Anesthesia & Critical Care, Fortis Malar Hospital, Chennai, India

(596) The Variance and Interplay Between Estimated Glomerular Filtration Rate Calculators and the Risk of Adverse Renal Outcomes After Heart Transplantation; M. Kahanda, H. Shah, E. Novak, J. Shuster, S. LaRue, J. Schilling. Internal Medicine, Barnes Jewish Hospital/Washington University in St. Louis, St. Louis, MO; Cardiology, Barnes Jewish Hospital/Washington University in St. Louis, St. Louis, MO

(597) Diagnostic of Acute Heart Transplant Rejection by Means of Speckle-Tracking Echocardiography; T. V. Stavenchuk, E. D. Kosmachova, I. A. Shelestova, K. O. Barbuhatty, V. A. Porhanov. Ultrasound Diagnostic, Regional Clinical Hospital n.a. professor S. V. Ochapovsky, Krasnodar, Russian Federation; Regional Clinical Hospital n.a. professor S. V. Ochapovsky, Krasnodar, Russian Federation

(598) The Impact of Race on Hemodynamics and Heart Transplant Outcomes; B. A. Smith, N. Bassi, C. Wright, S. Kalantari-Tannenbaum, J. Grinstein, G. Kim, G. Sayer, S. Adatya, N. Sarswat, S. Fedson, T. Ota, V. Jeewanandan, N. Uriel. Division of Cardiology, University of Chicago, Chicago, IL; Internal Medicine, University of Pennsylvania, Philadelphia, IL; Cardiac Surgery, University of Chicago, Chicago, IL

(599) Peak Exercise Oxygen Consumption and Heart Transplantation Outcomes; B. P. Dhakal, S. G. Al-Kindi, C. M. Bianco, M. Ginwalla, M. R. Robinson, G. Oliveira, C. ElAmm. Cardiology, Heart Failure and Transplant Division, University Hospitals Cleveland Medical Center, Cleveland, OH

Wednesday, April 5

(601) Impact of Pre-Transplant Pulmonary Hypertension Grading on Early- to Long-Term Hemodynamics, Right Ventricular Graft Function and Survival After Heart Transplantation. A. Lofforte¹, G. Barberio¹, G. Jafrancesco¹, M. Cefarelli², C. Mariani², L. Potena², M. Masetti², A. Russo², S. Martin Suarez¹, F. Grigioni², G. Marinelli¹. ¹Cardiovascular Surgery and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy, ²Cardiology and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy

(602) Incidence of Chronic Renal Dysfunction Prior to Cardiac Transplantation: A Retrospective Single Center Analysis. K. L. Freystaetter¹, G. A. Bohmig², A. Aliabadi-Zuckermann¹, R. Moayedifar¹, E. Osorio¹, K. Uyanik-Uenal¹, G. Laufer¹, A. Zuckermann¹. ¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria


(604) Gender Differences in Clinical Characteristics and Outcomes in Patients Undergoing Heart Transplantation. C. Baum¹, N. Ruebsamen¹, F. M. Ojeda¹, S. Blankenberg¹, H. Reichenspurner², R. B. Schnabel², A. M. Bernhardt². ¹Department of General and Interventional Cardiology, Univ Heart Ctr Hamburg, Hamburg, Germany, ²Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany

(605) Strain Rejection Score to Diagnose Acute Cellular Rejection After Heart Transplantation. K. Anto &#324;czyk¹, M. Zakliczynski¹, R. Anto &#324;czyk¹, M. Zembala¹, T. Kukulski². ¹Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland, ²Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland

(606) Impact of Severe Renal Dysfunction on Outcomes of Isolated Heart Transplantation - A Single Centre Experience. B. Komarashi¹, M. Tanguturu¹, K. G. Suresh Rao¹, R. Ratnagiri¹. ¹Cardiac Surgery, Fortis Malar Hospital, Chennai, India, ²Cardiac Anesthesia & Critical Care, Fortis Malar Hospital, Chennai, India


(609) Correlation of Individual Gene Expression Variability with the Variability of Combined Gene Expression Scores. E. C. DePasquale¹, M. C. Deng¹, S. Emani², R. Woodward³, M. Machrus³, J. Sninsky³, S. Krim³. ¹UCLA, Los Angeles, CA, ²Ohio State University Wexner Medical Center, Columbus, OH, ³CareDx, Brisbane, CA, ⁴Ochsner Medical Center, New Orleans, LA

(610) Tricuspid Regurgitation in Heart Transplant Patients: The Relationship with Surgical Technique and Endomyocardial Biopsy. N. K. Bart, P. C. Jansz, P. S. Macdonald, M. Namasivayam, A. M. Keogh. Heart Transplant, St Vincents Hospital, Sydney, Australia

(611) Family Caregiver Activation in the Advanced Heart Failure Population Associated with 6-Month Mortality. S. A. Carey¹, K. Bass¹, K. M. Tecson², J. Felius¹, S. A. Hall¹. ¹Baylor University Medical Center, Dallas, TX, ²Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX

Wednesday, April 5
(612) High Rate of Returning to Work After Heart Transplantation in Japan; K. Nawata, O. Kinoshita, M. Kimura, H. Yamauchi, M. Hatano, Y. Hirata, I. Komuro, M. Ono. 1Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan, 2Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan

(613) Walk the Line-Therapy of Rejection and BK Virus Nephropathy After Heart Transplantation; H. Grahn, M. Rybszynski, F. Wagner, S. Blankenberg, H. Reichenspurner, M. Barten. 1General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany, 2Clinics of Heart and Vascular Surgery, University Heart Center Hamburg, Hamburg, Germany

INFECTIOUS DISEASES
(Seaport Foyer)

Poster Discussants: Young-Jae Cho, MD (Korea), Martha L Mooney, MD (USA), Simon Urschel, MD (Canada)

(614) Improving Hepatitis B Vaccination in Heart Transplant Candidates; E. S. Sukerman, M. Fine, M. Ackerman, A. Chen, S. Wedlake, V. Stosor. 1Infectious Diseases, Northwestern University, Chicago, IL, 2Cardiology, Northwestern University, Chicago, IL, 3Medicine, David Geffen School of Medicine UCLA, Los Angeles, CA

(615) Is There a Role for Pre-Transplant Cytomegalovirus (CMV) Immunoglobulin G Optical Density to Predict CMV Infection in Seropositive Lung Transplant Recipients?; A. Hirji, D. Kabbani, C. Hernandez, H. Malhi, S. Chandrarathne, K. Halloran, A. Kapasi, J. Weinkauf, D. Lien, J. Preiksaitis, C. Cervera. 1University of Alberta Lung Transplant Program, University of Alberta, Edmonton, AB, Canada, 2Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, AB, Canada

(616) Management of Tuberculosis After Lung Transplantation in na Endemic Region; S. V. Campos, M. N. Samano, P. M. Pego-Fernandes, R. O. Teixeira, L. M. Fernandes, L. G. Abdalla, R. M. Carraro, J. E. Afonso-Junior, A. N. Costa. 1Pneumology, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil, 2Thoracic Surgery, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil

(617) WITHDRAWN


(619) Clinical Features Associated with Streptococcus pneumoniae in a Lung Transplant Recipients Cohort; C. Picard, L. Beaumont, E. Farfour, A. Hamid, G. Trebbia, F. Parquin, E. Sage, A. Roux. 1Respiratory Medicine, Foch Hospital, Suresnes, France, 2Microbiology Department, Foch Hospital, Suresnes, France, 3Intensive Care Unit, Foch Hospital, Suresnes, France, 4Thoracic Surgery, Foch Hospital, Suresnes, France

(620) Correlation of Radiological Imaging with Microbiological Cure or Mortality from Invasive Pulmonary Aspergillosis (IPA) in Lung Transplant Recipients (LTRs); F. Alofi, L. G. Singer, D. Kumar, A. Humar, C. Rotstein, S. Keshavjee, S. Husain. 1Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, 2Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

(621) Role of Echinocandins as Antifungal Prophylaxis Agents in Lung Transplant Recipients; R. Pavan, S. Husain. Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada

(622) Voriconazole Therapeutic Drug Monitoring Among Lung Transplant Recipients Receiving Targeted Therapy for Invasive Aspergillosis; G. Butler-Laporte, C. Poirier, P. Ferraro, M. Langevin, C. Lemieux, Y. Theoret, M. Luong. 1McGill University, Montreal, QC, Canada, 2Medicine, Division Respiratory, Hopital Notre Dame, Montreal, QC, Canada, 3Hopital Notre Dame, Montreal, QC, Canada, 4Hopital Ste-Justine, Montreal, QC, Canada, 5St. Luc Hospital, Montreal, QC, Canada

(623) EBV Related BOS Development Is Not Associated with Over-Immunosuppression; J. Magnusson, J. Westin, R. Nordén, L. Andersson, G. Riise. 1Pulmonary Medicine and Allergology, Institute of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Infectious Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Infectious Medicine, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg, Sweden

Wednesday, April 5
(624) **Characteristics of Perioperative Airway Pathogens in Living and Cadaveric Lung Transplantation; H. Oda, T. F. Chen-Yoshikawa, Y. Goda, H. Kayawake, S. Ueda, M. Hamaji, H. Motoyama, K. Hijiya, A. Aoyama, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto City, Japan**

(625) **Candida Blood Stream Infections Post Lung Transplant; S. K. Gadre¹, C. Koval², M. Budev¹. ¹Respiratory Institute, Cleveland Clinic Foundation, Cleveland, OH, ²Infectious Disease Institute, Cleveland Clinic Foundation, Cleveland, OH**

(626) **Histoplasmosis in Adult Lung Transplant Recipients; Y. Furuya, C. Witt, E. P. Trulock, D. Byers, R. Yusen, R. Hachem. Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO**

(627) **Life on the Driveline: F. Schönträth¹, J. Kikkhney², L. Kursawe¹, K. Schönträth¹, J. Schulze¹, E. Potapov¹, T. Krabatsch¹, F. Kaufmann¹, V. Falk¹, A. Moter¹. ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Institute for Microbiology and Hygiene, Charité University Hospital, Berlin, Germany**


(629) **Is Multidrugresistance Pathogens Colonization a Contraindication to LVAD Implant? A Single Center Experience; S. Sciaccà¹, G. Panarello², M. O. Campanella³, R. Alduino³, F. Clemenza⁴, M. Pilato¹. ¹Cardiac Surgery, ISMETT, Palermo, Italy, ²Anesthesia, ISMETT, Palermo, Italy, ³ISMETT, Palermo, Italy, ⁴Cardiology, ISMETT, Palermo, Italy**

(630) **Long Term Management of Deep Mediastinal Infection for Durable Mechanical Circulatory Support Devices; D. G. Tang¹, O. De La Cruz², M. Quader³, V. Kasirajan³. ¹Virginia Commonwealth University, Richmond, VA, ²Division of Infectious Diseases, Virginia Commonwealth University, Richmond, VA, ³Cardiothoracic Surgery, Virginia Commonwealth University, Richmond, VA**

(631) **Contemporary Report on Infectious Complications in Pediatric Patients Supported by Ventricular Assist Devices; A. G. Cabrera¹, J. F. Price¹, I. Adachi², A. Jeewa¹, B. Elias², S. W. Dentfield¹, W. J. Dreyer¹, G. F. Jason¹, N. J. Rodgers¹, J. Vallejo¹, C. E. Bocchini¹. ¹Pediatrics, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Surgery, Baylor College of Medicine/Texas Children's Hospital, Houston, TX**

**MECHANICAL CIRCULATORY SUPPORT**

(Regatta Foyer)

**Poster Discussants:** Deepak Acharya, MD (USA), Mary M Bradbury, PharmD (USA), Fabio De Robertis, MD (United Kingdom), Shashank S Desai, MD (USA), Sangjin Lee, MD (USA), Anna L Meyer, MD (Germany), Sebastian G A Michel, MD (Germany), Jia Lin Soon, FRCS (CTh) (Singapore), Diyar Saeed, MD (Germany), Josef Stehlik, MD, MPH (USA), Nir Uriel, MD (USA)

(632) **Bivalirudin Experience in a Heterogenous VAD Population; J. L. Conway¹, A. Bates², D. Freed³, R. MacArthur⁴, H. Buchholz⁴. ¹Division of Cardiology, Department of Paediatrics, University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada, ²Division of Critical Care Medicine, Department of Paediatrics, University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada, ³Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, ⁴Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada**

(633) **Experience and Perspective of Heparin -Antiplatelet Factor IV Antibody Testing for the Diagnosis of Heparin Induced Thrombocytopenia in Veno-Arterial Extracorporeal Membrane Oxygenation; H. M. Gonzalez Bonilla¹, P. A. Alvarez², D. Hailiemariam³, R. Ogunti³, M. Puppala³, S. N. Homer³, F. R. Bostan³, J. E. Fetter³, L. Rice⁵. ¹Internal Medicine, Houston Methodist Hospital, Houston, TX, ²Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, ³Hematology Department, Houston Methodist Hospital, Houston, TX**

(634) **Pump Thrombosis in Japanese Patients with HeartMate II Continuous-Flow LVAD Pump Thrombosis in Japanese Patients with HeartMate II Continuous-Flow LVAD; M. Ono¹, Y. Sawa², N. Fukushima³, Y. Salki³, A. Shiose⁵, G. Matsumiya⁶, H. Arai⁷. ¹Dept. of Cardiac Surgery, University of Tokyo, Tokyo, Japan, ²Dept. of Cardiovascular Wednesday, April 5
(635) Management of RVAD Thrombosis in Biventricular HVAD Supported Patients; J. Silva Enciso, M. Brambatti, H. Tran, G. V. Pretorius, E. Adler. Department of Cardiology, University of California San Diego, San Diego, CA

(636) In Vitro Acoustic Fingerprint of an Axial Cone Bearing Left Ventricular Assist Device; G. Di Giammarco, D. Marinelli, R. Navarra. Dipartimento di Neuroscienze, Imaging e Scienze Cliniche, University, Chieti, Italy

(637) Hemostatic Analyzes of HeartMate II Patients Surviving without Anticoagulation; R. Zayat, M. A. Khattab, A. Goetzenich, H. Steffen, M. Shoaib, N. Chernigov, L. Tewarie, A. Moza, R. Autschbach. Department of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany

(638) Early Post-Implant Lactate Dehydrogenase Level and LVAD Thrombosis: A Comparison of Heartmate II and Heartmate III; S. Lim, T. Musa, N. Howell, A. Ranasinghe, J. Mascaro. University Hospital Birmingham, Birmingham, United Kingdom

(639) Role of Pre-Operative Right Ventricle Longitudinal Strain in Predicting Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices; M. Brambatti1, J. Silva Enciso1, H. Tran1, A. Mizeracki1, C. J. Baeza1, G. V. Pretorius2, E. Adler1. 1Department of Cardiology, University of California San Diego, La Jolla, CA, 2Department of Cardiothoracic Surgery, University of California San Diego, La Jolla, CA

(640) Is Bridging Anticoagulation Required in LVAD Patients with Subtherapeutic INR?; D. C. Shisler1, R. Vijayakrishnan1, A. J. Lenneman1, E. J. Birks1, L. Muncy1, M. Slaughter2, D. Abramov1. 1Cardiovascular Medicine, University of Louisville, Louisville, KY, 2Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY


(642) Low Dose tPA as a Therapeutic Strategy in Suspected Pump Thrombosis in HeartMate II; A. S. Cruz-Solbes, M. I. Achi, J. Amione-Guerra, E. Karanja, B. Trachtenberg, A. Bhimaraj, J. Estep, G. Torre-Amione, I. Hussain, M. Park, B. Bruckner, A. Guha. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(643) Hemolysis and Von Willebrand Factor Levels During Continuous Flow Left Ventricular Assist Device Support; Q. Saeed1, S. Rangasamy1, A. Luke1, S. R. Patel1, J. Shin1, D. B. Sims1, M. Reyes Gil2, D. J. Goldstein3, M. J. Slepian4, H. H. Billett5, U. Jorde1. 1Medicine (Cardiology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 2Medicine (Hematology), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 3Surgery (Cardiothoracic), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, 4Medicine (Cardiology), University of Arizona, Phoenix, AZ

(644) The Effect of Recombinant-Activated Factor VII on Patients Requiring ECMO Support; H. Merritt Genore, S. Smith, I. Shoiaib, A. Siddique, E. Lyden, T. Ryan, J. Um, A. Burdorf, M. Moulton. Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE

(645) WITHDRAWN

(646) Per-Interventional Discontinuation of Anticoagulation Appears Safe in Patients with HeartMate 3; H. Kirov, G. Faerber, T. Sandhaus, S. Tkebuchava, T. Doenst. Department of Cardiothoracic Surgery, University Hospital Jena, Jena, Germany

(647) The Effect of HeartMate2 and HeartMate3 Implantation on Plasma Markers of Angiogenesis and Inflammation; C. E. Tabit1, G. H. Kim1, J. Maly2, G. Sayer1, Z. Tucanoiva2, S. Adayta2, P. Ivak2, N. Uriel1, I. Netuka2. 1Cardiology, The University of Chicago Medical Center, Chicago, IL, 2Institute for Clinical and Experimental Medicine, Prague, Czech Republic
(648) Thromboelastogram Directed Anticoagulation After Left Ventricular Assist Device Implantation; M. Abdou1, R. J. Chen2, I. Wang2, E. Gleissner3, J. Pickrell3, M. Caccamo1, A. Hadi3. 1Division of Cardiology, Indiana University, Indianapolis, IN, 2Division of Cardiac Surgery, Indiana University, Indianapolis, IN, 3Cardiology Service Line, Indiana University, Indianapolis, IN

(649) Use of Pre-Device Exchange Computed Tomography Angiography for Left Ventricular Assist Device Thrombosis; S. N. Yu1, J. Han1, K. Takeda2, J. N. Ginns3, P. A. Kurlansky2, A. R. Garan3, M. Yuzefpolskaya3, V. K. Topkara1, P. C. Colombo3, Y. Naka2, H. Takayama2. 1Columbia University Medical Center, New York, NY, 2Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY, 3Division of Cardiology, Columbia University Medical Center, New York, NY

(650) Markers of Coagulation and Hemostasis Activation in Left Ventricular Assist Device Recipients; A. F. Moorman, M. L. Hurtik, A. Pekarek, S. Laskar, D. Gupta. Emory University Hospital, Atlanta, GA

(651) Preoperative Predictors of Surgical Bleeding with Implantation of Durable Mechanical Circulatory Support Devices; K. Lietz1, C. Barreiro1, J. Philpott1, C. Flink2, M. McGrath1, J. Herre1. 1Division of Advanced Heart Failure, Sentara Heart Hospital, Norfolk, VA, 2Sentara Cardiovascular Research Institute, Norfolk, VA

(652) De-Airing Method of HeartMate II LVAD Influences Post-Operative LDH: A Possible Explanation for Some Thrombotic Events; D. Tanaka1, A. Boyle2, J. W. Entwistle1. 1Cardiothoracic Surgery, Thomas Jefferson University, Philadelphia, PA, 2Cardiology, Thomas Jefferson University, Philadelphia, PA

(653) Bridging Anti-Coagulation with Low-Molecular-Weight Heparin in HVAD Patients - A Safe and Effective Option; B. Schrage, J. Braetz, A. Bernhardt, M. Rybczynski, M. Barten, H. Reichenspurner, S. Blankenberg, H. Grahn. University Heart Center Hamburg, Hamburg, Germany

(654) Management of Antiplatelet Therapy During Left Ventricular Assist Device Support After Thrombo-Hemorrhagic Events; M. Gallo, J. R. Trivedi, E. J. Birks, D. Abramov, M. S. Slaughter. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

(655) Prior Clotting Events as Predictors of Post LVAD Morbidity and Mortality; J. Johannesen1, J. Whittier2, S. Feitell1, S. R. Hanks2, W. Fischer3, H. J. Eisen2. 1Medicine, Drexel University, Philadelphia, PA, 2Cardiology/Medicine, Drexel University, Philadelphia, PA, 3Cardiothoracic Surgery, Drexel University, Philadelphia, PA

(656) Antiphospholipid Syndrome in Patients with Left Ventricular Assist Device; A. Al-Naamani1, A. L. Meyer1, K. Jawad1, J. Fischer1, A. Siegemund2, T. Siegemund2, A. Oberbach1, J. Hahn1, S. Lehmann1, F. W. Mohr1, J. Garbade1. 1Leipzig Heart Center, Leipzig, Germany, 2MVZ Labor Leipzig, Leipzig, Germany

(657) Incidence of Gastrointestinal Bleeding and Acquired von Willebrand Syndrome in Japanese Recipients of Continuous-Flow Left Ventricular Assist Devices - Comparison Between Axial and Centrifugal-Flow Pumps; S. Nakajima1, K. Kuroda1, H. Sunami1, T. Sato1, O. Seguchi1, M. Yanase1, Y. Matsumoto2, H. Hata2, T. Fujita2, J. Kobayashi2, N. Fukushima1. 1Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Department of Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

(658) Examining Pump Exchange and Laboratory Markers of Organ Function Among LVAD Related Hospitalizations for Hemolytic Events; G. Murtaza, T. Yousuf, C. Kabir, C. Desai. UIC/Advocate Christ Medical Center, Oak Lawn, IL

(659) The Impact of LVAD Pump Thrombosis (PT) on Renal Function in Patients Undergoing Continuous Flow (CF) Left Ventricular Device (LVAD) Exchange; F. Kamdar1, M. Urban2, D. Szczech3, R. John3, R. C. Starling2, N. Moazami1. 1Cleveland Clinic, University of Minnesota, Minneapolis, MN, 2Cleveland Clinic, Cleveland, OH, 3University of Minnesota, Minneapolis, MN

(660) Pre-Implant Atrial Fibrillation Predicts Gastrointestinal Bleeding Following Left Ventricular Assist Device Implantation; M. A. Psotka1, J. Svetlichnaya1, V. N. Selby1, M. Janmohamed1, T. De Marco1, G. Wieseltiher2, L. Klein1. 1Cardiology, University of California San Francisco, San Francisco, CA, 2Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA

Wednesday, April 5
(662) Does Angiotensin Pathway Inhibition Influence Non-Surgical Bleeding in Durable Mechanical Circulatory Support?, J. W. Schurr1, C. A. Stevens2, L. Coakley1, M. Mehr1. 1Brigham and Women's Hospital, Boston, MA, 2UC San Diego Medical Center, San Diego, CA

(663) Outcomes of Low Dose Strategy of Thrombolytic Therapy for Pump Thrombosis; S. Ertugay1, P. Ozturk1, C. Engin1, E. Demir2, S. Nalbantgil2, T. Yagdi1, M. Ozbaran1. 1Cardiovascular Surgery, Ege University Medical School Hospital, IZMIR, Turkey, 2Cardiology, Ege University Medical School Hospital, IZMIR, Turkey

(664) Outcomes of Asian-Americans Undergoing Left Ventricular Assist Device Implantations as a Bridge to Transplant or Destination Therapy: An INTERMACS Analysis; J. R. Wever Pinzon1, W. Wang2, N. Hu3, R. Larsen1, T. Yu2, L. Yin2, I. Taleb1, A. Koliopoulou1, S. Mckellar1, J. Stehlik1, J. Fang1, A. Kfouri4, C. Selzman1, S. Drakos1. 1Cardiovascular Medicine, University of Utah, Salt Lake City, UT, 2Cardiovascular Medicine, Sichuan Academy of Sciences, Chengdu, China, 3University of Utah, Salt Lake City, UT, 4Cardiovascular Medicine, Intermountain Medical Center, Salt Lake City, UT

(665) Increased Frequency of Bleeding Complications in Females Following LVAD Implant; Z. Yavar, J. Cowger, S. Moainie, C. Salerno, A. K. Ravichandran. St. Vincent Heart Center of Indiana, Indianapolis, IN

(666) Post-Operative Bridging Anticoagulation and HeartMate II Pump Thrombosis; D. M. Nemer1, J. M. Connors2, M. Puligandla3, D. S. Neuberg3, G. C. Stewart4. 1Division of Hospital Medicine, Brigham and Women's Hospital, Boston, MA, 2Division of Hematology, Brigham and Women's Hospital, Boston, MA, 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 4Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA

(667) Medical Management of Device Thrombosis in Continuous-Flow Left Ventricular Assist Device Patients: Success Rate and Outcomes; E. Coromilas1, R. Garan1, M. Yuzefpolskaya1, H. Takayama2, K. Takeda2, M. Farr1, Y. Naka2, P. C. Colombo1, V. K. Topkara1. 1Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY

(668) Low Antithrombin Levels Pre-ECMO May Predict Venous Thromboembolism After Lung Transplantation; E. Todd1, S. Biswas Roy1, P. Kang2, H. Abdelrazeck1, R. Walia1, R. M. Bremner1, M. A. Smith1. 1Norton Thoracic Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ, 2University of Arizona College of Public Health, Phoenix, AZ

(669) Anti-Platelet Drug Efficacy In Vitro Under VAD-Like Shear Stress Conditions; L. Valerio1, P. L Tran2, M. Hutchinson2, F. Consolo1, A. Redaelli1, M. Slepian2. 1Politecnico di Milano, Milano, Italy, 2University of Arizona, Tucson, AZ


(671) Very Low Incidence of Clinically Significant Thrombocytopenia After Extended Intra Aortic Balloon Pump Support; J. Amione-Guerra, A. Ali, A. S. Cruz-Solbes, R. Araujo-Gutierrez, B. H. Trachtenberg, A. Bhimaraj, A. Guha, M. Park, J. D. Estep, G. Torre-Amione. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(672) Early Detection of Pump Thrombosis in Patients with Left Ventricular Assist Device; J. Grabska1, T. Schlöglhofer2, C. Gross1, K. Dimitrov3, D. Wiedemann3, D. Zimpfer3, H. Schima2, F. Moscati1. 1Center for Medical Physics and Biomedical Engineering, Medical University of Vienna; Ludwig-Boltzmann-Cluster for Cardiovascular Research, Vienna, Austria, 2Center for Medical Physics and Biomedical Engineering, Department of Cardiac Surgery, Medical University of Vienna; Ludwig-Boltzmann-Cluster for Cardiovascular Research, Vienna, Austria, 3Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

(674) Safety and Efficacy of Thalidomide in the Treatment of Recurrent Gastrointestinal Bleeding in Patients on Left Ventricular Assist Device Support; C. Lim1, M. Lim1, L. Teo1, L. Chan1, K. Kerk2, D. Sim1, T. Tan2, C. Sivathasan2. 1Cardiology, National Heart Centre Singapore, Singapore, Singapore, 2Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore

(675) Negative Pressure Dressings Reduce the Incidence of Driveline Infections Following LVAD Implantation; K. Balsara, L. Jolliff, M. Masood, A. Itoh. Surgery, Washington University in St Louis, St Louis, MO

Wednesday, April 5
(676) **Mycobacterium Abscessus Infection in Patients with Ventricular Assist Devices**; C. R. Wolfe, A. W. Baker, C. B. Patel, P. A. Patel, C. A. Milano, J. N. Schroder, M. A. Daneshmand, B. D. Alexander, E. K. Maziarz. 1Duke University Medical Center, Durham, NC, 2Infectious Disease, Duke University Medical Center, Durham, NC

(677) **Anonymous Driveline Care Survey Reveals Home Driveline Care Practices**; D. Szczech, M. Thompson, L. Hamann, R. John, R. Gogswell. 1CV Specialty Nursing, University of MN Health, Minneapolis, MN, 2CV Surgery, University of MN Health, Minneapolis, MN, 3Cardiology, University of MN Health, Minneapolis, MN

(678) **C-Reactive Protein (CRP) Correlates Poorly with Infection in the Post-Surgical Period Following Left Ventricular Assist Device (LVAD) Implantation**; E. J. McKay, K. Heyes, P. Chaggar, P. Foden, S. Williams, J. Bernard, N. Yonan, R. Venkateswaran. 1The Transplant Unit, University Hospital South Manchester, Manchester, United Kingdom, 2Medical Statistics, University Hospital South Manchester, Manchester, United Kingdom

(679) **Greater Omentum Plasty for the Treatment of Deep Driveline Infection in Chronic Mechanical Circulatory Support**; S. Schulte Eistrup, J. D. Schmitto, N. Reiss, O. Gaubitz, A. Schmidtke, R. Bach, H. Warnecke. 1Cardiac Surgery, Schuchtermann Klinik, Bad Rothenfelde, Germany, 2Cardiac Surgery, Medical School, Hannover, Germany, 3Rehabilitation, Schuchtermann Klinik, Bad Rothenfelde, Germany, 4General Surgery, Marienhospital, Osnabrück, Germany

(680) **Association of Body Mass Index and Age on Risk of Driveline Infection Post Ventricular Assist Device Implantation**; T. Schofield, F. Foroutan, S. Ryoo, K. O’Brien, A. C. Alba, S. Hussain, V. Rao, H. Ross, F. Billia. Cardiology, Toronto General Hospital, Toronto, ON, Canada

(681) **Bridge to Transplant Status Is Associated with Improved Survival After the Development of Left Ventricular Assist Device Infection**; A. Leuck, J. Schultz, F. Mazzulla, R. John, J. Spratt, A. N. Walts, R. Cogswell. 1Infectious Disease, University of Minnesota, Minneapolis, MN, 2Medicine, University of Minnesota, Minneapolis, MN, 3Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, 4Cardiology, University of Minnesota, Minneapolis, MN

(682) **Bloodstream Infections in Continuous Flow Left Ventricular Assist Device Recipients: The Utility of Systemic Inflammatory Response Syndrome for Diagnosing Sepsis and Prediction of Mortality**; A. Kyvernitakis, O. Pappas, A. Wani, D. Farmakiotis, E. T. Horn, S. Murali, R. L. Benza, S. H. Bailey, R. Agarwal. 1Internal Medicine, Allegheny General Hospital, Pittsburgh, PA, 2Cardiovascular Disease, Allegheny General Hospital, Pittsburgh, PA, 3Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, 4Pharmacy, Allegheny General Hospital, Pittsburgh, PA, 5Cardiothoracic Surgery, Allegheny General Hospital, Pittsburgh, PA

(683) **Echocardiographic and Hemodynamic Characteristics of Total Artificial Heart Recipients**; E. J. Sawey, J. T. Owens, R. Cooke, V. Kasirajan, R. Markley, K. Rao, M. C. Smallfield, D. Tang, I. Tchoukina, K. B. Shah. Cardiology, VCU, Richmond, VA

(684) **High Intensity Activity with a Subclavian Artery Intra-Aortic Balloon Pump**; M. Stulberg, C. Stratton, V. Jeevanandam. 1Therapy Services, University of Chicago Medicine, Chicago, IL, 2Cardiac & Thoracic Surgery, University of Chicago Medicine, Chicago, IL


(687) **Prolonged Circulatory Support (Five Years or Longer) with Left Ventricular Assist Devices for Patients with Advanced Heart Failure**; A. Segura, A. Nair, C. Kurihara, S. Carranza, A. Civitello, J. Morgan, O. Frazier. 1Texas Heart Institute, Houston, TX, 2Baylor College of Medicine, Houston, TX

Wednesday, April 5
(688) Self-Reported and Directly Measured Physical Activity in Children and Youth with Cardiomyopathies; J. Conway, L. Glass, C. Cunningham, J. Stearns, V. Carson, P. F. Kantor, S. Urschel, J. C. Spence. 1Stollery Children’s Hospital, Edmonton, AB, Canada, University of Alberta, Edmonton, AB, Canada

(689) WITHDRAWN

(690) Ventricular Arterial Coupling: A Novel Echocardiographic Risk Factor for Poor Outcome in Patients with Acute Decompensated Heart Failure; C. A. Capone, J. Lorenzo, B. Tria, S. S. Medar, S. I. Aydin, J. M. Lamour, D. T. Hsu, J. Mahgerefteh. The Children’s Hospital of Montefiore-Albert Einstein College of Medicine, Bronx, NY

(691) Hospitalization-Related Resource Utilization in Congenital Heart Disease with Advanced Heart Failure; D. S. Burstein, P. Shamszad, C. S. Almond, J. F. Price, K. Y. Lin, M. J. O’Connor, R. E. Shaddy, C. E. Mascio, J. W. Rossano. 1Pediatric Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Cardiology, Stanford Children’s Hospital, Palo Alto, CA, 3Pediatric Cardiology, Texas Children’s Hospital, Houston, TX

(692) Peak Troponin I Is Associated with Death and Extracorporeal Membrane Oxygenation in Pediatric Myocarditis; A. Butto, J. Rossano, D. Nandi, C. Ravishankar, K. Y. Lin, M. J. O’Connor, R. E. Shaddy, P. Shamszad. 1Division of Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, 2Cardiology, The Heart Center, Nationwide Children’s Hospital, Columbus, OH

(693) The Association of Carvedilol Use on Transplant Free Survival in Pediatric Patients with Dilated Cardiomyopathy: An Analysis from the Pediatric Cardiomyopathy Registry; J. W. Rossano, L. J. Addonizio, C. E. Canter, S. D. Colan, D. A. Dodd, M. D. Everitt, B. Harty, D. Hsu, J. L. Jefferies, P. F. Kantor, A. Lal, J. M. Lamour, T. M. Lee, E. Pahl, L. Shi, J. A. Towbin, S. M. Ware, S. A. Webber, D. J. D. Wilkinson, S. E. Lipschultz. 1Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2Morgan Stanley Children’s Hospital, New York, NY, 3Washington University School of Medicine, St. Louis, MO, 4Boston Children’s Hospital, Boston, MA, 5Vanderbilt University, Nashville, TN, 6Children’s Hospital Colorado, Denver, CO, 7New England Research Institutes, Watertown, MA, 8Children’s Hospital at Montefiore, Bronx, NY, 9Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 10Stollery Children’s Hospital, Edmonton, AB, Canada, 11Primary Children’s Hospital, Salt Lake City, UT, 12Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 13Le Bonheur Children’s Hospital, Memphis, TN, 14Indiana University School of Medicine, Indianapolis, IN, 15Wayne State University School of Medicine, Detroit, MI

(694) Utilizing HCV and HBV Infected Donor Organs for Pediatric Thoracic Transplantation; Y. Radzi, L. Danziger-Isakov, R. Bryant III, C. Chin, D. Morales, F. Zafar. 1Division of Cardiothoracic Surgery, Cincinnati Children’s Hospital, Cincinnati, OH, 2Division of Infectious Diseases, Cincinnati Children’s Hospital, Cincinnati, OH, 3Division of Cardiology, Cincinnati Children’s Hospital, Cincinnati, OH

(695) Mixed Rejection in Pediatric Heart Transplant Patients: An Observational Study; L. X. Wu, M. Carroll, W. T. Mahle, S. R. Deshpande. 1Pediatrics, Emory University, Atlanta, GA, 2Children’s Healthcare of Atlanta, Atlanta, GA, 3Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA

(696) Old Dogs with New Tricks: A Standardized Flow Cytometry Panel Measuring Donor-Recipient Alloreactivity; A. Halpin, M. Sosniuk, S. Urschel, P. Campbell, I. Larsen, L. West. 1Dept of Pediatrics, Laboratory Medicine and Pathology, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, 2Department of Pediatrics, University of Alberta, Edmonton, AB, Canada, 3Dept of Pediatrics, Alberta Transplant Institute, Canadian National Transplant Research Program, University of Alberta, Edmonton, AB, Canada, 4Dept of Laboratory Medicine and Pathology, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, 5Dept of Pediatrics, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada

(697) The Impact of Pediatric Ventricular Assist Device Support Before Cardiac Transplant on Post-Transplant Outcomes; H. P. Tunuguntla, S. W. Denfield, K. Puri, I. Adachi, A. G. Cabrera, N. J. Rodgers, J. Goldberg, J. F. Price, W. J. Dreyer, A. Jeewa. 1Pediatric Cardiology, Baylor College of Medicine, Houston, TX, 2Congenital Heart Surgery, Baylor College of Medicine, Houston, TX
(698) Maximizing Survival in Hypoplastic Left Heart Syndrome: Evolution of a Balanced Institutional Strategy; T. Karamlou1, S. Zangwill2, S. Pophal3, D. Velez2, J. Nigro1. 1Pediatric Cardiac Surgery, Phoenix Children’s Hospital, Phoenix, AZ; 2Pediatric Cardiology, Phoenix Children’s Hospital, Phoenix, AZ

(699) Center Variability in Selecting High-Risk Donors: Does It Affect the Outcomes in Pediatric Heart Transplantation?; R. Rizwan1, F. Zafar1, R. Bryant III1, C. Chin2, A. Lorts2, J. S. Tweddell3, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH; 2Cardiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

(700) Pediatric Heart Transplantation: Transitioning to Adult Care; E. Pahl1, K. Van’t Hof1, A. Andrei2, T. Shankel3, R. Chinnock3, S. Miyamoto4, A. Ambardekar5, L. Addonizio6, F. Latifi7, D. Lefkowitz7, L. Goldberg6, S. Hollander8, M. Pham9, K. Grady10. 1Cardiology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL; 2Northwestern University, Chicago, IL; 3Loma Linda University Medical Center, Loma Linda, CA; 4Children’s Hospital Colorado, Aurora, CO; 5University of Colorado Hospital, Aurora, CO; 6Columbia University Medical Center, New York, NY; 7The Children’s Hospital of Philadelphia, Philadelphia, PA; 8University of Pennsylvania, Philadelphia, PA; 9Stanford University, Palo Alto, CA; 10Northwestern Memorial Hospital, Chicago, IL

(701) Understanding Hypertension in Pediatric Patients After Heart Transplantation; P. Patel1, K. LaPorte2, M. Carroll2, W. T. Mahle3, K. Kanter3, S. R. Deshpande3. 1Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA; 2Heart Transplantation, Children’s Healthcare of Atlanta, Atlanta, GA; 3Department of Cardiothoracic Surgery, Emory University, Atlanta, GA

(702) Incidence and Risk Factors for Failed Recovery of Pediatric Donor Hearts; A. Ghavam1, N. Ghanayem1, R. K. Woods2, S. J. Kinde3, N. E. Thompson4. 1Pediatric Critical Care, Medical College of Wisconsin, Milwaukee, WI; 2Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI; 3Pediatric Cardiology, Medical College of Wisconsin, Milwaukee, WI

(703) Relationship Between eGFR and Survival Before and After Heart Transplantation in Children; R. R. Davies, M. A. McCulloch, C. Brailler, C. Pizarro. Nemours Cardiac Center, Nemours/A.I. duPont Hospital for Children, Wilmington, DE

(704) Correlation of Allomap® Scores in Pediatric Heart Transplant Recipients: Are We Ready to Apply This to Our Patients?; D. Gupta, S. Bartra, R. Shih, L. M. Breault, M. S. Bleiweis, F. J. Fricker, B. A. Pietra. Congenital Heart Center, Department of Pediatrics, University of Florida, Gainesville, FL

(705) Do the Characteristics and Outcomes of Pediatric Patients with Restrictive Cardiomyopathy Differ from Those with Dilated Cardiomyopathy? A UNOS Database Analysis; K. Ramakrishnan1, J. Collins2. 1Children’s National Health System, Washington, DC; 2MUSC, Charleston, SC

(706) Avoidance of a C1q Positive Crossmatch Prevents Both Early and Late Antibody-Mediated Rejection in Pediatric Heart Transplant Recipients; S. A. Hollander1, D. M. Peng2, M. Mills3, G. J. Berry4, M. Pedrigo5, S. Chen1, D. B. Tyam6, D. Bernstein1, D. N. Rosenthal1. 1Pediatrics (Cardiology), Stanford University, Palo Alto, CA; 2Pediatrics (Cardiology), University of Michigan, Ann Arbor, MI; 3Pediatrics, Stanford University, Palo Alto, CA; 4Pathology, Stanford University, Palo Alto, CA; 5Pathology, University of Padova, Padova, Italy

(707) A Minimal Biopsy Reliant Surveillance for Rejection in Children Is Not Associated with Inferior Outcomes Post-Heart Transplant; P. D. Evers1, N. Jorgensen2, B. Hong3, E. Albers3, M. Kemna3, J. Friedland-Little3, Y. Law3. 1Pediatric Cardiology, Cincinnati Children’s Hospital, Cincinnati, OH; 2Biostatistics, Seattle Children’s Hospital, Seattle, WA; 3Pediatric Cardiology, Seattle Children’s Hospital, Seattle, WA

(708) Early versus Late Retransplantation in Pediatric Patients: Risk Factors and Impact on Survival; F. Altin1, C. McCracken2, K. Kanter1, B. Alsoufi1, S. R. Deshpande3. 1Cardiothoracic Surgery, Emory University, Atlanta, GA; 2Emory University, Atlanta, GA; 3Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA


Wednesday, April 5
(710) The Primary Diagnosis for Pediatric Heart Transplantation Results in Diminished Heart Rate Response; N. M. Singh, R. S. Loomba, J. R. Kovach, S. J. Kindel. Pediatric Cardiology, Children's Hospital of Wisconsin, Milwaukee, WI

(711) High Pulmonary Vascular Resistance in Pediatric Heart Transplant Patients and Role of Sildenafil; P. Patel1, A. Glumova2, K. LaPorte3, W. T. Mahle2, S. R. Deshpande3. 1Emory University, Atlanta, GA, 2Children's Healthcare of Atlanta, Atlanta, GA, 3Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA

(712) Effect of Thyroid Hormone on Cardiac Function Following Orthotopic Heart Transplantation in Piglets; T. S. Kumar1, C. Mathis1, S. Sathanandam2, D. Zurakowski3, S. Subramanian2, J. Allen1, M. Solimine1, L. Berrios1, S. Jackson1, M. Landers4, R. Sullivan4, S. Barnett4, C. Loffts1, L. Price1, J. B. Tansey1, D. Hoskoppal5, C. Knott-Craig1. 1Cardiothoracic Surgery, Le Bonheur Children's Hospital, Memphis, TN, 2Pediatric Cardiology, Le Bonheur Children's Hospital, Memphis, TN, 3Surgery, Boston Children's Hospital, Boston, MA, 4Comparative Medicine, University of Tennessee Health Science Center, Memphis, TN, 5Pathology, University of Tennessee Health Science Center, Memphis, TN

(713) Echocardiographic Measurements of Longitudinal Strain Decrease with the Development of Coronary Vasculopathy in Pediatric Heart Transplant Recipients; J. Godown1, W. A. McEachern2, M. W. Stanley1, C. J. Havens1, K. A. Wujcik1, J. H. Soslowsky1, D. A. Dodd1. 1Pediatric Cardiology, Monroe Carell Jr. Children's Hospital, Nashville, TN, 2Pediatrics, Monroe Carell Jr. Children's Hospital, Nashville, TN

(714) Neutropenia in Pediatric Heart Transplant Recipients; K. Rose-Felker1, A. Mukhtar2, M. S. Kelleman3, W. T. Mahle1, S. R. Deshpande1. 1Department of Pediatrics, Sibley Heart Center Cardiology, Emory University, Atlanta, GA, 2Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, 3Department of Pediatrics, Emory University, Atlanta, GA

(715) Challenges of Heart Transplant in Patients with L-Transposition of the Great Vessels; A. Magalski1, S. Beauchamp2, A. Borkon2, A. Kao1, S. Aggarwal2, A. Pak2, J. Wang3, K. Allen2. 1Cardiology, Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO, 2Cardiovascular Surgery, Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, 3Biostatistics, Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO

(716) Outcomes After Listing for Heart Transplantation in Pediatric and Young Adult Patients with Hypertrophic Cardiomyopathy: An Analysis of the Scientific Recipient Transplant Registry (SRTR); D. Cheong1, D. T. Hsu2, J. M. Lamour2. 1School of Medicine, University of Connecticut Health Center, Farmington, CT, 2Pediatric Cardiology, The Children’s Hospital at Montefiore, Bronx, NY

(717) Variability in Tacrolimus Levels Is Associated with Biopsy Proven Rejection in Pediatric Heart Transplant Recipients; M. Cousino1, K. Rea1, M. Zamberlan2, J. Jordan1, H. Lim1, D. Peng1, K. Schumacher1. 1Pediatrics, C.S. Mott Children's Hospital, Ann Arbor, MI, 2Cardiac Surgery, C.S. Mott Children's Hospital, Ann Arbor, MI

(718) Pancreatitis Following Paediatric Heart Transplantation; T. G. Day1, A. Sylvan2, S. Christoforides1, E. Hannon2, J. Curry2, M. Fenton1, M. Burch1, J. Simmonds1. 1Cardiology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 2Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

(719) Improving Outcomes of Cardiac Transplantation in Patients with Cavopulmonary Connection; L. E. De León1, J. S. Heinle1, E. McKenzie1, C. M. Mery1, L. C. Kane1, W. Dreyer2, S. W. Denfield2, J. F. Price2, A. G. Cabrera2, C. D. Fraser, Jr.1, I. Adachi1. 1Division of Congenital Heart Surgery, Texas Children's Hospital; Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, 2Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Houston, TX

(720) Primary Graft Dysfunction After Pediatric Heart Transplant: A Single Center Experience; K. Mowers, K. Simpson, P. Eghtesadi, O. Petrucci, C. Canter, C. Castleberry. Washington University School of Medicine, St. Louis, MO

(721) AMR in the Current Era: Clinical, Pathologic, and Immunologic Features in Pediatric Heart Transplant Recipients; D. Drogalis-Kim1, M. J. Hickey2, M. C. Fishbein3, J. C. Alejos1, E. F. Reed2, N. J. Halnon1. 1Pediatrics, UCLA, Los Angeles, CA, 2Immunogenetics Center, Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, 3Pathology and Laboratory Medicine, UCLA, Los Angeles, CA

(722) PreoperativeRecipient Factors Predict Outcome in Pediatric Heart Transplant Recipients Using a Novel Risk Factor Score; M. J. O'Connor1, A. C. Glatz2, J. W. Rossano1, R. E. Shaddy1, R. M. Ryan1, C. Ravishankar1, S. Fuller2, T. L. Spray2, C. E. Mascio2, J. W. Gaynor2, K. Y. Lin1. 1Division of Cardiology, The Children's Hospital of...

(723) CMV-Specific T-Cell Immunity and CMV NAAT in Assignment of CMV Status in Pediatric SOT Candidates; C. Burton1, J. Preikaisaitis1, M. Sester2, Y. Tong1, F. Wong1, S. Urschel1. 1University of Alberta, Edmonton, AB, Canada, 2Saarland University, Homburg, Germany

(724) The Safety and Efficacy of Total Lymphoid Irradiation in Pediatric Patients with Progressive Chronic Lung Allograft Dysfunction; G. Low1, P. Aurora1, M. Gaze2, N. Muthialu1, H. Spencer1. 1Great Ormond Street Hospital, London, United Kingdom, 2University College Hospital, London, United Kingdom

(725) The Burden of Influenza Infection and Disease in Pediatric Lung Transplant Patients; K. C. Hannegan, F. M. Munoz, S. Das, E. Elliott. Baylor College of Medicine, Houston, TX

(726) Immune Monitoring-Guided Treatment of a Pediatric Patient with Sequential GvHD, Acute Rejection and CMV Infection Following Lung Transplantation; C. Falk1, N. Schwerk2, C. Mueller2, I. Tudorache3, W. Sommer3, K. Daemen1, J. Keil1, C. Neudörfli1, G. Hansen2, A. Haverich3, G. Warnecke3. 1Institute of Transplant Immunology, IFB-Tx, Hannover Med Sch Hannover Medical School, Hannover, Germany, 2Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Med Sch Hannover Medical School, Hannover, Germany, 3Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Med Sch Hannover Medical School, Hannover, Germany


(728) Nissen’s Fundoplication Is Safe and Prevents Decrease in Forced Expiratory Volume in One Second (FEV1) in Paediatric Lung Transplant Patients; R. Pabary1, P. Aurora1, J. Curry2, C. Hulsker2, N. Muthialu1, H. Spencer1. 1Department of Paediatric Lung Transplantation, Great Ormond Street Hospital, London, United Kingdom, 2Department of Paediatric General Surgery, Great Ormond Street Hospital, London, United Kingdom


(730) Reduced Use of Intensive Care After Pediatric Lung Transplantation: Influence of Early Extubation; C. Brooks1, S. Labarinas2, J. Bujan1, C. Pymento3, J. M. Pena4, E. Melicoff-Portillo1, M. C. Gazzaneo5. 1Lung Transplant, Texas Children's Hospital, Houston, TX, 2Critical Care, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 3Critical Care, Texas Children's Hospital, Houston, TX, 4Critical Care, University Hospital of Maracaibo/University of Zulia, Maracaibo, Venezuela, Bolivarian Republic of, 5Critical Care/Lung Transplant, Texas Children's Hospital, Houston, TX


(732) Outcomes After First Infection in Adolescents and Young Adults with Ventricular Assist Devices: An Analysis of the PEDIMACS/INTERMACS Database; S. Chen1, D. N. Rosenthal1, R. C. Cantor2, B. Hong3, R. D. Jaquiss4, S. R. Auerbach5, K. R. Schumacher6, J. C. Alejos7, B. Das8, C. S. Almond1, P. Egtesady9, J. K. Kirklin10, A. Jeewa11, 1Stanford University, Palo Alto, CA, 2Kirklin Institute for Research and Surgical Outcomes, The University of Alabama at Birmingham, Birmingham, AL, 3Seattle Children's Hospital, Seattle, WA, 4Duke University School of Medicine, Durham, NC, 5Children's Hospital Colorado Heart Institute, Aurora, CO, 6C.S. Mott Children's Hospital, Ann Arbor, MI, 7UCLA Mattel Children's Hospital, Los Angeles, CA, 8UT South Western Medical Center, Dallas, TX, 9Washington University School of Medicine, St. Louis, MO, 10Department of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, 11The Hospital for Sick Children, Toronto, ON, Canada

(734) Use of TEG/Platelet Mapping to Dose-Adjust Platelet Inhibitors in Children Supported with the Berlin EXCOR: In Search of a Correlation; L. J. May¹, X. Liu², C. Sherwin², L. Yang³, J. Zhender³, J. Lee³, S. Chen⁴, D. N. Rosenthal⁴, C. S. Almond⁴. ¹Pediatric Cardiology, University of Utah, Salt Lake City, UT, ²Pediatrics, Division of Clinical Pharmacology, University of Utah, Salt Lake City, UT, ³Stanford University, Palo Alto, CA, ⁴Pediatric Cardiology, Stanford University, Palo Alto, CA


(736) Durable Ventricular Assist Devices for Infants Improve Organ Utilization and Survival; B. Sheridan¹, J. Brink², I. Konstantinov², L. Eastaugh³, G. Callea³, J. Mathew³, M. Cheung³, C. Brizard³, Y. d'Udekem³. ¹Departments of Cardiology and Intensive Care, The Royal Children's Hospital, Melbourne, Australia, ²Department of Cardiac Surgery, The Royal Children's Hospital, Melbourne, Australia, ³Department of Cardiology, The Royal Children's Hospital, Melbourne, Australia


(738) Feasibility and Potential Utility of Three-Dimensional Echocardiography in Pediatric Patients with Ventricular Assist Device; J. Spinner¹, R. Pignatelli¹, I. Adachi², D. M. Feagin¹, S. W. Denfield¹, A. G. Cabrera¹, J. F. Price¹, H. Tunuguntla¹, W. J. Dreyer¹, A. Jeewa¹. ¹Pediatrics, Baylor College of Medicine, Houston, TX, ²Surgery, Baylor College of Medicine, Houston, TX

(739) Continuous Flow VAD Support at a Tertiary Pediatric Center: Compared to PediMACS Data; I. Adachi¹, S. Burki¹, D. Horne¹, A. Jeewa², B. Elias¹, E. McKenzie¹, A. G. Cabrera², C. E. Bocchini³, W. Dreyer², S. W. Denfield², J. F. Price², C. D. Fraser, Jr.¹. ¹Division of Congenital Heart Surgery, Texas Children's Hospital; Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, ²Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Houston, TX, ³Division of Infectious Diseases, Texas Children's Hospital, Houston, TX

(740) Prevalence of Anemia and Iron Deficiency in Pediatric Patients on Ventricular Assist Devices; K. Puri¹, A. Jeewa¹, I. Adachi², S. W. Denfield³, A. G. Cabrera³, J. F. Price¹, T. J. Humlek¹, W. J. Dreyer¹, M. D. Shah³. ¹Pedatology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Congenital Heart Surgery, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ³Hematology-Oncology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX

(741) Pediatric Mechanical Circulatory Support with Berlin Heart EXCOR System: Experiences in Single Japanese Pediatric Heart Transplantation Center; T. Ueno¹, M. Taira², H. Ozawa³, K. Toda³, T. Kuratani¹, Y. Sawa². ¹Department of Minimally Invasive Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ²Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan

(742) Pilot Study of Warfarin Genotype Polymorphisms in Pediatric Patients with Ventricular Assist Devices; F. Iodice¹, A. Baban¹, A. Di Molfetta¹, L. Di Chiara¹, A. Novelli², E. Agolini², A. Amodeo³, G. Testa¹. ¹Cardiac Surgery and Intensive Care Unit, Children's Hospital Bambino Gesù, Rome, Italy, ²Laboratory Analysis, Children's Hospital Bambino Gesù, Rome, Italy

(743) Cardiac Predictors of Renal Recovery After Pediatric Left Ventricular Assist Device (LVAD) Implantation; C. Chen¹, M. E. Montez-Rath², L. J. May³, K. Maeda⁴, S. A. Hollander¹, D. N. Rosenthal¹, S. M. Sutherland⁵, C. D. Krawczeski¹. ¹Pediatric Cardiology, Stanford University, Palo Alto, CA, ²Nephrology, Stanford University, Palo Alto, CA

Wednesday, April 5
(744) Prevalence and Characteristics of Anemia and Hemolysis in Percutaneous Ventricular Assist Devices in a Pediatric Center: K. Puri¹, A. Jeewa¹, S. C. Tume², I. Adachi³, S. W. Denfield¹, A. G. Cabrera¹, J. F. Price¹, H. P. Tunuguntla¹, W. J. Dreyer¹, M. D. Shah⁴. ¹Cardiology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Critical Care Medicine, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ³Congenital Heart Surgery, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ⁴Hematology-Oncology, Baylor College of Medicine/Texas Children's Hospital, Houston, TX


JUNIOR FACULTY CLINICAL CASE REPORTS (Coronado D and Foyer)

Poster Discussants: Sirtaz Adaty, MD (USA), Meredith A Brisco, MD MSCE (USA), Marco A Caccamo, DO (USA), Laveena Chhatwani, MD (USA), Robert T Cole, MD (USA), Jennifer Eshelman, PharmD (USA), Laura Frye, MD (USA), Arthur R Garan, MD (USA), Laurent Godinas, MD (Belgium), Ranny Goldwasser, MD (Germany), Heather T Henderson, MD (USA), Hanine Inaty, MD (USA), Victor Rossel, MD (Chile), Keyur B Shah, MD (USA), Palak Shah, MD, MS (USA), Mitesh V Thakrar, MD (Canada), Himabindu Vidula, MD (USA)

(746) Intractable Pulmonary Hemorrhage in a Cardiac Transplant Patient on Sirolimus with an Unexpected Pathologic Finding: D. R. Fermin¹, J. Becker¹, A. Booth¹, J. Maleszewski², B. Edwards³, M. Dickinson¹. ¹Spectrum Health, Grand Rapids, MI, ²Mayo Clinic, Rochester, MN


(748) Transaxillary Ventricular Partitioning Device Implantation To Improve Clinical Symptoms of Chronic Heart Failure - A First in Human Case Report: E. K. Harmel, U. Schäfer, N. Schofer, F. Deuschl, D. Reichart, S. Blankenberg, H. Reichenspurner, L. Conradi. Departments of Cardiac Surgery and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany

(749) LVAD Averted: A Case of Reversible Cardiogenic Shock Due to Acute Fibrin Deposition Across a Tissue Pericardial Valve: J. N. Patel¹, B. S. Clemson¹, A. S. Anderson², D. T. Pham³. ¹Cardiology, University of Illinois - Peoria, Peoria, IL, ²Cardiology, Northwestern Memorial Hospital, Chicago, IL, ³Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL

(750) Early Calcineurin Inhibitor Withdrawal in a Young Patient with Renal Failure Results in De-Novo Donor Specific Antibodies Triggering Cardiac Allograft Vasculopathy Post Heart Transplantation: J. Tauber¹, M. Rybczynski², F. M. Wagner¹, H. Reichenspurner¹, M. J. Barten¹. ¹Department of Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany, ²Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany

(751) Fatal Steatohepatitis and Vasoplegia After Heart Transplant in an LVAD Patient on Amiodarone: P. Suryanarayana¹, S. Gregoire¹, R. Sobonya², Z. Khalfey³, S. Lick³, N. Sweitzer¹. ¹Cardiology, University of Arizona, Tucson, AZ, ²Pathology, University of Arizona, Tucson, AZ, ³Cardiothoracic Surgery, University of Arizona, Tucson, AZ

(752) Total Artificial Heart Salvage of a Heterotopic Heart Transplant Patient with Chronic Rejection and Biventricular Heart Failure: I. D. Salas de Armas, M. H. Akay, S. Nathan, S. Stojanovic, R. Radovancevic, P. Loyalka, B. Kar, I. D. Gregoric. The University of Texas Health Science Center at Houston, Houston, TX

(753) Unusual Case of Biopette Perforation in Transplanted Heart: Three-Dimensional Computed Tomography Reconstruction of Superior Vena Cava: I. Kim¹, J. Oh¹, S. Lee², Y. Youn², S. Kang¹. ¹Cardiology, Severance Hospital, Jeju Island, Republic of Korea, ²Gastroenterology, Severance Hospital, Jeju Island, Republic of Korea

Wednesday, April 5
Cardiovascular Hospital, Yonsei University, Seoul, Korea, Republic of, 2Thoracic and Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University, Seoul, Korea, Republic of

(754) Cardiac Magnetic Resonance-Established Rejection in a Heart Transplant Recipient with a Negative Myocardial Biopsy: A Case Report; G. Poglaie1, R. Zbancik2, A. Cerar3, P. Berden2, B. Vrtovec1. 1Advanced Heart Failure and Transplantation Programme, Dept. of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia, 2Institute of Radiology, University Medical Center Ljubljana, Ljubljana, Slovenia

(755) A Case of Acute on Chronic Myocarditis Due to HHV-6 Infection; A. Nguyen, K. Mullane, G. Kim, N. Sarswat, S. Adatya, G. Sayer, N. Uriel. University of Chicago, Chicago, IL

(756) A Rare Case of a Idiopathic Cardiomyopathy Complicated by Acute Pulmonary Emboli in the Setting of Antiphospholipid Syndrome with Successful Bridge to Heart Transplantation via BIVAD Implantation; K. Shah, D. Vucicевич, L. Honoris, A. Baas. Cardiology, University of California Los Angeles, Los Angeles, CA

(757) EGPA Mediated Eosinophilic Myocarditis with Initial Normal Eosinophil Count with Rapid Progressive Decrease in Cardiac Function; K. Carlson. Cardiology, St. Vincent's Hospital Indianapolis, Indianapolis, IN

(758) Cardiopulmonary Resuscitation, Extracorporeal Life Support, BVAD and Successful Heart Transplantation within 2 Months: A Single Center Case Series in 2 Young, High-Urgent Listed Patients; A. Schmidt1, D. Saeed1, A. Mehdiani1, B. Sowinski1, R. Westenfeld2, P. Akhyari1, A. Lichtenberg1, U. Boeken1. 1Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, 2Cardiology, University Hospital, Duesseldorf, Germany

(759) Renal Cell Carcinoma in Identical Twins Following Heart Transplantation; Y. Peled, Y. Har-Zahav, Y. Kassif, Y. Shemesh, D. Freimark, Z. Dotan, J. Lavee. Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel

(760) De Novo Eosinophilic Myocarditis After Heart Transplantation; M. Abdou, A. Hadi, A. Brittsman, M. Caccamo. Division of Cardiology, Indiana University, Indianapolis, IN

(761) Successful Cardiac Transplantation in a Patient with Familial Hypercholesterolemia Treated with a PCSK9 Inhibitor; V. Ton1, E. Feller1, G. Ramani1, T. Trobiani1, A. Asser2, M. McLenon3, Z. Kon3, S. Pham2. 1Cardiology, University of Maryland Medical Center, Baltimore, MD, 2Adventist Healthcare Shady Grove Medical Center, Rockville, MD, 3Cardiothoracic Surgery, University of Maryland Medical Center, Baltimore, MD

(762) Cardiac Transplantation in a Patient with Situs Inversus Totals and Congenitally Corrected Transposition; N. S. Clarke1, M. Drazner2, M. E. Jessen1, M. Peltz1. 1Department of Cardiovascular & Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, 2Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX


(764) Spontaneous Remission of Giant Cell in Fulminant Lymphocytic Myocarditis; T. Sato1, Y. Ikeda2, O. Seguchi1, Y. Kumai1, K. Kuroda1, H. Sunami1, S. Matsuda3, S. Nakajima1, Y. Matsumoto4, K. Wada3, H. Hata4, M. Yanase1, T. Fujita4, H. Ishibashi-Ueda2, J. Kobayashi4, N. Fukushima1. 1Transplantation, National Cardiovascular Center, Osaka, Japan, 2Pathology, National Cardiovascular Center, Osaka, Japan, 3Pharmacy, National Cardiovascular Center, Osaka, Japan, 4Cardiovascular Surgery, National Cardiovascular Center, Osaka, Japan

(765) Native Myocardial Embolus to Donor Left Anterior Descending Artery After Total Artificial Heart Explant: A Cautionary Note; T. Kazui1, B. T. Larsen2, R. G. Smith3, Z. I. Khalpey1, S. D. Lick1. 1Cardiothoracic Surgery, Banner University Medical Center Tucson, Tucson, AZ, 2Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, 3Artificial Heart, Banner University Medical Center Tucson, Tucson, AZ

(766) Amiodarone Induced Pulmonary Toxicity After Orthotopic Heart Transplantation: Possible Synergistic Toxicity of Amphiphilic Drugs; P. Gosain, V. Panik, D. Rinde-Hoffman. Tampa General Hospital, Tampa, FL

(767) First Successful In Vitro Fertilization (IVF) - Induced Twins Pregnancy Following Heart Transplantation (HTX): Long Term Follow-Up; Y. Peled1, Y. Har-Zahav1, Y. Kassif1, Y. Shemesh1, D. Freimark1, D. Zacut2, J. Lavee1. 1Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel, 2Hadassah Medical Center, Jerusalem, Israel

Wednesday, April 5
(768) Reversible Vasocostriction Syndrome Soon After Heart Transplantation: Y. Kumai1, O. Seguchi1, K. Wada2, K. Kuroda1, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, Y. Matsumoto2, H. Hata1, T. Fujita4, J. Kobayashi2, N. Fukushima2. 1Transplantation, National Cerebral and Cardiovascular Center, Suita-City Osaka, Japan, 2Pharmacy, National Cerebral and Cardiovascular Center, Suita-City Osaka, Japan, 3Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita-City Osaka, Japan

(769) Significant Improvement in Cardiac Sarcoidosis with Once Monthly Intravenous Methylprednisolone Infusions: R. Cogswell1, D. Shapiro2, D. Perlman3, H. Roukoz1, M. Bhargava3. 1Cardiology, University of Minnesota, Minneapolis, MN, 2Midwest Immunology Clinic, University of Minnesota, Plymouth, MN, 3Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, MN

(770) Angina Early After Heart Transplant: A Unique Case of a Congenitally Absent LMCA with a Superdominant RCA in the Donor Heart: K. K. Jain1, A. Magalski1, T. M. Khumri1, B. A. Austin1, A. Kao1, S. L. Lawhorn1, S. Aggarwal2, J. R. Davis2, K. B. Allen2, V. E. Thompson2, A. M. Borkon2. 1Department of Cardiology, St. Luke’s Mid America Heart & Vascular Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, 2Department of Cardiothoracic/Vascular Surgery, St. Luke’s Mid America Heart & Vascular Institute, Kansas City, MO

(771) Increase in Lung Fluid Content in Response to Milrinone Therapy - Insights into the Activity of Milrinone Using ReDS Technology: S. Kalantar1, J. Grinstein, G. Sayer, G. H. Kim, N. Sarswat, S. Adatya, N. Uriel. University of Chicago, Chicago, IL

(772) A Robot to Diagnosis Cardiac Tumors: B. H. Trachtenberg, R. Araujo-Gutiérrez, M. Valderrábano. DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

(773) Longest Duration of Successful Recycled Cardiac Allograft in Intermediate Donor: T. Pollema1, H. Tran2, E. Adler2, V. Pretorius1. 1Division of Cardiovascular and Thoracic Surgery, University of California San Diego, LA Jolla, CA, 2Division of Cardiology, University of California San Diego, LA Jolla, CA

(774) Catheter Ablation of Early Native and Late Donor Atrial Arrhythmias After Cardiac Transplantation: K. Limmer1, C. A. Athill2, L. Hazard3, K. Ortiz3, P. M. Hoagland4. 1Cardiothoracic Surgery, Sharp Memorial Hospital, San Diego, CA, 2Electrophysiology, Sharp Memorial Hospital, San Diego, CA, 3Heart Transplant/LVAD, Sharp Memorial Hospital, San Diego, CA, 4Cardiology, Transplant, Sharp Memorial Hospital, San Diego, CA

(775) HeartWare Left Ventricular Assist Device (HVAD) Inflow Canula Obstruction Caused by Strep Gordonii Endocarditis: B. A. Smith1, S. Mitter2, K. Ghafourian2, J. Wilcox2, J. Rich2, A. Anderson2, D. Pham3, E. Vorovich2. 1Northwestern Memorial Hospital, Chicago, IL, 2Division of Cardiology, Northwestern Memorial Hospital, Chicago, IL, 3Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL

(776) Left-Ventricular Assist Device Implantation and Radiofrequency Ablation for Ventricular Arrhythmia in a Patient with Prior Transcatheter Aortic Valve Replacement: V. Garibyan, A. Bitar, R. Mohan, A. Srivastava. Advanced Heart Failure, Scripps La Jolla, La Jolla, CA

(777) Once Muscles Twitch, It’s Time for Catecholamine Switch: A. Z. Turk1, L. Tirpaek1, E. Khan1, F. Katsikeris1, V. A. Grewal1, S. Shaikh1, K. Maqsood2, D. Landry3, J. Hernandez-Montfort4. 1Internal Medicine, Baystate Medical Center, Springfield, MA, 2Cardiology, Baystate Medical Center, Springfield, MA, 3Nephrology, Baystate Medical Center, Springfield, MA, 4Cardiology and Advanced Heart Diseases, Baystate Medical Center, Springfield, MA

(778) Combined Heart and Kidney Transplantation in MELAS Syndrome: J. Dumfarth1, M. Kofler1, G. Pölzl2, D. Höfer1, S. Eschertzhuber3, K. Kienzl-Wagner4, M. Grimm1, H. Antretter1. 1Dep. for Cardiac Surgery, University Clinic Innsbruck, Innsbruck, Austria, 2Dep. for Cardiology, University Clinic Innsbruck, Innsbruck, Austria, 3Dep. for Anesthesia, University Clinic Innsbruck, Innsbruck, Austria, 4Dep. for General Surgery, University Clinic Innsbruck, Innsbruck, Austria

(779) First in Human Robotic Assisted Myocardial Biopsy to Diagnose Cardiac Sarcoidosis: A. Bhimaraj, M. Valderrábano. Cardiology, Houston Methodist Hospital, Houston, TX


Wednesday, April 5
(781) **Eculizumab in Pediatric Cardiac Antibody Mediated Rejection**: D. Nandi¹, P. Baker², H. Missler¹, L. Fisher¹, R. J. Gajarski³, C. M. Phelps¹. ¹The Heart Center, Nationwide Children's Hospital, Columbus, OH, ²Department of Pathology, Nationwide Children's Hospital, Columbus, OH


(783) **Improved Muscle Strength and Quality of Life After Resistance Training in a Patient with Continuous Flow Left Ventricular Assist Device**: E. P. Tigges¹, S. Schmidt¹, M. J. Barten², S. Capel³, H. Grahn¹, S. Blankenberg¹, H. Reichenspurner², M. Rybczynski³. ¹Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany, ²Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, ³Athletic Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

(784) **Perforation of a HeartMate II Outflow Graft**: M. Kawabori, C. Kurihara, W. E. Cohn, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Baylor College of Medicine, Houston, TX

(785) **Right Ventricular Pressures Monitoring During Cardiac Surgery**: K. P. Mody¹, A. Chiricolo², G. P. Siroky¹, C. D. Maulion³, D. B. Iyer¹, J. L. Almendral¹, J. Feliberti¹, G. Batsides³. ¹Cardiology, Robert Wood Johnson University Hospital, New Brunswick, NJ, ²Anesthesia, Robert Wood Johnson University Hospital, New Brunswick, NJ, ³Cardiothoracic Surgery, Robert Wood Johnson University Hospital, New Brunswick, NJ

(786) **Fighting the Flail Leaflet**: D. M. Mooney¹, K. Rick², R. Kocio³, E. W. Grandin³. ¹Advanced Heart Failure, Tufts University Medical Center, Boston, MA, ²Advanced Heart Failure, Beth Israel Deaconess Medical Center, Boston, MA

(787) **Hemodynamic Optimization via Ramp Study for Treatment of Elevated Defibrillation Threshold**: J. D. Moss¹, E. E. Flatley¹, G. H. Kim¹, N. Saraswat¹, S. Adatya¹, T. Ota², G. Sayer¹, V. Jeevanandam², N. Uriel¹. ¹Section of Cardiology, University of Chicago, Chicago, IL, ²Cardiothoracic Surgery, University of Chicago, Chicago, IL

(788) **The Sea Captain’s LVAD: The Story of an Insidious Source of Device Thrombosis**: L. H. Stein¹, S. Zarafshar², D. Banerjee³, R. Ha⁴. ¹Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, ²Department of Cardiovascular Medicine, Stanford University, Stanford, CA

(789) **Myasthenia Crisis Complicated by Cardiogenic Shock: Bridge to Recovery with Extracorporeal Membrane Oxygenation**: J. H. Kim¹, C. S. King², G. Banez-Se³, L. P. Ryan⁴, P. Shah⁵. ¹Virginia Commonwealth University, Richmond, VA, ²Medical Critical Care Service, Inova Fairfax Hospital, Falls Church, VA, ³Inova Pathology Institute, Inova Fairfax Hospital, Falls Church, VA, ⁴Cardiac Vascular and Thoracic Surgery Associates, Falls Church, VA, ⁵Heart Failure and Transplant Program, Inova Heart and Vascular Institute, Falls Church, VA

(790) **In-Vivo Pressure Differential Measurement of an Occluded LVAD Outflow Graft**: K. J. Mesa¹, K. Ihnken¹, H. Smith¹, D. Sato¹, S. Logani¹, T. B. Icenogle¹, V. Kapustin², L. Passey¹, A. Coletti¹. ¹Mechanical Circulatory Support, Providence Sacred Heart Medical Center, Spokane, WA, ²Cardiology, Providence Sacred Heart Medical Center, Spokane, WA

(791) **Left Anterior Descending Artery Thrombosis in a Patient with a Descending Aortic Left Ventricular Assist System Cannulation**: S. Mitter, B. Smith, J. Wilcox, J. Rich, D. Pham, A. Anderson, E. E. Eorovich, K. Ghaforian. Northwestern University, Chicago, IL

(792) **Long-Term RVAD Support in an Adult with Pulmonary Atresia and Intact Ventricular Septum**: J. Hermesen¹, A. Stempien-Otero², K. K. Stout², E. D. Verrier³, C. Mah³, N. A. Mokadam¹. ¹Surgery, University of Washington, Seattle, WA, ²Medicine, University of Washington, Seattle, WA, ³Meicine, University of Washington, Seattle, WA

(793) **Persistent Right Ventricular Failure and Mitral Regurgitation in a Patient with a Left Ventricular Outflow Graft Thrombus**: S. S. Mitter, B. A. Smith, K. Ghaforian, J. E. Wilcox, J. Rich, D. Pham, A. S. Anderson, E. Vorovich. Northwestern University, Feinberg School of Medicine, Chicago, IL

(794) **Safety and Efficacy of an Impella Supported Open Cholecystectomy**: G. P. Siroky¹, C. D. Maulion¹, D. B. Iyer¹, J. L. Almendral¹, K. P. Mody¹, G. Batsides². ¹Cardiology, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, ²Cardiothoracic Surgery, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ

Wednesday, April 5
(795) Paranormal Activity: Para-Esophageal/Gastric Hemorrhage in a Patient with a HeartMate II LVAD; A. Sleder, A. Ravichandran. St. Vincent Hospital, Indianapolis, IN

(796) Successful Delivery in a Patient with LVAD and Unplanned Pregnancy; M. Y. Jan1, L. E. Holton2, J. Abraham3. 1Pharmacy, Providence St. Vincent Med Ctr, Portland, OR, 2Internal Medicine, Legacy Health System, Vancouver, WA, 3Center for Advanced Heart Disease, Providence Heart and Vascular Institute, Portland, OR

(797) LVAD Related Aortic Root Thrombus Complicated by Myocardial Infarction Treated with Intra-Aortic Tissue Plasminogen Activator; Y. Xu1, L. E. Holton2, J. Abraham3. 1Pharmacy, Providence St. Vincent Med Ctr, Portland, OR, 2Internal Medicine, Legacy Health System, Vancouver, WA, 3Center for Advanced Heart Disease, Providence Heart and Vascular Institute, Portland, OR

(798) Substrate Guided Surgical Ablation for Ventricular Tachycardia in a Patient Undergoing Left Ventricular Assist Device Implantation; N. Akoun1, C. Mahr1, C. S. Masri1, M. Robinson1, J. Beckman1, J. Pa2, J. W. Smith2, N. A. Mokadam2. 1Cardiology, University of Washington, Seattle, WA, 2Cardiothoracic Surgery, University of Washington, Seattle, WA


(800) A Case Report of Total Artificial Heart Implantation for Biventricular Failure Due to Eosinophilic Myocarditis; A. Critsinelis, C. Kurihara, M. Kawabori, K. A. Heck, W. E. Cohn, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Division of Cardiothoracic Transplant and Assist Devices, Baylor College of Medicine, Houston, TX

(801) A Successful Conversion from Heartmate II to Heartware Continuous-Flow Mechanical Assist Device in a Pediatric Patient with Pump Thrombosis; N. Alami Laroussi1, D. N. Rosenthal1, J. Murray1, O. Reinhaert2, K. Maeda2, R. After Rescue VV ECMO Implantation Following Pneumonectomy as Treatment for Paraneoplastic Autoimmune Hemolytic Anemia; N. Akoum1, C. Mahr1, C. S. Masri1, M. Robinson1, J. Beckman1, J. Pa2, J. W. Smith2, N. A. Mokadam2, R. After Rescue VV ECMO Implantation Following Pneumonectomy as Treatment for Paraneoplastic Autoimmune Hemolytic Anemia; N. Akoum1, C. Mahr1, C. S. Masri1, M. Robinson1, J. Beckman1, J. Pa2, J. W. Smith2, N. A. Mokadam2, 1Cardiology, University of Washington, Seattle, WA, 2Cardiothoracic Surgery, University of Washington, Seattle, WA

(802) A Case Report of Total Artificial Heart Implantation for Biventricular Failure Due to Eosinophilic Myocarditis; A. Critsinelis, C. Kurihara, M. Kawabori, K. A. Heck, W. E. Cohn, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Division of Cardiothoracic Transplant and Assist Devices, Baylor College of Medicine, Houston, TX

(803) Impella RP Supported VT Ablation Following HeartMate II Implantation; C. D. Maulion1, J. Xu2, W. J. Kostis1, D. Saluja1, K. Mody1, G. Batsides3, D. Iyer1, J. Almendral1. 1Cardiology, Rutgers Robert Wood Johnson, New Brunswick, NJ, 2Internal Medicine, Rutgers Robert Wood Johnson, New Brunswick, NJ, 3Cardiothoracic Surgery, Rutgers Robert Wood Johnson, New Brunswick, NJ

(804) Distal Limb Perfusion: Cannulation of Low Superficial Femoral Artery (SFA) for Perfusion Cannula Placement in Patients on Peripheral Venoarterial Extracorporeal Membrane Oxygenation; A. Ghodsizad MD, PhD1, M. Loebe MD, PhD2. 1Department of Cardiac Surgery, Hershey, PA, 2Department of Cardiac Surgery, University of Miami Miller School of Medicine, Miami, FL

(805) Application of ECCO2R After Rescue VV ECMO Implantation Following Pneumonectomy as Treatment for Narcotizing Pneumonia; A. Ghodsizad, B. Forsberg, I. Shulman, S. Chapparo, N. Brozzi, P. Rusconi, J. Bauerlein, A. Badiye, M. Loebe. University of Miami, Department of Surgery, Miami Transplant Institute, Miami, FL

(806) Autonomic Failure Following Continuous Flow Left Ventricular Assist Device Implantation; N. C. Sharma1, D. Chew2, S. Raj3. 1Cardiology, Libin Heart Institute, Calgary, AB, Canada, 2Cardiology, Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada

(807) Successful Treatment of Giant-Cell Myocarditis Complicated by Heparin-Induced Thrombocytopenia; J. P. Covelliers, D. De Bock, I. Rodrigus. Cardiac Surgery, Antwerp University, Edegem, Belgium

Wednesday, April 5
(808) **Biventricular Standstill in a Patient with Left Ventricular Assist Device**; C. Teoh¹, K. Ho¹, L. Louis Teo¹, K. David Sim¹, T. Tan², S. Cumaraswamy², K. Kerk³, C. Lim¹. ¹Cardiology, National Heart Centre, Singapore, Singapore, ²Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore, ³Mechanical Circulatory Support, HL Unit, National Heart Centre, Singapore, Singapore

(809) **Unusual Life-threatening Complication in a Left Ventricular Assist Device Recipient**; P. S. Joy, H. Ayinde, M. C. Giudici, V. Cotarlan. University of Iowa, Iowa City, IA

(810) **Successful Implantation of Left Ventricular Assist Device for Cardiogenic Shock Secondary to Left Ventricular Non-Compaction**; K. Balsara¹, M. Ogawa¹, A. Bierhals², J. Vander³, G. Ewald³, L. Jolliff¹, M. Pasque¹, M. Masood¹, A. Itoh¹. ¹Surgery, Washington University in St Louis, St Louis, MO, ²Radiology, Washington University in St Louis, St Louis, MO, ³Cardiology, Washington University in St Louis, St Louis, MO

(811) **Utilization of VenoVenous ECMO with Atrial Septostomy as a Strategy for Bridge to Lung Transplant in a Patient with Pulmonary Arterial Hypertension**; K. Morris¹, D. Gutteridge², D. Roe², T. Wozniak³, Z. Hashmi³, M. Caccamo⁴. ¹Indiana University School of Medicine, Indianapolis, IN, ²Division of Pulmonary and Critical Care, Indiana University School of Medicine, Indianapolis, IN, ³Division of Cardiothoracic Surgery, Indiana University School of Medicine, Indianapolis, IN, ⁴Kranert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN

(812) **Continuous Flow Left Ventricular Assist Device Implantation Concomitant with Aortic Root and Valve Replacement**; M. Bazavan¹, H. Keshmiri², A. Andrade¹, T. Suboc¹, G. Bhat¹, S. Pauwaa¹, G. Macaluso¹, P. Pappas¹, A. Tatooles¹, M. Dia¹, W. Cotts¹. ¹Advocate Christ Medical Center, Oak Lawn, IL, ²Advocate Illinois Masonic Medical Center, Chicago, IL

(813) **Biventricular Impella in a Patient with Atrial Septostomy Post Mitral Valve Repair**; C. D. Maulion¹, G. Batsides². ¹Cardiology, Rutgers Robert Wood Johnson, New Brunswick, NJ, ²Cardiothoracic Surgery, Rutgers Robert Wood Johnson, New Brunswick, NJ


(815) **Can a Left Ventricular Assist Device Cause Autotriggering of a Mechanical Ventilator?**; J. D. Plamenac¹, J. Kumar¹, D. Edmundowicz², Y. Toyoda³, R. Alvarez³, E. Hamad². ¹Internal Medicine, Temple University Hospital, Philadelphia, PA, ²Section of Cardiology, Temple University Hospital, Philadelphia, PA, ³Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA

(816) **A Case of Long-Affecting Pulmonary Arterial Hypertension Associated with Systemic Sclerosis Who Showed Hemodynamic Improvement with Immunosuppressive Therapy**; A. Saito¹, M. Hatano, S. Minatsuki, H. Maki, I. Komuro. The University of Tokyo Hospital, Tokyo, Japan

(817) **Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia: Importance of the Hemodynamic Evaluation**; T. Weitsman, T. Hasin, G. Weisz. Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel

(818) WITHDRAWN

(819) **Peripheral Pulmonary Artery Stenosis Treated as Idiopathic Pulmonary Arterial Hypertension for 10 Years: A Case Report**; G. Numata¹, M. Hatano¹, S. Minatsuki¹, E. Amiya¹, H. Maki¹, M. Watanabe¹, H. Matsubara², I. Komuro¹. ¹Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan, ²Department of Cardiovascular Medicine, Okayama Medical Center, Okayama, Japan

(820) **Ease the Squeeze! A Case of Partial Anomalous Pulmonary Venous Return (PAPVR)**; H. Fakih¹, S. Daouk¹, R. Helton², A. Ataya¹, J. Wynne¹. ¹Pulmonary Critical Care, University of Florida, Gainesville, Gainesville, FL, ²Internal Medicine, University of Florida, Gainesville, Gainesville, FL

(821) **Clearance of Hepatitis C Viremia Prior to Lung Transplantation**; A. E. Shafii, M. Baz. Surgery, University of Kentucky, Lexington, KY

Wednesday, April 5

(823) Lung Re-Transplantation for Recurrent Lymphangionleiomyomatosis in a Premenopausal Recipient: A Case Report; Y. Shikatani1, S. Sugimoto1, S. Otani2, T. Kuroasaki2, K. Miyoshi1, M. Yamane1, S. Miyoshi1, T. Oto2. 1Department of General Thoracic Surgery, Okayama University Hospital, Okayama, Japan; 2Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(824) Monocular Blindness Post Lung Transplant; J. Lee, M. Lindner, N. Holder, C. Migliore, P. Patel, H. Seethamraju. Newark Beth Israel Medical Center, Newark, NJ

(825) Use of Arterial Stenting to Relieve Post-Transplant Left Main Pulmonary Artery Obstruction; R. M. Hassan Charles1, J. P. Cheatham2, A. L. Pope-Harman3, C. J. Daniels2, B. A. Whiston1. 1Cardiothoracic Surgery, The Ohio State University, Columbus, OH; 2Interventional Cardiology, Nationwide Childrens Hospitals, Columbus, OH; 3Pulmonology, The Ohio State University, Columbus, OH

(826) Post Lung Transplant Chylothorax Effectively Treated with Thoracic Duct Embolization; D. J. Franco-Palacios1, A. W. Brown1, C. King1, F. S. Nunes1, A. Mahajan1, S. Khandhar1, A. Venbrux2, O. A. Shlobin1. 1Advance Lung Disease and Transplant, Inova Fairfax Hospital, Falls Church, VA; 2Interventional Radiology, The George Washington University Hospital, Washington, DC

(827) Right Ventricular Outflow Tract Reconstruction During Lung Transplantation; S. M. Bell1, J. Javidfar2, M. G. Hartwig1, J. C. Haney1, M. A. Daneshmand1. 1Surgery, Duke Univ Med Ctr, Durham, NC; 2Surgery, Emory University, Atlanta, GA

(828) Successful Long-Term Outcome After Lung Transplant Using Donor Intubated for More Than Ten Months; S. Tanaka, K. Miyoshi, T. Kuroasaki, S. Otani, S. Sugimoto, M. Yamane, T. Oto. Department of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(829) Once Daily LCP-Tacrolimus in a Cystic Fibrosis Lung Transplant Recipient; A. T. Logan1, A. Brueckner1, T. Haddad2. 1Department of Pharmacy, Tampa General Hospital, Tampa, FL; 2Department of Pulmonary Critical Care, Tampa General Hospital, Tampa, FL

(830) Tracheal Bronchus in Donor Lungs: A Technical Challenge; S. Tokman1, R. Serrone2, M. A. Smith3, A. Hashimi3, A. Omar1, R. Walia1, R. M. Bremner2. 1Advanced Lung Disease, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ; 2Department of General Surgery, St. Joseph Hospital and Medical Center, Phoenix, AZ; 3Division of Thoracic Surgery, Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ

(831) Atypical Hemolytic Uremic Syndrome: An Intraoperative Complication of Lung Transplantation; V. Rusanov1, N. S. Sharma1, C. W. Hoopes2, C. R. Baker3, V. G. Valentine1, K. M. Wille1. 1Division of Pulmonary, Allergy & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL; 2Department of Surgery, Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; 3Critical Care, University of Alabama at Birmingham Hospital, Birmingham, AL

(832) Complications Following Lung Transplantation in a Patient with Short Telomere Syndrome; C. Naik, M. Morrell. Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA

(833) Diaphragmatic Spasm: A Technique To Overcome Severe Size Mismatch in Lung Transplantation; M. H. Ahmed1, W. N. Saleh1, I. Y. Nizami2, S. M. Ahmed2, K. M. Alkattan3. 1Thoracic Surgery, King Faisal Specialist Hospital And Research Centre, Riyadh, Saudi Arabia; 2Organ Transplant Centre, King Faisal Specialist Hospital And Research Centre, Riyadh, Saudi Arabia; 3Alfaisal University, Riyadh, Saudi Arabia

(834) Severe Primary Graft Failure in Lung Recipients That Required ECMO Had High Level of Donor Derived Cell Free DNA; I. Timofte1, S. Agbor-Enoh2, A. Iacono1, J. Orens3, P. Shah3, S. Gorham2, K. Bhatti2, A. Marishta2, M. Jang2, Y. Yang2, U. Fidelii2, I. Tunc2, J. Zhu2, S. D. Nathan4, A. W. Brown1, S. Pham1, H. Valentine2. 1UMMC, Baltimore, MD; 2NIH, Bethesda, MD; 3JHU, Baltimore, MD; 4Inova, Falls Church, VA

(836) Successful Management of Hyperammonemia Syndrome Post Lung Transplantation Syndrome Post Lung Transplantation; A. Y. Kamel1, H. Fakh1, S. Daouk2, J. Salgado2, S. Chandrashhekar2, J. Ashton1, D. Driscoll3, G. Maegawa3, T. Machuca4, A. M. Emerijazio5. 1Department of Pharmacy, University of Florida, Gainesville, FL, 2Division of Pulmonary, Critical Care & Sleep Medicine, University of Florida, Gainesville, FL, 3Division of Genetics and Metabolism, University of Florida, Gainesville, FL, 4Division of Cardiothoracic Surgery, University of Florida, Gainesville, FL

(837) Lung Transplantation for Kartagener Syndrome: Technical Aspects and Morphological Changes of the Transplanted Lungs; H. Yamamoto, S. Sugimoto, S. Otani, T. Kurosaki, K. Miyoshi, M. Yamane, S. Miyoshi, T. Oto. Department of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(838) Healing the Broken Heart Following Lung Transplant; S. Kapadia1, A. Kharad2, A. Logan3, R. Hooker4, D. Weill5, K. Patel6. 1Department of Pulmonary, Critical Care, and Transplant, University of South Florida, Tampa, FL, 2Department of Cardiovascular Disease, University of South Florida, Tampa, FL, 3Department of Pharmacy, University of South Florida, Tampa, FL, 4Department of Cardiothoracic Surgery, University of South Florida, Tampa, FL

(839) A 26-Year Survivor of Heart-Lung Transplant: Complications of Chronic Immunosuppression; E. G. Jernigan, V. J. Gonzalez, J. M. Long, J. S. Nelson. University of North Carolina School of Medicine, Chapel Hill, NC

(840) New Approach for Bridge to Lung Transplant in the Candidates Who Are Not Able to Tolerate Peripheral Venovenous Extracorporeal Membrane Oxygenation; T. Yoshizumi1, S. H. Brann1, S. Keshavamurthy1, J. Gomez-Abraham1, M. A. Kashem1, K. Minakata1, F. Cordova2, Y. Toyoda1. 1Cardiovascular Surgery, Temple University, Philadelphia, PA, 2Thoracic Medicine and Surgery, Temple University, Philadelphia, PA


(842) Applying Positive End-Expiratory Pressure Titration During Ex-Vivo Lung Perfusion: One Way of Recruiting Clinically Rejected Donor Lungs; K. S. Ayyat, H. Niikawa, T. Okamoto, K. R. McCurry. Cleveland Clinic Foundation, Cleveland, OH

(843) Hyperammonemia in Lung Transplant Patients; H. M. Gonzalez Bonilla1, A. Goodarzi2, A. S. Siddiqui3, M. Pendurthi3, T. S. Kaleeka2. 1Medicine, Houston Methodist Hospital, Houston, TX, 2Pulmonary and Critical Care Division, Houston Methodist Hospital, Houston, TX, 3Pulmonary and Critical Care Division, Baylor College of Medicine, Houston, TX

(844) Replacement of Artificial Trachea with New Reconstruction of the Trachea and Bronchial Artery Along with Lung Transplantation; A. Kashem1, S. Keshavamurthy1, J. Gomez-Abraham1, T. Yoshizumi1, F. Cordova2, S. Kartik2, A. J. Mamary2, G. Criner2, Y. Toyoda1. 1Cardiovascular Surgery, Temple University, Philadelphia, PA, 2Thoracic and Pulmonary Medicine, Temple University, Philadelphia, PA

(845) Central Canulation for Extracorporeal Circulation in Minimal Invasive Lung Transplantation; L. Moneke, S. Wiesemann, B. Passlick, P. von Samson. Thoracic Surgery, University Hospital Freiburg, Freiburg, Germany

(846) Contemporary Networks of Care: How Eleven Physicians Across Four Subspecialties and Two Countries United to Care for a Critically Ill Twenty-Three-Year-Old Female; L. Harper1, J. Grewal2, G. Finlayson3, R. Nador1, M. Kiess2, J. Swiston1, J. Granton4, L. Klein5, T. De Marco5, J. Yee6, J. Golden7, R. Levy1. 1Division of Respirology, University of British Columbia, Vancouver, BC, Canada, 2Division of Cardiology, University of British Columbia, Vancouver, BC, Canada, 3Division of Critical Care Medicine, University of British Columbia, Vancouver, BC, Canada, 4Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada, 5Division of Cardiology, University of California San Francisco, San Francisco, CA, 6Division of Thoracic Surgery, University of British Columbia, Vancouver, BC, Canada, 7Division of Respirology, University of California San Francisco, San Francisco, CA


(848) Coxsackie B Infection with Multi-Organ Involvement Resulting in Shock; K. Hopkins1, M. Abdou2, I. Gradus-Pizio1, M. Caccamo1, Z. Hashmi3, T. Wozniak3, A. Brittsan1, J. E. Finet1, A. Hadi2. 1Department of Medicine, Indiana
(849) Novel Outpatient Strategy for Managing Resistant CMV Infection Post Lung Transplant; K. Santhanakrishnan, E. Karimi, M. Alaloul, R. Venkateswaran, N. Yonan. Transplant Department, Wythenshawe Hospital, Manchester, United Kingdom

(850) Paradoxical Reaction of Tuberculosis During Anti-Tuberculosis Therapy in a Heart Transplant Recipient; A. Wakamiya¹, O. Seguchi², M. Kumamoto³, Y. Kumai⁴, H. Sunami⁵, K. Kuroda⁶, S. Nakajima⁷, T. Sato⁸, M. Yanase⁹, N. Fukushima¹⁰. ¹Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, ³Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Osaka, Japan

(851) Invasive Pulmonary Aspergillosis in Tuberculosis Cavitation Successfully Treated by Combined Surgery and Antifungal Therapy in a Heart Recipient; P. Avellana, A. Ini, M. Ajzenszlos, D. Radlovachki, S. Belforte, L. Ahualli. Hospital Cosme Argerich, Buenos Aires, Argentina


(854) Simultaneous Pulmonary Cunninghamella and Nocardia Infections; B. Wolf, V. Stosor, M. Angarone, A. Anderson. Infectious Diseases, Northwestern Memorial Hospital, Chicago, IL

(855) Asymptomatic Disseminated Cryptococcus neoformans Infection in a Lung Transplant Recipient Detected by Surveillance Bronchoscopy; R. J. Hadley¹, E. T. Murphy², R. E. Girgis¹. ¹Pulmonary Medicine, Spectrum Health, Grand Rapids, MI, ²Thoracic Surgery, Spectrum Health, Grand Rapids, MI

(856) Disseminated Adenovirus Infection in Heart and Kidney Transplant; K. V. Patel¹, J. Xu², J. Almendral¹, K. Mody¹, D. Iyer¹. ¹Cardiology, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ, ²Internal Medicine, Rutgers - Robert Wood Johnson University Hospital, New Brunswick, NJ

(857) Invasive Fungal Pneumonia Due to Aspergillus Terreus After Heart Transplant: To Treat Medically or Surgically?; J. Leoni, M. Avila, P. Patel, D. Yip, M. Thomas, J. Hosenpud. Mayo Clinic, Jacksonville, FL


(859) Left Ventricle Assisted Device Driveline Infections: The Unusual Suspect; G. A. Hernandez¹, J. D. Nunez Breton², J. Simkins Cohen³, S. V. Chaparro¹. ¹Cardiology, University of Miami/Jackson Memorial Hospital, Miami, FL, ²Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, FL, ³Infectious Diseases, University of Miami/Jackson Memorial Hospital, Miami, FL

(860) Severe MMF-related Colon Toxicity in a Pediatric Heart Transplant Patient Following Treated EBV-Associated Tumors; J. E. Ryan, M. A. McCulloch, R. R. Davies. Cardiac Center, Al duPont Hospital for Children/Nemours, Wilmington, DE

(861) Unusual Presentation of Multifocal Cardiac Rhabdomyoma Requiring Orthotropic Heart Transplantation; D. Gupta¹, D. Rush², R. M. Bryant¹, M. S. Bleiweis¹, B. A. Pietra¹, F. J. Fricker¹. ¹Congenital Heart Center, Department of Pediatrics, University of Florida, Gainesville, FL, ²Department of Pathology, University of Florida, Gainesville, FL

(862) Heart Transplantation in Neonatal Marfan Syndrome: Progress in a Rare and Fatal Disease; J. A. Laks, O. Honjo, L. Grosse-Wortmann, A. I. Dipchand. Cardiology, The Hospital for Sick Children, Toronto, ON, Canada

(863) Successful Heart Transplant for Turner’s Syndrome and Hypoplastic Left Heart Syndrome: Is Primary Transplant the Answer?; D. Gupta, J. Philip, H. V. Vyas, F. J. Fricker, B. A. Pietra, M. S. Bleiweis. Congenital Heart Center, Department of Pediatrics, University of Florida, Gainesville, FL
(864) **Biventricular Pacing in an Infant Following Resection of Large Cardiac Fibroma and Surgical AV Block**; J. J. Parent, R. K. Darragh, A. C. Kean, M. D. Ayers. Pediatric Cardiology, Riley Hospital at Indiana University Health, Indianapolis, IN

(865) **Pay Me Now or Pay Me Later: A Tale of Two Sensitized Pediatric Heart Transplant Candidates**; M. Mangiola1, B. Feingold2, D. Magnetta3, S. West4, S. Miller5, M. Zinn6, M. Marrari7, A. Zeevi1. 1Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Heart Failure and Transplantation Programs, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA

(866) **Pediatric Heart Transplantation from a Donor with Methanol Intoxication**; H. R. Martinez, J. J. Parent. Pediatric Cardiology, Riley Hospital for Children, Indianapolis, IN


(868) **Myocardial Recovery in a Teenager After a Large Anteroseptal Myocardial Infarction: Novel Management with a Temporary Left Ventricular Assist Device**; L. J. May1, K. M. Molina1, E. Griffiths2, H. S. Magdo3, A. K. Lal4, C. Delgado4, C. H. Selzman4, A. Eckhauser4. 1Pediatric Cardiology, Primary Children's Hospital, Salt Lake City, UT, 2Cardiothoracic Surgery, Primary Children's Hospital, Salt Lake City, UT, 3Pediatric Critical Care, Primary Children's Hospital, Salt Lake City, UT, 4Cardiothoracic Surgery, University of Utah, Salt Lake City, UT

(869) **Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in a Two-Year-Old Heart Transplant Patient**; J. Spinner1, M. A. Balderas2, C. E. Bocchini1, R. A. Luna2, S. W. Denfield1, W. J. Dreyer1, D. Nagy-Szakal1, F. D. Ihekweazu1, T. Savidge2, R. Kellermayer1. 1Pediatrics, Baylor College of Medicine, Houston, TX, 2Pathology and Immunology, Baylor College of Medicine, Houston, TX

(870) **Disseminated Adenovirus Infection Successfully Treated with Brincidofovir in a Pediatric Heart Transplant Recipient**; S. J. Wilkens1, P. T. Thrush1, C. L. Backer2, E. Pahl1. 1Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Cardiovascular Thoracic Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

(871) **Clinical Variance in Two Sisters with Complex Congenital Heart Disease and Cardiomyopathy Sharing a Homozygous Variant in the CAP2 Gene**; S. M. Mitchell1, R. Bradshaw2, C. Reddy3, S. Al-Jureidini3, S. Braddock2, M. Willing4, L. Cerny5. 1Pediatrics, Saint Louis University School of Medicine-Cardinal Glennon Children's Medical Center, Saint Louis, MO, 2Medical Genetics, Saint Louis University School of Medicine-Cardinal Glennon Children's Medical Center, Saint Louis, MO, 3Pediatric Cardiology, Saint Louis University School of Medicine-Cardinal Glennon Children's Medical Center, Saint Louis, MO, 4Pediatric Cardiology, Saint Louis University School of Medicine-Cardinal Glennon Children's Medical Center, Saint Louis, MO, 5Neonatology, Saint Louis University School of Medicine-Cardinal Glennon Children's Medical Center, Saint Louis, MO

(872) **Neurologic Events in Patients with Ventricular Assist Device: Don't Forget the Basics**; L. D. Glass1, H. Buchholz2, S. Urschel3, C. Cunningham1, P. Holinski3, V. Anand4, J. Conway4. 1Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada, 2Cardiac Surgery, Stollery Children's Hospital, Edmonton, AB, Canada, 3Pediatric Critical Care, Stollery Children's Hospital, Edmonton, AB, Canada

(873) **Airway Plaque Presenting After Alteration of Immunosuppression in a Pediatric Patient Remote from Heart Transplantation**; T. D. Ryan1, M. J. Absalon2, A. de Alarcon3, A. Gupta4, A. Lorts1, L. A. Danziger-Isakov5, C. Chinn1. 1Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Division of Pediatric Otolaryngology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

(874) **HeartWare Ventricular Assist Device as Bridging Therapy for Transplant in 6-Year Old Child with Myocarditis**; A. Garg1, X. Vilad2, A. Ghodsizad2, M. Loeb3, N. Brozzi3, E. R. Rosenkranz3, P. Rusconi4. 1Pediatrics, Jackson Memorial Hospital, Miami, FL, 2Surgery, Miami Transplant Institute/University of Miami/Miller School of Medicine, Miami, FL, 3Surgery, University of Miami/Miller School of Medicine, Miami, FL, 4Pediatrics, Miami Transplant Institute/University of Miami/Miller School of Medicine, Miami, FL

Wednesday, April 5
(875) Cardiac Transplantation in a Neonate - First Case in Switzerland and European Overview; M. Schweiger¹, B. Stiasny¹, F. Immer², C. Buerki³, O. Kretschmar¹, H. Dave¹, A. Cavigelli-Brunnerb¹, M. Schmiady¹, V. Cannizzaro¹, O. Kretschmar¹, M. Huebler¹. ¹Children's Hospital, Zurich, Switzerland, ²Swiss Transplant, Bern, Switzerland

(876) Giant Coronary Artery Aneurysms and Heart Failure in Kawasaki Disease Leading to VAD Placement; A. Butto¹, D. Nandi², C. E. Mascio³, J. W. Rossano¹. ¹Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Cardiology, The Heart Center, Nationwide Children's Hospital, Columbus, OH, ³Pediatric Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA

(877) Hypertensive Cardiomyopathy in an Infant : A Diagnostic Challenge; P. Patel¹, K. Rose-Felker², H. Viamonte², W. T. Mahle², S. R. Deshpande². ¹Emory University, Atlanta, GA, ²Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA
NOTE: Poster presenters and discussants will be present during the evening poster viewing session from 6:15 PM – 7:15 PM.

ECONOMICS, ETHICS, PUBLIC POLICY
(Conrado Foyer)

Poster Discussants: Cristiano Amarelli, MD (Italy), Melanie D Everitt, MD (USA), Kathleen L Grady, PhD, APN, FAAN (USA)

(878) Association of Insurance Coverage on the Development of Coronary Allograft Vasculopathy After Pediatric Heart Transplant; E. Pruitt1, S. Urschel2, M. D. Everitt3, J. K. Kirklin1, D. C. Naftel1. 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alberta, Edmonton, AB, Canada, 3Children’s Hospital Colorado Heart Institute, Aurora, CO

(879) Socioeconomic Status and Heart Transplantation; N. Harati1, A. Iyengar1, E. Adams1, C. Eisenring2, L. Reardon3, M. Deng3, A. Ardehali3, E. DePasquale3. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2Department of Cardiology, University of California - Los Angeles, Los Angeles, CA, 3Department of Cardiology, University of California - Los Angeles, Los Angeles, CA

(880) The In-Hospital Cost of Heart Transplantation; A. Iyengar1, E. Adams1, C. Eisenring2, N. Satou2, L. Reardon3, M. Deng3, R. J. Shemin2, A. Ardehali3, E. DePasquale3. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2Department of Cardiology, University of California - Los Angeles, Los Angeles, CA, 3Department of Cardiology, University of California - Los Angeles, Los Angeles, CA

(881) Simplification of Cyclosporine a Dosing Strategy to Improve Medication Adherence; E. K. Harmel1, M. H. Goldmann1, N. Hasait2, M. Rybczynski3, H. Reichenspurner4, M. J. Barten1. 1Department of Cardiac Surgery, University Heart Center Hamburg, Hamburg, Germany, 2Department of Pharmacology, University Heart Center Hamburg, Hamburg, Germany, 3Department of Cardiology, University Heart Center Hamburg, Hamburg, Germany

(882) Can Lungs Be Recovered Quickly from First Person Authorized (FPA) Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs)? The Law vs Knowledge and Attitudes Among FPA Adults; T. M. Egan1, J. Requard III2, T. Edwards2. 1Surgery, U. North Carolina Sch Med, Chapel Hill, NC, 2Lung Banks of America, Chapel Hill, NC, 3ODUM Institute, U. North Carolina Sch Med, Chapel Hill, NC

(883) Causes and Preventability of Unplanned Rehospitalization Following Lung Transplantation; A. Courtwright1, D. Zaleski2, V. Ahya1, C. Bermudez3, N. Blumenthal1, E. Cantu3, J. Christie1, T. Claridge1, M. Crespo1, J. Golato1, D. Hadjiladi1, E. Hobson1, J. Lee1, M. Molina3, N. Patel1, M. Porteous1, J. Diamond1. 1Pulmonary and Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, 2Good Shepard Penn Partners, Philadelphia, PA, 3Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, PA

(884) Terminal Withdrawal of ECMO in the ICU: A Retrospective Analysis; N. A. Braus1, P. S. Mueller2, G. J. Schears3. 1Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, 2General Internal Medicine, Mayo Clinic, Rochester, MN, 3Anesthesiology, Mayo Clinic, Rochester, MN

(885) Subclavian Artery Access Intra-Aortic Balloon Pump (sIABP): An Excellent Value-Based Bridge to Transplant Therapy; T. Lammy1, C. Juricek1, V. Kagan1, D. Onsager1, T. Song1, T. Ota1, N. Uriel1, V. Jeevanandam1. 1Cardiothoracic Surgery, University of Chicago Medicine, Chicago, IL, 2Cardiology, University of Chicago Medicine, Chicago, IL

(886) Patient and Clinician Insights for Dissemination and Implementation Planning of a Patient-Centered Decision Aid for Left Ventricular Assist Device (LVAD) Treatment; K. M. Kostick1, R. J. Volk2, C. R. Bruce1, S. A. McCurdy3, J. D. Estep4, J. S. Blumenthal-Barby1. 1Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, 2Department of Health Services Research, The M.D. Anderson Cancer Center, University of Texas, Houston, TX, 3School of Public Health, University of Texas, Houston, TX, 4Houston Methodist DeBakey Heart & Vascular Center and J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX
(887) **Mechanical Circulatory Support Devices (MSCD) Therapy in the Era of the Affordable Care Act (ACA): National Trends in Hospitalization Costs and In-Hospital Mortality;** L. Sridharan1, R. Givens1, A. R. Garan1, M. Yuzefpolskaya1, K. Takeda2, H. Takayama1, F. Latif1, J. Haythe1, S. Restaino1, M. Maurer1, D. Mancini3, M. J. Farr1, Y. Naká2, P. Colombo1, V. K. Topkara1. 1Cardiology, Columbia University, New York, NY, 2Cardiothoracic Surgery, Columbia University, New York, NY, 3Cardiology, Mount Sinai, New York, NY

(888) **Destination to Nowhere: The Ethics of Acute Mechanical Circulatory Support;** V. Kagan1, R. Rose1, H. Costantini1, C. Juricke1, T. Lammy1, T. Ota1, D. Onsager1, S. Adatyam2, N. Uriel2, P. Angelos3, V. Jeevanandum1, T. Song1. 1Cardiothoracic Surgery, University of Chicago Medicine, Chicago, IL, 2Cardiology, University of Chicago Medicine, Chicago, IL, 3General Surgery, University of Chicago Medicine, Chicago, IL

(889) **Doing the Math: The Costs of Long Term Mechanical Circulatory Support;** J. J. Chung1, R. Stetson2, C. W. Chen1, A. C. Gaffey1, J. Rame3, M. A. Acker4, P. Atluri4. 1Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Corporate Office of Strategic Decision Support, University of Pennsylvania, Philadelphia, PA, 3Department of Medicine, University of Pennsylvania, Philadelphia, PA, 4Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

(890) **Building a More Cost-Efficient ECLS Team by Inviting Everyone to the Table;** R. A. Rose1, R. M. Piech2, V. Kagan2, A. F. Linden3, N. Uriel4, V. Jeevanandum2, T. H. Song2. 1ECMO / MCS Services, University of Chicago Medicine, Chicago, IL, 2Cardiothoracic Surgery, University of Chicago Medicine, Chicago, IL, 3Pediatric Surgery, University of Chicago Medicine, Chicago, IL, 4Cardiology, University of Chicago Medicine, Chicago, IL

**HEART TRANSPLANTATION**

(Regatta Foyer)

**Poster Discussants:** Mark B Connellan, MD, FC(Cardio) (Australia), Eugene C DePasquale, MD (USA), Sitaramesh Emani, MD (USA), Eileen M Hsich, MD (USA), Kiran Khush, MD, MAS (USA), Lucian Lozonschi, MD (USA), Daniel B Sims, MD (USA), Mustafa Toma, MD (Canada), Adriana Torres, MD (Colombia), Marian Urban, MD (United Kingdom), Tahir Yagdi, MD (Turkey)


(892) WITHDRAWN


(894) **High Levels of Galectin 3 in Heart Recipients with a History of Acute Cellular Rejection;** E. Sarmiento1, M. Sarwa1, T. Sigdel1, Y. Ng1, L. Li5, C. Rodriguez6, Y. Castro7, I. Sousa8, E. Zatarain8, J. Carbone1. 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Division of Multiorgan Transplant, University of California San Francisco, San Francisco, CA, 3Surgery, School of Medicine, University of California San Francisco, San Francisco, CA, 4Surgery, University of California San Francisco, San Francisco, CA, 5Department of Biostatistics, Mount Sinai School of Medicine, New York, NY, 6Biochemistry, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 7Pathology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 8Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain


(896) WITHDRAWN

(897) **Can We Use Tissue Doppler Imaging to Screen for Cardiac Allograft Rejection and Coronary Vasculopathy?;** M. D. Yu1, E. Sampene2, J. Nan1, P. Rahko3, R. Dhingra3. 1Department of Medicine, University of Wisconsin, Madison, WI, 2Department of Biostatistics, University of Wisconsin, Madison, WI, 3Advanced Heart Failure and Transplant Cardiology, University of Wisconsin, Madison, WI

Friday, April 7
(898) Human Leucocyte Antigen (HLA) Matching in Heart Transplantation: Impact on Cellular Rejection and Survival?; U. Boeken1, A. Albert1, A. Mehdiani1, G. Petrov1, B. Sowinski1, R. Westenfeld2, D. Saeedi1, P. Akhyari1, A. Lichtenberg1. 1Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, 2Cardiology, University Hospital, Duesseldorf, Germany.

(899) Early Exposure to ISHLT Grade 1R Rejection Reduces Long-Term Mortality in Heart Transplant Recipients Surviving the First Year; M. Yin, A. Esmaeeli, A. Morris, D. Gupta, D. Vega, R. Laskar, A. Smith, R. Cole. Emory University School of Medicine, Atlanta, GA.


(902) Acute Cellular Rejection in Heart Transplant Recipients May Not Be Acute After All; N. Bassi1, G. Sayer1, L. Benes1, C. Murks2, J. Raikhelkar2, S. Adatya2, G. Kim2, N. Sarswat2, T. Ota3, V. Jeevanandam3, N. Uriel2. 1University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL, 3Cardiac Surgery, University of Chicago, Chicago, IL.

(903) Early Antibody Mediated Rejection Post Orthotopic Heart Transplantation: A Single Center Experience; L. Rajapreyar1, S. Nathan2, A. Ghotra3, M. Nolan2, P. Weeks4, a. Sieg5, B. Kar6, P. Loyalka2, C. Paruthi6, I. Gregoric6. 1University of Alabama, Birmingham, Birmingham, AL, 2University of Texas, Houston, Houston, TX, 3University of Texas, Houston, Birmingham, AL, 4Memorial Hermann Hospital, Houston, TX, 5University of Kentucky, Louisville, KY, 6University of Texas, Houston, Houston, TX.

(904) Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction in the Transplanted Heart; P. Kim1, F. Contijoch1, D. Wong1, R. Ingle2, A. Hsiao3, J. Santos2, A. Kahn1, M. Pham4, E. McVeigh5, E. Adler1, P. Nguyen1. 1Medicine, University of California, San Diego, San Diego, CA, 2HeartVista, Mountain View, CA, 3Radiology, University of California, San Diego, San Diego, CA, 4Medicine, California Pacific Medical Center, San Francisco, CA, 5Bioengineering, University of California, San Diego, San Diego, CA, 6Medicine, Stanford University, Palo Alto, CA.

(905) Should We Pharmacologically Modulate Renin-Aldosterone-Angiotensin System (RAAS) to Attenuate Cardiac Allograft Vasculopathy? A Prospective Study Using Highly Automated Coronary Optical Coherence Tomography Segmentation Software in 3D; M. Pazderkin1, T. Kovarnik1, M. Sonka2, A. Wahle2, Z. Chen2, V. Karmazin2, J. Kautzner1, A. Tomasek1, V. Melenovsky3, H. Bedanova3. 1IKEM, Prague, Czech Republic, 2University of Iowa, Iowa City, IA, 3Centre of Cardiovascular and Transplantation Surgery, Brno, Czech Republic.


(907) Serial Evaluation of Plaque Characteristics in Coronary Artery Lesions Using Optical Coherence Tomography After Heart Transplantation; Y. Tsukamoto1, T. Ohtani1, T. Shiraki1, Y. Ichibori1, S. Saito2, M. Awata1, K. Toda2, O. Yamauchi1, Y. Sawa2, Y. Sakata1. 1Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan, 2Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan.


Friday, April 7
(910) WITHDRAWN

(911) Higher Heart Rate Is Associated with Lower Incidence of Coronary Allograft Vasculopathy Requiring Angioplasty; A. Selim¹, R. Zolty¹, A. Burdorff¹, A. Siddique², J. Um², M. J. Moulton², B. D. Lowes¹, E. Raichlin¹.
¹Cardiology, University of Nebraska Medical Center, Omaha, NE; ²Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE


(913) Angiogenesis on Coronary Angiography Is a Marker for Accelerated Cardiac Allograft Vasculopathy as Assessed by Intravascular Ultrasound; R. Cheng, B. Azarbal, D. Chang, T. Aintablian, L. Czer, J. Patel, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(914) Reduced Coronary Flow Reserve by PET Predicts Cardiovascular Events Following Cardiac Transplantation; M. C. Konerman¹, J. J. Lazarus¹, R. L. Weinberg¹, M. Ghannam¹, A. Salehi¹, H. Yun¹, V. M. Moles¹, S. L. Hummel¹, R. V. Shah¹, J. R. Corbett¹, K. D. Aaronson¹, M. M. Colvin¹, T. M. Koelling¹, V. L. Murthy¹. ¹University of Michigan, Ann Arbor, MI; ²Beth Israel Deaconess Medical Center, Boston, MA

(915) Use of Gene Expression Profiling Score Variability to Predict Cardiac Allograft Vasculopathy: A Single Center Experience; L. Reijal¹, O. Aldibasi², S. Sidhu¹, S. Ware¹, K. Canales¹, R. Vasquez¹, D. Dumas-Hicks¹, S. Desai¹, H. Ventura¹, S. Krim¹. ¹Ochsner Clinic Foundation, New Orleans, LA; ²Louisiana State Univ Health Sciences Center, New Orleans, LA

(916) Cocaine Use Does Not Contribute to Accelerated CAD as Determined by Angiography or IVUS; S. Beauchamp¹, A. Borkon², K. Karl¹, S. Aggarwal¹, A. Kao¹, A. Magalski², K. Allen¹, B. Austin³, T. Khumari³, S. Lawhorn³, N. Long¹, J. Wang¹, R. Davis¹, E. Thompson¹, A. Pak¹. ¹Cardiovascular Surgery, Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO; ²Mid America Heart & Lung/St. Luke’s, Kansas City, MO; ³Cardiology, Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO

(917) Cardiopulmonary Stress Test One Year After HTx Predicts the Development of CAV; E. Raichlin¹, A. Selim¹, R. Zolty¹, A. Burdorff¹, A. Siddique², M. J. Moulton², J. Um², B. D. Lowes¹. ¹Cardiology, University of Nebraska Medical Center, Omaha, NE; ²Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE

(918) Rubidium 82 Positron Emission Tomography in Cardiac Allograft Vasculopathy; S. Chih, A. Chong, F. Erthal, R. A. deKemp, D. So, R. A. Davies, E. Stadnick, L. M. Mieleniczuk, R. S. Beanlands. Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada

(919) Coronary Computed Tomography to Screen for Cardiac Allograft Vasculopathy Post Orthotopic Heart Transplant; R. Tanner¹, J. Buckley¹, D. Murphy², L. Lawler², N. Mahon³, J. O’Neill¹. ¹Heart Transplant, Mater Misericordiae University Hospital, Dublin, Ireland; ²Radiology, Mater Misericordiae University Hospital, Dublin, Ireland; ³Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland

(920) Time Dependent Covariate Method for Assessing Impact of CAV Severity on Mortality After Cardiac Transplantation; F. Foroutan¹, A. Alba¹, S. Bhaqa¹, J. Duero Posada¹, M. Alhussein¹, A. K. McDiarmid¹, A. Malik¹, G. Guyatt², H. Ross¹. ¹Cardiology, Toronto General Hospital, Toronto, ON, Canada; ²Health Research Methodology, McMaster University, Hamilton, ON, Canada

(921) Increased Heart Rate After Heart Transplant Is Not Associated with Early Progression of Cardiac Allograft Vasculopathy (CAV) - A Prospective Study Using Highly Automatic Coronary Optical Coherence Tomography Segmentation Software in 3D; M. Pazdernik¹, T. Kovarnik¹, Z. Chen², A. Wahle², V. Karmazin¹, V. Melenovsky¹, J. Kautzner¹, A. Tomasek³, H. Bedanova³, M. Sonka³. ¹IKEM, Prague, Czech Republic; ²University of Iowa, Iowa City, IA; ³Centre of Cardiovascular and Trasplation Surgery, Brno, Czech Republic

(922) Percutaneous Intervention Improves Outcome in Cardiac Allograft Vasculopathy; R. Sappa¹, D. Zanuttini¹, S. Sponga¹, D. Piani¹, C. Nalli¹, V. Tursi¹, T. Banelli², A. Proclemer¹, U. Livi¹. ¹Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy; ²Scienze Mediche e Biotecnologiche, Università degli Studi di Udine, Udine, Italy
(923) Hypomagnesemia and the Risk of Cardiac Allograft Vasculopathy; R. Gorantla, S. Sikanderkhel, M. F. Almahmoud, R. Roark, W. Khalife. University of Texas Medical Branch, Galveston, TX

(924) First Experience with MeltDose-Tacrolimus (Envarsus) in Heart Transplantation; K. Uyanik-Uenal, R. Moayedifar, E. Osorio, A. Aliabadi-Zuckermann, T. Haberl, G. Lauter, A. Zuckermann. Department of Cardiac Surgery, Medical University of Vienna (AKH), Vienna, Austria

(925) The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Exercise Capacity in De-Novo Heart Transplant Recipients: Results of the SCHEDULE Trial After 36 Months; S. Arora1, E. Gude1, K. Karason2, B. Andersson2, S. Bartfay3, D. Solbu3, G. Dellgren2, A. Andreassen1, L. Gullestad1. 1Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Novartis Norge, Oslo, Norway

(926) May Intraoperative Immunosuppressive Therapy Reduce the Rejection Episodes at Cardiac Transplant Recipients?: M. B. Rabus1, D. Cekmecelioglu2, P. Ata2, S. Salihi3, E. Selcuk1, M. Balkanay4. 1Cardiovascular Surgery, Kartal Kosuyolu Heart Research and Training Hospital, Istanbul, Turkey, 2Cardiology, Marmara University Medical Faculty, Istanbul, Turkey, 3Cardiovascular Surgery, Ouk University Medical Faculty, Istanbul, Turkey, 4Cardiovascular Surgery, Katip Celebi University Medical Faculty, Izmir, Turkey

(927) Heart Transplantation in Patients with Low or High Titer Pre-Formed DSA Is Safe When Performed with a Specific Desensitization Program; G. Coutance1, V. D’Orio1, S. Ouldhammar1, P. Rouvier2, S. Saheb3, P. Demondion1, N. Bréchot1, N. Ait Hamou1, G. Lebretoun1, J. Taupin6, A. Combes4, J. Amour5, P. Leprince1, S. Varnous1. 1Thoracic and Cardiovascular Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 2Pathology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 3Hemiotherapy, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 4Medical Genetics, Marmara University Medical Faculty, Istanbul, Turkey, 5Anesthesiology and Reanimation, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 6Histocompatibility, Hôpital Saint Louis, Paris, France

(928) Survival with Induction Therapy for Simultaneous Heart-Kidney Transplant Recipients on Tacrolimus/Mycophenolate; A. A. Amin1, V. K. Ariyamuthu2, M. A. Urey1, F. G. Araj1, M. H. Drazner1, P. P. Mammen1, B. Tanriover1. 1Cardiology, UT Southwestern, Dallas, TX, 2Nephrology, UT Southwestern, Dallas, TX

(929) Impact of Low-Dose Steroids Protocol on Early Outcomes After Cardiac Transplantation: A Brazilian Experience; R. M. Carneiro1, V. S. Monteiro1, F. A. Figueira2, D. L. Ferraz2, C. B. Cunha2, J. D. Carvalho Jr2, J. P. Oliveira2, F. R. Walter2, A. H. Baia1, G. C. Silva3, C. A. Medeiros4, S. Steremberg4, A. R. Lafayette1, A. Kelner2. 1Cardiology, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, 2Cardiac Surgery, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, 3Faculdade Pernambucana de Saúde, Recife, Brazil, 4Intensive Care Unit, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil

(930) Outcomes Assessment Based on a Risk-Stratified Simple Score After Orthotopic Heart Transplantation; K. Morris1, K. A. Lane2, E. Lushin3, J. Finet4, I. Gradus-Pizlo4, A. Hadi4, M. Caccamo4. 1Indiana University School of Medicine, Indianapolis, IN, 2Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, 3Pharmacy, Indiana University School of Medicine, Indianapolis, IN, 4Cardiology, Indiana University School of Medicine, Indianapolis, IN

(931) WITHDRAWN


(933) Calcineurin Inhibitor Free Immunosuppression in Heart Transplant Recipients Is Associated with Preserved Renal Function and Good Survival: Long Term Follow-Up; C. Barbero, S. Fitzsimons, C. Lewis, J. Parameshwar, S. J. Pettit. Transplant Unit, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom

(934) The Effect of Donor Arginine Vasopressin Use within 24 Hours of Aortic Cross-Clamp on 1-Year Recipient Survival; S. K. Lella1, K. Zolfaghari2, L. A. Copeland2, C. B. Sai-Sudhakar3, Y. Ravi4. 1College of Medicine, Texas A&M University, Dallas, TX, 2Center for Applied Health Research, Baylor Scott and White Health, Temple, TX, 3Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare, Temple, TX

Friday, April 7
(935) **Absolute Lymphocyte Count Before Induction Therapy with Basiliximab Can Predict Fatal Infection in Heart Transplant Recipients**; J. Oh, I. Kim, S. Lee, H. Park, Y. Yoon, S. Kang. Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

(936) **Extended Use of rATG or Basiliximab Allows Delayed CNI Initiation in Patients with Renal Dysfunction After Heart Transplantation**; V. Manfredini, S. Pettit, C. Lewis, D. Brahmbatt, J. Parameshwar, A. Kydd. Papworth Hospital, Cambridge, United Kingdom

(937) **Is Tacrolimus/Proliferation Signal Inhibitor (PSI) Comparable to Cyclosporine/PSI After Heart Transplantation?**; D. Chang, M. Kittleson, J. Patel, T. Aintabli, A. Velleca, G. Jamero, E. Kransdorf, D. Geft, L. Czer, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA


(940) **The Use of Intra-Aortic Balloon Pump Pre-Transplant Is Associated with Worse Outcomes in Heart Transplant Recipients**; D. Vucicević, L. Honoris, A. Chang, E. Moreno, A. Salimbangon, M. Moore, L. Sweet, S. Shah, A. Iyengar, K. Panda, A. Ardehali, M. Deng, E. DePasquale. 1Department of Cardiology, UCLA, Los Angeles, CA, 2Department of Cardiology, UC Davis, Davis, CA, 3Department of Cardiothoracic Surgery, UCLA, Los Angeles, CA

(941) **Severe Obesity in Heart Transplant Correlates with Increased Primary Graft Dysfunction but Not with One-Year Mortality**; M. J. Sherwood, S. M. Joseph, G. Saracino, S. A. Carey, J. Felixus, T. Chamogeorgakis, A. E. Rafael, J. C. MacHannaford, G. V. Gonzalez-Stawinski, S. A. Hall, B. Lima. Baylor University Medical Center, Dallas, TX

(942) **Mid- to Long-Term Experience of Multiple Organ Heart Transplantation in a Mid-Size Center in Germ**; T. Sandhaus, M. Leuze, M. Dordevic, G. Faerber, H. Kirov, M. Breuer, M. Grimm, U. Settmacher, T. Doenst. 1Department of Cardiothoracic Surgery, Friedrich Schiller University, Jena, Germany, 2Department of Cardiac Surgery, Central Clinic, Bad Berka, Germany, 3Department of Urology, Friedrich Schiller University, Jena, Germany, 4Department of General, Abdominal and Vascular Surgery, Friedrich Schiller University, Jena, Germany

(943) **The Impact of Socioeconomic Factors on Heart Transplant Outcomes**; A. L. Clark, R. Watkins, J. Katz, B. Jensen, L. Rose-Jones, S. Waters, M. Andrews, P. Chang. 1Internal Medicine, University of North Carolina, Chapel Hill, NC, 2University of North Carolina, Chapel Hill, NC, 3Cardiology, University of North Carolina, Chapel Hill, NC

(944) **Contemporary Analysis of Heart Transplantation Outcomes in Patients with Neuromuscular Cardiomyopathies**; F. Kamdar, R. Urban, L. B. Edwards, P. P. Mammen, J. Stehlik, D. O. Taylor. 1Cleveland Clinic, University of Minnesota, Minneapolis, MN, 2United Network for Organ Sharing, Richmond, VA, 3United Network for Organ Sharing, International Society of Heart and Lung Transplantation Registry, Richmond, VA, 4University of Texas Southwestern, Dallas, TX, 5International Society of Heart and Lung Transplantation Registry, University of Utah, Salt Lake City, UT, 6Cleveland Clinic, Cleveland, OH

(945) **High Urgency Heart Transplantation in Vienna, Austria**; E. N. Osorio-Jaramillo, A. Z. Aliabadi-Zuckermann, R. Moayedifar, K. L. Freystaetter, T. Haberlí, K. Uyanik-Uenali, G. Laufer, A. O. Zuckermann. 1Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Cardiovascular Surgery, Bern University Hospital, Bern, Switzerland

LUNG TRANSPLANTATION
(Harbor Foyer)

Poster Discussants: Hakim A Ali, MD (USA), Cecilia Chaparro, MD (Canada), Christopher Ensor, PharmD, BCPS-CV (USA), Steven C Juvet, MD, PhD, FRCPC (Canada), Tanya J McWilliams, MD, PhD (New Zealand), Antoine Roux, MD, PhD (France), Helen M Whitford, MBBS, FRACP (Australia), Keith M Wille, MD, MSPH (USA), Bryan A Whitson, MD (USA)

(947) WITHDRAWN

(948) WITHDRAWN

(949) Pirfenidone as a Bridge Therapy for Lung Transplantation: S. Tanaka, K. Miyoshi, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, T. Oto. Department of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(950) Post Lung Transplant Survival of Recipients with Sarcoidosis in LAS Era: J. Mooney¹, J. Boyd², L. Chhatwani¹, G. S. Dhillon¹. ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA


(952) Pre-Transplant Delayed Gastric Emptying Does Not Correlate with Incidence of Acute Rejection or Bronchiolitis Obliterans Syndrome After Lung Transplantation: A. Kafi¹, J. Falk¹, G. Chaux¹, S. Ghandehari¹, W. Cheng², D. Ramzy³. ¹Pulmonary and Critical Care, Cedars Sinai Medical Center, Los Angeles, CA, ²Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA

(953) Association of Methacholine Challenge Test with Diagnosis of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients: A. Siddiqui¹, F. Zahiruddin¹, G. Kumar², A. Goodarzi³, J. Yousef³, T. Majumdar³, N. Sinha³, T. Kaleekal³. ¹Pulmonary and Critical Care, Houston Methodist Hospital, Houston, TX, ²Pulmonary and Critical Care, Northeast Georgia Medical Center, Gainesville, FL, ³Pulmonary Transplant, Houston Methodist Hospital, Houston, TX

(954) Normal Impact of Restrictive and Obstructive Subtypes of Chronic Lung Allograft Dysfunction on Graft Survival - Single Center 13 Year Experience: A. I. Nykänen¹, M. Halme², C. Stark³, P. Hämmäinen³, K. B. Lemström¹, P. Raivio¹. ¹Cardiac Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ²Pulmonary Diseases, Helsinki University Hospital, Helsinki, Finland, ³Cardiac Surgery, Helsinki University Hospital, Helsinki, Finland

(955) Automating the Diagnosis of Potential CLAD and Its Subtypes in Lung Transplant Recipients: W. Klement¹, J. Tikkanen², S. Juvet³, J. L. Todd³, S. S. Weigt³, L. D. Snyder³, S. Azad³, J. A. Belperio³, S. M. Palmer³, L. G. Singer², S. Keshavjee³, T. Martinu². ¹Latner Thoracic Surgery Laboratories, University Health Network / University of Toronto, Toronto, ON, Canada, ²Toronto Lung Transplant Program, University Health Network / University of Toronto, Toronto, ON, Canada, ³Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University, Durham, NC, ⁴Dept. of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁵Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ⁶Toronto Lung Transplant Program, Latner Thoracic Surgery Laboratories, University Health Network / University of Toronto, Toronto, ON, Canada, ⁷Division of Respirology & Lung Transplant Program, University Health Network / University of Toronto, Toronto, ON, Canada

(956) Lung Retransplantation for CLAD- Does the Phenotype of CLAD Affect the Survival? A Retrospective Exploratory Study: M. M. Schuster, G. Muraközy, C. Lambers, A. Benazzo, S. Schwarz, W. Klepetko, P. Jakusch. Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria


(958) Increased Interstitial Neutrophils in Lung Transplant Recipients with Donor Specific Antibodies as a Potential Marker of Subclinical AMR-Related Events: L. Godinas¹, J. Lepavec², V. de Montpreville², M. Ghigna², S.
Mussot², O. Mercier², E. Fadel², P. Dorfmüller². ¹CHU UCL Namur, Yvoir, Belgium, ²Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France


(960) Clinical Characteristics & Outcomes of Restrictive CLAD After Bilateral Living-Donor Lobar Lung Transplantation; K. Mesaki, K. Miyoshi, S. Namura, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, S. Miyoshi, T. Oto. Department of Thoracic Surgery, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(961) In Vitro Analysis of RBC-Mediated Lung Injury in Prolonged Ex Vivo Lung Perfusion; J. R. Spratt¹, G. Loo¹, L. M. Mattison², C. Meyer³, M. Ehrhardt³, H. Helms³, A. Panoskaltsis-Mortari³. ¹Department of Surgery, University of Minnesota, Minneapolis, MN, ²Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, ³Department of Pediatrics, University of Minnesota, Minneapolis, MN

(962) Cytokine Levels in Steen Solution Perfusate Increase During Ex-Vivo Lung Perfusion (EVLP) of Lungs from Conventional Donors (Conv) and Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs); S. Masuo¹, J. Blackwell², P. Stewart², T. M. Egan¹. ¹Surgery, U. North Carolina Sch Med, Chapel Hill, NC, ²Biostatistics, Gillings Global School of Public Health, UNC, Chapel Hill, NC

(963) Lung Transplantation from DCD Donors After Prolonged Normothermic Portable EVLP; J. R. Spratt¹, L. M. Mattison², P. A. Iaizzo¹, C. Meyer³, T. L. Iles¹, A. Panoskaltsis-Mortari³, G. Loo¹. ¹Department of Surgery, University of Minnesota, Minneapolis, MN, ²Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, ³Department of Pediatrics, University of Minnesota, Minneapolis, MN

(964) EVLP: A Monocentric Five Year Experience; V. Rossetti¹, L. Morlacchi¹, P. Tarsia¹, G. Ruggeri², L. Rosso³, M. Nosotti³, F. Blasi¹, D. Tosi¹, F. Valenza⁴. ¹Department of Pathophysiology and Transplantation, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ²Dipartimento di Anestesia Rianimazione (Intensiva e Subintensiva) e Terapia del dolore, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ³U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ⁴Dipartimento di Anestesia (Intensiva e Subintensiva) e Terapia del Dolore, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

(965) How to Resolve Large Atelectasis in Ex Vivo Lung Perfusion?; T. Okamoto¹, H. Niikawa², D. Wheeler³, B. Soliman¹, K. Ayyat², G. Sunagawa⁴, K. R. McCurry⁴. ¹Transplant Center, Cleveland Clinic, Cleveland, OH, ²Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, ³Pediatric Respiratory Therapy, Medical University of South Carolina, Charleston, SC, ⁴Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, ⁵Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

(966) Post-Lung Transplant Outcome & Risk Matching Between Donor & Recipient - Score-Based Analyses; K. Miyoshi, T. Kurosaki, S. Otani, S. Sugimoto, M. Yamane, T. Oto. Department of Thoracic Surgery / Organ Transplant Centre, Okayama University Hospital, Okayama, Japan

(967) Lung Transplant from Donors After Previous Cardiac Surgery: Ideal Graft in Marginal Donor?; A. Palleschi¹, D. Tosi¹, P. Mendogni¹, M. Montoli¹, P. Tarsia², V. Rossetti², F. Valenza³, M. Nosotti¹, L. Santambrogio¹. ¹Thoracic Surgery and Lung Transplant Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, ²Pneumology Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy, ³Anesthesia and Intensive Care Unit, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy

(968) Does Post-Lung Transplant Mortality Vary by Diagnosis For a Given Lung Allocation Score?; H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University, Baltimore, MD, ²Department of Medicine, Johns Hopkins University, Baltimore, MD

(969) Effect of Favorable Donor Factors on Outcomes After Bilateral Lung Transplantation: Preliminary Prospective Analysis of the University of Minnesota Donor Lung Quality Index (UMN-DLQI); G. Loo¹, S. Huddleston¹, S. Jackson³, S. Elde³, T. Grabowski², R. Kelly¹, S. Shumway¹, M. Hertz². ¹Surgery, University of Minnesota, Minneapolis, MN, ²Fairview Medical Center, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN

Friday, April 7
(970) 5-Year Mortality Is Superior in COPD Patients That Receive Double vs Single Lung Transplants; T. C. Crawford1, A. Suarez-Pierre1, J. Magruder1, J. C. Grimm1, J. Ha1, R. Stephens2, B. S. Kim2, C. A. Merlo2, S. Broderick3, E. L. Bush2. 1General Surgery, Johns Hopkins University, Baltimore, MD; 2Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD; 3General Surgery, Division of Thoracic Surgery, Johns Hopkins University, Baltimore, MD

(971) ABO-Identical Matching Has No Superiority in Survival in Comparison to ABO-Compatible Matching in Lung Transplantation; M. Fakhro1, R. Ingemansson1, L. Algotsson2, S. Lindstedt1. 1Dept. of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden; 2Dept. of Thoracic Intensive Care and Anesthesia, Skåne University Hospital, Lund University, Lund, Sweden

(973) The Effect of Oversizing Donor Lungs for Recipients with Pulmonary Fibrosis Undergoing Single or Bilateral Lung Transplantation; H. Doshi, E. Pavlushkov, B. Marius, P. Catarino, J. David, J. Parmar. Papworth Hospital, Papworth Everard, United Kingdom

(974) Influence of Ischemic Time on Post Lung Transplant (LT) Outcomes; A. Iyengar1, E. Adams1, N. Harati1, C. Eisenring2, D. Ross3, E. DePasquale4, A. Ardehali2. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA; 2Department of Cardiac Surgery, University of California - Los Angeles, Los Angeles, CA; 3Department of Pulmonology, University of California - Los Angeles, Los Angeles, CA; 4Department of Cardiology, University of California - Los Angeles, Los Angeles, CA


(976) Impact of Diabetes Mellitus and Glycemic Control in Lung Transplant Donors on Recipient Survival; V. R. Esposito1, M. S. Mulvihill2, M. G. Hartwig3. 1Duke University School of Medicine, Durham, NC; 2Duke Surgery, Duke Health, Durham, NC; 3Duke Cardiovascular and Thoracic Surgery, Duke Health, Durham, NC

(977) Impaired Preoperative Renal Function Should Not Be a Barrier to Transplantation in Patients with Cystic Fibrosis; T. C. Crawford1, J. Magruder1, J. C. Grimm1, A. Suarez-Pierre1, X. Zhou1, J. S. Ha2, S. R. Broderick1, C. A. Merlo2, B. S. Kim3, E. L. Bush1. 1General Surgery, Johns Hopkins University, Baltimore, MD; 2Cardiothoracic Surgery, Johns Hopkins University, Baltimore, MD; 3Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD

(978) Smoking Donors in Lung Transplantation: Clinical and Pathological Study of Their Impact at Short- and Long-Term Outcomes; M. Schiavon1, G. Marulli1, M. Loy1, F. Lunardi1, G. Di Gregorio2, A. Lloret1, F. Calabrese1, F. Rea1. 1Cardiac, Thoracic and Vascular Sciences, University of Padua, Padova, Italy; 2Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy

(979) Suicidal Hanging Donors for Lung Transplantation: Is This Chapter Still Closed? Midterm Experience from a Single Centre; O. Ananiadou1, B. Zych1, D. Garcia Saez1, P. Mohite1, B. Schmack1, L. Fazekas1, M. Husain1, A. Jothidasan1, A. Sabashnikov1, A. Weymann1, A. Reed2, M. Carby2, F. De Robertis1, A. R. Simon1, A. Popov1. 1Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital, Harefield, United Kingdom; 2Transplant and Respiratory Medicine, Harefield Hospital, Harefield, United Kingdom


(981) Lung Transplant Outcomes in Donors Managed with Airway Pressure Release Ventilation; S. Biswas Roy1, C. Haworth2, M. Olson3, P. Kang4, K. E. Varsch1, T. S. Panchabhai1, R. M. Bremner1, M. A. Smith1, R. Walia1. 1Norton Thoracic Institute, St. Joseph's Hospital & Medical Center, Phoenix, AZ; 2A.T. Still University, Mesa, AZ; 3Grand Canyon University, Phoenix, AZ; 4University of Arizona College of Public Health, Phoenix, AZ

(982) Lung Transplantation with Controlled Donation After Circulatory Death Donors: Initial Experience in Switzerland; I. Inci, R. Lennherr, S. Hillinger, D. Schneiter, M. Beschir, I. Schmitt-Optiz, R. Schuepbach, M. Schuermans, C. Benden, W. Weder. University Hospital, Zurich, Switzerland
(983) Impact of Prolonging CMV Prophylaxis in High Risk (CMV D+/R-) Lung Transplant Recipients; B. Khan1, S. Husain1, M. Binne1, C. Chow1, T. Martinu1, C. Chaparro1, S. Keshtavjee2, L. G. Singer1, J. Tikkanen1.
1Toronto General Hospital, Toronto, ON, Canada, 2Department of Thoracic Surgery, Toronto General Hospital, Toronto, ON, Canada

(984) CMV: Reactivation and Prematurely Discontinued Prophylaxis; D. Briganti1, G. Lunghi2, A. D'adda1, L. Morlacchi1, A. Palleschi1, P. Mendogni1, I. Righi1, F. Blasi1. 1Department of Pathophysiology and Transplantation, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Universita&#768; degli Studi di Milano, Milano, Milano, Italy, 2U.O.S. Virologia, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Universita&#768; degli Studi di Milano, Milano, Italy, 3U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Universita&#768; degli Studi di Milano, Milano, Italy

(985) Posaconazole Extended-Release Tablets for Pre-Emptive Anti-Fungal Therapy Post Lung Transplantation; S. P. Ivulich1, D. Seymour1, L. Hunt1, G. Snell2. 1Pharmacy, Alfred Hospital, Melbourne, Australia, 2Lung Transplant Service, Alfred Hospital, Melbourne, Australia

(986) The Unnatural History of Early Lower Respiratory Tract Infection After Lung Transplantation ; A. B. Mitchell1, G. Calligaro2, M. A. Malouf2, M. Benzmira2, A. Rigby2, R. Pearson2, A. Havryk2, M. Pilt2, A. R. Glanville2. 1Molecular Biology, University of Technology, Sydney, Australia, 2Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia

(987) Clinical Assessment of Cytomegalovirus Specific Cell Mediated Immunity in a Prospective Cohort of Lung Transplant Recipients; S. V. Campos1, M. N. Samano2, P. M. Pego-Fernandes2, R. O. Teixeira1, R. M. Carraro1, J. E. Afonso-Junior1, A. N. Costa1, C. M. Machado3, A. C. Souza4, B. B. Pereira5, L. M. Fernandes2, L. Abdalla2. 1Pneumology, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil, 2Thoracic Surgery, Heart Institute of Sao Paulo Medical School, Sao Paulo, Brazil, 3Virology Laboratory (LIM 52-HCFMUSP), Institute of Tropical Medicine of Sao Paulo Medical School, Sao Paulo, Brazil, 4Virology Laboratory (LIM 52 HCFCMUSP), Institute of Tropical Medicine of Sao Paulo Medical School, Sao Paulo, Brazil, 5Virology Laboratory (LIM 52-HCFMUSP), Institute of Tropical Medicine of Sao Paulo Medical School of Sao Paulo Medical School of Sao Paulo Medical School of Sao Paulo Medical School of Sao Paulo Medical School, Sao Paulo, Brazil

(988) A Prophylaxis-Free, Pre-Emptive Approach to the Management of CMV After Lung Transplantation: Single Center Results; A. Bertani1, P. Vitulo2, A. Mularoni2, P. Grossi2, L. De Monte1, E. Russo1, M. Beretta2, L. Martino2, A. Callari2. 1Thoracic Surgery and Lung Transplantation, IRCCS ISMETT- UPMC Italy, Palermo, Italy, 2Pulmonology, IRCCS ISMETT- UPMC Italy, Palermo, Italy, 3Infectious Diseases, IRCCS ISMETT- UPMC Italy, Palermo, Italy

(989) Donors with Bacterial Meningitis: Outcomes in Lung Transplant Recipients; H. Grewal1, M. Budev2. 1Cleveland Clinic Foundation, Parma, OH, 2Cleveland Clinic Foundation, Cleveland, OH

(990) Acute Rejection Interaction with Viral Pneumonia Augments CLAD Risk; A. L. Gregson, J. Grotts, M. Shino, S. S. Weigt, J. Belperio. UCLA, Los Angeles, CA

(991) Management of Pseudomonas aeruginosa Infection After Lung Transplantation Across the UK and the Impact on Long-Term Survival; T. C. Gan1, A. E. Cockburn2, H. Yung3, E. Karimi4, L. Dirmaintaite5, M. Khan6, A. Perry2, R. Gell3, M. Al-Aloui3, R. D. Thompson2, J. Parmar3, M. Carby5, A. J. Fisher6. 1Clinical Assessment of Bacterial Pneumonia, University of Roehampton; London, UK, 2Pulmonary Diseases, Tuberculosis and Lung Transplantation, University Medical Center Groningen, Groningen, Netherlands, 3Cardiopulmonary Transplantation Unit, Freeman Hospital, Newcastle, United Kingdom, 4Lung Transplantation Unit, Papworth Hospital, Cambridge, United Kingdom, 5Lung Transplantation Unit, University Hospital South Manchester, Manchester, United Kingdom, 6Lung Transplantation Unit, Royal Brompton and Harefield, Middlesex, United Kingdom, 7Respiratory Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, 8Lung Transplantation Unit, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

MECHANICAL CIRCULATORY SUPPORT (Seaport Foyer)

Poster Discussants: Dipanjan Banerjee, MD (USA), Markus J Barten, MD, PhD (Germany), Alexander M Bernhardt, MD (Germany), Edo Y Birati, MD (USA), Pamela Combs, PhD, RN (USA), Jennifer A Cowger, MD, MS (USA), Sung-Ho Jung, MD (Korea), Liviu Klein, MD (USA), Brent C Lampert, DO (USA), Antonio Lofforte, MD (Italy), Simon Maltais, MD, PhD (USA), Nahush A Mokadam, MD (USA), Chetan B Patel, MD (USA), Sarah Schettle, PA-C (USA), Garrick C Stewart, MD (USA), Andre Vincentelli, MD, PhD (France), Andrae Wasler, MD (Austria), Daniel Zimpfer, MD (Austria)
(992) **Biologically-Inspired Spiral Flow Generation for Mechanically Assisted Circulation**; C. D. Tkatch¹, P. S. Huang Zhang¹, W. Fischer¹, H. Eisen², J. Yasha Kresh¹. ¹Cardiothoracic Surgery, Drexel University College of Medicine, Philadelphia, PA, ²Department of Medicine, Drexel University College of Medicine, Philadelphia, PA

(993) **Percutaneous Right Ventricular Assist Device Outcomes: Protek Duo**; A. Ravichandran¹, D. A. Baran², J. A. Cowger¹, C. T. Salerno², K. Stelling², S. Kapoor², T. Martin², J. Pieretti², C. Gidea², M. J. Zucker², B. Dinicola³, M. Camacho². ¹St Vincents Heart Center, Indianapolis, IN, ²Transplant Center, Newark Beth Israel Medical Ctr, Livingston, NJ, ³Cardiac Surgery, St Vincents Heart Center, Indianapolis, IN, ²Heart Transplant, St Vincents Heart Center, Indianapolis, IN

(994) **Outcomes of Tandem Percutaneous LVAD Support**; D. A. Baran, K. Stelling, J. Pieretti, C. Gidea, S. Kapoor, M. Zucker, T. Martin, B. Dinicola, M. Camacho. Newark Beth Israel Medical Ctr, Newark, NJ

(995) **Comparisons in Clotting Parameters Between Species for Preclinical Animal Studies**; T. Mizuno, T. Tsukiya, Y. Takewa, E. Tatsumi. Dept of Artificial Organs, Natl Cerebral CV Ctr, Suita, Japan

(996) **Experimental and Numerical Analysis of Dye Washout in Ventricular Assist Devices**; A. Molteni¹, H. Yousse², K. Low², H. Porter³, K. Fraser³. ¹Calon Cardio - Technology, Swansea, United Kingdom, ²ASTUTE 2020, Swansea University, Swansea, United Kingdom, ³Mechanical Engineering, University of Bath, Bath, United Kingdom

(997) **Testing 3D Pulsatile Prototypes of Left Ventricular Assist Device**; I. G. Berra¹, M. L. Berra², M. A. Lewis³, H. Vogelfang¹, G. Naiman¹, S. Berra³. ¹Heart Transplant Department, Hospital Garaahan Argentina, Buenos Aires, Argentina, ²Clinica Department, Hospital Posadas Argentina, Buenos Aires, Argentina, ³Medical Research, Lew Supplies and Innovations, Buenos Aires, Argentina, ²Control Department - Facultad de Ingenieria, Universidad de Buenos Aires, Buenos Aires, Argentina

(998) **Development of a Novel Tip Less Inflow Conduit for Left Ventricular Assist Device**; K. Iizuka¹, K. Yamazaki², T. Motomura³, T. Nishinaka³, Y. Takewa¹, T. Mizuno¹, T. Tsukiya¹, N. Naito¹, D. Akiyama¹, E. Tatsumi¹. ¹Department of Artificial Organs, National Cerebral and Cardiovascular Center, Osaka, Japan, ²Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan, ²Evaheart, Inc., Houston, TX

(1000) **Utility of Computation Fluid Dynamics in Assessing Relationship of Aortic Regurgitation with Outflow Graft Orientation in Patients with Left Ventricular Assist Devices**; M. Kassi, J. A. Guerra, A. Bhimaraj, S. Chang, C. Karmonik, J. Estep. Cardiology, Houston Methodist Hospital, Houston, TX

(1001) **Reliability of a Cuff-Deflation System for Serial Monitoring of Aortic Pulse Wave Velocity in Patients with Continuous-Flow Left Ventricular Assist Devices**; F. Castagna¹, A. Pinsino¹, E. J. Stöhr¹, B. McDonnell², M. Yuzefpolskaya¹, A. Clemens¹, N. Akter¹, D. Onat¹, D. L. Brunjes¹, K. Ross¹, M. Tiburcio¹, V. K. Topkara¹, A. R. Garan¹, H. Takayama¹, K. Takeda¹, Y. Naka¹, J. Cockcroft², P. C. Colombo¹. ¹New York Presbyterian Hospital - Columbia University Medical Center, New York, NY, ²Cardiff Metropolitan University, Cardiff, United Kingdom


(1003) **Older Age Combined with Reduced Renal Function Has a Strong Cumulative Adverse Effect on Survival in Left Ventricular Assist Device Patients**; R. Muslem¹, K. Caliskan¹, S. Akin¹, E. Y. Yasar¹, A. J. Bogers², D. Hesselink³, G. J. Whitman⁴, R. J. Tedford⁴, O. C. Manintveld⁴, S. D. Russell⁴. ¹Cardiology, Erasmus MC, Rotterdam, Netherlands, ²Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands, ³Nephrology, Erasmus MC, Rotterdam, Netherlands, ⁴Cardiothoracic Surgery, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Cardiology, Johns Hopkins School of Medicine, Baltimore, MD

(1004) **Cardiac Rotational Mechanics as a Predictor of Favorable Functional Response Induced by Cardiac Assist Devices in Advanced Heart Failure**; S. G. Drakos¹, I. Taleb¹, R. Larsen¹, O. Wever-Pinzon¹, A. G. Kfoury², R. Alharethi², J. Nativi-Nicolau³, W. Caine³, S. H. McKellar³, A. Kolipoupolu³, C. H. Selzman³, S. G. Drakos¹. ¹University of Utah, Salt Lake City, UT, ²Intermountain Medical Center, Salt Lake City, UT

ECMO-Bridge to LVAD Therapy Is a Safe and Effective Strategy for Critically Ill Patients; J. J. Han¹, C. Chen¹, J. Chung¹, A. C. Gaffey¹, A. Sotolongo¹, C. M. Justice¹, J. E. Rame², C. Bermudez¹, M. A. Acker¹, P. Atluri¹. ¹Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA

The Impact of a VAD Prior Authorization Program on Patient Outcomes; L. L. Ten Eyck¹, W. M. Bannister¹, E. Liu¹, A. Bonagura², D. Irwin², M. Chen². ¹Optum Consumer Solutions Group Healthcare Analytics, Optum, Minneapolis, MN, ²Complex Medical Conditions, Optum, Minneapolis, MN

Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure Is the Strongest Negative Prognostic Factor Post Continuous Flow Ventricular Assist Device Implantation; T. Imamura¹, G. Sayer¹, S. Adaty¹, N. Sarswat¹, G. Kim¹, J. Raikhelkar¹, T. Ota¹, T. Song¹, C. Juricek¹, V. Kagan¹, D. Rodgers¹, V. Jeewanandam¹, D. Burkhoff², M. Mehra³, N. Uriel¹. ¹University of Chicago, Chicago, IL, ²University of Columbia, New York, NY, ³Brigham and Women’s Hospital, Boston, MA

Adult ECMO for Acute Cardiorespiratory Failure: Should There Be a Formula for Futility?; D. C. Mauchley¹, J. K. Kirklin¹, K. M. Wille², K. F. Cornelius³, M. A. Tresler¹, M. S. Blood⁴, E. D. Zavala⁵, J. J. Martinez⁶, W. C. Erwin⁶, S. C. Ballot¹, C. W. Hoopes¹. ¹Surgery - Cardiovascular/Thoracic, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine / Division of Pulmonary Allergy and Critical Care, University of Alabama at Birmingham, Birmingham, AL, ³Division of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, ⁴Perioperative Services, University of Alabama at Birmingham, Birmingham, AL, ⁵Med - Pulmonary/Allergy/Critical Care, University of Alabama at Birmingham, Birmingham, AL, ⁶UAB General Surgery Residency, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL


Experience with Extracorporeal Membranous Oxygenation Support for Cardiocirculatory Arrest Following Acute Myocardial Infarction; A. F. Shaikh¹, G. V. Gonzalez-Stawinski², J. J. Squiers², T. Chamogeorgakis², J. C. MacHannahford², A. E. Rafael², R. Vallabhan², J. E. Choi², J. M. Schussler², M. DiMaio², R. C. Stoler², B. Lima². ¹College of Medicine, Texas A&M University, Dallas, TX, ²Baylor University Medical Center, Dallas, TX

Employment Status and Wait-List Outcomes in Patients Bridged with Left Ventricular Assist Devices; L. Meece, S. G. Al-Kindi, C. Blanco, B. Dhakal, M. Ginwalla, C. Elamm, G. H. Oliveira. Harrington Heart and Vascular Institute, University Hospitals, Cleveland, OH

Depression in Patients Undergoing Left Ventricular Assist Device Implantation; S. Lundgren, E. Raichlin, A. Selim, B. Lowes, R. Zolty, M. Moulton, J. Um, C. Poon. University of Nebraska Medical Center, Omaha, NE

Predicting Outcomes in Patients Requiring Extracorporeal Membrane Oxygenation; S. Wu¹, M. Fong², L. Saxon², G. Fox³, L. Wiggins⁴, A. Hackmann⁴. ¹Internal Medicine, University of Southern California, Los Angeles, CA, ²Cardiology, University of Southern California, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Cardiothoracic Surgery, University of Southern California, Los Angeles, CA

Assessment of Lean Dorsal Muscle Surface Area by CT Scan and Effect on Outcomes in Heart Transplant Recipients: Results from a Single Center; S. Joseph, G. Gonzalez-Stawinski, J. Hasse, G. Saracino, M. Edens, J. Felius, A. Jamil, S. A. Hall, B. Lima. Baylor University Medical Center, Dallas, TX

Successful Bridge to Continuous-Flow Left Ventricular Assist Device Using Extracorporeal Membrane Oxygenation Support for INTERMACS Profile I Patients; K. L. Kerk¹, T. E. Tan¹, D. Sim², C. P. Lim², J. H. Tay¹, C. L. Neo¹, J. L. Tan¹, C. Sivathasan¹. ¹Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore, ²Cardiology, National Heart Centre, Singapore, Singapore

Outcomes of Patients Who Require Temporary Mechanical Circulatory Support Prior to Left Ventricular Assist Device Placement; F. Mazzulla¹, R. Cogswell², J. Schultz¹, A. Waits², J. Misialek², T. Thenappan², M. Pritzker², E. Misso², C. M. Martin², K. Liao³, R. John³. ¹Department of Medicine, University of Minnesota, Minneapolis, MN, ²Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ³Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN

Friday, April 7
(1019) Predictors of Mortality in Cardiogenic Shock Patients Treated with Extra-Corporeal Cardiopulmonary Resuscitation; S. J. Stein1, H. Takayama2, A. R. Garan3, V. K. Topkara3, M. Salna1, J. Han1, P. A. Kurlansky4, M. Yuzetpolskaya3, M. A. Farr3, P. C. Colombo3, Y. Naka2, K. Takeda2. 1Columbia University, New York, NY, 2Department of Surgery, Division of Cardiothoracic Surgery, Columbia University, College of Physicians and Surgeons, New York, NY, 3Department of Medicine, Division of Cardiology, Columbia University, College of Physicians and Surgeons, New York, NY, 4Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY

(1019) Bridge to Bridge Strategy: The Challenging Task of Selecting Ideal VAD Candidates on Short Term Circulatory Support; D. Saeed, R. Wieloch, G. Petrov, B. Maxhera, M. Abdeen, N. Sadat, U. Boeken, A. Lichtenberg, A. Albert. Cardiovascular Surgery, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

(1020) Division of the Patient Selection Committee (PSC) Process into Two Segments Has Improved the Rigor, Efficiency and Satisfaction in the Selection Process; M. G. Dickinson, S. Lee, D. Fermin, K. Veine, T. Boeve, P. Wilton, A. Khaghani. Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, MI

(1021) Is the Cardiac Allocation Score (CAS) a Predictor of Therapy Failure After HU Listing; J. Sunavsky, B. Fujita, E. Prashovikj, S. Ensminger, J. Gummert, U. Schulz, M. Bengaluru. Bad Oeynhausen, Germany

(1022) Early RV Failure Is Much More Common Than Late RV Failure Post LVAD Implant; M. El Baba, V. Cotarlan, M. Bengaluru-Jayanna, J. Bhama, R. Chawla. University of Iowa, Iowa City, IA

(1023) Delivery During ECMO: A Single-Center Case Series; M. Morsolini1, S. Sciacca1, G. Panarello2, G. Martucci2, A. Bertani1, R. Longo3, P. Vitulo1, A. Arcadipane2, M. Pilato1. 1Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS - ISMETT, Palermo, Italy, 2Department of Anesthesia and Intensive Care, IRCCS - ISMETT, Palermo, Italy, 3Service of Cardiovascular Perfusion, IRCCS - ISMETT, Palermo, Italy


(1025) Preoperative Total Serum Bilirubin Is an Independent Predictor of Post LVAD Outcomes; L. H. Stein1, S. Zeigler1, W. Hiesinger1, Y. J. Woo1, D. Banerjee2, C. Hii1, R. Ha1. 1Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, 2Department of Cardiovascular Medicine, Stanford University, Stanford, CA, 3Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA

(1026) Veno-Arterial Extracorporeal Membrane Oxygenation as Bridge to LVAD Is Associated with Good Long Term Outcomes and Quality of Life; D. Miranda1, B. Magod2, K. Wilson2, R. Garberich2, K. Hryniewicz1. 1Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, 2Minneapolis Heart Institute Foundation, Minneapolis, MN

(1027) A Big (Clot) Problem! Extreme Obesity Is Associated with a Higher Incidence of Durable LVAD Thrombosis; A. Y. Lee1, B. Lima2, K. M. Tecson3, A. F. Shaikh4, S. Stil1, J. Collier5, R. Baxter6, S. Carey6, G. V. Gonzalez-Stawinski7, S. A. Hall8, S. M. Joseph8. 1Department of Cardiovascular Disease, Baylor University Medical Center, Dallas, TX, 2Division of Cardiac Surgery, Department of Surgery, Baylor University Medical Center, Dallas, TX, 3Baylor Heart and Vascular Institute, Baylor Scott & White Research Institute, Dallas, TX, 4Texas A&M College of Medicine, Bryan, TX, 5Department of Surgery, Baylor University Medical Center, Dallas, TX, 6Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX, 7Department of Cardio and Thoracic Surgery, Baylor University Medical Center, Dallas, TX

(1028) Moderate Baseline Pulmonary Hypertension with a Robust Reduction in Mean Pulmonary Artery Pressures Post-LVAD Is Associated with Improved 1-Year Survival; S. A. Smith1, B. Lampert1, R. Emani1, R. Hasson2, B. Whitson2, A. Hasan1, A. Kilic2. 1Internal Medicine, The Ohio State University, Columbus, OH, 2Cardiothoracic Surgery, The Ohio State University, Columbus, OH

(1029) AST/ALT (DeRitis)-Ratio Predicts Mid- and Longterm Mortality After LVAD Implantation; H. Carstens1, A. Koch1, N. Pizanis1, J. Heckmann1, P. Lüdi1, T. Rassaf1, M. Kamler1. 1Thoracic Transplant, University Essen, Essen, Germany, 2Cardiology, University Essen, Essen, Germany

(1031) ECMO Use in INTERMACS 1 Patients as a Bridge to LVAD with Intention to Transplant versus Bridge to Direct Heart Transplant. Single Center Experience; J. I. Gentile1, M. R. Molina1, P. Atluri1, J. E. Rame1, J. W. Wald2, E. Y. Birati3, L. R. Goldberg4, R. McLean1, M. I. Acker1, C. A. Bermudez1. 1Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, 2Clinical Medicine, University of Pennsylvania, Philadelphia, PA, 3Cardiology, University of Pennsylvania, Philadelphia, PA, 4Heart Failure and Cardiac Transplant Center, University of Pennsylvania, Philadelphia, PA

(1032) Predictors of Survival in Patients Undergoing VA-ECMO and the Utility of the SAVE Score in a UK Transplant Population; E. J. McKay1, P. S. Chagarb1, K. Heyes1, P. Foden2, S. G. Williams1, J. Bernard1, N. Yonan1, R. Venkateswaran1, S. M. Shaw1. 1The Transplant Unit, University Hospital South Manchester, Manchester, United Kingdom, 2Medical Statistics, University Hospital South Manchester, Manchester, United Kingdom

(1033) Psychosocial Factors and Outcomes with Left Ventricular Assist Device Therapy; S. Lundgren, R. High, C. Poon, E. Raichlin, R. Zoltz, A. Burdorf, J. Um, B. Lowes. University of Nebraska Medical Center, Omaha, NE

(1034) Usefulness of the INTERMACS Scale to Predict Outcomes in Patients Undergoing Ventricular Assist Device Implant Through Less Invasive Surgery; S. V. Rojas, J. S. Hanke, A. Uribarri, M. Avsar, G. Dogan, E. Deniz, M. Ricklefs, A. Haverich, J. D. Schmitto. Department of Cardiothoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany


(1036) Correlation Between Skeletal Muscle Mass and Other Prognostic Markers in Left Ventricular Assist Device Recipients; L. M. Teigen1, A. J. Kuchnia1, C. P. Earthman1, A. N. Walts2, R. John3, R. Cogswell2. 1Food Science and Nutrition, University of Minnesota, St. Paul, MN, 2Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, 3Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN

(1037) Outcomes of Veno-Arterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock in the Elderly. Large Single Center Experience; J. I. Gentile1, P. Atluri1, N. D. Desai1, P. VallabhaJosyula1, J. W. Wald2, J. E. Rame1, J. T. Gutsche2, J. Horak3, M. I. Acker1, C. A. Bermudez1. 1Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, 2Clinical Medicine, University of Pennsylvania, Philadelphia, PA, 3Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA

(1038) Extremes of Body Mass Index Should Not Preclude Left Ventricular Assist Device Implantation in the Current Era; A. McDavid1, A. Kilic2, J. Gustafson1, S. Smith1, B. Lampert1, B. A. Whitson1, A. Hasan1, A. Kilic1. 1The Ohio State University, Columbus, OH, 2The University of Pennsylvania, Philadelphia, PA


(1040) Ventricular Assist Device Support for Ischemic Cardiomyopathy: A Single-Center Experience in Japan; K. Kuroda1, Y. Kuma1, H. Sunami1, S. Nakajima1, T. Sato1, O. Seguchi1, M. Yanase1, Y. Matsumoto2, H. Hata2, T. Fujita2, J. Kobayashi2, N. Fukushima1. 1Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

(1041) Effect of Preoperative Small Left Ventricle on Patients with Chronic Heart Failure Undergoing Implantation of Long-Term Continuous Flow Ventricular Assist Devices: Comparative Analysis of HeartMate II and HeartWare Devices; M. Kawabori, C. Kurihara, T. Sugiura, A. B. Civitello, W. E. Cohn, O. H. Fraizer, J. A. Morgan. Texas Heart Institute, Baylor College of Medicine, Houston, TX

Friday, April 7
(1042) Right Atrial to Pulmonary Capillary Wedge Pressure Ratio as Predictor for Postoperative Outcomes in Left Ventricular Assist Device Implantation; G. Bhat, A. Ali, G. Yost, A. Tatooles. Heart Institute, Advocate Christ Med Center, Oak Lawn, IL

(1043) WITHDRAWN

(1044) Veno-Veno-Arterial Extracorporeal Membrane Oxygenation in Patients with Respiratory Failure; F. Ius¹, W. Sommer¹, I. Tudorache¹, M. Avsar¹, T. Siemeni¹, D. Böthig¹, J. Puntigam¹, J. Openthalöfel¹, T. Welte², A. Haverich², M. Hoepf², C. Kühn², G. Warnecke¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

(1045) The Accuracy of Physical Exam Compared to RHC in LVAD Patients; E. C. Anyanwu¹, A. Bhatia¹, D. M. Tehrani¹, A. Deshmukh¹, D. Rodgers², S. Adatya², N. Sarswat³, G. Kim³, G. Sayer³, T. Ota³. ¹Internal Medicine, University of Chicago, Chicago, IL, ²Advanced Heart Failure, University of Chicago, Chicago, IL, ³Cardiac Surgery, University of Chicago, Chicago, IL

(1046) ECPR as a Tool to Improve Outcome of Refractory Cardiac Arrest; D. Pabst¹, A. El-Banayosy², B. Soleimani³, C. Brehm¹. ¹Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA, ²INTEGRIS Baptist Medical Center, Oklahoma City, OK

(1047) Monitoring Aspirin Levels in Patients with LVAD; R. Hards, G. Edwards, M. Hedger, A. R. Simon. Transplant and Mechanical Circulatory Support, Harefield Hospital, uXbridge, United Kingdom

(1048) Increased Post-Operative Mortality in Patients Undergoing Coronary Artery Bypass Grafting During Left Ventricular Assist Device Implantation; P. Mehta¹, C. Juricek², T. Imamura³, S. Adatya², N. Sarswat³, G. Kim³, J. Raikhelkar³, T. Ota², V. Jeevanandam², G. Sayer³, N. Uriel³. ¹Internal Medicine Residency Program, Department of Medicine, University of Chicago, Chicago, IL, ²Section of Cardiothoracic Surgery, University of Chicago, Chicago, IL, ³Section of Cardiology, University of Chicago, Chicago, IL

(1049) Blood Pressure Measurement in Patients with a HeartMate; J. Fischer, A. L. Meyer, K. Jawad, A. Addas, M. Zoric, S. Lehmann, J. Hahn, F. W. Mohr, J. Garbade. Leizpig Heart Center, Leizpig, Germany

(1050) Effect of LVAD Speed Titration on Microvascular Perfusion; I. Tchoukina, M. D. Kozak, A. N. Iness, J. R. Coleman, S. Gunda, M. C. Smallfield, K. B. Shah. Virginia Commonwealth University, Richmond, VA

(1051) Peak Oxygen Consumption and Six-Minute Walk Distance in Patients with an HVAD Left Ventricular Assist Device at Discharge from Cardiac Rehabilitation; T. Schmidt¹, B. Bjarnason-Wehrens², M. Hannig¹, M. Altesellmeier¹, S. Schulte-Eistrup¹, D. Willemsen¹, N. Reiss¹. ¹Schüchtermann Klinik, Bad Rothenfelde, Germany, ²Department for Preventive and Rehabilitative Sport and Exercise Medicine, Institute for Cardiology and Sports Medicine, German Sports University Cologne, Cologne, Germany

(1052) Absence of Valvular Disease Following Left Ventricular Assist Device Implantation Is Associated with Improved Midterm Survival; T. Ota¹, A. Tanaka¹, H. Kitahara¹, T. Song¹, D. Onsager¹, J. Raikhelkar², G. Kim², N. Sarswat², S. Adatya², G. Sayer², N. Uriel², V. Jeevanandam¹. ¹Surgery, The University of Chicago, Chicago, IL, ²Medicine, The University of Chicago, Chicago, IL

(1053) High Grade Mitral Regurgitation After a Left Ventricular Assist Device May Adversely Affect Survival; A. Sotolongo. Department of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

(1054) Red Cell Distribution Width and Outcomes After Ventricular Assist Device Implantation; S. Sundararajan¹, J. N. Upshaw², M. S. Kiernan², D. DeNoorio³, G. S. Couper³, A. R. Vest³. ¹Department of Medicine, Mount Auburn Hospital, Cambridge, MA, ²Division of Cardiology, Tufts Medical Center, Boston, MA, ³Division of Cardiac Surgery, Tufts Medical Center, Boston, MA

(1055) Cardiac Output and Oxygen Kinetic in Patients with Left Ventricular Assist Device; S. Paolillo¹, C. Vignati², A. Apostolo², N. Bonini², N. Bruno², S. Scuri², P. Agostoni². ¹SDN, IRCCS, Naples, Italy, ²Centro Cardiologico Monzino, IRCCS, Milan, Italy, ³Centro Cardiologico Monzino, Milano, Italy, 4Centro Cardiologico Monzino, IRCCS, Milan, Italy
(1056) Exercise-Induced Elevation of Left Atrial Pressure Limits Functional Capacity in LVAD Patients: Insights from LA Pressure Sensor Monitoring; J. Abraham. Center for Advanced Heart Disease, Providence Heart and Vascular Institute, Portland, OR

(1057) Log Files: A Vital Patient Tool; H. R. Smith, D. J. Sato, K. J. Mesa, K. A. Ihnken, A. T. Coletti. Mechanical Heart Program, Providence Sacred Heart Medical Center, Spokane, WA

(1058) Outcomes of Veno Arterial Extracorporeal Membrane Oxygenation at University of Kentucky Based on Etiology of Cardiogenic Shock; A. R. Kolodziej, A. Burchett, T. A. Tribble, R. Charnigo, S. Smyth, M. Guglin. Cardiology, University of Kentucky, Lexington, KY


(1061) Configuration of Extracorporeal Circulation and Association with Outcomes; R. A. Rose†, V. Kagan‡, R. M. Piech‡, A. F. Linden‡, N. Uriel¶, V. Jeevanandam¶, T. H. Song¶. ECMO / MCS Services, University of Chicago Medicine, Chicago, IL, Cardiothoracic Surgery, University of Chicago Medicine, Chicago, IL, Pediatric Surgery, University of Chicago Medicine, Chicago, IL, Cardiology, University of Chicago Medicine, Chicago, IL

(1062) Lactic Acid Is the Most Important Factor Predicting Survival on VA ECMO; A. Kolodziej†, A. Burchett†, T. Tribble†, A. Y. Grigorian‡, M. Guglin†. Cardiology, University of Kentucky, Lexington, KY, Gastroenterology, University of Kentucky, Lexington, KY

(1063) Biventricular Pacing Has No Acute Hemodynamic Benefit Over Right Ventricular Pacing or Intrinsic Rhythm in LVAD Patients; V. Cotarlan†, F. Johnson†, J. Franzwa†, C. Inampudi§, U. Emerenini§, R. Tandon§, R. Tahir², Y. Nabeel¹, J. Goerbig³, K. Light-McGroary³, G. Goldsmith³, M. Giudici³. Univ of Iowa Hospital, Iowa City, IA, Geisinger Medical Center, Danville, PA, Iowa Heart Center, Des Moines, IA

(1064) Impact of Change in Body Mass Index on Outcomes After Left Ventricular Assist Device Implantation in Obese Patients; A. Mano. Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Osaka, Japan

(1065) Not All INTERMACS Level 1’s Are the Same: Survival After Total Artificial Heart Implantation with or without Temporary Circulatory Support; H. J. Reich¹, D. Ramzy², J. Mirocha², M. A. De Robertis², J. Chung², F. Esmailian², D. Chang³, J. Moriguchi³, L. Czer³, A. Trento², F. Arabia². Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, Cardiothoracic Surgery, Cedars-Sinai Heart Institute, Los Angeles, CA, Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA


(1067) Longitudinal Neutrophil to Lymphocyte Ratio Assessment After Left Ventricular Assist Device Implantation; G. Yost, K. Ibrahim, A. Tatooles, G. Bhat. Heart Institute, Advocate Christ Med Center, Oak Lawn, IL


(1069) WITHDRAWN

(1070) Impact of Chronic Obstructive Pulmonary Disease on Early Right Ventricular Dysfunction and Failure Following Left Ventricular Assist Device Implantation; R. M. Hasson Charles, S. D. Moffatt-Bruce, E. Cerier, S. A. Smith, B. C. Lampert, A. McDavid, B. A. Whitson, M. K. Essandoh, A. Kilic. Cardiothoracic Surgery, The Ohio State University, Columbus, OH, Thoracic Surgery, The Ohio State University, Columbus, OH, Medicine, The Ohio State University, Columbus, OH, Thoracic Surgery, The Ohio State University, Columbus, OH
(1071) The Changing Flow Patterns in Carotid Arteries and the Effect of Aortic Valve Opening on Carotid and Middle Cerebral Arteries in LVAD Patients; M. Pac1, M. Karahan1, S. Kocabeyoglu1, Z. Catav1, D. Sert1, B. Demirkan2, M. Tola3, O. Kursun4, E. Aygun1, U. Kervan1. 1Cardiovascular Surgery, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, 2Cardiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, 3Radiology, Turkiye Yuksek Ihtisas Hospital, Ankara, Turkey, 4Neurology, Ankara Numune Hospital, Ankara, Turkey

(1072) The Influence of a Dedicated and Protocolized Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) Strategy on Patient Outcomes: A Before and After Study; R. Williams1, S. Coffin2, S. Derryberry1, M. Djunaidi1, A. Shah1, S. Huang3, S. McGrane4, C. Cropsey4, C. Henson4, W. Costello4, J. Kennedy4, E. Haddad6, M. Danter1. 1Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 2Cardiology, Maine Health Partners MaineHealth Cardiology-Scarborough, Scarborough, ME, 3Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 4Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, 6Cardiology, Vanderbilt University Medical Center, Nashville, TN

(1073) Acoustic Characterisation of the HeartWare Ventricular Assist Device as a Novel Non-Invasive Diagnostic and Management Technique; M. Shah1, D. Bull1, P. Markey1, H. C. Chew2, C. Cheong3, D. Robson4, P. MacDonald5, K. Dhital6. 1Faculty of Medicine, University of New South Wales, Sydney, Australia, 2Department of Cardiothoracic Surgery, St Vincent's Hospital, Sydney, Australia, 3Department of Cardiology, St Vincent's Hospital, Sydney, Australia


(1076) Analysis of Post-LVAD Clinical Pathways; F. Movahedi1, L. Carey2, Y. Zhang3, R. Padman4, J. Antaki5, M. Kanwar6. 1Electrical Engineering, University of Pittsburgh, Pittsburgh, PA, 2Biomedical Engineering, University of Pittsburgh, Pittsburgh, PA, 3Heinz College, Carnegie Mellon University, Pittsburgh, PA, 4University of Texas at Austin, Pittsburgh, PA, 5Mechanical Engineering, University of Pittsburgh, Pittsburgh, PA, 6Allegheny General Hospital, Division of Cardiology, University of Pittsburgh, Pittsburgh, PA

(1077) Patients with End-Stage Heart Failure: Two Takes on Health Engagement; L. C. Lohmuller1, C. K. McIvannan2, M. Kanwar3, J. F. Antaki1. 1Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, 2Cardiovascular Institute, University of Colorado, Denver, Denver, CO, 3Cardiology, Allegheny General Hospital, Pittsburgh, PA


(1080) Noninvasive Assessment of Lung Fluid Percentage in Patients with Left Ventricular Assist Devices; G. H. Kim1, D. Rodgers1, T. Imamura1, A. Nguyen1, B. Chung1, N. Sarswat1, J. Raikhelkar1, S. Adatya1, G. Sayer1, R. Abbo2, D. Burkhoff3, N. Uriel1. 1University of Chicago, Chicago, IL, 2Sensible Medical, Netanya, Israel, 3Department of Medicine, Columbia University, New York, NY

(1081) Beat-to-Beat Detection of Aortic Valve Opening in Continuous Flow LVAD Patients with Irregular Cardiac Rhythm and with Hemodynamic Maneuvers; R. Clifford1, D. Robson1, C. Gross2, F. Moscato2, H. Schima2, P. S. Macdonald1, P. Jansz1, C. S. Hayward1. 1Heart Failure and Transplant Unit, St Vincent's Hospital, Sydney, Australia, 2Medical University of Vienna, Vienna, Austria
(1082) Pre-Operative Predictors of Mortality in Adults Supported with Short-Term Continuous Flow Ventricular Assist Devices; S. J. Bozso1, J. Conway2, D. H. Freed1, B. Martin1, R. G. MacArthur1, H. Buchholz3. 1Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada, 2Division of Cardiology, University of Alberta, Edmonton, AB, Canada, 3Division of Pediatric Cardiac Surgery, University of Alberta, Edmonton, AB, Canada


NURSING, HEALTH SCIENCES, ALLIED HEALTH
(Coronado Foyer)

Poster Discussants: Tiffany M Buda, BSN (USA), Annette J DeVito-Dabbs, PhD, RN (USA), Connie White-Williams, PhD, RN (USA), Rachel A Zomak, RN, MS (USA)


(1085) Psychosocial Screening in Pediatric Heart Transplant Recipients and Their Families; M. Cousino1, K. Rea1, M. Zamberlan2, J. Jordan1, S. Eder1, E. Fredericks1, K. Schumacher1. 1Pediatrics, C.S. Mott Children’s Hospital, Ann Arbor, MI, 2Cardiac Surgery, C.S. Mott Children’s Hospital, Ann Arbor, MI


(1087) Putting Your Best Foot Forward: The High Incidence of Foot Fractures After Lung Transplantation; L. M. Fuller1, H. Curry2, K. Hackman2, G. Snell2, L. Kimmel1. 1Physiotherapy, Alfred Hospital, Melbourne, Australia, 2Orthopaedic Surgery, Alfred Hospital, Melbourne, Australia

(1088) The ERO Form: The European Retrieval of Organs Initiative to Standardise Essential Information; C. Ellis, K. Morley. Transplant Unit, Papworth Hospital, Cambridge, United Kingdom

(1089) Tick, Tock - Shrinking Ischemic Times in Pediatric Heart Transplantation Through Process Standardization; S. L. Stark1, C. Chin1, J. Gossett2, A. Lorts1, T. D. Ryan2, L. Wilmot1, J. L. Jefferies1, R. Bryant III1. 1Heart Institute, Cincinnati Children's Hosp Med Ctr, Cincinnati, OH, 2Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH

(1090) Management of a Counterpulsation Device Outside of the Intensive Care Unit; H. Costantini1, C. Juricek1, V. Kagan1, T. Song1, D. Onsager1, T. Ota1, N. Uriel2, V. Jeevanandam1. 1Cardiothoracic Surgery, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL

(1091) Yes We Can. A Multidisciplinary, Trans Center and Multi Device Journey of Pediatric Patient on the Road to Heart Transplantation; A. Wypych-Zych1, K. Egert1, S. Mather1, R. Hards1, M. Hedger1, B. Zych2, D. Garcia2, A. R. Simon1. 1Intensive Care Unit, Royal Brompton and Harefield Foundation Trust, Harefield, United Kingdom, 2Cardio-Thoracic Transplantation & Mechanical Circulatory Support, Royal Brompton and Harefield Foundation Trust, Harefield, United Kingdom, 3Cardio-Thoracic Transplantation & Mechanical Circulatory Support, Royal Brompton and Harefield Foundation Trust, Harefield, United Kingdom

(1092) Obstacles to Acquiring Quality of Life Assessments for Pediatric Ventricular Assist Device Support: Perspectives from VAD Coordinators; B. M. Hawkins1, M. Priest2, J. Murray3, B. Elias4, M. Mehegan5, J. Lantz6, A. Shubert7, R. Cantor8, D. Koehl9, K. Uzark10. 1Cardiology, Boston Children's Hospital, Boston, MA, 2Cardiology, Alfred I. duPont Hospital for Children, Wilmington, DE, 3Cardiology, Lucile Packard Children's Hospital, Stanford, CA, 4Cardiology, Texas Children's Hospital, Houston, TX, 5Cardiology, St. Louis Children's Hospital, St. Louis, MO, 6Cardiology, Dallas Children's Hospital, Dallas, TX, 7Cardiology, Cincinnati Children's Hospital, Cincinnati, OH, 8The University of Alabama at Birmingham, Birmingham, AL, 9University of Alabama and Birmingham, Birmingham, AL, 10Cardiology, University of Michigan Congenital Heart Center, Ann Arbor, MI
Do Heart Transplant Centers Have a Multidisciplinary Team as Indicated by ISHLT Guidelines? Findings from the International BRIGHT Study; M. Cajita\textsuperscript{1}, E. Baumgartner\textsuperscript{2}, L. Berben\textsuperscript{2}, K. Denhaerynck\textsuperscript{2}, R. Helmy\textsuperscript{2}, S. Schönfeld\textsuperscript{2}, G. Berger\textsuperscript{2}, C. Vetter\textsuperscript{2}, F. Dobbels\textsuperscript{3}, C. L. Russell\textsuperscript{4}, S. M. De Geest\textsuperscript{2}, O. the BRIGHT Study Team\textsuperscript{5}. \textsuperscript{1}School of Nursing, Johns Hopkins University, Baltimore, MD, \textsuperscript{2}Institute of Nursing Science, University of Basel, Basel, Switzerland, \textsuperscript{3}Academic Center for Nursing and Midwifery, KU Leuven, Leuven, Belgium, \textsuperscript{4}School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO, \textsuperscript{5}University of Basel, Basel, Switzerland


Pair Donor Exchange in Lung Transplantation-Attitude Survey; C. Yokoyama, M. Morioka, S. Tanaka, K. Miyoshi, Y. Sahara, T. Oto. Lung Transplant Unit, Organ Transplant Center, Okayama University Hospital, Okayama, Japan

Does Caring for Heart and Lung Transplant Patients Lead to Psychological Stress in Multi-Disciplinary Care Teams?; S. A. Carey, J. W. Roden-Foreman, M. M. Bennett, J. Felius, S. A. Hall, A. Warren. Baylor University Medical Center, Dallas, TX

Got: The Psychological Impact of Hallucinations Whilst in Intensive Care - The New Zealand Heart and Lung Transplant Experience; L. Painter, I. S. Fontanilla. Heart/Lung Transplant, Auckland District Health Board, Auckland, New Zealand

Implementing Practices to Improve Self-Care Among Caregivers of Patients with Mechanical Circulatory Support; H. Barone, B. Coleman, H. Aronow, C. Runyan, J. Hajj, N. Huie, E. Passano, L. Czer, J. A. Kobashigawa, J. Moriguchi, F. Arabia. Cedars-Sinai Heart Institute, Los Angeles, CA

PULMONARY HYPERTENSION (Harbor Foyer)

Poster Discussants: Rachel M Crackett, MSc (United Kingdom), Chandra Kunavarapu, MD (USA), Fabiana G Marcondes-Braga, MD, PhD (Brazil)

Right Ventricular Dysfunction Is the Strongest Determinant of Abnormal Left Ventricular Ejection Fraction in Pulmonary Arterial Hypertension; T. Meeran, J. R. PO, A. Elapavaluru, R. L. Benza, A. Raina. Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA
Comparison of Indirect Fick and Thermodilution Cardiac Output with Right Ventricular Function in Pulmonary Hypertension; A. Al-Khodair, M. Y. Tsang, N. W. Brunner. Cardiology, University of British Columbia, Vancouver, BC, Canada

RVOT-VTI/PASP a Novel Non-Invasive Metric of Pulmonary Arterial Compliance Differs Across the Spectrum of Pulmonary Hypertension; A. Fox, M. S. Tanna, P. T. Bhattacharya, G. S. Troutman, F. Mao, J. Menachem, E. Y. Birati, P. R. Forfia, A. Vaidya, J. A. Mazurek. Univ of Pennsylvania, Philadelphia, PA, Temple University Hospital, Philadelphia, PA


The Recent Prognosis and Treatment of Idiopathic and Heritable Pulmonary Arterial Hypertension; The Report from Single Pulmonary Hypertension Center in Japan; H. Maki, M. Hatano, S. Minatsuki, I. Komuro. Cardiovascular Medicine, University of Tokyo, Tokyo, Japan, Therapeutic Strategy for Severe Heart Failure, University of Tokyo, Tokyo, Japan


WITHDRAWN

Left Ventricular Assist Device Improves Type II Pulmonary Hypertension with High Pulmonary Vascular Resistance; A. Selim, E. Raichlin, A. Burdorf, J. Um, A. Siddique, M. Moulton, B. D. Lowes, R. Zolty. Cardiology, University of Nebraska Medical Center, Omaha, NE, Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE

Clinical Characteristics and Survival in Pulmonary Hypertension Due to Chronic Lung Disease; K. Prins, L. Rose, C. Carlson, M. Pritzker, K. E. Weir, F. Kazmirczak, T. Thenappan. Medicine- Cardiology, University of Minnesota, Minneapolis, MN

Effects of Ambulatory Inhaled Nitric Oxide on Exercise Induced Increases in Pulmonary Pressures; R. A. Davey, A. Raina, R. L. Benza. Division of Cardiology, Western University, London, ON, Canada, Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA

WITHDRAWN

WITHDRAWN

Perioperative Extracorporeal Membrane Oxygenation-Based Protocol for Acute Pulmonary Embolectomy: Technique and Preliminary Results; F. Ius, C. Fegbeutel, C. Kühn, I. Tudorache, G. Warnecke, M. Roumieh, N. Koigeldiyev, K. Olsson, M. Hoofer, A. Haverich, S. Cebotari. Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

Meticulous Closure of Collateral Blood Flow in the Perihilar Mediastinal Pleura Decreases Bleeding and Surgical Mortality in Lung Transplant Recipients with Pulmonary Hypertension; K. Hashimoto, S. Sugimoto, K. Imanishi, T. Kurosaki, K. Miyoshi, S. Otani, M. Yamane, T. Otto. Department of General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, Department of Organ Transplant Center, Okayama University Hospital, Okayama, Japan

PHARMACY & PHARMACOLOGY
Coronado Foyer

Poster Discussants: Kyle Dawson, PharmD, BCPS (USA), Patricia Ging, PharmD (Ireland), Walter Uber, PharmD (USA)
(1120) Safety and Efficacy of Four Factor Prothrombin Complex Concentrate for the Reversal of Warfarin in LVAD Patients Prior to Heart Transplantation; L. To, A. Jantz, L. Hencken, C. William, H. Nemeh. Henry Ford Hospital, Sterling Heights, MI

(1121) Reduced Dose 4-Factor Prothrombin Complex Concentrate Prior to Heart Transplant in Patients with Ventricular Assist Devices; I. Lam, A. A. Feist, K. Derry, J. Lane, M. Mariski, V. Pretorius. Pharmacy, UC San Diego Health, San Diego, CA, Surgery, UC San Diego Health, San Diego, CA


(1123) Still Inferior? Risks of Azathioprine in Tacrolimus Based Regimens for Heart Transplant Recipients; J. P. Casale, A. T. Logan, C. T. Doligalski. Tampa General Hospital, Lutz, FL

(1124) Vaccinating Lung Transplant Candidates; M. G. Cortez, L. Potter. Department of Pharmacy, The University of Chicago Medicine, Chicago, IL

(1125) Penicillium Species: Prevalence and Impact on Clinical Outcomes Following Lung Transplantation; N. Hudec, C. King, M. Fregoso, A. Brown, O. A. Shlobin, A. B. Cochrane. Butler University, Indianapolis, IN, Inova Fairfax, Falls Church, VA

(1126) Pain Pathway in Lung Transplantation Is Associated with Excellent Peri-Operative Outcomes: A Case Series; D. B. Berkheim, T. A. Nicholas, M. J. Moulton, H. M. Strah, A. Siddique. Surgery Division of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, Anesthesiology, University of Nebraska Medical Center, Omaha, NE, Internal Medicine Division of Pulmonary, Critical Care, Sleep & Allergy, University of Nebraska Medical Center, Omaha, NE

(1127) Intra-Patient Variability of Tacrolimus Levels and Lung Allograft Outcomes: A Single Centre Experience; L. Diannelidou-Stamelou, L. Spurr, N. Leaver, J. Smith, A. Simon, M. Carby, A. Reed, L. Wei, H. Lyster. Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom, Department of Practice and Policy, University College London, London, United Kingdom

(1128) Prevalence of Venous Thromboembolic Events in ILD Lung Transplant Patients Treated with Sirolimus; G. Waldman, M. Mariski, A. Feist, L. Awdishu, K. Afshar, G. Yung. University of California San Diego Health, San Diego, CA

(1129) Rabbit Antithymocyte Globulin for the Treatment of Chronic Lung Allograft Dysfunction; S. January, K. Fester, K. Bain, R. Hachem. Pharmacy, Barnes-Jewish Hospital, St Louis, MO, Pulmonary and Critical Care, Washington University in St. Louis, St Louis, MO


(1131) Utilization of a Multidisciplinary Approach for Inpatient Anticoagulation Management in Left Ventricular Assist Device Recipients; N. Siddiqi, A. Luke, S. Watts, U. P. Jorde, O. Saeed, D. B. Sims, J. Shin, S. R. Patel, S. Murthy, S. Forest, D. J. Goldstein. Department of Pharmacy, Montefiore Medical Center, Bronx, NY, Department of Medicine (Cardiology), Montefiore Medical Center, Bronx, NY, Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

(1132) Bivalirudin for Suspected Pump Thrombosis in Patients with Left Ventricular Assist Devices: A Single-Center Experience; P. A. Weeks, A. Sieg, I. Rajapreyar, S. Nathan. Pharmacy, Memorial Hermann - Texas Medical Center, Houston, TX, University of Kentucky College of Pharmacy, Lexington, KY, The University of Alabama at Birmingham, Birmingham, AL, Center for Advanced Heart Failure, University of Texas Health Science Center, Houston, TX

Friday, April 7
Friday, April 07, 2017
5:45 PM - 6:45 PM

NOTE: Poster presenters and discussants will be present during the evening poster viewing session from 5:45 PM – 6:45 PM.

BASIC SCIENCE & TRANSLATIONAL RESEARCH
(Harbor Foyer)

Poster Discussants: Sharon Chih, MD (Canada), Tobias Deuse, MD, PhD (USA), Howard Eisen, MD (USA), Stephan Ensminger, MD, DPhil (Germany), Andrew E Gelman, PhD (USA), Tereza Martinu, MD, PhD (Canada), Erin Lowery, MD (USA), Johan Nilsson, MD, PhD (Sweden), Meinoshin Okumura, MD (Japan), Simon Pecha, MD (Germany), William E Stansfield, MD (Canada), Stijn E Verleden, PhD (Belgium), Christopher H Wigfield, MD, FRCS (USA), Andrew E Gelman, PhD (USA), Tereza Martinu, MD, PhD (Canada), Erin Lowery, MD

(1135) Tyrosine Kinase Inhibitor Nintedanib Reduces Development of Transplant Vasculopathy in a Murine Aortic Transplantation Model; A. Gocht1, S. M. Ensminger2, J. Distler3, B. Spriewald3, M. Ramsperger-Gleixner1, M. Weyand1, C. Heim1. 1University of Erlangen Department of Cardiac Surgery, Erlangen, Germany, 2HDZ NRW, Bad Oeynhausen, Germany, 3University of Erlangen, Erlangen, Germany

(1136) WITHDRAWN

(1137) Advancing the Science of Hemocompatibility: Oncostatin M, a Novel Biomarker for Blood Pump Induced Neutrophil Activation; J. Long1, K. Nelson1, J. Mayes1, D. Schmidknecht2, T. Snyder1, Z. Liu3, R. McEver2, H. Setiadi3. 1Advanced Cardiac Care, INTEGRIS Baptist Medical Center, Oklahoma City, OK, 2The University of Texas at Dallas, Richardson, TX, 3Oklahoma Medical Research Foundation, Oklahoma City, OK

(1138) Pulmonary Hypertension: Macrophage Infiltration Correlates with Right Ventricle Remodeling in an Experimental Model of Pulmonary Hypertension; J. Guihaire1, T. Deuse2, D. Wang1, E. Fadel3, H. Reichenspurner4, R. C. Robbins5, S. Schreper1. 1Transplant and Stem Cell Immunobiology Lab (TSI), Hamburg, Germany, 2CT Surgery, UCSF, Hamburg, CA, 3Thoracic and Vascular Surgery and Heart-Lung Transplantation, Paris, France, 4Cardiovascular Surgery, UHZ, Hamburg, Germany, 5CT Surgery, Stanford University, Stanford, CA

(1139) H-Y-Incompatible Stem Cell Transplantation Causes Rejection of Nucleus Matched Cells; X. Hu1, S. T. Kueppers2, T. Deuse1, M. Alawi3, D. Wang1, H. Reichenspurner4, S. Schreper1. 1Surgery, TSI Lab, UCSF, San Francisco, CA, 2Surgery, TSI Lab, UHZ, Hamburg, Germany, 3Heinrich Pette, UKE, Hamburg, Germany, 4Cardiovascular Surgery, UHZ, Hamburg, Germany

(1140) N-acetylcysteine Potentiates the Protective Effects of α-1-Antitrypsin in a Mouse Model of Orthotopic Lung Transplantation; K. Patel1, Q. Cheng2, L. Rucker2, G. Bazzle2, S. Nadig1, C. Atkinson1. 1 Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC, 2 Departments of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC

(1141) Janus Kinase Inhibitor Tofacitinib Moderates De Novo Donor Specific Antibody Production in a Mouse Model of HLA-A2 Sensitization; N. Chai, I. Kim, S. Jordan, A. Klein, G. D. Wu. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

(1142) Use of Exosome for Alloantibody Suppression: A Study in a Mouse Model of HLA-A2 Sensitization; L. Kim1, G. De Couto2, N. Chai3, G. D. Wu3, A. S. Klein3, S. Jordan3. 1 Comprehensive Transplant Center/Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, 2Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 3Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

(1143) Novel Therapeutic Strategies for Neutropenia in Transplantation; D. Sykes, M. Callahan, M. K. Mansour. Massachusetts General Hospital, Boston, MA

(1144) Suppression of Recall Alloantibody Responses by CTLA4Ig Is Associated with Reduction of CD138+ Plasma Cells in a Mouse Model of Allosensitization; G. D. Wu, I. Kim, N. Chai, S. Jordan, A. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

(1146) WITHDRAWN

(1147) Pyroptosis of Passenger Leukocytes Negatively Impacts the Quality of Lung Grafts During Ex Vivo Lung Perfusion; K. Noda, S. Tane, A. J. Hayanga, J. D'Cunha, J. D. Luketich, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA


(1149) Effect of Interleukin 10 Gene-Modified Human Umbilical Cord Mesenchymal Stem Cells on Lung Ischemia Reperfusion Injury in a Rat Lung Transplantation Model; W. Mao, J. Chen. Department of Lung Transplant Center, Key Laboratory of Human Organ Transplant in Jiangsu Province, Nanjing Medical University Affiliated Wuxi People’s Hospital, Wuxi, China

(1150) Static Cold Storage Induces Metabolic Alterations and Autophagy in Models of Cardiac Transplantation; D. T Tran, C. Dong, A. Alawieh, G. Beeson, C. Atkinson, S. N. Nadig. 1Microbiology & Immunology, Medical University of South Carolina, Charleston, SC, 2College of Medicine, Medical University of South Carolina, Charleston, SC, 3Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, 4Microbiology & Immunology; Surgery, Division of Transplant Surgery, Medical University of South Carolina, Charleston, SC, 5Surgery, Division of Transplant Surgery, Medical University of South Carolina, Charleston, SC

(1151) Optimal Perfusate Oxygenation During Ex Vivo Lung Perfusion Can Promote Alveolar Proliferation in Lung Grafts; K. Noda, S. Tane, A. J. Hayanga, J. D'Cunha, J. D. Luketich, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

(1152) Warm Retrograde Perfusion Can Remove More Fat from Lung Grafts with Fat Embolism in a Porcine Donor Model; M. Irie, S. Otani, T. Kurosaki, Y. Shikatani, K. Mesaki, K. Hashimoto, S. Tanaka, K. Miyahara, T. Ohki, K. Miyoshi, S. Sugimoto, M. Yamane, S. Miyoshi, T. Oto. 1Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan, 2Department of Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(1153) Identifying Cell Type-Specific or Common Biomarkers for Ischemia-Reperfusion Induced Injury in Lung Transplantation; A. K. Wong, Y. Lu, R. Zameli, M. Liu. 1Institute of Medical Science, University of Toronto, Toronto, ON, Canada, 2Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, Toronto, ON, Canada

(1154) DUAL Ex Vivo Lung Perfusion Techniques Can Contribute to Better Posttransplant Outcomes Through Reconditioning Hypoxic Cells in Lung Grafts; K. Noda, S. Tane, A. J. Hayanga, J. D'Cunha, J. D. Luketich, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

(1155) ST266 Improves Oxygenation and Reduces Tissue Injury in an In-Situ Rat Left Lung Ischemia-Reperfusion Model; C. F. Evans, X. Wang, X. Liu, R. Mishra, V. Mishra, S. Rahimpour, A. Zeevi, R. Banas, S. M. Pham. 1Surgery, University of Maryland, Baltimore, MD, 2Cardiac Surgery, Shanxi Dayi Hospital, Shanxi Academy of Medical Sciences, Beijing, China, 3University of Maryland, Baltimore, MD, 4Pathology, University of Pittsburgh, Pittsburgh, PA, 5Novoome Biotherapeutics, Inc., Pittsburgh, PA

(1156) Protective Effect of Anesthetic Preconditioning During Ex Vivo Lung Perfusion in a Rat Lung Transplantation Model; A. Ohsumi, K. Marseu, P. Slinger, K. McRae, T. Waddell, M. Liu, S. Keshavjee, M. Cypel. 1Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, Toronto, ON, Canada, 2Department of Anesthesiology, Toronto General Hospital, University of Toronto, Toronto, ON, Canada
(1157) Microvascular Integrity Can Be Preserved by Anti-Platelet Therapy and in Combination with mTOR Inhibitor; C. Heim1, M. A. Khan2, B. Motsch1, A. Gocht1, M. Ramsperger-Gleixner1, T. Stamminger3, M. R. Nicolls2, M. Weyand1, S. M. Ensminger1. 1University of Erlangen Department of Cardiac Surgery, Erlangen, Germany, 2Stanford University, Palo Alto, CA, 3University of Erlangen, Erlangen, Germany, 4HDZ NRW, Bad Oeynhausen, Germany


(1159) Impairment of the Protective PI3K/Akt Signaling Pathway in Transplanted Type-1 Diabetic Hearts Increases Post-Transplant Myocardial Injury; S. Korkmaz-Içöz1, S. Li1, S. Loganathan1, T. Radovits2, M. Ruppert1, P. Brlecic1, T. Fleming3, M. Brune3, P. Most4, M. Karck1, G. Szabó1. 1Cardiac Surgery, University of Heidelberg, Heidelberg, Germany, 2Heart and Vascular Center, Semmelweis University, Budapest, Hungary, 3Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany, 4Molecular and Translational Cardiology, Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany

(1160) Bronchial Artery Sparing Lung Preservation: Is It Feasible?; S. Tane, K. Noda, A. J. Hayanga, J. D'Cunha, J. D. Luketich, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

(1161) Nitrite Improves Mitochondrial Dysfunction Induced by Hypoxia/Reoxygenation in Lung Epithelial Cells: Implications for Ischemia-Reperfusion (I/R) Injury in Lung Transplantation; A. Kumar, C. Corey, S. Shiva, M. T. Gladwin, J. D'Cunha. University of Pittsburgh Medical Center, Pittsburgh, PA

(1162) Augmentation of UW Solution with a Gap and Tight Junction Stabilizing Peptide, αCT1, Ameliorates Ischemia Reperfusion Injury, Facilitates Prolonged Graft Storage, and Protects Against the Development of Allograft Vasculopathy; K. Patel1, Q. Cheng1, R. Finnegan2, Z. Ballish2, L. Rucker2, S. Nadig1, C. Atkinson1. 1Departments of Microbiology and Immunology, and Surgery, Medical University of South Carolina, Charleston, SC, 2Departments of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC

(1163) Continuous Hypothermic Perfusion of Old Donor Heart with a Preservation Solution Supplemented with Mesenchymal Stem Cell Conditioned Medium Improves Functional Graft Recovery During Prolonged Ischemic Time; S. Li1, S. Korkmaz1, M. Ruppert1, T. Radovits2, K. Li1, X. Sun1, P. Brlecic1, M. Karck1, G. Szabó1. 1Cardiac Surgery, University of Heidelberg, Heidelberg, Germany, 2Heart and Vascular Center, Semmelweis University, Budapest, Hungary

(1164) Preservation Solution Affects the Immunological Milieu in Lung Transplantation and Alters the Inflammatory Balance; M. Seyda1, R. Bellmas-Sanz1, B. Wiegmann2, C. A. Neudorfl1, A. Haverich1, C. S. Falk1, G. Warnecke2. 1Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, 2Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

(1165) Involvement of Interleukin-17 During Acute and Chronic Allograft Rejection in Two Orthotopic Lung Transplantation Models; F. Calabrese1, F. Lunardi1, S. E. Vuljan1, M. Vadori2, D. Zampieri1, N. Nannini1, E. Cozzi1, F. Rea1. 1University of Padova, Padova, Italy, 2CORIT, Padova, Italy, 3Padova University Hospital, Padova, Italy

(1166) Can Dantrolene Protect the Donor Heart Against Ischaemia-Reperfusion Injury?; J. E. Villanueva1, L. Gao1, H. C. Chew1, M. Hicks2, A. Doyle1, M. Qi3, P. S. Macdonald4, A. Jabbour4. 1Transplant Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, Australia, 2Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, Australia, 3SydPath Anatomical Pathology, St Vincent's Hospital, Darlinghurst, Australia, 4Heart and Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia

(1167) Using a Cell Culture Model to Optimize Lung Preservation Solutions: Effects of Buffer and Nutrients; L. Jing, Z. Guan, S. Moodley, M. Zhao, M. Cypel, S. Keshavjee, M. Liu. Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

(1168) ST266 Attenuates Acute Elastase-Induced Lung Emphysema in Mice; S. Rahimpour1, X. Liu1, X. Wang1, R. Banas2, C. Miller3, A. Zeevi4, S. M. Pham1. 1Surgery, University of Maryland, Baltimore, MD, 2Noveome Biotherapeutics, Pittsburgh, PA, 3Noveome Biotherapeutics, Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA

(1169) Paradoxical Mechno-Energetic Costs of Acute Mechanical Intra-Ventricular Unloading: A Key to Understand Myocardial Recovery with Left-Ventricular Mechanical Support?; S. Bennett1, C. L. del Rio2, J. Noel-
Morgan3, E. Geist2, Y. Ueyama2, E. Ferris2, B. Youngblood2, P. I. McConnell1. 1The Ohio State University, Columbus, OH, 2QTest Labs, Dublin, OH, 3Nationwide Children’s Hospital, Columbus, OH

(1170) WITHDRAWN

(1171) Induction and Release of Exosomes Play a Significant Role in the Rejection of Syngeneic Murine Cardiac Grafts Following Administration of Antibodies to Cardiac Myosin; M. Sharma1, W. Liu2, M. Gunasekaran2, T. Mohanakumar2. 1St. Joseph’s Hospital & Medical Center, Phoenix, AZ, 2St. Joseph’s, Phoenix, AZ

(1172) Beneficial Pleiotropic Effects of Multilineage-Differentiating Stress Enduring Cells on Acute Lung Ischemia-Reperfusion Injury; H. Yabuki1, S. Waka2, Y. Kushida2, M. Dezawa2, Y. Okada1. 1Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan, 2Stem Cell Biology and Histology, Tohoku University Graduate School of Medicine, Sendai, Japan

(1173) Cardio-Supportive Activity of Human Blood Monocytes in Human Engineered Heart Muscle; B. Fujita1, M. Tiburcy1, F. Bremmer2, S. Ensminger3, W. Zimmermann1. 1Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany, 2Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany, 3Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany

(1174) Novel Method of Creating Three-Dimensional Myocardial Sheet Using Heart Scaffold and Isolated Cardiomyocytes; M. Kasai, H. Yagi, K. Okamoto, Y. Kitagawa, H. Shimizu. Keio University, Tokyo, Japan

(1175) Cardiomyocytological Phosphorylation Alterations in Mechanical Unloaded Hypertrophic and Failing Hearts; A. Schaefer1, Y. Schneeberger1, J. Stenzig2, A. P. Schoorer2, T. Eschenhagen2, H. Ehmke2, H. Reichenspurger1, F. Cuello2. 1University Heart Center Hamburg, Hamburg, Germany, 2University Medical Center Eppendorf, Hamburg, Germany

(1176) Non-Nucleosidic DNA Methyl Transferase Inhibition Attenuates Pressure Overload Induced Cardiac Hypertrophy in Rats; Y. Schneeberger1, J. Stenzig2, A. Löser2, A. Schaefer1, E. Wong3, W. Tan3, H. Reichenspurger1, R. Foo3, T. Eschenhagen2. 1University Heart Center Hamburg, Hamburg, Germany, 2University Medical Center Eppendorf, Hamburg, Germany, 3Genome Institute of Singapore, Singapore, Singapore

(1177) Role of Club Cells in the Development of Obliterative Bronchiolitis in Murine Transplanted Lungs; C. Konoeda, Z. Guan, P. Duchesneau, T. Watanabe, S. Juvet, M. Liu, T. Martinu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, Toronto General Hospital, Toronto, ON, Canada

(1178) The Ubiquitin Proteasome System as Potential Therapeutic Target in Dilated and Ischemic Cardiomyopathy; F. Emrich1, Y. D. Barac2, S. Steinbach1, K. Kellermann1, M. T. Dieterlen1, S. Lehmann1, T. Noack1, K. Penov1, D. Aravot1, A. Ciechanover4, F. W. Mohr1, J. Garbade1. 1Dep. of Cardiac Surgery, University of Leipzig, Heartcenter, Leipzig, Germany, 2The Cardiothoracic Surgery Department, Rabin Medical Center, Haifa, Israel, 3Dep. of Cardiothoracic Surgery, Stanford University, Stanford, CA, 4Tumor and Vascular Biology Research Center, Technion - Israel Institute of Technology, Haifa, Israel

(1179) Donor Endothelial Inflammation and Recipient Leukocytes Contribute Independently to Primary Graft Dysfunction in Lung Transplant Recipients - Insights from a Humanized Mouse Model; A. Knoefel1, T. Siemeni1, N. Madrahimov1, W. Sommer1, M. Avsar1, F. Ius1, L. Pauksch1, K. Jansson1, J. Salman1, I. Tudorache1, C. Kühn1, A. Haverich1, C. S. Falk2, G. Warnecke1. 1HTTG, MHH, Hannover, Germany, 2Transplant Immunology, MHH, Hannover, Germany

(1180) Evidence of Endothelial to Mesenchymal Transition (EndMT) in the Clinically Non-Failing Left Ventricle (CNFLV) of End Stage Right Ventricular Pressure Overload Patients; A. S. Cruz-Solbes, K. Youker, J. Amione-Guerra, J. D. Estep, B. H. Trachtenberg, A. Guha, G. Torre-Amione, A. Bhimaraj. Methodist DeBakey Heart Center, Houston Methodist Hospital, Houston, TX

(1181) Mitochondrial Dysfunction in Heart Failure: Similar Patterns in Rats and Humans; G. Faerber, E. Heyne, M. Schwarzer, H. Kirov, T. Doenst. Department of Cardiothoracic Surgery, University Hospital Jena, Jena, Germany
(1182) **Senescence Gene Signature of the Transplanted Heart**: R. Araujo-Gutierrez, C. Uribe, K. A. Youker, M. H. Park, J. D. Estep, A. Guha, B. H. Trachtenberg, G. Torre-Amione, A. Bhimraj. *DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX*

(1183) **Investigation of Watershed Areas During Femoro-Femoral Venoarterial Extracorporeal Membrane Oxygenation (VA-ECMO) Using a Mock Loop Circuit**: C. Cheong1, A. Xie1, H. Chew2, M. Shah1, S. Shehab3, P. MacDonald5, H. Buscher4, K. Dhitla5. 1Faculty of Medicine, University of New South Wales, Kensington, Australia, 2Department of Cardiovascular Surgery, St Vincent's Hospital, Darlinghurst, Australia, 3Intensive Care Unit, St Vincent's Hospital, Darlinghurst, Australia, 4Department of Cardiovascular Surgery, St Vincent's Hospital, Darlinghurst, Australia

(1184) **In Vitro Hypoxia Pre-Conditioning of Stromal Vascular Fraction Cell-Based Constructs for Chronical Heart Ischemia Treatment**: M. Mytsyk1, G. Cerino2, M. R. Grapow1, M. G. Muraro3, F. S. Eckstein1, A. Marsano2. 1Cardiac Surgery, University Hospital of Basel, Basel, Switzerland, 2Department of Biomedicine, University of Basel, Basel, Switzerland, 3Department of Pediatrics/Biomedical Sciences, UCSF, San Francisco, CA

(1185) **The “Giraffe Paradox”: What Humans Can Learn from Giraffe in Heart Failure**: D. Wang1, T. Deuse1, K. Ameri1, M. Stubbendorff3, H. Reichenspurner4, H. Schoon5, T. Theuss5, D. R. Cavener6, S. Schrepfer1. 1Surgery, TSI Lab, UCSF, San Francisco, CA, 2of Pediatrics/Biomedical Sciences, UCSF, San Francisco, CA, 3Cardiovascular Surgery, TSI Lab, UHZ, Hamburg, Germany, 4Cardiovascular Surgery, UHZ, Hamburg, Germany, 5Veterinary, Pathology University Leipzig, Leipzig, Germany, 6Genomics and Bioinformatics, University Pennsylvania, Pennsylvania, PA

**HEART TRANSPLANTATION**

(Coronado Foyer)

**Poster Discussants**: Jason A Gluck, DO (USA), Feras Khaliel, MD, PhD (Saudi Arabia), Mehmet K Kirali, MD (Turkey), Maria M Mountis, DO (USA), Matthias Peltz, MD (USA), Ajay V Srivastava, MD (USA), John y Um, MD (USA), Andreas Zuckermann, MD (Austria)

(1186) **Heart Transplantation in Prostate Cancer Patients**: A. Iyengar1, N. Harati1, E. D. Adams1, C. Eisenring2, L. Reardon3, M. Deng3, A. Ardehali2, E. DePasquale3. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2Department of Cardiovascular Surgery, University of California - Los Angeles, Los Angeles, CA, 3Department of Cardiology, University of California - Los Angeles, Los Angeles, CA


(1188) **Outcomes of Combined vs. Sequential Heart-Kidney Transplant**: M. Gallo, J. R. Trivedi, W. M. Whited, M. S. Slaughter. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

(1189) **Transplant Volume Is Associated with Center Resource Availability and Graft Acceptance Threshold**: C. W. Chen1, J. J. Chung2, A. C. Gaffey1, C. A. Bermudez1, L. R. Goldberg2, M. A. Acker1, P. Atluri1. 1Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Department of Medicine, University of Pennsylvania, Philadelphia, PA


(1191) **Transthyretin Amyloid Patients > 70 Years of Age Appear as Good Candidates for Heart Transplantation**: J. Patel, M. Kiritleson, R. Vescio, T. Aintablian, R. Sharoff, R. Levine, D. Geft, D. Chang, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

(1192) **Informative and Uninformative Variables in the Scientific Registry of Transplant Recipients**: E. M. Hsich1, L. Thuita2, D. McNamara3, J. G. Rogers4, J. Schold5, E. H. Blackstone6, H. Ishwaran6. 1Cardiology, Cleveland Clinic Foundation, Cleveland, OH, 2Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, 3Cardiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Cardiology, Duke University, Durham, NC, 5Thoracic and
The Effect of Donor Anticonvulsant Use within 24 Hours of Aortic Cross-Clamp on 1-Year Recipient Survival: S. Lella, K. Zolfaghari, L. A. Copeland, C. B. Sai-Sudhakar, Y. Ravi. 1College of Medicine, Texas A&M University, Dallas, TX, 2Center for Applied Health Research, Baylor Scott & White Health, Temple, TX, 3Cardiothoracic Surgery-Surgery, Baylor Scott & White Healthcare, Temple, TX

Expanding the Donor Service Area to Greater Than 500 Miles Is Safe and Effective: H. Copeland, D. Baran, J. Copeland, G. Katiaps, B. Dharmaraj. 1McGuire VA Medical Center, Richmond, VA, 2Newark Beth Israel Medical Ctr, Livingston, NJ

To Accept or Not Accept, That Is the Question: Donor Heart Selection Process and Outcome of Discarded Organs Transplanted in Another Center: A. Z. Aliabadi-Zuckermann, J. Goekler, A. Kaider, K. Uyanik-Uenal, J. Riebandt, R. Moayedifar, E. Osorio, T. Haberl, G. Laufer, J. Smits, A. O. Zuckermann. 1Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Medical Statistics, Medical University of Vienna, Vienna, Austria, 3Eurotransplant Foundation, Leiden, Netherlands


Towards a Cardiac Allocation Score: A Retrospective Calculation for 73 Patients from a German Transplant Center: S. Grundmann, S. Claes, M. Berchtold-Herz, Q. Zhou, G. Trummer, A. Zirlik, F. Beyersdorf, C. Bode. University Heart Center Freiburg, Freiburg, Germany

Heart Transplantation as an Option for End-Stage Chronic Chagas Heart Disease. A Public Hospital Experience: P. Avellan, A. Ini, D. Radlovachki, M. Ajzenszlos, J. Giorgini, M. Tibaudin, A. Rodriguez, A. Stewart Harris, L. Ahualli. Hospital Cosme Argerich, Buenos Aires, Argentina


Post-Operative Acute Renal Failure Adversely Impacts Long-Term Survival After Successful Heart Transplant: Analysis of a National Database: S. Deo, S. E. Altarabsheh, N. Sarabu, S. Dunlay, A. Klic, G. Fonarow, S. J. Park. 1Cardiac Surgery, University Hospitals, Cleveland, OH, 2Cardiac Surgery, Queen Alia Heart Institute, Jordan, Jordan, 3Nephrology, University Hospitals, Cleveland, OH, 4Cardiology, Mayo Clinic, Rochester, MN, 5Cardiac Surgery, Wexner Heart Center, Ohio State University, Columbus, OH, 6Cardiology, Ronald Reagan Medical Center, University of California, Los Angeles, Los Angeles, CA

Pregnancy After Heart Transplantation: A Well-Thought-Out Decision?: O. Dagher, N. Laroussi, B. Cantin, M. Carrier, R. Cecere, E. Charbonneau, S. De Denu, N. Giannetti, L. Leduc, S. Levesque, N. Poirier, M. Raboissino, M. White, A. Ducharme. 1Montreal's Heart Institute (MHI), Montreal, QC, Canada, 2Sainte-Justine's University Hospital, Montreal, QC, Canada, 3Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, QC, Canada, 4McGill University Health Centre, Montreal, QC, Canada, 5Montreal Health Innovations Coordinating Center (MHICC), Montreal, QC, Canada

Risk of Early, Intermediate, and Late Rejection Following Heart Transplantation (HT): Trends Over the Past 25 Years and Relation to Changes in Medical Management: Y. Peled, M. Katz, M. Arad, Y. Kassif, Y. Shemesh, E. Asher, D. Elian, Y. Har-Zahav, N. Shlomo, D. Freimark, J. Lavee, I. Goldenberg. Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel

Total Peripheral Resistance Does Not Increase During Orthostatic Challenge in Recently Heart Transplanted Patients: S. I. Nygaard, G. Dahlen, V. B. Wyller. 1Oslo University Hospital, Oslo, Norway, 2Dept. of Paediatrics, Akershus University Hospital, Lorenskog, Norway, Lorenskog, Norway

(1205) **Does Stroke in the Perioperative Post Cardiac Transplant Period Impact Survival?**; N. Nair¹, S. Yang², E. Gongora². ¹Cardiology, Texas Tech Health Sciences Center, Lubbock, TX; ²Internal Medicine, Texas Tech Health Sciences Center, Lubbock, TX; ³Cardiothoracic Surgery, Memorial Cardiac and Vascular Institute, Hollywood, FL

(1206) **Heart Transplantation Bridged by Extracorporeal Life Support in the Adults: Experience from Samsung Medical Center in South Korea**; J. Lee, Y. Cho. Thoracic and Cardiovascular Surgery, Samsung Medical Center, Seoul, Korea, Republic of

(1207) **The Transmitial Peak Flow Velocity-Mitral Annular Diastolic Velocity Ratio (e/e') Does Not Predict Left Ventricular Filling Pressure Post Cardiac Transplant**; A. Selim¹, R. Zolty¹, A. Burdort¹, J. Um², A. Siddique², M. Moulton², B. Lowes¹, E. Raichlin¹. ¹Cardiology, University of Nebraska Medical Center, Omaha, NE; ²Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE

(1208) **Does Type of Mechanical Circulatory Support Influence Stroke Risk in the Perioperative Post Transplant Period?**; N. Nair¹, S. Yang², E. Gongora². ¹Cardiology, Texas Tech Health Sciences Center, Lubbock, TX; ²Internal Medicine, Texas Tech Health Sciences Center, Lubbock, TX; ³Cardiothoracic Surgery, Memorial Cardiac and Vascular Institute, Hollywood, FL


(1210) **WITHDRAWN**

(1211) **Outcomes of US Patients with Marfans Syndrome Listed for Heart Transplantation**; B. D. Kaufman¹, S. E. Tierney¹, D. Bernstein¹, S. H. Chen¹, J. Dykes¹, S. A. Hollander¹, D. H. Lianq², K. Maeda³, J. Priest¹, O. Reinhartz³, D. N. Rosenthal¹, C. Almond¹. ¹Pediatrics, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; ²Medicine, Stanford University, School of Medicine, Palo Alto, CA; ³Cardiothoracic Surgery, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA

(1212) **Modified Bicaval Technique in Orthotopic Heart Transplantation: Comparison with Conventional Bicaval Technique**; H. Kim¹, S. Jung¹, J. Kim², T. Yun¹, J. Lee¹. ¹Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Seoul, Korea, Republic of; ²Department of Cardiology, Asan Medical Center, Seoul, Korea, Republic of

(1213) **Outcome of HVAD Bridged to Transplantation Patients After Heart Transplantation - A Single Center Experience**; R. Moayedifar¹, D. Zimpfer¹, D. Wiedemann¹, J. Riebandt¹, K. Dimitrov¹, T. Schlügghofer², T. Habert¹, A. Aliabadi¹, E. Osorio¹, K. Freystaetter¹, K. Uyanik-Uenal¹, G. Laufer¹, A. Zuckermann¹. ¹Cardiac Surgery, Vienna General Hospital, Vienna, Austria; ²Center for Medical Physics and Biomedical Engineering, Vienna General Hospital, Vienna, Austria


(1215) **The Immediate Response in Markers of Inflammation and Angiogenesis During Exercise in Heart Transplant Recipients**; M. Yardley¹, T. Ueland², P. Aukrust³, A. Michelsen², E. Bjerkelund¹, L. Gullestad¹, K. Nytrøen¹. ¹Cardiology, OUS-HF Rikshospitalet, Oslo, Norway; ²Research Institute of Internal Medicine, OUS-HF Rikshospitalet, Oslo, Norway; ³Research Institute of Internal Medicine, Section of Clinical Immunology and Infectious Disease, OUS-HF Rikshospitalet, Oslo, Norway

(1216) **Alterations in Vascular Endothelial Growth Factors After Heart Transplantation**; J. Lundgren¹, S. Nielsen², C. Scheele², G. Rådegran¹. ¹Cardiology, Clinical Sciences, Lund University, Sweden; ²Centre of Inflammation and Metabolism, University of Copenhagen, Denmark


Friday, April 7
(1219) Association Between LVAD and Cardiac Allograft Injury Following Heart Transplantation as Assessed by Cell-Free DNA; M. E. Rodrigo¹, S. Agbor-Enoh², S. Gorham², U. Fidelis², I. Tunc², M. Jang², Y. Yang², K. Bhatti³, A. Marishta¹, P. Shah⁴, S. Pham⁴, K. Shah⁵, S. Russell⁶, E. Feller⁷, S. S. Najjar¹, H. Valantine⁸, *Cardiology, Medstar Washington Hospital Center, Washington, DC, ²National Institutes of Health, Bethesda, MD, ³Cardiology, INOVA Fairfax, Falls Church, VA, ⁴University of Maryland, Baltimore, MD, ⁵Cardiology, Virginia Commonwealth University, Richmond, VA, ⁶Cardiology, Johns Hopkins Hospital, Baltimore, MD, ⁷Cardiology, University of Maryland, Baltimore, MD

(1218) Analysis of Individual Gene Expression Levels Indicates the Impact of Physiological Functions on Gene Expression Profiling Scores; S. A. Hall¹, S. Pinney², J. Sninsky³, M. Machrus³, R. Woodward³, A. Kao⁴, *Cardiology, Baylor University Medical Center, Dallas, TX, ²Cardiology, Mount Sinai Health System, New York, NY, ³CareDx, Brisbane, CA, ⁴Cardiology, St. Luke’s Health System, Mid America Heart Institute, Kansas City, MO


(1221) Incidence and Implications of Primary Graft Dysfunction in Heart Transplantation Using the ISHLT Consensus Criteria; C. A. Bermudez¹, M. R. Molina¹, L. R. Goldberg², S. Chambers², P. Atluri¹, R. Forde-Mclean², J. I. Gentile¹, J. Wald², E. Rame², M. Jessup², E. Y. Birati², M. A. Acker¹, *Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Heart Failure and Cardiac Transplant Program, Hospital of the University of Pennsylvania, Philadelphia, PA

(1222) A Pilot Evaluation of the Post-Operative Glasgow Transplant Score (Post-GTS™) for Heart Transplants; S. Avtaar Singh¹, T. Vassalos², F. Nolan³, J. Sharp³, A. M. Young³, N. Al-Atta³, *Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom, ²Anaesthetics and Intensive Care, Golden Jubilee National Hospital, Glasgow, United Kingdom, ³Physiotherapy, Golden Jubilee National Hospital, Glasgow, United Kingdom, ⁴Clinical Psychology, Golden Jubilee National Hospital, Glasgow, United Kingdom, ⁵Dietetics and Nutrition, Golden Jubilee National Hospital, Glasgow, United Kingdom, ⁶Scottish National Adult Heart Failure Service, Golden Jubilee National Hospital, Glasgow, United Kingdom

(1223) Successful One-Year Survival in Heart Transplant Recipients Requiring Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction; N. Rajagopalan, D. R. Dennis, T. Mooney, T. Tribble, P. Tessmann, A. Shafii, M. E. Sekela. University of Kentucky, Lexington, KY


(1225) Dose-Dependent Association Between Amiodarone and Primary Graft Dysfunction in Heart Transplantation; M. Wright¹, K. Takeda¹, C. Mauro², D. Jennings¹, P. Kurlansky¹, J. Han¹, L. Truby¹, S. Stein¹, V. Topkara¹, A. R. Garan¹, M. Yuzefpolskaya¹, P. Colombo¹, Y. Naka¹, M. Farr¹, H. Takayama¹. *Columbia University Medical Center, New York, NY, ²Columbia University, Mailman School of Public Health, New York, NY

(1226) Primary Graft Dysfunction (PGD) After Heart Transplantation (HTx): Veno-Arterial ECMO as Bridge-to-Recovery?; U. Boeken¹, A. Mehdiani¹, B. Sowinski¹, A. Schmidt¹, H. Daleyanoglou¹, R. Westenfeld², P. Akhyari³, D. Saeed³, A. Lichtenberg¹, *Cardiovascular Surgery, University Hospital, Duesseldorf, Germany, ²Cardiology, University Hospital, Duesseldorf, Germany

(1227) Reoperative Sternotomy Is Not Associated with Increased Rates of Primary Graft Dysfunction Following Cardiac Transplantation; B. Lima, S. Still, A. Shaikh, G. Saracino, A. K. Jamil, J. Felius, S. M. Joseph, S. A. Hall, A. E. Rafael, J. C. MacHannahford, G. V. Gonzalez-Stawinski. Baylor University Medical Center, Dallas, TX

(1228) Genomic Research Alliance for Transplantation (GRAfT) A Unique Cohort to Address Age, Sex and Race in Heart Transplants; U. S. Fidelis¹, S. Agbor-Enoh¹, S. Gorham¹, M. Jang¹, Y. Yang¹, K. Bhatti¹, A. Marishta¹, M. E. Rodrigo², S. Najjar¹, K. Shah³, S. Russell³, S. Pham³, E. Feller³, P. Shah³, H. Valantine¹. *National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, MD, ²Medstar Washington Hospital Center, Washington, DC, ³Virginia Commonwealth University, Richmond, VA, ⁴Johns Hopkins University, Baltimore, MD, ⁵University of Maryland Medical Center, Baltimore, MD, ⁶Inova Heart and Vascular Institute, Falls Church, VA

Friday, April 7
LUNG TRANSPLANTATION
(Regatta Foyer)

Poster Discussants: Céline Bergeron, MD (Canada), Maria M Crespo, MD (USA), Marcelo Cypel, MD (Canada), Joshua Diamond, MD (USA), Daniel F Dilling, MD (USA), Maria C Gazzaneo, MD (USA), Matthew G Hartwig, MD (USA), Monique Malouf, FRACP (Australia), Richard N Pierson, III, MD (USA), Anna Reed, MBChB, MRCP, PhD (United Kingdom)

(1229) Eplet-Defined DQ Mismatches Predict for HLA Class II DSA Early Post-Lung Transplant: A Role in RAS?
D. Walton1, G. Snell2, L. Cantwell1, M. Paraskeva2, B. Levvey2, G. P. Westall2, 1Victorian Transplantation and Immunogenetics Service, Melbourne, Australia, 2Alfred Hospital, Melbourne, Australia

(1230) The Implications of Immunophenotypic Analysis of Lung Allograft Biopsies: L. Timofte1, J. Heath2, J. Kim1, R. N. Pierson3, Z. Kon3, S. Pham3, A. Iacono4, A. Burke2. 1Pulmonary and Critical Care, UMMC, Baltimore, MD, 2Pathology, UMMC, Baltimore, MD, 3Surgery, UMMC, Baltimore, MD, 4UMMC, Baltimore, MD

(1231) Plasmapheresis for the Treatment of Antibody-Mediated Rejection in Lung Transplant Recipients: M. Dordevic1, T. Sandhaus1, M. Leuze1, T. Steinke2, H. Kirov1, S. Rumiroller2, M. Steinert1, G. Faerber1, T. Doenst1. 1Department of Cardiothoracic Surgery, Friedrich Schiller University Jena, Jena, Germany, 2Institute of Transfusion Medicine, Friedrich Schiller University Jena, Jena, Germany

(1232) Elevated Serum BAFF Levels Are Associated with an Increased Risk of Acute Rejection in Lung Recipients: L. Calahorra1, J. Cifrian2, E. Sarmiento1, I. Ezzahouri1, C. Bravo3, S. Lopez4, R. Laporta4, P. Ussetti4, A. Sole5, A. De Pablos6, M. Jaramillo6, M. G. Snell1, Z. Kon3, A. Iacono4, A. Burke2. 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Pneumology, Hospital Marqués de Valdecilla, Santander, Spain, 3Pneumology, Hospital Vall de Hebron, Barcelona, Spain, 4Pneumology, Hospital Puerta de Hierro, Madrid, Spain, 5Pneumology, Hospital La Fe, Valencia, Spain, 6Pneumology, Hospital Doce de Octubre, Madrid, Spain

(1233) Coronary Disease and Lung Transplantation: Pulmonary Fibrosis Is a Cardiovascular Risk Factor?: F. Revuelta, L. A. Arvelo-Castro, M. Aguilar-Perez, N. Martos-Gisbert, S. Aguado-Ibáñez, J. Carrillo, P. Ussetti. Pulmonary Medicine, University Hospital Puerta de Hierro, Madrid, Spain

(1234) Decline in DLCO Precedes Decline in FEV1 or FVC After Lung Transplantation: C. M. Shaver, M. P. Steele, I. M. Robbins. Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN

(1235) WITHDRAWN

(1236) Post-Lung Transplant Survival After Venous Thromboembolism: B. C. Cahill1, T. G. Liou2, K. Peterson-Short3, T. Maughan3, W. Doidge3, B. Sirandas3, A. Carlson3, C. Truax3, L. Cotiguala3, S. Raman1, S. H. McKellar4, C. H. Selzman5. 1Division of Pulmonary Medicine and Lung Transplant Program, University of Utah School of Medicine, SLC, UT, 2Division of Pulmonary Medicine, University of Utah School of Medicine, SLC, UT, 3University of Utah Lung Transplant Program, SLC, UT, 4Division of Cardiothoracic Surgery and Lung Transplant Program, University of Utah School of Medicine, SLC, UT

(1237) Which Extracorporeal Support Should We Use During Lung Transplantation? - Impact of CPB and ECMO on Peri-Operative Outcome: A. Siama1, V. Besa2, O. Abu Issa3, A. Koch3, N. Pizanis3, H. Teschler2, M. Kamler3, A. Clemens1. 1Dept. for Thoracic Surgery, Essen University Hospital, Essen, Germany, 2Dept. for Pneumology, Essen University Hospital, Essen, Germany, 3Dept. for Thoracic Organ Transplantation, Essen University Hospital, Essen, Germany

(1238) Differences in De Novo Donor-Specific Anti-HLA Antibodies Between Living-Donor Lobar and Cadaveric Lung Transplantation: F. Gochi1, T. F. Chen-Yoshikawa, T. Kondo, A. Ohsumi, K. Ohata, A. Takahagi, M. Saito, R. Okabe, H. Yamagishi, M. Hamaji, K. Hijiya, H. Motoyama, A. Aoyama, H. Date. Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan

(1239) Characteristics and Outcome of Patients with Stroke After Lung Transplant Surgery in the Lung Allocation Score Era: A. Banga, M. Mohanka, S. Bollineni, J. Mullins, V. Kaza, F. Torres. UT Southwestern Medical Center, Dallas, TX

Friday, April 7
(1240) Value of Portable Perfusion Scans in the Immediate Post-Operative Period Following Lung Transplantation; R. L. Rosenblatt, A. Mock, P. Garcha, H. Huang, K. Ausloos, P. Aguilar, G. Schwartz, D. Mason. Pulmonary, Simmons Transplant Institute, Dallas, TX

(1241) CT Derived Estimates of Total Lung Volume in Transplant Candidates: Can We Do without Plethysmography?; C. Culshaw, H. Newton, R. Sutcliffe, J. Nuttall, A. Sharman, M. Al-Aloul. Cardiothoracic Transplant Unit, University Hospital of South Manchester, Manchester, United Kingdom

(1242) Short-Term Outcomes in Patients Taking Antifibrotic Agents for Idiopathic Pulmonary Fibrosis (IPF) After Lung Transplantation; A. Kafi1, J. Falk1, G. Chaux1, S. Ghandehari2, W. Chang2, D. Ramzy2. 1Pulmonary and Critical Care, Cedars Sinai Medical Center, Los Angeles, CA, 2Cardiothoracic Surgery, Cedars Sinai Medical Center, Los Angeles, CA

(1243) Lung Transplantation from the ICU: Is It Justified?: T. C. Gan1, G. D. Nossent1, M. E. Erasmus2, A. Oude Lansink3, E. A. Verschuuren1, W. van der Bij1. 1Pulmonary Diseases, Tuberculosis and Lung Transplantation, University Medical Center Groningen, Groningen, Netherlands, 2Cardiothoracic Surgery, University Medical Center Groningen, Groningen, Netherlands, 3Intensive Care Medicine, University Medical Center Groningen, Groningen, Netherlands

(1244) Systematic Review and Meta-Analysis of Death After Posttransplant Lymphoproliferative Disease in Lung Transplantation; C. A. Moore1, J. Cheng1, C. J. Isella1, A. R. Glanville2, M. R. Morrell1, R. B. Smith1, J. Hayanga1, J. F. McDyer1, C. R. Enson1. 1University of Pittsburgh, Pittsburgh, PA, 2St Vincent's Hospital, Sydney, Australia

(1245) Accuracy of Ecocardiographic Assessment of Pulmonary Pressure in Lung Transplant Candidates; E. J. Wainstein1, H. M. Castro1, M. L. Orazzi1, G. N. Svetliza1, J. Maritano Furcada1, J. A. Precerutti1, A. Da Lozzo2, E. Beveraggi2, D. E. Smith1. 1Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Thoracic Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

(1246) Tracheostomy After Lung Transplantation Predicts Decreased Mid and Long Term Survival; S. J. Huddleston1, B. Roland2, K. Rudser2, U. Goswami2, S. J. Shumway1, M. Hertz2, G. Loor1, T. Rade1. 1Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, 2Biostatistical Design and Analysis Center, Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, 3Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, MN

(1247) Chronic Pain One to Five Years After Lung Transplantation - A Multicentre Study; A. Forsberg1, M. Claëson2, M. Lundmark3, M. Almgren3, A. Lennerling4. 1Institute of Health Sciences, Lund University, Lund, Sweden, 2The Department of Transplantation and Cardiology, Skåne University Hospital, Lund, Sweden, 3The Thoracic Intensive Care Unit, Skåne University Hospital, Lund, Sweden, 4The Transplant Unit, Sahlgrenska University Hospital, Gothenburg, Sweden


(1249) WITHDRAWN

(1250) HFpEF Associated with Reduced Survival Following Lung Transplantation; J. P. Scott1, B. A. Bolison2, R. C. Daly3, M. E. Wylam4, S. G. Peters4, C. C. Kennedy4. 1Mayo Clinic, Rochester, MN, 2Cardiology, Mayo Clinic, Rochester, MN, 3Cardiac Surgery, Mayo Clinic, Rochester, MN, 4Pulmonary and Critical Care, Mayo Clinic, Rochester, MN

(1251) Bronchial Complications After Living-Donate Lobar Lung Transplantation: Bronchial Stenoses in the Lobar to Segmental Bronchi Necessitating Earlier Intervention; S. Sugimoto1, T. Kurosaki2, K. Miyoshi1, S. Ota2, M. Yamane1, S. Miyoshi1, T. Oto2. 1General Thoracic Surgery, Okayama University Hospital, Okayama, Japan, 2Organ Transplant Center, Okayama University Hospital, Okayama, Japan

(1252) Impact of Elevated Pulmonary Artery Pressure in Lung Recipients Transplanted for COPD; E. Poli1, P. Yerly2, T. Krueger3, M. Gonzalez2, H. F. Ris3, L. P. Nicod4, P. M. Soccal4, A. Brill5, M. Tamm7, J. D. Aubert8. 1Medical School, University of Lausanne, Lausanne, Switzerland, 2Cardiology, Lausanne University Hospital, Lausanne, Switzerland, 3Thoracic Surgery, Lausanne University Hospital, Lausanne, Switzerland, 4Pulmonary Medicine, Lausanne University Hospital, Lausanne, Switzerland, 5Pulmonary Medicine, Geneva University Hospital, Geneva, Switzerland,
(1253) Leucopenia After Lung Transplantation: Incidence & Outcomes; M. Greer1, F. Ius2, T. Steinberg1, I. Tudorache2, T. Wette1, J. Gottlieb1. 1Respiratory Medicine, Hanover Medical School, Hannover, Germany, 2Heart, Thoracic, Transplantation & Vascular Surgery, Hanover Medical School, Hannover, Germany

(1254) Three Years Experience with an IgM Enriched Human Intravenous Immunoglobulins Based Treatment for Patients with Early Donor Specific Antibodies After Lung Transplantation; F. Ius1, W. Sommer1, M. Verboom2, C. Kühn1, M. Avsar1, A. Knöfel1, T. Siemeni1, J. Salmon1, D. Böttig1, M. Hallensleben2, T. Wette3, N. Schwerk4, C. Müller4, A. Haverich1, I. Tudorache1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany, 3Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, 4Department of Paediatric Pneumology, Hannover Medical School, Hannover, Germany


(1256) Intravenous Immune Globulin (IVIg) Monotherapy for Pre-Existing and De-Novo Donor-Specific Antibody (DSA) After Lung Transplantation (LTX); R. E. Gigris1, M. Strueber1, E. Beuker1, J. A. Gerlach2, A. Khaghani1. Richard DeVos Heart and Lung Transplant Program, Spectrum Health Hospitals, Grand Rapids, MI, 2Biomedical Laboratory Diagnostics Program, Michigan State University College of Human Medicine, East Lansing, MI

(1257) The Effect of Immunosuppression on Airway Integrity; H. Bellon1, E. Vandermeulen1, S. E. Verleden1, T. Heigl1, H. Vriens2, E. Lammertyn1, L. Verlinden2, S. Götze2, M. Verstuyf3, P. M. Hoet2, R. Vos1, G. M. Verleden1, B. M. Vanaudenaerde1. 1Department of Clinical and Experimental Medicine, KU Leuven University, Leuven, Belgium, 2Environment and Health, KU Leuven University, Leuven, Belgium, 3Clinical and Experimental Endocrinology, KU Leuven University, Leuven, Belgium, 4Institut für Klinische Chemie, Universitätsmedizin Göttingen, Göttingen, Germany

(1258) Lumacaftor-Ivacaftor Combination Therapy in Phe508del Homozygous CF Lung Transplant Candidates - Preliminary Results; C. Murer, L. C. Huber, T. Kurowski, A. Hirt, C. Robinson, U. Bürgi, C. Benden. Pneumology, University Hospital Zurich, Zurich, Switzerland

(1259) The Impact of Intravenous Immunoglobulin in Sensitized Lung Transplant Recipients with a cPRA <25%; A. L. Hulbert1, C. Benedetti1, K. Beermann1, A. Gray2, M. Hartwig3, J. M. Reynolds2. 1Pharmacy, Duke University Hospital, Durham, NC, 2Pulmonology, Duke University Hospital, Durham, NC, 3Surgery, Duke University Hospital, Durham, NC


(1261) Outcomes of Treatment of Donor Specific Antibodies: A Single Center Experience; D. Sullivan1, F. Torres1, A. Banga1, M. R. Mohanka1, S. Bollineni1, J. Mullins1, U. Rao1, C. Lacelle2, P. Duddupudi3, D. Surapaneni3, W. S. Ring5, M. Wait6, V. Kaza1. 1Division of Pulmonary and Critical Care Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, 2Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, 3The University of Texas at Dallas, Dallas, TX, 4Michigan State University, East Lansing, MI, 5Department of Cardiovascular and Thoracic Surgery, The University of Texas Southwestern Medical Center, Dallas, TX

(1262) A New Formulation of Itraconazole (Lozanoc®) Is Associated with Improved Bioavailability After Lung Transplantation; T. Tse, P. Hopkins, D. Chambers. The Prince Charles Hospital, Brisbane, Australia


(1264) Monthly Basiliximab Treatment Improves Chronic Renal Dysfunction with Allograft Stability After Lung Transplantation; D. J. Ross. Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
(1265) Predictors of Early Mortality After Lung Transplantation in the Lung Allocation Score Era: A. Banga, M. Mohanka, J. Mullins, S. Bollineni, V. Kaza, F. Torres. UT Southwestern Medical Center, Dallas, TX

(1266) Rothman Index Predicts Perioperative Outcomes After Lung Transplantation: S. Daouk¹, H. Fakih¹, L. Mramba², T. Machuca³, S. Chandra shekaran¹, A. Em tiazjoo¹, I. Far uqi¹, A. Pelaez¹, ¹Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, ²Internal Medicine, Biostatistics, University of Florida, Gainesville, FL, ³Cardio-Thoracic Surgery, University of Florida, Gainesville, FL

(1267) Demographic Disparities in Post-Lung Transplant Mortality: H. Maredia¹, M. Bowring¹, A. Massie¹, S. Oyetunji¹, C. Merlo², R. Higgins¹, D. Segev¹, E. Bush¹. ¹Department of Surgery, Johns Hopkins University, Baltimore, MD, ²Department of Medicine, Johns Hopkins University, Baltimore, MD

(1268) Lung and Heart Lung Transplantation for Scleroderma Lung Disease: Indications, Survival and Prognosis; P. Pradere¹, J. Gottlieb², B. Olivier³, B. Douvry⁴, M. Reynaud-Gaubert⁴, J. Claustre⁵, A. Le Borgne⁷, A. Holm⁵, H. Schultz⁷, S. Hirschi², ¹Service de Chirurgie Thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France, ²Hannover Medical School, Biomedical Research in End-Stage and Obstructive Lung Disease, Hannover, Germany, ³Service de Pneumologie, Hôpital Bichat, Paris, France, ⁴Service de Pneumologie, Hôpital Fch, Suresnes, France, ⁵Service de Pneumologie, Hôpital Nord, Marseille, France, ⁶Service de Pneumologie, Clinique Universitaire de Pneumologie, Grenoble, France, ⁷Service de Pneumologie, CHU Toulouse, Toulouse, France, ⁸Hospital Rikshospitalet, Oslo University, Oslo, Norway, ⁹Hospital, Rigshospitalet, Copenhagen University, Copenhagen, Denmark, ¹⁰Service de Pneumologie, CHU Strasbourg, Strasbourg, France


(1270) Fertility, Pregnancy and Child Birth in Women Post Lung Transplantation (a Single Center Experience); O. Shtreichman, I. Bakal, D. Rosengarten, D. Shitenberg, Y. Shostak, M. R. Kramer. Pulmonary Institute, Rabin Medical Center Belinson Campus, Petach Tikva, Israel

(1272) Lung Transplant Symposium: A Team’s Ideas Put into Action; S. Mockett. Transplant Center, Duke University Medical Center, Durham, NC

(1273) Description of Airway Complications in Re-Transplantation: 10 Year Experience; J. C. Fernandez-Castillo¹, R. R. Mehta², E. Mahoney², S. Quddus². ¹Loyola University Medical Center, Chicago, IL, ²Pulmonary and Critical Care Medicine, Loyola University Medical Center, Chicago, IL


(1275) Effect of Gender Mismatch on Outcome in Lung Transplantation: R. Erlebach, Y. Yamada, M. Schuurmans, W. Jungrahlthmayr, I. Schmitt-Opitz, C. Benden, W. Weder, I. Inci. University Hospital, Zurich, Switzerland

(1276) One Hundred Cases of Lung Transplantation in Saudi Arabia: Challenges and Outcomes; M. H. Ahmed¹, I. Y. Nizami², W. N. Saleh¹, S. M. Ahmed², K. M. Alkattan³. ¹Thoracic Surgery, King Faisal Specialist Hospital And Research Centre, Riyadh, Saudi Arabia, ²Organ Transplant Centre, King Faisal Specialist Hospital And Research Centre, Riyadh, Saudi Arabia, ³Alfaisa University, Riyadh, Saudi Arabia

(1277) Donor Chest X-Ray and Bronchoscopy Findings Are Poor Predictive Measures for Lung Transplant Recipient Survival; A. Mani¹, F. Zafar², R. Bryant III³, D. Morales³, C. Towe⁴, M. Schecter⁴. ¹Department of Medicine, University of Cincinnati, Cincinnati, OH, ²Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Cardiothoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Lung Transplant Department, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

(1278) A Downward Trajectory of Body Mass Index in the First 12 Months Post Lung Transplant Predicts Poor Survival; D. Hickling, J. McMillan, S. Yerkovich, D. C. Chambers, P. Hopkins. Queensland Lung Transplant Service, Queensland Health, Brisbane, Australia

Friday, April 7
(1279) WITHDRAWN

(1280) Tapering, Not Discontinuation, of Epoprostenol Prevents PGD Requiring ECMO Support in Recipients with Severe Pulmonary Hypertension; A. Aoyama1, H. Kinoshita2, T. Yoneda3, Y. Goda1, H. Oda1, H. Kayawake1, S. Ueda1, K. Minakata4, H. Motoyama1, M. Hamaji1, K. Hijiya1, T. F. Chen-Yoshikawa1, H. Date1. 1Thoracic Surgery, Kyoto University, Kyoto, Japan, 2Cardiovascular Medicine, Kyoto University, Kyoto, Japan, 3Clinical Laboratory, Kyoto University Hospital, Kyoto, Japan, 4Cardiovascular Surgery, Kyoto University, Kyoto, Japan


(1282) Gene Set Enrichment Analysis Identifies a Potential Link Between Smoking and Upregulation of Olfactory Receptor and Cytokine Enrichment Pathways; C. Schaufler1, J. Lasky1, B. Lim1, Y. Suzuki1, D. Mallem1, M. Oyster2, D. J. Lederer3, K. Meyer4, C. A. Bermudez1, J. Tobias5, V. M. Van Deerlin6, K. Olthoff1, A. Shaked1, J. M. Diamond2, E. Cantu1, J. D. Christie2. 1Division of Cardiovascular Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 3Department of Medicine and Epidemiology, Columbia University College of Physicians and Surgeons, New York, NY, 4University of Wisconsin School of Medicine and Public Health, Madison, WI, 5Penn Molecular Profiling Facility, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 6Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

(1283) Does PGD3 at 0-48 Hours After Lung Transplantation Matter?: A. Iyengar1, O. Kwon2, N. Harati1, C. Eisenring2, E. DePasquale3, D. Ross4, A. Ardehali2. 1David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA, 2Department of Cardiac Surgery, University of California - Los Angeles, Los Angeles, CA, 3Department of Cardiology, University of California - Los Angeles, Los Angeles, CA, 4Department of Pulmonology, University of California - Los Angeles, Los Angeles, CA

(1284) Effectiveness of Inhaled Nitric Oxide (NO) in Lung Transplantation: Clinical and Morphological Study; F. Calabrese1, E. Forin2, M. Schiavon1, E. Perissinotto2, N. Cacco2, G. Marulli2, F. Lunardi2, S. Vuljan2, G. Di Gregorio2, F. Rea1. 1Cardiac, Thoracic and Vascular Sciences, University of Padua, Padova, Italy, 2University of Padua, Padova, Italy

MECHANICAL CIRCULATORY SUPPORT

(Seaport Foyer)

Poster Discussants: David A Baran, MD (USA), Christian A Bermudez, MD (USA), Andrew J Boyle, MD (USA), Patricia P Chang, MD (USA), Dawn M Christensen, MS, CRNP (USA), Eric Epailly, MD (France), Matthew Fenton, MRCPCH (United Kingdom), Jaime A Hernandez-Montfort, MD, MPH (USA), Theodorus Kofidis, MD, PhD, FRCS (Singapore), Claudius Mahr, DO (USA), Francis D Pagani, MD, PhD (USA), Maryse Palardy, MD (USA), Sebastian V Rojas, MD (Germany), Melana Yuzefpolskaya, MD (USA)


(1288) Morbidity Risks with Long Term Left Ventricular Assist Device (LVAD) Support; S. Schettle1, N. Pereira2, S. Kushwaha2, R. Daly1, D. Joyce1, L. Joyce1, S. Maltais1, J. Stulak1. 1Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, MN, 2Cardiology, Mayo Clinic Rochester, Rochester, MN

Friday, April 7
Risk Factors for the Development of Right Ventricular Failure After LVAD Implantation - A Single Centre Retrospective on Echocardiographic Speckle Tracking Findings; R. Zayat, N. Bögerhausen, A. Goetztenich, L. Tewarie, A. Moza, R. Autschbach, N. Hatam. Department of Thoracic and Cardiovascular Surgery, RWTH University Hospital, Aachen, Germany

Unexpected Mechanical Device Failures of Left Ventricular Assist Devices: An Urgent Call for More Intensive Regular Inspections; R. Muslem1, S. Akin1, A. A. Constantinescu1, C. Van der Heiden1, O. C. Manintveld1, O. Birim2, A. J. Bogers2, K. Caliskan1. 1Cardiology, Erasmus MC, Rotterdam, Netherlands, 2Cardiothoracic Surgery, Erasmus MC, Rotterdam, Netherlands

Extracorporeal Life Support (ECLS) as Bridge to Ventricular Assist Device (VAD) Implantation, Friend or Foe?; H. Carstens1, N. Pizanis1, A. Koch1, J. Heckmann1, T. Rassaf2, M. Kamler1. 1Thoracic Transplant, University Essen, Essen, Germany, 2Cardiology, University Essen, Essen, Germany

Prognostic Relevance of INTERMACS Defined Right Heart Failure After Left Ventricular Assist Device Implantation; R. Muslem1, C. Ong2, N. A. Gilotra2, K. Sharma2, B. A. Houston2, K. J. Zehri2, D. C. Duquaine2, G. J. Whitman4, K. Caliskan1, S. D. Russell2, R. J. Tedford2. 1Cardiology, Erasmus MC, Rotterdam, Netherlands, 2Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, 3Cardiology, Medical University of South Carolina, Charleston, SC, 4Cardiothoracic Surgery, Johns Hopkins School of Medicine, Baltimore, MD

D-dimer as a Prognostic Indicator for Survival or Death in Mechanical Circulatory Support Device Patients; T. Kazui1, R. H. Cosgrove2, D. A. Hewlett2, R. L. Basken2, R. G. Smith3, R. J. Avery4, P. G. Suryanarayana5, E. B. Juneman5, J. L. Cook5, S. D. Lick5, N. K. Sweitzer5, Z. I. Khalpey4. 1Cardiothoracic Surgery, Banner University Medical Center Tucson, Tucson, AZ, 2Pharmacy, Banner University Medical Center Tucson, Tucson, AZ, 3Artificial Heart, Banner University Medical Center Tucson, Tucson, AZ, 4Radiology, Banner University Medical Center Tucson, Tucson, AZ, 5Cardiology, Sarver Heart Center, Banner University Medical Center Tucson, Tucson, AZ

Predicting Right Ventricular Failure in the Current Continuous Flow Left Ventricular Assist Device Era; A. Loforte1, A. Montalto2, V. Polizzi2, F. Sbaraglia3, M. Lo Presti3, L. Potena4, M. Masetti4, G. Marinelli1, F. Musumeci2. 1Cardiovascular Surgery and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy, 2Cardiac Transplantation and Transplantation, S. Camillo-Fiorani Hospital, Rome, Italy, 3Cardiology and Transplantation, S. Camillo-Fiorani Hospital, Rome, Italy, 4Cardiology and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy

Predictors of Acute Kidney Injury Following Left Ventricular Assist Device Implantation; B. Lima1, J. Collier1, A. Shaikh1, K. M. Tecson2, S. Still1, R. D. Baxter1, J. Felius1, S. A. Hall1, G. V. Gonzalez-Stawinski1, S. M. Joseph1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX

Long Term Survivors of LVAD Support: What Attributes Describe Their Survival Advantage?; J. A. Cowger1, P. Shah2, R. Singh3, F. D. Pagani4, K. D. Aaronson4, T. F. Dardas4, S. Maltais7, N. A. Mokadam4, J. Stulak7, S. M. Dunlay9, C. T. Salerno10. 1Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN, 2Cardiovascular Medicine, Inova Heart & Vascular, Fall Church, VA, 3Surgery, Inova Heart & Vascular, Falls Church, VA, 4Cardiac Surgery, University of Michigan, Ann Arbor, MI, 5Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 6Cardiovascular Medicine, University of Washington, Seattle, WA, 7Cardiac Surgery, Mayo Clinic, Rochester, MN, 8Cardiovascular Surgery, University of Washington, Seattle, WA, 9Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 10Cardiac Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN

Elevated Pre-Operative Creatinine Is a Risk Factor for Late-Onset Right Heart Failure After Left Ventricular Assist Device Implantation; J. Kim, A. Pekarek, D. Nguyen, J. Vega, R. Cole, A. A. Morris, A. Smith, S. Laskar, D. Gupta. Emory University, Atlanta, GA


Clinical Relevance of Late and Very Late Right Heart Failure After LVAD Implantation; H. Vidula, S. McNitt, A. Papernov, M. Wang, V. Kutyla, J. D. Alexis. Medicine, Univ of Rochester, Rochester, NY
(1300) Predicting Right Ventricular Failure in Patients Undergoing Continuous Flow-Left Ventricular Assist Device Implantation with Multiple Predictive Models; L. Smith, A. Peters, B. Lawlor, D. Harrison, E. Benton, L. Kirchoff, K. Bilchick, J. Kennedy, S. Mazimba. University of Virginia, Charlottesville, VA

(1301) Allosensitization in New Generation Left Ventricular Assist Device Recipients; M. Carrozzini1, T. Bottio1, V. Tarzia1, F. Toto1, M. Comisso1, E. Manzan1, M. Cardillo2, E. Cozzi1, J. Bejko1, G. Gerosa1. 1Cardiac, Thoracic and Vascular Sciences, University of Padova, Cardiac Surgery Unit, Padova, Italy, 2Rigenerative Medicine, Milano Hospital, Transplant Immunology, Milano, Italy

(1302) Outcomes and Predictors of Lymphatic Leak Following Femoral Cannulation for Veno Arterial Extracorporeal Life Support; M. F. Masood, W. Padovano, M. Pisi, A. K. Basha, Y. D. Kim. Cardiothoracic Surgery, Washington University in St. Louis / Barnes Jewish Hospital, Saint Louis, MO

(1303) Pre-Implant Under-Expression of CCR3 and Its Ligands Predicts One-Year Mortality in Left Ventricular Assist Device Patients; A. Nayak1, C. Neill2, R. L. Kormos3, L. Lagazzi3, I. Halder4, C. McTiernan4, J. Larsen2, A. Inashvili1, J. Teuteberg3, T. N. Bachman6, K. Hanley-Yanez4, D. M. McNamara3, M. A. Simon3. 1Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 2School of Medicine, University of Pittsburgh, Pittsburgh, PA, 3Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA

(1304) Readmission within 30 Days After Continuous Flow Ventricular Assist Devices Implantation - Comparative Analysis of HeartMate II and HeartWare Devices; T. Sugiura, C. Kurihara, M. Kawabori, W. E. Cohn, A. B. Civitello, O. H. Frazier, J. A. Morgan. Texas Heart Institute, Houston, TX

(1305) Heparin Induced Thrombocytopenia Type II in Mechanical Circulatory Support Recipients; M. Urban, J. Jungschleger, N. Robinson-Smith, A. Woods, S. Schueler, G. MacGowan. Freeman Hospital, Newcastle upon Tyne, United Kingdom

(1306) Iron Deficiency Prior to cf-LVAD Implant Predicts Anemia Post Implant; R. J. Varipapa1, J. M. Canada2, K. B. Shah1. 1VCU, Richmond, VA, 2Pauley Heart Center, VCU, Richmond, VA

(1307) Model of End-Stage Liver Disease (MELD) and MELD-Sodium Scoring Systems Predict Development of Early Right Heart Failure in Patients Undergoing Ventricular Assist Device Implant; A. F. Stein-Merlob1, M. A. Psotka1, J. Svetlichnyna1, V. N. Selby1, M. Jammohamed1, T. De Marco1, G. M. Wieselthaler2, L. Klein1. 1Cardiology, Univ of California, San Francisco, CA, 2Cardiac Surgery, Univ of California, San Francisco, CA


(1309) An Evaluation of Long-Term Durability of the Motor and Driveline of the HVAD System; M. Koprivanac1, D. T. Pham2, S. Raza4, D. Meyer4, C. Koidel5, C. Salerno6, M. Kelava7, J. Chow8, J. Graham9, N. Moazami2. 1General Surgery/Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH, 2Cardiothoracic Surgery, Northwestern University, Chicago, IL, 3Cardiothoracic Surgery, Cleveland Clinic, Cleveland, OH, 4Cardiothoracic Surgery, UT Southwestern Medical Center, Dallas, TX, 5Cardiothoracic Surgery, Division of Thoracic and Cardiovascular Surgery University of Florida, Gainesville, OH, 6Cardiothoracic Surgery, St. Vincent's Heart Center of Indiana, Indianapolis, IN, 7Cardiac Anesthesiology, Cleveland Clinic, Cleveland, OH, 8Medical Affairs, HeartWare, Medical Affairs, HeartWare, Framingham, MA, 9Medical Affairs, HeartWare, Medical Affairs, HeartWare, | Framingham, MA

(1310) Cerebrovascular Events in Patients with Continuous Flow Left Ventricular Assist Devices; Y. D. Kim, D. Robson, P. S. Macdonald, P. Spratt, P. Jansz, C. S. Hayward. St Vincent's Hospital, Sydney, Australia

(1311) Late-Onset Right Heart Failure After Left Ventricular Assist Device Implantation Is Associated with Poor Prognosis; J. Kim, A. Pekarek, D. Nguyen, J. Vega, R. Cole, A. Morris, A. Smith, S. Laskar, D. Gupta. Emory University, Atlanta, GA

Friday, April 7
(1312) **RA Pressure and RV Enlargement Are Predictive of Heart Failure Hospitalizations in Patients with LVAD**; J. Pillarella, G. Vaidya, B. Salgado, C. Dunbar Matos, R. Vijayakrishnan, A. Lenneman, M. Slaughter, E. Birks, D. Abramov. Division of Cardiovascular Medicine, University of Louisville, Louisville, KY

(1313) **Venoarterial Extracorporeal Membrane Oxygenation as a Direct Bridge to Heart Transplant**; J. Sahbaz1, E. P. Kastner1, Z. N. Kon2, E. D. Feller3, V. Ton3, S. M. Pham2, E. N. Sorensen2, G. V. Ramani3. 1Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, 2Department of Surgery, Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, 3Department of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, MD, 4Division of Clinical Engineering, University of Maryland School of Medicine, Baltimore, MD

(1314) **Circadian Variation in Hemodynamics and Device Parameters in HeartMate II Patients**; A. Pinsino1, F. Castagna1, E. J. Stöhr1, B. McDonnell2, M. Yuzefpolskaya1, A. Clemons1, M. Tiburcio1, M. Pineda1, K. Ross1, V. K. Topkara1, A. R. Garan1, H. Takayama1, K. Takeda2, Y. Naka2, J. Cockcroft2, P. C. Colombo1. 1New York Presbyterian Hospital - Columbia University Medical Center, New York, NY, 2Cardiff Metropolitan University, Cardiff, United Kingdom


(1316) **Characteristics and Outcomes of LVAD Recipients with Cardiac Sarcoidosis**; S. Ahmed1, S. F. Mohammed1, D. T. Majure2, M. E. Rodrigo1, E. J. Molina1, S. W. Boyce1, S. S. Najjar1, F. H. Sheikh1. 1MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, 2Advanced Heart Failure, Northwell Health, New York, NY

(1317) **Outcomes of Extra Corporeal Membrane Oxygenation by Etiology: A Single Center Experience**; D. Miranda1, B. Magod2, K. Wilson2, R. Garberich2, D. Williams3, K. Hryniewicz3. 1Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN, 2Minneapolis Heart Institute Foundation, Minneapolis, MN, 3Critical Care Medicine, Abbott Northwestern Hospital, Minneapolis, MN

(1318) **The Impact of LVAD Duration on Short-Term Outcomes After Heart Transplantation**; H. Shah1, M. Kahanda1, E. Novak2, S. Sitner2, J. Shuster2, S. LaRue2, J. Schilling2. 1Barnes Jewish Hospital/Washington University, Saint Louis, MO, 2Cardiology, Barnes Jewish Hospital/Washington University, Saint Louis, MO

(1319) **Utilization of Physical and Occupational Therapy Services in Patients Waiting Heart Transplant with an Ambulatory Durable Counterpulsation System**; M. Stulberg1, C. Esbrook1, V. Kagan2, C. Juricek2, V. Jeevanandam2. 1Therapy Services, University of Chicago Medicine, Chicago, IL, 2Cardiac & Thoracic Surgery, University of Chicago Medicine, Chicago, IL

(1320) **Conservative Weight Reduction Is Insufficient in Obese Patients Receiving a Left-Ventricular Assist Device as Bridge-to-Candidacy**; P. Angleitner1, D. Wiedemann1, T. Schöglohofer2, J. Riebandt1, K. Dimitrov1, A. Zuckermann1, G. Lauter1, D. Zimmer1. 1Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria


(1323) **Single Center Experience of Long Term Outcomes of Severe Cardiogenic Shock Patients Needing IMPELLA 5.0 Placement**; S. H. Ibarra-Cortez, R. Araujo-Gutierrez, A. S. Cruz-Solbes, B. Bruckner, J. D. Estep, E. E. Suarez, A. Bhimaraj. DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

(1324) **Ventricular Arrhythmias in Long Term LVAD Patients - Life Threatening Situation or Nothing to Worry About?**; J. G. Jungschlegel, M. M. Mydin, A. Woods, M. Urban, N. Robinson, G. MacGowan, S. Schueler. Dept of Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Friday, April 7

(1326) WITHDRAWN

(1327) WITHDRAWN

(1328) Comparison Between Italian and Unites States Centers on Outcome and Likelihood of Heart Transplantation in Patients Treated with Left Ventricular Assist Device as Bridge to Transplantation; E. Ammirati1, M. Brambatti2, M. Cipriani1, E. Perna1, A. Mizeracki2, J. Silva Enciso2, H. Tran2, A. R. Calini1, G. V. Pretorius3, C. F. Russo1, M. Frigerio1, E. Adler2. 1De Gasperis CardioCenter, Niguarda Hospital, Milan, Italy, 2Cardiology, University of California San Diego, La Jolla, CA, 3Cardiothoracic Surgery, University of California San Diego, La Jolla, CA


(1330) Effective Mechanical Circulatory Support with Impella in Postcardiotomy Cardiogenic Shock; D. G. Tanq1, G. W. Vetrovec2, C. Toma3, A. B. Civitello4, M. Silver5, M. B. Anderson6. 1Virginia Commonwealth University, Richmond, VA, 2Cardiology, Virginia Commonwealth University, Richmond, VA, 3Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Baylor St. Luke's Medical Center / Texas Heart Institute, Houston, TX, 5GeneSys Regional Medical Center, Grand Blanc, MI, 6Cardiothoracic Surgery, Einstein Medical Center, Philadelphia, PA


(1332) Increasing Severity of Periprocedural Right Heart Failure Leads to Incrementally Worse Outcomes Following Left Ventricular Assist Device Implantation; B. Lima1, A. Shaikh1, K. M. Tescos2, S. Still1, J. Collier1, R. D. Baxter1, J. Fellis1, S. A. Hall1, G. V. Gonzalez-Stawinski1, S. M. Joseph1. 1Baylor University Medical Center, Dallas, TX, 2Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX

(1333) Prolonged Ventilator Dependence Following LVAD Implant Is an Independent Predictor of Reduced Survival; K. Balsara, L. Jolliff, M. Masood, A. Itoh. Surgery, Washington University in St Louis, St Louis, MO

(1334) Biventricular Pacing Does Not Seem to Provide Any Clinical Benefit Over RV Pacing or Intrinsic Rhythm in Most LVAD Patients; C. Inampudi, C. Johnson, K. Jenn, J. Franzwa, H. Doshi, A. Mazur, M. Giudici, V. Cotarlan. Univ of Iowa Hospital, Iowa City, IA


(1336) Post-Hospital Care in LVAD Patients - Experiences of Two Large German Heart Centers; T. Schmidt1, N. Reiss1, J. D. Hoffmann1, C. Feldmann2, E. Deniz2, K. Roske2, R. Bach1, S. Schulte-Eistrup1, D. Willemsen1, J. D. Schmitto2. 1Schuchtermann Klinik, Bad Rothenfelde, Germany, 2Hannover Medical School, Hannover, Germany

(1337) Where Do Patients with VADs Prefer to Spend Their Last Days?; S. G. Cooper, C. G. Caballero, C. Mahr, N. A. Mokadam, J. N. Kirkpatrick. University of Washington, Seattle, WA

(1338) Peak Oxygen Consumption and VE/VCO2 Correlates with 6 Minutes' Walk Test in Patients Supported with Continuous Flow LVAD; A.epadigmas1, E. S. Pak2, T. C. Hanff2, J. A. Mazurek2, M. E. Seigerman1, J. Menachem2, J. Marble2, L. R. Goldberg2, J. Wald2, P. Atluri2, J. E. Rame2, E. Y. Birati2. 1Internal Medicine, University of Pennsylvania, Philadelphia, PA, 2Cardiology, University of Pennsylvania, Philadelphia, PA, 3Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

(1339) Impact of Support Period and Type of Ventricular Assist Device on Patient Survival After Heart Transplantation: Japanese Heart Transplantation Registry 2016; N. Fukushima1, M. Ono2, Y. Saiki3, Y. Sawa4. 1Department of Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan, 2Department of Cardiac
Surgery, University of Tokyo, Tokyo, Japan, 3Department of Cardiovacular Surgery, Tohoku University, Sendai, Japan, 4Department of Cardiovascular Surgery, Osaka University, Suita, Japan


(1341) A Novel Technique for Measuring Outflow Graft Length During HeartMate II Left Ventricular Assist Device Implant; J. P. Slater1, L. Suplicki2, M. Goldschmidt3. 1Cardiothoracic Surgery, Morristown Medical Center, Morristown, NJ, 2Heart Success, Morristown Medical Center, Morristown, NJ, 3Cardiovascular Medicine, Morristown Medical Center, Morristown, NJ

(1342) A New Cannulation Technique for Ambulatory Percutaneous RVAD; T. H. Song1, T. Wombacher1, H. Kitahara1, D. Onsager1, T. Ota1, N. Uriel2, V. Jeevanandam1. 1Section of Cardiac and Thoracic Surgery, University of Chicago, Chicago, IL, 2Section of Cardiology, University of Chicago, Chicago, IL


(1344) Transcatheter Aortic Valve Replacement Management of Aortic Insufficiency in Patients with Left Ventricular Assist Device Support; B. Kar, P. Prathipati, F. Y. Macedo, S. Nathan, R. Radovancevic, P. Loyalka, I. D. Gregoric. The University of Texas Health Science Center at Houston, Houston, TX

(1345) Moderate Hypothermia Technique for Chronic Implantation of a Total Artificial Heart in Calves; J. H. Karimov, P. Grady, M. Sinkewic, R. Dessoffy, N. Byram, N. Moazami, K. Fukamachi. The Cleveland Clinic, Cleveland, OH

(1346) Clinical Benefits and Complications in Patients with Percutaneous VAD versus Surgical LV Vent with ECLS: Multicenter REgiStry for Cardiogenic Shock - Utilization and Efficacy of Device Therapy (RESCUE); A. Itoh1, M. Pisani1, M. Baltalzar2, K. R. Balsara2, M. F. Masood2, S. Tepper1, J. Han2, D. Ranney2, M. Daneshmand3, B. Sun4, M. Kai5, M. Camacho6, H. Takayama7. 1Surgery, Washington University in St. Louis, Saint Louis, MO, 2Surgery, Columbia University, New York, NY, 3General and Thoracic Surgery, Duke University, Durham, NC, 4Cardiothoracic Surgery, Minneapolis Heart Institute, Minneapolis, MN, 5Cardiothoracic Surgery, Westchester Medical Center, Valhalla, NY, 6Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, NJ, 7Cardiothoracic Surgery, Columbia University, New York, NY

(1347) Bridge to Transplantation with Long-Term Mechanical Assist Device in Adults with Transposition of the Great Arteries; E. J. Orozco Hernandez1, D. H. Enter1, M. Monge2, J. Nakano3, J. Rich3, A. Anderson3, C. Backer2, M. McCarthy1, D. T. Pham1. 1Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL, 2Congenital Cardiac Surgery, Northwestern Memorial Hospital, Chicago, IL, 3Cardiology, Northwestern Memorial Hospital, Chicago, IL

(1348) Single Center Experience of Minimally-Invasive Left Ventricular Assist Device Implantation; D. Reichart1, C. Brand1, A. Schäfer1, S. Schmidt1, T. Deuse2, F. Wagner1, A. Bernhardt1, H. Reichenspurner1, M. Barten1. 1Univ Hamburg Heart Center, Hamburg, Germany, 2University of California-San Francisco, San Francisco, CA

(1349) A Minimally Invasive Left Ventricular Assist Device Surgical Approach Is More Durable at Protecting Right Ventricular Function Than a Full Sternotomy; T. Kazui1, P. G. Suryanarayana2, S. Singh2, R. G. Smith3, R. J. Aver4, E. B. Juneman2, J. L. Cook2, N. K. Sweitze2, S. D. Lick1, Z. I. Khalpey1. 1Cardiothoracic Surgery, University of Arizona Medical Center, Tucson, AZ, 2Cardiology, Sarver Heart Center, Banner University Medical Center Tucson, Tucson, AZ, 3Artificial Heart, University of Arizona Medical Center, Tucson, AZ, 4Radiology, Banner University Medical Center Tucson, Tucson, AZ


(1352) Technology and Techniques: Tools to Mitigate Adverse Events and Improve Survival in Left Ventricular Assist Device Patients: Y. Tarzia, G. Di Giammarco, M. Maccherini, M. Maiani, P. Agostoni, L. Bagozzi, D. Marinelli, V. Turri, A. Apostolo, S. Bernazzali, J. Beiko, H. Ortis, M. Di Mauro, A. Dokollari, G. Bortolussi, F. Alamanni, G. Sani, T. Bottiol, U. Livi, G. Gerosa. 1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy, 2Cardiac Surgery, University of Chieti, Chieti, Italy, 3Cardiac Surgery, University of Siena, Siena, Italy, 4Cardiac Surgery, University of Udine, Udine, Italy, 5Cardiac Surgery, University of Milan, Milan, Italy

(1353) Minimally Invasive Off-Pump HVAD vs Full Sternotomy On-Pump LVAD Placement: A Better Option?: T. Kazui, S. D. Lick, R. G. Smith, R. J. Avery, P. G. Suryanarayana, E. B. Juneman, J. L. Cook, N. K. Sweitzer, Z. I. Khalpey. 1Cardiothoracic Surgery, Banner University Medical Center Tucson, Tucson, AZ, 2Artificial Heart, Banner University Medical Center Tucson, Tucson, AZ, 3Radiology, Banner University Medical Center Tucson, Tucson, AZ, 4Cardiology, Sarver Heart Center, Banner University Medical Center Tucson, Tucson, AZ

(1354) Short-Term Results with Minimally Invasive Implantation Technique vs Conventional Sternotomy Technique Implantation of New Generation Left Ventricular Assist Device: U. Kervan, S. S. Kocabeyoglu, A. Temizhan, B. Demirkan, D. E. Sert, A. Aygun, Y. Guray, Z. Cata, O. Beyazal, U. Unal, M. Pac. 1Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey, 2Cardiology, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey

(1355) Minimally Invasive Left Ventricular Assist Device Implantation: Which One HeartWare or HeartMate?: S. S. Kocabeyoglu, U. Kervan, D. E. Sert, B. Demirkan, Y. Guray, Z. Cata, O. Beyazal, U. Unal, M. Pac. 1Cardiovascular Surgery, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey, 2Cardiology, Turkey Yuksek Ihtisas Hospital, Ankara, Turkey

(1356) Comparison of Activated Partial Thromboplastin Time (aPTT) and Anti-Factor Xa for Low Intensity Unfractionated Heparin Monitoring in Patients with Mechanical Circulatory Support Devices (MCSD): O. Volod, L. D. Lam, M. Barglowskii, J. Mirocha, C. Runyan, J. Moriguchi, L. S. Czer, F. Arabia. 1Pathology, Cedars Sinai Medical Center, Los Angeles, CA, 2Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA, 3Cedars Sinai Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, 4Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, 5Center for Surgical Device Management, Cedars Sinai Medical Center, Los Angeles, CA


(1358) Initiation of a Standardized International Normalized Ratio Management Protocol Reduces Out of Range Days in an Ambulatory LVAD Population: M. A. Thompson, R. C. Jackson, M. Frakes, L. T. Hamann, R. John, R. J. Cogswell. 1CV Specialty Nursing, University of MN Health, Minneapolis, MN, 2Fairview Pharmacy Services, University of MN Health, Minneapolis, MN, 3Cardiovascular Surgery, University of MN Health, Minneapolis, MN, 4Cardiology, University of MN Health, Minneapolis, MN

(1359) Does Aspirin Effectively Inhibit Platelet Activation During Left Ventricular Assist Device Support?: F. Consolo, L. Pozzi, G. Motolone, G. Sferrazza, M. Pieri, P. Della Valle, A. Zangrillo, M. J. Sleipan, A. D’Angelo, F. Pappalardo. 1Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Vita Salute University, Milano, Italy, 2Coagulation Service and Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy, 3Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milano, Italy, 4Department of Medicine and Biomedical Engineering, Sarver Heart Center, The University of Arizona, Tucson, AZ

(1360) Incidence of Early Right Heart Failure After Left Ventricular Assist Device Implantation in Patients Managed without Inhaled Nitric Oxide: C. Michaud, G. Marco, A. Schaap, M. Dickinson, P. Wilton. Spectrum Health, Grand Rapids, MI

(1361) Incidence of High On-Treatment Platelet Reactivity in Continuous-Flow LVAD Patients Treated with P2Y12 Inhibitors: E. N. Sorensen, L. Dees, E. D. Feller. 1Clinical Engineering, University of Maryland, Baltimore, MD, 2Cardiology, University of Maryland, Baltimore, MD

Friday, April 7
(1362) **Pre-Implant Digoxin Utilization and Impact on Survival in Left Ventricular Assist Device Recipients**: M. Ahmed1, J. R. Trivedi², E. J. Birks², M. S. Slaughter³, H. Roukoz⁴, A. Bhan⁵, G. Bhat⁵, J. Cowger⁶, A. Ravichandran⁶, R. Gopinathannair². 1Cardiovascular Medicine, University of Florida, Gainesville, FL, 2Cardiovascular Medicine, University of Louisville, Louisville, KY, 3Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, 4Cardiovascular Medicine, University of Minnesota, Minneapolis, MN, 5Advocate Christ Medical Center, Oak Lawn, IL, 6St Vincent Hospital, Indianapolis, IN

(1363) **Use of Abciximab and Heparin Can Safely Facilitate LVAD Implantation in Patients with Heparin-Induced Thrombocytopenia**: C. Lee, P. C. Colombo, D. Jennings, J. Han, M. P. Salma, M. A. Wright, K. Takeda, P. A. Kurlansky, M. Yuzefpolskaya, A. R. Garan, C. Chan, Y. Naka, H. Takayama. Columbia University Medical Center, New York City, NY

**PATHOLOGY**

(Poster Harbor Foyer)

Poster Discussants: Anja C Roden, MD (USA), Carmela D Tan, MD (USA)

(1364) **Is Vasculitis on Endomyocardial Biopsies a Marker of Circulating Donor Specific Antibodies in Adult Heart Transplanted Patients?**: M. Fedrigo¹, A. Romano¹, A. Di Francesco¹, C. Castellani¹, A. Fraiase¹, G. Toscano¹, G. Feltrin¹, A. Nocco², E. Benazzi², A. Veronesi³, G. Thiene³, G. Gerosa³, A. Angelini¹. ¹Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ²Fondazione IRCC S Ca Granda Ospedale Maggiore, Milano, Italy, ³Transfusion Medicine, Regional Laboratory of Transplant, Camposampiero Hospital, Camposampiero, Italy

(1365) **In Vivo Anti-MicroRNA Treatment in a Humanized Mouse Model for Allograft Vasculopathy**: M. Huibers¹, L. Qin², L. Li², J. Renes¹, C. Venema¹, E. Siera-de Koning¹, J. van Kuik¹, T. Peeters¹, G. Tellides², R. de Weerger¹. ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Surgery, Yale University, School of Medicine, New Haven, CT

(1366) **Ultrastructural Alterations in Explanted Failed Cardiac Allografts: Insights into “Chronic Rejection”**: M. Revelo¹, E. H. Hammond², J. Stehlik³, R. Alharethi³, B. Reid¹, S. Drakos³, C. Selzman⁴, K. Afsar³, O. Weyer-Pinzen³, S. McKellar¹, A. G. Kfoury⁵, D. V. Miller⁵. ¹Pathology, Utah Cardiac Transplant Program, Salt Lake City, UT, ²Pathology, Utah Cardiac Transplant Program, Murray, UT, ³Cardiology, Utah Cardiac Transplant Program, Salt Lake City, UT, ⁴Surgery, Utah Cardiac Transplant Program, Salt Lake City, UT, ⁵Pathology, Intermountain Central Lab, Murray, UT, ⁶Intermountain Central Lab, Murray, UT

(1367) **Does Endomyocardial Biopsy (EMB) Contribute to Management of Patients with Myocardial Involvement in Autoimmune Disease?**: D. Lee¹, N. Narula², K. Axsom³, M. Karas³, J. Gordon⁴, S. Seshan², J. Kim³, E. Horn³, I. Sobol³. ¹Department of Medicine, NYP-Well Cornell Medical Center, New York, NY, ²Department of Pathology and Laboratory Medicine, NYP-Weill Cornell Medical Center, New York, NY, ³Division of Cardiology, NYP-Well Cornell Medical Center, New York, NY, ⁴Department of Rheumatology, Hospital for Special Surgery, New York, NY

(1368) **Is Histopathological Assessment Going to Remain the Gold Standard for Diagnosis of Pulmonary Allograft Rejection?**: K. Wassilew¹, M. Perch², E. Santoni Rugiu¹. ¹Pathology Department, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²Department of Clinical Medicine- Hjertecentret, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

(1369) **How to Improve the Survival of Future Transplant Recipients: An Autopsy Study**: T. Hermida¹, M. Delgado², J. Pombo¹, R. Fernández², M. Escalante¹, M. Paradela², M. Haz¹, E. Fieira², P. Marcos³, J. Ovalle², A. Reguera¹, M. De La Torre², A. Concha¹. ¹Pathology Department, A Coruña University Hospital, A Coruña, Spain, ²Thoracic Surgery Department, A Coruña University Hospital, A Coruña, Spain, ³Pneumology Department, A Coruña University Hospital, A Coruña, Spain

**JUNIOR FACULTY CLINICAL CASE REPORTS**

(Poster Coronado Foyer)

Poster Discussants: Jorge Silva Enciso, MD (USA), Cameron R Wolfe, MBBS, MPH (USA), Jong-Chan Youn, MD, PhD (Korea)

(1370) **Less Intense CPR for Right Ventricle Chest Compressions as a Paradigm for LVAD Patients Who Needing Resuscitation**: A. Bhimaraj, J. D. Estep, E. E. Suarez. Cardiology, Houston Methodist Hospital, Houston, TX

Friday, April 7
[1371] Continuous Flow Implantable Biventricular Assist Device as Bridge to Transplantation in a Small Child with Restrictive Cardiomyopathy: Technical Pearls and Pitfalls; L. D. Glass¹, O. Haddad², A. Savage³, M. N. Kavarana⁴. ¹Pediatric Cardiology, Stollery Children’s Hospital, Edmonton, AB, Canada, ²Pediatric Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, ³Pediatric Cardiology, Medical University of South Carolina, Charleston, SC

[1372] Percutaneous Left Atrial Unloading for Prevention of Pulmonary Edema Under Extracorporeal Membrane Oxygenation Therapy; A. M. Bernhardt¹, M. Hillebrand², Y. Yildirim¹, S. Hakmi¹, F. M. Wagner¹, S. Blankenberg², H. Reichenspurner¹, E. Lubos². ¹Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, ²Department of General and Interventional Cardiology, Univ Heart Ctr Hamburg, Hamburg, Germany


[1374] Right Ventricular Failure Secondary to Apical Muscular VSD in an LVAD Patient; T. Suboc¹, G. Murtaza², G. Macaluso¹, K. Meehan³, S. Pauwaa¹, A. Andrade³, G. Bhat¹, M. Bazavan¹, A. Tatooles³, P. Pappas³, W. Cotts¹. ¹Advanced Heart Failure/VAD/Transplant, University of Illinois at Chicago/Advocate Christ Medical Center, Chicago, IL, ²Internal Medicine, University of Illinois at Chicago/Advocate Christ Medical Center, Chicago, IL, ³Advanced Heart Failure/VAD/Transplant, Advocate Christ Medical Center, Chicago, IL


[1376] Candida albicans Mycotic Embolism in a LVAD Recipient; K. Kapoor¹, P. Shah², S. Desai², C. W. May², A. C. Carter², S. Katugaha². ¹Virginia Commonwealth University School of Medicine, Inova Campus, Fairfax, VA, ²Inova Heart & Vascular Institute, Falls Church, VA


[1378] Concomitant Left Ventricular Assist Device Implantation and Aortic Valve Replacement Using a Rapid Deployment Valve Prosthesis as a Rescue Reoperation; M. Linder, E. Girdauskas, F. M. Wagner, A. Bernhardt, H. Reichenspurner, M. J. Barten. Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

[1379] Tension Pneumopericardium in an LVAD, Rare but Real; H. Merritt Genore¹, N. Markin², A. Siddique¹, J. Um¹, M. Moulton¹. ¹Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE

[1380] Acute Reversal of Chronic Cardiorenal Syndrome from Severe Tricuspid Regurgitation with Impella RP - A Novel Use of Percutaneous Mechanical Circulatory Support of the Right Ventricle; T. Raymond, R. Shah, A. Greenbaum. Henry Ford Hospital, Detroit, MI

[1381] Use of Venovenous Extracorporeal Membrane Oxygenation in Airway Obstruction as a Bridge to Rescue; V. Fikfak¹, P. G. Khaitan², E. E. Suarez³, M. P. Kim², E. Y. Chan². ¹Department of Surgery, Houston Methodist Hospital, Houston, TX, ²Division of Thoracic Surgery, Department of Surgery, Houston Methodist Hospital, Houston, TX, ³Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

[1382] A Case Study of LVAD Withdrawal in an Ambulatory Patient; S. Nakagawa¹, P. C. Colombo², Y. Naka³, C. D. Blinderman¹. ¹Adult Palliative Care Services, Department of Medicine, Columbia University Medical Center, New York, NY, ²Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY, ³Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, NY


Friday, April 7
ISHLT ACADEMY
CORE COMPETENCIES IN INFECTIOUS DISEASES IN THORACIC TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT

Tuesday, April 4, 2017

Scientific Program Committee
Chair: Martha Mooney, MD, FACP, Sentara Norfolk Transplant Center/Eastern Virginia Medical School, Norfolk, VA, USA
Co-Chair: Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada
Members: Michele Estabrook, MD, St. Louis Children's Hospital, St. Louis, MO, USA
Robin Avery, MD, Johns Hopkins University, Baltimore, MD, USA
Kate Gould, FRCPath, NUTH NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training and/or are part of a new program or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of infectious disease concerns in cardiothoracic transplantation and mechanical circulatory support, rather than as a detailed update for those who are already proficient experts in the field.

Learning Objectives
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

- Explain how to utilize pre-transplant evaluation and screening of the cardiothoracic transplant recipient and donor to minimize the risk of infections in cardiothoracic transplant and MCS recipients
- Describe how to control and prevent infection in cardiothoracic transplantation and MCS recipients
- Identify clinical infections and how to use diagnostic methodology for the detection of bacterial, fungal, viral, and parasitic infectious diseases
- Discuss the pharmacology of anti-infective agents in cardiothoracic transplant and MCS recipients.

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This course is co-provided by AMEDCO and ISHLT. Maximum of 7.75 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 7:45 AM
REGISTRATION & MORNING COFFEE

7:45 AM – 8:00 AM
WELCOME & OVERVIEW
Martha Mooney, MD, FACP, Sentara Norfolk Transplant Center/EVMS, Norfolk, VA, USA
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

8:00 AM – 9:20 AM
SESSION 1: IMPACT OF SURGERY AND IMMUNOSUPPRESSION ON INFECTION IN CT TX RECIPIENT AND DONOR SELECTION CONSIDERATIONS

8:00 AM  Impact of the Surgical Transplant Procedure on Infection Risk in CT TX
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

8:15 AM  The Devil Made Me Do It: Impact of Immunosuppression on Infection Risk in CT TX
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

8:30 AM  Not All Transplant Recipients are Created Equal! Pre-transplant Screening of Recipients
Michele Estabrook, MD, St. Louis Children’s Hospital, St. Louis, MO, USA

8:50 AM  Beware the Trojan Horse: Pre-transplant Screening of Donors and Donor Derived Infections
Valentina Stosor, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

9:10 AM Q & A

9:20 AM – 10:20 AM
SESSION 2: DIAGNOSING INFECTION IN CT TX AND TREATMENT CONSIDERATIONS

9:20 AM  Diagnostic Microbiology and Pathology for Infections in CT TX
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

9:40 AM  Diagnostic Radiology for Infections in CT TX
Allan Glanville, MBBS, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia

9:55 AM  This Could Happen to You...Drug Interactions and Toxicity Errors to Avoid with Anti-infectives and Immunosuppression and Cracking the Therapeutic Drug Monitoring Code
Christopher Ensor, PharmD, BCPS-CV, University of Pittsburgh, Pittsburgh, PA, USA

10:15 AM Q & A

10:20 AM – 10:35 AM
COFFEE BREAK

10:35 AM – 11:35 AM
SESSION 3: BACTERIAL AND PARASITIC PATHOGENS

10:35 AM  Nosocomial Threats and Tackling Multidrug Resistant Bacteria: If We Persist, We Will Wear Down the Resistance!
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

10:55 AM  Bugs that Upset Us and Send Us into Orbit: Mycobacteria and Nocardia
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

11:10 AM  Unwelcome Visitors: Parasitic Infections in CT TX: Toxoplasmosis, Strongyloidiasis, Chagas
Fernando Bacal, MD, University of Sao Paulo, Sao Paulo, Brazil

11:25 AM Q & A
11:35 AM – 12:45 PM
SESSION 4: VIRAL INFECTIONS IN CT TX

11:35 AM  **CMV: a Perennial Problem**
Martha Mooney, MD, FACP, Sentara Norfolk Transplant Center/EVMS, Norfolk, VA, USA

11:50 AM  **EBV/PTLD: a Continual Conundrum**
Erik Verschuuren, MD, PhD, University Medical Centre Groningen, Groningen, The Netherlands

12:05 PM  **Challenges from the Community: Respiratory Viruses, Parvovirus, Norovirus and Others**
Joanna Schaenman, MD, PhD, University of California Los Angeles, Los Angeles, CA, USA

12:20 PM  **HIV, HCV, HBV: Risks Redefined?**
Emily Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

12:40 PM  Q & A

12:45 PM - 1:45 PM
LUNCH BREAK (a box lunch is included in the registration fee)

1:45 PM – 2:55 PM
SESSION 5: FUNGAL INFECTIONS AND OTHER AREAS OF CONCERN FOR TRAVEL AND SAFE LIVING AFTER CT TX

1:45 PM  **There is a Fungus Among Us. Perils from Without: Mold, Yeast, and Guidelines**
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

2:05 PM  **Perils from Within: Endemic Fungi**
Me-Linh Luong, MD, St. Luc Hospital, Montreal, PQ, Canada

2:20 PM  **Emerging Fungal Pathogens**
Orla Morrissey, MD, The Alfred Hospital, Melbourne, Australia

2:35 PM  **Life in the Global Community after Transplant: Travel, Safe Living and Emerging Pathogens. Real Risks Outside the Bubble: Roaming Charges**
Michele Estabrook, MD, St. Louis Children’s Hospital, St. Louis, MO, USA

2:50 PM  Q & A

2:55 PM - 3:10 PM
COFFEE BREAK

3:10 PM – 4:10 PM
SESSION 6: INFECTION IN THE SETTING OF MECHANICAL CIRCULATORY SUPPORT (MCS)

3:10 PM  **An Ounce of Prevention Saves a Pound of Hurt: Prevention and Diagnosis of Infections in MCS**
Saima Aslam, MD, MS, University of California San Diego, San Diego, CA, USA

3:25 PM  **VAD Gone Bad: Medical and Surgical Remedies of VAD Specific and VAD Related Infections**
Martha Mooney, MD, FACP, Sentara Norfolk Transplant Center/EVMS, Norfolk, VA, USA

3:45 PM  **Hungry Circuits in Extracorporeal Support (ECMO, Plasmapheresis, Renal Replacement Therapy) and Steering Clear of Anticoagulation Glitches with Antibiotics in Mechanical Circulatory Support**
Haifa Lyster, MSc, Royal Brompton, Middlesex, United Kingdom

4:00 PM  Q & A

4:10 PM – 5:00 PM
SESSION 7: WHEN THE RUBBER HITS THE ROAD: CASE PRESENTATIONS
CASE 1: HIV/HBV/HCV in Cardiothoracic Transplantation
Emily Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

CASE 2: Lung Transplant Recipient with Pulmonary Infiltrates: Transplant Infectious Disease Consults Transplant Pulmonologist to Make the Diagnosis
Aric Gregson, MD, University of California Los Angeles School of Medicine, Los Angeles, CA, USA
Allan Glanville, MBBS, MD, FRACP, St. Vincent’s Hospital, Sydney, Australia

Q & A

COURSE SUMMARY & EVALUATION
Martha Mooney, MD, FACP, Sentara Norfolk Transplant Center/EVMS, Norfolk, VA, USA
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

ADJOURN
Scientific Program Committee
Chair: Jennifer Cowger, MD, MS, St. Vincent Heart Center of Indiana, Indianapolis, Indiana, USA
Co-Chair: Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, Virginia, USA
Co-Chair: Diyar Saeed, MD, Heinrich-Heine University, Dusseldorf, Germany

Educational Goals
The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of patients during assessment as candidates and as recipients of mechanical circulatory support.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training and/or are part of a new program or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles of mechanical support, rather than as a detailed update for those who are already proficient experts in the field.

Learning Objectives
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Explain how to risk stratify patient with advanced heart failure in order to assess MCS surgical risk and optimally time mechanical circulatory support (MCS) implantation.
2. Discuss the medical and social factors which impact patient outcomes during short- and long-term MCS.
3. Recognize the various types of MCS support available for patients with advanced single or biventricular heart failure and the technological differences that may impact pump selection and patient/device management.
4. Identify MCS implantation techniques and patient/pump management during the index admission intensive care unit and inpatient general care periods.
5. Describe how to manage patients and the MCS during outpatient long-term support with an understanding of interventions that can reduce patient- and device-related adverse events during MCS.
6. Diagnose and manage common clinical dilemmas and adverse encountered after MCS.

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by AMEDCO and ISHLT. Maximum of 8.00 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
7:00 AM – 8:00 AM
REGISTRATION & MORNING COFFEE

8:00 AM – 8:05 AM
WELCOME AND OVERVIEW
Jennifer Cowger, MD, MS, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA

8:05 AM - 9:15 AM
SESSION 1 – REVIEW OF THE CURRENT STATE OF MCS
Chair: Diyar Saeed, MD

8:05 AM  MCS Technology 101
Scott Silvestry, MD, Florida Transplant Institute, Orlando, FL, USA
Review of current technologies available, pump behaviors with different loading conditions, and the TAH.

8:25 AM  BTT and DT Outcomes
Lynne Warner Stevenson, MD, Brigham & Women's Hospital, Boston, MA, USA
Review state of outcomes and adverse events with current technologies

8:40 AM  Short-term Support and Shock
Jonathan Haft, MD, University of Michigan, Ann Arbor, MI, USA
Overview of percutaneous technologies, biventricular support considerations, and ECMO.

9:00 AM  Q&A with Panel

9:15 AM – 10:30 AM
SESSION 2 – PATIENT SELECTION
Chair: Scott Silvestry, MD

9:15 AM  When Should Patients be Referred: Warning Signs
Douglas Horstmanshoff, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA
Risk factors which presage patient decline (renal function, intolerance of medications, hospitalizations, etc, helping to risk stratify patients based on HF severity and MCS operative risk.

9:35 AM  Assessing and Optimizing RV Function Preoperatively
Jerry Estep, MD, The Methodist Hospital, Houston, TX, USA
Impact of RV failure, pre-operative assessment and management of the RV including imaging and risk prediction. Cases included.

9:55 AM  Quality of Life After VAD and the Impact of Frailty and Social Behaviors on VAD Success
Kathleen Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL, USA
Other factors that can have a significant impact on success after VAD and some screening tools available for risk assessment.

10:15 AM  Q&A with Panel

10:30 AM – 10:45 AM
COFFEE BREAK

10:45 AM – NOON
SESSION 3 – SURGICAL CONSIDERATIONS
Chair: Vivek Rao, MD, PhD

10:45 AM  Key Surgical Aspects of Implantation
Nader Moazami, MD, Cleveland Clinic, Cleveland, OH, USA
Overview of the most crucial surgical considerations: inflow cannula/pump placement, driveline, etc.

11:05 AM  How Much Else Is Too Much?
Daniel Zimpfer, MD, Medical University of Vienna, Vienna, Austria
Concomitant operative procedures: TV, Aortic valve, prior Dor, congenitals

11:25 AM  Tailoring Pumps to Patients
Diyar Saeed, MD, Heinrich-Heine University, Dusseldorf, Germany
Case based discussion of considerations for pump-patient matching

11:45 AM  Q&A with Panel

NOON – 1:00 PM
LUNCH BREAK (a box lunch is included in the registration fee)

1:00 PM – 2:15 PM
SESSION 4 – POSTOPERATIVE CARE
Chair: Andreas Zuckerman, MD

1:00 PM  Managing the RV Postop
Christopher Salerno, MD, St Vincent Heart Center of Indiana, Indianapolis, Indiana, USA
Considerations for impact of LVAD pump speed on RV function and use of inotropes, pulmonary vasodilators, and temporary RV support postoperatively

1:20 PM  Anticoagulation and Antiplatelet Therapy
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
Current MCS recommendation on when to start anticoagulation, antiplatelet therapy regimens, as well as data on platelet function testing and heparin level monitoring.

1:40 PM  Pump Speed Optimization: The Role of Imaging and Hemodynamics
Jerry Estep, MD, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA
Overview of how to meld imaging and hemodynamics to optimize pump settings

2:00 PM  Q&A with Panel

2:15-3:15 PM
SESSION 5 – TRANSITION TO HOME
Chair: Nir Uriel, MD

2:15 PM  VAD Education: Patient/Caregiver Assessments and Strategies for Successful VAD Self-Care
Thomas Schläghlofer, BSc, Medical University of Vienna, Vienna, Austria
Approaches to education of the patient and caregiver prior to discharge, and strategies for educating the local medical community

2:30 PM  Starting New: How to Start and Succeed in MCS
Michael Dickinson, MD, Spectrum Health, Grand Rapids, MI, USA
Challenges to starting a VAD program and key elements of success.

2:45 PM  Optimal Outpatient Management of VAD Recipients
Jennifer Cowger, MD, MS, St. Vincent Heart Center of Indiana, Indianapolis, IN, USA
Lab, blood pressure and echo monitoring of VAD patients in the outpatient setting.

3:00 PM  Q&A with Panel

3:15 PM - 3:30 PM  COFFEE BREAK

3:30 PM – 5:20 PM
SESSION 6 – LONG TERM MANAGEMENT OF PATIENTS AND COMPLICATIONS
Chair: Nader Moazami, MD

3:30 PM  LVAD Infections: Prevention, Diagnosis, and Management
Paolo A Grossi, MD, PhD, University of Insubria, Varese, Italy
VAD infections, radiology studies important for diagnosis, and therapeutic recommendations
3:50 PM  **Stroke: Risk Factors for Hemorrhagic and Embolic CNS Complications and Management Strategies**
Samer Najjar MD, MedStar Washington Hospital Center, Washington, DC, USA
*Discuss diagnosis, risk factors, and management strategies for CNS events in MCS patients.*

4:10 PM  **Pump Thrombosis: Diagnostic Strategies and Management Algorithms**
Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA, USA
*Frequency, diagnosis, and management strategies for suspected pump thrombosis.*

4:30 PM  **Aortic Insufficiency in LVAD Recipients: Incidence, Screening, and Management**
Jennifer Cowger, MD, MS, St Vincent Heart Center of Indiana, Indianapolis, IN, USA
*Cumulative incidence, clinical consequences, and management of AI after LVAD.*

4:50 PM  **GI Bleeding**
Anna Meyer, MD, Leipzig University Heart Center, Leipzig, Germany
*Frequency, diagnosis and management of GI bleeding after LVAD therapy, including new data on octreotide*

5:10 PM  **Q&A with Panel**

5:20 PM  **SUMMARY**
Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA, USA

5:30 PM  **ADJORN**
CORE COMPETENCIES IN
PEDIATRIC AND ADULT CONGENITAL
MECHANICAL CIRCULATORY SUPPORT

Tuesday, April 4, 2017

Scientific Program Committee
Chair: Angela Lorts, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA
Co-Chair: Holger Buchholz, MD, University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada
Members:
Jenna Murray, MSN, RN, CPNP-AC, Stanford University, Stanford, California, USA
Leonardo Salazar, MD, Fundacion Cardiovascular de Columbia, Bucaramanga, Columbia
Martin Schweiger, MD, PhD, FEBS Children’s Hospital Zurich, Zurich Switzerland
Asif Hasan, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Course Summary
The pediatric mechanical circulatory support field continues to grow and has enough unique challenges to justify an entire session dedicated to learning about pediatric support strategies. The basic principles of MCS, including patient/device selection, peri-operative management, and basics of transition to home will be discussed. The goal will be to learn from didactics but also allow for discussion in order to share experiences and learn from each other.

In addition to the core academy that will be conducted at the 2017 ISHLT annual meeting, an extensive Core Competency Curriculum Document has been written by a diverse international committee and can be found on the ISHLT education website. This document is in outline form with current references and includes all topics that are important to the management of this unique patient population.

Educational Goals
The educational goals of this activity are to provide a concise review of clinical knowledge and essential professional skills to facilitate best practice of surgical and medical aspects involved in the care of pediatric patients and adult congenital heart disease patients that require ventricular assist device support.

Target Audience
While all members are invited to enroll, this course is primarily designed to be of benefit for clinicians and allied professionals who are in the early stages of their careers or who are in training, are part of a new program or desire an update on the current state of the field. The information presented is intended to provide a strong foundation of the overarching principles of ventricular assist support in children, rather than as a detailed update for those who are already proficient in the field.

Learning Objectives
At the conclusion of this meeting, participants will have improved competence and professional performance in their ability to:

1. Evaluate a patient for VAD implantation including preoperative assessment, preparation of patient prior to VAD implantation, and optimal timing of placement.
2. Understand device selection, strategies for VAD implantation, intraoperative assessment techniques and postoperative management.
3. Define device-specific anticoagulation management as well as the recognition and care of adverse events related to both temporary and chronic device therapy.

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
ISHLT designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This course is co-provided by AMEDCO and ISHLT. Maximum of 8.00 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
7:00 AM – 7:45 AM
REGISTRATION & MORNING COFFEE

7:45 AM – 8:00 AM
WELCOME AND OVERVIEW
Angela Lorts, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA
Holger Buchholz, MD, University of Alberta Hospital, Edmonton, AB, Canada

8:00 AM – 9:05 AM
SESSION 1: REVIEW OF THE CURRENT STATE OF MCS IN PEDIATRIC AND ADULT CONGENITAL HEART DISEASE
Chair: Richard Kirk, FRCP, FRCPC

8:00 AM Current State: Durable Device Options, Indications and Outcomes (Pulsatile)
David Morales, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA
A review of current technologies available, update on future developments.

8:15 AM Current State: Durable Device Options, Indications and Outcomes (Continuous)
Martin Schweiger, MD, PhD, Children’s Hospital, Zurich, Switzerland
Overview of MCS in ACHD patients.

8:30 AM Current State: Temporary Device Options, Indications and Outcomes
Jennifer Conway, MD, Stollery Children’s Hospital, Edmonton, AB, Canada
Overview of temporary support in variety of scenarios as bridge to other forms of support, transplantation or recovery.

8:45 AM Case Presentation with Discussion: Child Presenting with Probable Myocarditis – Device Selection for Size and Indication
Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Bucaramanga, Colombia

9:05 AM – 10:10 AM
SESSION 2: PATIENT SELECTION
Chair: Angela Lorts, MD

9:05 AM An Art, Not Always a Science - When is the Right Time for Referral?
Aamir Jeewa, MD, Hospital for Sick Children, Toronto, ON, Canada
Evaluating timing for implantation.

9:20 AM Pre-VAD Work Up Prior to Implantation: Including Psychosocial Considerations
Oliver Miera, MD, Deutsches Herzzentrum Berlin, Berlin, Germany
Pre-VAD evaluation to be done prior to decision to implant.

9:35 AM Medical Co-Morbidities and That May VAD Success and Potential Strategies for Optimization
Janet Scheel, MD, Children's National Health System, Washington, DC, USA
End-organ dysfunction and the effect on VAD patient outcome.

9:50 AM Case Presentation with Discussion: Infant with End-Organ Dysfunction- Patient Selection and Optimization Prior to VAD Implantation
Richard Kirk, FRCP, FRCPC, UT Southwestern Medical Center, Dallas, TX, USA

10:10 AM – 10:30 AM
COFFEE BREAK

10:30 AM – 11:20 AM
SESSION 3: SURGICAL CONSIDERATIONS FOR BOTH PEDIATRICS AND ADULT CONGENITAL
Chair: Martin Schweiger, MD, PhD
10:30 AM  VAD Implantation (Extracorporeal Berlin Heart, Temporary Continuous Flow Devices): Key Surgical Aspects
Jake Jaquiss, MD, Duke Children’s Heart Center, Durham, NC, USA
Key surgical techniques to implanting pulsatile devices in children.

10:45 AM  VAD Implantation (Intracorporeal HVAD, HeartMate II): Key Surgical Aspects
Antonio Amodeo, MD, Bambino Gesu Pediatric Hospital, Rome, Italy
Key surgical techniques to implanting continuous flow devices in children

11:00 AM  Case Presentation with Discussion: Assessment of Optimal Inflow Placement with Hemodynamics and Echocardiography in the Immediate Peri-Operative Setting
Lucas Eastaugh, MBBS, Royal Children’s Hospital, Melbourne, Australia

11:20 AM – 12:00 PM
SESSION 4: “UNIQUE PATIENT POPULATION”
Chair: Jennifer Conway, MD

11:20 AM  Case Presentation with Discussion: Adult Congenital VAD Case
Robert Jaquiss, MD, Duke Children’s Heart Center, Durham, NC, USA

11:40 AM  Case Presentation with Discussion: Adolescent Risky Behavior
Jenna Murray, MSN, RN, CPNP-AC, Lucile Packard Children’s Hospital, Palo Alto, CA, USA

12:00 PM - 1:00 PM LUNCH BREAK (a box lunch is included in the registration fee)

1:00 PM - 2:05 PM
SESSION 5: PERI-OPERATIVE CARE OF THE VAD PATIENT
Chair: Leonardo Salazar, MD

1:00 PM  Managing the RV after LVAD Placement
Richard Kirk, FRCP, FRCPCH, UT Southwestern Medical Center, Dallas, TX, USA
How to detect RV failure and to support the RV to prevent a Bi-VAD.

1:15 PM  Is There a “Standard” for Post-Operative Care?
Angela Lorts, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA
Routine post-operative care of the VAD patient in both the ICU and step down unit.

1:30 PM  Pump Speed Optimization: Tailoring Post-Operative Management to Clinical and Echocardiographic Assessment
Lucas Eastaugh, MBBS, Royal Children’s Hospital, Melbourne, Australia
Using hemodynamic monitoring to optimize the pump function.

1:45 PM  Case Presentation with Discussion: Driveline Infection
Holger Buchholz, MD, University of Alberta Hospital, Edmonton, AB, Canada

2:05 PM – 3:10 PM
SESSION 6: HEMATOLOGIC MANAGEMENT OF THE PEDIATRIC VAD PATIENT
Chair: Holger Buchholz, MD

2:05 PM  Overview of Anticoagulation of the Various Pump Types
Christina Vanderpluym, MD, Boston Children’s Hospital, Boston, MA, USA
Brief overview of anticoagulation goals for various pump types and how the goals differ between adults and children.

2:20 PM  Pump Thrombosis: Detection and Management
Jennifer Conway, MD, Stollery Children’s Hospital, Edmonton, AB, Canada
How to determine if a pump is thrombosed and treatment options.

2:35 PM  Stroke in Pediatric VAD Patients: What are Our Options?
Oliver Miera, MD, Deutsches Herzzentrum Berlin, Berlin, Germany
Characterizing pediatric strokes and discussing changes in therapy after they occur.
2:50 PM  Case Presentation with Discussion: Tamponade Post HVAD Implantation
David Morales, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA

3:10 PM – 3:30 PM COFFEE BREAK

3:30 PM – 5:00 PM
SESSION 7: NOW WE ARE GOING TO SEND THEM HOME?
Chair: Antonio Amodeo, MD

3:30 PM  The Beginning of a New Program: Necessary Team Components?
Christina Vanderpluym, MD, Boston Children’s Hospital, Boston, MA, USA
The building blocks to starting a pediatric VAD program, the challenges faced, and the key elements of success.

3:45 PM  Preparing the Patient, Family and Community for Discharge
Jenna Murray, MSN, RN, CPNP-AC, Lucile Packard Children’s Hospital, Paolo Alto, CA, USA
Creative multidisciplinary approaches to patient/caregiver education and comprehensive preparation for the local community.

4:00 PM  The Outpatient Clinical Assessment: Blood Pressure, Laboratory Testing, Echo Monitoring and Rehabilitation
Aamir Jeewa, MD, Hospital for Sick Children, Toronto, ON, Canada
Effective clinical assessment and monitoring strategies of the child outpatient on VAD support.

4:15 PM  Destination/Palliative Care Considerations
Janet Scheel, MD, Children’s National Health System, Washington, DC, USA
Challenges in offering destination therapy to a child and how to maneuver failed VAD support.

4:30 - 5:00 PM
QUESTIONS/DISCUSSION
Panel members will reflect on day and open up for discussion

5:00 PM – 5:15 PM
CLOSING ADDRESS
Angela Lorts, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA
Holger Buchholz, MD, University of Alberta Hospital, Edmonton, AB, Canada

5:15 PM ADJOURN
ISHLT MASTER CLASS IN
MECHANICAL CIRCULATORY SUPPORT

Tuesday, April 4, 2017

Scientific Program Committee
Chair: Stavros Drakos, MD, PhD, University of Utah School of Medicine, Salt Lake City, UT, USA
Co-Chair: Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Members: Keith Aaronson, MD, University of Michigan, Ann Arbor, Michigan, USA
Anson Cheung, MD, University of British Columbia, Vancouver, BC, Canada
Chris Hayward, MD, St. Vincent's Hospital, Sydney, Australia
Lars Lund, MD, Karolinska Institute, Stockholm, Sweden

Course Summary
The MCS Master Class is intended for members with higher levels of expertise (completed the core curriculum course on MCS and/or primary practice in MCS ≥ 5 years). The course setting will generate a highly interactive environment composed of a small group of individuals and designed to enhance individual expertise and network development. Utilizing the concept of “convergent discussion” and the technique of “audience response system”, faculty moderators will use complex situations and controversial statements during practical case presentations in order to lead the group through active audience participation, towards specific answers based on practice gaps and learning objectives. The MCS Master Class is arranged in advanced breakout sessions for every participant to take full advantage of an integrated curriculum and the exceptional networking opportunity. The specific topics are devised according to defined clinical practice gaps in this fast developing specialty.

Practice Gaps
1: The outcomes of cardiogenic shock have remained poor, large randomized trials are scarce and the management of these patients remains challenging. Comprehensive clinical expertise of advanced usage of evolving MCS options including patient and device selection and transition to next step therapies constitute currently major limitations in the care of these critically ill patients.

2: Specific approaches to optimize the exercise capacity of MCS patients is an unmet clinical need.

3: The disparities in the cardiac recovery outcomes observed between various centers indicate that implementing targeted patient selection and subsequently effective diagnostic and therapeutic protocols to facilitate cardiac recovery is challenging for the majority of practitioners.

4: The diagnosis and management of complex and combined adverse events such as cerebrovascular hemorrhagic accidents, device thrombosis and gastrointestinal bleeding is challenging and practitioners often face difficulties in developing effective strategies to appropriately identify and treat these adverse events.

5: The diagnostic and therapeutic approaches for early and late right ventricular failure in MCS patients has been evolving with the introduction of new diagnostic criteria and new technologies/therapeutic options. Such practice gaps in specialist knowledge and clinical skills constitute major limitations in the care of MCS patients.

6: With the rapid evolution of minimally invasive surgical approaches the individual practitioners may lack the extensive expertise required to appropriately select patients and surgical approaches to achieve the best possible outcome.

Educational Goals
The overarching goal is to provide an advanced learning opportunity for specialists and developing experts in the field of MCS and devices for treatment of heart failure patients.
Target Audience
The target audience for this class includes cardiothoracic surgeons and cardiologists with MCS experience, specialists in heart failure care, allied health professionals with involvement in MCS patients, VAD coordinators, transplant coordinators, critical care specialists, and heart transplant professionals.

Learning Objectives
Upon completion of the Master Class, participants will be able to:
1: Identify the challenges during the diagnosis and management of complex cardiogenic shock patients and the potential benefits of a multidisciplinary team approach.
2: List effective strategies to optimize exercise capacity and facilitate myocardial recovery in MCS patients.
3: Explain how to appropriately select patients for long-term MCS options with particular consideration in anticipated surgical management aspects.
4: Describe how to develop a systematic approach to diagnosis and therapy of complex and combined adverse events such as device thrombosis, recurrent gastrointestinal bleeding and stroke.
5: Name the diagnostic and therapeutic challenges of early and late RV failure.

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This course is co-provided by AMEDCO and ISHLT. Maximum of 4.25 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. Please refer to the Participant Notification document for a list of all disclosures. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
SCIENTIFIC PROGRAM SCHEDULE

7:00 AM – 7:45 AM
REGISTRATION AND MORNING COFFEE

7:45 AM – 8:00 AM
WELCOME AND INTRODUCTIONS
Stavros Drakos, MD, PhD, University of Utah School of Medicine, Salt Lake City, UT, USA

8:00 AM – 9:00 AM
SMALL GROUP INTERACTIVE DISCUSSION A: ACUTE MCS FOR PROFOUND CARDIOGENIC SHOCK/INTERMACS 0-1 PROFILES
Moderator: Stavros Drakos, MD, PhD

8:00 AM
CASE SCENARIO: Management Challenges for ‘Crash and Burn’ Patients: ‘Shock Team’ Approach to MCS
Hiroo Takayama, MD, Columbia University, New York, NY, USA

Teaching/Discussion Points
1. Challenges of assessing patients in profound cardiogenic shock:
   a. Lack of universally accepted classification system of cardiogenic shock and its influence on patient management
   b. Important factors to consider at initial evaluation
2. Challenges in choosing the appropriate timing for MCS
3. Challenges in choosing the appropriate MCS device
   a. Theoretical advantages/disadvantages of each device
   b. Existing clinical evidence
4. SHOCK team approach to cardiogenic shock: patient benefits and logistical difficulties
5. Initial attempts in developing an algorithm for MCS therapy for cardiogenic shock

8:30 AM
CASE SCENARIO: Transition from Short to Long-Term Support
Keith Aaronson, MD, University of Michigan, Ann Arbor, MI, USA

Teaching/Discussion Points
1. When is the optimal time to transition from temporary to durable MCS?
2. How should you assess and prioritize end organ function in the decision to proceed with durable MCS?
3. How does temporary MCS affect the risk of RV failure post durable VAD?
4. What are the other considerations when bridging from temporary to durable MCS?

9:00 AM – 9:05 AM
Speakers switch rooms; delegates remain seated

9:05 AM – 10:05 AM
SMALL GROUP INTERACTIVE DISCUSSION B: COMPLEX COAGULATION ISSUES IN MCS PATIENTS
Moderator: Ivan Netuka, MD, PhD

9:05 AM
CASE SCENARIO: Recurrent GI Bleeding and Pump Thrombosis
Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, USA

Teaching/Discussion Points
1. Definition, risk factors, and the inevitable “conundrum”.
2. Treatment of recurrent GI bleeding — overreacting on an imprecise science?
3. Treatment of clotting while bleeding: how to treat medically, and when to refer for surgery.
4. Evidence-based approach for pump thrombosis: from prevention to treatment algorithm.
5. Implications and management of neurologic events on treatment.
CASE SCENARIO: Management of Cerebrovascular Hemorrhagic Accidents
Chris Hayward, MD, St. Vincent's Hospital, Sydney, Australia

Teaching/Discussion Points
1. Epidemiology and risk factors for intracerebral hemorrhage (ICH) in the MCS population.
2. After the bleed, where to next? What are the immediate management priorities?
3. Recommendations for anticoagulation in the setting of intracerebral hemorrhage.
4. Current evidence for alternate anticoagulation options available to minimize ICH.
5. Should we expect a poor outcome post ICH?

10:05 AM – 10:30 AM
COFFEE BREAK

10:30 AM – 11:30 AM
SMALL GROUP INTERACTIVE DISCUSSION C: PATIENT SELECTION AND MANAGEMENT (I)
Moderator: Stavros Drakos, MD, PhD

CASE SCENARIO: Bridge to Recovery: From Prediction to Implementation
Snehal Patel, MD, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA

Teaching/Discussion Points
1. What accounts for the observed differences in rates of recovery between registry analysis and prospective single center studies?
2. Managing and testing for recovery is hard work… can we target specific populations to limit the effort? – The role of clinical prediction tools.
3. The role of adjuvant pharmacologic therapy in addition to mechanical unloading of the left ventricle to promote reverse remodeling.
4. Practical considerations for cardiac recovery testing – when, how, and what are the endpoints.
5. Recovery or remission? Histopathologic changes and long term follow up of explanted patients.

11:00 AM
CASE SCENARIO: Optimizing the Exercise Capacity of Chronic MCS Pts: Implications for Heart Recovery Assessment
Bart Meyns, MD, PhD, University Hospitals Leuven, Leuven, Belgium

Teaching/Discussion Points
1. Indicate the limitations of exercise capacity in MCS patients, the evolution in time after MCS implantation and illustrate the effect of pump rotational speed.
2. Explain the mechanism of limitation of exercise capacity and learn from patient variability.
3. Indicate the role of potential underlying mechanisms such as underlying left and right ventricular function, anemia, and peripheral muscle deficiencies.
4. Understand the differences in exercise performance of patients after heart transplantation.
5. Draw conclusions on how to optimize exercise capacity

11:30 AM – 11:35 AM
Speakers switch rooms; delegates remain seated

11:35 AM – 12:35 PM
SMALL GROUP INTERACTIVE DISCUSSION D: PATIENT SELECTION AND MANAGEMENT (II)
Moderator: Ivan Netuka, MD, PhD

CASE SCENARIO: Early and Late RV Failure: From Prediction to Management
Lars Lund, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

Teaching/Discussion Points
1. RV failure risk prediction: how useful are risk prediction tools and models?
2. RV failure risk minimization: pre- and peri-operative measures.
3. TAH vs. BiVAD vs. temporary RVAD: how to select and deciding on prophylactic versus “as needed” RVAD?
5. Late RV failure: prediction, prevention and management.

12:05 PM
CASE SCENARIO: Minimally Invasive Surgical Approaches from Implant to Explant
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Teaching/Discussion Points
1. Advantages and disadvantages of less invasive surgical MCS device implantation
2. Technical “do” and “don’t” for less invasive surgical MCS device implantation
3. Alternative outflow options for usual anatomy
4. Technical tips for less invasive LVAD explantation for cardiac recovery

12:35 PM – 12:50 PM
CLOSING REMARKS
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

12:50 PM
ADJOURN

SCIENTIFIC PROGRAM - AFTERNOON CLASS SCHEDULE

1:45 PM – 2:00 PM
WELCOME AND INTRODUCTIONS
Stavros Drakos, MD, PhD, University of Utah School of Medicine, Salt Lake City, UT, USA

2:00 PM – 3:00 PM
SMALL GROUP INTERACTIVE DISCUSSION A: ACUTE MCS FOR PROFOUND CARDIogenic SHock/INTERMACS 0-1 PROFILES
Moderator: Stavros Drakos, MD, PhD

2:00 PM
CASE SCENARIO: Management Challenges for ‘Crash and Burn’ Patients: ‘Shock Team’ Approach to MCS
Hiroo Takayama, MD, Columbia University, New York, NY, USA

Teaching/Discussion Points
6. Challenges of assessing patients in profound cardiogenic shock:
   a. Lack of universally accepted classification system of cardiogenic shock and its influence on patient management
   b. Important factors to consider at initial evaluation
7. Challenges in choosing the appropriate timing for MCS
8. Challenges in choosing the appropriate MCS device
   a. Theoretical advantages/disadvantages of each device
   b. Existing clinical evidence
9. SHOCK team approach to cardiogenic shock: patient benefits and logistical difficulties
10. Initial attempts in developing an algorithm for MCS therapy for cardiogenic shock

2:30 PM
CASE SCENARIO: Transition from Short to Long-Term Support
Keith Aaronson, MD, University of Michigan, Ann Arbor, MI, USA

Teaching/Discussion Points
5. When is the optimal time to transition from temporary to durable MCS?
6. How should you I assess and prioritize end organ function in the decision to proceed with durable MCS?
7. How does temporary MCS affect the risk of RV failure post durable VAD?
8. What are the other considerations when bridging from temporary to durable MCS?
3:00 PM – 3:05 PM
Speakers switch rooms; delegates remain seated

3:05 PM – 4:05 PM
SMALL GROUP INTERACTIVE DISCUSSION B: COMPLEX COAGULATION ISSUES IN MCS PATIENTS
Moderator: Ivan Netuka, MD, PhD

3:05 PM
CASE SCENARIO: Recurrent GI Bleeding and Pump Thrombosis
Simon Maltais, MD, PhD, Mayo Clinic, Rochester, MN, USA

Teaching/Discussion Points
6. Definition, risk factors, and the inevitable "conundrum".
7. Treatment of recurrent GI bleeding — overreacting on an imprecise science?
8. Treatment of clotting while bleeding: how to treat medically, and when to refer for surgery.
9. Evidence-based approach for pump thrombosis: from prevention to treatment algorithm.
10. Implications and management of neurologic events on treatment.

3:35 PM
CASE SCENARIO: Management of Cerebrovascular Hemorrhagic Accidents
Chris Hayward, MD, St. Vincent's Hospital, Sydney, Australia

Teaching/Discussion Points
6. Epidemiology and risk factors for intracerebral hemorrhage (ICH) in the MCS population.
7. After the bleed, where to next? What are the immediate management priorities?
8. Recommendations for anticoagulation in the setting of intracerebral hemorrhage.
9. Current evidence for alternate anticoagulation options available to minimize ICH.
10. Should we expect a poor outcome post ICH?

4:05 PM – 4:30 PM
COFFEE BREAK

4:30 PM – 5:30 PM
SMALL GROUP INTERACTIVE DISCUSSION C: PATIENT SELECTION AND MANAGEMENT (I)
Moderator: Stavros Drakos, MD, PhD

4:30 PM
CASE SCENARIO: Bridge to Recovery: From Prediction to Implementation
Snehal Patel, MD, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA

Teaching/Discussion Points
6. What accounts for the observed differences in rates of recovery between registry analysis and prospective single center studies?
7. Managing and testing for recovery is hard work... can we target specific populations to limit the effort? – The role of clinical prediction tools.
8. The role of adjuvant pharmacologic therapy in addition to mechanical unloading of the left ventricle to promote reverse remodeling.
9. Practical considerations for cardiac recovery testing – when, how, and what are the endpoints.
10. Recovery or remission? Histopathologic changes and long term follow up of explanted patients.

5:00 PM
CASE SCENARIO: Optimizing the Exercise Capacity of Chronic MCS Pts: Implications for Heart Recovery Assessment
Bart Meyns, MD, PhD, University Hospitals Leuven, Leuven, Belgium

Teaching/Discussion Points
6. Indicate the limitations of exercise capacity in MCS patients, the evolution in time after MCS implantation and illustrate the effect of pump rotational speed.
7. Explain the mechanism of limitation of exercise capacity and learn from patient variability.
8. Indicate the role of potential underlying mechanisms such as underlying left and right ventricular function, anemia, and peripheral muscle deficiencies.
9. Understand the differences in exercise performance of patients after heart transplantation.
10. Draw conclusions on how to optimize exercise capacity

5:30 PM – 5:35 PM
Speakers switch rooms; delegates remain seated

5:35 PM – 6:35 PM
SMALL GROUP INTERACTIVE DISCUSSION D: PATIENT SELECTION AND MANAGEMENT (II)
Moderator: Ivan Netuka, MD, PhD

5:35 PM
CASE SCENARIO: Early and Late RV Failure: From Prediction to Management
Lars Lund, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

Teaching/Discussion Points
6. RV failure risk prediction: how useful are risk prediction tools and models?
7. RV failure risk minimization: pre- and peri-operative measures.
8. TAH vs. BiVAD vs. temporary RVAD: how to select and deciding on prophylactic versus “as needed” RVAD?
10. Late RV failure: prediction, prevention and management.

6:05 PM
CASE SCENARIO: Minimally Invasive Surgical Approaches from Implant to Explant
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Teaching/Discussion Points
5. Advantages and disadvantages of less invasive surgical MCS device implantation
6. Technical “do” and “don’t” for less invasive surgical MCS device implantation
7. Alternative outflow options for usual anatomy
8. Technical tips for less invasive LVAD explantation for cardiac recovery

6:35 PM – 6:50 PM
CLOSING REMARKS
Ivan Netuka, MD, PhD, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

6:50 PM
ADJOURN
ISHLT ACADEMY
MASTER CLASS IN PULMONARY HYPERTENSION

Tuesday, April 4, 2017

Scientific Program Committee
Chair: Myung Park, MD, Houston Methodist, Houston, TX, USA
Co-Chair: Ioana Preston, MD, Tufts Medical Center, Boston, MA, USA
Members: Robert Frantz, MD, Mayo Clinic, Rochester, MN, USA
Marco Guazzi, MD, PhD, IRCCS Pol San Donato, Milan, Italy
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Steven Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

Course Summary
The Pulmonary Hypertension (PH) Master Class is intended for members with higher levels of expertise (completed the core curriculum course on PH and/or primary practice in PH ≥ 5 years) who have managed patients with one or more of the topics intended for discussion. The course setting will generate a highly interactive environment composed of a small group of individuals and designed to enhance individual expertise and network development. Utilizing the concept of “convergent discussion” and the technique of “audience response system”, faculty moderators will use complex situations and controversial statements during practical case presentations in order to lead the group through active audience participation, towards specific answers based on practice gaps and learning objectives. The MCS Master Class is arranged in advanced breakout sessions for every participant to take full advantage of an integrated curriculum and the exceptional networking opportunity. The four topics covered include: advanced pulmonary arterial hypertension (PAH Group 1); PH due to left heart failure (PH Group 2); PH due to advanced lung disease (PH Group 3); and chronic thromboembolic PH (CTEPH, PH Group 4). The topics chosen will cover the major aspects of various forms of PH and highlight the significant differences in the diagnosis and management of these entities. We anticipate that this method of collaborative and interactive learning will lead to application and integration of new knowledge into participant practice.

Practice Gaps
1: Advanced medical therapies and treatment algorithms for PAH have evolved tremendously in the recent years. The management of patients with advanced PAH and acute (or acute on chronic) right heart failure poses real challenges: their mortality is extremely high and salvage therapies used as bridge to a successful transplantation are complex. The implementation of advanced supportive measures in a failing right heart such as parenteral prostanooid replacement therapies, inotropic support and ECMO are often delayed or never utilized in advanced PAH patients. Recently published literature identified significant gaps in the recognition of signs that require adjustment of therapies in PAH management, including usage of parenteral therapies. Therefore, there is a real practice gap that limits their appropriate use in selected patients.

2: The presence of right ventricular dysfunction in the setting of systolic heart failure (PH due to heart failure with reduced ejection fraction, PH-HFrEF) represents a complex challenge for practitioners. The use of advanced support systems such as LVADs in the setting of right heart failure needs very careful consideration, including detailed evaluation of the RV function with noninvasive and invasive tests; heart failure specialists may lack the intricate details of these complicated patients and will benefit from the expertise of our speakers in addressing these challenging and commonly encountered issues. Lastly, PH from left ventricular diastolic dysfunction (PH-HFpEF) is often refractory to currently available therapies and its management is very challenging. Moreover, therapies that are effective for PAH Group 1 have not been carefully evaluated in PH due to left heart disease (PH Group 2). Therefore, a deep understanding of the pathophysiology of PH Group 2 and how it differs (or not) from PAH Group 1 is necessary before making a decision of whether or not to treat.

3: PH due to advanced lung disease (PH Group 3) occurs in the vast majority of patients being evaluated for lung transplant and is associated with increased mortality. Identification of PH, correct determination of PH type and decision whether or not to treat are complex aspects of care of patients with advanced lung disease. Because many patients in this
category are being diagnosed when PH is already advanced, there is a clear gap in early recognition of PH Group 3. Assessment of patients with lung disorders such as pulmonary fibrosis, COPD and sarcoidosis for the presence and severity of PH is therefore an important step in improving their management.

4: Annual incidence rates of deep venous thrombosis (DVT) and pulmonary embolism (PE) are approximately 0.5 to 1.0 per 1000 inhabitants and CTEPH develops in approximately 2-15% of patients who had a PE. Therefore, the estimated prevalence of CTEPH is high. Several reports highlight the significant gaps that exist between guidelines and clinical practice in regards diagnostic approaches and management of CTEPH, such as the lack of utilization of the ventilation/perfusion scan for screening and delay or omission of referral to a specialized surgical center for evaluation of operability. Therapies for CTEPH have been recently diversified and include sophisticated surgical approaches such as pulmonary endarterectomy, balloon angioplasty and medical treatment. Therefore, reviewing and clarifying the diagnostic algorithm, as well as different therapeutic approaches will be of great benefit for physicians and allied health care practitioners.

Educational Goals
The overarching goal is to provide an advanced learning opportunity for specialists in the field of PH on the treatment of PAH Group 1, as well as PH in the setting of advanced left heart and lung disease and in chronic thromboembolic PH; all these entities have very different management approaches.

Target Audience
The target audience for this class includes pulmonologists/respirologists, cardiologists, thoracic surgeons, nurses, physician assistants, and allied health professionals with experience in PH. The course is intended for health care professionals whose primary practice is focused in PH for at least 5 years or who have completed the ISHLT Core Competency Course on PH.

Learning Objectives
Upon completion of the Master Class, participants will be able to:
1. Initiate advanced therapies for PAH
2. Apply advanced supportive measures in severe right heart failure
3. Manage complex patients with HFpEF and HFrEF complicated with PH
4. Understand pathophysiology, correctly diagnose and manage PH associated with advanced lung disease of different etiologies, such as emphysema, pulmonary fibrosis, or sarcoidosis.
5. Correctly define the type and severity of vascular compromise in CTEPH
6. Determine the best therapeutic option in CTEPH, such as surgical eligibility, medical treatment, or invasive nonsurgical approaches (balloon angioplasty).

Accreditation Statement
The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
ISHLT designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Credit
AMEDCO is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This course is co-provided by AMEDCO and ISHLT. Maximum of 5.0 contact hours.

Disclosure
Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.
SCIENTIFIC PROGRAM SCHEDULE

2:00 PM - 2:15 PM
WELCOME AND INTRODUCTIONS, Myung Park, MD, Houston Methodist, Houston, TX, USA

2:15 PM – 3:15 PM
SMALL GROUP INTERACTIVE DISCUSSION A: ADVANCED PAH: CHALLENGES IN MANAGEMENT
Moderator: Robert Frantz, MD

2:15 PM
CASE SCENARIO: Idiopathic PAH with Advanced Right Ventricular Failure
Paul Corris, MB FRCP, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Teaching/Discussion Points
a. Understanding of optimal management strategies for RV failure (diuretics, inotropes, pressors)
b. Discuss the role of atrial septostomy and ECMO
c. Timing of lung transplantation and factors impacting outcome

2:45 PM
CASE SCENARIO: PAH with Suboptimal Control on Double Combination Therapy: What Next?
Mardi Gomberg-Maitland, MD, Inova Heart and Vascular Institute, Falls Church, VA, USA
Teaching/Discussion Points
a. Utilization of optimal therapy lags behind guideline recommendations.
b. Recognition of disease progression requires sophisticated integration of clinical, imaging and hemodynamic parameters that is insufficiently employed.
c. Discussion of when to initiate parenteral therapy and various options available
d. Recognition of practice gaps suggesting that many PAH patients with advanced disease are not initiated on parenteral therapies and discussion of possible factors influencing this outcome

3:15 PM – 3:20 PM
Speakers switch rooms; delegates remain seated

3:20 PM – 4:20 PM
SMALL GROUP INTERACTIVE DISCUSSION B: Challenges in PH Due to Left Heart Disease: An Increasingly Recognized Complication
Moderator: Marco Guazzi, MD, PhD

3:20 PM
CASE SCENARIO: PH Due to Heart Failure with Reduced Ejection Fraction
Ray Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Teaching/Discussion Points
a. Hemodynamic definition and its limitations
b. Epidemiology and phenotypes. Understanding the role of the right ventricle in HFrEF
c. Pathophysiology of PH-HFrEF and the importance of mitral regurgitation
d. Discussion of transplant and advanced support in the presence of PH
e. Targeting the pulmonary microcirculation; a critical appraisal of current therapies for PH-HFrEF

3:50 PM
CASE SCENARIO: PH Due to Heart Failure with Preserved Ejection Fraction
C. Dario Vizza, MD, University of Rome, Rome, Italy
Teaching/Discussion Points
a. Hemodynamic and clinical definitions;
b. Epidemiology and phenotypic characteristics.
c. Challenging LV filling and diastolic properties: exercise vs fluid loading
d. Challenges in the management of patients with HFpEF and significant RV dysfunction. Discussion whether targeting the pulmonary vasculature is effective and safe.

4:20 PM – 4:45 PM COFFEE BREAK
4:45 PM – 5:45 PM
SMALL GROUP INTERACTIVE DISCUSSION C: PH DUE TO ADVANCED LUNG DISEASE
Moderator: Steven Nathan, MD

4:45 PM
CASE SCENARIO: PH Due to Combined Chronic Obstructive Lung Disease and Pulmonary Fibrosis
Fernando Torres, MD, University of Texas Southwestern Medical Center, Dallas, TX, USA

Teaching/Discussion Points
a. Understand the implications of PH in diffuse parenchymal lung disease
b. Epidemiology: advances in screening techniques and diagnostic algorithms.
c. Interpretation of hemodynamic testing in the setting of advanced lung disease
d. Challenges in the treatment of advanced pulmonary vascular disease in patients with COPD and IPF.
e. Clinical trial conundrums

5:15 PM
CASE SCENARIO: PH Associated with Sarcoidosis
Oksana Shlobin, MD, Inova Fairfax Hospital, Falls Church, VA, USA

Teaching/Discussion Points
a. Is PH complicating sarcoidosis different to the PH of other forms of diffuse parenchymal lung disease?
b. What factors are unique to sarcoidosis? If PH in sarcoidosis similar to PAH Group 1?
c. Epidemiology: the role of PH screening in sarcoidosis
d. Implications with regards to transplantation
e. Treatment options, limitations of current therapies

5:45 PM – 5:50 AM Speakers switch rooms; delegates remain seated

5:50 PM – 6:00 PM
SMALL GROUP INTERACTIVE DISCUSSION D: CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)
Moderator: Manreet Kanwar, MD

5:50 PM
CASE SCENARIO: CTEPH with Mixed Type 3 and Type 4 Disease
Irene Lang, MD, Medical University of Vienna, Vienna, Austria

Teaching/Discussion Points
a. Distal disease: What is the right therapeutic approach?
b. Is there a role for combined surgical (PTE) and medical (BPA) approach in type 3/4 combined disease?
c. Surgical challenges in patients with distal disease
d. Optimizing patient selection for surgical candidacy in patients with high pulmonary vascular resistance and distal disease

6:20 PM
CASE SCENARIO: CTEPH with Discordant Diagnostic Results Between Imaging, Hemodynamics and Clot Burden
William Auger, MD, University of California San Diego Medical Center, San Diego, CA, USA

Teaching/Discussion Points
a. Patient selection for optimal therapeutic options for CTEPH
b. Predicting surgical outcomes from pre-op data
c. Diseases that mimic CTEPH
d. Identifying patients with likely post PTE persistent PH

6:50 PM – 7:00 PM
CLOSING REMARKS, Ioana Preston, MD, Tufts Medical Center, Boston, MA, USA

7:00 PM
ADJOURN
AFFILIATE EVENTS

Tuesday, April 4

8:00 AM – 1:00 PM
**U.S. CTEPH Registry Steering Committee Meeting** (Bankers Hill)
Attendees: The attendees will be the Steering Committee members of the U.S. CTEPH Registry. They are all Faculty members at academic medical centers.

9:00 AM - 5:00 PM
**ISO/TC 150/SC 6/WG 6, Mechanical Circulatory Support Systems** (Cove)
Attendees: Physicians, surgeons, members of ISHLT Mechanical Circulatory Support Council, members of FDA, MCS industry partners, ISO/TC 150/SC 6/WG 6 members, domestic and international.

12:00 PM - 6:00 PM
**Toronto Lung Transplant Program Annual Lung Transplant Biospecimen Workshop** (off-site)
Attendees: World-leading experts in lung transplantation and thoracic surgery, and/or experts in biobanking, sample storage, data collection and translational research. All attendees are active members of ISHLT.

Wednesday, April 5

7:00 AM – 8:00 AM
**Consensus Statement on Donor Heart and Lung Procurement Writing Group** (Gaslamp B)
Attendees: The attendees will be taskforce leaders, and contributing writers for this project.

7:00 AM – 8:00 AM
**Pulmonary AMR WorkGroup Steering Committee Meeting** (Gaslamp A)

7:00 AM – 8:00 AM
**SUSTAIN-IT Investigators Meeting** (Cove Room)
Attendees: SUSTAIN-IT investigators and coordinators

12:30 PM - 2:30 PM
**ISHLT Lung Quality of Life Workforce Meeting** (La Jolla AB)
Attendees: Cross-disciplinary group of pulmonologists, social workers, nurses

12:30 PM - 2:30 PM
**UCSD Faculty Luncheon** (Promenade AB)
Attendees: UCSD Faculty

1:00 PM - 2:00 PM
**I2C2 Latin American Group Meeting** (America’s Cup A-D)
Attendees: Latin American transplant professional

1:15 PM - 2:15 PM
**REVIVAL Steering Committee Meeting** (Pier Room)
Attendees: Principal investigators participating in the study, who will be in attendance at the conference. from various sites across the nation.

6:00 PM – 7:15 PM
**Psychosocial Evaluation Consensus Workgroup Meeting** (Gaslamp A)
Attendees: Individuals who received invitations to join the Consensus workgroup and who have been participating in the project.

6:00 PM – 8:00 PM
**IPLTC Meeting** (La Jolla AB)
Attendees: Pediatricians engaged in Pediatric Lung Transplantation with the aim to unite pediatric lung transplant centers worldwide, to promote interaction between lung transplant physicians to enhance the care of children with lung transplants or those being considered for lung Transplantation, to provide a forum for the exchange of ideas about the science and art of pediatric lung Transplantation, to establish and maintain a prospective database of pediatric lung transplant recipients.
6:00 PM – 9:00 PM
**Inflammatory Burden Multicenter Study Meeting** (Ocean Beach Room)
Attendees: Members of the Pathology Council

7:00 PM - 8:30 PM
**Immunomodulators Consensus Conference** (Hillcrest A-D)
Attendees: Consensus Conference invited participants

7:00 PM - 9:30 PM
**CCTN Educational Meeting** (Mission Beach A-C)
Attendees: HF and transplant specialists, cardiologists and surgeons, nurses and trainees - all involved in heart transplant in Canada

7:30 PM – 10:00 PM
**ICCAC Annual Meeting** (Grand Hall C)

---

**Thursday, April 6**

7:00 AM - 8:00 AM
**EUROMACS Committee Meeting** (Gaslamp D)
Attendees: EUROMACS Members

8:00 AM - 9:15 AM
**EUROMACS Members Meeting** (Gaslamp D)
Attendees: Surgeons and Cardiologists contributing to the EUROMACS Registry, as well as scientists who execute studies based on the data provided by EUROMACS

12:30 AM – 2:00 PM
**ID Symposium Working Group Meeting** (Gaslamp D)
Attendees: Select members from the ID council (ISHLT members only) who have manifested interest in participating in this working group.

12:30 AM – 2:00 PM
**NHLBI-NIH Follow-Up Meeting at ISHLT – Clinical Trial Design for cfDNA** (La Jolla AB)
Attendees: ISHLT attendees/Conference research Group.

7:00 PM - 8:30 PM
**Immunomodulators Consensus Conference** (Gaslamp A-C)
Attendees: Consensus Conference invited participants

---

**Friday, April 7**

11:30 AM - 1:30 PM
**IMACS Users Group Meeting** (Gaslamp A-C)

12:00 PM – 1:00 PM
**I2C2 Asian Meeting** (America’s Cup A-D)
Attendees: Asian Transplant Leaders

12:00 PM - 1:00 PM
**Meeting of the ID Council Working Group on the Older Transplant and MCSD Recipient** (Old Town B)
Attendees: Interested ISHLT members from both the ID Council as well as other interested physicians, nurses, coordinators, pharmacists, and scientists from other Councils who are interested in the care and study of the older transplant or MCSD recipient.

5:30 PM – 7:00 PM
**Barnes-Jewish Hospital/Washington University School of Medicine Reception** (Ocean Beach)
Attendees: BJH/Washington University physicians, fellows, etc.
CORPORATE EVENTS AND INDUSTRY THEATERS LISTINGS

The following approved Corporate Events and Industry Theaters are taking place during the ISHLT Annual Meeting. All events are taking place at the Manchester Grand Hyatt Hotel unless noted as off-site. The Industry Theaters will take place inside the Exhibit Hall located in the Harbor Ballroom.

Monday, April 3

8:00 AM – 2:00 PM
UNIVERSITY OF PITTSBURGH MEDICAL CENTER:  *Donor Heart/Lung Procurement Simulation Lab* (Offsite venue: The Center for the Future of Surgery, UCSD, 9500 Gilman Drive MC0740, Medical Education & Telemedicine Building, La Jolla, CA 92039)

Tuesday, April 4

12:00 PM – 5:00 PM
ABBOTT:  *Commercial Leadership Meeting* (Solona Beach AB)

4:00 PM – 8:00 PM
CARDIOVASCULAR RESEARCH FOUNDATION:  *Training and Education in Advanced Cardiovascular Hemodynamics* (Cortez Hill A-C)
*Supported by an educational grant from Abiomed*

Wednesday, April 5

6:30 AM – 8:00 AM
MEDTRONIC:  *Investigators Meeting* (Torrey Hills AB)

12:00 PM – 12:30 PM
MEDTRONIC:  *Investor & Analyst Briefing* (Golden Hill AB Room)

12:30 PM – 2:30 PM
MEDTRONIC:  *Lunch Symposium* (Grand Hall B)

12:30 PM – 2:30 PM
ONE LAMDBA:  *Precision Medicine in Transplantation: Reclassifying Graft Rejection and Injury with the Molecular Microscope and Integrative Diagnostics* (Hillcrest A-D)

6:00 PM – 7:00 PM
ABBOTT:  *MCS Turkish Physician Reception* (Cortez Hills A-C)

6:00 PM – 8:00 PM
LUNG BIOENGINEERING:  *Investigators Meeting* (Solana Beach AB)

6:30 PM – 9:30 PM
ABBOTT:  *CardioMEMS in PH Study Steering Committee Meeting* (Cove)

Thursday, April 6

6:30 AM – 8:00 AM
ACTELION PHARMACEUTICALS:  *Nordic Expert Group Meeting* (Cove)

6:30 AM – 8:00 AM
ALERE:  *VADWatch Outcomes* (Ocean Beach Room)

6:30 AM – 8:00 AM
MEDTRONIC:  *Investigators Meeting* (Promenade AB)
7:00 AM – 8:00 AM  
**RELIANTHEART**: *Clinical Breakfast Meeting* (Golden Hill AB Room)

7:30 AM – 9:30 AM  
**ACTELION PHARMACEUTICALS**: *Medical Debrief 1 Meeting* (Pier Room)

10:00 AM – 10:30 AM  
**SENSIBLE MEDICAL**: *Industry Theater* (Harbor I)

12:00 PM – 2:00 PM  
**RELIANTHEART**: *aVAD Surgical Users Group Lunch Meeting* (Golden Hill AB Room)

12:30 PM – 1:30 PM  
**GENENTECH**: *Industry Theater* (Harbor I)

12:30 PM – 1:30 PM  
**MEDTRONIC**: *Investigators Meeting* (Ocean Beach Room)

12:30 PM – 2:00 PM  
**ABBOTT**: *ELEVATE Investigators Meeting* (Cove)

12:30 PM – 2:00 PM  
**BAYER**: *Managing what’s important to you and your PAH (WHO Group 1) patients. An interactive session on a treatment option for PAH (WHO Group 1) patients* (Coronado DE)

3:15 PM - 4:15 PM  
**MEDTRONIC**: *Industry Theater* (Harbor I)

6:00 PM – 8:00 PM  
**NOVARTIS**: *Recruitment Meeting* (Promenade AB Room)

Friday, April 7

7:00 AM – 8:00 AM  
**ABBOTT**: *Japanese MCS Breakfast Meeting* (Promenade AB Room)

7:00 AM – 8:00 AM  
**SENSIBLE MEDICAL**: *SMILE Study Investigator Meeting* (Golden Hill AB Room)

7:30 AM – 9:30 AM  
**ACTELION PHARMACEUTICALS**: *Medical Debrief 2 Meeting* (Cove Room)

11:30 AM – 1:30 PM  
**CORWAVE**: *Focus Group Meeting* (Pier Room)

11:30 AM – 1:30 PM  
**GILEAD SCIENCES, INC.**: *Clinical Decision-Making in PAH: Experts Explore the Evidence for Combination Therapy* (Hillcrest A-D)

12:00 PM – 1:30 PM  
**ABBOTT**: *MOMENTUM 3 Investigators Meeting* (Cortez Hill A-C)

12:00 PM – 1:30 PM  
**RELIANTHEART**: *aVAD Surgical Users Group Meeting* (Golden Hill AB Room)

12:30 PM – 1:30 PM  
**MEDTRONIC**: *Investigator Meeting* (Promenade AB)
6:00 PM – 8:00 PM
ABOTT: Product Fair (off-site venue)

7:30 PM – 10:30 PM
MALLINCKRODT/THERAKOS: Meet the Expert Reception – Immune Modulation of Sensitized Patients (off-site venue)
2017 EXHIBITORS AND BOOTH NUMBERS

205  Abbott (Formerly St. Jude Medical)
416  Abiomed, Inc.
422  Actelion Pharmaceuticals US, Inc.
106  ActiCare Health
603  Alere VADCare Program
524  Astellas
105  Bayer
222  Bellerophon Therapeutics
609  Berlin Heart, Inc.
516  BiologicTX
224  Bridge to Life
121  CareDx
118  CryoLife
225  DNV GL Healthcare
220  Elsevier
520  Essential Pharmaceuticals, LLC
613  Evaheart, Inc.
325  Forever Flawless
218  Genentech, A Member of the Roche Group
108  Getinge Group
317  Gilead Sciences, Inc.
125  HemoCue America
423  International Institute for the Advancement of Medicine
117  ISHLT Mechanically Assisted Circulatory Support Registry (IMACS)
120  ISHLT Registries
318  Jarvik Heart, Inc.
522  Joe DiMaggio Children’s Hospital at Memorial
420  Kroger Specialty Pharmacy
111  Medtronic
518  Millar, Inc.
607  Miller Pharmacal Group, Inc.
417  One Lambda, A Thermo Fisher Scientific Brand
124  OTTR, Inc.
321  Paragonix Technologies, Inc.
119  Pediatric Heart Transplant Study (PHTS)
324  Piedmont Healthcare
316  Scanlan International, Inc.
320  Sensible Medical, Inc.
223  Surrogen, A Recombinetics Company
216  SynCardia Systems, LLC
217  Tandem Life
104  Texas Children’s Hospital
305  Transmedics, Inc.
221  The Transplantation Society
122  TS Consulting
421  United Therapeutics
425  Waters Medical Systems, LLC
424  Wexler Surgical
323  Wound Care Resources
311  XVIVO Perfusion AB
2017 EXHIBITOR PRODUCT DESCRIPTIONS

ABBOTT (FORMERLY ST. JUDE MEDICAL) Booth #205
6035 Stoneridge Dr.
Pleasanton, Ca. 94588 – USA
www.sjm.com

At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world — in nutrition, diagnostics, medical devices and branded generic pharmaceuticals — that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

ABIOMED, INC. Booth #416
22 Cherry Hill Drive
Danvers, MA
www.abiomed.com

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.

The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
For additional information, please visit: www.abiomed.com.

ACTELION PHARMACEUTICALS US, INC. Booth # 422
5000 Shoreline Court South
San Francisco CA, 94080
www.actelionus.com

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for diseases with significant unmet medical needs.

ACTICARE HEALTH Booth #106
6111 Southfront Road, Suite M
Livermore, CA 94551
http://acticarehealth.com

ActiCare Health (Booth #106) enables resource-constrained coordinators to serve more outpatients with better efficiency through a state-of-the-art telehealth platform and 24x7 support, empowering both patients and clinicians to achieve improved outcomes with reduced stress. In response to the immense administrative and operational challenges faced by VAD and transplant departments, we’ve designed a program to provide enhanced visibility into patients’ health status, modernize patient safety and communication, optimize discharge plan adherence, and minimize adverse clinical and financial events. Our program is designed to positively affect health outcomes and quality of life, enhance care coordination and staff efficiency, and reduce costs.
The comprehensive Alere VADCare® Program helps you carefully and efficiently manage your patients after discharge to reduce the risk of hospital readmission. Alere fully supports the transition of VAD patients from hospital to home. Patients receive all of the necessary equipment and wound care supplies they need to take care of their VAD equipment and driveline exit site. Additional services through the Alere VADWatch® program include home INR monitoring; weight and blood pressure management; and tracking of VAD metrics in the Alere VADWatch® Data Management application, which gives clinicians secure, anytime access to patient data.

Astellas Booth #524
Northbrook, IL

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power.

Bellerophon Therapeutics Booth #222
184 Liberty Corner Road, Suite 302
Warren, NJ 07059

We are a clinical-stage biotherapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Three product candidates are in development under our INOpulse platform, a proprietary pulsatile nitric oxide device system. The first is for the treatment of pulmonary arterial hypertension (PAH), which is currently in Phase 3 clinical testing. The other two product candidates are for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) which are both in Phase 2 development.

Berlin Heart, Inc. Booth #609
200 Valleywood Rd. Suite B100
The Woodlands, TX 77380
www.berlinheart.de

Berlin Heart, the only company worldwide, that develops, manufactures and distributes VADs for patients of every age and body size. EXCOR® Pediatric provides medium to long-term circulatory support specifically for infants and children awaiting heart transplants. EXCOR Pediatric is approved for use in the USA under HDE regulations by FDA.

BiologicTx booth #516
40-D Commerce Way
Totowa, NJ 07512
www.BiologicTx.com

BiologicTx is a national specialty pharmacy that joins the administration of therapeutics, research, and digital health to advance the practice of solid organ transplant and chronic specialties. BiologicTx is comprised of four operating segments: BiologicTx Pharmacy and Therapeutic Services, BiologicTx Clinical Trials™, BiologicTx Sequence, and BiologicTx Paired Donation™.
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. The Company markets AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is pursuing the development of additional products for transplant monitoring using a variety of technologies, including AlloSure™, a proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation.

CryoLife® is one of the world’s leading contemporary medical device companies providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers, PhotoFix™ bovine pericardium patch, and most recently, On-X® prosthetic heart valves. CryoLife’s products and tissues have been used in an estimation of >1,000,000 procedures worldwide.

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey — and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

Essential Pharmaceuticals, LLC is a specialty pharmaceutical company devoted to the development and sales of pharmaceutical and biopharmaceutical products including Custodiol® HTK organ preservation solution. Originally developed for cardiac surgery, Custodiol® HTK offers superior convenience due to its easy handling characteristics, water like viscosity and no need for additives or filters which makes it a preferred solution for many transplant centers.
The EVAHEART Left Ventricular Assist System (LVAS)™ is a continuous-flow, hydraulically levitated centrifugal pump designed to support patients with end-stage heart failure as bridge-to-transplant therapy. The EVAHEART LVAS has been commercially available in Japan since 2010 and has successfully obtained CE Marking approval.

Evaheart, Inc. (EVI) is a medical device company based in the Texas Medical Center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART LVAS™ in North America and to start distribution in Europe. Under an FDA-approved IDE, a bridge-to-transplant (BTT) clinical trial of the EVAHEART LVAS™ is ongoing in the US.

For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.

We are headquartered in South San Francisco, California.

Getinge Group is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, Getinge and Maquet. Our unique value proposition mirrors the continuum of care for patients. We build quality and safety into every system and offer solutions that enhance efficiency throughout the clinical pathway. With our first-hand experience and close partnerships with industry leaders, we are able to exceed our customers’ expectations. With a genuine passion for life, we work to improve patients’ lives every day – both today and tomorrow.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.

The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure. The Jarvik 15mm VAD has been designed for pediatric patients and will enter a clinical trial in the USA in 2017.

Kroger Specialty Pharmacy is a clinical pharmacy that offers highly individualized and comprehensive Total Life Care programs to patients and their families. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. Kroger Specialty Pharmacy provides specialty medication and support services for Crohn’s Disease, Cystic Fibrosis, Gaucher’s Disease, Growth Hormone Deficiency, Hemophilia and Bleeding Disorders, Hepatitis C, Hereditary Angioedema, HIV/AIDS, Immunoglobulin G (IVI/SQIg), Multiple Sclerosis, Oncology (Cancer), Psoriasis, Rheumatoid Arthritis, and Transplant.

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by healthcare systems today. Let’s take healthcare Further, Together. Learn more at Medtronic.com.
Millar is committed to making the improbable possible in cardiovascular diagnostics and research by delivering products that enable a deeper understanding of hemodynamic function. From clean, pressure waveforms with the Mikro-CathTM pressure catheter to plotting the complete cardiac cycle with the Inca® PV Loop System, expert insight is within reach. Millar is a unique provider of cardiovascular products that cover device and drug development from the first animal model through the final clinical trial.

Miller Pharmacal's 'MG PLUS PROTEIN' (TM) magnesium supplement treats and prevents the hypomagnesemia caused by diuretics (or immunosuppressants) without causing the GI disturbances common with magnesium oxide. Each easy-to-swallow, glazed, non-enteric coated tablet contains 133 mg of magnesium.

One Lambda, Inc., a Thermo Fisher Scientific brand, is a global leader in transplant diagnostics offering a full range of HLA Typing and antibody monitoring products to support clinicians and laboratories in the management of transplant patients. Visit www.onelambda.com to discover how we can help you improve patient outcomes.

The Pediatric Heart Transplant Study (PHTS) is an international registry established in 1993 for pediatric patients listed for heart transplantation. PHTS is dedicated to the advancement of the science and treatment of children during listing for and following heart transplantation. The purposes of the group are to establish and maintain a prospective, event driven database for heart transplantation, to encourage and stimulate basic and clinical research in the field of pediatric heart transplantation, and to promote new therapeutic strategies. The ultimate goal is to improve patient outcomes. The registry resides at the University of Alabama at Birmingham.
PIEDMONT HEALTHCARE  Booth #324
2727 Paces Ferry Rd, Suite 1-1100
Atlanta, GA 30339
http://www.piedmont.org

Piedmont Healthcare is a not-for-profit health system that serves nearly two million patients primarily in North Georgia but also across the state. Piedmont Healthcare is compromised of the following entities: Piedmont Athens Regional Medical Center, Piedmont Atlanta Hospital, Piedmont Fayette Hospital, Piedmont Henry Hospital, Piedmont Mountainside Hospital, Piedmont Newnan Hospital, Piedmont Newton Hospital, Piedmont Heart Institute, Piedmont Physician Group, Piedmont Clinic, and Piedmont Healthcare Foundation. Piedmont is revolutionizing healthcare in the Southeast by combining the traditions that have given us national prominence with cutting edge research and techniques that keep us on the forefront of medicine.

SCANLAN INTERNATIONAL, INC.  Booth #316
One Scanlan Plaza
Saint Paul, Minnesota  55107
info@scanlangroup.com
www.scanlaninternational.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS / MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps; Scanlan® SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: Scanlan® VASCU-STAT™ bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

SENSIBLE MEDICAL, INC  Booth #320
90 Park Avenue, Suite 1700
New York, New York 10016
www.sensible-medical.com

Sensible’s vision is to lead a new standard of care for monitoring and managing patients with lung fluid problems, including Heart Failure. Our ReDS™ medical radar technology provides an accurate, absolute and actionable result, and is embedded in a non-invasive system which tracks and monitors their lung fluid in a single daily measurement. Results are uploaded to a cloud service and may be observed by a dedicated service center and the treating physician to better manage the patient. We believe our offering will become the standard of care to determine the right timing of the right treatment for such patients.

SURROGEN, A RECOMBINETICS COMPANY  Booth #223
St. Paul, MN
SYNCARDIA SYSTEMS, LLC  Booth #216
1992 E. Silverlake Rd
Tucson, AZ 85713
www.syncardia.com

The SynCardia temporary Total Artificial Heart (TAH-t), the world’s most used artificial heart, is now available in two sizes to serve more patients. The 70cc TAH-t is FDA, Health Canada and CE approved as a bridge to transplant for patients with end-stage biventricular failure. The new, smaller 50cc TAH-t, CE approved in Europe and undergoing an Investigational Device Exemption clinical study in the U.S., is designed for patients of smaller stature, including women and adolescents. Stable patients can be discharged to wait for a matching donor heart at home using the Freedom® portable driver. Visit our booth to learn more.
TANDEM LIFE  Booth #217
240 Alpha Drive
Pittsburgh, PA 15238

One Pump. Massive Potential. TandemLife (formerly, CardiacAssist, Inc.) exists to deliver Life Support Simplified, with one small pump enabling any type of extracorporeal circulatory support your patients may need. The TandemHeart pump was the driving force behind the world’s first percutaneous left heart support system. We’ve added on to this legacy of innovation by developing three new product lines with the same reliability you’ve come to expect; TandemLife, TandemLung, and Protek Duo. Visit us to learn how we can empower your program to deliver breakthrough performance in extracorporeal support.

TEXAS CHILDREN’S HOSPITAL  Booth #104
6621 Fannin St
Houston, TX 77030
www.texaschildrens.org

Texas Children’s Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children’s hospital in Texas, and among the top in the nation, Texas Children’s has garnered widespread recognition for its expertise and breakthroughs in pediatric and women’s health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Center for pediatric research; Texas Children’s Pavilion for Women, a comprehensive obstetrics/gynecology facility; Texas Children’s Hospital West Campus; and Texas Children’s Hospital The Woodlands.

TRANSMEDICS, INC.  Booth #305
200 Minuteman Road, Suite 302
Andover, MA 01810
www.transmedics.com

The Organ Care System (OCS™) is the only portable, multi-organ, normothermic ex-vivo perfusion platform that maintains donor organs in a functioning state outside of the body. The OCS™ System minimizes ischemic injury and allows for continuous clinical evaluation of organs to increase donor organ utilization and improve post-transplant clinical outcomes.

The OCS™ Heart, Lung and Liver systems are CE Marked in Europe. In the USA, they are Investigational Devices limited by Federal Law to Investigational Use.

THE TRANSPLANTATION SOCIETY  Booth #221
505 Boulevard René-Lévesque Ouest, Suite 1401
Montreal, QC, Canada H2Z 1Y7
www.tts.org

Over the last 50 years The Transplantation Society has grown exponentially and has become the largest international transplant community. Established in 1966, it serves as the principle International forum for the advancement of both basic and clinical transplantation science throughout the world. The Transplantation Society is a Non-Governmental Organization (NGO) which is composed of over 6700 professionals including but not limited to, physicians, surgeons and scientists in over 105 countries. The Transplantation Society’s mission is to provide the focus for global leadership in transplantation through the development of the science and clinical practice, scientific communication, continuing education and the guidance on ethical practice.

TS CONSULTING  Booth #122
8255 Las Vegas Blvd
Las Vegas, NV 89123
UNITED THERAPEUTICS  Booth #421
55 T.W. Alexander Drive
Research Triangle Park, NC 27709
www.uniter.com

Medical Affairs/Medical Information Booth supporting United Therapeutics’ marketed products for the treatment of symptoms of pulmonary arterial hypertension. Also supporting near term and long term plans for the treatment of symptoms and cure of PAH/PH. Information on the Jenesis Awards, which supports junior investigators in the field of pulmonary hypertension, is available.

WATERS MEDICAL SYSTEMS, LLC  Booth #425
2112 15th St NW
Rochester, MN 55901
www.wtrs.com

We, at Waters Medical Systems, design, manufacture, and market proprietary and generic products for organ preservation. Our products are essential for the success of organ transplantations. Our extensive clinical experience of over 45 years has forged the reputation of our products in terms of safety and efficiency.

Waters Medical Systems is a sister company of Institut Georges Lopez (known as IGL), located in France. Waters Medical Systems and IGL, together, represent a key player in the world of organ preservation, uniquely positioned by providing a comprehensive offer for the organ storage.


WEXLER SURGICAL  Booth #424
11333 Chimney Rock Rd, Suite 110
Houston, TX 77305
www.wexlersurgical.com

Wexler Surgical designs and manufactures a variety of titanium and stainless steel specialty surgical instruments and products for Cardiac, Vascular, Thoracic, and Micro Surgery.

Come see our VATS/MICS instruments and ask about our Optimus Series. Visit us online at www.wexlersurgical.com for more information about our products and services.

WOUND CARE RESOURCES  Booth #323
4 Newbern Hwy
Yorkville, TN 38389
www.VADsupplies.com
www.woundcareresources.net

Wound Care Resources, a niche DME specializing in the formulation, usage and billing of surgical dressings since 2006, has been billing VAD dressing supplies nationwide since 2010. The company offers an extensive selection of surgical dressings and prepackaged customized kits with an emphasis on antimicrobials and unique "gentle" products for those having skin sensitivities associated with traditional adhesives and cleansers. WCR bills Medicare, Medicaid and commercial insurance for all products and dressings needed for VAD outpatient driveline maintenance.
XVIVO PERFUSION AB  Booth #311
Box 53015
SE-400 14 Gothenburg, Sweden
www.xvivoperfusion.com

XVIVO Perfusion manufactures and markets solutions and systems for transplantation:
- Perfadex® for hypothermic flushing and preservation of donor lungs during transport
- STEEN Solution™ for normothermic ex vivo lung perfusion and evaluation
- XPS™ and LS™ platforms for warm perfusion and evaluation of lungs ex vivo, after donation and prior to transplantation

XPS™, disposables and the perfusates are CE-marked, approved in Canada, Australia and US. LS™ and disposables are approved in Europe, Canada and Australia.

XVIVO aims to increase the number of organs available for transplantation and transplantation success rates using new transplantation concepts and techniques.
FUTURE ANNUAL MEETINGS

2018
38th Annual Meeting and Scientific Sessions
Nice, France
April 11-14, 2018

2019
39th Annual Meeting and Scientific Sessions
Orlando, FL, USA
April 3-6 2019

2020
40th Annual Meeting and Scientific Sessions
Montreal, Canada
April 2020